
<html lang="en"     class="pb-page"  data-request-id="3565a5ab-17db-4d6b-b9b6-0320419a9556"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.1c00683;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist" /></meta><meta name="dc.Creator" content="Xiangqian  Li" /></meta><meta name="dc.Creator" content="Xiaowei  Li" /></meta><meta name="dc.Creator" content="Fang  Liu" /></meta><meta name="dc.Creator" content="Shuo  Li" /></meta><meta name="dc.Creator" content="Dayong  Shi" /></meta><meta name="dc.Description" content="The development of multitarget-directed ligands (MTDLs) has become a widely focused research topic, but rational design remains as an enormous challenge. This paper reviews and discusses the design..." /></meta><meta name="Description" content="The development of multitarget-directed ligands (MTDLs) has become a widely focused research topic, but rational design remains as an enormous challenge. This paper reviews and discusses the design..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 27, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00683" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00683" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00683" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00683" /></link>
        
    
    

<title>Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00683" /></meta><meta property="og:title" content="Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0038.jpeg" /></meta><meta property="og:description" content="The development of multitarget-directed ligands (MTDLs) has become a widely focused research topic, but rational design remains as an enormous challenge. This paper reviews and discusses the design strategy of incorporating the second activity into an existing single-active ligand. If the binding sites of both targets share similar endogenous substrates, MTDLs can be designed by merging two lead compounds with similar functional groups. If the binding sites are large or adjacent to the solution, two key pharmacophores can be fused directly. If the binding regions are small and deep inside the proteins, the linked-pharmacophore strategy might be the only way. The added pharmacophores of second targets should not affect the binding mode of the original ones. Moreover, the inhibitory activities of the two targets need to be adjusted to achieve an optimal ratio." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00683"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00683">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00683&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00683&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00683&amp;href=/doi/10.1021/acs.jmedchem.1c00683" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, XXXX</span><span class="cit-fg-issue">, XXX</span><span class="cit-fg-pageRange">, XXX-XXX</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/0/0" title="Return to Articles ASAP" id="returnToASAP" class="content-navigation__btn--return"><span>RETURN TO ARTICLES ASAP</span></a><a href="/doi/10.1021/acs.jmedchem.1c00665" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.1c00734" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xiangqian Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiangqian Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Microbial Technology, Shandong University, 72 Binhai Road, Qingdao 266237, Shandong, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiangqian++Li">Xiangqian Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Xiaowei Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaowei Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Microbial Technology, Shandong University, 72 Binhai Road, Qingdao 266237, Shandong, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaowei++Li">Xiaowei Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Fang Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fang Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Microbial Technology, Shandong University, 72 Binhai Road, Qingdao 266237, Shandong, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fang++Liu">Fang Liu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Shuo Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuo Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Microbial Technology, Shandong University, 72 Binhai Road, Qingdao 266237, Shandong, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuo++Li">Shuo Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Dayong Shi</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dayong Shi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Microbial Technology, Shandong University, 72 Binhai Road, Qingdao 266237, Shandong, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#6d1e0504090c1402030a2d1e091843080918430e03"><span class="__cf_email__" data-cfemail="017269686560786e6f66417265742f6465742f626f">[emailÂ protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dayong++Shi">Dayong Shi</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-5807-5633" title="Orcid link">https://orcid.org/0000-0002-5807-5633</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00683&amp;href=/doi/10.1021%2Facs.jmedchem.1c00683" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, XXXX</span><span class="cit-issue">, XXX</span><span class="cit-pageRange">, XXX-XXX</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 27, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 April 2021</li><li><span class="item_label"><b>Published</b> online</span>27 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00683" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00683</a></div><div class="article_header-article-copyright"><strong>Â© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXiangqian%2BLi%252C%2BXiaowei%2BLi%252C%2BFang%2BLiu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D0%26issueNum%3D0%26contentID%3Dacs.jmedchem.1c00683%26title%3DRational%2BMultitargeted%2BDrug%2BDesign%2BStrategy%2Bfrom%2Bthe%2BPerspective%2Bof%2Ba%2BMedicinal%2BChemist%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D25%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00683"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">764</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00683" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xiangqian&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Xiaowei&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Fang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Shuo&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Dayong&quot;,&quot;last_name&quot;:&quot;Shi&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;volume&quot;:&quot;0&quot;,&quot;pages&quot;:&quot;&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00683&quot;},&quot;abstract&quot;:&quot;The development of multitarget-directed ligands (MTDLs) has become a widely focused research topic, but rational design remains as an enormous challenge. This paper reviews and discusses the design strategy of incorporating the second activity into an existing single-active ligand. If the binding sites of both targets share similar endogenous substrates, MTDLs can be designed by merging two lead compounds with similar functional groups. If the binding sites are large or adjacent to the solution, two key pharmacophores can be fused directly. If the binding regions are small and deep inside the proteins, the linked-pharmacophore strategy might be the only way. The added pharmacophores of second targets should not affect the binding mode of the original ones. Moreover, the inhibitory activities of the two targets need to be adjusted to achieve an optimal ratio.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00683&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00683" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00683&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00683" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00683&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00683" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00683&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00683&amp;href=/doi/10.1021/acs.jmedchem.1c00683" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00683" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00683" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (11 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00683%26sid%3Dliteratum%253Aachs%26pmid%3D34313432%26genre%3Darticle%26aulast%3DLi%26date%3D2021%26atitle%3DRational%2BMultitargeted%2BDrug%2BDesign%2BStrategy%2Bfrom%2Bthe%2BPerspective%2Bof%2Ba%2BMedicinal%2BChemist%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D0%26issue%3D0%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290663" title="Pharmacophores">Pharmacophores</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=291120" title="Hydrophobicity">Hydrophobicity</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/0/0" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0038.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The development of multitarget-directed ligands (MTDLs) has become a widely focused research topic, but rational design remains as an enormous challenge. This paper reviews and discusses the design strategy of incorporating the second activity into an existing single-active ligand. If the binding sites of both targets share similar endogenous substrates, MTDLs can be designed by merging two lead compounds with similar functional groups. If the binding sites are large or adjacent to the solution, two key pharmacophores can be fused directly. If the binding regions are small and deep inside the proteins, the linked-pharmacophore strategy might be the only way. The added pharmacophores of second targets should not affect the binding mode of the original ones. Moreover, the inhibitory activities of the two targets need to be adjusted to achieve an optimal ratio.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88852" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88852" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">During the past several decades, drug development has focused on single drugs that are highly potent and selective for specific biological targets.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Surely, this âone-molecule, one-targetâ strategy has provided notable achievements, and many successful drugs have been obtained.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> However, highly selective ligands for specific targets do not always produce clinically effective drugs. The interaction with a single target does not affect the diseased system enough to restore it effectively, especially for these complex multifactorial diseases, such as diabetes, neurodegenerative syndromes, cardiovascular diseases, and cancer.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Recent studies have focused on modulating multiple targets simultaneously.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> It is proposed to combine two different inhibitory activities into one molecule (multitarget drug strategy) to achieve combination therapy.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> This multitarget drug strategy is different from the multiple-medication therapy, in which two or more different drugs are used simultaneously.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8â10)</a> Multitarget drugs may offer multiple advantages, such as superior therapeutic effects, lower risk of drugâdrug interaction, and more predictable pharmacokinetics (PK) and pharmacodynamics (PD).<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11â13)</a> In addition, MTDLs may be a new way to reduce the incidence of drug resistance. For example, Choong-Kun Lee found that the multitarget angiokinase inhibitor TKI258 can overcome the resistance of colorectal cancer to EGFR or VEGF inhibitors.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a></div><div class="NLM_p">In 2004, Morphy et al. presented a new concept of drug discovery: designed multiple ligands (DMLs).<a onclick="showRef(event, 'ref2 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref4">(2,4)</a> Since then, the research and development of multitarget drugs have entered a new period. Anighoro et al. and Lu et al. assessed the merits of multitarget drugs versus single-target and combination therapies.<a onclick="showRef(event, 'ref1 ref16'); return false;" href="javascript:void(0);" class="ref ref1 ref16">(1,16)</a> Meanwhile, some successful examples of multitargeted agents were also listed, based on pharmacophore modes, anticancer agents, neurodegenerative diseases, Alzheimerâs disease, anti-inflammatory drugs, and multitarget therapeutics.<a onclick="showRef(event, 'ref3 ref9 ref11 ref17 ref18 ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref3 ref9 ref11 ref17 ref18 ref19 ref20 ref21 ref22 ref23">(3,9,11,17â23)</a> Zhou et al. discussed the establishment of target combinations and the identification, optimization, and synthesis of MTDLs.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Andrew Anighoro compared the advantages and disadvantages of MTDLs versus combination therapies.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Ewgenij Proschak assessed the importance and possibility of MTDLs design.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p last">Rational design of MTDLs remains an enormous challenge and still needs further implementation and methodological development.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> Different from previous reviews, the objective of this Perspective is to demonstrate the rational design of multitarget agents from the perspective of medicinal chemists based on existing information. This paper reviews and discusses the design strategy of incorporate the second activity into an existing single activity ligand while retaining affinity for the original target.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Rational Design of Multitargeted Ligands</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08481" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08481" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Four commonly known strategies for obtaining MTDLs are merged-pharmacophore mode, fused-pharmacophore mode, noncleavable linked-pharmacophore mode, and cleavable linked-pharmacophore mode (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref12 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref12 ref25 ref26">(12,25,26)</a> Moreover, dozens of successful examples have been reported based on these strategies.<a onclick="showRef(event, 'ref9 ref11 ref19 ref23'); return false;" href="javascript:void(0);" class="ref ref9 ref11 ref19 ref23">(9,11,19,23)</a> Here, we discuss how to choose an appropriate strategy based on known information and imitate similar examples to design multitargeted ligands.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Four types of the multipharmacophore model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The main design idea of multitargeted ligands is to obtain the second activity while maintaining the original activity. The key pharmacophores of MTDLs should be able to maintain the interaction with the original target, while being compatible with the second target.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> First, the key pharmacophore elements of individual ligands should be identified and analyzed before promiscuity of individual ligands. Then, an appropriate strategy should be employed to yield hybrid molecules according to the characteristics of key pharmacophore elements and scaffold structures. Moreover, the activities of the two targets must be adjusted to achieve an optimal ratio.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">According to the similarities of pharmacophoric elements and scaffold structures, a dual target inhibitor can be obtained from two lead molecules in several ways (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). If the binding sites of two targets can bind ligands with similar geometry and pharmacophore distribution, a dual-target inhibitor can be designed by merged-pharmacophore mode.<a onclick="showRef(event, 'ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30">(27â30)</a> Two similar or partially similar compounds can be merged into one molecular skeleton with key pharmacophore elements, such as ionic bond, hydrogen bond, and hydrophobic interaction.<a onclick="showRef(event, 'ref27 ref28 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30 ref31">(27â31)</a> These dual target inhibitors were often obtained with small structural changes but inspiring designs.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design strategy of dual target inhibitors. The blue graphics represent the molecular scaffold, and the red graphics represent the pharmacophoric elements.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">If the two lead compounds do not have similar structures or the binding regions of the two target proteins are not similar, the merged-pharmacophore strategy is difficult to implement. Under the premise of maintaining the original pharmacophore binding, the pharmacophores of the two lead compounds can be fused directly or connected with a linker. If the binding regions are large or adjacent to the solution, two key pharmacophores can be fused directly.<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32â34)</a> If the binding regions are small and deep inside the protein, the linked-pharmacophore strategy might be the only way to design dual-target inhibitors.<a onclick="showRef(event, 'ref6 ref35'); return false;" href="javascript:void(0);" class="ref ref6 ref35">(6,35)</a></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Similar Pharmacophoric Elements</h3><div class="NLM_p">Ligands with clear binding modes can be preferentially selected as lead compounds. X-ray structure information is essential for identifying the key pharmacophore elements, such as crucial hydrogen bonds, charges, and hydrophobic groups.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> If the selected ligands have structural similarities, including similar functional groups or molecular backbones, the merged-pharmacophore method can be employed to make the pharmacophores overlap with each other.</div><div class="NLM_p">The merged-pharmacophore method is to superimpose the same structural parts of different ligands or to modify one of the ligands to obtain a new compound that integrates another pharmacophore. This strategy is the most elegant way to design MTDLs. Compared with the linked and fused molecules, the merged molecules have higher ligand efficiency, smaller molecular weight, and better physical and chemical properties. However, the design of merged molecules is a very difficult task. The merged sites and manners should be carefully evaluated and optimized to avoid mutual influence. Several successful examples of merged molecules with similar pharmacophoric elements are listed as follows.</div><div id="sec2_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i5" class="anchor-spacer"></div><h4 class="article-section__title" id="_i5"> HDAC and HMGR</h4><div class="NLM_p">Histone deacetylases (HDACs) are important targets for the treatment of cancer and neurodegenerative diseases.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Typically, the classical pharmacophore for HDACi, such as vorinostat (SAHA, <b>1</b>), contains a cap group, a linker, and a hydroxamic acid group. Among them, the most critical one is the terminal hydroxamic acid group, which coordinates with zinc ion at the bottom of the HDAC pocket (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Statins, such as lovastatin (<b>2</b>), can effectively reduce total cholesterol and low-density lipoprotein by inhibiting the activity of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The terminal carboxylate and hydroxyls (HMG-moiety) of <b>2</b> form a hydrogen-bonding network with the enzyme active site of HMGR, which is characterized by a loop (residues 682â694, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The rigid hydrophobic groups of the statins are situated in a shallow groove of HMGR.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a><i>In vitro</i> experiments showed that the combination of HDACi and HMGRi can synergistically induce HeLa cell apoptosis.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structures of (A) HDAC with SAHA (<b>1</b>), PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1C3S">1C3S</a>; (B) HMGR with lovastatin (<b>2</b>), PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1HW9">1HW9</a>. Compounds <b>1</b> and <b>2</b> are shown with green carbon in stick representation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">SAHA (<b>1</b>) and lovastatin (<b>2</b>) share similar pharmacophore elements, including a hydrophilic head, a flexible long chain, and a hydrophobic tail. The hydroxamic acid of <b>1</b> is considered to be a bioisostere of carboxylic acid of <b>2</b>. By merging these similar pharmacophores of two compounds, the combined molecule <b>3</b> can act as a dual-targeting inhibitor of HDAC-HMGR (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The hydroxamate group of <b>3</b> consistently inserts into the catalytic pocket of HDAC, while the hydrophobic moiety can be used as a cap group. <i>In vitro</i> results showed that compound <b>3</b> can selectively kill A549 lung cancer cells (IC<sub>50</sub> = 18.2 Î¼M).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Design of MTDL <b>3</b> targeting HDACs and HMGR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i6" class="anchor-spacer"></div><h4 class="article-section__title" id="_i6"> HDAC and VDR</h4><div class="NLM_p">A similar strategy is also reflected in the design of triciferol (<b>6</b>), a hybrid molecule in which the terminal hydroxyl of 1,25-dihydroxyvitamin D3 (1,25D, <b>5</b>) was replaced with the hydroxamic acid of trichostatin A (TSA, <b>4</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> TSA (<b>4</b>) inhibits cell growth and induces apoptosis by regulating the acetylation state of histones.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> 1Î±,25-dihydroxyvitamin D<sub>3</sub> (1,25 D, <b>5</b>), a vitamin D receptor (VDR) agonist, exerts antiproliferative effects on cervical cancer cells <i>in vitro</i>.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The antiproliferative action of <b>5</b> can be ârestoredâ by cotreatment with <b>4</b> in the 1,25D-resistant cancer cells.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Design of MTDL <b>6</b> targeting HDACs and VDR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The side chain substitution and length change of <b>5</b> can be accommodated by VDR, while the three hydroxyl groups that form hydrogen bonds need to be maintained (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00683/suppl_file/jm1c00683_si_001.pdf" class="ext-link">Figure S1</a>).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> A dual target inhibitor triciferol (<b>6</b>) was obtained by merging the dienyl hydroxamic acid of <b>4</b> with the steroid backbone of <b>5</b>. The binding mode of compound <b>6</b> and the VDR binding domain is roughly similar to that of <b>4</b>.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> As an efficient replacement of the 25OH group, the hydroxamic acid of <b>6</b> can form hydrogen bonds with His-397 and His-305. In combination with HDACs, the steroid backbone of <b>6</b> can function as the âcapâ structure of HDACi. Compound <b>6</b> showed more effective antiproliferation and cytotoxic activity than either <b>4</b> or <b>5</b> alone in cancer cells <i>in vitro</i>.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div></div><div id="sec2_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i7" class="anchor-spacer"></div><h4 class="article-section__title" id="_i7"> IN and RT</h4><div class="NLM_p">The integration and synthesis of proviral DNA in HIV replication are regulated by integrase (IN) and reverse transcriptase (RT). As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, a dual-target inhibitor of RT and IN (<b>9</b>) was designed based on RT inhibitor <b>7</b> and IN inhibitor <b>8</b>.<a onclick="showRef(event, 'ref29 ref48'); return false;" href="javascript:void(0);" class="ref ref29 ref48">(29,48)</a> The ingenious design only involves 3-N hydroxylation of the pyrimidine ring to produce a chelating triplet that meets the main structural requirements of IN binding. This RT/IN dual inhibitor <b>9</b> shows high inhibitory activity against HIV-1 replication in cell culture (EC<sub>50</sub> = 8 nM).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Design of MTDL <b>9</b> targeting RT and IN.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The H bond between N(3)H and the carbonyl group of Lys101 is essential for the binding affinity of <b>7</b> to RT.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The hydroxylation of the N-3 does not significantly impair the overall conformation of inhibitor (<b>9</b>) and the binding affinity to RT. The newly added OH still retains H-bonding ability to the carbonyl group of Lys101. The minimal pharmacophorse of IN inhibitors, such as DKAs (<b>8</b>), consists of a hydrophobic benzyl moiety and a chelating triad capable of binding two Mg<sup>2+</sup> ions.<a onclick="showRef(event, 'ref50 ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref50 ref51 ref52 ref53">(50â53)</a> Docking results of inhibitor <b>9</b> in complex with IN and Mg<sup>2+</sup> showed that the 3-N hydroxyl group simultaneously chelates two Mg<sup>2+</sup> ions, while the benzyl group occupies the hydrophobic pocket of the DNAâprotein interface.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.2.  Similar Scaffold Structures</h3><div class="NLM_p">More often, two ligands might only have âcompatibility districtsâ that have little effect on activity instead of the similar crucial functional groups. These compatibility districts usually have similar skeleton structures, and their changes have little effect on the binding of ligands to proteins. After these similar compatibility districts have merged, the functional groups of the two ligands can be added at appropriate positions, respectively.</div><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9"> FXR and sEH</h4><div class="NLM_p">In view of the clinical efficacy of farnesol X receptor (FXR) activation in reducing lipid accumulation and the important role of soluble epoxide hydrolase (sEH) inhibition in anti-hepatitis and anti-steatosis, dual regulation of FXR and sEH may be a new strategy for the treatment of nonalcoholic fatty liver and nonalcoholic steatohepatitis. Schmidt et al. combined sEH inhibitor <b>10</b> and FXR agonist <b>11</b> to produce a dual modulator (<b>12</b>), which can be used to treat nonalcoholic steatohepatitis and related metabolic diseases (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00683/suppl_file/jm1c00683_si_001.pdf" class="ext-link">Figure S2A</a>, the active site in sEH is formed by a channel between two large, solvent-accessible pockets.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The amide group of sEH inhibitor <b>10</b> forms two hydrogen bonds with the residues Tyr383 and Asp335.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The 4-cyano-phenyl group forms a Ï-stacking interaction with Trp336. The 4-fluorophenyl group occupies a deep hydrophobic pocket, whereas the 4-methanesulfonyl-substituted phenyl group is directed toward the solvent.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Design of MTDL <b>12</b> targeting sEH and FXR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The ligand binding pocket in the full agonistic conformation of FXR is narrow and long (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00683/suppl_file/jm1c00683_si_001.pdf" class="ext-link">Figure S2B</a>). The critical lipophilic substituents of <b>11</b>, the 4-<i>tert</i>-butylbenzoyl group and the central aromatic ring, were buried in two hydrophobic pockets, respectively. The benzoic acid is exposed to the solvent without any significant interaction with the protein.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The sEH inhibitor <b>10</b> containing the <i>N</i>-benzylamide group has some structural similarities with the FXR agonist <b>11</b>.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> These similar scaffold structures were extracted and merged as the key structure of the dual modulator. Other critical pharmacophore elements were added to obtain a potent dual modulator (<b>12</b>), which could activate FXR and inhibit sEH <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10"> FXR and PPARÎ´</h4><div class="NLM_p">Simultaneous activation of peroxisome proliferator-activated receptor Î´ (PPARÎ´) and FXR may hold synergies in nonalcoholic steatohepatitis. A dual activator of FXR and PPARÎ´ was designed by merging the similar pharmacophores and structural parts of FXR agonist <b>13</b> and PPARÎ´ agonist <b>14</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Compounds <b>13</b> and <b>14</b> share similar scaffold structures and pharmacophore elements.<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a> These two compounds contain a trisubstituted five-membered heterocycle that defines their geometry. The ortho-substituted phenyl substituent is adjacent to the methyleneoxyphenyl linker of the carboxylate side chain.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Design of MTDL <b>15</b> targeting FXR and PPARÎ´.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">However, there are still many structural differences between <b>13</b> and <b>14</b>, such as the linker type and the length of the carboxylic acid moiety. The key aspect of merged ligand design is to find an appropriate linker between the terminal carboxylic acid and the isoxazole moiety. The finally obtained agonist <b>15</b> showed high activation effects on both PPARÎ´ and FXR. Docking results showed that this dual modulator can bind to the ligand binding sites of FXR and PPARÎ´ reasonably.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div></div><div id="sec2_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> AT<sub>1</sub> and ET<sub>A</sub></h4><div class="NLM_p">Dual antagonists of the angiotensin II (AT<sub>1</sub>) and endothelin A receptor (ET<sub>A</sub>) for the treatment of hypertension are representative examples of MTDL design through scaffold structure overlap (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61,62)</a> Natesan Murugesan described a series of potent dual AT1 and ETA receptor antagonists, exemplified by BMS-248360 (<b>18</b>) and BMS-346567 (<b>19</b>). These dual antagonists showed greater therapeutic benefits than single-target inhibitors that antagonize AT<sub>1</sub> or ET<sub>A</sub> receptors alone.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Design of MTDLs <b>18</b> and <b>19</b> targeting AT<sub>1</sub> and ET<sub>A</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Biphenyl sulfonamide of ETA receptor antagonist BMS-193884 (<b>16</b>) is similar to the biphenyl tetrazole core of AT<sub>1</sub> receptor antagonist irbesartan (<b>17</b>).<a onclick="showRef(event, 'ref63 ref64 ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref63 ref64 ref65 ref66">(63â66)</a> The isoxazole sulfonamide located at C2 of the biphenyl core is an essential group for compound <b>16</b> to antagonize ET<sub>A</sub> receptor. Substitution at C2â² of the biphenyl core usually leads to an increase in affinity for the ET<sub>A</sub> receptor. In AT<sub>1</sub> receptor antagonist <b>17</b>, the heterocycle at C4â² of the biphenyl core that can form hydrogen bonds is essential for antagonizing the AT<sub>1</sub> receptor.</div><div class="NLM_p last">The first oral dual-action receptor antagonist that blocks both ET<sub>A</sub> and AT<sub>1</sub> receptors (BMS-248360, <b>18</b>) was yielded through merging these structural elements of <b>16</b> and <b>17</b>.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Through modifying the side chain at C2â²of the biphenyl core, a second-generation dual-action receptor antagonist <b>19</b> was discovered with improved pharmacokinetic properties.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> In conscious normotensive rats, compound <b>19</b> showed more potent and longer action than <b>17</b>.</div></div><div id="sec2_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> HDAC and NAMPT</h4><div class="NLM_p">Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) that can dramatically impact nicotinamide adenine dinucleotide (NAD) metabolism is a promising target for cancer treatment.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Simultaneously antagonizing NAMPT and HDAC will be a promising antitumor strategy.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Dong et al. discovered a series of dual HDAC and NAMPT inhibitors simultaneously targeting cancer metabolism and epigenetics (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> The pharmacophore of the NAMPT inhibitor MS0 (<b>20</b>) consists of a core NAM mimic (pyridylmethylthiourea), a tail group (piperidinylsulfonyl), and a linker (phenyl). HDAC inhibitor CI-994 (<b>21</b>) shares a similar molecular shape and pharmacophore elements, containing a zinc binding group (ZBG, ortho-aminoanilide), a hydrophobic tail group, and a linker (phenyl).<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Design of MTDLs <b>22</b> and <b>23</b> targeting NAMPT and HDAC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">A HDAC and NAMPT dual inhibitor (<b>22</b>) was designed by combining the core NAM mimic group of <b>20</b> with the ZBG of <b>21</b> using a phenyl linker. Compound <b>22</b> showed IC<sub>50</sub> values of 1.6 Î¼M and 116 nM against HDAC1 and NAMPT, respectively. Molecule docking showed that compound <b>22</b> shares similar binding modes with <b>20</b> and <b>21</b>, respectively. In further optimization, the introduction of a 1,2,3-triazole group enables compound <b>23</b> to achieve balanced dual inhibition of HDAC1 and NAMPT. In the HCT116 xenograft model, compound <b>23</b> showed excellent antitumor efficacy.</div></div><div id="sec2_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Multiple Anti-AD Activities</h4><div class="NLM_p">Many factors play important roles in the pathophysiology of Alzheimerâs disease (AD), such as neurotransmitter system dysfunction, metal ion dyshomeostasis, and Î²-amyloid (AÎ²) deposits. Multitarget drugs that can interfere with two or more causes of AD may achieve better clinical treatment effects.<a onclick="showRef(event, 'ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref71 ref72">(71,72)</a> Sheng et al. reported a multitarget molecule (<b>27</b>) by merging the key pharmacophores of three compounds with different activities (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> MK0249 (<b>24</b>), a potent H3 inverse agonist (IC<sub>50</sub> = 1.7 nM), is composed of three critical pharmacophore elements: an âeastern partâ containing a polar group, an aromatic central core, and a âwestern partâ consisting of a tertiary basic amine.<a onclick="showRef(event, 'ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref73 ref74">(73,74)</a> A metal chelator deferiprone (<b>25</b>), which is similar to the âeastern partâ of <b>24</b>, was chosen to generate a new hybrid with multiple functions.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Design of MTDL <b>27</b> with multiple anti-AD activities.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In addition, AÎ² aggregation inhibitor SKF-64346 (<b>26</b>) shares similar structural elements with âwestern and central partsâ of <b>24</b>.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Compound <b>27</b> was designed by incorporating <b>25</b> into the merged scaffold structure of <b>24</b> and <b>26</b>. The resulting compound <b>27</b> exhibited multiple anti-AD activities, including AÎ² aggregation inhibition (IC<sub>50</sub> = 2.85 Î¼M), H3 receptor antagonism (IC<sub>50</sub> = 0.32 nM), and metal ion chelation.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> In addition, <i>in vivo</i> studies revealed that <b>27</b> can efficiently cross the brain-blood barrier.</div></div><div id="sec2_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> MMP-1 and Cathepsin L</h4><div class="NLM_p">The activation of cathepsins and matrix metalloproteinase (MMP) is related to cartilage and bone degradation. Dual inhibitor of cathepsin and MMP might be used to treat osteoporosis and rheumatoid arthritis.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> The hydroxamic acid of MMP inhibitor <b>28</b> is a functional group that chelates zinc at the active site of MMP.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> The aldehyde group of cathepsin inhibitor <b>29</b> is the key functional group that interacts with the thiol group in the active site.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Interestingly, there is a close similarity between <b>28</b> and <b>29</b>, even if their targets are classified as different classes of proteinases. Based on this similar peptide scaffold, Minoru Yamamoto designed a dual inhibitor (<b>30</b>) of cathepsin L (IC<sub>50</sub> = 15 nM) and MMP (IC<sub>50</sub> = 25 nM) by adding hydroxamic acid and aldehyde groups (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Design of MTDL <b>30</b> targeting MMP and cathepsin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">2.3.  Targets Lacking Similar Ligands or Similar Endogenous Substrates</h3><div class="NLM_p">In these merged MTDLs, multiple functional groups are integrated into a compatible molecular scaffold. In order to allow such pharmacophore hybridization, the similar pharmacophores or scaffolds should be present in two single target ligands. However, most selected ligands that bind different targets do not have structural similarities. Without similar pharmacophores or scaffold structures, two selected lead compounds can be connected directly (fused) or by using a linker to obtain a new molecule that retains most of the original key pharmacophore elements.</div><div class="NLM_p">For linked-pharmacophore mode, the biggest advantage is that such linked molecules are relatively easy to obtain. The key pharmacophores of the original ligands and their activities on the multiple targets can almost be retained with only a linker. However, this method also has obvious shortcomings. If the linker is a stable, noncleavable fragment, the dual-target compound can recognize and bind to two or multiple targets separately as an integral molecule <i>in vivo</i>. In this case, the properties of these linkers, such as length, hydrophobicity, and rigidity, may affect the overall efficacy of MTDLs, including physical and chemical properties, and the degree of adaptation to the two targets. These linked molecules often have an increase in volume and molecular weight and a decrease in ligand efficiency, which might make their properties deviate from the Lipinskiâs âRule of Fiveâ.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></div><div id="sec2_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">2.3.1.  Targets with Deep and Narrow Pockets</h4><div class="NLM_p">The active binding regions of many targets penetrate deep into the proteins and connect to the peripheral binding regions through long channels or narrow gorges. For example, the active region of acetylcholinesterase (AChE) spans 20 Ã from the outer peripheral binding site to the catalytic triad, deep within the molecule.<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81,82)</a> The catalytic site of HDAC is an 11 Ã tubular channel with a zinc ion at the bottom.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Targeting such a protein with a narrow throat area, the principles of dual target molecular design are that (a) the designed hybrid can reproduce the interaction between the key pharmacophore and the original catalytically active site, (b) the flexible linker spans across the gorge, and (c) the added fragment acts as a binder for the peripheral binding site.</div><div id="sec2_3_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i17" class="anchor-spacer"></div><h5 class="article-section__title" id="_i17"> AChE and GSK-3Î²</h5><div class="NLM_p">Tacrine (<b>31</b>) is the first AChE inhibitor used in clinical trials for the treatment of AD patients.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In the complex with AChE, the acridine of <b>31</b> is sandwiched between the aromatic rings of Trp-84 and Phe-330 in the âanionicâ subsite of the active site (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>A). Its primary amine group is located at the solvent interface and points toward the solvent through a narrow gorge (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>B).<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> The pyridine carboxamide of glycogen synthase kinase-3Î² inhibitor (GSK-3Î²I, <b>32</b>) acts as a hinge to form two hydrogen bonds with V135. Thiazolyl primary amide is another key pharmacophore that forms a hydrogen bond with Lys85 (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>C).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> The primary amide exposed to the solvent is the best position to connect primary amine of <b>31</b> via an appropriate linker (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>D).</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. X-ray crystal structures of (A, B) AChE with <b>31</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ACJ">1ACJ</a>; (C, D) GSK-3Î² with <b>32</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PTC">4PTC</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As the main pathogenesis of AD, GSK-3Î² and AChE are ideal target combinations for multitarget methods. Jiang et al. designed a new multitarget ligand <b>33</b> by connecting <b>31</b> to the solvent-exposed area of <b>32</b> with an alkylene diamine tether as a linker (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Docking studies showed that the position and orientation of the tacrine fragment of <b>33</b> are consistent with those of <b>31</b> in AChE active-site gorge. The flexible chain threads through the narrow gorge, and the pyridoxathiazole fragment is located in the PAS of AChE binding groove. In the complex with GSK-3Î², the pyridine carboxamide pharmacophore maintains the GSK-3Î² kinase domain critical binding components, occupying the ATP binding site. Compound <b>33</b> significantly improved the cognitive disorder of ICR mice treated with scopolamine and showed lower liver toxicity than <b>31</b>.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Design of MTDL <b>33</b> targeting AChE and GSK-3Î².</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the similar way, Lu et al. combined the tacrine moiety with the selegiline moiety (MAO inhibitory activity), using carbon spacers of different lengths (<b>34</b>, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).<a onclick="showRef(event, 'ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref85 ref86">(85,86)</a> Fernandez-Bachiller et al. designed a MTDL of AChE and BACE-1 by hybridizing the key pharmacophores of tacrine and flavonoids with a flexible linker (<b>35</b>, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).<a onclick="showRef(event, 'ref87 ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref87 ref88 ref89">(87â89)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Design of MTDLs <b>34</b> and <b>35</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i18" class="anchor-spacer"></div><h5 class="article-section__title" id="_i18"> HDAC and JAK2</h5><div class="NLM_p">HDAC and janus kinase (JAK) inhibitors are used in clinical treatment for similar tumor treatments. The pharmacophore of classic HDACi, such as vorinostat (<b>1</b>), contains a zinc-binding group (ZBG) at the bottom of the pocket, a âcapâ group exposed to the solvent, and a long chain linking these two parts along a narrow channel (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>A,B).<a onclick="showRef(event, 'ref6 ref39 ref83 ref90 ref91'); return false;" href="javascript:void(0);" class="ref ref6 ref39 ref83 ref90 ref91">(6,39,83,90,91)</a> Ruxolitinib (<b>36</b>) is a marketed JAK inhibitor for the treatment of polycythemia vera and myelofibrosis.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> The pyrrolpyrimidine group of <b>36</b> forms hydrogen bonds with the kinase hinge residues Glu930 and Leu932 (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00683/suppl_file/jm1c00683_si_001.pdf" class="ext-link">Figure S3</a>).</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. X-ray crystal structures of HDAC with <b>1</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1C3S">1C3S</a>: (A) side view; (B) front view.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The ZBG of <b>1</b> was linked with the critical pharmacophore of <b>36</b>, leading to a dual inhibitor targeted JAK/HDAC (<b>37</b>, <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Compound <b>37</b> showed highly effective JAK1 and HDACs inhibitory activity, as well as more effective cytotoxicity than <b>1</b> and <b>36</b>. Docking studies showed that compound <b>37</b> inserts its aliphatic chain and ZBG into the tubular channel of HDACs in a manner similar to <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>A). The pyrrolopyrimidine group serves as a hydrophobic recognition capping group that can interact with the edge of the catalytic region. In the docking study of <b>37</b> with JAK1, the pyrrolopyrimidine of <b>37</b> reproduced two hydrogen bonds with kinase hinge residues. The hydroxamic acid is exposed to the solvent without obvious hindrance (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>B). In a similar way, Yang et al. and Ning et al. designed a series of HDAC and JAK2 bispecific inhibitors, using vorinostat and pacritinib as initial templates (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00683/suppl_file/jm1c00683_si_001.pdf" class="ext-link">Figure S4</a>).<a onclick="showRef(event, 'ref93 ref94 ref95 ref96'); return false;" href="javascript:void(0);" class="ref ref93 ref94 ref95 ref96">(93â96)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Design of MTDL <b>37</b> targeting HDAC and JAK2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Docking studies of compound <b>37</b> with (A) HDAC6 and (B) JAK1.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i19" class="anchor-spacer"></div><h5 class="article-section__title" id="_i19"> HDAC and EGFR</h5><div class="NLM_p">Epidermal growth factor receptor (EGFR) inhibitors are anticancer drugs approved by the FDA against a variety of solid tumor cancers.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> However, it has been found that clinical medications of such drugs alone may lead to drug resistance. To overcome resistance, Ding et al. and Mahaboobi et al. designed a series of MTDLs of HDAC, EGFR, and human epidermal growth factor receptor 2 (HER2) by introducing ZBG of HDAC inhibitors into EGFR inhibitor Lapatinib (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref91 ref98'); return false;" href="javascript:void(0);" class="ref ref91 ref98">(91,98)</a></div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Design of MTDL <b>39</b> targeting HDACs, EGFR, and HER2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>A, the quinazoline moiety of <b>38</b> forms a hydrogen bond with Met793 of EGFR. The methylsulfonylethylaminomethylfuryl group is located at the solvent interface and does not show any significant interactions with the protein (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>B).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> New HDAC/EGFR/HER2 inhibitors were obtained by linking ZBG of HDACi with the C6 position of the crucial quinazoline moiety.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Compound <b>39</b> showed the highest inhibitory activity against HDACs, EGFR, and HER2.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. (A,B) X-ray crystal structures of EGFR with <b>38</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The binding mode of compound <b>39</b> with EGFR showed that the quinazoline group retains the key binding mode with EGFR and the hydroxamic acid is exposed to the solvent.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> In the binding mode of compound <b>39</b> with HDAC2, the 4-aminoquinazoline group is located at the rim of the catalytic tunnel, and the length of six-carbon linker extends to an appropriate distance, thereby bringing ZBG to the bottom of the catalytic cavity. <i>In vitro</i> test results showed that <b>39</b> showed high cytotoxicity in five human cancer cells, but still did not overcome the drug resistance caused by the EGFR T790 M mutation.</div><div class="NLM_p">Similarly, Cai et al. also designed a series of 4-anilinoquinazoline derivatives as multiacting HDAC, EGFR, and HER2 inhibitors by incorporating ZBG of vorinostat into the pharmacophore of erlotinbib (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00683/suppl_file/jm1c00683_si_001.pdf" class="ext-link">Figure S5</a>).<a onclick="showRef(event, 'ref101 ref102 ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref101 ref102 ref103 ref104">(101â104)</a> With the linked-pharmacophore mode, lots of MTDLs were obtained by incorporating ZBG of the HDAC inhibitor into different core structure pharmacophores of inosine monophosphate dehydrogenase (IMPDH, <b>40</b>), phosphodiesterase 5 (PDE5, <b>41</b>), phosphoinositide 3-kinase (PI3K, <b>42</b>), mammalian target of rapamycin (mTOR, <b>43</b>), vascular endothelial growth factor receptor-2 (VEGFR-2), signal transducer and activator of transcription 3 (STAT3), lanosterol 14a-demethylase (CYP51), focal adhesion kinase (FAK), bromodomain-containing protein 4 (BRD4), topoisomerase I/II, and estrogen receptor (ER) (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref83 ref105 ref106 ref107 ref108 ref109 ref110 ref111 ref112 ref113 ref114 ref115 ref116 ref117 ref118 ref119 ref120'); return false;" href="javascript:void(0);" class="ref ref83 ref105 ref106 ref107 ref108 ref109 ref110 ref111 ref112 ref113 ref114 ref115 ref116 ref117 ref118 ref119 ref120">(83,105â120)</a></div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Design of MTDLs with linked-pharmacophore mode.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i20" class="anchor-spacer"></div><h5 class="article-section__title" id="_i20"> Src and EGFR</h5><div class="NLM_p">The overexpression of EGFR and c-Src is related to tumor metastasis and invasion. The catalytic domain of Src, the nucleotide-binding pocket, is a deep and narrow gorge.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>A, inhibitor PP1 (<b>44</b>) binds in the nucleotide binding pocket of Src.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> An array of hydrogen bonds are formed, the phenyl ring occupies a largely hydrophobic cavity, and the <i>t</i>-butyl substituent is exposed to the solvent. The catalytic site of EGFR kinase is also a deep and narrow cleft, which is occupied by erlotinib (<b>45</b>, <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>B).<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> The N1 of quinazoline forms an H bond with the amide of Met769 and the anilino substituent occupies a hydrophobic pocket. The ether chains at the C6 and C7 positions of the quinazoline protrude into the solvent.</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. X-ray crystal structures of (A) Src with <b>44</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QCF">1QCF</a>; (B) EGFR with <b>45</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Both the 9-position of pyrazolopyrimidine (<b>44</b>) and the 6-position of quinazoline (<b>45</b>) are exposed to the solvent, which is the best position for connection with the linker. Based on these X-ray crystal structures, a dual inhibitor of Src and EGFR (SB163, <b>46</b>) was designed by combining two pharmacophore moieties of <b>44</b> and <b>45</b> with an appropriate linker (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Compound <b>46</b> showed high EGFR inhibitory activity (IC<sub>50</sub> = 0.32 Î¼M) and moderate Src inhibitory activity (IC<sub>50</sub> = 2.9 Î¼M).</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Design of MTDL <b>46</b> targeting Src and EGFR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21">2.3.2.  Targets with Solvent Exposed or Unoccupied Binding Pockets</h4><div class="NLM_p">In addition to being connected with a linker, two individual pharmacophore moieties can also be fused directly. Some target proteins have large binding pockets, and the lead inhibitors do not occupy the entire binding area. The fused pharmacophores can be accommodated in these unoccupied binding pockets without affecting the original binding modes. More commonly, noncritical groups of some inhibitors bind to the solvent-exposed area or extend directly into the solution. The pharmacophore moieties fused at these positions may not affect the binding mode of the original ones.</div><div id="sec2_3_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22"> AChE and SERT</h5><div class="NLM_p">Inhibition of AChE is an effective clinical method for the treatment of AD. However, the clinical utility of commercially available AChE inhibitors is mainly limited by their side effects, such as depression, which can be alleviated by using serotonin transporter (SERT) inhibitors in combination.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Simultaneous inhibition of SERT and AChE can result in greater therapeutic benefits. A series of AChE and SERT dual inhibitors were designed by Hiroshi Kogen et al. using the fusion method (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Design of MTDLs <b>49</b> and <b>50</b> targeting AChE and SERT.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The pharmacophore of rivastigmine (<b>47</b>), a marketed AChE inhibitor, consists of three components: a carbamate moiety that binds to the catalytic triad site, an aromatic ring that binds to the hydrophobic binding site A, and an amino moiety that binds to the ionic site. However, compound <b>47</b> is short of the fourth pharmacophoric element, a large hydrophobic group, which can be accommodated by the hydrophobic binding site B (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>). Focusing on this missing binding site, a SERT inhibitor fluoxetine (<b>48</b>) was selected as the fourth pharmacophoric element.</div><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>A, the methylphenoxy ring of <b>48</b> inserts into a hydrophobic pocket of SERT, and the amine tail points toward the solvent.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> This ethylamine moiety overlapping with that of <b>47</b> is the best fusion site. Compound <b>49</b> obtained by fusing <b>47</b> and <b>48</b> in the shared ethylamine moiety showed dual inhibitory activity against AChE and SERT. In further optimization, conformationally constrained compound <b>50</b> showed extremely high inhibitory activity against AChE and SERT.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a></div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. X-ray crystal structures of (A) SERT with fluoxetine (<b>48</b>), PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3gwv">3gwv</a>. (B) Tyrosine kinase with Imatinib (<b>51</b>), PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP">1IEP</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> HDAC and Tyrosine Kinase</h5><div class="NLM_p">Cotreatment with HDAC inhibitors can increase the potency of imatinib (STI571, <b>51</b>).<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Mahboobi et al. presented a fusion example by combining inhibition of HDACs and tyrosine kinases in one synthetic small molecule (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Imatinib (<b>51</b>) consists of a core pharmacophore (<i>N</i>-(3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)amide) and a hydrophobic tail.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Only the pyridine and pyrimidine rings of <b>51</b> occupy the active area of ATP binding. The terminal piperazinyl ring is located in a partially hydrophobic pocket at the solvent interface and points toward the solvent (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>B).</div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Design of MTDLs <b>54</b> and <b>55</b> targeting HDAC and tyrosine kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Two MTDLs targeting HDAC and tyrosine kinase (<b>54</b> and <b>55</b>) were obtained by combining the core scaffold of <b>51</b> with the Zn binding head groups of HDAC inhibitors <b>52</b> and <b>53</b> (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>). Both <b>54</b> and <b>55</b> displayed significant cytotoxicity with IC<sub>50</sub> values of 3.6 Î¼M and 6.1 Î¼M, which were higher than that of <b>51</b> (mean IC<sub>50</sub> = 27.6 Î¼M). Docking studies showed that ZBG of <b>54</b> binds to the bottom of the HDAC catalytic pocket, while the 4-((pyridin-3-yl)pyrimidin-2-ylamino)phenyl moiety protrudes into the solvent.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> For Abi binding, the hydrogen bonds of the core pharmacophore with Met318, Thr315, and Glu286 are reproduced, while the Zn binding head groups extend into the solvent.</div></div><div id="sec2_3_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> IN and RT</h5><div class="NLM_p">Rational design of dual-target inhibitors of IN and RT is an effective strategy for the treatment of HIV. IN binding requires minimally a DKA type of metal-chelating functionality and a hydrophobic aromatic ring directly connected to the chelator.<a onclick="showRef(event, 'ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref129 ref130">(129,130)</a> However, the binding pocket of RT is largely hydrophobic and is not a suitable environment for the binding of DKA group. As shown in <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>A, a hydrogen bond network is formed among the pyrimidine ring of TNK-651 (<b>7</b>), a water molecule, and Lys101 and Glu138 in the RT inhibitor binding pocket of RT.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> A large (benzyloxy)methyl tail extends to the protein/solvent interface through a narrow channel (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>B). This phenyl group provides a suitable site for linking the DKA moiety to reproduce the IN inhibitory activity.</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. (A, B) X-ray crystal structures of RT with <b>7</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RT2">1RT2</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on RT inhibitor <b>7</b> and IN inhibitor DKAs (<b>8</b>), bifunctional inhibitors were directly fused (<b>56</b>) or combined by a linker (<b>57</b>, <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>).<a onclick="showRef(event, 'ref34 ref131'); return false;" href="javascript:void(0);" class="ref ref34 ref131">(34,131)</a> Both <b>56</b> and <b>57</b> showed higher potency against HIV than <b>7</b> and <b>8</b>. Docking studies showed that the DKA functional groups are located at the protein/solvent interface and may be solvated without hydrogen bonding with RT. Similarly, the methyl sulfonamide group of the RT inhibitor delavirdine is located in an open area that can tolerate structural modifications (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KLM">1KLM</a>).<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Using DKA functional group instead of sulfonamide group can not only affect the RT inhibitory activity, but also obtain the inhibitory activity of IN (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00683/suppl_file/jm1c00683_si_001.pdf" class="ext-link">Figure S6</a>).<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a></div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Design of MTDLs <b>56</b> and <b>57</b> targeting RT and IN.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25">2.3.3.  Unknown Binding Modes</h4><div class="NLM_p">Frequently, the molecular structures of two selected inhibitors are not similar, and the binding modes are also unclear. Then, we can try to simply fuse them or connect them with a linker. These hybrid compounds can retain all or part of the original structural characteristics. When the key pharmacophore group of one lead compound is small, fusing it in the appropriate position of the other compound is usually a feasible method.</div><div class="NLM_p">Potter and co-workers have reported a series of dual inhibitors (<b>60</b>) by fusing the sulfamate ester moiety of steroid sulfatase inhibitor (STSi, <b>58</b>) with the aminotriazole moiety of aromatase inhibitor (YM511, <b>59</b>, <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>).<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> These potent dual inhibitors were found with IC<sub>50</sub>âs of 20â227 nM for STS and 0.82â100 nM for aromatase in JEG-3 cells.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> The most potent compound (<b>60</b>) <i>in vitro</i> (JEG-3 cells) was discovered to show inhibitory effects on aromatase (IC<sub>50</sub> = 0.82 nM) and sulfatase (IC<sub>50</sub> = 39 nM).<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a></div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Design of some MTDLs without binding mode.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Similarly, the Fujita group identified a novel agent (<b>61</b>) which express potent dual platelet activating factor activity <i>in vitro</i> by fusing the PAF antagonist and the thromboxane A2 synthase inhibitor (TxSI).<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> DÃ­az et al. designed a dual-target inhibitor (<b>64</b>) that acts on the Î±2Î´-1 subunit of voltage-gated calcium channels (CavÎ±2Î´-1) and the norepinephrine transporter (NET), two mechanisms in the treatment of pain.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The pyrimidodiazepinone nucleus of compound <b>63</b> was selected for fusing with the more homogeneous NET pharmacophore (<b>62</b>).</div><div class="NLM_p">Bonifazi et al. designed a series of bivalent dual-target analogues (<b>65</b>, <b>66</b>) by fusing and linking the pharmacophore of Î¼-opioid receptor (MOR) agonist with dopamine D3 receptor (D3R) antagonist (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>).<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> BG-P-TAT (<b>67</b>) is a MTDL targeting norepinephrine transporter (NET) and the thyrointegrin Î±vÎ²3 receptors.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Compound <b>67</b> at treatment concentration of 3 mg/kg body weight resulted in maximal (80â100%) suppression of neuroblastoma tumor weight. The <i>N</i>-hydroxy urea pharmacophore of 5-lipoxygenase (5-LOX) inhibitor and the amide moiety in soluble epoxide hydrolase (sEH) inhibitor were combined to form a dual sEH/5-LOX inhibitor <b>68</b>.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Treatment with <b>68</b> strongly diminished unilateral ureter obstruction (UUO) induced tubulointerstitial fibrosis.</div><figure id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0030.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Design of some MTDLs without binding mode.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26">2.3.4.  Cleavable Functional Prodrugs</h4><div class="NLM_p">In addition, two pharmacophore molecules lacking commonality could also be connected with a cleavable linker, which can be hydrolyzed by plasma esterase in the blood. These combi-molecules can be cleaved into two molecules <i>in vivo</i>, acting on their corresponding targets.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Cleavable linkers include linkers that are labile to acid, reducing agents, or enzymes.<a onclick="showRef(event, 'ref142 ref143 ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref142 ref143 ref144 ref145">(142â145)</a> For the design of coupling agents with cleavable linkers, the expected cleavage site and release mode are the main considerations for selecting a suitable linker.</div><div id="sec2_3_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> Avoid Gastrointestinal Ulceration</h5><div class="NLM_p">Nonsteroidal anti-inflammatory drugs (NSAIDs), represented by aspirin and ibuprofen, are widely used for the treatment of pain, inflammation, and fever. Aspirin acts as an anti-inflammatory by inhibiting the activities of cyclooxygenase enzymes (COX1 and COX2) involved in the biosynthesis of prostaglandin (PG).<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> The common side effects of NSAIDs are the gastrointestinal diseases, such as bleeding, ulcers, and perforation.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Therefore, there is an unmet medical need for âSafe NSAIDsâ.</div><div class="NLM_p">As a potential solution to this problem, a new class of nitric oxide (NO)-releasable prodrugs of NSAIDs (NO-NSAIDs) have been developed by adding the NO-releasing moiety to the existing NSAIDs (<a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>).<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> The rationale behind this strategy is to harness the beneficial effects of the NO that is released from these NO-NSAIDs. Many NO-NSAIDs have been designed and synthesized, such as aspirin-linsidomine, NO-Aspirin, NCX 4016, NCX4215, NO-Ibuprofen, and NO-Indomethacin.<a onclick="showRef(event, 'ref149 ref150 ref151 ref152 ref153 ref154'); return false;" href="javascript:void(0);" class="ref ref149 ref150 ref151 ref152 ref153 ref154">(149â154)</a> These mixed prodrugs show anti-inflammatory activity roughly equivalent to that of the parent NSAID, and there is no obvious gastrointestinal toxicity during long-term oral administration.</div><figure id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0031.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Nonsteroidal anti-inflammatory drug (NO-NSAID).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> Improve the Bioavailability</h5><div class="NLM_p">The cleavable linked-pharmacophore strategy could be also employed to enhance the oral bioavailability. For example, ZRX1 (<b>71</b>) was designed as a combination molecule in which capecitabine (<b>69</b>) is connected to the EGFR inhibitor FD105 (<b>70</b>) via a cleavable ethoxyethyl linker (<a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">32</a></a>).<a onclick="showRef(event, 'ref155 ref156 ref157'); return false;" href="javascript:void(0);" class="ref ref155 ref156 ref157">(155â157)</a> In the human body, ZRX1 can be metabolized and converted into 5-FU and FD105 (<b>70</b>), two drugs with a synergistic mechanism. In the presence of CES, ZRX1 showed stronger cytotoxicity than any of <b>69</b>, 5-FU, and <b>70</b>. Another âcombi-moleculeâ, ZRF1, contains a trifluoromethyl benzamide moiety to enhance its Bcr-Abl potency and a methyl-1,2,3 triazene moiety to produce high levels of DNA damage (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00683/suppl_file/jm1c00683_si_001.pdf" class="ext-link">Figure S7</a>).<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> This combi-molecule penetrates the cells and binds to the ATP site of Bcr-Abl or degrades to generate ZRF0 and DNA-damaging methyldiazonium species. In p53 wild-type Mo7p210 cells, the potency of ZRF1 was f1,000-fold higher than the potency of the equivalent combinations of Imatinib and Temodal.</div><figure id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0032.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Design of cleavable MTDL ZRX1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">2.4.  Balance of Multiple Activities</h3><div class="NLM_p">In the subsequent optimization phase of the lead compounds with at least minimal activity for both targets, the biggest challenge is to properly balance the required activities for multiple targets.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> If the difference in activity between two targets is too large, the poorly binding target might be ignored during drug use. The optimal <i>in vitro</i> activity ratio is affected by many factors, such as the number and the density distribution of the receptor at each target in different tissues.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> At present, most multitarget drug researchers are aimed at obtaining compounds with the same order of magnitude <i>in vitro</i> activity.</div><div id="sec2_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> ATI and PPARÎ³</h4><div class="NLM_p">Telmisartan (<b>72</b>) is an angiotensin II type I (ATI) receptor antagonist used to treat essential hypertension. In addition, telmisartan is also a partial agonist of peroxisome proliferator-activated receptor-Î³ (PPARÎ³), a major regulator of adipocyte differentiation.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Telmisartan and its derivatives could provide treatment opportunities for high-risk populations with both diabetes and cardiovascular disease.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> However, the ability of <b>72</b> to activate PPARÎ³ is too weak and needs further optimization. The ligand-binding domain (LBD) of the PPARÎ³ is a Y-shaped cavity composed of three branches (<a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>A, B).<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> The central benzimidazole group forms a hydrogen bond with Tyr473, and the benzimidazole group extends into branch I of the ligand binding pocket and conducts extensive ÏâÏ interactions with Phe363. The benzoic acidic group extend to branch III of the LBD with minimal contact with the Î²-sheet region.</div><figure id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0033.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Crystal structure of Telmisartan (<b>72</b>) bound to the PPAR ligand binding domain, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VN2">3VN2</a>. (A) 2D diagram. (B) 3D stereogram.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Through structureâactivity relationship analysis of <b>72</b>, Matthias Goebel found that 1-(biphenyl-4-ylmethyl)-1<i>H</i>-benzimidazole scaffold is an essential moiety (<a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">34</a></a>).<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> The alkyl chains at C-2, such as ethyl or propyl, are appropriate for dual activities, while the methyl group at C-4 contributes to partial activity.<a onclick="showRef(event, 'ref164 ref165'); return false;" href="javascript:void(0);" class="ref ref164 ref165">(164,165)</a> Substitution at C-5 is not conducive to ATI antagonism and PPARÎ³ activation.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> The hydrophobic substitution at position 6 will help to enhance the activity of PPARÎ³ without affecting the antagonism of ATI.<a onclick="showRef(event, 'ref164 ref167'); return false;" href="javascript:void(0);" class="ref ref164 ref167">(164,167)</a> Yann Lamotte demonstrated that the replacement of the 1-methylbenzimidazole group in position 6 of <b>72</b> by an easily accessible carboxamide revealed a potent PPARÎ³ partial agonist GSK7b.<a onclick="showRef(event, 'ref168 ref169'); return false;" href="javascript:void(0);" class="ref ref168 ref169">(168,169)</a></div><figure id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0034.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Overview of important moieties of <b>72</b> for PPARÎ³ activation and the design of <b>73</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">A series of imidazo[4,5-<i>b</i>]pyridines and imidazo[4,5-<i>c</i>]pyridin-4-one derivatives were designed via introducing conformational restriction to the main scaffold of telmisartan.<a onclick="showRef(event, 'ref170 ref171'); return false;" href="javascript:void(0);" class="ref ref170 ref171">(170,171)</a> The most potent compound <b>73</b> was identified as an effective ATI receptor antagonist with partial PPARÎ³ agonism and oral bioavailability in rat (<a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">34</a></a>).<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> An additional lipophilic benzyl group at position 6 will be beneficial to possess potent dual pharmacology and good ADME properties.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a></div></div><div id="sec2_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> PI3K and PARP</h4><div class="NLM_p">Phosphoinositide 3-kinase (PI3K) and poly(ADP-ribose) polymerase (PARP) are two suitable targets to design MTDLs for the treatment of BRCA-proficient cancer. The phthalazine moiety of PARP inhibitor <b>74</b>, which binds to the catalytic domain, is critical for its binding with PARP (<a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">35</a></a>A).<a onclick="showRef(event, 'ref172 ref173'); return false;" href="javascript:void(0);" class="ref ref172 ref173">(172,173)</a> The cyclopropanecarbonyl group, which extends out toward the solvent, is not necessary for PARP inhibition.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> The morpholine group of BKM120 (<b>75</b>), a potent bioavailable PI3K inhibitor, has not been found to interact with the ATP binding domain and can be replaced by the pharmacophores of PARP inhibitors without interference (<a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">35</a></a>B).<a onclick="showRef(event, 'ref174 ref175 ref176'); return false;" href="javascript:void(0);" class="ref ref174 ref175 ref176">(174â176)</a></div><figure id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0035.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. X-ray crystal structures of (A) PARP-1 with Olaparib (<b>74</b>), PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DS3">5DS3</a>. (B) PI3Ka with BKM120 (<b>75</b>), PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JPS">4JPS</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A series of MTDLs were designed by connecting the blue part of <b>74</b> to the red part of <b>75</b> through a piperazine linker (<a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">36</a></a>).<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> The most effective compound <b>76</b> has good PARP-1 inhibitory activity and moderate PI3KÎ± inhibitory activity. Docking studies showed that compound <b>76</b> occupies the active sites of PARP-1 and PI3KÎ± in a similar manner to <b>74</b> and <b>75</b>, respectively. Due to the imbalance of the inhibitory activities on two targets, further structural optimization was performed to enhance the inhibitory activity on PI3KÎ±.</div><figure id="fig36" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0036.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 36. Design of MTDL <b>76</b> targeting PARP and PI3K.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig36"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Wang et al. combined the piperazine and pyrimidine groups of <b>76</b> into a bicyclic structure through scaffold hopping (<a data-tab="pane-pcw-Figures" href="#fig37" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig37" id="" class=" internalNav">37</a></a>).<a onclick="showRef(event, 'ref174 ref177'); return false;" href="javascript:void(0);" class="ref ref174 ref177">(174,177)</a> The obtained compound <b>77</b> showed balanced and improved PI3KÎ± and PARP-1 inhibitory activities with IC<sub>50</sub> values of 5.62 nM and 6.03 nM, respectively. In another attempt to improve the inhibitory activity of PI3K, the pyrimidine scaffold of <b>76</b> was replaced with 1,3,5-triazine, resulting in compound <b>78</b> with improved but still unbalanced PI3KÎ± and PARP-1 inhibitory activities (<a data-tab="pane-pcw-Figures" href="#fig37" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig37" id="" class=" internalNav">37</a></a>).<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div><figure id="fig37" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0037.jpeg" id="gr37" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 37. Further structural optimization of lead compound <b>76</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig37"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Then, an attempt was made to replace the phthalazine moiety of <b>78</b> with a smaller pharmacophore benzofuran-7-carboxamide.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> The resulting compound <b>79</b> showed effective and balanced PI3KÎ± and PARP-1 inhibitory activities. On the basis of compounds <b>78</b> and <b>79</b>, Wang et al. replaced the ATP domain binding groups with the corresponding pharmacophore of GDC-0980, a potent PI3KÎ± inhibitor in phase-II clinical research.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> The resulting compounds <b>80</b> and <b>81</b> showed excellent and balanced inhibitory activities against PI3KÎ± and PARP-1. <i>In vitro</i> cell experiments showed that these two compounds showed high antiproliferative activity against BRCA-proficient and BRCA-deficient tumor cells.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">3.  Discussion and Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21082" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21082" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Incorporating the second activity into an existing single-active ligand, while maintaining affinity for the original target, is a challenging task. In order to overcome this challenge, we must identify the common characteristics, key pharmacophores, and substitutable sites of two single-target ligands to perform molecular hybridization without interfering with the original binding activity. First, each pharmacophore of the multitargeted agents should retain the ability to interact with its specific site(s) on original targets. The crucial hydrogen bonds need to be maintained, and the structure alterations of hydrophobic groups should be accommodated by the binding domain. Second, the added pharmacophores of second targets should not affect the binding of the original ones. These added groups can (1) be accommodated by the catalytic active sites; (2) bind to the peripheral binding sites; (3) bind to the surface of the protein or be exposed to solution.</div><div class="NLM_p">In the design of MTDLs, the appropriate method should be selected based on the similarity of the framework structures and pharmacophore elements of two lead compounds. For example, there are a number of HDAC MTDLs that were obtained with different approaches. According to the similarity and binding modes of lead compounds, different strategies were adopted for the design of HDAC MTDLs:<table class="listgroup" border="0" width="95%" list-type="label"><tr class="li1"><td valign="top">(a)</td><td colspan="5" valign="top" class="paragraph"><p class="last">Merge the similar functional groups. SAHA (<b>1</b>, HDAC inhibitor) and lovastatin (<b>2</b>, HMGR inhibitor) have similar pharmacophores, including a hydrophilic head, a flexible long chain, and a hydrophobic tail. A dual-targeting inhibitor of HDAC-HMGR (<b>3</b>) was designed by merging these two lead compounds with similar functional groups.</p></td></tr><tr class="li1"><td valign="top">(b)</td><td colspan="5" valign="top" class="paragraph"><p class="last">Merge the similar skeletal groups. NAMPT inhibitor MS0 (<b>20</b>) shares similar structural features and molecular shape with HDAC inhibitor CI-994 (<b>21</b>). A dual-targeting inhibitor of NAMPT and HDAC (<b>22</b>) was obtained by merging the core skeletal groups of <b>20</b> and <b>21</b>.</p></td></tr><tr class="li1"><td valign="top">(c)</td><td colspan="5" valign="top" class="paragraph"><p class="last">Link the critical pharmacophores. There are no similar pharmacophores or scaffold structures between SAHA (<b>1</b>, HDAC inhibitor) and ruxolitinib (<b>36</b>, JAK1/2 inhibitor). The zinc-binding headgroup of <b>1</b> was linked with the critical pharmacophore of <b>36</b>, leading to a dual inhibitor targeted JAK/HDAC (<b>37</b>).</p></td></tr><tr class="li1"><td valign="top">(d)</td><td colspan="5" valign="top" class="paragraph"><p class="last">Fuse the critical pharmacophores. Imatinib (<b>51</b>, Tyrosine kinase inhibitor) holds no similar pharmacophores or scaffold structures with HDAC inhibitor <b>52</b>. Only the leftmost part of <b>51</b> occupies the ATP binding area, and the terminal piperazine ring is located in an open pocket that can accommodate different group substitutions. The pharmacophores of the two inhibitors (<b>51</b> and <b>52</b>) are directly fused in one synthetic small molecule (<b>54</b>).</p></td></tr></table></div><div class="NLM_p">In addition, the choice of design strategy is not rigid. Multiple different strategies might be employed for the combination of two lead compounds. For example, TNK-651 (<b>7</b>, RT inhibitor) shares similar pharmacophore elements with DKAs (<b>8</b>, IN inhibitor). A RT/IN dual inhibitor <b>9</b> was obtained by merged-pharmacophore mode through 3-N hydroxylation of the pyrimidine ring of <b>7</b>, which can play the same function as a chelating triad of <b>8</b>. Two RT/IN dual inhibitors (<b>56</b> and <b>57</b>) can also be obtained by fusing and linking the key pharmacophore of <b>8</b> (a chelating triad) with the solvent-exposed group of <b>7</b>. Although all three compounds have RT/IN inhibitory activities, the merged product (<b>9</b>) has a lower molecular weight and higher cell activity compared with the fused product (<b>56</b>) and the linked product (<b>57</b>). The merged-pharmacophore method makes it easier to obtain multitarget agents with excellent physicochemical property.</div><div class="NLM_p">In order to meet the requirements of multiple targets for different pharmacophores, multitarget drug molecules are usually larger in molecular size than single-target drug molecules. The average molecular weight of general multitarget drug molecules often exceeds 500, which is higher than that of oral drugs in clinical use. As the relative molecular weight and lipophilicity increases, the oral absorption and water solubility of dual-target drugs will decrease. Therefore, the design of multitarget drugs must not only ensure the activity and selectivity for multitargets, but also take into account their physicochemical property, such as PK and PD.</div><div class="NLM_p last">In conclusion, the design of multitarget molecules should accurately grasp the key pharmacophore of the target and look for similar pharmacophores as shared fragments. Under the premise of maintaining the orientation and spatial distance of original pharmacophores, two lead ligands can be merged, fused or linked together. Duplicate or unnecessary fragments are removed to reduce molecular size and relative molecular mass. The flexibility and lipophilicity should not be too large to prevent the influence on the pharmacokinetic problems such as drug absorption and distribution.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00683" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87226" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87226" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00683?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00683</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">X-ray crystal structures; Designs of multitargeted agents (Figures S1âS7) (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00683/suppl_file/jm1c00683_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00683/suppl_file/jm1c00683_si_001.pdf">jm1c00683_si_001.pdf (263.01 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00683" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54287" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54287" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dayong Shi</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Microbial Technology, Shandong University, 72 Binhai Road, Qingdao 266237, Shandong, P. R. China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-5807-5633" title="Orcid link">https://orcid.org/0000-0002-5807-5633</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#087b60616c697167666f487b6c7d266d6c7d266b66"><span class="__cf_email__" data-cfemail="5e2d36373a3f273130391e2d3a2b703b3a2b703d30">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiangqian Li</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Microbial Technology, Shandong University, 72 Binhai Road, Qingdao 266237, Shandong, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaowei Li</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Microbial Technology, Shandong University, 72 Binhai Road, Qingdao 266237, Shandong, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fang Liu</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Microbial Technology, Shandong University, 72 Binhai Road, Qingdao 266237, Shandong, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuo Li</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Microbial Technology, Shandong University, 72 Binhai Road, Qingdao 266237, Shandong, P. R. China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24660" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24660" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Xiangqian Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=BIO-d7e2857-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xiangqian Li</b> is an assistant researcher at Drug Design at State Key Laboratory of Microbial Technology at Shandong University. He has worked on hit identification and hit-to-lead optimization for inhibitors of Bcl-2, Mcl-1, PTP1B, SHP2. His current research interests are the design and synthesis of multitarget drugs for the treatment of diabetes.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Xiaowei Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=BIO-d7e2862-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xiaowei Li</b> is a doctoral student at Drug Design at State Key Laboratory of Microbial Technology at Shandong University. She is mainly engaged in the design and synthesis of compounds that regulate STAT3/NFÎºB.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Fang Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=BIO-d7e2867-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Fang Liu</b> is a master student at Drug Design at State Key Laboratory of Microbial Technology at Shandong University. She is mainly engaged in the design and synthesis of PARP inhibitors.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Shuo Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=BIO-d7e2872-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Shuo Li</b> is a master student at Drug Design at State Key Laboratory of Microbial Technology at Shandong University. She is mainly engaged in the design and synthesis of DPP4 inhibitors.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Dayong Shi</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=BIO-d7e2877-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Dayong Shi</b> a full professor at Drug Design at State Key Laboratory of Microbial Technology at Shandong University. He is engaged in the research of marine drugs and marine biological products.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70308" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70308" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by National Natural Science Foundation of China (No. 81872906), the Fundamental Research Funds of Shandong University (2020GN033), Funded by National Program for Support of Top-notch Young Professionals, Fund of Taishan scholar project, Qingdao Science and Technology Benefit People Demonstration Guide Special Project (20-3-4-20 nsh).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AChE</td><td class="NLM_def"><p class="first last">acetylcholinesterase</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimerâs disease</p></td></tr><tr><td class="NLM_term">AI</td><td class="NLM_def"><p class="first last">aromatase inhibitor</p></td></tr><tr><td class="NLM_term">AT1</td><td class="NLM_def"><p class="first last">angiotensin II</p></td></tr><tr><td class="NLM_term">AÎ²Os</td><td class="NLM_def"><p class="first last">amyloid-Î² oligomers</p></td></tr><tr><td class="NLM_term">BACE 1</td><td class="NLM_def"><p class="first last">beta-site APP cleaving enzyme 1</p></td></tr><tr><td class="NLM_term">BRD4</td><td class="NLM_def"><p class="first last">bromodomain-containing protein 4</p></td></tr><tr><td class="NLM_term">CYP51</td><td class="NLM_def"><p class="first last">Lanosterol 14a-demethylase</p></td></tr><tr><td class="NLM_term">DMLs</td><td class="NLM_def"><p class="first last">designed multiple ligands</p></td></tr><tr><td class="NLM_term">D3R</td><td class="NLM_def"><p class="first last">dopamine D3 receptor</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">half maximal effective concentration</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">Epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term">ETA</td><td class="NLM_def"><p class="first last">endothelin A receptor</p></td></tr><tr><td class="NLM_term">FAK</td><td class="NLM_def"><p class="first last">focal adhesion kinase</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FXR</td><td class="NLM_def"><p class="first last">farnesoid X receptor</p></td></tr><tr><td class="NLM_term">GSK-3Î²</td><td class="NLM_def"><p class="first last">glycogen synthase kinase-3Î²</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">HIV</td><td class="NLM_def"><p class="first last">human immunodeficiency virus</p></td></tr><tr><td class="NLM_term">HMGR</td><td class="NLM_def"><p class="first last">3-hydroxy-3-methylglutaryl coenzyme A reductase</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximum inhibitory concentration</p></td></tr><tr><td class="NLM_term">IN</td><td class="NLM_def"><p class="first last">integrase</p></td></tr><tr><td class="NLM_term">IMPDH</td><td class="NLM_def"><p class="first last">inosine monophosphate dehydrogenase</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>i</sub></td><td class="NLM_def"><p class="first last">inhibition constant</p></td></tr><tr><td class="NLM_term">LOX</td><td class="NLM_def"><p class="first last">lipoxygenase</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">MMP</td><td class="NLM_def"><p class="first last">matrix metalloproteinase</p></td></tr><tr><td class="NLM_term">MOR</td><td class="NLM_def"><p class="first last">Î¼-opioid receptor</p></td></tr><tr><td class="NLM_term">MTDLs</td><td class="NLM_def"><p class="first last">multitarget-directed ligands</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">NAMPT</td><td class="NLM_def"><p class="first last">nicotinamide phosphoribosyltransferase</p></td></tr><tr><td class="NLM_term">NET</td><td class="NLM_def"><p class="first last">norepinephrine transporter</p></td></tr><tr><td class="NLM_term">NO</td><td class="NLM_def"><p class="first last">nitric oxide</p></td></tr><tr><td class="NLM_term">NSAIDs</td><td class="NLM_def"><p class="first last">nonsteroidal anti-inflammatory drugs</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly ADP-ribose polymerase</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">PDE5</td><td class="NLM_def"><p class="first last">Phosphodiesterase 5</p></td></tr><tr><td class="NLM_term">PG</td><td class="NLM_def"><p class="first last">prostaglandin</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PPAR</td><td class="NLM_def"><p class="first last">peroxisome proliferator-activated receptor</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">reverse transcriptase</p></td></tr><tr><td class="NLM_term">sEH</td><td class="NLM_def"><p class="first last">soluble epoxide hydrolase</p></td></tr><tr><td class="NLM_term">SERT</td><td class="NLM_def"><p class="first last">serotonin transporter</p></td></tr><tr><td class="NLM_term">STAT3</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 3</p></td></tr><tr><td class="NLM_term">STS</td><td class="NLM_def"><p class="first last">steroid sulfatase</p></td></tr><tr><td class="NLM_term">TxSI</td><td class="NLM_def"><p class="first last">Thromboxane A2 synthase inhibitor</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr><tr><td class="NLM_term">VDR</td><td class="NLM_def"><p class="first last">vitamin D receptor</p></td></tr><tr><td class="NLM_term">VEGFR-2</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor-2</p></td></tr><tr><td class="NLM_term">ZBG</td><td class="NLM_def"><p class="first last">zinc binding group</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32043" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32043" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 180 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: challenges and opportunities in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7874</span>â <span class="NLM_lpage">7887</span>, <span class="refDoi">Â DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0li8ccruHI6k7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">641</span>â <span class="NLM_lpage">651</span>, <span class="refDoi">Â DOI: 10.1016/S1359-6446(04)03163-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands&doi=10.1016%2FS1359-6446%2804%2903163-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lhLrwvGVW8RJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D641%26epage%3D651%26doi%3D10.1016%2FS1359-6446%2804%2903163-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minarini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Multi-target-directed ligands to combat neurodegenerative diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">347</span>â <span class="NLM_lpage">372</span>, <span class="refDoi">Â DOI: 10.1021/jm7009364</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7009364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=347-372&author=A.+Cavalliauthor=M.+L.+Bolognesiauthor=A.+Minariniauthor=M.+Rosiniauthor=V.+Tumiattiauthor=M.+Recanatiniauthor=C.+Melchiorre&title=Multi-target-directed+ligands+to+combat+neurodegenerative+diseases&doi=10.1021%2Fjm7009364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-Directed Ligands to Combat Neurodegenerative Diseases</span></div><div class="casAuthors">Cavalli, Andrea; Bolognesi, Maria Laura; Minarini, Anna; Rosini, Michela; Tumiatti, Vincenzo; Recanatini, Maurizio; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The authors review the investigations reported in the past decade that illustrate the ability of medicinal chemists to design multi-target-directed ligands (MTDLs) to confront neurodegenerative diseases.  The authors briefly illustrate the multifactorial nature of these diseases before discussing the possible development of MTDLs in light of the known mol. bases of the main neurodegenerative pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYY0I0UHEir7Vg90H21EOLACvtfcHk0lhLrwvGVW8RJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D&md5=c682235151489316d043cf97f78e56f3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm7009364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7009364%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMulti-target-directed%2520ligands%2520to%2520combat%2520neurodegenerative%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D347%26epage%3D372%26doi%3D10.1021%2Fjm7009364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>â <span class="NLM_lpage">6543</span>, <span class="refDoi">Â DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lhLrwvGVW8RJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Besnard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruda, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidah, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constam, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickerton, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Automated design of ligands to polypharmacological profiles</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>492</i></span>,  <span class="NLM_fpage">215</span>â <span class="NLM_lpage">220</span>, <span class="refDoi">Â DOI: 10.1038/nature11691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fnature11691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23235874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=215-220&author=J.+Besnardauthor=G.+F.+Rudaauthor=V.+Setolaauthor=K.+Abecassisauthor=R.+M.+Rodriguizauthor=X.-P.+Huangauthor=S.+Norvalauthor=M.+F.+Sassanoauthor=A.+I.+Shinauthor=L.+A.+Websterauthor=F.+R.+C.+Simeonsauthor=L.+Stojanovskiauthor=A.+Pratauthor=N.+G.+Seidahauthor=D.+B.+Constamauthor=G.+R.+Bickertonauthor=K.+D.+Readauthor=W.+C.+Wetselauthor=I.+H.+Gilbertauthor=B.+L.+Rothauthor=A.+L.+Hopkins&title=Automated+design+of+ligands+to+polypharmacological+profiles&doi=10.1038%2Fnature11691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Automated design of ligands to polypharmacological profiles</span></div><div class="casAuthors">Besnard, Jeremy; Ruda, Gian Filippo; Setola, Vincent; Abecassis, Keren; Rodriguiz, Ramona M.; Huang, Xi-Ping; Norval, Suzanne; Sassano, Maria F.; Shin, Antony I.; Webster, Lauren A.; Simeons, Frederick R. C.; Stojanovski, Laste; Prat, Annik; Seidah, Nabil G.; Constam, Daniel B.; Bickerton, G. Richard; Read, Kevin D.; Wetsel, William C.; Gilbert, Ian H.; Roth, Bryan L.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7428</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy and safety of a drug is detd. by its activity profile across many proteins in the proteome.  However, designing drugs with a specific multi-target profile is both complex and difficult.  Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery.  Here is described a new approach for the automated design of ligands against profiles of multiple drug targets.  The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug donepezil (I) into brain-penetrable ligands with either specific polypharmacol. or exquisite selectivity profiles for G-protein-coupled receptors.  Overall, 800 ligand-target predictions of prospectively designed ligands were tested exptl., of which 75% were confirmed to be correct.  Target engagement in vivo is also demonstrated.  The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNu5bwrBD3tbVg90H21EOLACvtfcHk0lhLrwvGVW8RJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN&md5=ace6cced250cf968d327b482a5bf1798</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature11691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11691%26sid%3Dliteratum%253Aachs%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAbecassis%26aufirst%3DK.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DShin%26aufirst%3DA.%2BI.%26aulast%3DWebster%26aufirst%3DL.%2BA.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DConstam%26aufirst%3DD.%2BB.%26aulast%3DBickerton%26aufirst%3DG.%2BR.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DAutomated%2520design%2520of%2520ligands%2520to%2520polypharmacological%2520profiles%26jtitle%3DNature%26date%3D2012%26volume%3D492%26spage%3D215%26epage%3D220%26doi%3D10.1038%2Fnature11691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of ligand efficient dual inhibitors of janus kinase (JAK) and histone deacetylase (HDAC) based on ruxolitinib and vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>â <span class="NLM_lpage">8357</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.+D.+Duong-Thiauthor=J.+X.+T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yen&title=Design+and+synthesis+of+ligand+efficient+dual+inhibitors+of+janus+kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+based+on+ruxolitinib+and+vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0lj5_8r03d3MBw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BX.%2BT.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520ligand%2520efficient%2520dual%2520inhibitors%2520of%2520janus%2520kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520based%2520on%2520ruxolitinib%2520and%2520vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, S.</span></span> <span> </span><span class="NLM_article-title">From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">422</span>â <span class="NLM_lpage">432</span>, <span class="refDoi">Â DOI: 10.2174/092986708783503212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.2174%2F092986708783503212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=18288997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVyisL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=422-432&author=A.+Petrelliauthor=S.+Giordano&title=From+single-+to+multi-target+drugs+in+cancer+therapy%3A+when+aspecificity+becomes+an+advantage&doi=10.2174%2F092986708783503212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">From single- to multi-target drugs in cancer therapy: when a specificity becomes an advantage</span></div><div class="casAuthors">Petrelli, A.; Giordano, S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">422-432</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeted therapies by means of compds. that inhibit a specific target mol. represent a new perspective in the treatment of cancer.  In contrast to conventional chemotherapy which acts on all dividing cells generating toxic effects and damage of normal tissues, targeted drugs allow to hit, in a more specific manner, subpopulations of cells directly involved in tumor progression.  Mols. controlling cell proliferation and death, such as Tyrosine Kinase Receptors (RTKs) for growth factors, are among the best targets for this type of therapeutic approach.  Two classes of compds. targeting RTKs are currently used in clin. practice: monoclonal antibodies and tyrosine kinase inhibitors.  The era of targeted therapy began with the approval of Trastuzumab, a monoclonal antibody against HER2, for treatment of metastatic breast cancer, and Imatinib, a small tyrosine kinase inhibitor targeting BCR-Abl, in Chronic Myeloid Leukemia.  Despite the initial enthusiasm for the efficacy of these treatments, clinicians had to face soon the problem of relapse, as almost invariably cancer patients developed drug resistance, often due to the activation of alternative RTKs pathways.  In this view, the rationale at the basis of targeting drugs is radically shifting.  In the past, the main effort was aimed at developing highly specific inhibitors acting on single RTKs.  Now, there is a general agreement that mols. interfering simultaneously with multiple RTKs might be more effective than single target agents.  With the recent approval by FDA of Sorafenib and Sunitinib - targeting VEGFR, PDGFR, FLT-3 and c-Kit - a different scenario has been emerging, where a new generation of anti-cancer drugs, able to inhibit more than one pathway, would probably play a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8AXb2ROTStLVg90H21EOLACvtfcHk0lj5_8r03d3MBw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVyisL0%253D&md5=d90df6a670921b6fad58caa46db01fa5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F092986708783503212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708783503212%26sid%3Dliteratum%253Aachs%26aulast%3DPetrelli%26aufirst%3DA.%26aulast%3DGiordano%26aufirst%3DS.%26atitle%3DFrom%2520single-%2520to%2520multi-target%2520drugs%2520in%2520cancer%2520therapy%253A%2520when%2520aspecificity%2520becomes%2520an%2520advantage%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D422%26epage%3D432%26doi%3D10.2174%2F092986708783503212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Rahman, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouad, M.</span></span> <span> </span><span class="NLM_article-title">Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1275</span>â <span class="NLM_lpage">1290</span>, <span class="refDoi">Â DOI: 10.2217/fon.14.302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.2217%2Ffon.14.302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=25832882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslaqsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=1275-1290&author=O.+Abdel-Rahmanauthor=M.+Fouad&title=Temozolomide-based+combination+for+advanced+neuroendocrine+neoplasms%3A+a+systematic+review+of+the+literature&doi=10.2217%2Ffon.14.302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature</span></div><div class="casAuthors">Abdel-Rahman, Omar; Fouad, Mona</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1275-1290</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Background: In this systematic review, we explored the value of using temozolomide (TMZ)-based combinations for advanced neuroendocrine neoplasms (NENs).  Methods: Database search were conducted using the terms 'NENs' and 'TMZ' and 'systemic therapy.  ' Outcomes of interest included progression-free survival and overall survival, toxicities and tumor response.  Results: In total, 16 trials including 348 patients were included.  Median progression-free survival ranged from 6 to 31 mo.  The disease control rate ranged from 65 to 100%.  Frequently reported grade 3/4 toxicities were leukopenia, lymphopenia and elevated transaminases.  Conclusion: The published clin. data suggest that TMZ-based combination with some anticancer agents (esp. capecitabine) could be an effective treatment option for advanced low-intermediate grade NENs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUw4muUhdI07Vg90H21EOLACvtfcHk0lj2RlC_bqN7HQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslaqsbs%253D&md5=671f80ff6f8e109a62d8b6022d171ee9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2217%2Ffon.14.302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.14.302%26sid%3Dliteratum%253Aachs%26aulast%3DAbdel-Rahman%26aufirst%3DO.%26aulast%3DFouad%26aufirst%3DM.%26atitle%3DTemozolomide-based%2520combination%2520for%2520advanced%2520neuroendocrine%2520neoplasms%253A%2520a%2520systematic%2520review%2520of%2520the%2520literature%26jtitle%3DFuture%2520Oncol.%26date%3D2015%26volume%3D11%26spage%3D1275%26epage%3D1290%26doi%3D10.2217%2Ffon.14.302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, R.</span></span> <span> </span><span class="NLM_article-title">The potential of combi-molecules with DNA-damaging function as anticancer agents</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">403</span>â <span class="NLM_lpage">435</span>, <span class="refDoi">Â DOI: 10.4155/fmc-2016-0229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.4155%2Ffmc-2016-0229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=28263086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Smu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=403-435&author=G.+Sunauthor=T.+Fanauthor=L.+Zhaoauthor=Y.+Zhouauthor=R.+Zhong&title=The+potential+of+combi-molecules+with+DNA-damaging+function+as+anticancer+agents&doi=10.4155%2Ffmc-2016-0229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The potential of combi-molecules with DNA-damaging function as anticancer agents</span></div><div class="casAuthors">Sun, Guohui; Fan, Tengjiao; Zhao, Lijiao; Zhou, Yue; Zhong, Rugang</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">403-435</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">DNA-damaging agents, such as methylating agents, chloroethylating agents and platinum-based agents, have been extensively used as anticancer drugs.  However, the side effects, high toxicity, lack of selectivity and resistance severely limit their clin. applications.  In recent years, a strategy combining a DNA-damaging agent with a bioactive mol. (e.g., enzyme inhibitors) or carrier (e.g., steroid hormone and DNA intercalators) to produce a new 'combi-mol.' with improved efficacy or selectivity has been attempted to overcome these drawbacks.  The combi-mol. simultaneously acts on two targets and is expected to possess better potency than the parent compds.  Many studies have shown DNA-damaging combi-mols. exhibiting excellent anticancer activity in vitro and in vivo.  This review focuses on the development of combi-mols., which possess increased DNA-damaging potency, anticancer efficacy and tumor selectivity and reduced side reactions than the parent compds.  The future opportunities and challenges in the discovery of combi-mols. were also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9Yal02uIMu7Vg90H21EOLACvtfcHk0lj2RlC_bqN7HQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Smu7g%253D&md5=a1017aca1482b8bd1052cfd376009650</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2016-0229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2016-0229%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DG.%26aulast%3DFan%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhong%26aufirst%3DR.%26atitle%3DThe%2520potential%2520of%2520combi-molecules%2520with%2520DNA-damaging%2520function%2520as%2520anticancer%2520agents%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2017%26volume%3D9%26spage%3D403%26epage%3D435%26doi%3D10.4155%2Ffmc-2016-0229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">GarcÃ­a, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virgili, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alegret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farran, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FernÃ¡ndez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BurgueÃ±o, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal-Torres, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FernÃ¡ndez de Henestrosa, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-SalamÃ¡n, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of EST73502, a dual Î¼-opioid receptor agonist and Ï 1 receptor antagonist clinical candidate for the treatment of pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">15508</span>â <span class="NLM_lpage">15526</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c01127</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01127" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVykurnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=15508-15526&author=M.+Garc%C3%ADaauthor=M.+Virgiliauthor=M.+Alonsoauthor=C.+Alegretauthor=J.+Farranauthor=B.+Fern%C3%A1ndezauthor=M.+Bordasauthor=R.+Pascualauthor=J.+Burgue%C3%B1oauthor=A.+Vidal-Torresauthor=A.+R.+Fern%C3%A1ndez+de+Henestrosaauthor=E.+Ayetauthor=M.+Merlosauthor=J.+M.+Velaauthor=C.+R.+Plata-Salam%C3%A1nauthor=C.+Almansa&title=Discovery+of+EST73502%2C+a+dual+%CE%BC-opioid+receptor+agonist+and+%CF%83+1+receptor+antagonist+clinical+candidate+for+the+treatment+of+pain&doi=10.1021%2Facs.jmedchem.0c01127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of EST73502, a Dual Î¼-Opioid Receptor Agonist and Ï1 Receptor Antagonist Clinical Candidate for the Treatment of Pain</span></div><div class="casAuthors">Garcia, Monica; Virgili, Marina; Alonso, Monica; Alegret, Carles; Farran, Joan; Fernandez, Begona; Bordas, Magda; Pascual, Rosalia; Burgueno, Javier; Vidal-Torres, Alba; Fernandez de Henestrosa, Antonio R.; Ayet, Eva; Merlos, Manuel; Vela, Jose Miguel; Plata-Salaman, Carlos R.; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">15508-15526</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and pharmacol. activity of a new series of 4-alkyl-1-oxa-4,9-diazaspiro[5.5]undecane derivs. as potent dual ligands for the Ï1 receptor (Ï1R) and the Î¼-opioid receptor (MOR) are reported.  A lead optimization program over the initial 4-aryl analogs provided 4-alkyl derivs. with the desired functionality and good selectivity and ADME profiles.  Compd. I (EST73502) showed MOR agonism and Ï1R antagonism and a potent analgesic activity, comparable to the MOR agonist oxycodone in animal models of acute and chronic pain after single and repeated administration.  Contrary to oxycodone, I produces analgesic activity with reduced opioid-induced relevant adverse events, like intestinal transit inhibition and naloxone-pptd. behavioral signs of opiate withdrawal.  These results provide evidence that dual MOR agonism and Ï1R antagonism may be a useful strategy for obtaining potent and safer analgesics and were the basis for the selection of I as a clin. candidate for the treatment of pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaRTQFyc0JxrVg90H21EOLACvtfcHk0lj2RlC_bqN7HQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVykurnM&md5=099d21c6d818c53a8e195be0ff5d7b77</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01127%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa%26aufirst%3DM.%26aulast%3DVirgili%26aufirst%3DM.%26aulast%3DAlonso%26aufirst%3DM.%26aulast%3DAlegret%26aufirst%3DC.%26aulast%3DFarran%26aufirst%3DJ.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DB.%26aulast%3DBordas%26aufirst%3DM.%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DBurgue%25C3%25B1o%26aufirst%3DJ.%26aulast%3DVidal-Torres%26aufirst%3DA.%26aulast%3DFern%25C3%25A1ndez%2Bde%2BHenestrosa%26aufirst%3DA.%2BR.%26aulast%3DAyet%26aufirst%3DE.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DPlata-Salam%25C3%25A1n%26aufirst%3DC.%2BR.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520EST73502%252C%2520a%2520dual%2520%25CE%25BC-opioid%2520receptor%2520agonist%2520and%2520%25CF%2583%25201%2520receptor%2520antagonist%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D15508%26epage%3D15526%26doi%3D10.1021%2Facs.jmedchem.0c01127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D. F.</span></span> <span> </span><span class="NLM_article-title">Designing multi-targeted agents: An emerging anticancer drug discovery paradigm</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">195</span>â <span class="NLM_lpage">211</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2017.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2017.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=28494256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2rtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2017&pages=195-211&author=R.+G.+Fuauthor=Y.+Sunauthor=W.+B.+Shengauthor=D.+F.+Liao&title=Designing+multi-targeted+agents%3A+An+emerging+anticancer+drug+discovery+paradigm&doi=10.1016%2Fj.ejmech.2017.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multi-targeted agents: An emerging anticancer drug discovery paradigm</span></div><div class="casAuthors">Fu, Rong-geng; Sun, Yuan; Sheng, Wen-bing; Liao, Duan-fang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">195-211</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is to design ligands with max. selectivity to act on individual drug targets.  With the target-based approach, many new chem. entities have been discovered, developed, and further approved as drugs.  However, there are a large no. of complex diseases such as cancer that cannot be effectively treated or cured only with one medicine to modulate the biol. function of a single target.  As simultaneous intervention of two (or multiple) cancer progression relevant targets has shown improved therapeutic efficacy, the innovation of multi-targeted drugs has become a promising and prevailing research topic and numerous multi-targeted anticancer agents are currently at various developmental stages.  However, most multi-pharmacophore scaffolds are usually discovered by serendipity or screening, while rational design by combining existing pharmacophore scaffolds remains an enormous challenge.  In this review, four types of multi-pharmacophore modes are discussed, and the examples from literature will be used to introduce attractive lead compds. with the capability of simultaneously interfering with different enzyme or signaling pathway of cancer progression, which will reveal the trends and insights to help the design of the next generation multi-targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGjXR-zscrArVg90H21EOLACvtfcHk0li5dxhV2VhZnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2rtL8%253D&md5=511561bd2cd186d5dafa905b7257bf32</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DR.%2BG.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DW.%2BB.%26aulast%3DLiao%26aufirst%3DD.%2BF.%26atitle%3DDesigning%2520multi-targeted%2520agents%253A%2520An%2520emerging%2520anticancer%2520drug%2520discovery%2520paradigm%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D136%26spage%3D195%26epage%3D211%26doi%3D10.1016%2Fj.ejmech.2017.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mondello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derenzini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asgari, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brea, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheinberg, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14017</span>â <span class="NLM_lpage">14028</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.14876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.18632%2Foncotarget.14876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=28147336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A280%3ADC%252BC1c3hslamtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14017-14028&author=P.+Mondelloauthor=E.+Derenziniauthor=Z.+Asgariauthor=J.+Philipauthor=E.+J.+Breaauthor=V.+Seshanauthor=R.+C.+Hendricksonauthor=E.+de+Stanchinaauthor=D.+A.+Scheinbergauthor=A.+Younes&title=Dual+inhibition+of+histone+deacetylases+and+phosphoinositide+3-kinase+enhances+therapeutic+activity+against+B+cell+lymphoma&doi=10.18632%2Foncotarget.14876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma</span></div><div class="casAuthors">Mondello Patrizia; Derenzini Enrico; Asgari Zahra; Younes Anas; Philip John; Hendrickson Ronald C; Brea Elliott J; Scheinberg David A; Seshan Venkatraman; de Stanchina Elisa</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">14017-14028</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K) and Myc are known to cooperate in promoting the survival and growth of a variety of B-cell lymphomas.  While currently there are no small molecule inhibitors of Myc protein, histone deacetylase (HDAC) inhibitors have been shown to reduce levels of Myc protein by suppressing its transcription.  We assessed the efficacy of CUDC-907, a new rationally designed dual inhibitor of PI3K and HDACs, in a panel of lymphoma cell lines.  CUDC-907 treatment resulted in a dose- and time-dependent growth inhibition and cell death of DLBCL cell lines, irrespective of the cell of origin.  CUDC-907 treatment down-regulated the phosphorylation of PI3K downstream targets, including AKT, PRAS40, S6, and 4EBP1, increased histone 3 acetylation, and decreased Myc protein levels.  SILAC-based quantitative mass spectrometry demonstrated that CUDC-907 treatment decreased the protein levels of several components of the B cell receptor (BCR) and Toll like receptor (TLR) pathways, including BTK, SYK, and MyD88 proteins.  These cellular changes were associated with an inhibition of NF-kB activation.  CUDC-907 demonstrated in vivo efficacy with no significant toxicity in a human DLBCL xenograft mouse model.  Collectively, these data provide a mechanistic rationale for evaluating CUDC-907 for the treatment of patients with Myc and PI3K-dependent lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHhpmYpq2kzUwlCcfExbvbfW6udTcc2eZPPDm9z-LJWrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3hslamtg%253D%253D&md5=57e637ca88cd4a23c0c069a8564404d1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14876%26sid%3Dliteratum%253Aachs%26aulast%3DMondello%26aufirst%3DP.%26aulast%3DDerenzini%26aufirst%3DE.%26aulast%3DAsgari%26aufirst%3DZ.%26aulast%3DPhilip%26aufirst%3DJ.%26aulast%3DBrea%26aufirst%3DE.%2BJ.%26aulast%3DSeshan%26aufirst%3DV.%26aulast%3DHendrickson%26aufirst%3DR.%2BC.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DScheinberg%26aufirst%3DD.%2BA.%26aulast%3DYounes%26aufirst%3DA.%26atitle%3DDual%2520inhibition%2520of%2520histone%2520deacetylases%2520and%2520phosphoinositide%25203-kinase%2520enhances%2520therapeutic%2520activity%2520against%2520B%2520cell%2520lymphoma%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D14017%26epage%3D14028%26doi%3D10.18632%2Foncotarget.14876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibli, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kircher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Olmos, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scriba, G. K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krait, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer-Posovszky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span> <span> </span><span class="NLM_article-title">Combined cardioprotective and adipocyte browning effects promoted by the eutomer of dual seh/pparÎ³ modulator</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">2815</span>â <span class="NLM_lpage">2828</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c02063</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c02063" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXks1Oqu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=2815-2828&author=M.+Hartmannauthor=S.+I.+Bibliauthor=D.+Tewsauthor=X.+Niauthor=T.+Kircherauthor=J.+S.+Kramerauthor=W.+Kiluauthor=J.+Heeringauthor=V.+Hernandez-Olmosauthor=L.+Weizelauthor=G.+K.+E.+Scribaauthor=S.+Kraitauthor=S.+Knappauthor=A.+Chaikuadauthor=D.+Merkauthor=I.+Flemingauthor=P.+Fischer-Posovszkyauthor=E.+Proschak&title=Combined+cardioprotective+and+adipocyte+browning+effects+promoted+by+the+eutomer+of+dual+seh%2Fppar%CE%B3+modulator&doi=10.1021%2Facs.jmedchem.0c02063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Cardioprotective and Adipocyte Browning Effects Promoted by the Eutomer of Dual sEH/PPARÎ³ Modulator</span></div><div class="casAuthors">Hartmann, Markus; Bibli, Sofia-Iris; Tews, Daniel; Ni, Xiaomin; Kircher, Theresa; Kramer, Jan S.; Kilu, Whitney; Heering, Jan; Hernandez-Olmos, Victor; Weizel, Lilia; Scriba, Gerhard K. E.; Krait, Sulaiman; Knapp, Stefan; Chaikuad, Apirat; Merk, Daniel; Fleming, Ingrid; Fischer-Posovszky, Pamela; Proschak, Ewgenij</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2815-2828</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The metabolic syndrome (MetS) is a constellation of cardiovascular and metabolic symptoms involving insulin resistance, steatohepatitis, obesity, hypertension, and heart disease, and patients suffering from MetS often require polypharmaceutical treatment.  PPARÎ³ agonists are highly effective oral antidiabetics with great potential in MetS, which promote adipocyte browning and insulin sensitization.  However, the application of PPARÎ³ agonists in clinics is restricted by potential cardiovascular adverse events.  We have previously demonstrated that the racemic dual sEH/PPARÎ³ modulator RB394 (3) simultaneously improves all risk factors of MetS in vivo.  In this study, we identify and characterize the eutomer of 3.  We provide structural rationale for mol. recognition of the eutomer.  Furthermore, we could show that the dual sEH/PPARÎ³ modulator is able to promote adipocyte browning and simultaneously exhibits cardioprotective activity which underlines its exciting potential in treatment of MetS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqETySvJySH6rVg90H21EOLACvtfcHk0li5dxhV2VhZnA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXks1Oqu7w%253D&md5=bb534a62931621e09a9a610290059ec8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c02063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c02063%26sid%3Dliteratum%253Aachs%26aulast%3DHartmann%26aufirst%3DM.%26aulast%3DBibli%26aufirst%3DS.%2BI.%26aulast%3DTews%26aufirst%3DD.%26aulast%3DNi%26aufirst%3DX.%26aulast%3DKircher%26aufirst%3DT.%26aulast%3DKramer%26aufirst%3DJ.%2BS.%26aulast%3DKilu%26aufirst%3DW.%26aulast%3DHeering%26aufirst%3DJ.%26aulast%3DHernandez-Olmos%26aufirst%3DV.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DScriba%26aufirst%3DG.%2BK.%2BE.%26aulast%3DKrait%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DMerk%26aufirst%3DD.%26aulast%3DFleming%26aufirst%3DI.%26aulast%3DFischer-Posovszky%26aufirst%3DP.%26aulast%3DProschak%26aufirst%3DE.%26atitle%3DCombined%2520cardioprotective%2520and%2520adipocyte%2520browning%2520effects%2520promoted%2520by%2520the%2520eutomer%2520of%2520dual%2520seh%252Fppar%25CE%25B3%2520modulator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D2815%26epage%3D2828%26doi%3D10.1021%2Facs.jmedchem.0c02063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ko, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffey, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandvold, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soellner, M. B.</span></span> <span> </span><span class="NLM_article-title">Development of a chimeric c-Src kinase and HDAC inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">779</span>â <span class="NLM_lpage">783</span>, <span class="refDoi">Â DOI: 10.1021/ml400175d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400175d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKit7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=779-783&author=K.+S.+Koauthor=M.+E.+Steffeyauthor=K.+R.+Brandvoldauthor=M.+B.+Soellner&title=Development+of+a+chimeric+c-Src+kinase+and+HDAC+inhibitor&doi=10.1021%2Fml400175d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Chimeric c-Src Kinase and HDAC Inhibitor</span></div><div class="casAuthors">Ko, Kristin S.; Steffey, Michael E.; Brandvold, Kristoffer R.; Soellner, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">779-783</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of synergism obsd. between a selective c-Src kinase inhibitor with an HDAC inhibitor, the development of the first chimeric c-Src kinase and HDAC inhibitor is described.  The optimized chimeric inhibitor is shown to be a potent c-Src and HDAC inhibitor.  Chimeric inhibitor (I) is further shown to be highly efficacious in cancer cell lines and significantly more efficacious than a dual-targeting strategy using discrete c-Src and HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzi2suGn-7ErVg90H21EOLACvtfcHk0lg4O8-fR1GfVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKit7rL&md5=5f34ce3b1f65a8ac1a4341f563a5e1d9</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fml400175d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400175d%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DK.%2BS.%26aulast%3DSteffey%26aufirst%3DM.%2BE.%26aulast%3DBrandvold%26aufirst%3DK.%2BR.%26aulast%3DSoellner%26aufirst%3DM.%2BB.%26atitle%3DDevelopment%2520of%2520a%2520chimeric%2520c-Src%2520kinase%2520and%2520HDAC%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D779%26epage%3D783%26doi%3D10.1021%2Fml400175d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choong-Kun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myung Eun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won Suk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong Min, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyu Hyun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tae Soo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joong
Bae, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyun Cheol, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. S.</span></span> <span> </span><span class="NLM_article-title">Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer</span>. <i>Am. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">72</span>â <span class="NLM_lpage">86</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=25628921" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=72-86&author=L.+Choong-Kunauthor=L.+Myung+Eunauthor=L.+Won+Sukauthor=K.+Jeong+Minauthor=P.+Kyu+Hyunauthor=K.+Tae+Sooauthor=L.+K.+Youngauthor=A.+Joong%0ABaeauthor=C.+Hyun+Cheolauthor=R.+S.+Young&title=Dovitinib+%28TKI258%29%2C+a+multi-target+angiokinase+inhibitor%2C+is+effective+regardless+of+KRAS+or+BRAF+mutation+status+in+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChoong-Kun%26aufirst%3DL.%26aulast%3DMyung%2BEun%26aufirst%3DL.%26aulast%3DWon%2BSuk%26aufirst%3DL.%26aulast%3DJeong%2BMin%26aufirst%3DK.%26aulast%3DKyu%2BHyun%26aufirst%3DP.%26aulast%3DTae%2BSoo%26aufirst%3DK.%26aulast%3DYoung%26aufirst%3DL.%2BK.%26aulast%3DJoong%2BBae%26aufirst%3DA.%26aulast%3DHyun%2BCheol%26aufirst%3DC.%26aulast%3DYoung%26aufirst%3DR.%2BS.%26atitle%3DDovitinib%2520%2528TKI258%2529%252C%2520a%2520multi-target%2520angiokinase%2520inhibitor%252C%2520is%2520effective%2520regardless%2520of%2520KRAS%2520or%2520BRAF%2520mutation%2520status%2520in%2520colorectal%2520cancer%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2015%26volume%3D5%26spage%3D72%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. T.</span></span> <span> </span><span class="NLM_article-title">Multi-target drugs: the trend of drug research and development</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e40262</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0040262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1371%2Fjournal.pone.0040262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=22768266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVaisr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=J.+J.+Luauthor=W.+Panauthor=Y.+J.+Huauthor=Y.+T.+Wang&title=Multi-target+drugs%3A+the+trend+of+drug+research+and+development&doi=10.1371%2Fjournal.pone.0040262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target drugs: the trend of drug research and development</span></div><div class="casAuthors">Lu, Jin-Jian; Pan, Wei; Hu, Yuan-Jia; Wang, Yi-Tao</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e40262</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Summarizing the status of drugs in the market and examg. the trend of drug research and development is important in drug discovery.  In this study, we compared the drug targets and the market sales of the new mol. entities approved by the U.S. Food and Drug Administration from Jan. 2000 to Dec. 2009.  Two networks, namely, the target-target and drug-drug networks, have been set up using the network anal. tools.  The multi-target drugs have much more potential, as shown by the network visualization and the market trends.  We discussed the possible reasons and proposed the rational strategies for drug research and development in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrapZATY1GnWbVg90H21EOLACvtfcHk0lg4O8-fR1GfVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVaisr8%253D&md5=79489aaf7a36ee9c30287621a7244a6a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0040262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0040262%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.%2BJ.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DY.%2BJ.%26aulast%3DWang%26aufirst%3DY.%2BT.%26atitle%3DMulti-target%2520drugs%253A%2520the%2520trend%2520of%2520drug%2520research%2520and%2520development%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0040262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorja, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laster, K. V.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel dual-target inhibitor against RSK1 and MSK2 to suppress growth of human colon cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">6733</span>â <span class="NLM_lpage">6746</span>, <span class="refDoi">Â DOI: 10.1038/s41388-020-01467-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fs41388-020-01467-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=32963350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFOqu7nF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2020&pages=6733-6746&author=G.+Jinauthor=M.+Yanauthor=K.+Liuauthor=K.+Yaoauthor=H.+Chenauthor=C.+Zhangauthor=Y.+Yiauthor=K.+Reddyauthor=D.+R.+Gorjaauthor=K.+V.+Laster&title=Discovery+of+a+novel+dual-target+inhibitor+against+RSK1+and+MSK2+to+suppress+growth+of+human+colon+cancer&doi=10.1038%2Fs41388-020-01467-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel dual-target inhibitor against RSK1 and MSK2 to suppress growth of human colon cancer</span></div><div class="casAuthors">Jin, Guoguo; Yan, Mingyang; Liu, Kangdong; Yao, Ke; Chen, Hanyong; Zhang, Chengjuan; Yi, Yang; Reddy, Kanamata; Gorja, Dhilli Rao; Laster, Kyle Vaughn; Guo, Zhiping; Dong, Zigang</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">6733-6746</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Colon cancer is the most aggressive tumor in both men and women globally.  As many the chemotherapeutic regimens have adverse side effects and contribute to the resistance and recurrence, therefore, finding novel therapeutic targets and developing effective agents are urgent.  Based on the TCGA and GTEx database anal., RSK1 and MSK2 were found abnormal expressed in colon cancer.  RSK1 and MSK2 were overexpressed in colon cancer tissues confirmed by western blot and IHC.  After knocking down RSK1 or MSK2, cell proliferation and anchorage-independent cell growth were markedly inhibited.  Using a computer docking model, we identified a novel dual-target inhibitor, APIO-EE-07, that could block both RSK1 and MSK2 kinase activity in a dose-dependent manner.  APIO-EE-07 inhibited cell growth and induced apoptosis and also increased expression of Bax as well as cleaved caspase-3 and -PARP in colon cancer cells by downregulating RSK1 and MSK2 downstream targets, including CREB and ATF1.  Furthermore, APIO-EE-07 decreased tumor vol. and wt. in human patient-derived xenografts tumors implanted in SCID mice.  In summary, our results demonstrate that RSK1 and MSK2 are the potential targets for the treatment of colon cancer.  APIO-EE-07, a novel dual-target inhibitor of RSK1 and MSK2, can suppress the growth of colon cancer by attenuating RSK1 and MSK2 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8s_EQXi7hv7Vg90H21EOLACvtfcHk0lg4O8-fR1GfVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFOqu7nF&md5=806739debaeb3e24aa15630344a265cf</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fs41388-020-01467-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-020-01467-w%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DG.%26aulast%3DYan%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DYi%26aufirst%3DY.%26aulast%3DReddy%26aufirst%3DK.%26aulast%3DGorja%26aufirst%3DD.%2BR.%26aulast%3DLaster%26aufirst%3DK.%2BV.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520dual-target%2520inhibitor%2520against%2520RSK1%2520and%2520MSK2%2520to%2520suppress%2520growth%2520of%2520human%2520colon%2520cancer%26jtitle%3DOncogene%26date%3D2020%26volume%3D39%26spage%3D6733%26epage%3D6746%26doi%3D10.1038%2Fs41388-020-01467-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span> <span> </span><span class="NLM_article-title">Recent advances of dual FGFR inhibitors as a novel therapy for cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>214</i></span>,  <span class="NLM_fpage">113205</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2021.113205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2021.113205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=33556787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXjvVemtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2021&pages=113205&author=Q.+Liangauthor=J.+Wangauthor=L.+Zhaoauthor=J.+Houauthor=Y.+Huauthor=J.+Shi&title=Recent+advances+of+dual+FGFR+inhibitors+as+a+novel+therapy+for+cancer&doi=10.1016%2Fj.ejmech.2021.113205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances of dual FGFR inhibitors as a novel therapy for cancer</span></div><div class="casAuthors">Liang, Qi; Wang, Juelan; Zhao, Liyun; Hou, Jun; Hu, Yonghe; Shi, Jianyou</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113205</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Fibroblast growth factor receptor (FGFR) includes four highly conserved transmembrane receptor tyrosine kinases (FGFR1-4).  FGF and FGFR regulate many biol. processes, such as angiogenesis, wound healing and tissue regeneration.  The abnormal expression of FGFR is related to the tumorigenesis, tumor progression and drug resistance of anti-tumor treatments in many types of tumors.  Nowadays there are many anti-cancer drugs targeting FGFR.  However, traditional single-target anti-tumor drugs are easy to acquire drug resistance.  The therapeutic effect can be enhanced by simultaneously inhibiting FGFR and another target (such as VEGFR, EGFR, PI3K, CSF-1R, etc.).  We know drug combination can bring problems such as drug interactions.  Therefore, the development of FGFR dual target inhibitors is an important direction.  In this paper, we reviewed the research on dual FGFR inhibitors in recent years and made brief comments on them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotL9RCNkt2O7Vg90H21EOLACvtfcHk0lhv1Z-BlzYB3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXjvVemtbc%253D&md5=1666f197816386044b0a9def9933d2da</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113205%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DJ.%26atitle%3DRecent%2520advances%2520of%2520dual%2520FGFR%2520inhibitors%2520as%2520a%2520novel%2520therapy%2520for%2520cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D214%26spage%3D113205%26doi%3D10.1016%2Fj.ejmech.2021.113205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minarini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Tacrine derivatives and Alzheimerâs disease</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1825</span>â <span class="NLM_lpage">1838</span>, <span class="refDoi">Â DOI: 10.2174/092986710791111206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.2174%2F092986710791111206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=20345341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmvFCnu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=1825-1838&author=V.+Tumiattiauthor=A.+Minariniauthor=M.+L.+Bolognesiauthor=A.+Milelliauthor=M.+Rosiniauthor=C.+Melchiorre&title=Tacrine+derivatives+and+Alzheimer%E2%80%99s+disease&doi=10.2174%2F092986710791111206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Tacrine derivatives and Alzheimer's disease</span></div><div class="casAuthors">Tumiatti, V.; Minarini, A.; Bolognesi, M. L.; Milelli, A.; Rosini, M.; Melchiorre, C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1825-1838</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  To date, the pharmacotherapy of Alzheimer's disease (AD) has relied on acetylcholinesterase (AChE) inhibitors (AChEIs) and, more recently, an N-methyl-D-aspartate receptor (NMDAR) antagonist.  AD is a multifactorial syndrome with several target proteins contributing to its etiol.  "Multi-target-directed ligands" (MTDLs) have great potential for treating complex diseases such as AD because they can interact with multiple targets.  The design of compds. that can hit more than one specific AD target thus represents an innovative strategy for AD treatment.  Tacrine was the first AChEI introduced in therapy.  Recent studies have demonstrated its ability to interact with different AD targets.  Furthermore, numerous tacrine homo- and heterodimers were developed with the aim of improving and enlarging its biol. profile beyond its ability to act as an AChEI.  Several tacrine hybrid derivs. were designed and synthesized with the same goal.  This review will focus on and summarize the last 2 years of research into the development of tacrine derivs. able to hit AD targets beyond simple AChE inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoAUhZIxP33LVg90H21EOLACvtfcHk0lhv1Z-BlzYB3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmvFCnu78%253D&md5=0506197d9fdaa47d5a76bdf2099cf483</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F092986710791111206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986710791111206%26sid%3Dliteratum%253Aachs%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMilelli%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DTacrine%2520derivatives%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2010%26volume%3D17%26spage%3D1825%26epage%3D1838%26doi%3D10.2174%2F092986710791111206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, J. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albuquerque, H. M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, A. M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, V. L. M.</span></span> <span> </span><span class="NLM_article-title">Dual-target compounds for Alzheimerâs disease: natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>221</i></span>,  <span class="NLM_fpage">113492</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2021.113492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2021.113492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=33984802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhtVynur7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=221&publication_year=2021&pages=113492&author=J.+P.+S.+Ferreiraauthor=H.+M.+T.+Albuquerqueauthor=S.+M.+Cardosoauthor=A.+M.+S.+Silvaauthor=V.+L.+M.+Silva&title=Dual-target+compounds+for+Alzheimer%E2%80%99s+disease%3A+natural+and+synthetic+AChE+and+BACE-1+dual-inhibitors+and+their+structure-activity+relationship+%28SAR%29&doi=10.1016%2Fj.ejmech.2021.113492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR)</span></div><div class="casAuthors">Ferreira, Joao P. S.; Albuquerque, Helio M. T.; Cardoso, Susana M.; Silva, Artur M. S.; Silva, Vera L. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">221</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113492</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a chronic neurodegenerative disease and represents the major cause of dementia worldwide.  Currently, there are no available treatments capable to deliver disease-modifying effects, and the available drugs can only alleviate the symptoms.  The exact pathol. of AD is not yet fully understood and several hallmarks such as the presence of amyloid-Î² (AÎ²) senile plaques, neurofibrillary tangles (NFTs) as well as the loss of cholinergic function have been assocd. to AD.  Distinct pharmacol. targets have been validated to address AD, with acetylcholinesterase (AChE) and Î²-secretase-1 (BACE-1) being two of the most explored ones.  A great deal of research has been devoted to the development of new AChE and BACE-1 effective inhibitors, tackled sep. or in combination of both.  The multi-factorial nature of AD conducted to the development of multi-target directed ligands (MTDLs), defined as single mols. capable to modulate more than one biol. target, as an alternative approach to the old paradigm one-target one-drug.  In this context, this review describes a collection of natural and synthetic compds. with dual-inhibitory properties towards both AChE and BACE-1 in the MTDLs context.  Furthermore, this review also provides a crit. comprehensive anal. of structure-activity relationships (SAR) of the synthetic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb68thD_MLErVg90H21EOLACvtfcHk0lhv1Z-BlzYB3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhtVynur7O&md5=adf20088921c4b80c74f17917bcc66d3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113492%26sid%3Dliteratum%253Aachs%26aulast%3DFerreira%26aufirst%3DJ.%2BP.%2BS.%26aulast%3DAlbuquerque%26aufirst%3DH.%2BM.%2BT.%26aulast%3DCardoso%26aufirst%3DS.%2BM.%26aulast%3DSilva%26aufirst%3DA.%2BM.%2BS.%26aulast%3DSilva%26aufirst%3DV.%2BL.%2BM.%26atitle%3DDual-target%2520compounds%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520natural%2520and%2520synthetic%2520AChE%2520and%2520BACE-1%2520dual-inhibitors%2520and%2520their%2520structure-activity%2520relationship%2520%2528SAR%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D221%26spage%3D113492%26doi%3D10.1016%2Fj.ejmech.2021.113492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malafaia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albuquerque, H. M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, A. M. S.</span></span> <span> </span><span class="NLM_article-title">Amyloid-Î² and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>214</i></span>,  <span class="NLM_fpage">113209</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2021.113209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2021.113209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=33548635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXjsVCgsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2021&pages=113209&author=D.+Malafaiaauthor=H.+M.+T.+Albuquerqueauthor=A.+M.+S.+Silva&title=Amyloid-%CE%B2+and+tau+aggregation+dual-inhibitors%3A+A+synthetic+and+structure-activity+relationship+focused+review&doi=10.1016%2Fj.ejmech.2021.113209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid-Î² and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review</span></div><div class="casAuthors">Malafaia, Daniela; Albuquerque, Helio M. T.; Silva, Artur M. S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113209</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is one of the most common types of dementia, esp. in elderly, with an increasing no. of people suffering from this disease worldwide.  There are no available disease-modifying therapies and only four drugs are approved for the relief of symptoms.  Currently, the therapeutic approach used for AD treatment is based on single target drugs, which are not capable to stop its progression.  To address this issue, multi-target compds., combining two or more pharmacophores in a single mol. entity, have gained increasing interest to deal with the multiple factors related to AD.  The exact cause of AD is not yet completely disclosed, and several hallmarks have been assocd. to this neurodegenerative disease.  Even though, the accumulation of both amyloid-Î² plaques (AÎ²) and neurofibrillary tangles (NFTs) are fully accepted as the main AD hallmarks, being object of lots of research for early-stage diagnosis and pharmacol. therapy.  In this context, this review summarizes the state-of-the-art in the field of dual-target inhibitors of both AÎ² and tau aggregation simultaneously, including the design and synthetic strategy of the dual-target compds., as well as a brief structure-activity relationships (SAR) anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp59jHb3soMnLVg90H21EOLACvtfcHk0lg0_oUdcK7ZYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXjsVCgsLo%253D&md5=cb2925fe31b2a1597540ad49bdb062da</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113209%26sid%3Dliteratum%253Aachs%26aulast%3DMalafaia%26aufirst%3DD.%26aulast%3DAlbuquerque%26aufirst%3DH.%2BM.%2BT.%26aulast%3DSilva%26aufirst%3DA.%2BM.%2BS.%26atitle%3DAmyloid-%25CE%25B2%2520and%2520tau%2520aggregation%2520dual-inhibitors%253A%2520A%2520synthetic%2520and%2520structure-activity%2520relationship%2520focused%2520review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D214%26spage%3D113209%26doi%3D10.1016%2Fj.ejmech.2021.113209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qandil, A. M.</span></span> <span> </span><span class="NLM_article-title">Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: a critical review</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">17244</span>â <span class="NLM_lpage">17274</span>, <span class="refDoi">Â DOI: 10.3390/ijms131217244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.3390%2Fijms131217244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23247285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVagtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=17244-17274&author=A.+M.+Qandil&title=Prodrugs+of+nonsteroidal+anti-inflammatory+drugs+%28NSAIDs%29%2C+more+than+meets+the+eye%3A+a+critical+review&doi=10.3390%2Fijms131217244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: a critical review</span></div><div class="casAuthors">Qandil, Amjad M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17244-17274</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The design and the synthesis of prodrugs for nonsteroidal anti-inflammatory drugs (NSAIDs) have been given much attention by medicinal chemists, esp. in the last decade.  As a therapeutic group, NSAIDs are among the most widely used prescribed and over the counter (OTC) medications.  The rich literature about potential NSAID prodrugs clearly shows a shift from alkyl, aryalkyl or aryl esters with the sole role of masking the carboxylic acid group, to more elaborate conjugates that contain carefully chosen groups to serve specific purposes, such as enhancement of water soly. and dissoln., nitric oxide release, hydrogen sulfide release, antioxidant activity, anticholinergic and acetylcholinesterase inhibitory (AChEI) activity and site-specific targeting and delivery.  This review will focus on NSAID prodrugs that have been designed or were, later, found to possess intrinsic pharmacol. activity as an intact chem. entity.  Such intrinsic activity might augment the anti-inflammatory activity of the NSAID, reduce its side effects or transform the potential therapeutic use from classical anti-inflammatory action to something else.  Reports discussed in this review will be those of NO-NSAIDs, anticholinergic and AChEI-NSAIDs, Phospho-NSAIDs and some misc. agents.  In most cases, this review will cover literature dealing with these NSAID prodrugs from the year 2006 and later.  Older literature will be used when necessary, e.g., to explain the chem. and biol. mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocrOffS6FFb7Vg90H21EOLACvtfcHk0lg0_oUdcK7ZYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVagtA%253D%253D&md5=33e4147b763e4f6ccf1700572d45b236</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3390%2Fijms131217244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms131217244%26sid%3Dliteratum%253Aachs%26aulast%3DQandil%26aufirst%3DA.%2BM.%26atitle%3DProdrugs%2520of%2520nonsteroidal%2520anti-inflammatory%2520drugs%2520%2528NSAIDs%2529%252C%2520more%2520than%2520meets%2520the%2520eye%253A%2520a%2520critical%2520review%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2012%26volume%3D13%26spage%3D17244%26epage%3D17274%26doi%3D10.3390%2Fijms131217244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LehÃ¡r, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, C. T.</span></span> <span> </span><span class="NLM_article-title">Multi-target therapeutics: when the whole is greater than the sum of the parts</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">34</span>â <span class="NLM_lpage">42</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2006.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.drudis.2006.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=17198971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=34-42&author=G.+R.+Zimmermannauthor=J.+Leh%C3%A1rauthor=C.+T.+Keith&title=Multi-target+therapeutics%3A+when+the+whole+is+greater+than+the+sum+of+the+parts&doi=10.1016%2Fj.drudis.2006.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics: when the whole is greater than the sum of the parts</span></div><div class="casAuthors">Zimmermann Grant R; Lehar Joseph; Keith Curtis T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Drugs designed to act against individual molecular targets cannot usually combat multigenic diseases such as cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders.  Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in many important therapeutic areas.  The combination drugs currently employed are primarily of rational design, but the increased efficacy they provide justifies in vitro discovery efforts for identifying novel multi-target mechanisms.  In this review, we discuss the biological rationale for combination therapeutics, review some existing combination drugs and present a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI14vYK2Q1LENHe_gFldTbfW6udTcc2eaQ7lb5mYXQUrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D&md5=66715499ce21c2855dc6c477aa87f161</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DLeh%25C3%25A1r%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DMulti-target%2520therapeutics%253A%2520when%2520the%2520whole%2520is%2520greater%2520than%2520the%2520sum%2520of%2520the%2520parts%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D34%26epage%3D42%26doi%3D10.1016%2Fj.drudis.2006.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Rational design of multi-target-directed ligands: strategies and emerging paradigms</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8881</span>â <span class="NLM_lpage">8914</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlKrt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8881-8914&author=J.+Zhouauthor=X.+Jiangauthor=S.+Heauthor=H.+Jiangauthor=F.+Fengauthor=W.+Liuauthor=W.+Quauthor=H.+Sun&title=Rational+design+of+multi-target-directed+ligands%3A+strategies+and+emerging+paradigms&doi=10.1021%2Facs.jmedchem.9b00017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms</span></div><div class="casAuthors">Zhou, Junting; Jiang, Xueyang; He, Siyu; Jiang, Hongli; Feng, Feng; Liu, Wenyuan; Qu, Wei; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8881-8914</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Due to the complexity of multifactorial diseases, single-target drugs do not always exhibit satisfactory efficacy.  Recently, increasing evidence indicates that simultaneous modulation of multiple targets may improve both therapeutic safety and efficacy, compared with single-target drugs.  However, few multitarget drugs are on market or in clin. trials, despite the best efforts of medicinal chemists.  This article discusses the systematic establishment of target combination, lead generation, and optimization of multitarget-directed ligands (MTDLs).  Moreover, we analyze some MTDLs research cases for several complex diseases in recent years and the physicochem. properties of 117 clin. multitarget drugs, with the aim to reveal the trends and insights of the potential use of MTDLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraLqk7hMZnoLVg90H21EOLACvtfcHk0lhXWBslqwaljg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlKrt7k%253D&md5=37adb9bc31802e62fd7f8d0d6e7697e3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00017%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DQu%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DRational%2520design%2520of%2520multi-target-directed%2520ligands%253A%2520strategies%2520and%2520emerging%2520paradigms%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8881%26epage%3D8914%26doi%3D10.1021%2Facs.jmedchem.9b00017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by Design: A Medicinal Chemistâs Perspective on Multitargeting Compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">420</span>â <span class="NLM_lpage">444</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+Design%3A+A+Medicinal+Chemist%E2%80%99s+Perspective+on+Multitargeting+Compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0lhXWBslqwaljg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520Design%253A%2520A%2520Medicinal%2520Chemist%25E2%2580%2599s%2520Perspective%2520on%2520Multitargeting%2520Compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">Can we rationally design promiscuous drugs?</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">127</span>â <span class="NLM_lpage">136</span>, <span class="refDoi">Â DOI: 10.1016/j.sbi.2006.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.sbi.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=16442279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=127-136&author=A.+L.+Hopkinsauthor=J.+S.+Masonauthor=J.+P.+Overington&title=Can+we+rationally+design+promiscuous+drugs%3F&doi=10.1016%2Fj.sbi.2006.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Can we rationally design promiscuous drugs?</span></div><div class="casAuthors">Hopkins, Andrew L.; Mason, Jonathan S.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Structure-based drug design is now used widely in modern medicinal chem.  The application of structural biol. to medicinal chem. has heralded the 'rational drug design' vision of discovering exquisitely selective ligands.  However, recent advances in post-genomic biol. are indicating that polypharmacol. may be a necessary trait for the efficacy of many drugs, therefore questioning the 'one drug, one target' assumption of current rational drug design.  By combining advances in chemoinformatics and structural biol., it might be possible to rationally design the next generation of promiscuous drugs with polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWdh60x9AHrVg90H21EOLACvtfcHk0lhXWBslqwaljg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D&md5=8f9e95a41976b8e3ac790f2fff2c406f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DCan%2520we%2520rationally%2520design%2520promiscuous%2520drugs%253F%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2006%26volume%3D16%26spage%3D127%26epage%3D136%26doi%3D10.1016%2Fj.sbi.2006.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, T.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J.-M.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3645</span>â <span class="NLM_lpage">3655</span>, <span class="refDoi">Â DOI: 10.1021/jm400179b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400179b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsV2gt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3645-3655&author=J.-B.+Chenauthor=T.-R.+Chernauthor=T.-T.+Weiauthor=C.-C.+Chenauthor=J.-H.+Linauthor=J.-M.+Fang&title=Design+and+synthesis+of+dual-action+inhibitors+targeting+histone+deacetylases+and+3-hydroxy-3-methylglutaryl+coenzyme+A+reductase+for+cancer+treatment&doi=10.1021%2Fjm400179b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Dual-Action Inhibitors Targeting Histone Deacetylases and 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase for Cancer Treatment</span></div><div class="casAuthors">Chen, Jhih-Bin; Chern, Ting-Rong; Wei, Tzu-Tang; Chen, Ching-Chow; Lin, Jung-Hsin; Fang, Jim-Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3645-3655</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual inhibitors of histone deacetylase (HDAC) and 3-hydroxy-3-methylglutaryl CoA reductase (HMGR) such as I (X = bond, CH2; Y = bond, 1,4-benzenediyl; Z = bond, 1,2,3-triazole-4,1-diyl) and II were prepd. by incorporating the hydroxamate moieties of HDAC inhibitors into statins such as lovastatin known as HMGR inhibitors.  Hydroxamic acids such as II derived from ring-opening of the lactone moieties of statins were the most effective of the compds. tested at inhibiting HDAC and HMGR in vitro and in human leukemia cells, with IC50 values of 12-44 nM against HMGR, 63-125 nM against HDAC1, 414-600 nM against HDAC2, and 51-133 nM against HDAC6.  Statin-derived hydroxamic acids such as II inhibited the growth of human cancer cells with IC50 values of 18-20 Î¼M and greater than five-fold selectivity for human cancer cells over normal human cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYxyB-8TwI0LVg90H21EOLACvtfcHk0ljq5at65yJogA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsV2gt7c%253D&md5=e212e0f2e9d565b215f69e66dfd8adac</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm400179b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400179b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.-B.%26aulast%3DChern%26aufirst%3DT.-R.%26aulast%3DWei%26aufirst%3DT.-T.%26aulast%3DChen%26aufirst%3DC.-C.%26aulast%3DLin%26aufirst%3DJ.-H.%26aulast%3DFang%26aufirst%3DJ.-M.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dual-action%2520inhibitors%2520targeting%2520histone%2520deacetylases%2520and%25203-hydroxy-3-methylglutaryl%2520coenzyme%2520A%2520reductase%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3645%26epage%3D3655%26doi%3D10.1021%2Fjm400179b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tavera-Mendoza, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quach, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dabbas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palijan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleason, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. H.</span></span> <span> </span><span class="NLM_article-title">Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">8250</span>â <span class="NLM_lpage">8255</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0709279105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1073%2Fpnas.0709279105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=18550844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVyku7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=8250-8255&author=L.+E.+Tavera-Mendozaauthor=T.+D.+Quachauthor=B.+Dabbasauthor=J.+Hudonauthor=X.+Liaoauthor=A.+Palijanauthor=J.+L.+Gleasonauthor=J.+H.+White&title=Incorporation+of+histone+deacetylase+inhibition+into+the+structure+of+a+nuclear+receptor+agonist&doi=10.1073%2Fpnas.0709279105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist</span></div><div class="casAuthors">Tavera-Mendoza, Luz E.; Quach, Tan D.; Dabbas, Basel; Hudon, Jonathan; Liao, Xiaohong; Palijan, Ana; Gleason, James L.; White, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8250-8255</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">1,25-Dihydroxyvitamin D3 (1,25D) regulates gene expression by signaling through the nuclear vitamin D receptor (VDR) transcription factor and exhibits calcium homeostatic, anticancer, and immunomodulatory properties.  Histone deacetylase inhibitors (HDACis) alter nuclear and cytoplasmic protein acetylation, modify gene expression, and have potential for treatment of cancer and other indications.  The function of nuclear receptor ligands, including 1,25D, can be enhanced in combination with HDACi.  The authors designed triciferol, a hybrid mol. in which the 1,25D side chain was replaced with the dienyl hydroxamic acid of HDACi trichostatin A.  Triciferol binds directly to the VDR, and functions as an agonist with 1,25D-like potency on several 1,25D target genes.  Moreover, unlike 1,25D, triciferol induces marked tubulin hyperacetylation, and augments histone acetylation at concns. that largely overlap those where VDR agonism is obsd.  Triciferol also exhibits more efficacious antiproliferative and cytotoxic activities than 1,25D in four cancer cell models in vitro.  The bifunctionality of triciferol is notable because (i) the HDACi activity is generated by modifying the 1,25D side chain without resorting to linker technol. and (ii) 1,25D and HDACi have sympathetic, but very distinct biochem. targets; the hydrophobic VDR ligand binding domain and the active sites of HDACs, which are zinc metalloenzymes.  These studies demonstrate the feasibility of combining HDAC inhibition with nuclear receptor agonism to enhance their therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqnUsEiyCAYbVg90H21EOLACvtfcHk0ljq5at65yJogA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVyku7o%253D&md5=ae7adac8555096f10e4bf0f90976155d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709279105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709279105%26sid%3Dliteratum%253Aachs%26aulast%3DTavera-Mendoza%26aufirst%3DL.%2BE.%26aulast%3DQuach%26aufirst%3DT.%2BD.%26aulast%3DDabbas%26aufirst%3DB.%26aulast%3DHudon%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DX.%26aulast%3DPalijan%26aufirst%3DA.%26aulast%3DGleason%26aufirst%3DJ.%2BL.%26aulast%3DWhite%26aufirst%3DJ.%2BH.%26atitle%3DIncorporation%2520of%2520histone%2520deacetylase%2520inhibition%2520into%2520the%2520structure%2520of%2520a%2520nuclear%2520receptor%2520agonist%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D8250%26epage%3D8255%26doi%3D10.1073%2Fpnas.0709279105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sham, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">N-3 hydroxylation of pyrimidine-2,4-diones yields dual inhibitors of HIV reverse transcriptase and integrase</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">63</span>â <span class="NLM_lpage">67</span>, <span class="refDoi">Â DOI: 10.1021/ml1002162</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1002162" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlalurzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=63-67&author=J.+Tangauthor=K.+Maddaliauthor=C.+D.+Dreisauthor=Y.+Y.+Shamauthor=R.+Vinceauthor=Y.+Pommierauthor=Z.+Wang&title=N-3+hydroxylation+of+pyrimidine-2%2C4-diones+yields+dual+inhibitors+of+HIV+reverse+transcriptase+and+integrase&doi=10.1021%2Fml1002162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase</span></div><div class="casAuthors">Tang, Jing; Maddali, Kasthuraiah; Dreis, Christine D.; Sham, Yuk Y.; Vince, Robert; Pommier, Yves; Wang, Zhengqiang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-67</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new mol. scaffold featuring an N-hydroxyimide functionality and capable of inhibiting both reverse transcriptase (RT) and integrase (IN) of human immunodeficiency virus (HIV) was rationally designed based on 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) non-nucleoside RT inhibitors (NNRTIs).  The design involves a minimal 3-N hydroxylation of the pyrimidine ring of HEPT compd. to yield a chelating triad which, along with the existing benzyl group, appeared to satisfy major structural requirements for IN binding.  In the mean time, this chem. modification did not severely compromise the compd.'s ability to inhibit RT.  A preliminary structure-activity relationship (SAR) study reveals that this N-3 OH is essential for IN inhibition and that the benzyl group on N-1 side chain is more important for IN binding than the one on C-6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqONtaoARK-6bVg90H21EOLACvtfcHk0ljq5at65yJogA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlalurzP&md5=8b20b2ac50ef44513cdcfe51664790ca</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fml1002162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1002162%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DMaddali%26aufirst%3DK.%26aulast%3DDreis%26aufirst%3DC.%2BD.%26aulast%3DSham%26aufirst%3DY.%2BY.%26aulast%3DVince%26aufirst%3DR.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DN-3%2520hydroxylation%2520of%2520pyrimidine-2%252C4-diones%2520yields%2520dual%2520inhibitors%2520of%2520HIV%2520reverse%2520transcriptase%2520and%2520integrase%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D63%26epage%3D67%26doi%3D10.1021%2Fml1002162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angioni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurglics, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahnt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span> <span> </span><span class="NLM_article-title">A dual modulator of farnesoid x receptor and soluble epoxide hydrolase to counter nonalcoholic steatohepatitis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7703</span>â <span class="NLM_lpage">7724</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00398</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00398" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2ls73J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7703-7724&author=J.+Schmidtauthor=M.+Rotterauthor=T.+Weiserauthor=S.+Wittmannauthor=L.+Weizelauthor=A.+Kaiserauthor=J.+Heeringauthor=T.+Goebelauthor=C.+Angioniauthor=M.+Wurglicsauthor=A.+Paulkeauthor=G.+Geisslingerauthor=A.+Kahntauthor=D.+Steinhilberauthor=E.+Proschak&title=A+dual+modulator+of+farnesoid+x+receptor+and+soluble+epoxide+hydrolase+to+counter+nonalcoholic+steatohepatitis&doi=10.1021%2Facs.jmedchem.7b00398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis</span></div><div class="casAuthors">Schmidt, Jurema; Rotter, Marco; Weiser, Tim; Wittmann, Sandra; Weizel, Lilia; Kaiser, Astrid; Heering, Jan; Goebel, Tamara; Angioni, Carlo; Wurglics, Mario; Paulke, Alexander; Geisslinger, Gerd; Kahnt, Astrid; Steinhilber, Dieter; Proschak, Ewgenij; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7703-7724</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonalcoholic steatohepatitis arising from Western diet and lifestyle is characterized by accumulation of fat in liver causing inflammation and fibrosis.  It evolves as serious health burden with alarming incidence, but there is no satisfying pharmacol. therapy to date.  Considering the disease's multifactorial nature, modulation of multiple targets might provide superior therapeutic efficacy.  In particular, farnesoid X receptor (FXR) activation that revealed antisteatotic and antifibrotic effects in clin. trials combined with inhibition of sol. epoxide hydrolase (sEH) as anti-inflammatory strategy promises synergies.  To exploit this dual concept, we developed agents exerting partial FXR agonism and sEH inhibitory activity.  Merging known pharmacophores and systematic exploration of the structure-activity relationship on both targets produced dual modulators with low nanomolar potency.  Extensive in vitro characterization confirmed high dual efficacy in cellular context combined with low toxicity, and pilot in vivo data revealed favorable pharmacokinetics as well as engagement on both targets in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUx3OFEKCgyrVg90H21EOLACvtfcHk0lgu9ZUIQqFbYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2ls73J&md5=a35ceea141c78ed9885d7f9a99f4852b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00398%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DRotter%26aufirst%3DM.%26aulast%3DWeiser%26aufirst%3DT.%26aulast%3DWittmann%26aufirst%3DS.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DHeering%26aufirst%3DJ.%26aulast%3DGoebel%26aufirst%3DT.%26aulast%3DAngioni%26aufirst%3DC.%26aulast%3DWurglics%26aufirst%3DM.%26aulast%3DPaulke%26aufirst%3DA.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DKahnt%26aufirst%3DA.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DProschak%26aufirst%3DE.%26atitle%3DA%2520dual%2520modulator%2520of%2520farnesoid%2520x%2520receptor%2520and%2520soluble%2520epoxide%2520hydrolase%2520to%2520counter%2520nonalcoholic%2520steatohepatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7703%26epage%3D7724%26doi%3D10.1021%2Facs.jmedchem.7b00398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Dual-target-directed 1,3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimerâs disease</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5610</span>â <span class="NLM_lpage">5615</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2010.06.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmc.2010.06.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=20620068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlGhur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=5610-5615&author=W.+Huangauthor=D.+Lvauthor=H.+Yuauthor=R.+Shengauthor=C.+K.+Sunauthor=P.+Wuauthor=K.+Luoauthor=J.+Liauthor=Y.+Hu&title=Dual-target-directed+1%2C3-diphenylurea+derivatives%3A+BACE+1+inhibitor+and+metal+chelator+against+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.bmc.2010.06.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-target-directed 1,3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer's disease</span></div><div class="casAuthors">Huang, Wenhai; Lv, Dan; Yu, Haiping; Sheng, Rong; Kim, Sun Chol; Wu, Peng; Luo, Kedi; Li, Jia; Hu, Yongzhou</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5610-5615</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dual-target-directed 1,3-diphenylurea derivs. were designed by hybridizing BACE 1 inhibitor 1 with metal chelator LR-90.  A database consisted of 1,3-diphenylurea derivs. was built and screened by the pharmacophore model (Hypo 1) of BACE 1 inhibitor.  Based on the predicted results, 11 compds. (6a-d, 9a-g) with favorable Fitvalues were selected, synthesized and evaluated for their BACE 1 inhibitory activities, which showed that the predicted results were in good agreement with the exptl. values.  Besides, the synthesized compds. also displayed the ability to chelate metal ions.  The most effective BACE 1 inhibitor 9f (27.85 Â± 2.46Î¼mol/L) was selected for further receptor-binding studies, the result of which indicated that an essential hydrogen bonds was formed between the urea group of 9f and the catalytic aspartate Asp228.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgKAHualJvhbVg90H21EOLACvtfcHk0lgu9ZUIQqFbYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlGhur8%253D&md5=eba5ad753bbf43134f7f3acc1561bc5a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.06.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.06.042%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DLv%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DSheng%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DC.%2BK.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DLuo%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DDual-target-directed%25201%252C3-diphenylurea%2520derivatives%253A%2520BACE%25201%2520inhibitor%2520and%2520metal%2520chelator%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D5610%26epage%3D5615%26doi%3D10.1016%2Fj.bmc.2010.06.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kogen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tago, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naruto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyagi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter targeting potential agents for Alzheimerâs disease</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">3359</span>â <span class="NLM_lpage">3362</span>, <span class="refDoi">Â DOI: 10.1021/ol026418e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol026418e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1Omtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=3359-3362&author=H.+Kogenauthor=N.+Todaauthor=K.+Tagoauthor=S.+Marumotoauthor=K.+Takamiauthor=M.+Oriauthor=N.+Yamadaauthor=K.+Koyamaauthor=S.+Narutoauthor=K.+Abeauthor=R.+Yamazakiauthor=T.+Haraauthor=A.+Aoyagiauthor=Y.+Abeauthor=T.+Kaneko&title=Design+and+synthesis+of+dual+inhibitors+of+acetylcholinesterase+and+serotonin+transporter+targeting+potential+agents+for+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fol026418e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Dual Inhibitors of Acetylcholinesterase and Serotonin Transporter Targeting Potential Agents for Alzheimer's Disease</span></div><div class="casAuthors">Kogen, Hiroshi; Toda, Narihiro; Tago, Keiko; Marumoto, Shinji; Takami, Kazuko; Ori, Mayuko; Yamada, Naho; Koyama, Kazuo; Naruto, Shunji; Abe, Kazumi; Yamazaki, Reina; Hara, Takao; Aoyagi, Atsushi; Abe, Yasuyuki; Kaneko, Tsugio</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3359-3362</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Highly efficient acetylcholinesterase (AChE) and serotonin transporter (SERT) dual inhibitors, I and II, were designed on the basis of the hypothetical model of AChE active site and synthesized.  Both compds. showed potent inhibitory activities against AChE and SERT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ_JFWyj5kyLVg90H21EOLACvtfcHk0lgu9ZUIQqFbYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1Omtbg%253D&md5=1bb01165b917e2e896f0b489e04f3d5a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fol026418e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol026418e%26sid%3Dliteratum%253Aachs%26aulast%3DKogen%26aufirst%3DH.%26aulast%3DToda%26aufirst%3DN.%26aulast%3DTago%26aufirst%3DK.%26aulast%3DMarumoto%26aufirst%3DS.%26aulast%3DTakami%26aufirst%3DK.%26aulast%3DOri%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DN.%26aulast%3DKoyama%26aufirst%3DK.%26aulast%3DNaruto%26aufirst%3DS.%26aulast%3DAbe%26aufirst%3DK.%26aulast%3DYamazaki%26aufirst%3DR.%26aulast%3DHara%26aufirst%3DT.%26aulast%3DAoyagi%26aufirst%3DA.%26aulast%3DAbe%26aufirst%3DY.%26aulast%3DKaneko%26aufirst%3DT.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dual%2520inhibitors%2520of%2520acetylcholinesterase%2520and%2520serotonin%2520transporter%2520targeting%2520potential%2520agents%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DOrg.%2520Lett.%26date%3D2002%26volume%3D4%26spage%3D3359%26epage%3D3362%26doi%3D10.1021%2Fol026418e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dove, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongratz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciossek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckers, T.</span></span> <span> </span><span class="NLM_article-title">Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2265</span>â <span class="NLM_lpage">2279</span>, <span class="refDoi">Â DOI: 10.1021/jm800988r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800988r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFemurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2265-2279&author=S.+Mahboobiauthor=S.+Doveauthor=A.+Sellmerauthor=M.+Winklerauthor=E.+Eichhornauthor=H.+Pongratzauthor=T.+Ciossekauthor=T.+Baerauthor=T.+Maierauthor=T.+Beckers&title=Design+of+chimeric+histone+deacetylase-+and+tyrosine+kinase-inhibitors%3A+a+series+of+imatinib+hybrides+as+potent+inhibitors+of+wild-type+and+mutant+BCR-ABL%2C+PDGF-Rbeta%2C+and+histone+deacetylases&doi=10.1021%2Fjm800988r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-RÎ², and Histone Deacetylases</span></div><div class="casAuthors">Mahboobi, Siavosh; Dove, Stefan; Sellmer, Andreas; Winkler, Matthias; Eichhorn, Emerich; Pongratz, Herwig; Ciossek, Thomas; Baer, Thomas; Maier, Thomas; Beckers, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2265-2279</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of histone deacetylases are a new class of cancer therapeutics with possibly broad applicability.  Combinations of HDAC inhibitors with the kinase inhibitor 1 (Imatinib) in recent studies showed additive and synergistic effects.  Here we present a new concept by combining inhibition of protein kinases and HDACs, two independent pharmacol. activities, in one synthetic small mol.  In general, the HDAC inhibition profile, the potencies, and the probable binding modes to HDAC1 and HDAC6 were similar as for 6 (SAHA).  Inhibition of Abl kinase in biochem. assays was maintained for most compds., but in general the kinase selectivity profile differed from that of 1 with nearly equipotent inhibition of the wild-type and the Imatinib resistant Abl T315I mutant.  A potent cellular inhibition of PDGFR and cytotoxicity toward EOL-1 cells, a model for idiopathic hypereosinophilic syndrome (HES), are restored or enhanced for selected analogs (12b, 14b, and 18b).  Cytotoxicity was evaluated by using a broad panel of tumor cell lines, with selected analogs displaying mean IC50 values between 3.6 and 7.1 Î¼M.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCa_uPm33uzLVg90H21EOLACvtfcHk0lgRnWfFHomh7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFemurc%253D&md5=2e65e8c0cf3daed2cc7415173209d630</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm800988r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800988r%26sid%3Dliteratum%253Aachs%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DDove%26aufirst%3DS.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DWinkler%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DCiossek%26aufirst%3DT.%26aulast%3DBaer%26aufirst%3DT.%26aulast%3DMaier%26aufirst%3DT.%26aulast%3DBeckers%26aufirst%3DT.%26atitle%3DDesign%2520of%2520chimeric%2520histone%2520deacetylase-%2520and%2520tyrosine%2520kinase-inhibitors%253A%2520a%2520series%2520of%2520imatinib%2520hybrides%2520as%2520potent%2520inhibitors%2520of%2520wild-type%2520and%2520mutant%2520BCR-ABL%252C%2520PDGF-Rbeta%252C%2520and%2520histone%2520deacetylases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2265%26epage%3D2279%26doi%3D10.1021%2Fjm800988r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Rationally designed dual inhibitors of HIV reverse transcriptase and integrase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">3416</span>â <span class="NLM_lpage">3419</span>, <span class="refDoi">Â DOI: 10.1021/jm070512p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070512p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVehtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3416-3419&author=Z.+Wangauthor=E.+M.+Bennettauthor=D.+J.+Wilsonauthor=C.+Salomonauthor=R.+Vince&title=Rationally+designed+dual+inhibitors+of+HIV+reverse+transcriptase+and+integrase&doi=10.1021%2Fjm070512p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally Designed Dual Inhibitors of HIV Reverse Transcriptase and Integrase</span></div><div class="casAuthors">Wang, Zhengqiang; Bennett, Eric M.; Wilson, Daniel J.; Salomon, Christine; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3416-3419</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bifunctional inhibitors were designed and synthesized based on 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) non-nucleoside reverse transcriptase (RT) inhibitors and diketoacid (DKA) integrase (IN) inhibitors.  Biochem. studies revealed activity against RT and IN at low nanomolar and low micromolar concns., resp.  Exceptionally low IC50 values from a cell-based assay were achieved along with remarkably high therapeutic indexes.  Compd. I was identified as the best compd. of the series (IC50: 24 nM against RT, 4.4 Î¼M against IN, and 10 nM against HIV-1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvKQ5ZDoIQqLVg90H21EOLACvtfcHk0lgRnWfFHomh7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVehtbo%253D&md5=021d763f7f62919cc1fe9d010ab56e60</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm070512p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070512p%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBennett%26aufirst%3DE.%2BM.%26aulast%3DWilson%26aufirst%3DD.%2BJ.%26aulast%3DSalomon%26aufirst%3DC.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DRationally%2520designed%2520dual%2520inhibitors%2520of%2520HIV%2520reverse%2520transcriptase%2520and%2520integrase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D3416%26epage%3D3419%26doi%3D10.1021%2Fjm070512p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. P.</span></span> <span> </span><span class="NLM_article-title">Dual GSK-3Î²/AChE inhibitors as a new strategy for multitargeting anti-alzheimerâs disease drug discovery</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">171</span>â <span class="NLM_lpage">176</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.7b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2gtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=171-176&author=X.+Y.+Jiangauthor=T.+K.+Chenauthor=J.+T.+Zhouauthor=S.+Y.+Heauthor=H.+Y.+Yangauthor=Y.+Chenauthor=W.+Quauthor=F.+Fengauthor=H.+P.+Sun&title=Dual+GSK-3%CE%B2%2FAChE+inhibitors+as+a+new+strategy+for+multitargeting+anti-alzheimer%E2%80%99s+disease+drug+discovery&doi=10.1021%2Facsmedchemlett.7b00463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Dual GSK-3Î²/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer's Disease Drug Discovery</span></div><div class="casAuthors">Jiang, Xue-Yang; Chen, Ting-Kai; Zhou, Jun-Ting; He, Si-Yu; Yang, Hong-Yu; Chen, Yao; Qu, Wei; Feng, Feng; Sun, Hao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-176</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget-directed ligands (MTDLs) is considered to be a promising approach to address complex and multifactorial maladies such as Alzheimer's disease (AD).  The concurrent inhibition of the two crucial AD targets, glycogen synthase kinase-3Î² (GSK-3Î²) and human acetylcholinesterase (hAChE), might represent a breakthrough in the quest for clin. efficacy.  Thus, a novel family of GSK-3Î²/AChE dual-target inhibitors was designed and synthesized.  Among these hybrids, I showed the most promising profile as a nanomolar inhibitor on both hAChE (IC50 = 6.5 nM) and hGSK-3Î² kinase activity (IC50 = 66 nM).  It also showed good inhibitory effect on Î²-amyloid self-aggregation (inhibitory rate = 46%) at 20 Î¼M.  Western blot anal. revealed that compd. I inhibited hyperphosphorylation of tau protein in mouse neuroblastoma N2a-Tau cells.  In vivo studies confirmed that I significantly ameliorated the cognitive disorders in scopolamine-treated ICR mice and less hepatotoxicity than tacrine.  This study provides new leads for assessment of GSK-3Î² and AChE pathway dual inhibition as a promising strategy for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq103h9q_6uaLVg90H21EOLACvtfcHk0lgRnWfFHomh7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2gtrY%253D&md5=8858bb4cbc503c79896ccbc00fb23153</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00463%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DX.%2BY.%26aulast%3DChen%26aufirst%3DT.%2BK.%26aulast%3DZhou%26aufirst%3DJ.%2BT.%26aulast%3DHe%26aufirst%3DS.%2BY.%26aulast%3DYang%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DH.%2BP.%26atitle%3DDual%2520GSK-3%25CE%25B2%252FAChE%2520inhibitors%2520as%2520a%2520new%2520strategy%2520for%2520multitargeting%2520anti-alzheimer%25E2%2580%2599s%2520disease%2520drug%2520discovery%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D171%26epage%3D176%26doi%3D10.1021%2Facsmedchemlett.7b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>205</i></span>,  <span class="NLM_fpage">112645</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2020.112645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2020.112645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=32791399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsF2ju7nN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2020&pages=112645&author=B.+Sunauthor=Y.+Dongauthor=Y.+Anauthor=M.+Liuauthor=X.+Y.+Liu&title=Design%2C+synthesis+and+bioactivity+evaluation+of+novel+arylalkene-amide+derivatives+as+dual-target+antifungal+inhibitors&doi=10.1016%2Fj.ejmech.2020.112645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors</span></div><div class="casAuthors">Sun, Bin; Dong, Yue; An, Yunfei; Liu, Min; Han, Jun; Zhao, Liyu; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112645</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Ergosterol as the core component of fungal cell membrane plays a key role in maintaining cell morphol. and permeability.  The squalenee epoxidase (SE) and 14-demethylase (CYP51) are the important rate-limiting enzymes for ergosterol synthesis.  In the study, these active fragments, which is derived from the structural groups of the common antifungal agents, were docked into the active sites of dual targets (SE, CYP51), resp.  Some of active fragments with the matching MCSS_Score values were selected and connected to construct three different series of novel arylalkene-amide derivs. as dual-target (SE, CYP51) antifungal inhibitors.  Subsequently, these compds. were further synthesized, and their bioactivity was evaluated.  Most of compds. showed a certain degree of antifungal activity in vitro.  It was worth noting that the target compds. 17a and 25a with excellent antifungal activity (0.125-4 Î¼g/mL) can inhibit the fluconazole-resistant Candida Strain 17#, CaR, 632, and 901 in the range of MIC values (4-8 Î¼g/mL).  Furthermore, their mol. mechanism, structural stability and low toxicity were further confirmed.  The mol. docking and ADMET properties were predicted to guide the subsequent optimization of target compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhh-pS7MDiqLVg90H21EOLACvtfcHk0lgzk_zve9tgMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsF2ju7nN&md5=b3a1142e95bea42964d78009f670924a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112645%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DB.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26atitle%3DDesign%252C%2520synthesis%2520and%2520bioactivity%2520evaluation%2520of%2520novel%2520arylalkene-amide%2520derivatives%2520as%2520dual-target%2520antifungal%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D205%26spage%3D112645%26doi%3D10.1016%2Fj.ejmech.2020.112645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span> <span> </span><span class="NLM_article-title">Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">112991</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2020.112991</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2020.112991" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=33183866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlemsbjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2021&pages=112991&author=Y.+Anauthor=Y.+Dongauthor=M.+Liuauthor=J.+Hanauthor=L.+Zhaoauthor=B.+Sun&title=Novel+naphthylamide+derivatives+as+dual-target+antifungal+inhibitors%3A+Design%2C+synthesis+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2020.112991"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation</span></div><div class="casAuthors">An, Yunfei; Dong, Yue; Liu, Min; Han, Jun; Zhao, Liyu; Sun, Bin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112991</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In the study, a series of active fragments were screened through the method of De Novo Link, and these active fragments with the higher Ludi_Scores were selected, which can show the obvious binding ability with the dual targets (SE, CYP51).  Subsequently, three series of target compds. with naphthyl amide scaffolds were constructed by connecting these core fragments, and their structures were synthesized.  Most of compds. showed the antifungal activity in the treatment of pathogenic fungi.  It was worth noting that compds.I [R = pyridin-4-ylmethyl] and II [R = methyl] with the excellent broad-spectrum antifungal properties also exhibited the obvious antifungal effects against drug-resistant fungi.  Preliminary mechanism study has proved these target compds. can block the biosynthesis of ergosterol by inhibiting the activity of dual targets (SE, CYP51).  Furthermore, target compds. I [R = pyridin-4-ylmethyl] and II [R = methyl] with low toxicity side effects also demonstrated the excellent pharmacol. effects in vivo.  The mol. docking and ADMET prediction were performed, which can guide the optimization of subsequent lead compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTY6whYEevkbVg90H21EOLACvtfcHk0lgzk_zve9tgMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlemsbjM&md5=d10af85cc7298f8961dbba6abc1408eb</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112991%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DB.%26atitle%3DNovel%2520naphthylamide%2520derivatives%2520as%2520dual-target%2520antifungal%2520inhibitors%253A%2520Design%252C%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D210%26spage%3D112991%26doi%3D10.1016%2Fj.ejmech.2020.112991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falkenberg, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">673</span>, <span class="refDoi">Â DOI: 10.1038/nrd4360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fnrd4360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=25131830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=673&author=K.+J.+Falkenbergauthor=R.+W.+Johnstone&title=Histone+deacetylases+and+their+inhibitors+in+cancer%2C+neurological+diseases+and+immune+disorders&doi=10.1038%2Fnrd4360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span></div><div class="casAuthors">Falkenberg, Katrina J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-691</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters.  Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small mols.  This Review discusses the role of altered expression and/or function of one class of epigenetic regulators - histone deacetylases (HDACs) - and their role in cancer, neurol. diseases and immune disorders.  We highlight the development of small-mol. HDAC inhibitors and their use in the lab., in preclin. models and in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXiWEG49LhebVg90H21EOLACvtfcHk0lgzk_zve9tgMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI&md5=ccfb68fa3fd4685e2305cdf8a6a9c81a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnrd4360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4360%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenberg%26aufirst%3DK.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DHistone%2520deacetylases%2520and%2520their%2520inhibitors%2520in%2520cancer%252C%2520neurological%2520diseases%2520and%2520immune%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D673%26doi%3D10.1038%2Fnrd4360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span> <span> </span><span class="NLM_article-title">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">84</span>â <span class="NLM_lpage">90</span>, <span class="refDoi">Â DOI: 10.1038/nbt1272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fnbt1272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=17211407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=84-90&author=P.+A.+Marksauthor=R.+Breslow&title=Dimethyl+sulfoxide+to+vorinostat%3A+development+of+this+histone+deacetylase+inhibitor+as+an+anticancer+drug&doi=10.1038%2Fnbt1272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span></div><div class="casAuthors">Marks, Paul A.; Breslow, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-90</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In our quest to understand why DMSO (DMSO) can cause growth arrest and terminal differentiation of transformed cells, we followed a path that led us to discover suberoylanilide hydroxamic acid (SAHA; vorinostat (Zolinza)), which is a histone deacetylase inhibitor.  SAHA reacts with and blocks the catalytic site of these enzymes.  Extensive structure-activity studies were done along the path from DMSO to SAHA.  SAHA can cause growth arrest and death of a broad variety of transformed cells both in vitro and in tumor-bearing animals at concns. not toxic to normal cells.  SAHA has many protein targets whose structure and function are altered by acetylation, including chromatin-assocd. histones, nonhistone gene transcription factors and proteins involved in regulation of cell proliferation, migration and death.  In clin. trials, SAHA has shown significant anticancer activity against both hematol. and solid tumors at doses well tolerated by patients.  A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma.  More potent analogs of SAHA have shown unacceptable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK3endE54rQ7Vg90H21EOLACvtfcHk0lhldam21Gal9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D&md5=cc2a39d80d5d5bea0a1377bdf48a957d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnbt1272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1272%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26atitle%3DDimethyl%2520sulfoxide%2520to%2520vorinostat%253A%2520development%2520of%2520this%2520histone%2520deacetylase%2520inhibitor%2520as%2520an%2520anticancer%2520drug%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D84%26epage%3D90%26doi%3D10.1038%2Fnbt1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawk, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span> <span> </span><span class="NLM_article-title">Statins and cancer--beyond the âone drug, one diseaseâ model</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">2238</span>â <span class="NLM_lpage">2239</span>, <span class="refDoi">Â DOI: 10.1056/NEJMe058074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1056%2FNEJMe058074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15917390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFOltrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=2238-2239&author=E.+Hawkauthor=J.+L.+Viner&title=Statins+and+cancer%2D%2Dbeyond+the+%E2%80%9Cone+drug%2C+one+disease%E2%80%9D+model&doi=10.1056%2FNEJMe058074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Statins and cancer - beyond the "one drug, one disease" model</span></div><div class="casAuthors">Hawk, Ernest; Viner, Jaye L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2238-2239</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp06htVsp0AYLVg90H21EOLACvtfcHk0lhldam21Gal9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFOltrw%253D&md5=464f54c85ef32f740839de5baa9c6f68</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1056%2FNEJMe058074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe058074%26sid%3Dliteratum%253Aachs%26aulast%3DHawk%26aufirst%3DE.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26atitle%3DStatins%2520and%2520cancer--beyond%2520the%2520%25E2%2580%259Cone%2520drug%252C%2520one%2520disease%25E2%2580%259D%2520model%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D2238%26epage%3D2239%26doi%3D10.1056%2FNEJMe058074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Istvan, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deisenhofer, J.</span></span> <span> </span><span class="NLM_article-title">Structural mechanism for statin inhibition of HMG-CoA reductase</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">1160</span>â <span class="NLM_lpage">1164</span>, <span class="refDoi">Â DOI: 10.1126/science.1059344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1126%2Fscience.1059344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=11349148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjs1Cgtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2001&pages=1160-1164&author=E.+S.+Istvanauthor=J.+Deisenhofer&title=Structural+mechanism+for+statin+inhibition+of+HMG-CoA+reductase&doi=10.1126%2Fscience.1059344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for statin inhibition of HMG-CoA reductase</span></div><div class="casAuthors">Istvan, Eva S.; Deisenhofer, Johann</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">5519</span>),
    <span class="NLM_cas:pages">1160-1164</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase (HMGR) catalyzes the committed step in cholesterol biosynthesis.  Statins are HMGR inhibitors with inhibition const. values in the nanomolar range that effectively lower serum cholesterol levels and are widely prescribed in the treatment of hypercholesterolemia.  We have detd. structures of the catalytic portion of human HMGR complexed with six different statins.  The statins occupy a portion of the binding site of HMG-CoA, thus blocking access of this substrate to the active site.  Near the carboxyl terminus of HMGR, several catalytically relevant residues are disordered in the enzyme-statin complexes.  If these residues were not flexible, they would sterically hinder statin binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDsSOnK9675bVg90H21EOLACvtfcHk0lhldam21Gal9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjs1Cgtbo%253D&md5=235644ee8cca3d2e061093e93bd1d702</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1126%2Fscience.1059344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1059344%26sid%3Dliteratum%253Aachs%26aulast%3DIstvan%26aufirst%3DE.%2BS.%26aulast%3DDeisenhofer%26aufirst%3DJ.%26atitle%3DStructural%2520mechanism%2520for%2520statin%2520inhibition%2520of%2520HMG-CoA%2520reductase%26jtitle%3DScience%26date%3D2001%26volume%3D292%26spage%3D1160%26epage%3D1164%26doi%3D10.1126%2Fscience.1059344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span> <span> </span><span class="NLM_article-title">Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2375</span>â <span class="NLM_lpage">2383</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-07-5807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1158%2F0008-5472.CAN-07-5807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=18381445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktV2jsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=2375-2383&author=Y.+Linauthor=J.+Linauthor=C.+Chouauthor=Y.+Changauthor=S.+Yehauthor=C.+Chen&title=Statins+increase+p21+through+inhibition+of+histone+deacetylase+activity+and+release+of+promoter-associated+HDAC1%2F2&doi=10.1158%2F0008-5472.CAN-07-5807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Statins Increase p21 through Inhibition of Histone Deacetylase Activity and Release of Promoter-Associated HDAC1/2</span></div><div class="casAuthors">Lin, Yi-Chu; Lin, Jung-Hsin; Chou, Chia-Wei; Chang, Yu-Fan; Yeh, Shu-Hao; Chen, Ching-Chow</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2375-2383</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Statins are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors broadly used for the control of hypercholesterolemia.  Recently, they are reported to have beneficial effects on certain cancers.  In this study, we show that statins inhibited the histone deacetylase (HDAC) activity and increased the accumulation of acetylated histone-H3 and the expression of p21WAF/CIP in human cancer cells.  Computational modeling showed the direct interaction of the carboxylic acid moiety of statins with the catalytic site of HDAC2.  In the subsequent enzymic assay, it was shown that lovastatin inhibited HDAC2 activity competitively with a Ki value of 31.6 Î¼mol/L.  Sp1 but not p53 sites were the statins-responsive element shown by p21 luciferase-promoter assays.  DNA affinity protein binding assay and chromatin immunopptn. assay showed the dissocn. of HDAC1/2 and assocn. of CBP, leading to the histone-H3 acetylation on the Sp1 sites of p21 promoter.  In vitro cell proliferation and in vivo tumor growth were both inhibited by statins.  These results suggest a novel mechanism for statins through abrogation of the HDAC activity and promoter histone-H3 acetylation to regulate p21 expression.  Therefore, statins might serve as novel HDAC inhibitors for cancer therapy and chemoprevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWO3elyAbZFLVg90H21EOLACvtfcHk0lhldam21Gal9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktV2jsrk%253D&md5=2a8cfc0aa492b742d2c00cd695710030</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-5807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-5807%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DStatins%2520increase%2520p21%2520through%2520inhibition%2520of%2520histone%2520deacetylase%2520activity%2520and%2520release%2520of%2520promoter-associated%2520HDAC1%252F2%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D2375%26epage%3D2383%26doi%3D10.1158%2F0008-5472.CAN-07-5807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villar-Garea, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteller, M.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: understanding a new wave of anticancer agents</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">171</span>â <span class="NLM_lpage">178</span>, <span class="refDoi">Â DOI: 10.1002/ijc.20372</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1002%2Fijc.20372" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15352027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvVejs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2004&pages=171-178&author=A.+Villar-Gareaauthor=M.+Esteller&title=Histone+deacetylase+inhibitors%3A+understanding+a+new+wave+of+anticancer+agents&doi=10.1002%2Fijc.20372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: Understanding a new wave of anticancer agents</span></div><div class="casAuthors">Villar-Garea, Ana; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-178</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Cancer is as much an epigenetic disease as it is a genetic and cytogenetic disease.  The discovery that drastic changes in DNA methylation and histone modifications are commonly found in human tumors has inspired various labs. and pharmaceutical companies to develop and study epigenetic drugs.  One of the most promising groups of agents is the inhibitors of histone deacetylases (HDACs), which have different biochem. and biol. properties but have a single common activity: induction of acetylation in histones, the key proteins in nucleosome and chromatin structure.  One of the main mechanisms of action of HDAC inhibitors is the transcriptional reactivation of dormant tumor-suppressor genes, such as p21WAF1.  However, their pleiotropic nature leaves open the possibility that their well-known differentiation, cell-cycle arrest and apoptotic properties are also involved in other functions assocd. with HDAC inhibition.  Many phase I clin. trials indicate that HDAC inhibitors appear to be well-tolerated drugs.  Thus, the field is ready for rigorous biol. and clin. scrutiny to validate the therapeutic potential of these drugs.  Our current data indicate that the use of HDAC inhibitors, probably in assocn. with classical chemotherapy drugs or in combination with DNA-demethylating agents, could be promising for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrobWV6s_G7N7Vg90H21EOLACvtfcHk0lhfKWS0C9263g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvVejs70%253D&md5=e30161130cd0bee731ca196a2a635da1</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fijc.20372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.20372%26sid%3Dliteratum%253Aachs%26aulast%3DVillar-Garea%26aufirst%3DA.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520understanding%2520a%2520new%2520wave%2520of%2520anticancer%2520agents%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2004%26volume%3D112%26spage%3D171%26epage%3D178%26doi%3D10.1002%2Fijc.20372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanim, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gommersall, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalvo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peehl, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M. J.</span></span> <span> </span><span class="NLM_article-title">Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6712</span>â <span class="NLM_lpage">6725</span>, <span class="refDoi">Â DOI: 10.1038/sj.onc.1207772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fsj.onc.1207772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15300237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFGnu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=6712-6725&author=F.+L.+Khanimauthor=L.+M.+Gommersallauthor=V.+H.+Woodauthor=K.+L.+Smithauthor=L.+Montalvoauthor=L.+P.+O%E2%80%99Neillauthor=Y.+Xuauthor=D.+M.+Peehlauthor=P.+M.+Stewartauthor=B.+M.+Turnerauthor=M.+J.+Campbell&title=Altered+SMRT+levels+disrupt+vitamin+D3+receptor+signalling+in+prostate+cancer+cells&doi=10.1038%2Fsj.onc.1207772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells</span></div><div class="casAuthors">Khanim, Farhat L.; Gommersall, Lyndon M.; Wood, Victoria H. J.; Smith, Kirsty L.; Montalvo, Leire; O'Neill, Laura P.; Xu, Yue; Peehl, Donna M.; Stewart, Paul M.; Turner, Bryan M.; Campbell, Moray J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">6712-6725</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We hypothesized that key antiproliferative target genes for the vitamin D receptor (VDR) were repressed by an epigenetic mechanism in prostate cancer cells resulting in apparent hormonal insensitivity.  To explore this possibility, we examd. nuclear receptor corepressor expression in a panel of nonmalignant and malignant cell lines and primary cultures, and found frequently elevated SMRT corepressor mRNA expression often assocd. with reduced sensitivity to 1Î±,25-dihydroxyvitamin D3 (1Î±,25(OH)2D3).  For example, PC-3 and DU-145 prostate cancer cell lines had 1.8-fold and twofold increases in SMRT mRNA relative to normal PrEC cells (P<0.05).  Similarly, 10/15 primary tumor cultures (including three matched to normal cells from the same donors) had elevated SMRT mRNA levels; generally NCoR1 and Alien were not as commonly elevated.  Corepressor proteins often have assocd. histone deacetylases (HDAC) and reflectively the antiproliferative action of 1Î±,25(OH)2D3 can be 'restored' by cotreatment with low doses of HDAC inhibitors such as trichostatin A (TSA, 15 nM) to induce apoptosis in prostate cancer cell lines.  To decipher the transcriptional events that lead to these cellular responses, we undertook gene expression studies in PC-3 cells after cotreatment of 1Î±,25(OH)2D3 plus TSA after 6 h.  Examn. of known VDR target genes and cDNA microarray analyses revealed cotreatment of 1Î±,25(OH)2D3 plus TSA cooperatively upregulated eight (out of 1176) genes, including MAPK-APK2 and GADD45Î±.  MRNA and protein time courses and inhibitor studies confirmed these patterns of regulation.  Subsequently, we knocked down SMRT levels in PC-3 cells using a small interfering RNA (siRNA) approach and found that GADD45Î± induction by 1Î±,25(OH)2D3 alone became very significantly enhanced.  The same distortion of gene responsiveness, with repressed induction of GADD45Î± was found in primary tumor cultures compared and to matched peripheral zone (normal) cultures from the same donor.  These data demonstrate that elevated SMRT levels are common in prostate cancer cells, resulting in suppression of target genes assocd. with antiproliferative action and apparent 1Î±,25(OH)2D3-insensitivity.  This can be targeted therapeutically by combination treatments with HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9l8XsE78U77Vg90H21EOLACvtfcHk0lhfKWS0C9263g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFGnu74%253D&md5=2dcf1e06322b812483950d388c1a4dec</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207772%26sid%3Dliteratum%253Aachs%26aulast%3DKhanim%26aufirst%3DF.%2BL.%26aulast%3DGommersall%26aufirst%3DL.%2BM.%26aulast%3DWood%26aufirst%3DV.%2BH.%26aulast%3DSmith%26aufirst%3DK.%2BL.%26aulast%3DMontalvo%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%2BP.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DPeehl%26aufirst%3DD.%2BM.%26aulast%3DStewart%26aufirst%3DP.%2BM.%26aulast%3DTurner%26aufirst%3DB.%2BM.%26aulast%3DCampbell%26aufirst%3DM.%2BJ.%26atitle%3DAltered%2520SMRT%2520levels%2520disrupt%2520vitamin%2520D3%2520receptor%2520signalling%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D6712%26epage%3D6725%26doi%3D10.1038%2Fsj.onc.1207772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span> <span> </span><span class="NLM_article-title">Promise of vitamin D analogues in the treatment of hyperproliferative conditions</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">797</span>â <span class="NLM_lpage">808</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-05-0539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1158%2F1535-7163.MCT-05-0539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=16648549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFCksb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=797-808&author=S.+Masudaauthor=G.+Jones&title=Promise+of+vitamin+D+analogues+in+the+treatment+of+hyperproliferative+conditions&doi=10.1158%2F1535-7163.MCT-05-0539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Promise of vitamin D analogs in the treatment of hyperproliferative conditions</span></div><div class="casAuthors">Masuda, Sonoko; Jones, Glenville</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">797-808</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  1Î±,25-Dihydroxyvitamin D3 [1Î±,25-(OH)2D3; calcitriol] is best known as a hormone involved in calcium homeostasis but is also a potent antiproliferative agent in many cell types, particularly epithelial cells.  1Î±,25(OH)2D3 mediates its actions through a classic steroid hormone-like transcriptional mechanism by influencing the expression of hundreds of genes.  Effects of 1Î±,25(OH)2D3 have been obsd. on the expression of cell cycle regulators, growth factors and their receptors, apoptotic machinery, metastatic potential, and angiogenesis; all of which have some effect on hyperproliferative conditions.  This minireview focuses on the anticancer potential of 1Î±,25(OH)2D3 and its analogs by summarizing the promising data from animal and human trials of 1Î±,25(OH)2D3 and some of the more interesting synthetic vitamin D analogs in the treatment of a variety of different animal cancer models and in human patients with advanced cancer.  Optimal administration of vitamin D analogs is only just being achieved with high-dose intermittent administration overcoming bioavailability and hypercalcemia problems and combination therapy with cytotoxic agents (taxols and cisplatins), antiresorptive agents (bisphosphonates), or cytochrome P 450 inhibitors being attempted.  Although the potential of vitamin D as an antiproliferative drug has been realized in the treatment of psoriasis and in parathyroid cell hyperplasia assocd. with secondary hyperparathyroidism, the search for an anticancer treatment incorporating a vitamin D analog remains elusive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovCSrw9h-W57Vg90H21EOLACvtfcHk0lhfKWS0C9263g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFCksb8%253D&md5=80a25e1feb2d3f2e6d591f12ebb656b8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0539%26sid%3Dliteratum%253Aachs%26aulast%3DMasuda%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DG.%26atitle%3DPromise%2520of%2520vitamin%2520D%2520analogues%2520in%2520the%2520treatment%2520of%2520hyperproliferative%2520conditions%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D797%26epage%3D808%26doi%3D10.1158%2F1535-7163.MCT-05-0539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanim, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gommersall, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, V. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalvo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peehl, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M. J.</span></span> <span> </span><span class="NLM_article-title">Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6712</span>â <span class="NLM_lpage">6725</span>, <span class="refDoi">Â DOI: 10.1038/sj.onc.1207772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fsj.onc.1207772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15300237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFGnu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=6712-6725&author=F.+L.+Khanimauthor=L.+M.+Gommersallauthor=V.+H.+J.+Woodauthor=K.+L.+Smithauthor=L.+Montalvoauthor=L.+P.+O%E2%80%99Neillauthor=Y.+Xuauthor=D.+M.+Peehlauthor=P.+M.+Stewartauthor=B.+M.+Turnerauthor=M.+J.+Campbell&title=Altered+SMRT+levels+disrupt+vitamin+D3+receptor+signalling+in+prostate+cancer+cells&doi=10.1038%2Fsj.onc.1207772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells</span></div><div class="casAuthors">Khanim, Farhat L.; Gommersall, Lyndon M.; Wood, Victoria H. J.; Smith, Kirsty L.; Montalvo, Leire; O'Neill, Laura P.; Xu, Yue; Peehl, Donna M.; Stewart, Paul M.; Turner, Bryan M.; Campbell, Moray J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">6712-6725</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We hypothesized that key antiproliferative target genes for the vitamin D receptor (VDR) were repressed by an epigenetic mechanism in prostate cancer cells resulting in apparent hormonal insensitivity.  To explore this possibility, we examd. nuclear receptor corepressor expression in a panel of nonmalignant and malignant cell lines and primary cultures, and found frequently elevated SMRT corepressor mRNA expression often assocd. with reduced sensitivity to 1Î±,25-dihydroxyvitamin D3 (1Î±,25(OH)2D3).  For example, PC-3 and DU-145 prostate cancer cell lines had 1.8-fold and twofold increases in SMRT mRNA relative to normal PrEC cells (P<0.05).  Similarly, 10/15 primary tumor cultures (including three matched to normal cells from the same donors) had elevated SMRT mRNA levels; generally NCoR1 and Alien were not as commonly elevated.  Corepressor proteins often have assocd. histone deacetylases (HDAC) and reflectively the antiproliferative action of 1Î±,25(OH)2D3 can be 'restored' by cotreatment with low doses of HDAC inhibitors such as trichostatin A (TSA, 15 nM) to induce apoptosis in prostate cancer cell lines.  To decipher the transcriptional events that lead to these cellular responses, we undertook gene expression studies in PC-3 cells after cotreatment of 1Î±,25(OH)2D3 plus TSA after 6 h.  Examn. of known VDR target genes and cDNA microarray analyses revealed cotreatment of 1Î±,25(OH)2D3 plus TSA cooperatively upregulated eight (out of 1176) genes, including MAPK-APK2 and GADD45Î±.  MRNA and protein time courses and inhibitor studies confirmed these patterns of regulation.  Subsequently, we knocked down SMRT levels in PC-3 cells using a small interfering RNA (siRNA) approach and found that GADD45Î± induction by 1Î±,25(OH)2D3 alone became very significantly enhanced.  The same distortion of gene responsiveness, with repressed induction of GADD45Î± was found in primary tumor cultures compared and to matched peripheral zone (normal) cultures from the same donor.  These data demonstrate that elevated SMRT levels are common in prostate cancer cells, resulting in suppression of target genes assocd. with antiproliferative action and apparent 1Î±,25(OH)2D3-insensitivity.  This can be targeted therapeutically by combination treatments with HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9l8XsE78U77Vg90H21EOLACvtfcHk0lgW05vV9bhh1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFGnu74%253D&md5=2dcf1e06322b812483950d388c1a4dec</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207772%26sid%3Dliteratum%253Aachs%26aulast%3DKhanim%26aufirst%3DF.%2BL.%26aulast%3DGommersall%26aufirst%3DL.%2BM.%26aulast%3DWood%26aufirst%3DV.%2BH.%2BJ.%26aulast%3DSmith%26aufirst%3DK.%2BL.%26aulast%3DMontalvo%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%2BP.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DPeehl%26aufirst%3DD.%2BM.%26aulast%3DStewart%26aufirst%3DP.%2BM.%26aulast%3DTurner%26aufirst%3DB.%2BM.%26aulast%3DCampbell%26aufirst%3DM.%2BJ.%26atitle%3DAltered%2520SMRT%2520levels%2520disrupt%2520vitamin%2520D3%2520receptor%2520signalling%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D6712%26epage%3D6725%26doi%3D10.1038%2Fsj.onc.1207772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tocchini-Valentini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurtz, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moras, D.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1956</span>â <span class="NLM_lpage">1961</span>, <span class="refDoi">Â DOI: 10.1021/jm0310582</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0310582" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitValsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1956-1961&author=G.+Tocchini-Valentiniauthor=N.+Rochelauthor=J.+M.+Wurtzauthor=D.+Moras&title=Crystal+structures+of+the+vitamin+D+nuclear+receptor+liganded+with+the+vitamin+D+side+chain+analogues+calcipotriol+and+seocalcitol%2C+receptor+agonists+of+clinical+importance.+Insights+into+a+structural+basis+for+the+switching+of+calcipotriol+to+a+receptor+antagonist+by+further+side+chain+modification&doi=10.1021%2Fjm0310582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of the Vitamin D Nuclear Receptor Liganded with the Vitamin D Side Chain Analogues Calcipotriol and Seocalcitol, Receptor Agonists of Clinical Importance. Insights into a Structural Basis for the Switching of Calcipotriol to a Receptor Antagonist by Further Side Chain Modification</span></div><div class="casAuthors">Tocchini-Valentini, Giuseppe; Rochel, Natacha; Wurtz, Jean-Marie; Moras, Dino</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1956-1961</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The plethora of actions of 1Î±,25(OH)2D3 in various systems suggested wide clin. applications of vitamin D nuclear receptor (VDR) ligands in treatments of inflammation, dermatol. indication, osteoporosis, cancers, and autoimmune diseases.  More than 3000 vitamin D analogs have been synthesized in order to reduce the calcemic side effects while maintaining the transactivation potency of these ligands.  Here, we report the crystal structures of VDR ligand binding domain bound to two vitamin D agonists of therapeutical interest, calcipotriol and seocalcitol, which are characterized by their side chain modifications.  These structures show the conservation of the VDR structure and the adaptation of the side chain anchored by hydroxyl moieties.  The structure of VDR-calcipotriol helps us to understand the structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification.  The VDR-seocalcitol structure, in comparison with the structure of VDR-KH1060, a superagonist ligand closely related to seocalcitol, shows adaptation of the D ring and position of C-21 in order to adapt its more rigid side chain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPCp9Utnz2tbVg90H21EOLACvtfcHk0lgW05vV9bhh1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitValsLk%253D&md5=8a30a7bfca5475f48e2a1583915ec494</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm0310582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0310582%26sid%3Dliteratum%253Aachs%26aulast%3DTocchini-Valentini%26aufirst%3DG.%26aulast%3DRochel%26aufirst%3DN.%26aulast%3DWurtz%26aufirst%3DJ.%2BM.%26aulast%3DMoras%26aufirst%3DD.%26atitle%3DCrystal%2520structures%2520of%2520the%2520vitamin%2520D%2520nuclear%2520receptor%2520liganded%2520with%2520the%2520vitamin%2520D%2520side%2520chain%2520analogues%2520calcipotriol%2520and%2520seocalcitol%252C%2520receptor%2520agonists%2520of%2520clinical%2520importance.%2520Insights%2520into%2520a%2520structural%2520basis%2520for%2520the%2520switching%2520of%2520calcipotriol%2520to%2520a%2520receptor%2520antagonist%2520by%2520further%2520side%2520chain%2520modification%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1956%26epage%3D1961%26doi%3D10.1021%2Fjm0310582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sham, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">6-Benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV reverse transcriptase and integrase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2400</span>â <span class="NLM_lpage">2402</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2011.02.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmcl.2011.02.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=21392991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt12ku7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2400-2402&author=J.+Tangauthor=K.+Maddaliauthor=C.+D.+Dreisauthor=Y.+Y.+Shamauthor=R.+Vinceauthor=Y.+Pommierauthor=Z.+Wang&title=6-Benzoyl-3-hydroxypyrimidine-2%2C4-diones+as+dual+inhibitors+of+HIV+reverse+transcriptase+and+integrase&doi=10.1016%2Fj.bmcl.2011.02.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">6-Benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV reverse transcriptase and integrase</span></div><div class="casAuthors">Tang, Jing; Maddali, Kasthuraiah; Dreis, Christine D.; Sham, Yuk Y.; Vince, Robert; Pommier, Yves; Wang, Zhengqiang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2400-2402</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">N-3-Hydroxylation of pyrimidine-2,4-diones was recently found to yield inhibitors of both HIV-1 reverse transcriptase (RT) and integrase (IN).  An extended series of analogs featuring a benzoyl group at the C-6 position of the pyrimidine ring was synthesized.  Through biochem. studies it was found that these new analogs are dually active against both RT and IN in low micromolar range.  Antiviral assays confirmed that these new inhibitors are active against HIV-1 in cell culture at nanomolar to low micromolar range, further validating 3-hydroxypyrimidine-2,4-diones as a viable scaffold for antiviral development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsIm-OLOGzF7Vg90H21EOLACvtfcHk0lgW05vV9bhh1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt12ku7w%253D&md5=bcbbf988ce7835a8c6fcdf43241dc24e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.02.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.02.069%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DMaddali%26aufirst%3DK.%26aulast%3DDreis%26aufirst%3DC.%2BD.%26aulast%3DSham%26aufirst%3DY.%2BY.%26aulast%3DVince%26aufirst%3DR.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3D6-Benzoyl-3-hydroxypyrimidine-2%252C4-diones%2520as%2520dual%2520inhibitors%2520of%2520HIV%2520reverse%2520transcriptase%2520and%2520integrase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2400%26epage%3D2402%26doi%3D10.1016%2Fj.bmcl.2011.02.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esnouf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willcox, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span> <span> </span><span class="NLM_article-title">Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1589</span>â <span class="NLM_lpage">1600</span>, <span class="refDoi">Â DOI: 10.1021/jm960056x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960056x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK28XhslGqsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=1589-1600&author=A.+L.+Hopkinsauthor=J.+Renauthor=R.+M.+Esnoufauthor=B.+E.+Willcoxauthor=E.+Y.+Jonesauthor=C.+Rossauthor=T.+Miyasakaauthor=R.+T.+Walkerauthor=H.+Tanakaauthor=D.+K.+Stammers&title=Complexes+of+HIV-1+reverse+transcriptase+with+inhibitors+of+the+HEPT+series+reveal+conformational+changes+relevant+to+the+design+of+potent+non-nucleoside+inhibitors&doi=10.1021%2Fjm960056x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside Inhibitors</span></div><div class="casAuthors">Hopkins, Andrew L.; Ren, Jingshan; Esnouf, Robert M.; Willcox, Benjamin E.; Jones, E. Yvonne; Ross, Carl; Miyasaka, Tadashi; Walker, Richard T.; Tanaka, Hiromichi; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1589-600</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Crystal structures of HIV-1 reverse transcriptase (RT) complexed with a range of chem. diverse non-nucleoside inhibitors (NNIs) have shown a single pocket in which the inhibitors bind and details of the inhibitor-protein interactions.  To delineate the structural requirements for an effective inhibitor, the authors have detd. the structures of three closely related NNIs which vary widely in their potencies.  Crystal structures of HIV-1 RT complexed with two very potent inhibitors, MKC-442 and TNK-651, at 2.55 Ã resoln. complement the authors previous anal. of the complex with the less effective inhibitor, HEPT.  These structures reveal conformational changes which correlate with changes in potency.  The authors suggest that a major determinant of increased potency in the analogs of HEPT is an improved interaction between residue Tyr181 in the protein and the 6-benzyl ring of the inhibitors which stabilizes the structure of the complex.  This arises through a conformational switching of the protein structure triggered by the steric bulk of the 5-substituent of the inhibitor pyrimidine ring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1BU3pXNwf67Vg90H21EOLACvtfcHk0ljnxVpgPn6UGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhslGqsrc%253D&md5=a279a5fe9e82e231f0e898c3dff5bb66</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm960056x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960056x%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DEsnouf%26aufirst%3DR.%2BM.%26aulast%3DWillcox%26aufirst%3DB.%2BE.%26aulast%3DJones%26aufirst%3DE.%2BY.%26aulast%3DRoss%26aufirst%3DC.%26aulast%3DMiyasaka%26aufirst%3DT.%26aulast%3DWalker%26aufirst%3DR.%2BT.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26atitle%3DComplexes%2520of%2520HIV-1%2520reverse%2520transcriptase%2520with%2520inhibitors%2520of%2520the%2520HEPT%2520series%2520reveal%2520conformational%2520changes%2520relevant%2520to%2520the%2520design%2520of%2520potent%2520non-nucleoside%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D1589%26epage%3D1600%26doi%3D10.1021%2Fjm960056x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grobler, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillmock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felock, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espeseth, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egbertson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourgeois, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melamed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span> <span> </span><span class="NLM_article-title">Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">6661</span>â <span class="NLM_lpage">6666</span>, <span class="refDoi">Â DOI: 10.1073/pnas.092056199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1073%2Fpnas.092056199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=11997448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFCrs78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=6661-6666&author=J.+A.+Groblerauthor=K.+Stillmockauthor=B.+Huauthor=M.+Witmerauthor=P.+Felockauthor=A.+S.+Espesethauthor=A.+Wolfeauthor=M.+Egbertsonauthor=M.+Bourgeoisauthor=J.+Melamedauthor=J.+S.+Waiauthor=S.+Youngauthor=J.+Vaccaauthor=D.+J.+Hazuda&title=Diketo+acid+inhibitor+mechanism+and+HIV-1+integrase%3A+implications+for+metal+binding+in+the+active+site+of+phosphotransferase+enzymes&doi=10.1073%2Fpnas.092056199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes</span></div><div class="casAuthors">Grobler, Jay A.; Stillmock, Kara; Hu, Binghua; Witmer, Marc; Felock, Peter; Espeseth, Amy S.; Wolfe, Abigail; Egbertson, Melissa; Bourgeois, Michele; Melamed, Jeffrey; Wai, John S.; Young, Steve; Vacca, Joseph; Hazuda, Daria J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6661-6666</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The process of integrating the reverse-transcribed HIV-1 DNA into the host chromosomal DNA is catalyzed by the virally encoded enzyme integrase (IN).  Integration requires two metal-dependent reactions, 3' end processing and strand transfer.  Compds. that contain a diketo acid moiety have been shown to selectively inhibit the strand transfer reaction of IN in vitro and in infected cells and are effective as inhibitors of HIV-1 replication.  To characterize the mol. basis of inhibition, we used functional assays and binding assays to evaluate a series of structurally related analogs.  These studies focused on investigating the role of the conserved carboxylate and metal binding.  We demonstrate that an acidic moiety such as a carboxylate or isosteric heterocycle is not required for binding to the enzyme complex but is essential for inhibition and confers distinct metal-dependent properties on the inhibitor.  Binding requires divalent metal and resistance is metal dependent with active site mutants displaying resistance only when the enzymes are evaluated in the context of Mg2+.  The mechanism of action of these inhibitors is therefore likely a consequence of the interaction between the acid moiety and metal ion(s) in the IN active site, resulting in a functional sequestration of the crit. metal cofactor(s).  These studies thus have implications for modeling active site inhibitors of IN, designing and evaluating analogs with improved efficacy, and identifying inhibitors of other metal-dependent phosphotransferases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkSyCLCLHKbrVg90H21EOLACvtfcHk0ljnxVpgPn6UGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFCrs78%253D&md5=a5d2ccbecd621eaeb1901416e5154fc1</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1073%2Fpnas.092056199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.092056199%26sid%3Dliteratum%253Aachs%26aulast%3DGrobler%26aufirst%3DJ.%2BA.%26aulast%3DStillmock%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DWitmer%26aufirst%3DM.%26aulast%3DFelock%26aufirst%3DP.%26aulast%3DEspeseth%26aufirst%3DA.%2BS.%26aulast%3DWolfe%26aufirst%3DA.%26aulast%3DEgbertson%26aufirst%3DM.%26aulast%3DBourgeois%26aufirst%3DM.%26aulast%3DMelamed%26aufirst%3DJ.%26aulast%3DWai%26aufirst%3DJ.%2BS.%26aulast%3DYoung%26aufirst%3DS.%26aulast%3DVacca%26aufirst%3DJ.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26atitle%3DDiketo%2520acid%2520inhibitor%2520mechanism%2520and%2520HIV-1%2520integrase%253A%2520implications%2520for%2520metal%2520binding%2520in%2520the%2520active%2520site%2520of%2520phosphotransferase%2520enzymes%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D6661%26epage%3D6666%26doi%3D10.1073%2Fpnas.092056199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratanasuwan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prada, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Ramirez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crumpacker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilde, L.</span></span> <span> </span><span class="NLM_article-title">Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">125</span>â <span class="NLM_lpage">133</span>, <span class="refDoi">Â DOI: 10.1097/QAI.0b013e318157131c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1097%2FQAI.0b013e318157131c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=17721395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVOktbfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=125-133&author=M.+Markowitzauthor=B.+E.+Nguyenauthor=F.+Mendoauthor=W.+Ratanasuwanauthor=C.+Kovacsauthor=G.+Pradaauthor=J.+Morales-Ramirezauthor=C.+Crumpackerauthor=R.+Isaacsauthor=L.+Gilde&title=Rapid+and+durable+antiretroviral+effect+of+the+HIV-1+Integrase+inhibitor+raltegravir+as+part+of+combination+therapy+in+treatment-naive+patients+with+HIV-1+infection%3A+results+of+a+48-week+controlled+study&doi=10.1097%2FQAI.0b013e318157131c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study</span></div><div class="casAuthors">Markowitz, Martin; Nguyen, Bach-Yen; Gotuzzo, Eduardo; Mendo, Fernando; Ratanasuwan, Winai; Kovacs, Colin; Prada, Guillermo; Morales-Ramirez, Javier O.; Crumpacker, Clyde S.; Isaacs, Robin D.; Gilde, Lucinda R.; Wan, Hong; Miller, Michael D.; Wenning, Larissa A.; Teppler, Hedy</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-133</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>;
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Raltegravir is an HIV-1 integrase strand-transfer inhibitor with potent in vitro activity.  This study explored the antiretroviral activity and safety of raltegravir in treatment-naive patients with plasma HIV-1 RNA levels â¥5000 copies/mL and CD4 T-cell counts â¥100 cells/mm.  Methods: Multicenter, double-blind, randomized, controlled study of raltegravir at doses of 100, 200, 400, and 600 mg twice daily vs. efavirenz at a dose of 600 mg/d, all in combination with tenofovir at a dose of 300 mg/d and lamivudine at a dose of 300 mg/d (clinicaltrials.gov identifier: NCT00100048).  Results: In the 198 patients treated (160 on raltegravir and 38 on efavirenz), the mean HIV-1 RNA level ranged from 4.6 to 4.8 log10 copies/mL at baseline.  At weeks 2, 4, and 8, the proportion of patients achieving an HIV-1 RNA level <50 copies/mL was greater in each of the raltegravir treatment groups than in the efavirenz group.  By week 24, all treatment groups appeared similar, with plasma HIV-1 RNA levels <400 copies/mL in 85% to 98% of patients and <50 copies/mL in 85% to 95% of patients.  These redns. were maintained through week 48 in 85% to 98% of patients and in 83% to 88% of patients, resp.  Five (3%) patients on raltegravir and 1 (3%) on efavirenz experienced virol. failure before week 48.  Drug-related clin. adverse events were less common with raltegravir than with efavirenz.  After 24 and 48 wk of treatment, raltegravir did not result in increased serum levels of total cholesterol, low-d. lipoprotein cholesterol, or triglycerides.  Conclusions: Raltegravir at all doses studied was generally well tolerated in combination with tenofovir and lamivudine.  Raltegravir exhibited potent and durable antiretroviral activity similar to that of efavirenz at 24 and 48 wk but achieved HIV-1 RNA levels below detection at a more rapid rate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp70m84QdKjhLVg90H21EOLACvtfcHk0ljnxVpgPn6UGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVOktbfL&md5=cf4286357ea0f2daa2c7d7b919d56a21</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1097%2FQAI.0b013e318157131c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAI.0b013e318157131c%26sid%3Dliteratum%253Aachs%26aulast%3DMarkowitz%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DB.%2BE.%26aulast%3DMendo%26aufirst%3DF.%26aulast%3DRatanasuwan%26aufirst%3DW.%26aulast%3DKovacs%26aufirst%3DC.%26aulast%3DPrada%26aufirst%3DG.%26aulast%3DMorales-Ramirez%26aufirst%3DJ.%26aulast%3DCrumpacker%26aufirst%3DC.%26aulast%3DIsaacs%26aufirst%3DR.%26aulast%3DGilde%26aufirst%3DL.%26atitle%3DRapid%2520and%2520durable%2520antiretroviral%2520effect%2520of%2520the%2520HIV-1%2520Integrase%2520inhibitor%2520raltegravir%2520as%2520part%2520of%2520combination%2520therapy%2520in%2520treatment-naive%2520patients%2520with%2520HIV-1%2520infection%253A%2520results%2520of%2520a%252048-week%2520controlled%2520study%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2007%26volume%3D46%26spage%3D125%26epage%3D133%26doi%3D10.1097%2FQAI.0b013e318157131c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolly, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linghang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guare, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egbertson, M. S.</span></span> <span> </span><span class="NLM_article-title">A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">11233</span>â <span class="NLM_lpage">11238</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0402357101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1073%2Fpnas.0402357101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15277684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVKgtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=11233-11238&author=D.+J.+Hazudaauthor=N.+J.+Anthonyauthor=R.+P.+Gomezauthor=S.+M.+Jollyauthor=J.+S.+Waiauthor=Z.+Linghangauthor=T.+E.+Fisherauthor=E.+Markauthor=J.+P.+Guareauthor=M.+S.+Egbertson&title=A+naphthyridine+carboxamide+provides+evidence+for+discordant+resistance+between+mechanistically+identical+inhibitors+of+HIV-1+integrase&doi=10.1073%2Fpnas.0402357101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase</span></div><div class="casAuthors">Hazuda, Daria J.; Anthony, Neville J.; Gomez, Robert P.; Jolly, Samson M.; Wai, John S.; Zhuang, Linghang; Fisher, Thorsten E.; Embrey, Mark; Guare, James P., Jr.; Egbertson, Melissa S.; Vacca, Joseph P.; Huff, Joel R.; Felock, Peter J.; Witmer, Marc V.; Stillmock, Kara A.; Danovich, Robert; Grobler, Jay; Miller, Michael D.; Espeseth, Amy S.; Jin, Lixia; Chen, I-Wu; Lin, Jiunn H.; Kassahun, Kelem; Ellis, Joan D.; Wong, Bradley K.; Xu, Wei; Pearson, Paul G.; Schleif, William A.; Cortese, Riccardo; Emini, Emilio; Summa, Vincenzo; Holloway, M. Katharine; Young, Steven D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">11233-11238</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The increasing incidence of resistance to current HIV-1 therapy underscores the need to develop antiretroviral agents with new mechanisms of action.  Integrase, one of three viral enzymes essential for HIV-1 replication, presents an important yet unexploited opportunity for drug development.  The authors describe here the identification and characterization of L-870,810, a small-mol. inhibitor of HIV-1 integrase with potent antiviral activity in cell culture and good pharmacokinetic properties.  L-870,810 is an inhibitor with an 8-hydroxy-(1,6)-naphthyridine-7-carboxamide pharmacophore.  The compd. inhibits HIV-1 integrase-mediated strand transfer, and its antiviral activity in vitro is a direct consequence of this ascribed effect on integration.  L-870,810 is mechanistically identical to previously described inhibitors from the diketo acid series; however, viruses selected for resistance to L-870,810 contain mutations (integrase residues 72, 121, and 125) that uniquely confer resistance to the naphthyridine.  Conversely, mutations assocd. with resistance to the diketo acid do not engender naphthyridine resistance.  Importantly, the mutations assocd. with resistance to each of these inhibitors map to distinct regions within the integrase active site.  Therefore, the authors propose a model of the two inhibitors that is consistent with this observation and suggests specific interactions with discrete binding sites for each ligand.  These studies provide a structural basis and rationale for developing integrase inhibitors with the potential for unique and nonoverlapping resistance profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRpHqKKxVFjLVg90H21EOLACvtfcHk0lgW2HFnEF-1Vg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVKgtrY%253D&md5=a94bedb2c16c751c5a9298708504fa4d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0402357101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0402357101%26sid%3Dliteratum%253Aachs%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DAnthony%26aufirst%3DN.%2BJ.%26aulast%3DGomez%26aufirst%3DR.%2BP.%26aulast%3DJolly%26aufirst%3DS.%2BM.%26aulast%3DWai%26aufirst%3DJ.%2BS.%26aulast%3DLinghang%26aufirst%3DZ.%26aulast%3DFisher%26aufirst%3DT.%2BE.%26aulast%3DMark%26aufirst%3DE.%26aulast%3DGuare%26aufirst%3DJ.%2BP.%26aulast%3DEgbertson%26aufirst%3DM.%2BS.%26atitle%3DA%2520naphthyridine%2520carboxamide%2520provides%2520evidence%2520for%2520discordant%2520resistance%2520between%2520mechanistically%2520identical%2520inhibitors%2520of%2520HIV-1%2520integrase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D11233%26epage%3D11238%26doi%3D10.1073%2Fpnas.0402357101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metifiot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sham, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2282</span>â <span class="NLM_lpage">2292</span>, <span class="refDoi">Â DOI: 10.1021/jm1014378</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1014378" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisl2qu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2282-2292&author=J.+Tangauthor=K.+Maddaliauthor=M.+Metifiotauthor=Y.+Y.+Shamauthor=R.+Vinceauthor=Y.+Pommierauthor=Z.+Wang&title=3-Hydroxypyrimidine-2%2C4-diones+as+an+inhibitor+scaffold+of+HIV+integrase&doi=10.1021%2Fjm1014378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">3-Hydroxypyrimidine-2,4-diones as an Inhibitor Scaffold of HIV Integrase</span></div><div class="casAuthors">Tang, Jing; Maddali, Kasthuraiah; Sham, Yuk Y.; Vince, Robert; Pommier, Yves; Wang, Zhengqiang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2282-2292</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Integrase (IN) represents a clin. validated target for the development of antivirals against human immunodeficiency virus (HIV).  Inhibitors with a novel structure core are essential for combating resistance assocd. with known IN inhibitors (INIs).  We have previously disclosed a novel dual inhibitor scaffold of HIV IN and reverse transcriptase (RT).  Here we report the complete structure-activity relationship (SAR), mol. modeling, and resistance profile of this inhibitor type on IN inhibition.  These studies support an antiviral mechanism of dual inhibition against both IN and RT and validate 3-hydroxypyrimidine-2,4-diones as an IN inhibitor scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBxF_3fkEp67Vg90H21EOLACvtfcHk0lgW2HFnEF-1Vg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisl2qu7Y%253D&md5=8b53b8997bd2623f3f17851dce6c2ed0</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm1014378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1014378%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DMaddali%26aufirst%3DK.%26aulast%3DMetifiot%26aufirst%3DM.%26aulast%3DSham%26aufirst%3DY.%2BY.%26aulast%3DVince%26aufirst%3DR.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3D3-Hydroxypyrimidine-2%252C4-diones%2520as%2520an%2520inhibitor%2520scaffold%2520of%2520HIV%2520integrase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2282%26epage%3D2292%26doi%3D10.1021%2Fjm1014378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4716</span>â <span class="NLM_lpage">4723</span>, <span class="refDoi">Â DOI: 10.1021/bi036189j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi036189j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Ols7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=4716-4723&author=G.+A.+Gomezauthor=C.+Morisseauauthor=B.+D.+Hammockauthor=D.+W.+Christianson&title=Structure+of+human+epoxide+hydrolase+reveals+mechanistic+inferences+on+bifunctional+catalysis+in+epoxide+and+phosphate+ester+hydrolysis&doi=10.1021%2Fbi036189j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis</span></div><div class="casAuthors">Gomez, German A.; Morisseau, Christophe; Hammock, Bruce D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4716-4723</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The x-ray crystal structure of human sol. epoxide hydrolase (sEH) was detd. at 2.6 Ã resoln., revealing a domain-swapped quaternary structure identical to that obsd. for the murine enzyme.  As with the murine enzyme, the epoxide hydrolytic mechanism of the human enzyme proceeded through an alkyl-enzyme intermediate with Asp-333 in the C-terminal domain.  The structure of human sEH complexed with the inhibitor, N-cyclohexyl-N'-(iodophenyl)urea (CIU), at 2.35 Ã resoln. was also detd.  Tyr-381 and Tyr-465 donated H-bonds to the alkylurea carbonyl group of CIU, consistent with the proposed roles of these residues as proton donors in the 1st step of catalysis.  The N-terminal domain of mammalian sEH contained a 15 Ã deep cleft, but its biol. function was unclear.  Recent expts. demonstrated that the N-terminal domain of human sEH catalyzes the metal-dependent hydrolysis of phosphate esters.  The binding of Mg2+-HPO42- to the N-terminal domain of human sEH in its CIU complex revealed structural features relevant to those of the enzyme-substrate complex in the phosphatase reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRgQ3Rx-U2trVg90H21EOLACvtfcHk0lgbvogjxNNAMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Ols7g%253D&md5=c6cc1850d50daf2d1690c4024cb8d7bb</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fbi036189j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi036189j%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DG.%2BA.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructure%2520of%2520human%2520epoxide%2520hydrolase%2520reveals%2520mechanistic%2520inferences%2520on%2520bifunctional%2520catalysis%2520in%2520epoxide%2520and%2520phosphate%2520ester%2520hydrolysis%26jtitle%3DBiochemistry%26date%3D2004%26volume%3D43%26spage%3D4716%26epage%3D4723%26doi%3D10.1021%2Fbi036189j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eldrup, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soleymanzadeh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muegge, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrow, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKellop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukulka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lombaert, S.</span></span> <span> </span><span class="NLM_article-title">Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">5880</span>â <span class="NLM_lpage">5895</span>, <span class="refDoi">Â DOI: 10.1021/jm9005302</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9005302" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWqurvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5880-5895&author=A.+B.+Eldrupauthor=F.+Soleymanzadehauthor=S.+J.+Taylorauthor=I.+Mueggeauthor=N.+A.+Farrowauthor=D.+Josephauthor=K.+McKellopauthor=C.+C.+Manauthor=A.+Kukulkaauthor=S.+De+Lombaert&title=Structure-based+optimization+of+arylamides+as+inhibitors+of+soluble+epoxide+hydrolase&doi=10.1021%2Fjm9005302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Optimization of Arylamides as Inhibitors of Soluble Epoxide Hydrolase</span></div><div class="casAuthors">Eldrup, Anne B.; Soleymanzadeh, Fariba; Taylor, Steven J.; Muegge, Ingo; Farrow, Neil A.; Joseph, David; McKellop, Keith; Man, Chuk C.; Kukulka, Alison; De Lombaert, Stephane</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5880-5895</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Arylamides, particularly N-diarylethyl arylamides such as I, are prepd. as sol. epoxide hydrolase (sEH) inhibitors for potential use as antiinflammatory agents; their inhibition of human and rat sol. epoxide hydrolases and their half-lives on exposure to microsomes are detd., and the in vivo concns. in rats for selected compds. are detd.  While N-(3,3-diphenyl-propyl)nicotinamide (II) is found to be a potent inhibitor of sEH, it has short metabolic half-lives in microsomes and is cleared rapidly from the bodies of rats; the in vitro metabolic profile of II in rat liver microsomes shows extensive oxidative metab. and a propensity for metabolite switching.  The conformation of N-(3,3-diphenyl-propyl)-3-pyridinesulfonamide bound to sEH is detd. to understand its lack of activity and for further structure optimization; the conformation of N-(3,3-diphenyl-propyl)-2-pyridinecarboxamide bound to human sEH is also detd.  Based on the calcd. structures of compds. bound to sEH, N-diarylethyl arylamides such as I are prepd.  The racemate of I shows an attractive in vitro metabolic profile and high and sustained plasma exposure in the rat after oral administration; the structure of racemic I bound to sEH is also detd. by X-ray crystallog.  I and its enantiomer differ significantly in sEH-inhibiting activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm33erk-C157Vg90H21EOLACvtfcHk0lgbvogjxNNAMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWqurvL&md5=ceedf0d50217a4bb8b6fc87c34a65b27</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm9005302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9005302%26sid%3Dliteratum%253Aachs%26aulast%3DEldrup%26aufirst%3DA.%2BB.%26aulast%3DSoleymanzadeh%26aufirst%3DF.%26aulast%3DTaylor%26aufirst%3DS.%2BJ.%26aulast%3DMuegge%26aufirst%3DI.%26aulast%3DFarrow%26aufirst%3DN.%2BA.%26aulast%3DJoseph%26aufirst%3DD.%26aulast%3DMcKellop%26aufirst%3DK.%26aulast%3DMan%26aufirst%3DC.%2BC.%26aulast%3DKukulka%26aufirst%3DA.%26aulast%3DDe%2BLombaert%26aufirst%3DS.%26atitle%3DStructure-based%2520optimization%2520of%2520arylamides%2520as%2520inhibitors%2520of%2520soluble%2520epoxide%2520hydrolase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5880%26epage%3D5895%26doi%3D10.1021%2Fjm9005302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco Gomez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert-Zsilavecz, M.</span></span> <span> </span><span class="NLM_article-title">Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8035</span>â <span class="NLM_lpage">8055</span>, <span class="refDoi">Â DOI: 10.1021/jm500937v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500937v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCjt7bE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8035-8055&author=D.+Merkauthor=C.+Lamersauthor=K.+Ahmadauthor=R.+Carrasco+Gomezauthor=G.+Schneiderauthor=D.+Steinhilberauthor=M.+Schubert-Zsilavecz&title=Extending+the+structure-activity+relationship+of+anthranilic+acid+derivatives+as+farnesoid+X+receptor+modulators%3A+development+of+a+highly+potent+partial+farnesoid+X+receptor+agonist&doi=10.1021%2Fjm500937v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Extending the Structure-Activity Relationship of Anthranilic Acid Derivatives As Farnesoid X Receptor Modulators: Development of a Highly Potent Partial Farnesoid X Receptor Agonist</span></div><div class="casAuthors">Merk, Daniel; Lamers, Christina; Ahmad, Khalil; Carrasco Gomez, Roberto; Schneider, Gisbert; Steinhilber, Dieter; Schubert-Zsilavecz, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8035-8055</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ligand activated transcription factor nuclear farnesoid X receptor (FXR) is involved as a regulator in many metabolic pathways including bile acid and glucose homeostasis.  Therefore, pharmacol. activation of FXR seems a valuable therapeutic approach for several conditions including metabolic diseases linked to insulin resistance, liver disorders such as primary biliary cirrhosis or nonalcoholic steatohepatitis, and certain forms of cancer.  The available FXR agonists, however, activate the receptor to the full extent which might be disadvantageous over a longer time period.  Hence, partial FXR activators are required for long-term treatment of metabolic disorders.  Reported here are the SAR of anthranilic acid derivs. as FXR modulators and development, synthesis, and characterization of compd. (I), which is a highly potent partial FXR agonist in a reporter gene assay with an EC50 value of 8Â±3 nM and on mRNA level in liver cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxZMafrXUE1LVg90H21EOLACvtfcHk0lgbvogjxNNAMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCjt7bE&md5=1b0b248cf689ad910d91a078823a0001</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm500937v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500937v%26sid%3Dliteratum%253Aachs%26aulast%3DMerk%26aufirst%3DD.%26aulast%3DLamers%26aufirst%3DC.%26aulast%3DAhmad%26aufirst%3DK.%26aulast%3DCarrasco%2BGomez%26aufirst%3DR.%26aulast%3DSchneider%26aufirst%3DG.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DSchubert-Zsilavecz%26aufirst%3DM.%26atitle%3DExtending%2520the%2520structure-activity%2520relationship%2520of%2520anthranilic%2520acid%2520derivatives%2520as%2520farnesoid%2520X%2520receptor%2520modulators%253A%2520development%2520of%2520a%2520highly%2520potent%2520partial%2520farnesoid%2520X%2520receptor%2520agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8035%26epage%3D8055%26doi%3D10.1021%2Fjm500937v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kompa, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisennagel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thalji, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, J. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krum, H.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction</span>. <i>Int. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">210</span>â <span class="NLM_lpage">219</span>, <span class="refDoi">Â DOI: 10.1016/j.ijcard.2011.12.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ijcard.2011.12.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=22236509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A280%3ADC%252BC38vgt1Shug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2013&pages=210-219&author=A.+R.+Kompaauthor=B.+H.+Wangauthor=G.+Xuauthor=Y.+Zhangauthor=P.+Y.+Hoauthor=S.+Eisennagelauthor=R.+K.+Thaljiauthor=J.+P.+Marinoauthor=D.+J.+Kellyauthor=D.+J.+Behmauthor=H.+Krum&title=Soluble+epoxide+hydrolase+inhibition+exerts+beneficial+anti-remodeling+actions+post-myocardial+infarction&doi=10.1016%2Fj.ijcard.2011.12.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction</span></div><div class="casAuthors">Kompa Andrew R; Wang Bing H; Xu Guoying; Zhang Yuan; Ho Pei-Yu; Eisennagel Stephen; Thalji Reema K; Marino Joseph P Jr; Kelly Darren J; Behm David J; Krum Henry</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cardiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  A contributory role for soluble epoxide hydrolase (sEH) in cardiac remodeling post-myocardial infarction (MI) has been suggested; however effects of sEH inhibition following MI have not been evaluated.  In this study, we examined in vivo post-MI anti-remodeling effects of a novel sEH inhibitor (GSK2188931B) in the rat, and evaluated its direct in vitro effects on hypertrophy, fibrosis and inflammation.  METHODS AND RESULTS:  Post-MI administered GSK2188931B (80 mg/kg/d in chow) for 5 weeks improved left ventricular (LV) ejection fraction compared to vehicle-treated (Veh) rats (P<0.01; Sham 65 Â± 2%, MI+Veh 30 Â± 2%, MI+GSK 43 Â± 2%) without affecting systolic blood pressure.  Percentage area of LV tissue sections stained positive for picrosirius red (PS) and collagen I (CI) were elevated in LV non-infarct zone (P<0.05; NIZ; PS: Sham 1.46 Â± 0.13%, MI+Veh 2.14 Â± 0.22%, MI+GSK 1.28 Â± 0.14%; CI: Sham 2.57 Â± 0.17%, MI+Veh 5.06 Â± 0.58%, MI+GSK 2.97 Â± 0.34%) and peri-infarct zone (P<0.001; PIZ; PS: Sham 1.46 Â± 0.13%, MI+Veh 9.06 Â± 0.48%, MI+GSK 6.31 Â± 0.63%; CI: Sham 2.57Â±0.17%, MI+Veh 10.51 Â± 0.64%, MI+GSK 7.77 Â± 0.57%); GSK2188931B attenuated this increase (P<0.05).  GSK2188931B reduced macrophage infiltration into the PIZ (P<0.05).  GSK2188931B reduced AngII- and TNFÎ±-stimulated myocyte hypertrophy, AngII- and TGFÎ²-stimulated cardiac fibroblast collagen synthesis, including markers of gene expression ANP, Î²-MHC, CTGF and CI (P<0.05).  GSK2188931B reduced TNFÎ± gene expression in lipopolysaccharide (LPS)-stimulated monocytes (P<0.05).  CONCLUSION:  sEH inhibition exerts beneficial effects on cardiac function and ventricular remodeling post-MI, and direct effects on fibrosis and hypertrophy in cardiac cells.  These findings suggest that sEH is an important contributor to the pathological remodeling following MI, and may be a useful target for therapeutic blockade in this setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTn2zWSRyKzFjToTC3aBaesfW6udTcc2eZtmnKrmnXHarntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vgt1Shug%253D%253D&md5=576dd1ea415dc3a2a144f89110b296af</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.ijcard.2011.12.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijcard.2011.12.062%26sid%3Dliteratum%253Aachs%26aulast%3DKompa%26aufirst%3DA.%2BR.%26aulast%3DWang%26aufirst%3DB.%2BH.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHo%26aufirst%3DP.%2BY.%26aulast%3DEisennagel%26aufirst%3DS.%26aulast%3DThalji%26aufirst%3DR.%2BK.%26aulast%3DMarino%26aufirst%3DJ.%2BP.%26aulast%3DKelly%26aufirst%3DD.%2BJ.%26aulast%3DBehm%26aufirst%3DD.%2BJ.%26aulast%3DKrum%26aufirst%3DH.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520inhibition%2520exerts%2520beneficial%2520anti-remodeling%2520actions%2520post-myocardial%2520infarction%26jtitle%3DInt.%2520J.%2520Cardiol.%26date%3D2013%26volume%3D167%26spage%3D210%26epage%3D219%26doi%3D10.1016%2Fj.ijcard.2011.12.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schierle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Design and structural optimization of dual fxr/pparÎ´ activators</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8369</span>â <span class="NLM_lpage">8379</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c00618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVSiu7vI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8369-8379&author=S.+Schierleauthor=S.+Neumannauthor=P.+Heitelauthor=S.+Willemsauthor=A.+Kaiserauthor=J.+Pollingerauthor=D.+Merk&title=Design+and+structural+optimization+of+dual+fxr%2Fppar%CE%B4+activators&doi=10.1021%2Facs.jmedchem.0c00618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Structural Optimization of Dual FXR/PPARÎ´ Activators</span></div><div class="casAuthors">Schierle, Simone; Neumann, Sebastian; Heitel, Pascal; Willems, Sabine; Kaiser, Astrid; Pollinger, Julius; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8369-8379</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonalcoholic steatohepatitis (NASH) is considered as severe hepatic manifestation of the metabolic syndrome and has alarming global prevalence.  The ligand-activated transcription factors farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) Î´ have been validated as mol. targets to counter NASH.  To achieve robust therapeutic efficacy in this multifactorial pathol., combined peripheral PPARÎ´-mediated activity and hepatic effects of FXR activation appear as a promising multitarget approach.  We have designed a minimal dual FXR/PPARÎ´ activator scaffold by rational fusion of pharmacophores derived from selective agonists.  Our dual agonist lead compd. exhibited weak agonism on FXR and PPARÎ´ and was structurally refined to a potent and balanced FXR/PPARÎ´ activator in a computer-aided fashion.  The resulting dual FXR/PPARÎ´ modulator(I) comprises high selectivity over related nuclear receptors and activates the two target transcription factors in native cellular settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ1fSCkdgD7rVg90H21EOLACvtfcHk0lhRIUgG4xqaPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVSiu7vI&md5=ac821255509f52504ede8d644c446db8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00618%26sid%3Dliteratum%253Aachs%26aulast%3DSchierle%26aufirst%3DS.%26aulast%3DNeumann%26aufirst%3DS.%26aulast%3DHeitel%26aufirst%3DP.%26aulast%3DWillems%26aufirst%3DS.%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DPollinger%26aufirst%3DJ.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DDesign%2520and%2520structural%2520optimization%2520of%2520dual%2520fxr%252Fppar%25CE%25B4%2520activators%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8369%26epage%3D8379%26doi%3D10.1021%2Facs.jmedchem.0c00618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akwabi-Ameyaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravella, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creech, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deaton, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaldor, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madauss, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadyen, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iii, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parks, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spearing, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisely, G. B.</span></span> <span> </span><span class="NLM_article-title">Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4339</span>â <span class="NLM_lpage">4343</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2008.06.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmcl.2008.06.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=18621523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVeqtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4339-4343&author=A.+Akwabi-Ameyawauthor=J.+Y.+Bassauthor=R.+D.+Caldwellauthor=J.+A.+Caravellaauthor=L.+Chenauthor=K.+L.+Creechauthor=D.+N.+Deatonauthor=S.+A.+Jonesauthor=I.+Kaldorauthor=Y.+Liuauthor=K.+P.+Madaussauthor=H.+B.+Marrauthor=R.+B.+McFadyenauthor=A.+B.+Millerauthor=F.+N.+Iiiauthor=D.+J.+Parksauthor=P.+K.+Spearingauthor=D.+Toddauthor=S.+P.+Williamsauthor=G.+B.+Wisely&title=Conformationally+constrained+farnesoid+X+receptor+%28FXR%29+agonists%3A+Naphthoic+acid-based+analogs+of+GW+4064&doi=10.1016%2Fj.bmcl.2008.06.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064</span></div><div class="casAuthors">Akwabi-Ameyaw, Adwoa; Bass, Jonathan Y.; Caldwell, Richard D.; Caravella, Justin A.; Chen, Lihong; Creech, Katrina L.; Deaton, David N.; Jones, Stacey A.; Kaldor, Istvan; Liu, Yaping; Madauss, Kevin P.; Marr, Harry B.; McFadyen, Robert B.; Miller, Aaron B.; Navas, Frank, III; Parks, Derek J.; Spearing, Paul K.; Todd, Dan; Williams, Shawn P.; Wisely, G. Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4339-4343</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Starting from the known FXR agonist GW 4064 I, a series of stilbene replacements were prepd.  The 6-substituted 1-naphthoic acid II was an equipotent FXR agonist with improved developability parameters relative to I.  Analog II also reduced the severity of cholestasis in the ANIT acute cholestatic rat model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0IzFOXAysDrVg90H21EOLACvtfcHk0lhRIUgG4xqaPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVeqtbk%253D&md5=1007683ff89fa4257f063c63cd16481b</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.06.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.06.073%26sid%3Dliteratum%253Aachs%26aulast%3DAkwabi-Ameyaw%26aufirst%3DA.%26aulast%3DBass%26aufirst%3DJ.%2BY.%26aulast%3DCaldwell%26aufirst%3DR.%2BD.%26aulast%3DCaravella%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DDeaton%26aufirst%3DD.%2BN.%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DKaldor%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DMarr%26aufirst%3DH.%2BB.%26aulast%3DMcFadyen%26aufirst%3DR.%2BB.%26aulast%3DMiller%26aufirst%3DA.%2BB.%26aulast%3DIii%26aufirst%3DF.%2BN.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DSpearing%26aufirst%3DP.%2BK.%26aulast%3DTodd%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DS.%2BP.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26atitle%3DConformationally%2520constrained%2520farnesoid%2520X%2520receptor%2520%2528FXR%2529%2520agonists%253A%2520Naphthoic%2520acid-based%2520analogs%2520of%2520GW%25204064%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4339%26epage%3D4343%26doi%3D10.1016%2Fj.bmcl.2008.06.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacintho, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccei, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhead, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorrain, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messmer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective PPARÎ±/Î´ dual antagonists and initial biological studies</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">503</span>â <span class="NLM_lpage">508</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2018.12.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmcl.2018.12.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=30594433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1WhsLjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=503-508&author=J.+D.+Jacinthoauthor=C.+S.+Bacceiauthor=Y.+Bravoauthor=A.+Broadheadauthor=A.+Chenauthor=L.+Correaauthor=K.+Fischerauthor=B.+Laffitteauthor=C.+Leeauthor=D.+S.+Lorrainauthor=D.+Messmerauthor=P.+Prasitauthor=K.+J.+Stebbinsauthor=N.+S.+Stock&title=Discovery+of+potent+and+selective+PPAR%CE%B1%2F%CE%B4+dual+antagonists+and+initial+biological+studies&doi=10.1016%2Fj.bmcl.2018.12.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent and selective PPARÎ±/Î´ dual antagonists and initial biological studies</span></div><div class="casAuthors">Jacintho, Jason D.; Baccei, Christopher S.; Bravo, Yalda; Broadhead, Alex; Chen, Austin; Correa, Lucia; Fischer, Kim; Laffitte, Bryan; Lee, Catherine; Lorrain, Daniel S.; Messmer, Davorka; Prasit, Peppi; Stebbins, Karin J.; Stock, Nicholas S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">503-508</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We previously published on the design and synthesis of novel, potent and selective PPARÎ± antagonists suitable for either i.p. or oral in vivo administration for the potential treatment of cancer.  Described herein is SAR for a subsequent program, where we set out to identify selective and potent PPARÎ±/Î´ dual antagonist mols.  Emerging literature indicates that both PPARÎ± and PPARÎ´ antagonism may be helpful in curbing the proliferation of certain types of cancer.  This dual antagonism could also be used to study PPARs in other settings.  After testing for selective and dual potency, off-target counter screening, metabolic stability, oral bioavailability and assocd. toxicity, compd. 11, the first reported PPARÎ±/Î´ dual antagonist was chosen for more advanced preclin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIewbYoy3dErVg90H21EOLACvtfcHk0lirvqxI-0hiVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1WhsLjE&md5=b03ca081eb0222dfe7632060154c5d36</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.12.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.12.045%26sid%3Dliteratum%253Aachs%26aulast%3DJacintho%26aufirst%3DJ.%2BD.%26aulast%3DBaccei%26aufirst%3DC.%2BS.%26aulast%3DBravo%26aufirst%3DY.%26aulast%3DBroadhead%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DCorrea%26aufirst%3DL.%26aulast%3DFischer%26aufirst%3DK.%26aulast%3DLaffitte%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26aulast%3DMessmer%26aufirst%3DD.%26aulast%3DPrasit%26aufirst%3DP.%26aulast%3DStebbins%26aufirst%3DK.%2BJ.%26aulast%3DStock%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520PPAR%25CE%25B1%252F%25CE%25B4%2520dual%2520antagonists%2520and%2520initial%2520biological%2520studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D503%26epage%3D508%26doi%3D10.1016%2Fj.bmcl.2018.12.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunst, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadnis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baska, R. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monshizadegan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowala, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of n-isoxazolyl biphenylsulfonamides as potent dual angiotensin ii and endothelin a receptor antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3829</span>â <span class="NLM_lpage">3835</span>, <span class="refDoi">Â DOI: 10.1021/jm020138n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020138n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvVOrt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3829-3835&author=N.+Murugesanauthor=J.+E.+Tellewauthor=Z.+Guauthor=B.+L.+Kunstauthor=L.+Fadnisauthor=L.+A.+Corneliusauthor=R.+A.+F.+Baskaauthor=Y.+Yangauthor=S.+M.+Beyerauthor=H.+Monshizadeganauthor=K.+E.+Dickinsonauthor=B.+Panchalauthor=M.+T.+Valentineauthor=S.+Chongauthor=R.+A.+Morrisonauthor=K.+E.+Carlsonauthor=J.+R.+Powellauthor=S.+Morelandauthor=J.+C.+Barrishauthor=M.+C.+Kowalaauthor=J.+E.+Macor&title=Discovery+of+n-isoxazolyl+biphenylsulfonamides+as+potent+dual+angiotensin+ii+and+endothelin+a+receptor+antagonists&doi=10.1021%2Fjm020138n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists</span></div><div class="casAuthors">Murugesan, Natesan; Tellew, John E.; Gu, Zhengxiang; Kunst, Bridgette L.; Fadnis, Leena; Cornelius, Lyndon A.; Baska, Rose Ann F.; Yang, Yifan; Beyer, Sophie M.; Monshizadegan, Hossain; Dickinson, Kenneth E.; Panchal, Balkrushna; Valentine, Maria T.; Chong, Saeho; Morrison, Richard A.; Carlson, Kenneth E.; Powell, James R.; Moreland, Suzanne; Barrish, Joel C.; Kowala, Mark C.; Macor, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3829-3835</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ETA receptor antagonist N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-[1,1'-biphenyl]-2-sulfonamide (BMS-193884) shares the same biphenyl core as a large no. of AT1 receptor antagonists, including irbesartan.  Thus, it was hypothesized that merging the structural elements of BMS-193884 with those of the biphenyl AT1 antagonists (e.g., irbesartan) would yield a compd. with dual activity for both receptors.  This strategy led to the design, synthesis, and discovery of 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-[1,1'-biphenyl]-2-sulfonamide (BMS-248360) as a potent and orally active dual antagonist of both AT1 and ETA receptors.  Compd. BMS-248360 represents a new approach to treating hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocfowlxhsw47Vg90H21EOLACvtfcHk0lirvqxI-0hiVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvVOrt7Y%253D&md5=cd53a7af3c175c5877d45f0a25ea1159</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm020138n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020138n%26sid%3Dliteratum%253Aachs%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DTellew%26aufirst%3DJ.%2BE.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DKunst%26aufirst%3DB.%2BL.%26aulast%3DFadnis%26aufirst%3DL.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%26aulast%3DBaska%26aufirst%3DR.%2BA.%2BF.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DBeyer%26aufirst%3DS.%2BM.%26aulast%3DMonshizadegan%26aufirst%3DH.%26aulast%3DDickinson%26aufirst%3DK.%2BE.%26aulast%3DPanchal%26aufirst%3DB.%26aulast%3DValentine%26aufirst%3DM.%2BT.%26aulast%3DChong%26aufirst%3DS.%26aulast%3DMorrison%26aufirst%3DR.%2BA.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DPowell%26aufirst%3DJ.%2BR.%26aulast%3DMoreland%26aufirst%3DS.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DKowala%26aufirst%3DM.%2BC.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26atitle%3DDiscovery%2520of%2520n-isoxazolyl%2520biphenylsulfonamides%2520as%2520potent%2520dual%2520angiotensin%2520ii%2520and%2520endothelin%2520a%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3829%26epage%3D3835%26doi%3D10.1021%2Fjm020138n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadnis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baska, R. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monshizadegan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowala, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span> <span> </span><span class="NLM_article-title">Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2â²-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">171</span>â <span class="NLM_lpage">179</span>, <span class="refDoi">Â DOI: 10.1021/jm049548x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049548x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVyltrzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=171-179&author=N.+Murugesanauthor=Z.+Guauthor=L.+Fadnisauthor=J.+E.+Tellewauthor=R.+A.+F.+Baskaauthor=Y.+Yangauthor=S.+M.+Beyerauthor=H.+Monshizadeganauthor=K.+E.+Dickinsonauthor=M.+T.+Valentineauthor=W.+G.+Humphreysauthor=S.-J.+Lanauthor=W.+R.+Ewingauthor=K.+E.+Carlsonauthor=M.+C.+Kowalaauthor=R.+Zahlerauthor=J.+E.+Macor&title=Dual+angiotensin+II+and+endothelin+A+receptor+antagonists%3A+synthesis+of+2%E2%80%B2-substituted+N-3-isoxazolyl+biphenylsulfonamides+with+improved+potency+and+pharmacokinetics&doi=10.1021%2Fjm049548x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Angiotensin II and Endothelin A Receptor Antagonists: Synthesis of 2'-Substituted N-3-Isoxazolyl Biphenylsulfonamides with Improved Potency and Pharmacokinetics</span></div><div class="casAuthors">Murugesan, Natesan; Gu, Zhengxiang; Fadnis, Leena; Tellew, John E.; Baska, Rose Ann F.; Yang, Yifan; Beyer, Sophie M.; Monshizadegan, Hossain; Dickinson, Kenneth E.; Valentine, Maria T.; Humphreys, W. Griffith; Lan, Shih-Jung; Ewing, William R.; Carlson, Kenneth E.; Kowala, Mark C.; Zahler, Robert; Macor, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-179</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a previous report its was demonstrated that merging together key structural elements present in an AT1 receptor antagonist (irbesartan) with key structural elements in a biphenylsulfonamide ETA receptor antagonist followed by addnl. optimization provided a product which is a dual-action receptor antagonist (DARA), which potently blocked both AT1 and ETA receptors.  Described herein are our efforts directed toward improving both the pharmacokinetic profile as well as the AT1 and ETA receptor potency of 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-2-sulfonamide (I).  Efforts centered on modifying the 2'-side chain of I and examg. the (isoxazolyl)sulfonamide moiety in I.  This effort resulted in the discovery of 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)[1,1'-biphenyl]-2-sulfonamide (II) as a highly potent second-generation DARA.  This compd. also showed substantially improved pharmacokinetic properties compared to I.  In rats, DARA II reduced blood pressure elevations caused by i.v. infusion of Ang II or big ET-1 to a greater extent and with longer duration than DARA I or AT1 or ETA receptor antagonists alone.  II clearly demonstrated superiority over irbesartan (an AT1 receptor antagonist) in the normal SHR model of hypertension in a dose-dependent manner, demonstrating the synergy of AT1 and ETA receptor blockade in a single mol.  The crystal and mol. structures of II were reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2G8_AfjEVOrVg90H21EOLACvtfcHk0lirvqxI-0hiVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVyltrzO&md5=d4e66dc82cd65970cde8ca8f3094c8c6</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm049548x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049548x%26sid%3Dliteratum%253Aachs%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DFadnis%26aufirst%3DL.%26aulast%3DTellew%26aufirst%3DJ.%2BE.%26aulast%3DBaska%26aufirst%3DR.%2BA.%2BF.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DBeyer%26aufirst%3DS.%2BM.%26aulast%3DMonshizadegan%26aufirst%3DH.%26aulast%3DDickinson%26aufirst%3DK.%2BE.%26aulast%3DValentine%26aufirst%3DM.%2BT.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DLan%26aufirst%3DS.-J.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DKowala%26aufirst%3DM.%2BC.%26aulast%3DZahler%26aufirst%3DR.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26atitle%3DDual%2520angiotensin%2520II%2520and%2520endothelin%2520A%2520receptor%2520antagonists%253A%2520synthesis%2520of%25202%25E2%2580%25B2-substituted%2520N-3-isoxazolyl%2520biphenylsulfonamides%2520with%2520improved%2520potency%2520and%2520pharmacokinetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D171%26epage%3D179%26doi%3D10.1021%2Fjm049548x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisaha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misra, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafino, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abboa-Offei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giancarli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span> <span> </span><span class="NLM_article-title">Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2â²-amino-N-(3,4-dimethyl-5-isoxazolyl)-4â²-(2-ethylpropyl)[1,1â²-biphenyl]-2-sulfonamide (BMS-187308)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">5198</span>â <span class="NLM_lpage">5218</span>, <span class="refDoi">Â DOI: 10.1021/jm970872k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970872k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK1cXnsV2ksbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=5198-5218&author=N.+Murugesanauthor=Z.+Guauthor=P.+D.+Steinauthor=S.+Bisahaauthor=S.+Spergelauthor=R.+Girotraauthor=V.+G.+Leeauthor=J.+Lloydauthor=R.+N.+Misraauthor=J.+Schmidtauthor=A.+Mathurauthor=L.+Strattonauthor=Y.+F.+Kellyauthor=E.+Birdauthor=T.+Waldronauthor=E.+C.+K.+Liuauthor=R.+Zhangauthor=H.+Leeauthor=R.+Serafinoauthor=B.+Abboa-Offeiauthor=P.+Mathersauthor=M.+Giancarliauthor=A.+A.+Seymourauthor=M.+L.+Webbauthor=S.+Morelandauthor=J.+C.+Barrishauthor=J.+T.+Hunt&title=Biphenylsulfonamide+endothelin+antagonists%3A+structure-activity+relationships+of+a+series+of+mono-+and+disubstituted+analogues+and+pharmacology+of+the+orally+active+endothelin+antagonist+2%E2%80%B2-amino-N-%283%2C4-dimethyl-5-isoxazolyl%29-4%E2%80%B2-%282-ethylpropyl%29%5B1%2C1%E2%80%B2-biphenyl%5D-2-sulfonamide+%28BMS-187308%29&doi=10.1021%2Fjm970872k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Biphenylsulfonamide Endothelin Antagonists: Structure-Activity Relationships of a Series of Mono- and Disubstituted Analogs and Pharmacology of the Orally Active Endothelin Antagonist 2'-Amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1,1'-biphenyl]-2-sulfonamide (BMS-187308)</span></div><div class="casAuthors">Murugesan, Natesan; Gu, Zhengxiang; Stein, Philip D.; Bisaha, Sharon; Spergel, Steve; Girotra, Ravi; Lee, Ving G.; Lloyd, John; Misra, Raj N.; Schmidt, Joan; Mathur, Arvind; Stratton, Leslie; Kelly, Yolanda F.; Bird, Eileen; Waldron, Tom; Liu, Eddie C.-K.; Zhang, Rongan; Lee, Helen; Serafino, Randy; Abboa-Offei, Benoni; Mathers, Parker; Giancarli, Mary; Seymour, Andrea Ann; Webb, Maria L.; Moreland, Suzanne; Barrish, Joel C.; Hunt, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">5198-5218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Substitution at the ortho position of N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamide led to the identification of the biphenylsulfonamides as a novel series of endothelin-A (ETA) selective antagonists.  Appropriate substitution on the pendant Ph ring led to improved binding as well as functional activity.  A hydrophobic group such as iso-Bu or isopropoxy was found to be optimal at the 4'-position.  Introduction of an amino group at the 2'-position also led to improved analogs.  Combination of the optimal 4'-iso-Bu substituent with the 2'-amino function afforded an analog (BMS-187308) with improved ETA binding affinity and functional activity.  BMS-187308 also has good oral activity in inhibiting the pressor effect caused by an ET-1 infusion in rats.  Doses of 10 and 30 Î¼mol/kg i.v. BMS-187308 attenuated the pressor responses due to the administration of exogenous ET-1 to conscious monkeys, indicating that the compd. inhibits the in vivo activity of endothelin-1 in nonhuman primates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5OtFgVY5JrrVg90H21EOLACvtfcHk0lh5v_8Defz_Tg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnsV2ksbs%253D&md5=cf1a51cbfe916ab0f373d38e62db4eda</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm970872k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970872k%26sid%3Dliteratum%253Aachs%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DStein%26aufirst%3DP.%2BD.%26aulast%3DBisaha%26aufirst%3DS.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DGirotra%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DV.%2BG.%26aulast%3DLloyd%26aufirst%3DJ.%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DStratton%26aufirst%3DL.%26aulast%3DKelly%26aufirst%3DY.%2BF.%26aulast%3DBird%26aufirst%3DE.%26aulast%3DWaldron%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DE.%2BC.%2BK.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DSerafino%26aufirst%3DR.%26aulast%3DAbboa-Offei%26aufirst%3DB.%26aulast%3DMathers%26aufirst%3DP.%26aulast%3DGiancarli%26aufirst%3DM.%26aulast%3DSeymour%26aufirst%3DA.%2BA.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26aulast%3DMoreland%26aufirst%3DS.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26atitle%3DBiphenylsulfonamide%2520endothelin%2520antagonists%253A%2520structure-activity%2520relationships%2520of%2520a%2520series%2520of%2520mono-%2520and%2520disubstituted%2520analogues%2520and%2520pharmacology%2520of%2520the%2520orally%2520active%2520endothelin%2520antagonist%25202%25E2%2580%25B2-amino-N-%25283%252C4-dimethyl-5-isoxazolyl%2529-4%25E2%2580%25B2-%25282-ethylpropyl%2529%255B1%252C1%25E2%2580%25B2-biphenyl%255D-2-sulfonamide%2520%2528BMS-187308%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D5198%26epage%3D5218%26doi%3D10.1021%2Fjm970872k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leith, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span> <span> </span><span class="NLM_article-title">Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4â²-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">3111</span>â <span class="NLM_lpage">3117</span>, <span class="refDoi">Â DOI: 10.1021/jm000105c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000105c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvV2mu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3111-3117&author=N.+Murugesanauthor=Z.+Guauthor=P.+D.+Steinauthor=S.+Spergelauthor=A.+Mathurauthor=L.+Leithauthor=E.+C.+Liuauthor=R.+Zhangauthor=E.+Birdauthor=T.+Waldronauthor=A.+Marinoauthor=R.+A.+Morrisonauthor=M.+L.+Webbauthor=S.+Morelandauthor=J.+C.+Barrish&title=Biphenylsulfonamide+endothelin+receptor+antagonists.+2.+Discovery+of+4%E2%80%B2-oxazolyl+biphenylsulfonamides+as+a+new+class+of+potent%2C+highly+selective+ET%28A%29+antagonists&doi=10.1021%2Fjm000105c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Biphenylsulfonamide endothelin receptor antagonists: discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ETA antagonists</span></div><div class="casAuthors">Murugesan, Natesan; Gu, Zhengxiang; Stein, Philip D.; Spergel, Steven; Mathur, Arvind; Leith, Leslie; Liu, Eddie C.-K.; Zhang, Rongan; Bird, Eileen; Waldron, Tom; Marino, Anthony; Morrison, Richard A.; Webb, Maria L.; Moreland, Suzanne; Barrish, Joel C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3111-3117</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and structure-activity relationship (SAR) studies of a series of 4'-oxazolyl-N-(3,4-dimethyl-5-isoxazolyl)[1,1'-biphenyl]-2-sulfonamide derivs. as endothelin-A (ETA) receptor antagonists are described.  The data reveal a remarkable improvement in potency and metabolic stability when the 4'-position of the biphenylsulfonamide is substituted with an oxazole ring.  Addnl. 2'-substitution of an acylaminomethyl group further increased the binding activity and provided one of the first subnanomolar ETA-selective antagonists in the biphenylsulfonamide series (ETA Ki = 0.2 nM).  Among the compds. described, (N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfonamide; BMS-193884) had the optimum pharmacol. profile and was therefore selected as a clin. candidate for studies in congestive heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofLpYwTBrboLVg90H21EOLACvtfcHk0lh5v_8Defz_Tg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvV2mu78%253D&md5=de37003e51c462ddfb538829ab8f2718</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm000105c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000105c%26sid%3Dliteratum%253Aachs%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DStein%26aufirst%3DP.%2BD.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DLeith%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DE.%2BC.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DBird%26aufirst%3DE.%26aulast%3DWaldron%26aufirst%3DT.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DMorrison%26aufirst%3DR.%2BA.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26aulast%3DMoreland%26aufirst%3DS.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26atitle%3DBiphenylsulfonamide%2520endothelin%2520receptor%2520antagonists.%25202.%2520Discovery%2520of%25204%25E2%2580%25B2-oxazolyl%2520biphenylsulfonamides%2520as%2520a%2520new%2520class%2520of%2520potent%252C%2520highly%2520selective%2520ET%2528A%2529%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3111%26epage%3D3117%26doi%3D10.1021%2Fjm000105c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burnier, M.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II type 1 receptor blockers</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">904</span>â <span class="NLM_lpage">912</span>, <span class="refDoi">Â DOI: 10.1161/01.CIR.103.6.904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1161%2F01.CIR.103.6.904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=11171802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhs1Whtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2001&pages=904-912&author=M.+Burnier&title=Angiotensin+II+type+1+receptor+blockers&doi=10.1161%2F01.CIR.103.6.904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II type 1 receptor blockers</span></div><div class="casAuthors">Burnier, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">904-912</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 121 refs. regarding the use of angiotensin II type 1 receptor blockers for treatment of patients with hypertension.  There is now convincing evidence that the new class of specific, angiotensin II receptor antagonists is as effective as ACE inhibitors, Î²-blockers, calcium antagonists, and diuretics in treating patients with mild to moderate hypertension.  However, these antagonists are characterized by a better tolerability profile.  In contrast to most other recent classes of antihypertensive drugs, a large no. of outcome trials have been initiated to evaluate angiotensin II antagonists.  Their results will demonstrate whether angiotensin II receptor antagonists can prevent target organ damage and reduce cardiovascular morbidity and mortality.  They will also enable the more appropriate definition of the role of these antagonists in the management of patients with hypertension, heart failure, or renal diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDKCT3YAzeubVg90H21EOLACvtfcHk0lgjyLx_DlBh3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhs1Whtbk%253D&md5=f09230c7fa494dfcb03fea7da94fd057</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.103.6.904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.103.6.904%26sid%3Dliteratum%253Aachs%26aulast%3DBurnier%26aufirst%3DM.%26atitle%3DAngiotensin%2520II%2520type%25201%2520receptor%2520blockers%26jtitle%3DCirculation%26date%3D2001%26volume%3D103%26spage%3D904%26epage%3D912%26doi%3D10.1161%2F01.CIR.103.6.904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmermans, P. B.</span></span> <span> </span><span class="NLM_article-title">Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">625</span>â <span class="NLM_lpage">656</span>, <span class="refDoi">Â DOI: 10.1021/jm9504722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9504722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK28Xjt1Oltw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=625-656&author=R.+R.+Wexlerauthor=W.+J.+Greenleeauthor=J.+D.+Irvinauthor=M.+R.+Goldbergauthor=K.+Prendergastauthor=R.+D.+Smithauthor=P.+B.+Timmermans&title=Nonpeptide+angiotensin+II+receptor+antagonists%3A+the+next+generation+in+antihypertensive+therapy&doi=10.1021%2Fjm9504722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Nonpeptide Angiotensin II Receptor Antagonists: The Next Generation in Antihypertensive Therapy</span></div><div class="casAuthors">Wexler, Ruth R.; Greenlee, William J.; Irvin, John D.; Goldberg, Michael R.; Prendergast, Kristine; Smith, Ronald D.; Timmermans, Pieter B. M. W. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">625-56</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review, with 326 refs. which includes AT1-selective antagonists, AT2-selective antagonists, mol. modeling, and clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox8R0LMBNKD7Vg90H21EOLACvtfcHk0lgjyLx_DlBh3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjt1Oltw%253D%253D&md5=218425943d7b9f3bcf37c205eca08c6f</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjm9504722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9504722%26sid%3Dliteratum%253Aachs%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DIrvin%26aufirst%3DJ.%2BD.%26aulast%3DGoldberg%26aufirst%3DM.%2BR.%26aulast%3DPrendergast%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DR.%2BD.%26aulast%3DTimmermans%26aufirst%3DP.%2BB.%26atitle%3DNonpeptide%2520angiotensin%2520II%2520receptor%2520antagonists%253A%2520the%2520next%2520generation%2520in%2520antihypertensive%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D625%26epage%3D656%26doi%3D10.1021%2Fjm9504722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5766</span>â <span class="NLM_lpage">5779</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00324</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00324" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFSmu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5766-5779&author=J.+Baiauthor=C.+Liaoauthor=Y.+Liuauthor=X.+Qinauthor=J.+Chenauthor=Y.+Qiuauthor=D.+Qinauthor=Z.+Liauthor=Z.-C.+Tuauthor=S.+Jiang&title=Structure-Based+Design+of+Potent+Nicotinamide+Phosphoribosyltransferase+Inhibitors+with+Promising+in+Vitro+and+in+Vivo+Antitumor+Activities&doi=10.1021%2Facs.jmedchem.6b00324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities</span></div><div class="casAuthors">Bai, Jinhong; Liao, Chenzhong; Liu, Yanghan; Qin, Xiaochu; Chen, Jiaxuan; Qiu, Yatao; Qin, Dongguang; Li, Zheng; Tu, Zheng-Chao; Jiang, Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5766-5779</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) has the potential to directly limit NAD prodn. in cancer cells and is an effective strategy for cancer treatment.  Using a structure-based strategy, we have designed a new class of potent small-mol. inhibitors of NAMPT.  Several designed compds. showed promising antiproliferative activities in vitro. (E)-N-(5-((4-(((2-(1H-Indol-3-yl)ethyl)(isopropyl)amino)methyl)phenyl)amino)pentyl)-3-(pyridin-3-yl)acrylamide (I), bearing an indole moiety, has an IC50 of 25.3 nM for binding to the NAMPT protein and demonstrated promising inhibitory activities in the nanomolar range against several cancer cell lines (MCF-7 GI50 = 0.13 nM; MDA-MB-231 GI50 = 0.15 nM).  Triple-neg. breast cancer is the most malignant subtype of breast cancer with no effective targeted treatments currently available.  Significant antitumor efficacy of compd. 30 was achieved (TGI was 73.8%) in an orthotopic MDA-MB-231 triple-neg. breast cancer xenograft tumor model.  This paper reports promising lead mols. for the inhibition of NAMPT which could serve as a basis for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr87ZYT0b1BybVg90H21EOLACvtfcHk0lg0tJ2Ay4trhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFSmu7c%253D&md5=bbebaf9e5036168d0f30a141effce0aa</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00324%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DTu%26aufirst%3DZ.-C.%26aulast%3DJiang%26aufirst%3DS.%26atitle%3DStructure-Based%2520Design%2520of%2520Potent%2520Nicotinamide%2520Phosphoribosyltransferase%2520Inhibitors%2520with%2520Promising%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Antitumor%2520Activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5766%26epage%3D5779%26doi%3D10.1021%2Facs.jmedchem.6b00324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cea, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soncini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruscione, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffaghello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garuti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emionite, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoppoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reverberi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagnetta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamaschi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casciaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierri, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansaldi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pistoia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballestrero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patrone, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nencioni, A.</span></span> <span> </span><span class="NLM_article-title">Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">22739</span>â <span class="NLM_lpage">22739</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0022739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1371%2Fjournal.pone.0022739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOrsbnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=22739-22739&author=M.+Ceaauthor=D.+Sonciniauthor=F.+Fruscioneauthor=L.+Raffaghelloauthor=A.+Garutiauthor=L.+Emioniteauthor=E.+Moranauthor=M.+Magnoneauthor=G.+Zoppoliauthor=D.+Reverberiauthor=I.+Caffaauthor=A.+Salisauthor=A.+Cagnettaauthor=M.+Bergamaschiauthor=S.+Casciaroauthor=I.+Pierriauthor=G.+Damonteauthor=F.+Ansaldiauthor=M.+Gobbiauthor=V.+Pistoiaauthor=A.+Ballestreroauthor=F.+Patroneauthor=S.+Bruzzoneauthor=A.+Nencioni&title=Synergistic+interactions+between+HDAC+and+sirtuin+inhibitors+in+human+leukemia+cells&doi=10.1371%2Fjournal.pone.0022739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells</span></div><div class="casAuthors">Cea, Michele; Soncini, Debora; Fruscione, Floriana; Raffaghello, Lizzia; Garuti, Anna; Emionite, Laura; Moran, Eva; Magnone, Mirko; Zoppoli, Gabriele; Reverberi, Daniele; Caffa, Irene; Salis, Annalisa; Cagnetta, Antonia; Bergamaschi, Micaela; Casciaro, Salvatore; Pierri, Ivana; Damonte, Gianluca; Ansaldi, Filippo; Gobbi, Marco; Pistoia, Vito; Ballestrero, Alberto; Patrone, Franco; Bruzzone, Santina; Nencioni, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e22739</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Aberrant histone deacetylase (HDAC) activity is frequent in human leukemias.  However, while classical, NAD+-independent HDACs are an established therapeutic target, the relevance of NAD+-dependent HDACs (sirtuins) in leukemia treatment remains unclear.  Here, we assessed the antileukemic activity of sirtuin inhibitors and of the NAD+-lowering drug FK866, alone and in combination with traditional HDAC inhibitors.  Primary leukemia cells, leukemia cell lines, healthy leukocytes and hematopoietic progenitors were treated with sirtuin inhibitors (sirtinol, cambinol, EX527) and with FK866, with or without addn. of the HDAC inhibitors valproic acid, sodium butyrate, and vorinostat.  Cell death was quantified by propidium iodide cell staining and subsequent flow-cytometry.  Apoptosis induction was monitored by cell staining with FITC-Annexin-V/propidium iodide or with TMRE followed by flow-cytometric anal., and by measuring caspase3/7 activity.  Intracellular Bax was detected by flow-cytometry and western blotting.  Cellular NAD+ levels were measured by enzymic cycling assays.  Bax was overexpressed by retroviral transduction.  Bax and SIRT1 were silenced by RNA-interference.  Sirtuin inhibitors and FK866 synergistically enhanced HDAC inhibitor activity in leukemia cells, but not in healthy leukocytes and hematopoietic progenitors.  In leukemia cells, HDAC inhibitors were found to induce upregulation of Bax, a pro-apoptotic Bcl2 family-member whose translocation to mitochondria is normally prevented by SIRT1.  As a result, leukemia cells become sensitized to sirtuin inhibitor-induced apoptosis.  In conclusion, NAD+-independent HDACs and sirtuins cooperate in leukemia cells to avoid apoptosis.  Combining sirtuin with HDAC inhibitors results in synergistic antileukemic activity that could be therapeutically exploited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCsDV0zHyQfbVg90H21EOLACvtfcHk0lg0tJ2Ay4trhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOrsbnE&md5=382cf45927d9cb0b3555154246f28444</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0022739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0022739%26sid%3Dliteratum%253Aachs%26aulast%3DCea%26aufirst%3DM.%26aulast%3DSoncini%26aufirst%3DD.%26aulast%3DFruscione%26aufirst%3DF.%26aulast%3DRaffaghello%26aufirst%3DL.%26aulast%3DGaruti%26aufirst%3DA.%26aulast%3DEmionite%26aufirst%3DL.%26aulast%3DMoran%26aufirst%3DE.%26aulast%3DMagnone%26aufirst%3DM.%26aulast%3DZoppoli%26aufirst%3DG.%26aulast%3DReverberi%26aufirst%3DD.%26aulast%3DCaffa%26aufirst%3DI.%26aulast%3DSalis%26aufirst%3DA.%26aulast%3DCagnetta%26aufirst%3DA.%26aulast%3DBergamaschi%26aufirst%3DM.%26aulast%3DCasciaro%26aufirst%3DS.%26aulast%3DPierri%26aufirst%3DI.%26aulast%3DDamonte%26aufirst%3DG.%26aulast%3DAnsaldi%26aufirst%3DF.%26aulast%3DGobbi%26aufirst%3DM.%26aulast%3DPistoia%26aufirst%3DV.%26aulast%3DBallestrero%26aufirst%3DA.%26aulast%3DPatrone%26aufirst%3DF.%26aulast%3DBruzzone%26aufirst%3DS.%26aulast%3DNencioni%26aufirst%3DA.%26atitle%3DSynergistic%2520interactions%2520between%2520HDAC%2520and%2520sirtuin%2520inhibitors%2520in%2520human%2520leukemia%2520cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3D22739%26epage%3D22739%26doi%3D10.1371%2Fjournal.pone.0022739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors simultaneously targeting cancer metabolism and epigenetics: discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC) dual inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7965</span>â <span class="NLM_lpage">7983</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00467</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00467" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKhurrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7965-7983&author=G.+Dongauthor=W.+Chenauthor=X.+Wangauthor=X.+Yangauthor=T.+Xuauthor=P.+Wangauthor=W.+Zhangauthor=Y.+Raoauthor=C.+Y.+Miaoauthor=C.+Sheng&title=Small+molecule+inhibitors+simultaneously+targeting+cancer+metabolism+and+epigenetics%3A+discovery+of+novel+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors&doi=10.1021%2Facs.jmedchem.7b00467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors</span></div><div class="casAuthors">Dong, Guoqiang; Chen, Wei; Wang, Xia; Yang, Xinglin; Xu, Tianying; Wang, Pei; Zhang, Wannian; Rao, Yu; Miao, Chaoyu; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7965-7983</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer metab. and epigenetics are among the most intensely pursued research areas in anticancer drug discovery.  Here we report the first small mols. that simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT)and histone deacetylase (HDAC), two important targets of cancer metab. and epigenetics, resp.  Through iterative structure-based drug design, chem. synthesis, and biol. assays, a highly potent dual NAMPT and HDAC inhibitor was successfully identified.  Compd. 35 possessed excellent and balanced activities against both NAMPT (IC50 = 31 nM) and HDAC1 (IC50 = 55 nM).  It could effectively induce cell apoptosis and autophagy and ultimately led to cell death.  Importantly, compd. 35 showed excellent in vivo antitumor efficacy in the HCT116 xenograft model.  This proof-of-concept study demonstrates the feasibility of discovering an inhibitor targeting cancer metab. and epigenetics and provides an efficient strategy for multitarget antitumor drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9UvfGattu1rVg90H21EOLACvtfcHk0ljWY_hJT6FOtg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKhurrO&md5=65df0b485cbbc169886d34ae4421f814</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00467%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DC.%2BY.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DSmall%2520molecule%2520inhibitors%2520simultaneously%2520targeting%2520cancer%2520metabolism%2520and%2520epigenetics%253A%2520discovery%2520of%2520novel%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7965%26epage%3D7983%26doi%3D10.1021%2Facs.jmedchem.7b00467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moradei, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallais, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frechette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessier, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leit, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonfils, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trachy-Bourget, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahil, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaisburg, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besterman, J. M.</span></span> <span> </span><span class="NLM_article-title">Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5543</span>â <span class="NLM_lpage">5546</span>, <span class="refDoi">Â DOI: 10.1021/jm701079h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701079h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKksLrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5543-5546&author=O.+M.+Moradeiauthor=T.+C.+Mallaisauthor=S.+Frechetteauthor=I.+Paquinauthor=P.+E.+Tessierauthor=S.+M.+Leitauthor=M.+Fournelauthor=C.+Bonfilsauthor=M.+C.+Trachy-Bourgetauthor=J.+Liuauthor=T.+P.+Yanauthor=A.+H.+Luauthor=J.+Rahilauthor=J.+Wangauthor=S.+Lefebvreauthor=Z.+Liauthor=A.+F.+Vaisburgauthor=J.+M.+Besterman&title=Novel+aminophenyl+benzamide-type+histone+deacetylase+inhibitors+with+enhanced+potency+and+selectivity&doi=10.1021%2Fjm701079h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Aminophenyl Benzamide-Type Histone Deacetylase Inhibitors with Enhanced Potency and Selectivity</span></div><div class="casAuthors">Moradei, Oscar M.; Mallais, Tammy C.; Frechette, Sylvie; Paquin, Isabelle; Tessier, Pierre E.; Leit, Silvana M.; Fournel, Marielle; Bonfils, Claire; Trachy-Bourget, Marie-Claude; Liu, Jianhong; Yan, Theresa P.; Lu, Ai-Hua; Rahil, Jubrail; Wang, James; Lefebvre, Sylvain; Li, Zuomei; Vaisburg, Arkadii F.; Besterman, Jeffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5543-5546</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant effort is being made to understand the role of HDAC isotypes in human cancer and to develop antitumor agents with better therapeutic windows.  A part of this endeavor was the exploration of the 14 Ã internal cavity adjacent to the enzyme catalytic site, which led to the design and synthesis of compd. 4 (I) with the unusual bis(aryl)-type pharmacophore.  SAR studies around this lead resulted in optimization to potent, selective, nonhydroxamic acid HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlM848KF3mo7Vg90H21EOLACvtfcHk0ljWY_hJT6FOtg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKksLrL&md5=17012416f4be84479762acac0cff5e6f</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Fjm701079h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701079h%26sid%3Dliteratum%253Aachs%26aulast%3DMoradei%26aufirst%3DO.%2BM.%26aulast%3DMallais%26aufirst%3DT.%2BC.%26aulast%3DFrechette%26aufirst%3DS.%26aulast%3DPaquin%26aufirst%3DI.%26aulast%3DTessier%26aufirst%3DP.%2BE.%26aulast%3DLeit%26aufirst%3DS.%2BM.%26aulast%3DFournel%26aufirst%3DM.%26aulast%3DBonfils%26aufirst%3DC.%26aulast%3DTrachy-Bourget%26aufirst%3DM.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DT.%2BP.%26aulast%3DLu%26aufirst%3DA.%2BH.%26aulast%3DRahil%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DVaisburg%26aufirst%3DA.%2BF.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26atitle%3DNovel%2520aminophenyl%2520benzamide-type%2520histone%2520deacetylase%2520inhibitors%2520with%2520enhanced%2520potency%2520and%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5543%26epage%3D5546%26doi%3D10.1021%2Fjm701079h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as multifunctional agents for the therapy of alzheimerâs disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">69</span>â <span class="NLM_lpage">81</span>, <span class="refDoi">Â DOI: 10.1021/acschemneuro.5b00224</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00224" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1OhurnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=69-81&author=R.+Shengauthor=L.+Tangauthor=L.+Jiangauthor=L.+Hongauthor=Y.+Shiauthor=N.+Zhouauthor=Y.+Hu&title=Novel+1-phenyl-3-hydroxy-4-pyridinone+derivatives+as+multifunctional+agents+for+the+therapy+of+alzheimer%E2%80%99s+disease&doi=10.1021%2Facschemneuro.5b00224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 1-Phenyl-3-hydroxy-4-pyridinone Derivatives as Multifunctional Agents for the Therapy of Alzheimer's Disease</span></div><div class="casAuthors">Sheng, Rong; Tang, Li; Jiang, Liu; Hong, Lingjuan; Shi, Ying; Zhou, Naiming; Hu, Yongzhou</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-81</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 1-phenyl-3-hydroxy-4-pyridinone derivs. were designed and synthesized as multifunctional agents for Alzheimer's disease (AD) therapy through incorporation of 3-hydroxy-4-pyridinone moiety from deferiprone into the scaffold of H3 receptor antagonists.  Most of these new compds. displayed designed quadruple functions, H3 receptor antagonism, AÎ² aggregation inhibition, metal ion chelation, and radical scavenging.  Esp., the most promising compd. I displayed nanomolar IC50 values in H3 receptor antagonism with high selectivity, efficient capability to interrupt the formation of AÎ²1-42 fibrils, good copper and iron chelating properties, and more potent 2,2'-azino-bis(3-ethyl-benzothiazoline-6-sulfonic acid) radical cation (ABTSâ¢+) scavenging activity than Trolox.  Further biol. evaluation revealed that it did not show obvious cytotoxicity and hERG potassium channel inhibition at micromolar concn.  In addn., compd. I demonstrated suitable pharmacokinetic properties and acceptable blood-brain barrier permeability in vivo.  All these results indicate that compd. I is a potential multifunctional candidate for AD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOIWDXJyxn1bVg90H21EOLACvtfcHk0ljWY_hJT6FOtg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1OhurnJ&md5=66c8440d6a02d18c7cbbd948f5b97540</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00224%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DHong%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DNovel%25201-phenyl-3-hydroxy-4-pyridinone%2520derivatives%2520as%2520multifunctional%2520agents%2520for%2520the%2520therapy%2520of%2520alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D69%26epage%3D81%26doi%3D10.1021%2Facschemneuro.5b00224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bajda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzior, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ignasik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malawska, B.</span></span> <span> </span><span class="NLM_article-title">Multi-target-directed ligands in Alzheimerâs disease treatment</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4949</span>â <span class="NLM_lpage">4975</span>, <span class="refDoi">Â DOI: 10.2174/092986711797535245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.2174%2F092986711797535245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=22050745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOrtL3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=4949-4975&author=M.+Bajdaauthor=N.+Guziorauthor=M.+Ignasikauthor=B.+Malawska&title=Multi-target-directed+ligands+in+Alzheimer%E2%80%99s+disease+treatment&doi=10.2174%2F092986711797535245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-directed ligands in Alzheimer's disease treatment</span></div><div class="casAuthors">Bajda, M.; Guzior, N.; Ignasik, M.; Malawska, B.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">4949-4975</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Among the various drug discovery methods, a very promising modern approach consists in designing multi-target-directed ligands (MTDLs).  This methodol. has been specifically developed for treatment of disorders with complex pathol. mechanisms.  One such disorder is Alzheimer's disease (AD), currently the most common multifactorial neurodegenerative disease.  AD is related to increased levels of the amyloid Î² peptide (AÎ²) and the hyperphosphorylated tau protein, along with loss of neurons and synapses.  Moreover, there is some evidence pointing to the role of oxidative stress, metal ion deregulation, inflammation and cell cycle regulatory failure in its pathogenesis.  There are many attractive targets for the development of anti-AD drugs, and the multi-factor nature of this disease calls for multi-target-directed compds. which can be beneficial for AD treatment.  This review presents the discovery of dual- and multi-acting anti-AD drug candidates, focusing on the novel design strategy and the compds. it yields - particularly hybrids obtained by linking structurally active moieties interacting with different targets.  The first group of compds. includes cholinesterase inhibitors acting as dual binding site inhibitors and/or inhibitors with addnl. properties.  These compds. are characterized by increased potency against acetylcholinesterase (AChE) and AÎ² plaque formation with addnl. properties such as antioxidant activity, neuroprotective, and metal-complexing property, voltage-dependent calcium channel antagonistic activity, inhibitory activity against glutamate-induced excitotoxicity, histamine H3 receptor antagonism, cannabinoid CB1 receptor antagonism and Î²-secretase (BACE1) inhibition.  A novel class of compds. represents the combination of dual BACE1 inhibitors with metal chelators, and dual modulators of Î³-secretase with peroxisome proliferator-activated receptor Î³ (PPARÎ³).  We have reviewed the latest reports (2008-2011) presenting new multi-target-directed compds. in Alzheimer's disease treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZHSluHvxy4bVg90H21EOLACvtfcHk0lifYU9dFYVUGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOrtL3F&md5=c8f35f849c399d43c90570f71ca10e13</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.2174%2F092986711797535245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711797535245%26sid%3Dliteratum%253Aachs%26aulast%3DBajda%26aufirst%3DM.%26aulast%3DGuzior%26aufirst%3DN.%26aulast%3DIgnasik%26aufirst%3DM.%26aulast%3DMalawska%26aufirst%3DB.%26atitle%3DMulti-target-directed%2520ligands%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520treatment%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D4949%26epage%3D4975%26doi%3D10.2174%2F092986711797535245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitobe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimoto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takenaga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, N.</span></span> <span> </span><span class="NLM_article-title">Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4780</span>â <span class="NLM_lpage">4789</span>, <span class="refDoi">Â DOI: 10.1021/jm8003834</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8003834" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotFyisrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4780-4789&author=T.+Nagaseauthor=T.+Mizutaniauthor=S.+Ishikawaauthor=E.+Sekinoauthor=T.+Sasakiauthor=T.+Fujimuraauthor=S.+Itoauthor=Y.+Mitobeauthor=Y.+Miyamotoauthor=R.+Yoshimotoauthor=T.+Tanakaauthor=A.+Ishiharaauthor=N.+Takenagaauthor=S.+Tokitaauthor=T.+Fukamiauthor=N.+Sato&title=Synthesis%2C+structure-activity+relationships%2C+and+biological+profiles+of+a+quinazolinone+class+of+histamine+H3+receptor+inverse+agonists&doi=10.1021%2Fjm8003834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and Biological Profiles of a Quinazolinone Class of Histamine H3 Receptor Inverse Agonists</span></div><div class="casAuthors">Nagase, Tsuyoshi; Mizutani, Takashi; Ishikawa, Shiho; Sekino, Etsuko; Sasaki, Takahide; Fujimura, Takashi; Ito, Sayaka; Mitobe, Yuko; Miyamoto, Yasuhisa; Yoshimoto, Ryo; Tanaka, Takeshi; Ishihara, Akane; Takenaga, Norihiro; Tokita, Shigeru; Fukami, Takehiro; Sato, Nagaaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4780-4789</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of quinazolinone derivs. was synthesized and evaluated as nonimidazole H3 receptor inverse agonists.  2-Methyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-5-(trifluoromethyl)-4(3H)-quinazolinone (I) was identified as a promising deriv. for further evaluation following optimization of key parameters.  Compd. I has potent H3 inverse agonist activity and excellent selectivity over other histamine receptor subtypes and a panel of 115 unrelated diverse binding sites.  Compd. I also shows satisfactory pharmacokinetic profiles and brain penetrability in lab. animals.  Two hours after oral administration of 30 mg/kg of I to SD rats, significant elevation of brain histamine levels was obsd. where the brain H3 receptor was highly occupied (>90%).  On the basis of species differences in P-glycoprotein (P-gp) susceptibility of I between human and rodent P-gps, the obsd. rodent brain permeability of I is significantly limited by P-gp mediated efflux in rodents, whereas the extent of P-gp mediated efflux in humans should be very small or negligible.  The potential of I to be an efficacious drug was demonstrated by its excellent brain penetrability and receptor occupancy in P-gp-deficient CF-1 mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYR_RpqlBn7LVg90H21EOLACvtfcHk0lifYU9dFYVUGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotFyisrg%253D&md5=c65380137974083d49df8012687832c2</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fjm8003834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8003834%26sid%3Dliteratum%253Aachs%26aulast%3DNagase%26aufirst%3DT.%26aulast%3DMizutani%26aufirst%3DT.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DSekino%26aufirst%3DE.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DFujimura%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DS.%26aulast%3DMitobe%26aufirst%3DY.%26aulast%3DMiyamoto%26aufirst%3DY.%26aulast%3DYoshimoto%26aufirst%3DR.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DIshihara%26aufirst%3DA.%26aulast%3DTakenaga%26aufirst%3DN.%26aulast%3DTokita%26aufirst%3DS.%26aulast%3DFukami%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DN.%26atitle%3DSynthesis%252C%2520structure-activity%2520relationships%252C%2520and%2520biological%2520profiles%2520of%2520a%2520quinazolinone%2520class%2520of%2520histamine%2520H3%2520receptor%2520inverse%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4780%26epage%3D4789%26doi%3D10.1021%2Fjm8003834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazewska, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiec-Kononowicz, K.</span></span> <span> </span><span class="NLM_article-title">New developments around histamine H(3) receptor antagonists/inverse agonists: a patent review (2010 - present)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">111</span>, <span class="refDoi">Â DOI: 10.1517/13543776.2014.848197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1517%2F13543776.2014.848197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=24131059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFSlurvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=89-111&author=D.+Lazewskaauthor=K.+Kiec-Kononowicz&title=New+developments+around+histamine+H%283%29+receptor+antagonists%2Finverse+agonists%3A+a+patent+review+%282010+-+present%29&doi=10.1517%2F13543776.2014.848197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">New developments around histamine H3 receptor antagonists/inverse agonists: a patent review (2010 - present)</span></div><div class="casAuthors">Lazewska, Dorota; Kiec-Kononowicz, Katarzyna</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-111</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Histamine H3 receptor (H3R) is involved in the central and peripheral regulation of levels of histamine and other neurotransmitters (e.g., acetylcholine, noradrenaline, dopamine or serotonin).  H3R antagonists/inverse agonists constitute attractive targets in the search for new drugs.  Preclin. data indicate their potential utility in the treatment of various central nervous system (CNS), metabolic, pain and allergic disorders.  So far, many structurally diverse H3R ligands have been synthesized and pharmacol. evaluated.  Certain compds. have reached clin. trials.  The first results from these studies have appeared.  Areas covered: The literature covering patent applications (2010 through June 2013) found in the Espacenet database will be reported.  Expert opinion: In comparison with previous years, recently the no. of patent applications concerning H3R antagonists/inverse agonists has decreased.  The utility of compds. is still being verified in pharmacol. studies.  The first published results from clin. trials have shown not only pos. effects but also emerging drawbacks.  So far, BF2.649 is the most advanced in human trials (tiprolisant; Phase III trials).  New ligands are being intensively tested in preclin. tests.  Thus, it is expected that they will soon undergo clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrODgwIR7-v9bVg90H21EOLACvtfcHk0lhI4LT65SCJbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFSlurvF&md5=c621d18e4bb0a3e8d3c5fb99fc3ebbee</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.848197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.848197%26sid%3Dliteratum%253Aachs%26aulast%3DLazewska%26aufirst%3DD.%26aulast%3DKiec-Kononowicz%26aufirst%3DK.%26atitle%3DNew%2520developments%2520around%2520histamine%2520H%25283%2529%2520receptor%2520antagonists%252Finverse%2520agonists%253A%2520a%2520patent%2520review%2520%25282010%2520-%2520present%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D89%26epage%3D111%26doi%3D10.1517%2F13543776.2014.848197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Does, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantjes, A.</span></span> <span> </span><span class="NLM_article-title">Iron (III)-chelating resins. 3. Synthesis, iron (III)-chelating properties, and in vitro antibacterial activity of compounds containing 3-hydroxy-2-methyl-4(1H)-pyridinone ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2822</span>â <span class="NLM_lpage">2827</span>, <span class="refDoi">Â DOI: 10.1021/jm00071a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00071a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK3sXlsFKjsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=2822-2827&author=M.+H.+Fengauthor=L.+van+der+Doesauthor=A.+Bantjes&title=Iron+%28III%29-chelating+resins.+3.+Synthesis%2C+iron+%28III%29-chelating+properties%2C+and+in+vitro+antibacterial+activity+of+compounds+containing+3-hydroxy-2-methyl-4%281H%29-pyridinone+ligands&doi=10.1021%2Fjm00071a013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Iron(III)-chelating resins. 3. Synthesis, iron(III)-chelating properties, and in vitro antibacterial activity of compounds containing 3-hydroxy-2-methyl-4(1H)-pyridinone ligands</span></div><div class="casAuthors">Feng, Min Hua; van der Does, Leen; Bantjes, Adriaan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2822-7</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The synthesis, iron(III)-chelating properties, and antibacterial activity of several compds. contg. the 3-hydroxy-2-methyl-4(1H)-pyridinone (HMP) moiety are described.  Using the HMP derivs., iron(III) could be mobilized from iron(III)-binding proteins at physiol. pH with a rate order of transferrin > lactoferrin > ferritin.  Addn. of HMP-contg. compds. to a growth medium at a concn. of 20 mM/L resulted in a complete inhibition of the growth of Escherichia coli and about 90% inhibition for Listeria inocua after 7 h of incubation at 37 Â°C.  After inhibition of bacteria growth by the HMP derivs., growth started again when ferric ions were added to the medium, which implies that the antibacterial activity is due to a limitation of iron available to the organisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjP8tmq10cPbVg90H21EOLACvtfcHk0lhI4LT65SCJbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsFKjsLg%253D&md5=bb48168ab601c31942907e798617b027</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm00071a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00071a013%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DM.%2BH.%26aulast%3Dvan%2Bder%2BDoes%26aufirst%3DL.%26aulast%3DBantjes%26aufirst%3DA.%26atitle%3DIron%2520%2528III%2529-chelating%2520resins.%25203.%2520Synthesis%252C%2520iron%2520%2528III%2529-chelating%2520properties%252C%2520and%2520in%2520vitro%2520antibacterial%2520activity%2520of%2520compounds%2520containing%25203-hydroxy-2-methyl-4%25281H%2529-pyridinone%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D2822%26epage%3D2827%26doi%3D10.1021%2Fjm00071a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howlett, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godfrey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swatton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzfaden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadsworth, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markwell, R. E.</span></span> <span> </span><span class="NLM_article-title">Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>340</i></span>,  <span class="NLM_fpage">283</span>â <span class="NLM_lpage">289</span>, <span class="refDoi">Â DOI: 10.1042/bj3400283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1042%2Fbj3400283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10229684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK1MXjs12ks7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=1999&pages=283-289&author=D.+R.+Howlettauthor=A.+E.+Perryauthor=F.+Godfreyauthor=J.+E.+Swattonauthor=K.+H.+Jenningsauthor=C.+Spitzfadenauthor=H.+Wadsworthauthor=S.+J.+Woodauthor=R.+E.+Markwell&title=Inhibition+of+fibril+formation+in+beta-amyloid+peptide+by+a+novel+series+of+benzofurans&doi=10.1042%2Fbj3400283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of fibril formation in Î²-amyloid peptide by a novel series of benzofurans</span></div><div class="casAuthors">Howlett, David R.; Perry, Amanda E.; Godfrey, Fiona; Swatton, Jane E.; Jennings, Kevin H.; Spitzfaden, Claus; Wadsworth, Harry; Wood, Stephen J.; Markwell, Roger E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">283-289</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A series of benzofuran derivs. have been identified as inhibitors of fibril formation in the Î²-amyloid peptide.  The activity of these compds. has been assessed by a novel fibril-formation-specific immunoassay and for their effects on the prodn. of a biol. active fibril product.  The inhibition afforded by the compds. seems to be assocd. with their binding to Î²-amyloid, as identified by scintillation proximity binding assay.  Binding assays and NMR studies also indicate that the inhibition is assocd. with self-aggregation of the compds.  There is a close correlation between the activity of the benzofurans as inhibitors of fibril formation and their ability to bind to Î²-amyloid.  Non-benzofuran inhibitors of the fibril formation process do not seem to bind to the same site on the Î²-amyloid mol. as the benzofurans.  Thus a specific recognition site might exist for benzofurans on Î²-amyloid, binding to which seems to interfere with the ability of the peptide to form fibrils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxXU-nZHkgI7Vg90H21EOLACvtfcHk0lhI4LT65SCJbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjs12ks7c%253D&md5=bac96c369fe13814e21fcea7adfc4efc</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1042%2Fbj3400283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3400283%26sid%3Dliteratum%253Aachs%26aulast%3DHowlett%26aufirst%3DD.%2BR.%26aulast%3DPerry%26aufirst%3DA.%2BE.%26aulast%3DGodfrey%26aufirst%3DF.%26aulast%3DSwatton%26aufirst%3DJ.%2BE.%26aulast%3DJennings%26aufirst%3DK.%2BH.%26aulast%3DSpitzfaden%26aufirst%3DC.%26aulast%3DWadsworth%26aufirst%3DH.%26aulast%3DWood%26aufirst%3DS.%2BJ.%26aulast%3DMarkwell%26aufirst%3DR.%2BE.%26atitle%3DInhibition%2520of%2520fibril%2520formation%2520in%2520beta-amyloid%2520peptide%2520by%2520a%2520novel%2520series%2520of%2520benzofurans%26jtitle%3DBiochem.%2520J.%26date%3D1999%26volume%3D340%26spage%3D283%26epage%3D289%26doi%3D10.1042%2Fbj3400283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, S.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of dual inhibitors for matrix metalloproteinase and cathepsin</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">375</span>â <span class="NLM_lpage">378</span>, <span class="refDoi">Â DOI: 10.1016/S0960-894X(01)00755-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS0960-894X%2801%2900755-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=11814800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XpslKktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=375-378&author=M.+Yamamotoauthor=S.+Ikedaauthor=H.+Kondoauthor=S.+Inoue&title=Design+and+synthesis+of+dual+inhibitors+for+matrix+metalloproteinase+and+cathepsin&doi=10.1016%2FS0960-894X%2801%2900755-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of dual inhibitors for matrix metalloproteinase and cathepsin</span></div><div class="casAuthors">Yamamoto, Minoru; Ikeda, Shoji; Kondo, Hirosato; Inoue, Shintaro</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-378</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The first example of dual inhibitors for matrix metalloproteinase (MMP) and cathepsin is described.  An appropriate alignment of peptide parts and two different specific functional groups in one mol. led to the discovery of a potent dual inhibitor in pseudopeptide aldehyde I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWufpXfVOslrVg90H21EOLACvtfcHk0lhI4LT65SCJbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpslKktA%253D%253D&md5=f12ee37183639244b07ab55c4d5690fc</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900755-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900755-7%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DIkeda%26aufirst%3DS.%26aulast%3DKondo%26aufirst%3DH.%26aulast%3DInoue%26aufirst%3DS.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dual%2520inhibitors%2520for%2520matrix%2520metalloproteinase%2520and%2520cathepsin%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D375%26epage%3D378%26doi%3D10.1016%2FS0960-894X%2801%2900755-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grams, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crimmin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinnes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huxley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieper, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschesche, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, W.</span></span> <span> </span><span class="NLM_article-title">Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">14012</span>â <span class="NLM_lpage">14020</span>, <span class="refDoi">Â DOI: 10.1021/bi00043a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00043a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK2MXos1WmsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1995&pages=14012-14020&author=F.+Gramsauthor=M.+Crimminauthor=L.+Hinnesauthor=P.+Huxleyauthor=M.+Pieperauthor=H.+Tschescheauthor=W.+Bode&title=Structure+determination+and+analysis+of+human+neutrophil+collagenase+complexed+with+a+hydroxamate+inhibitor&doi=10.1021%2Fbi00043a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor</span></div><div class="casAuthors">Grams, Frank; Crimmin, Mike; Hinnes, Laurie; Huxley, Philip; Pieper, Michael; Tschesche, Harald; Bode, Wolfram</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">14012-20</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human neutrophil collagenase (I) represents 1 of the 3 interstitial collagenases that cleave triple-helical collagens types I, II, and III.  Its 163-residue catalytic domain (Met-80 to Gly-242) was expressed in Escherichia coli and crystd. as a noncovalent complex with the hydroxamate inhibitor, batimastat (II).  The crystal structure, refined to 2.1 Ã, demonstrated that II bound to the S1-S2' sites and coordinated to the catalytic Zn in a bidentate manner via the OH group and carbonyl O atoms of the hydroxamate group.  The I-II complex is described in detail, and the activities of II analogs are discussed in the light of the protein-inhibitor interactions revealed by the crystallog. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3Rs2OmOhJ1LVg90H21EOLACvtfcHk0lgxvXBhN0teaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXos1WmsLs%253D&md5=7b1fb4b420e580c72583b298265d7112</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fbi00043a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00043a007%26sid%3Dliteratum%253Aachs%26aulast%3DGrams%26aufirst%3DF.%26aulast%3DCrimmin%26aufirst%3DM.%26aulast%3DHinnes%26aufirst%3DL.%26aulast%3DHuxley%26aufirst%3DP.%26aulast%3DPieper%26aufirst%3DM.%26aulast%3DTschesche%26aufirst%3DH.%26aulast%3DBode%26aufirst%3DW.%26atitle%3DStructure%2520determination%2520and%2520analysis%2520of%2520human%2520neutrophil%2520collagenase%2520complexed%2520with%2520a%2520hydroxamate%2520inhibitor%26jtitle%3DBiochemistry%26date%3D1995%26volume%3D34%26spage%3D14012%26epage%3D14020%26doi%3D10.1021%2Fbi00043a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigeizumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K.</span></span> <span> </span><span class="NLM_article-title">Peptidyl aldehyde derivatives as potent and selective inhibitors of cathepsin L</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1501</span>â <span class="NLM_lpage">1504</span>, <span class="refDoi">Â DOI: 10.1016/0960-894X(95)00236-M</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2F0960-894X%2895%2900236-M" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK2MXntFKisrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1995&pages=1501-1504&author=J.+T.+Wooauthor=S.+Sigeizumiauthor=K.+Yamaguchiauthor=K.+Sugimotoauthor=T.+Koboriauthor=T.+Tsujiauthor=K.+Kondo&title=Peptidyl+aldehyde+derivatives+as+potent+and+selective+inhibitors+of+cathepsin+L&doi=10.1016%2F0960-894X%2895%2900236-M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Peptidyl aldehyde derivatives as potent and selective inhibitors of cathepsin L</span></div><div class="casAuthors">Woo, Je-Tae; Sigeizumi, Sanae; Yamaguchi, Kohji; Sugimoto, Kikuo; Kobori, Takeo; Tsuji, Tomoko; Kondo, Kiyosi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1501-4</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A series of peptidyl aldehyde derivs. were synthesized and tested for their inhibitory effects on several cysteine proteases and a serine protease.  These compds. showed no inhibition. for Î±-chymotrypsin at the concn. less than 1000 ng/mL, while they exhibited prominent inhibition for calpain II and cathepsins, esp. cathepsin L.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTkB6eOZAZ9rVg90H21EOLACvtfcHk0lgxvXBhN0teaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXntFKisrk%253D&md5=d070ff4b3c5775837b8d10cf58894daf</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2895%2900236-M&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252895%252900236-M%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DJ.%2BT.%26aulast%3DSigeizumi%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DSugimoto%26aufirst%3DK.%26aulast%3DKobori%26aufirst%3DT.%26aulast%3DTsuji%26aufirst%3DT.%26aulast%3DKondo%26aufirst%3DK.%26atitle%3DPeptidyl%2520aldehyde%2520derivatives%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520cathepsin%2520L%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1995%26volume%3D5%26spage%3D1501%26epage%3D1504%26doi%3D10.1016%2F0960-894X%2895%2900236-M" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3</span>â <span class="NLM_lpage">25</span>, <span class="refDoi">Â DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0lgxvXBhN0teaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberry, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallender, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, J. L.</span></span> <span> </span><span class="NLM_article-title">Three-dimensional structures of Drosophila melanogaster acetylcholinesterase and of its complexes with two potent inhibitors</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1063</span>â <span class="NLM_lpage">1072</span>, <span class="refDoi">Â DOI: 10.1110/ps.9.6.1063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1110%2Fps.9.6.1063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10892800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1Kqs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2000&pages=1063-1072&author=M.+Harelauthor=G.+Krygerauthor=T.+L.+Rosenberryauthor=W.+D.+Mallenderauthor=T.+Lewisauthor=R.+J.+Fletcherauthor=J.+M.+Gussauthor=I.+Silmanauthor=J.+L.+Sussman&title=Three-dimensional+structures+of+Drosophila+melanogaster+acetylcholinesterase+and+of+its+complexes+with+two+potent+inhibitors&doi=10.1110%2Fps.9.6.1063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Three-dimensional structures of Drosophila melanogaster acetylcholinesterase and of its complexes with two potent inhibitors</span></div><div class="casAuthors">Harel, Michal; Kryger, Gitay; Rosenberry, Terrone L.; Mallender, William D.; Lewis, Terence; Fletcher, Rodney J.; Guss, J. Mitchell; Silman, Israel; Sussman, Joel L.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1063-1072</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">We have crystd. Drosophila melanogaster acetylcholinesterase and solved the structure of the native enzyme and of its complexes with two potent reversible inhibitors, I and II, all three at 2.7 Ã resoln.  The refined structure of D. melanogaster acetylcholinesterase is similar to that of vertebrate acetylcholinesterases, for example, human, mouse, and fish, in its overall fold, charge distribution, and deep active-site gorge, but some of the surface loops deviate by up to 8 Ã from their position in the vertebrate structures, and the C-terminal helix is shifted substantially.  The active-site gorge of the insect enzyme is significantly narrower than that of Torpedo californica AChE, and its trajectory is shifted several angstroms.  The vol. of the lower part of the gorge of the insect enzyme is â¼50% of that of the vertebrate enzyme.  Upon binding of either of the two inhibitors, nine arom. side chains within the active-site gorge change their conformation so as to interact with the inhibitors.  Some differences in activity and specificity between the insect and vertebrate enzymes can be explained by comparison of their three-dimensional structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfFvuVy44a8LVg90H21EOLACvtfcHk0ljD-eKFzXs6ZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1Kqs70%253D&md5=b664cffd676e44e0311fc30920bcd280</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1110%2Fps.9.6.1063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1110%252Fps.9.6.1063%26sid%3Dliteratum%253Aachs%26aulast%3DHarel%26aufirst%3DM.%26aulast%3DKryger%26aufirst%3DG.%26aulast%3DRosenberry%26aufirst%3DT.%2BL.%26aulast%3DMallender%26aufirst%3DW.%2BD.%26aulast%3DLewis%26aufirst%3DT.%26aulast%3DFletcher%26aufirst%3DR.%2BJ.%26aulast%3DGuss%26aufirst%3DJ.%2BM.%26aulast%3DSilman%26aufirst%3DI.%26aulast%3DSussman%26aufirst%3DJ.%2BL.%26atitle%3DThree-dimensional%2520structures%2520of%2520Drosophila%2520melanogaster%2520acetylcholinesterase%2520and%2520of%2520its%2520complexes%2520with%2520two%2520potent%2520inhibitors%26jtitle%3DProtein%2520Sci.%26date%3D2000%26volume%3D9%26spage%3D1063%26epage%3D1072%26doi%3D10.1110%2Fps.9.6.1063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schalk, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehret-Sabatier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goeldner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axelsen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, J. L.</span></span> <span> </span><span class="NLM_article-title">Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">9031</span>â <span class="NLM_lpage">9035</span>, <span class="refDoi">Â DOI: 10.1073/pnas.90.19.9031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1073%2Fpnas.90.19.9031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=8415649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK3sXmsVCgtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=9031-9035&author=M.+Harelauthor=I.+Schalkauthor=L.+Ehret-Sabatierauthor=F.+Bouetauthor=M.+Goeldnerauthor=C.+Hirthauthor=P.+H.+Axelsenauthor=I.+Silmanauthor=J.+L.+Sussman&title=Quaternary+ligand+binding+to+aromatic+residues+in+the+active-site+gorge+of+acetylcholinesterase&doi=10.1073%2Fpnas.90.19.9031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase</span></div><div class="casAuthors">Harel, M.; Schalk, I.; Ehret-Sabatier, L.; Bouet, F.; Goeldner, M.; Hirth, C.; Axelsen, P. H.; Silman, I.; Sussman, J. L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9031-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The binding sites of Torpedo acetylcholinesterase (AChE; EC 3.1.1.7) for quaternary ligands were investigated by x-ray crystallog. and photoaffinity labeling.  The crystal structures of complexes with ligands were detd. at 2.8-Ã resoln.  In a complex with edrophonium, the quaternary N atom of the ligand interacted with the indole of Trp-84, and its m-OH group displayed bifurcated H-bonding to 2 members of the catalytic triad, Ser-200 and His-440.  In a complex with tacrine, the acridine was stacked against the indole of Trp-84.  The bisquaternary ligand, decamethonium, was oriented along the narrow gorge leading to the active site; one quaternary group was apposed to the indole of Trp-84 and the other to that of Trp-279, near the top of the gorge.  The only major conformational difference between the 3 complexes was in the orientation of the Ph ring of Phe-330.  In the decamethonium complex, it lay parallel to the surface of the gorge; in the other 2 complexes it was positioned to make contact with the bound ligand.  This close interaction was confirmed by photoaffinity labeling by the photosensitive probe, 3H-labeled p-(N,N-dimethylamino)benzenediazonium fluoroborate, which labeled, predominantly, Phe-330 within the active site.  The labeling of Trp-279 was also obsd.  One mole of label was incorporated per mol of AChE inactivated, indicating that the labeling of Trp-279 and that of Phe-330 were mutually exclusive.  The structural and chem. data, together, showed the important role of arom. groups as binding sites for quaternary ligands, and they provided complementary evidence assigning Trp-84 and Phe-330 to the anionic subsite of the active site and Trp-279 to the peripheral anionic site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVCccIwJSrW7Vg90H21EOLACvtfcHk0ljD-eKFzXs6ZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmsVCgtrc%253D&md5=6ee8dbaf1919d254a1cb62895f1a4444</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.19.9031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.19.9031%26sid%3Dliteratum%253Aachs%26aulast%3DHarel%26aufirst%3DM.%26aulast%3DSchalk%26aufirst%3DI.%26aulast%3DEhret-Sabatier%26aufirst%3DL.%26aulast%3DBouet%26aufirst%3DF.%26aulast%3DGoeldner%26aufirst%3DM.%26aulast%3DHirth%26aufirst%3DC.%26aulast%3DAxelsen%26aufirst%3DP.%2BH.%26aulast%3DSilman%26aufirst%3DI.%26aulast%3DSussman%26aufirst%3DJ.%2BL.%26atitle%3DQuaternary%2520ligand%2520binding%2520to%2520aromatic%2520residues%2520in%2520the%2520active-site%2520gorge%2520of%2520acetylcholinesterase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1993%26volume%3D90%26spage%3D9031%26epage%3D9035%26doi%3D10.1073%2Fpnas.90.19.9031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Arias, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez-GonzÃ¡lez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, E. H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espelosin, M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of first-in-class dual acting HDAC and PDE5 inhibitors for the treatment of Alzheimerâs disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8967</span>â <span class="NLM_lpage">9004</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00908</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00908" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyqtL7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8967-9004&author=O.+Rabalauthor=J.+A.+Sanchez-Ariasauthor=M.+D.+M.+Cuadrado-Tejedorauthor=I.+D.+Miguelauthor=M.+P%C3%A9rez-Gonz%C3%A1lezauthor=C.+Garcia-Barrosoauthor=A.+Ugarteauthor=E.+H.+D.+Mendozaauthor=E.+Saezauthor=M.+Espelosin&title=Design%2C+synthesis%2C+and+biological+evaluation+of+first-in-class+dual+acting+HDAC+and+PDE5+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Facs.jmedchem.6b00908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Rabal, Obdulia; Sanchez-Arias, Juan A.; Cuadrado-Tejedor, Mar; de Miguel, Irene; Perez-Gonzalez, Marta; Garcia-Barroso, Carolina; Ugarte, Ana; Estella-Hermoso de Mendoza, Ander; Saez, Elena; Espelosin, Maria; Ursua, Susana; Haizhong, Tan; Wei, Wu; Musheng, Xu; Garcia-Osta, Ana; Oyarzabal, Julen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8967-9004</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylases (HDAC) has recently been validated as a potentially novel therapeutic approach for Alzheimer's Disease (AD).  To further extend this concept, the authors designed and synthesized the first chem. series of dual acting PDE5 and HDAC inhibitors, and the authors validated this systems therapeutics approach.  Following the implementation of structure- and knowledge-based approaches, initial hits were designed and were shown to validate the hypothesis of dual in vitro inhibition.  Then, an optimization strategy was pursued to obtain a proper tool compd. for in vivo testing in AD models.  Initial hits were translated into mols. with adequate cellular functional responses (histone acetylation and cAMP/cGMP response element-binding (CREB) phosphorylation in the nanomolar range), an acceptable therapeutic window (>1 log unit) and the ability to cross the blood-brain barrier, leading to the identification of 7 as a candidate for in vivo proof-of-concept testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbHBoJlefNEbVg90H21EOLACvtfcHk0ljD-eKFzXs6ZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyqtL7O&md5=756a252809f05f5d7fc59e828736cfba</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00908%26sid%3Dliteratum%253Aachs%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DSanchez-Arias%26aufirst%3DJ.%2BA.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%2BD.%2BM.%26aulast%3DMiguel%26aufirst%3DI.%2BD.%26aulast%3DP%25C3%25A9rez-Gonz%25C3%25A1lez%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DMendoza%26aufirst%3DE.%2BH.%2BD.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DEspelosin%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520first-in-class%2520dual%2520acting%2520HDAC%2520and%2520PDE5%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8967%26epage%3D9004%26doi%3D10.1021%2Facs.jmedchem.6b00908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sivaprakasam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civiello, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacutin-Porte, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szapiel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newitt, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nophsker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1856</span>â <span class="NLM_lpage">1863</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.03.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmcl.2015.03.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=25845281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVKrsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1856-1863&author=P.+Sivaprakasamauthor=X.+Hanauthor=R.+L.+Civielloauthor=S.+Jacutin-Porteauthor=K.+Kishauthor=M.+Pokrossauthor=H.+A.+Lewisauthor=N.+Ahmedauthor=N.+Szapielauthor=J.+A.+Newittauthor=E.+T.+Baldwinauthor=H.+Xiaoauthor=C.+M.+Krauseauthor=H.+Parkauthor=M.+Nophskerauthor=J.+S.+Lippyauthor=C.+R.+Burtonauthor=D.+R.+Langleyauthor=J.+E.+Macorauthor=G.+M.+Dubowchik&title=Discovery+of+new+acylaminopyridines+as+GSK-3+inhibitors+by+a+structure+guided+in-depth+exploration+of+chemical+space+around+a+pyrrolopyridinone+core&doi=10.1016%2Fj.bmcl.2015.03.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core</span></div><div class="casAuthors">Sivaprakasam, Prasanna; Han, Xiaojun; Civiello, Rita L.; Jacutin-Porte, Swanee; Kish, Kevin; Pokross, Matt; Lewis, Hal A.; Ahmed, Nazia; Szapiel, Nicolas; Newitt, John A.; Baldwin, Eric T.; Xiao, Hong; Krause, Carol M.; Park, Hyunsoo; Nophsker, Michelle; Lippy, Jonathan S.; Burton, Catherine R.; Langley, David R.; Macor, John E.; Dubowchik, Gene M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1856-1863</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Glycogen synthase kinase-3 (GSK-3) has been proposed to play a crucial role in the pathogenesis of many diseases including cancer, stroke, bipolar disorders, diabetes and neurodegenerative diseases.  GSK-3 inhibition has been a major area of pharmaceutical interest over the last two decades.  A plethora of reports appeared recently on selective inhibitors and their co-crystal structures in GSK-3Î².  We identified several series of promising new GSK-3Î² inhibitors from a coherent design around a pyrrolopyridinone core structure.  A systematic exploration of the chem. space around the central spacer led to potent single digit and sub-nanomolar GSK-3Î² inhibitors.  When dosed orally in a transgenic mouse model of Alzheimer's disease (AD), an exemplary compd. showed significant lowering of Tau phosphorylation at one of the GSK-3 phosphorylating sites, Ser396.  X-ray crystallog. greatly aided in validating the binding hypotheses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTULEgiCtJ_bVg90H21EOLACvtfcHk0liNa7zi9WR84Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVKrsro%253D&md5=207523726b69167ee5318f90b2822af0</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.03.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.03.046%26sid%3Dliteratum%253Aachs%26aulast%3DSivaprakasam%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DJacutin-Porte%26aufirst%3DS.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DH.%2BA.%26aulast%3DAhmed%26aufirst%3DN.%26aulast%3DSzapiel%26aufirst%3DN.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DBaldwin%26aufirst%3DE.%2BT.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DKrause%26aufirst%3DC.%2BM.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DNophsker%26aufirst%3DM.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DBurton%26aufirst%3DC.%2BR.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26atitle%3DDiscovery%2520of%2520new%2520acylaminopyridines%2520as%2520GSK-3%2520inhibitors%2520by%2520a%2520structure%2520guided%2520in-depth%2520exploration%2520of%2520chemical%2520space%2520around%2520a%2520pyrrolopyridinone%2520core%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1856%26epage%3D1863%26doi%3D10.1016%2Fj.bmcl.2015.03.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimerâs disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">745</span>â <span class="NLM_lpage">753</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2013.01.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2013.01.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23454517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslWgu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=745-753&author=C.+Luauthor=Q.+Zhouauthor=J.+Yanauthor=Z.+Duauthor=L.+Huangauthor=X.+Li&title=A+novel+series+of+tacrine-selegiline+hybrids+with+cholinesterase+and+monoamine+oxidase+inhibition+activities+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2013.01.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Lu, Chuanjun; Zhou, Qi; Yan, Jun; Du, Zhiyun; Huang, Ling; Li, Xingshu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">745-753</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of tacrine-selegiline hybrids was synthesized and evaluated for application as inhibitors of cholinesterase (AChE/BuChE) and monoamine oxidase (MAO-A/B).  The results demonstrate that most of the synthesized compds. exhibit high inhibitory activity.  Among these compds., compd. I provided a good balance of activity towards all targets (with IC50 values of 22.6 nM, 9.37 nM, 0.3724 Î¼M, and 0.1810 Î¼M for AChE, BuChE, MAO-A and MAO-B, resp.).  These results indicated that I has the potential to be a multi-functional candidate for Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB-OnHqpBtBrVg90H21EOLACvtfcHk0liNa7zi9WR84Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslWgu7g%253D&md5=9e0cfdecbe4e8a2890482f8b32cbf4a4</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.01.039%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DA%2520novel%2520series%2520of%2520tacrine-selegiline%2520hybrids%2520with%2520cholinesterase%2520and%2520monoamine%2520oxidase%2520inhibition%2520activities%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D62%26spage%3D745%26epage%3D753%26doi%3D10.1016%2Fj.ejmech.2013.01.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Am, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amit, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinreb, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandel, S.</span></span> <span> </span><span class="NLM_article-title">Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">361</span>â <span class="NLM_lpage">371</span>, <span class="refDoi">Â DOI: 10.3233/JAD-2010-100150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.3233%2FJAD-2010-100150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=20555137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVKiurbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=361-371&author=O.+Bar-Amauthor=T.+Amitauthor=O.+Weinrebauthor=M.+B.+Youdimauthor=S.+Mandel&title=Propargylamine+containing+compounds+as+modulators+of+proteolytic+cleavage+of+amyloid-beta+protein+precursor%3A+involvement+of+MAPK+and+PKC+activation&doi=10.3233%2FJAD-2010-100150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Propargylamine Containing Compounds as Modulators of Proteolytic Cleavage of Amyloid Protein Precursor: Involvement of MAPK and PKC Activation</span></div><div class="casAuthors">Bar-Am, Orit; Amit, Tamar; Weinreb, Orly; Youdim, Moussa B. H.; Mandel, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-371</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  The anti-Parkinsonian, irreversible, selective monoamine oxidase (MAO)-B inhibitors, selegiline (deprenyl, (R)-N-methyl-N-(1-phenylpropan-2-yl) prop-2-yn-1-amine) and rasagiline (Azilect, N-propargyl-1(R)-aminoindan), have been proven to possess neuroprotective/neurorestorative activities in cell cultures and animal models of neurodegenerative diseases.  Structure-activity studies provide evidence that neuroprotection is assocd. with some intrinsic pharmacol. action of the propargylamine moiety in these drugs.  This indication and recent therapeutic approaches, entailing new drug candidates possessing diverse pharmacol. properties and acting on multiple targets, have stimulated the development of two multifunctional chimeric propargylamine-derivs.: 1) ladostigil (TV3326, [(N-propargyl-(3R) 1-(R)-aminoindan-5yl)-Et Me carbamate)], which combines the pharmacophore of rasagiline, with the carbamate moiety of the cholinesterase inhibitor rivastigmine, as a potential treatment for Alzheimer's disease and Lewy body disease; and 2) M30 5-[(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline], where the propargylamine moiety of rasagiline was embedded onto the backbone of the neuroprotective and brain permeable iron chelator 8-hydroxyquinoline-deriv., VK28 as a potential treatment for various neurodegenerative disorders.  Both multifunctional propargylamine-derivs. were found to possess neuroprotective and anti-apoptotic properties.  An addnl. and new neuroprotective effect, shared by the propargylamine-deriv. compds., is related to their ability to regulate the processing of amyloid-Î² protein precursor (AÎ²PP) by the non-amyloidogenic Î±-secretase pathway.  This effect was shown to involve activation of p42/44 mitogen-activated protein kinase (MAPK) and protein kinase C (PKC) signaling pathway.  This review will summarize and discuss current research, focused on the effect of propargylamine-related derivs. on the proteolytic processing of AÎ²PP and signal transduction mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotFS9dzcnX37Vg90H21EOLACvtfcHk0ljkiSc-6Kl16g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVKiurbE&md5=8250c3767772a7872029118692aba8fc</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.3233%2FJAD-2010-100150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2010-100150%26sid%3Dliteratum%253Aachs%26aulast%3DBar-Am%26aufirst%3DO.%26aulast%3DAmit%26aufirst%3DT.%26aulast%3DWeinreb%26aufirst%3DO.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DMandel%26aufirst%3DS.%26atitle%3DPropargylamine%2520containing%2520compounds%2520as%2520modulators%2520of%2520proteolytic%2520cleavage%2520of%2520amyloid-beta%2520protein%2520precursor%253A%2520involvement%2520of%2520MAPK%2520and%2520PKC%2520activation%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2010%26volume%3D21%26spage%3D361%26epage%3D371%26doi%3D10.3233%2FJAD-2010-100150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Bachiller, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monjas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rademann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Franco, M. I.</span></span> <span> </span><span class="NLM_article-title">New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimerâs disease, with cholinergic, antioxidant, and Î²-amyloid-reducing properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1303</span>â <span class="NLM_lpage">1317</span>, <span class="refDoi">Â DOI: 10.1021/jm201460y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201460y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFKisw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1303-1317&author=M.+I.+Fernandez-Bachillerauthor=C.+Perezauthor=L.+Monjasauthor=J.+Rademannauthor=M.+I.+Rodriguez-Franco&title=New+tacrine-4-oxo-4H-chromene+hybrids+as+multifunctional+agents+for+the+treatment+of+Alzheimer%E2%80%99s+disease%2C+with+cholinergic%2C+antioxidant%2C+and+%CE%B2-amyloid-reducing+properties&doi=10.1021%2Fjm201460y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">New Tacrine-4-Oxo-4H-chromene Hybrids as Multifunctional Agents for the Treatment of Alzheimer's Disease, with Cholinergic, Antioxidant, and Î²-Amyloid-Reducing Properties</span></div><div class="casAuthors">Fernandez-Bachiller, Maria Isabel; Perez, Concepcion; Monjas, Leticia; Rademann, Jorg; Rodriguez-Franco, Maria Isabel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1303-1317</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By using fragments endowed with interesting and complementary properties for the treatment of Alzheimer's disease (AD), a new family of tacrine-4-oxo-4H-chromene hybrids has been designed, synthesized, and evaluated biol.  The tacrine fragment was selected for its inhibition of cholinesterases, and the flavonoid scaffold derived from 4-oxo-4H -chromene was chosen for its radical capture and Î²-secretase 1 (BACE-1) inhibitory activities.  At nano- and picomolar concns., the new tacrine-4-oxo-4H-chromene hybrids inhibit human acetyl- and butyrylcholinesterase (h-AChE and h-BuChE), being more potent than the parent inhibitor, tacrine.  They are also potent inhibitors of human BACE-1, better than the parent flavonoid, apigenin.  They show interesting antioxidant properties and could be able to penetrate into the CNS according to the in vitro PAMPA-BBB assay.  Among the hybrids investigated, 6-hydroxy-4-oxo- N-{10-[(1,2,3,4-tetrahydroacridin-9-yl)amino]decyl}-4 H-chromene-2-carboxamide (I) shows potent combined inhibition of human BACE-1 and ChEs, as well as good antioxidant and CNS-permeable properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiMx-NagCpeLVg90H21EOLACvtfcHk0ljkiSc-6Kl16g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFKisw%253D%253D&md5=9391af9439e43f5eda518919839bd473</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjm201460y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201460y%26sid%3Dliteratum%253Aachs%26aulast%3DFernandez-Bachiller%26aufirst%3DM.%2BI.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DMonjas%26aufirst%3DL.%26aulast%3DRademann%26aufirst%3DJ.%26aulast%3DRodriguez-Franco%26aufirst%3DM.%2BI.%26atitle%3DNew%2520tacrine-4-oxo-4H-chromene%2520hybrids%2520as%2520multifunctional%2520agents%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%252C%2520with%2520cholinergic%252C%2520antioxidant%252C%2520and%2520%25CE%25B2-amyloid-reducing%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1303%26epage%3D1317%26doi%3D10.1021%2Fjm201460y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osseni, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debbasch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christen, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnet, J. M.</span></span> <span> </span><span class="NLM_article-title">Tacrine-induced reactive oxygen species in a human liver cell line: the role of anethole dithiolethione as a scavenger</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">683</span>â <span class="NLM_lpage">688</span>, <span class="refDoi">Â DOI: 10.1016/S0887-2333(99)00050-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS0887-2333%2899%2900050-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=20654534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK1MXlslWit7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1999&pages=683-688&author=R.+A.+Osseniauthor=C.+Debbaschauthor=M.+O.+Christenauthor=P.+Ratauthor=J.+M.+Warnet&title=Tacrine-induced+reactive+oxygen+species+in+a+human+liver+cell+line%3A+the+role+of+anethole+dithiolethione+as+a+scavenger&doi=10.1016%2FS0887-2333%2899%2900050-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Tacrine-induced reactive oxygen species in a human liver cell line: the role of anethole dithiolethione as a scavenger</span></div><div class="casAuthors">Osseni, R. A.; Debbasch, C.; Christen, M.-O.; Rat, P.; Warnet, J.-M.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology in Vitro</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4/5</span>),
    <span class="NLM_cas:pages">683-688</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The mechanisms leading to tacrine (THA) hepatotoxic effects are not yet fully understood.  Reactive oxygen species (ROS) overprodn. and intracellular reduced glutathione (GSH) depletion are common mechanisms involved in drug toxicity.  The aim of this study was to investigate, on the human liver cell line HepG2, whether THA at human blood concns. induces ROS prodn. stimulation and(or) GSH depletion.  A possible effect of a free radical scavenger, anethole dithiolethione (ADT), was also assessed.  ROS prodn. was measured with a fluorogen probe 2',7'-dichlorofluorescin diacetate (DCFH-DA).  Reduced GSH and cell viability were measured with, resp., monochlorobimane (mBCl) and neutral red probes.  Assays were performed directly on living adherent cells in 96-well microplates, and sensitive fluorescent detection used microplate cytofluorometry with cold light fluorometry technol.  The results showed that THA induced a concn.-dependent increase in ROS prodn. and a decrease in GSH.  Furthermore, for THA concns. between 10 and 100 Î¼M, ADT protected cells from ROS prodn. stimulation and GSH depletion induced by THA.  Thus, this in vitro study demonstrates that oxidative stress, evidenced by enhanced ROS prodn. and GSH depletion, is a mechanism involved in THA cytotoxicity.  Moreover, ADT is effective in preventing THA-induced injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsG1G2puSbFLVg90H21EOLACvtfcHk0ljkiSc-6Kl16g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlslWit7o%253D&md5=b3aedfa565619d92bb7cb27019a60be8</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2FS0887-2333%2899%2900050-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0887-2333%252899%252900050-8%26sid%3Dliteratum%253Aachs%26aulast%3DOsseni%26aufirst%3DR.%2BA.%26aulast%3DDebbasch%26aufirst%3DC.%26aulast%3DChristen%26aufirst%3DM.%2BO.%26aulast%3DRat%26aufirst%3DP.%26aulast%3DWarnet%26aufirst%3DJ.%2BM.%26atitle%3DTacrine-induced%2520reactive%2520oxygen%2520species%2520in%2520a%2520human%2520liver%2520cell%2520line%253A%2520the%2520role%2520of%2520anethole%2520dithiolethione%2520as%2520a%2520scavenger%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D1999%26volume%3D13%26spage%3D683%26epage%3D688%26doi%3D10.1016%2FS0887-2333%2899%2900050-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimmyo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akaike, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niidome, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, H.</span></span> <span> </span><span class="NLM_article-title">Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1780</i></span>,  <span class="NLM_fpage">819</span>â <span class="NLM_lpage">825</span>, <span class="refDoi">Â DOI: 10.1016/j.bbagen.2008.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bbagen.2008.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=18295609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvFWqurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1780&publication_year=2008&pages=819-825&author=Y.+Shimmyoauthor=T.+Kiharaauthor=A.+Akaikeauthor=T.+Niidomeauthor=H.+Sugimoto&title=Flavonols+and+flavones+as+BACE-1+inhibitors%3A+structure-activity+relationship+in+cell-free%2C+cell-based+and+in+silico+studies+reveal+novel+pharmacophore+features&doi=10.1016%2Fj.bbagen.2008.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Flavonols and flavones as BACE-1 inhibitors: Structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features</span></div><div class="casAuthors">Shimmyo, Yoshiari; Kihara, Takeshi; Akaike, Akinori; Niidome, Tetsuhiro; Sugimoto, Hachiro</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1780</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">819-825</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Generation and accumulation of the amyloid Î² peptide (AÎ²) following proteolytic processing of the amyloid precursor protein (APP) by BACE-1 (Beta-site APP Cleaving Enzyme-1, Î²-secretase) and Î³-secretase is a main causal factor of Alzheimer's disease (AD).  Consequently, inhibition of BACE-1, a rate-limiting enzyme in the prodn. of AÎ², is an attractive therapeutic approach for the treatment of AD.  In this study, we discovered that natural flavonoids act as non-peptidic BACE-1 inhibitors and potently inhibit BACE-1 activity and reduce the level of secreted AÎ² in primary cortical neurons.  In addn., we demonstrated the calcd. docking poses of flavonoids to BACE-1 and revealed the interactions of flavonoids with the BACE-1 catalytic center.  We firstly revealed novel pharmacophore features of flavonoids by using cell-free, cell-based and in silico docking studies.  These results contribute to the development of new BACE-1 inhibitors for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr69BA7p_u0orVg90H21EOLACvtfcHk0ljkiSc-6Kl16g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFWqurw%253D&md5=9e4ecbe2a53f79bdcc25581725e39ac7</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2008.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2008.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DShimmyo%26aufirst%3DY.%26aulast%3DKihara%26aufirst%3DT.%26aulast%3DAkaike%26aufirst%3DA.%26aulast%3DNiidome%26aufirst%3DT.%26aulast%3DSugimoto%26aufirst%3DH.%26atitle%3DFlavonols%2520and%2520flavones%2520as%2520BACE-1%2520inhibitors%253A%2520structure-activity%2520relationship%2520in%2520cell-free%252C%2520cell-based%2520and%2520in%2520silico%2520studies%2520reveal%2520novel%2520pharmacophore%2520features%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2008%26volume%3D1780%26spage%3D819%26epage%3D825%26doi%3D10.1016%2Fj.bbagen.2008.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolden, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Anticancer activities of histone deacetylase inhibitors</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">769</span>â <span class="NLM_lpage">784</span>, <span class="refDoi">Â DOI: 10.1038/nrd2133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fnrd2133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=16955068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=769-784&author=J.+E.+Boldenauthor=M.+J.+Peartauthor=R.+W.+Johnstone&title=Anticancer+activities+of+histone+deacetylase+inhibitors&doi=10.1038%2Fnrd2133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer activities of histone deacetylase inhibitors</span></div><div class="casAuthors">Bolden, Jessica E.; Peart, Melissa J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">769-784</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic regulation of gene expression.  In addn., the activity of non-histone proteins can be regulated through HDAC-mediated hypo-acetylation.  In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes assocd. with cancer, and several classes of HDAC inhibitors have been found to have potent and specific anticancer activities in preclin. studies.  However, such studies have also indicated that the effects of HDAC inhibitors could be considerably broader and more complicated than originally understood.  Here we summarize recent advances in the understanding of the mol. events that underlie the anticancer effects of HDAC inhibitors, and discuss how such information could be used in optimizing the development and application of these agents in the clinic, either as monotherapies or in combination with other anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhfqS1awkOHbVg90H21EOLACvtfcHk0lhS5gmBhAhfSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D&md5=91e55ee942fda3e4e2055ddf299fc866</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fnrd2133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2133%26sid%3Dliteratum%253Aachs%26aulast%3DBolden%26aufirst%3DJ.%2BE.%26aulast%3DPeart%26aufirst%3DM.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DAnticancer%2520activities%2520of%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D769%26epage%3D784%26doi%3D10.1038%2Fnrd2133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">27</span>â <span class="NLM_lpage">37</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2016.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmc.2016.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=27769671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslShu7%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=27-37&author=C.+Dingauthor=S.+Chenauthor=C.+Zhangauthor=G.+Huauthor=W.+Zhangauthor=L.+Liauthor=Y.+Z.+Chenauthor=C.+Tanauthor=Y.+Jiang&title=Synthesis+and+investigation+of+novel+6-%281%2C2%2C3-triazol-4-yl%29-4-aminoquinazolin+derivatives+possessing+hydroxamic+acid+moiety+for+cancer+therapy&doi=10.1016%2Fj.bmc.2016.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy</span></div><div class="casAuthors">Ding, Chao; Chen, Shaopeng; Zhang, Cunlong; Hu, Guangnan; Zhang, Wei; Li, Lulu; Chen, Yu Zong; Tan, Chunyan; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-37</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">By merging the crit. pharmacophore of EGFR/HER2 and HDAC inhibitors into one compd., a novel series of EGFR, HER-2, and HDAC multitarget inhibitors were synthesized.  Compds. 9a-l contained 4-anilinoquinazolines with C-6 triazole-linked long alkyl chains of hydroxamic acid and displayed excellent inhibition against these enzymes (compd. 9d exhibited the best inhibitory potency on wild-type EGFR, HDAC1, and HDAC6 with IC50 values 0.12 nM, 0.72 nM and 3.2 nM individually).  Furthermore, compds. 9b and 9d potently inhibited proliferation of five human cancer cell lines (with IC50 values between 0.49 and 8.76 Î¼M).  Further mechanistic study revealed that compd. 9d also regulated the phosphorylation of EGFR and HER2 and histone H3 hyperacetylation on the cellular level and induced remarkable apoptosis in BT-474 cells.  Therefore, our study suggested that a system network-based multi-target drug design strategy might provided an alternate drug design method, by taking into account the synergy effect of EGFR, HER-2 and HDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9Ow9m5nCSsbVg90H21EOLACvtfcHk0lhS5gmBhAhfSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslShu7%252FO&md5=8be7d3dbffe5f5b9b305280864e5b633</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520investigation%2520of%2520novel%25206-%25281%252C2%252C3-triazol-4-yl%2529-4-aminoquinazolin%2520derivatives%2520possessing%2520hydroxamic%2520acid%2520moiety%2520for%2520cancer%2520therapy%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D27%26epage%3D37%26doi%3D10.1016%2Fj.bmc.2016.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ali, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gisslinger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waltzman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalbovskaya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuitty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoops, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barosi, G.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">787</span>â <span class="NLM_lpage">798</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1110556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1056%2FNEJMoa1110556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=22375970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2qurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=787-798&author=C.+Harrisonauthor=J.+J.+Kiladjianauthor=H.+K.+Al-Aliauthor=H.+Gisslingerauthor=R.+Waltzmanauthor=V.+Stalbovskayaauthor=M.+McQuittyauthor=D.+S.+Hunterauthor=R.+Levyauthor=L.+Knoopsauthor=F.+Cervantesauthor=A.+M.+Vannucchiauthor=T.+Barbuiauthor=G.+Barosi&title=JAK+inhibition+with+ruxolitinib+versus+best+available+therapy+for+myelofibrosis&doi=10.1056%2FNEJMoa1110556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis</span></div><div class="casAuthors">Harrison, Claire; Kiladjian, Jean-Jacques; Al-Ali, Haifa Kathrin; Gisslinger, Heinz; Waltzman, Roger; Stalbovskaya, Viktoriya; McQuitty, Mari; Hunter, Deborah S.; Levy, Richard; Knoops, Laurent; Cervantes, Francisco; Vannucchi, Alessandro M.; Barbui, Tiziano; Barosi, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">787-798</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Treatment options for myelofibrosis are limited.  We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis.  METHODS: We assigned 219 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis to receive oral ruxolitinib or the best available therapy.  The primary end point and key secondary end point of the study were the percentage of patients with at least a 35% redn. in spleen vol. at week 48 and at week 24, resp., as assessed with the use of magnetic resonance imaging or computed tomog.  RESULTS: A total of 28% of the patients in the ruxolitinib group had at least a 35% redn. in spleen vol. at week 48, as compared with 0% in the group receiving the best available therapy (P<0.001); the corresponding percentages at week 24 were 32% and 0% (P<0.001).  At 48 wk, the mean palpable spleen length had decreased by 56% with ruxolitinib but had increased by 4% with the best available therapy.  The median duration of response with ruxolitinib was not reached, with 80% of patients still having a response at a median follow-up of 12 mo.  Patients in the ruxolitinib group had an improvement in overall quality-of-life measures and a redn. in symptoms assocd. with myelofibrosis.  The most common hematol. abnormalities of grade 3 or higher in either group were thrombocytopenia and anemia, which were managed with a dose redn., interruption of treatment, or transfusion.  One patient in each group discontinued treatment owing to thrombocytopenia, and none discontinued owing to anemia.  Nonhematol. adverse events were rare and mostly grade 1 or 2.  Two cases of acute myeloid leukemia were reported with the best available therapy.  CONCLUSIONS: Continuous ruxolitinib therapy, as compared with the best available therapy, was assocd. with marked and durable redns. in splenomegaly and disease-related symptoms, improvements in role functioning and quality of life, and modest toxic effects.  An influence on overall survival has not yet been shown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP7WEm5MUTc7Vg90H21EOLACvtfcHk0ljtePjv7IZvgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2qurs%253D&md5=80494b8923fa49536383523066b22b19</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1110556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1110556%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DKiladjian%26aufirst%3DJ.%2BJ.%26aulast%3DAl-Ali%26aufirst%3DH.%2BK.%26aulast%3DGisslinger%26aufirst%3DH.%26aulast%3DWaltzman%26aufirst%3DR.%26aulast%3DStalbovskaya%26aufirst%3DV.%26aulast%3DMcQuitty%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DD.%2BS.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DKnoops%26aufirst%3DL.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DBarbui%26aufirst%3DT.%26aulast%3DBarosi%26aufirst%3DG.%26atitle%3DJAK%2520inhibition%2520with%2520ruxolitinib%2520versus%2520best%2520available%2520therapy%2520for%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D787%26epage%3D798%26doi%3D10.1056%2FNEJMoa1110556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8233</span>â <span class="NLM_lpage">8262</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Yenauthor=B.+W.+Dymock&title=Design+and+synthesis+of+janus+kinase+2+%28JAK2%29+and+histone+deacetlyase+%28HDAC%29+bispecific+inhibitors+based+on+pacritinib+and+evidence+of+dual+pathway+inhibition+in+hematological+cell+lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0ljtePjv7IZvgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetlyase%2520%2528HDAC%2529%2520bispecific%2520inhibitors%2520based%2520on%2520pacritinib%2520and%2520evidence%2520of%2520dual%2520pathway%2520inhibition%2520in%2520hematological%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ning, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, N. F.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic compounds as anti-cancer agents: Design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">104</span>â <span class="NLM_lpage">115</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.03.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2015.03.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=25800646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVWitbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=104-115&author=C.+Q.+Ningauthor=C.+Luauthor=L.+Huauthor=Y.+J.+Biauthor=L.+Yaoauthor=Y.+J.+Heauthor=L.+F.+Liuauthor=X.+Y.+Liuauthor=N.+F.+Yu&title=Macrocyclic+compounds+as+anti-cancer+agents%3A+Design+and+synthesis+of+multi-acting+inhibitors+against+HDAC%2C+FLT3+and+JAK2&doi=10.1016%2Fj.ejmech.2015.03.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic compounds as anti-cancer agents: Design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2</span></div><div class="casAuthors">Ning, Cheng-Qing; Lu, Cheng; Hu, Liang; Bi, Yan-Jing; Yao, Lei; He, Yu-Jun; Liu, Li-Fei; Liu, Xiao-Yu; Yu, Nie-Fang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104-115</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of macrocyclic compds. I [X = O, CH2O; Y = CH2, CO; n = 1, 2; m = 1-5] were designed and synthesized as multi-target inhibitors targeting HDAC, FLT3 and JAK2.  Some of these compds. exhibited potent HDAC inhibition as well as FLT3 and JAK2 inhibition under both cell-free and cellular conditions.  In vitro antiproliferative assay indicated that these compds. were interestingly more cytotoxic to MV4-11 cells bearing FLT3-ITD mutation and HEL cells bearing JAK2V617F mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvwiDjzqtazLVg90H21EOLACvtfcHk0ljtePjv7IZvgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVWitbY%253D&md5=fc2b93fcbce2998ecd2d6de46a01811d</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.034%26sid%3Dliteratum%253Aachs%26aulast%3DNing%26aufirst%3DC.%2BQ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DBi%26aufirst%3DY.%2BJ.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DY.%2BJ.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26aulast%3DYu%26aufirst%3DN.%2BF.%26atitle%3DMacrocyclic%2520compounds%2520as%2520anti-cancer%2520agents%253A%2520Design%2520and%2520synthesis%2520of%2520multi-acting%2520inhibitors%2520against%2520HDAC%252C%2520FLT3%2520and%2520JAK2%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D95%26spage%3D104%26epage%3D115%26doi%3D10.1016%2Fj.ejmech.2015.03.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6). 1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4638</span>â <span class="NLM_lpage">4658</span>, <span class="refDoi">Â DOI: 10.1021/jm200326p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.+1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2Ffms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma&doi=10.1021%2Fjm200326p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Tan, Evelyn; Chen, Dizhong; Williams, Meredith; Sun, Eric T.; Goh, Kee Chuan; Ong, Wai Chung; Goh, Siok Kun; Hart, Stefan; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4638-4658</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF).  Herein, we describe the design and synthesis of a series of small mol. 4-aryl-2-aminopyrimidine macrocycles and their biol. evaluation against the JAK family of kinase enzymes and FLT3.  The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of I, a potent JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, resp.) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, resp.).  Further profiling of I in preclin. species and mouse xenograft and allograft models is described.  Compd. I (SB1518) was selected as a development candidate and progressed into clin. trials where it is currently in phase 2 for MF and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXtMiC4eaIMLVg90H21EOLACvtfcHk0ljzSBhy8RCK8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D&md5=1fa1a5250cae6ec8c59db67e593fb1f6</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.%25201%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252Ffms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658%26doi%3D10.1021%2Fjm200326p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duenas-Perez, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mead, A. J.</span></span> <span> </span><span class="NLM_article-title">Clinical potential of pacritinib in the treatment of myelofibrosis</span>. <i>Ther. Adv. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">186</span>, <span class="refDoi">Â DOI: 10.1177/2040620715586527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1177%2F2040620715586527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=26288713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1Wgurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=186&author=A.+B.+Duenas-Perezauthor=A.+J.+Mead&title=Clinical+potential+of+pacritinib+in+the+treatment+of+myelofibrosis&doi=10.1177%2F2040620715586527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical potential of pacritinib in the treatment of myelofibrosis</span></div><div class="casAuthors">Duenas-Perez, Ana B.; Mead, Adam J.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Hematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">186-201</span>CODEN:
                <span class="NLM_cas:coden">TAHHAT</span>;
        ISSN:<span class="NLM_cas:issn">2040-6207</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Myelofibrosis (MF) is a myeloid disorder caused by a clonal hematopoietic stem-cell proliferation assocd. with activation of the Janus kinase (JAK) signal transducer and activator of transcription (STAT) signaling pathways.  Patients with MF often develop severe splenomegaly, marked symptom burden and significant cytopenias, with a consequent marked neg. impact on quality of life and survival.  The management of MF patients has dramatically improved with the development of a group of drugs that inhibit JAK signaling.  The first of these agents to be approved was ruxolitinib, a JAK1/JAK2 inhibitor, which has been shown to improve both spleen size and symptoms in patients with MF.  However, myelotoxicity, particularly of the platelet lineage, significantly limits the patient population who can benefit from this agent.  Thus, there is an unmet need for novel agents with limited myelotoxicity to treat MF.  Pacritinib, a JAK2 and FMS-like tyrosine kinase 3 (FLT3) inhibitor, has shown promising results in early phase trials with limited myelotoxicity and clin. responses that are comparable with those seen with ruxolitinib, even in patients with severe thrombocytopenia.  Currently there are two large phase III clin. trials of pacritinib in MF, including patients with thrombocytopenia, and those previously treated with ruxolitinib.  If the encouraging results obsd. in early phase clin. trials are confirmed, pacritinib will represent a new and exciting treatment option for patients with MF and particularly patients with significant cytopenias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql0G1-XMNABbVg90H21EOLACvtfcHk0ljzSBhy8RCK8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1Wgurw%253D&md5=853e744c924e2ba7886dbd6cada43c4c</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1177%2F2040620715586527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040620715586527%26sid%3Dliteratum%253Aachs%26aulast%3DDuenas-Perez%26aufirst%3DA.%2BB.%26aulast%3DMead%26aufirst%3DA.%2BJ.%26atitle%3DClinical%2520potential%2520of%2520pacritinib%2520in%2520the%2520treatment%2520of%2520myelofibrosis%26jtitle%3DTher.%2520Adv.%2520Hematol.%26date%3D2015%26volume%3D6%26spage%3D186%26doi%3D10.1177%2F2040620715586527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Press, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, H. J.</span></span> <span> </span><span class="NLM_article-title">EGFR, HER2 and VEGF pathways: validated targets for cancer treatment</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">2045</span>â <span class="NLM_lpage">2075</span>, <span class="refDoi">Â DOI: 10.2165/00003495-200767140-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.2165%2F00003495-200767140-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=17883287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtleqsrrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=2045-2075&author=M.+F.+Pressauthor=H.+J.+Lenz&title=EGFR%2C+HER2+and+VEGF+pathways%3A+validated+targets+for+cancer+treatment&doi=10.2165%2F00003495-200767140-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR, HER2 and VEGF pathways: validated targets for cancer treatment</span></div><div class="casAuthors">Press, Michael F.; Lenz, Heinz-Josef</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2045-2075</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Targeted therapies are rationally designed to interfere with specific mol. events that are important in tumor growth, progression or survival.  Several targeted therapies with anti-tumor activity in human cancer cell lines and xenograft models have now been shown to produce objective responses, delay disease progression and, in some cases, improve survival of patients with advanced malignancies.  These targeted therapies include cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody; gefitinib and erlotinib, EGFR-specific tyrosine kinase inhibitors; trastuzumab, an anti-human EGFR type 2 (HER2)-related monoclonal antibody; lapatinib, a dual inhibitor of both EGFR- and HER2-assocd. tyrosine kinases; and bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody.  On the basis of preclin. and clin. evidence, EGFR, HER2 and VEGF represent validated targets for cancer therapy and remain the subject of intensive investigation.  Both EGFR and HER2 are targets found on cancer cells, whereas VEGF is a target that acts in the tumor microenvironment.  Clin. studies are focusing on how to best incorporate targeted therapy into current treatment regimens and other studies are exploring whether different strategies for inhibiting these targets will offer greater benefit.  It is clear that optimal use of targeted therapy will depend on understanding how these drugs work mechanistically, and recognising that their activities may differ across patient populations, tumor types and disease stages, as well as when and how they are used in cancer treatment.  The results achieved with targeted therapies to date are promising, although they illustrate the need for addnl. preclin. and clin. study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruB8rVI305xrVg90H21EOLACvtfcHk0ljzSBhy8RCK8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtleqsrrF&md5=d4e6b3997f2b0a252753cdc6a5137a15</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.2165%2F00003495-200767140-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200767140-00006%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DM.%2BF.%26aulast%3DLenz%26aufirst%3DH.%2BJ.%26atitle%3DEGFR%252C%2520HER2%2520and%2520VEGF%2520pathways%253A%2520validated%2520targets%2520for%2520cancer%2520treatment%26jtitle%3DDrugs%26date%3D2007%26volume%3D67%26spage%3D2045%26epage%3D2075%26doi%3D10.2165%2F00003495-200767140-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongratz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciossek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckers, T.</span></span> <span> </span><span class="NLM_article-title">Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8546</span>â <span class="NLM_lpage">8555</span>, <span class="refDoi">Â DOI: 10.1021/jm100665z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100665z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8546-8555&author=S.+Mahboobiauthor=A.+Sellmerauthor=M.+Winklerauthor=E.+Eichhornauthor=H.+Pongratzauthor=T.+Ciossekauthor=T.+Baerauthor=T.+Maierauthor=T.+Beckers&title=Novel+chimeric+histone+deacetylase+inhibitors%3A+a+series+of+lapatinib+hybrides+as+potent+inhibitors+of+epidermal+growth+factor+receptor+%28EGFR%29%2C+human+epidermal+growth+factor+receptor+2+%28HER2%29%2C+and+histone+deacetylase+activity&doi=10.1021%2Fjm100665z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrids as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity</span></div><div class="casAuthors">Mahboobi, Siavosh; Sellmer, Andreas; Winkler, Matthias; Eichhorn, Emerich; Pongratz, Herwig; Ciossek, Thomas; Baer, Thomas; Maier, Thomas; Beckers, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8546-8555</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reversible lysine-specific acetylation has been described as an important posttranslational modification, regulating chromatin structure and transcriptional activity in the case of core histone proteins.  Histone deacetylases (HDAC) are considered as a promising target for anticancer drug development, with I as pan-HDAC inhibitor approved for cutaneous T-cell lymphoma therapy and several other HDAC inhibitors currently in preclin. and clin. development.  Protein kinases are a well-established target for cancer therapy with the EGFR/HER2 inhibitor II approved for treatment of advanced, HER2 pos. breast cancer as a prominent example.  The present report presents a novel strategy for cancer drug development by combination of EGFR/HER2 kinase and HDAC inhibitory activity in one mol.  By combining the structural features of II with an (E)-3-(aryl)-N-hydroxyacrylamide motif known from HDAC inhibitors like III or IV, selective inhibitors were obtained for both targets with potent cellular activity (target inhibition and cytotoxicity) of selected compds. V (X = m-phenylene, 2,5-furandiyl).  By combining two distinct pharmacol. properties in one mol., a broader activity spectrum is postulated and less likelihood of drug resistance in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEElZRNfAQZ7Vg90H21EOLACvtfcHk0ljYcCrhdHQVTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL3I&md5=81bba7c00bb26b42c54075acce5ba525</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm100665z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100665z%26sid%3Dliteratum%253Aachs%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DWinkler%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DCiossek%26aufirst%3DT.%26aulast%3DBaer%26aufirst%3DT.%26aulast%3DMaier%26aufirst%3DT.%26aulast%3DBeckers%26aufirst%3DT.%26atitle%3DNovel%2520chimeric%2520histone%2520deacetylase%2520inhibitors%253A%2520a%2520series%2520of%2520lapatinib%2520hybrides%2520as%2520potent%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%252C%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520%2528HER2%2529%252C%2520and%2520histone%2520deacetylase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8546%26epage%3D8555%26doi%3D10.1021%2Fjm100665z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truesdale, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennisi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alligood, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shewchuk, L.</span></span> <span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">6652</span>â <span class="NLM_lpage">6659</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-04-1168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28Lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells&doi=10.1158%2F0008-5472.CAN-04-1168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0ljYcCrhdHQVTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659%26doi%3D10.1158%2F0008-5472.CAN-04-1168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finnin, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donigian, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rifkind, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span> <span> </span><span class="NLM_article-title">Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>401</i></span>,  <span class="NLM_fpage">188</span>â <span class="NLM_lpage">193</span>, <span class="refDoi">Â DOI: 10.1038/43710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2F43710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10490031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFKgtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=1999&pages=188-193&author=M.+S.+Finninauthor=J.+R.+Donigianauthor=A.+Cohenauthor=V.+M.+Richonauthor=R.+A.+Rifkindauthor=P.+A.+Marksauthor=R.+Breslowauthor=N.+P.+Pavletich&title=Structures+of+a+histone+deacetylase+homologue+bound+to+the+TSA+and+SAHA+inhibitors&doi=10.1038%2F43710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors</span></div><div class="casAuthors">Finnin, Michael S.; Donigian, Jill R.; Cohen, Alona; Richon, Victoria M.; Rifkind, Richard A.; Marks, Paul A.; Breslow, Ronald; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">401</span>
        (<span class="NLM_cas:issue">6749</span>),
    <span class="NLM_cas:pages">188-193</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression.  HDACs are involved in cell-cycle progression and differentiation, and their deregulation is assocd. with several cancers.  HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumor effects, as they can inhibit cell growth, induce terminal differentiation and prevent the formation of tumors in mice models, and they are effective in the treatment of promyelocytic leukemia.  Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homolog from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% identity with human HDAC1 over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA.  The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition.  The residues that make up the active site and contact the inhibitors are conserved across the HDAC family.  These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrG0lsZMMo37Vg90H21EOLACvtfcHk0ljYcCrhdHQVTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFKgtrc%253D&md5=29bbc6d3ba9a9d2a8c330349ae8199a8</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2F43710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F43710%26sid%3Dliteratum%253Aachs%26aulast%3DFinnin%26aufirst%3DM.%2BS.%26aulast%3DDonigian%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DStructures%2520of%2520a%2520histone%2520deacetylase%2520homologue%2520bound%2520to%2520the%2520TSA%2520and%2520SAHA%2520inhibitors%26jtitle%3DNature%26date%3D1999%26volume%3D401%26spage%3D188%26epage%3D193%26doi%3D10.1038%2F43710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2000</span>â <span class="NLM_lpage">2009</span>, <span class="refDoi">Â DOI: 10.1021/jm901453q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901453q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2000-2009&author=X.+Caiauthor=H.+X.+Zhaiauthor=J.+Wangauthor=J.+Forresterauthor=H.+Quauthor=L.+Yinauthor=C.+J.+Laiauthor=R.+Baoauthor=C.+Qian&title=Discovery+of+7-%284-%283-ethynylphenylamino%29-7-methoxyquinazolin-6-yloxy%29-N-hydroxyheptanamide+%28CUDc-101%29+as+a+potent+multi-acting+HDAC%2C+EGFR%2C+and+HER2+inhibitor+for+the+treatment+of+cancer&doi=10.1021%2Fjm901453q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Cai, Xiong; Zhai, Hai-Xiao; Wang, Jing; Forrester, Jeffrey; Qu, Hui; Yin, Ling; Lai, Cheng-Jung; Bao, Rudi; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compds. with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clin. development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, resp.  In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib.  In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers.  These results suggest that a single compd. that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBQl1iMXW3rVg90H21EOLACvtfcHk0lgyOvI_wYCWXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D&md5=d4dc339f2fd750d52e511abf3dbf18bd</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjm901453q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901453q%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25207-%25284-%25283-ethynylphenylamino%2529-7-methoxyquinazolin-6-yloxy%2529-N-hydroxyheptanamide%2520%2528CUDc-101%2529%2520as%2520a%2520potent%2520multi-acting%2520HDAC%252C%2520EGFR%252C%2520and%2520HER2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2000%26epage%3D2009%26doi%3D10.1021%2Fjm901453q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mann, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1247</span>â <span class="NLM_lpage">1252</span>, <span class="refDoi">Â DOI: 10.1634/theoncologist.12-10-1247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1634%2Ftheoncologist.12-10-1247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=17962618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1247-1252&author=B.+S.+Mannauthor=J.+R.+Johnsonauthor=M.+H.+Cohenauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+approval+summary%3A+vorinostat+for+treatment+of+advanced+primary+cutaneous+T-cell+lymphoma&doi=10.1634%2Ftheoncologist.12-10-1247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span></div><div class="casAuthors">Mann, Bhupinder S.; Johnson, John R.; Cohen, Martin H.; Justice, Robert; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1247-1252</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">On Oct. 6, 2006, the U.S. Food and Drug Administration granted regular approval to vorinostat (Zolinza; Merck & Co., Inc., Whitehouse Station, NJ), a histone deacetylase inhibitor, for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease on or following two systemic therapies.  The pivotal study supporting approval was a single-arm open-label phase II trial that enrolled 74 patients with stage IB and higher CTCL who had failed two systemic therapies (one of which must have contained bexarotene).  Patients received vorinostat at a dose of 400 mg orally once daily, which could be reduced for toxicity to 300 mg daily or 300 mg 5 days a week.  The median age of patients was 61 years.  Sixty-one patients (82%) had stage IIB or higher CTCL and 30 patients (41%) had Sezary syndrome.  The median duration of protocol treatment was 118 days.  The primary efficacy endpoint was objective response assessed by the Severity-Weighted Assessment Tool.  The objective response rate was 30% (95% confidence interval [CI], 19.7%-41.5%), the estd. median response duration was 168 days, and the median time to tumor progression was 202 days.  An addnl. single-center study enrolled 33 patients with similar baseline and demog. features as the pivotal trial.  Thirteen of the 33 received vorinostat (400 mg/day).  The response rate in these 13 patients was 31% (95% CI, 9.1%-61.4%).  The most common clin. adverse events (AEs) of any grade were diarrhea (52%), fatigue (52%), nausea (41%), and anorexia (24%).  Grade 3 or 4 clin. AEs included fatigue (4%) and pulmonary embolism (5%).  Hematol. lab. abnormalities included thrombocytopenia (26%) and anemia (14%).  Chem. lab. abnormalities included increased creatinine (16%), increased serum glucose (69%), and proteinuria (51%).  Most abnormalities were National Cancer Institute Common Terminol. Criteria for Adverse Events grade 1 or 2.  Grade 3 or greater chem. abnormalities included hyperglycemia, hypertriglyceridemia, and hyperuricemia, hypoglycemia, hypokalemia, hyponatremia, hyperkalemia, hypercholesterolemia, hypophosphatemia, and increased creatinine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPuO0Kd_rs9LVg90H21EOLACvtfcHk0lgyOvI_wYCWXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL&md5=c93fc0a46ebbed81873f1347db45421d</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-10-1247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-10-1247%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DB.%2BS.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520vorinostat%2520for%2520treatment%2520of%2520advanced%2520primary%2520cutaneous%2520T-cell%2520lymphoma%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D1247%26epage%3D1252%26doi%3D10.1634%2Ftheoncologist.12-10-1247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramaniam, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wax, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaron, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lara, P. N.,  Jr.</span></span> <span> </span><span class="NLM_article-title">A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">923</span>â <span class="NLM_lpage">932</span>, <span class="refDoi">Â DOI: 10.1007/s00280-017-3283-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1007%2Fs00280-017-3283-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=28352985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlt1SrsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2017&pages=923-932&author=H.+A.+Wakeleeauthor=S.+Gettingerauthor=J.+Engelmanauthor=P.+A.+Janneauthor=H.+Westauthor=D.+S.+Subramaniamauthor=J.+Leachauthor=M.+Waxauthor=Y.+Yaronauthor=D.+R.+Milesauthor=P.+N.+Lara&title=A+phase+Ib%2FII+study+of+cabozantinib+%28XL184%29+with+or+without+erlotinib+in+patients+with+non-small+cell+lung+cancer&doi=10.1007%2Fs00280-017-3283-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer</span></div><div class="casAuthors">Wakelee, Heather A.; Gettinger, Scott; Engelman, Jeffrey; Janne, Pasi A.; West, Howard; Subramaniam, Deepa S.; Leach, Joseph; Wax, Michael; Yaron, Yifah; Miles, Dale R.; Lara, Primo N., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">923-932</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Cabozantinib is a multi-kinase inhibitor that targets MET, AXL, and VEGFR2, and may synergize with EGFR inhibition in NSCLC.  Cabozantinib was assessed alone or in combination with erlotinib in patients with progressive NSCLC and EGFR mutations who had previously received erlotinib.  Methods: This was a phase Ib/II study (NCT00596648).  The primary objectives of phase I were to assess the safety, pharmacokinetics, and pharmacodynamics and to det. max. tolerated dose (MTD) of cabozantinib plus erlotinib in patients who failed prior erlotinib treatment.  In phase II, patients with prior response or stable disease with erlotinib who progressed were randomized to single-agent cabozantinib 100 mg qd vs cabozantinib 100 mg qd and erlotinib 50 mg qd (phase I MTD), with a primary objective of estg. objective response rate (ORR).  Results: Sixty-four patients were treated in phase I.  Doses of 100 mg cabozantinib plus 50 mg erlotinib, or 40 mg cabozantinib plus 150 mg erlotinib were detd. to be MTDs.  Diarrhea was the most frequent dose-limiting toxicity and the most frequent AE (87.5% of patients).  The ORR for phase I was 8.2% (90% CI 3.3-16.5).  In phase II, one patient in the cabozantinib arm (N = 15) experienced a partial response, for an ORR of 6.7% (90% CI 0.3-27.9), with no responses for cabozantinib plus erlotinib (N = 13).  There was no evidence that co-administration of cabozantinib markedly altered erlotinib pharmacokinetics or vice versa.  Conclusions: Despite responses with cabozantinib/erlotinib in phase I, there were no responses in the combination arm of phase II in patients with acquired resistance to erlotinib.  Cabozantinib did not appear to re-sensitize these patients to erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgi1kyff75wrVg90H21EOLACvtfcHk0lgyOvI_wYCWXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlt1SrsL8%253D&md5=95e3a80264e1413085360de2d5e03e07</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1007%2Fs00280-017-3283-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-017-3283-z%26sid%3Dliteratum%253Aachs%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DGettinger%26aufirst%3DS.%26aulast%3DEngelman%26aufirst%3DJ.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DWest%26aufirst%3DH.%26aulast%3DSubramaniam%26aufirst%3DD.%2BS.%26aulast%3DLeach%26aufirst%3DJ.%26aulast%3DWax%26aufirst%3DM.%26aulast%3DYaron%26aufirst%3DY.%26aulast%3DMiles%26aufirst%3DD.%2BR.%26aulast%3DLara%26aufirst%3DP.%2BN.%26atitle%3DA%2520phase%2520Ib%252FII%2520study%2520of%2520cabozantinib%2520%2528XL184%2529%2520with%2520or%2520without%2520erlotinib%2520in%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2017%26volume%3D79%26spage%3D923%26epage%3D932%26doi%3D10.1007%2Fs00280-017-3283-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radhakrishnan, R.</span></span> <span> </span><span class="NLM_article-title">Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">417</span>â <span class="NLM_lpage">423</span>, <span class="refDoi">Â DOI: 10.1042/BJ20121513</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1042%2FBJ20121513" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23101586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslelt7zK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2012&pages=417-423&author=J.+H.+Parkauthor=Y.+Liuauthor=M.+A.+Lemmonauthor=R.+Radhakrishnan&title=Erlotinib+binds+both+inactive+and+active+conformations+of+the+EGFR+tyrosine+kinase+domain&doi=10.1042%2FBJ20121513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain</span></div><div class="casAuthors">Park, Jin H.; Liu, Yingting; Lemmon, Mark A.; Radhakrishnan, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">417-423</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Erlotinib and gefitinib, tyrosine kinase inhibitors used to block EGFR (epidermal growth factor receptor) signalling in cancer, are thought to bind only the active conformation of the EGFR-TKD (tyrosine kinase domain).  Through parallel computational and crystallog. studies, we show in the present study that erlotinib also binds the inactive EGFR-TKD conformation, which may have significant implications for its use in EGFR-mutated cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprbzRYtaWcm7Vg90H21EOLACvtfcHk0ljJkgjnqihlsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslelt7zK&md5=170e0fe51a413edfbc15d4357ba6877b</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1042%2FBJ20121513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20121513%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DRadhakrishnan%26aufirst%3DR.%26atitle%3DErlotinib%2520binds%2520both%2520inactive%2520and%2520active%2520conformations%2520of%2520the%2520EGFR%2520tyrosine%2520kinase%2520domain%26jtitle%3DBiochem.%2520J.%26date%3D2012%26volume%3D448%26spage%3D417%26epage%3D423%26doi%3D10.1042%2FBJ20121513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimmesgern, E.</span></span> <span> </span><span class="NLM_article-title">The structure of inosine 5â²-monophosphate dehydrogenase and the design of novel inhibitors</span>. <i>Immunopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">163</span>â <span class="NLM_lpage">184</span>, <span class="refDoi">Â DOI: 10.1016/S0162-3109(00)00193-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS0162-3109%2800%2900193-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10878288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlKkt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2000&pages=163-184&author=M.+D.+Sintchakauthor=E.+Nimmesgern&title=The+structure+of+inosine+5%E2%80%B2-monophosphate+dehydrogenase+and+the+design+of+novel+inhibitors&doi=10.1016%2FS0162-3109%2800%2900193-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors</span></div><div class="casAuthors">Sintchak, M. D.; Nimmesgern, E.</div><div class="citationInfo"><span class="NLM_cas:title">Immunopharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">163-184</span>CODEN:
                <span class="NLM_cas:coden">IMMUDP</span>;
        ISSN:<span class="NLM_cas:issn">0162-3109</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with â¼120 refs.  The enzyme IMPDH is a homotetramer of â¼55 kDa subunits and consists of a (Î²/Î±)8 barrel core domain and a smaller subdomain.  The active site has binding pockets for the two substrates IMP and NAD.  The enzymic reaction of oxidn. of IMP to XMP proceeds through a covalent mechanism involving an active site cysteine residue.  This enzyme is a target for immunosuppressive agents because it catalyzes a key step in purine nucleotide biosynthesis which is important for the proliferation of lymphocytes.  Several x-ray structures of inhibitors bound to IMPDH have been published.  The uncompetitive IMPDH inhibitor MPA is the active metabolite of the immunosuppressive agent mycophenolate mofetil (CellCept) which is approved for the prevention of acute rejection after kidney and heart transplantation.  The bicyclic ring system of MPA packs underneath the hypoxanthine ring of XMP*, thereby trapping this covalent intermediate of the enzymic reaction.  Ribavirin monophosphate, the active metabolite of the antiviral agent ribavirin, is a substrate mimic of IMP.  The structure of the two inhibitors 6-Cl-IMP and SAD binding in the IMP and NAD pockets of IMPDH, resp., gives information for the binding mode of the di-nucleotide cofactor to the enzyme.  At Vertex Pharmaceuticals a structure-based drug design program for the design of IMPDH inhibitors was initiated.  Several new lead compd. classes unrelated to other IMPDH inhibitors were found.  Integrating structural information into an iterative drug-design process led to the design of VX-497.  VX-497 is a potent uncompetitive enzyme inhibitor of IMPDH.  The phenyl-oxazole moiety of the mol. packs underneath XMP*, analogous to MPA.  VX-497 also makes several new interactions that are not obsd. in the binding of MPA.  VX-497 is a potent immunosuppressive agent in vitro and in vivo.  A Phase I clin. trial has been successfully concluded and the compd. is currently in Phase II trials in psoriasis and hepatitis C.  The rapid progress from initiation of the drug design program to a compd. entering clin. trials illustrates the power of structure-based drug design to accelerate the drug discovery process.  The structural information on IMPDH has also significantly increased our knowledge about the mechanistic details of this fascinating enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfJBlQKGh0E7Vg90H21EOLACvtfcHk0ljJkgjnqihlsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlKkt7k%253D&md5=4141aa3b8d3343008473914bc0fc7edb</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2FS0162-3109%2800%2900193-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0162-3109%252800%252900193-4%26sid%3Dliteratum%253Aachs%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DNimmesgern%26aufirst%3DE.%26atitle%3DThe%2520structure%2520of%2520inosine%25205%25E2%2580%25B2-monophosphate%2520dehydrogenase%2520and%2520the%2520design%2520of%2520novel%2520inhibitors%26jtitle%3DImmunopharmacology%26date%3D2000%26volume%3D47%26spage%3D163%26epage%3D184%26doi%3D10.1016%2FS0162-3109%2800%2900193-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaram, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pankiewicz, K. W.</span></span> <span> </span><span class="NLM_article-title">Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">6685</span>â <span class="NLM_lpage">6691</span>, <span class="refDoi">Â DOI: 10.1021/jm070864w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070864w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOnurvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6685-6691&author=L.+Chenauthor=D.+Wilsonauthor=H.+N.+Jayaramauthor=K.+W.+Pankiewicz&title=Dual+inhibitors+of+inosine+monophosphate+dehydrogenase+and+histone+deacetylases+for+cancer+treatment&doi=10.1021%2Fjm070864w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibitors of Inosine Monophosphate Dehydrogenase and Histone Deacetylases for Cancer Treatment</span></div><div class="casAuthors">Chen, Liqiang; Wilson, Daniel; Jayaram, Hiremagalur N.; Pankiewicz, Krzysztof W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">6685-6691</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mycophenolic acid (MPA), an inhibitor of IMP-dehydrogenase (IMPDH), is used worldwide in transplantation.  Recently, numerous studies showed its importance in cancer treatment.  Consequently, MPA entered clin. trials in advanced multiple myeloma patients.  Suberoylanilide hydroxamic acid (SAHA), a potent differentiation agent acting through inhibition of histone deacetylases (HDACs), was recently approved for treatment of cutaneous T cell lymphoma.  The authors report herein the synthesis of dual inhibitors of IMPDH and HDACs.  The authors found that mycophenolic hydroxamic acid (MAHA) inhibits both IMPDH (Ki = 30 nM) and HDAC (IC50 = 5.0 Î¼M).  A modification of SAHA with groups known to interact with IMPDH afforded a SAHA analog (I), which inhibits IMPDH (Ki = 1.7 Î¼M) and HDAC (IC50 = 0.06 Î¼M).  Both MAHA (IC50 = 4.8 Î¼M) and SAHA analog I (IC50 = 7.7 Î¼M) were more potent than parent compds. as antiproliferation agents.  They were also significantly more potent as differentiation inducers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN5m_NrQtZGrVg90H21EOLACvtfcHk0ljJkgjnqihlsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOnurvO&md5=d23d2cfe279a638ec27431b89909626b</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm070864w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070864w%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DWilson%26aufirst%3DD.%26aulast%3DJayaram%26aufirst%3DH.%2BN.%26aulast%3DPankiewicz%26aufirst%3DK.%2BW.%26atitle%3DDual%2520inhibitors%2520of%2520inosine%2520monophosphate%2520dehydrogenase%2520and%2520histone%2520deacetylases%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D6685%26epage%3D6691%26doi%3D10.1021%2Fjm070864w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Card, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neiman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">279</span>â <span class="NLM_lpage">286</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2004.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.molcel.2004.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15260978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXms1ektLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=279-286&author=K.+Y.+Zhangauthor=G.+L.+Cardauthor=Y.+Suzukiauthor=D.+R.+Artisauthor=D.+Fongauthor=S.+Gilletteauthor=D.+Hsiehauthor=J.+Neimanauthor=B.+L.+Westauthor=C.+Zhangauthor=M.+V.+Milburnauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=G.+Bollag&title=A+glutamine+switch+mechanism+for+nucleotide+selectivity+by+phosphodiesterases&doi=10.1016%2Fj.molcel.2004.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases</span></div><div class="casAuthors">Zhang, Kam Y. J.; Card, Graeme L.; Suzuki, Yoshihisa; Artis, D. Richard; Fong, Daniel; Gillette, Sam; Hsieh, Davin; Neiman, Joshua; West, Brian L.; Zhang, Chao; Milburn, Michael V.; Kim, Sung-Hou; Schlessinger, Joseph; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-286</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) comprise a family of enzymes that modulate the immune response, inflammation, and memory, among many other functions.  There are three types of PDEs: cAMP-specific, cGMP-specific, and dual-specific.  Here we describe the mechanism of nucleotide selectivity on the basis of high-resoln. co-crystal structures of the cAMP-specific PDE4B and PDE4D with AMP, the cGMP-specific PDE5A with GMP, and the apo-structure of the dual-specific PDE1B.  These structures show that an invariant glutamine functions as the key specificity determinant by a "glutamine switch" mechanism for recognizing the purine moiety in cAMP or cGMP.  The surrounding residues anchor the glutamine residue in different orientations for cAMP and for cGMP.  The PDE1B structure shows that in dual-specific PDEs a key histidine residue may enable the invariant glutamine to toggle between cAMP and cGMP.  The structural understanding of nucleotide binding enables the design of new PDE inhibitors that may treat diseases in which cyclic nucleotides play a crit. role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorRXGTDdAa1bVg90H21EOLACvtfcHk0ljV88_B34un7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXms1ektLs%253D&md5=32fab6a75031a67290ec5eda2c3e080b</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DHsieh%26aufirst%3DD.%26aulast%3DNeiman%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DA%2520glutamine%2520switch%2520mechanism%2520for%2520nucleotide%2520selectivity%2520by%2520phosphodiesterases%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D15%26spage%3D279%26epage%3D286%26doi%3D10.1016%2Fj.molcel.2004.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lauffer, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mintzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zilberleyb, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flicke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritscher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorowicz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallero, R.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">26926</span>â <span class="NLM_lpage">26943</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M113.490706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1074%2Fjbc.M113.490706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23897821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=26926-26943&author=B.+E.+Laufferauthor=R.+Mintzerauthor=R.+Fongauthor=S.+Mukundauthor=C.+Tamauthor=I.+Zilberleybauthor=B.+Flickeauthor=A.+Ritscherauthor=G.+Fedorowiczauthor=R.+Vallero&title=Histone+deacetylase+%28HDAC%29+inhibitor+kinetic+rate+constants+correlate+with+cellular+histone+acetylation+but+not+transcription+and+cell+viability&doi=10.1074%2Fjbc.M113.490706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability</span></div><div class="casAuthors">Lauffer, Benjamin E. L.; Mintzer, Robert; Fong, Rina; Mukund, Susmith; Tam, Christine; Zilberleyb, Inna; Flicke, Birgit; Ritscher, Allegra; Fedorowicz, Grazyna; Vallero, Roxanne; Ortwine, Daniel F.; Gunzner, Janet; Modrusan, Zora; Neumann, Lars; Koth, Christopher M.; Lupardus, Patrick J.; Kaminker, Joshua S.; Heise, Christopher E.; Steiner, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">26926-26943</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are crit. in the control of gene expression, and dysregulation of their activity has been implicated in a broad range of diseases, including cancer, cardiovascular, and neurol. diseases.  HDAC inhibitors (HDACi) employing different zinc chelating functionalities such as hydroxamic acids and benzamides have shown promising results in cancer therapy.  Although it has also been suggested that HDACi with increased isoenzyme selectivity and potency may broaden their clin. utility and minimize side effects, the translation of this idea to the clinic remains to be investigated.  Moreover, a detailed understanding of how HDACi with different pharmacol. properties affect biol. functions in vitro and in vivo is still missing.  Here, we show that a panel of benzamide-contg. HDACi are slow tight-binding inhibitors with long residence times unlike the hydroxamate-contg. HDACi vorinostat and trichostatin-A.  Characterization of changes in H2BK5 and H4K14 acetylation following HDACi treatment in the neuroblastoma cell line SH-SY5Y revealed that the timing and magnitude of histone acetylation mirrored both the assocn. and dissocn. kinetic rates of the inhibitors.  In contrast, cell viability and microarray gene expression anal. indicated that cell death induction and changes in transcriptional regulation do not correlate with the dissocn. kinetic rates of the HDACi.  Therefore, our study suggests that detg. how the selective and kinetic inhibition properties of HDACi affect cell function will help to evaluate their therapeutic utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2goaOx8CDGbVg90H21EOLACvtfcHk0ljV88_B34un7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM&md5=af1074c79e8abd932313f4ae13333a98</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.490706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.490706%26sid%3Dliteratum%253Aachs%26aulast%3DLauffer%26aufirst%3DB.%2BE.%26aulast%3DMintzer%26aufirst%3DR.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DMukund%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DFlicke%26aufirst%3DB.%26aulast%3DRitscher%26aufirst%3DA.%26aulast%3DFedorowicz%26aufirst%3DG.%26aulast%3DVallero%26aufirst%3DR.%26atitle%3DHistone%2520deacetylase%2520%2528HDAC%2529%2520inhibitor%2520kinetic%2520rate%2520constants%2520correlate%2520with%2520cellular%2520histone%2520acetylation%2520but%2520not%2520transcription%2520and%2520cell%2520viability%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D26926%26epage%3D26943%26doi%3D10.1074%2Fjbc.M113.490706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amalini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">151</span>â <span class="NLM_lpage">161</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-12-0466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1158%2F1535-7163.MCT-12-0466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23270925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlWisr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=151-161&author=S.+Hartauthor=V.+Novotny-Diermayrauthor=K.+C.+Gohauthor=M.+Williamsauthor=Y.+C.+Tanauthor=L.+C.+Ongauthor=A.+Cheongauthor=B.+K.+Ngauthor=C.+Amaliniauthor=B.+Madanauthor=H.+Nagarajauthor=R.+Jayaramanauthor=K.+M.+Pashaauthor=K.+Ethirajuluauthor=W.+J.+Chngauthor=N.+Mustafaauthor=B.+C.+Gohauthor=C.+Benesauthor=U.+McDermottauthor=M.+Garnettauthor=B.+Dymockauthor=J.+M.+Wood&title=VS-5584%2C+a+novel+and+highly+selective+PI3K%2FmTOR+kinase+inhibitor+for+the+treatment+of+cancer&doi=10.1158%2F1535-7163.MCT-12-0466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Hart, Stefan; Novotny-Diermayr, Veronica; Goh, Kee Chuan; Williams, Meredith; Tan, Yong Cheng; Ong, Lai Chun; Cheong, Albert; Ng, Bee Kheng; Amalini, Chithra; Madan, Babita; Nagaraj, Harish; Jayaraman, Ramesh; Pasha, Khalid M.; Ethirajulu, Kantharaj; Chng, Wee Joo; Mustafa, Nurulhuda; Goh, Boon Cher; Benes, Cyril; McDermott, Ultan; Garnett, Mathew; Dymock, Brian; Wood, Jeanette M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-161</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Dysregulation of the PI3K/mTOR pathway, either through amplifications, deletions, or as a direct result of mutations, has been closely linked to the development and progression of a wide range of cancers.  Moreover, this pathway activation is a poor prognostic marker for many tumor types and confers resistance to various cancer therapies.  Here, we describe VS-5584, a novel, low-mol. wt. compd. with equiv. potent activity against mTOR (IC50 = 37 nmol/L) and all class I phosphoinositide 3-kinase (PI3K) isoforms IC50: PI3KÎ± = 16 nmol/L; PI3KÎ² = 68 nmol/L; PI3KÎ³ = 25 nmol/L; PI3KÎ´ = 42 nmol/L, without relevant activity on 400 lipid and protein kinases.  VS-5584 shows robust modulation of cellular PI3K/mTOR pathways, inhibiting phosphorylation of substrates downstream of PI3K and mTORC1/2.  A large human cancer cell line panel screen (436 lines) revealed broad antiproliferative sensitivity and that cells harboring mutations in PI3KCA are generally more sensitive toward VS-5584 treatment.  VS-5584 exhibits favorable pharmacokinetic properties after oral dosing in mice and is well tolerated.  VS-5584 induces long-lasting and dose-dependent inhibition of PI3K/mTOR signaling in tumor tissue, leading to tumor growth inhibition in various rapalog-sensitive and -resistant human xenograft models.  Furthermore, VS-5584 is synergistic with an EGF receptor inhibitor in a gastric tumor model.  The unique selectivity profile and favorable pharmacol. and pharmaceutical properties of VS-5584 and its efficacy in a wide range of human tumor models supports further investigations of VS-5584 in clin. trials.  Mol Cancer Ther; 12(2); 151-61. Â©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreO7JDy5Ta17Vg90H21EOLACvtfcHk0ljV88_B34un7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlWisr0%253D&md5=5fac255eea66aed674cc863fc578d975</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0466%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DNg%26aufirst%3DB.%2BK.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DK.%2BM.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DGoh%26aufirst%3DB.%2BC.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DGarnett%26aufirst%3DM.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DVS-5584%252C%2520a%2520novel%2520and%2520highly%2520selective%2520PI3K%252FmTOR%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D151%26epage%3D161%26doi%3D10.1158%2F1535-7163.MCT-12-0466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and preclinical evaluation of fused pyrimidine-based hydroxamates for the treatment of hepatocellular carcinoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1552</span>â <span class="NLM_lpage">1575</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01465</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01465" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGhsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1552-1575&author=D.+Chenauthor=K.+S.+Changauthor=H.+G.+Weiauthor=H.+Wang&title=Design%2C+synthesis%2C+and+preclinical+evaluation+of+fused+pyrimidine-based+hydroxamates+for+the+treatment+of+hepatocellular+carcinoma&doi=10.1021%2Facs.jmedchem.7b01465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma</span></div><div class="casAuthors">Chen, Dizhong; Soh, Chang Kai; Goh, Wei Huang; Wang, Haishan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1552-1575</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Class I histone deacetylases (HDACs) are highly expressed and/or upregulated in hepatocellular carcinoma (HCC) and are assocd. with aggressiveness, spread, and increased mortality of HCC.  Activation of phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway was involved in the development of HCC and acquired resistance to sorafenib.  A series of purine or 5H-pyrrolo[3,2-d]pyrimidine based hydroxamates were designed and developed as multitarget drugs to modulate both HDACs and the PI3K/Akt/mTOR pathway.  Among 39 cell lines screened, the mols. (e.g., I, II, and III) were the most selective against leukemia, lymphoma, and HCC cells; they also demonstrated target modulation in cancer cell lines and in mice bearing MV4-11 and HepG2 tumors.  Compd. II in particular showed significant single agent oral efficacy in hypervascular liver cancer models (e.g., HepG2, HuH-7, and Hep3B) and was well-tolerated.  These encouraging results, along with its favorable target profile and tissue distribution, warrant further development of II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOkc89pglhFLVg90H21EOLACvtfcHk0lgdRyZ77WBxgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGhsLk%253D&md5=7261ba423c033773f4b1b5cea80af725</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01465%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DK.%2BS.%26aulast%3DWei%26aufirst%3DH.%2BG.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520preclinical%2520evaluation%2520of%2520fused%2520pyrimidine-based%2520hydroxamates%2520for%2520the%2520treatment%2520of%2520hepatocellular%2520carcinoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1552%26epage%3D1575%26doi%3D10.1021%2Facs.jmedchem.7b01465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M.</span></span> <span> </span><span class="NLM_article-title">Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4104</span>â <span class="NLM_lpage">4113</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-12-0055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1158%2F1078-0432.CCR-12-0055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=22693356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4104-4113&author=C.+Qianauthor=C.+J.+Laiauthor=R.+Baoauthor=D.+G.+Wangauthor=J.+Wangauthor=G.+X.+Xuauthor=R.+Atoyanauthor=H.+Quauthor=L.+Yinauthor=M.+Samson&title=Cancer+network+disruption+by+a+single+molecule+inhibitor+targeting+both+histone+deacetylase+activity+and+phosphatidylinositol+3-kinase+signaling&doi=10.1158%2F1078-0432.CCR-12-0055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling</span></div><div class="casAuthors">Qian, Changgeng; Lai, Cheng-Jung; Bao, Rudi; Wang, Da-Gong; Wang, Jing; Xu, Guang-Xin; Atoyan, Ruzanna; Qu, Hui; Yin, Ling; Samson, Maria; Zifcak, Brian; Ma, Anna Wai See; Della Rocca, Steven; Borek, Mylissa; Zhai, Hai-Xiao; Cai, Xiong; Voi, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4104-4113</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Given that histone deacetylase (HDAC) inhibitors are known to induce multiple epigenetic modifications affecting signaling networks and act synergistically with phosphatidylinositol 3-kinase (PI3K) inhibitors, we developed a strategy to simultaneously inhibit HDACs and PI3K in cancer cells.  Exptl. Design: We constructed dual-acting inhibitors by incorporating HDAC inhibitory functionality into a PI3K inhibitor pharmacophore.  CUDC-907, a development candidate selected from these dual inhibitors, was evaluated in vitro and in vivo to det. its pharmacol. properties, anticancer activity, and mechanism of action.  Results: CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes.  Through its integrated HDAC inhibitory activity, CUDC-907 durably inhibits the PI3K-AKT-mTOR pathway and compensatory signaling mols. such as RAF, MEK, MAPK, and STAT-3, as well as upstream receptor tyrosine kinases.  CUDC-907 shows greater growth inhibition and proapoptotic activity than single-target PI3K or HDAC inhibitors in both cultured and implanted cancer cells.  Conclusions: CUDC-907 may offer improved therapeutic benefits through simultaneous, sustained disruption of multiple oncogenic signaling networks.  Clin Cancer Res; 18(15); 4104-13. Â©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnvXaG5-2QzbVg90H21EOLACvtfcHk0lgdRyZ77WBxgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL&md5=be0d379f13fded2bed326cece99af8d7</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0055%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DC.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26atitle%3DCancer%2520network%2520disruption%2520by%2520a%2520single%2520molecule%2520inhibitor%2520targeting%2520both%2520histone%2520deacetylase%2520activity%2520and%2520phosphatidylinositol%25203-kinase%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4104%26epage%3D4113%26doi%3D10.1158%2F1078-0432.CCR-12-0055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel dual histone deacetylases (HDACs) and mammalian target of rapamycin (mTOR) target inhibitor as a promising strategy for cancer therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1577</span>â <span class="NLM_lpage">1592</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01825</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01825" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFeguw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1577-1592&author=Y.+Chenauthor=X.+Yuanauthor=W.+Zhangauthor=M.+Tangauthor=L.+Zhengauthor=F.+Wangauthor=W.+Yanauthor=S.+Yang&title=Discovery+of+a+novel+dual+histone+deacetylases+%28HDACs%29+and+mammalian+target+of+rapamycin+%28mTOR%29+target+inhibitor+as+a+promising+strategy+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.8b01825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy</span></div><div class="casAuthors">Chen, Yong; Yuan, Xue; Zhang, Wanhua; Tang, Minghai; Zheng, Li; Wang, Fang; Yan, Wei; Yang, Shengyong; Wei, Yuquan; He, Jun; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1577-1592</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present study, a series of novel dual-target histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors were designed and synthesized using pyrimidine-pyrazolyl pharmacophore to append HDAC recognition cap and hydroxamic acid as a zinc-binding motif.  Among them, I was the optimal lead compd. with potent inhibition activities against mTOR and HDAC1 with half-maximal inhibitory concn. of 1.2 and 0.19 nM, resp.  Western blot confirmed that I could upregulate acetylation of H3 and Î±-tubulin and downregulate mTOR-related downstream mediators.  I could also stimulate cell cycle arrest in G0/G1 phase and induce tumor cell apoptosis.  I showed comparable antitumor activity with the combination medication in MM1S xenograft model with a tumor growth inhibitory rate of 72.5%, without causing significant loss of body wt. and toxicity.  All of the results indicated that I could be a promising dual target inhibitor for treating hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ3AdehNv1ObVg90H21EOLACvtfcHk0lgdRyZ77WBxgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFeguw%253D%253D&md5=7a2ff5020aedb0e3c302e65d993301e6</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01825%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520dual%2520histone%2520deacetylases%2520%2528HDACs%2529%2520and%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520target%2520inhibitor%2520as%2520a%2520promising%2520strategy%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1577%26epage%3D1592%26doi%3D10.1021%2Facs.jmedchem.8b01825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">12</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2015.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=26741358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVOj" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2016&pages=1-12&author=F.+W.+Pengauthor=J.+Xuanauthor=T.+T.+Wuauthor=J.+Y.+Xueauthor=Z.+W.+Renauthor=D.+K.+Liuauthor=X.+Q.+Wangauthor=X.+H.+Chenauthor=J.+W.+Zhangauthor=Y.+G.+Xu&title=Design%2C+synthesis+and+biological+evaluation+of+N-phenylquinazolin-4-amine+hybrids+as+dual+inhibitors+of+VEGFR-2+and+HDAC&doi=10.1016%2Fj.ejmech.2015.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC</span></div><div class="casAuthors">Peng, Fan-Wei; Xuan, Ji; Wu, Ting-Ting; Xue, Jia-Yu; Ren, Zi-Wei; Liu, Da-Ke; Wang, Xiu-Qi; Chen, Xin-Hang; Zhang, Jia-Wei; Xu, Yun-Gen; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this work, a series of hybrids bearing N-phenylquinazolin-4-amine and hydroxamic acid moieties I (R1, R2 = H, F, Cl, Br, n = 2, 3, 4, 5) were designed and identified as dual VEGFR-2/HDAC inhibitors.  Compd. I (R1 = H, R2 = Br, n = 5) exhibited the most potent inhibitory activity against HDAC with IC50 of 2.2 nM and strong inhibitory effect against VEGFR-2 with IC50 of 74 nM.  It also showed the most potent inhibitory activity against a human breast cancer cell line MCF-7 with IC50 of 0.85 Î¼M.  Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction at the active binding sites of VEGFR-2 and HDLP (Histone Deacetylase-Like Protein), which demonstrates that compd. I (R1 = H, R2 = Br, n = 5) is a potential agent for cancer therapy deserving further researching.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT_jbaom_UR7Vg90H21EOLACvtfcHk0ljFG5cRYm6Cdg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVOj&md5=1a0c299ec484daa522da5969e8a35cec</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DF.%2BW.%26aulast%3DXuan%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DT.%2BT.%26aulast%3DXue%26aufirst%3DJ.%2BY.%26aulast%3DRen%26aufirst%3DZ.%2BW.%26aulast%3DLiu%26aufirst%3DD.%2BK.%26aulast%3DWang%26aufirst%3DX.%2BQ.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%2BW.%26aulast%3DXu%26aufirst%3DY.%2BG.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520N-phenylquinazolin-4-amine%2520hybrids%2520as%2520dual%2520inhibitors%2520of%2520VEGFR-2%2520and%2520HDAC%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D109%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.ejmech.2015.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of STAT3 and histone deacetylase (HDAC) dual-Pathway inhibitors for the treatment of solid cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">7468</span>â <span class="NLM_lpage">7482</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.1c00136</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.1c00136" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhtFKhur3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=7468-7482&author=Y.+Renauthor=S.+Liauthor=R.+Zhuauthor=C.+Wanauthor=D.+Songauthor=J.+Zhuauthor=G.+Caiauthor=S.+Longauthor=L.+Kongauthor=W.+Yu&title=Discovery+of+STAT3+and+histone+deacetylase+%28HDAC%29+dual-Pathway+inhibitors+for+the+treatment+of+solid+cancer&doi=10.1021%2Facs.jmedchem.1c00136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer</span></div><div class="casAuthors">Ren, Yuhao; Li, Shanshan; Zhu, Ren; Wan, Chengying; Song, Dongmei; Zhu, Jiawen; Cai, Guiping; Long, Sihui; Kong, Lingyi; Yu, Wenying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7468-7482</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nowadays, simultaneous inhibition of multiple targets through drug combination is an important anticancer strategy owing to the complex mechanism behind tumorigenesis.  Recent studies have demonstrated that the inhibition of histone deacetylases (HDACs) will lead to compensated activation of a notorious cancer-related drug target, signal transducer and activator of transcription 3 (STAT3), in breast cancer through a cascade, which probably limits the anti-proliferation effect of HDAC inhibitors in solid tumors.  By incorporating the pharmacophore of the HDAC inhibitor SAHA (vorinostat) into the STAT3 inhibitor pterostilbene, a series of potent pterostilbene hydroxamic acid derivs. with dual-target inhibition activity were synthesized.  An excellent hydroxamate derivate, compd. 14, inhibited STAT3 (KD = 33 nM) and HDAC (IC50 = 23.15 nM) with robust potency in vitro.  Compd. 14 also showed potent anti-proliferation ability in vivo and in vitro.  Our study provides the first STAT3 and HDAC dual-target inhibitor for further exploration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPTnVkCD3wdbVg90H21EOLACvtfcHk0ljFG5cRYm6Cdg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhtFKhur3K&md5=7e54efab8eae1fa04e867d6522551b4e</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.1c00136%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DG.%26aulast%3DLong%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520STAT3%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual-Pathway%2520inhibitors%2520for%2520the%2520treatment%2520of%2520solid%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D7468%26epage%3D7482%26doi%3D10.1021%2Facs.jmedchem.1c00136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Lanosterol 14Î±-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>221</i></span>,  <span class="NLM_fpage">113524</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2021.113524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2021.113524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=33992927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhtFSgurfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=221&publication_year=2021&pages=113524&author=T.+Zhuauthor=X.+Chenauthor=C.+Liauthor=J.+Tuauthor=N.+Liuauthor=D.+Xuauthor=C.+Sheng&title=Lanosterol+14%CE%B1-demethylase+%28CYP51%29%2Fhistone+deacetylase+%28HDAC%29+dual+inhibitors+for+treatment+of+Candida+tropicalis+and+Cryptococcus+neoformans+infections&doi=10.1016%2Fj.ejmech.2021.113524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Lanosterol 14Î±-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections</span></div><div class="casAuthors">Zhu, Tianbao; Chen, Xi; Li, Chenglan; Tu, Jie; Liu, Na; Xu, Defeng; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">221</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113524</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Invasive fungal infections remain a challenge due to lack of effective antifungal agents and serious drug resistance.  Discovery of antifungal agents with novel antifungal mechanism is important and urgent.  Previously, we designed the first CYP51/HDAC dual inhibitors with potent activity against resistant Candida albicans infections.  To better understand the antifungal spectrum and synergistic mechanism, herein new CYP51/HDAC dual inhibitors were designed which showed potent in vitro and in vivo antifungal activity against C. neoformans and C. tropicalis infections.  Antifungal mechanism studies revealed that the CYP51/HDAC dual inhibitors acted by inhibiting various virulence factors of C. tropicalis and C. neoformans and down-regulating resistance-assocd. genes.  This study highlights the potential of CYP51/HDAC dual inhibitors as a promising strategy for the discovery of novel broad-spectrum antifungal agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_kDz4IKxl3LVg90H21EOLACvtfcHk0ljFG5cRYm6Cdg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhtFSgurfN&md5=caccd81358057ff760f9e3fad53bf087</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113524%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DLanosterol%252014%25CE%25B1-demethylase%2520%2528CYP51%2529%252Fhistone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%2520for%2520treatment%2520of%2520Candida%2520tropicalis%2520and%2520Cryptococcus%2520neoformans%2520infections%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D221%26spage%3D113524%26doi%3D10.1016%2Fj.ejmech.2021.113524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abd El-Hafeez, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelhamid, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katkar, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mostafa, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayallah, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abuo-Rahma, G. E.-D. A.</span></span> <span> </span><span class="NLM_article-title">A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>222</i></span>,  <span class="NLM_fpage">113569</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2021.113569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2021.113569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=34111829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXht1yrsbnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=222&publication_year=2021&pages=113569&author=M.+Mustafaauthor=A.+A.+Abd+El-Hafeezauthor=D.+Abdelhamidauthor=G.+D.+Katkarauthor=Y.+A.+Mostafaauthor=P.+Ghoshauthor=A.+M.+Hayallahauthor=G.+E.-D.+A.+Abuo-Rahma&title=A+first-in-class+anticancer+dual+HDAC2%2FFAK+inhibitors+bearing+hydroxamates%2Fbenzamides+capped+by+pyridinyl-1%2C2%2C4-triazoles&doi=10.1016%2Fj.ejmech.2021.113569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles</span></div><div class="casAuthors">Mustafa, Muhamad; Abd El-Hafeez, Amer Ali; Abdelhamid, Dalia; Katkar, Gajanan D.; Mostafa, Yaser A.; Ghosh, Pradipta; Hayallah, Alaa M.; Abuo-Rahma, Gamal El-Din A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">222</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113569</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Novel 5-pyridinyl-1,2,4-triazoles were designed as dual inhibitors of histone deacetylase 2 (HDAC2) and focal adhesion kinase (FAK).  Compds. 5d, 6a, 7c, and 11c were detd. as potential inhibitors of both HDAC2 (IC50 = 0.09-1.40 Î¼M) and FAK (IC50 = 12.59-36.11 nM); 6a revealed the highest activity with IC50 values of 0.09 Î¼M and 12.59 nM for HDAC2 and FAK, resp.  Compd. 6a was superior to ref. drugs vorinostat and valproic acid in its ability to inhibit growth/proliferation of A-498 and Caki-1 renal cancer cells.  Further investigation proved that 6a strongly arrests the cell cycle at the G2/M phase and triggers apoptosis in both A-498 and Caki-1 cells.  Moreover, the enhanced Akt activity that is obsd. upon chronic application of HDAC inhibitors was effectively suppressed by the dual HDAC2/FAK inhibitor.  Finally, the high potency and selectivity of 6a towards HDAC2 and FAK proteins were rationalized by mol. docking.  Taken together, these findings highlight the potential of 6a as a promising dual-acting HDAC2/FAK inhibitor that could benefit from further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozexEs2PUj_bVg90H21EOLACvtfcHk0lgT6aQfcZ07cw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXht1yrsbnM&md5=608d373857e2c87916557b09702b445a</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113569%26sid%3Dliteratum%253Aachs%26aulast%3DMustafa%26aufirst%3DM.%26aulast%3DAbd%2BEl-Hafeez%26aufirst%3DA.%2BA.%26aulast%3DAbdelhamid%26aufirst%3DD.%26aulast%3DKatkar%26aufirst%3DG.%2BD.%26aulast%3DMostafa%26aufirst%3DY.%2BA.%26aulast%3DGhosh%26aufirst%3DP.%26aulast%3DHayallah%26aufirst%3DA.%2BM.%26aulast%3DAbuo-Rahma%26aufirst%3DG.%2BE.-D.%2BA.%26atitle%3DA%2520first-in-class%2520anticancer%2520dual%2520HDAC2%252FFAK%2520inhibitors%2520bearing%2520hydroxamates%252Fbenzamides%2520capped%2520by%2520pyridinyl-1%252C2%252C4-triazoles%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D222%26spage%3D113569%26doi%3D10.1016%2Fj.ejmech.2021.113569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">112868</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2020.112868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2020.112868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=33077265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFaht7nE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2021&pages=112868&author=J.+Chenauthor=Y.+Liauthor=J.+Zhangauthor=M.+Zhangauthor=A.+Weiauthor=H.+Liuauthor=Z.+Xieauthor=W.+Renauthor=W.+Duanauthor=Z.+Zhangauthor=A.+Shenauthor=Y.+Hu&title=Discovery+of+selective+HDAC%2FBRD4+dual+inhibitors+as+epigenetic+probes&doi=10.1016%2Fj.ejmech.2020.112868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes</span></div><div class="casAuthors">Chen, Jingjing; Li, Yalei; Zhang, Jie; Zhang, Minmin; Wei, Aihuan; Liu, Hongchun; Xie, Zhicheng; Ren, Wenming; Duan, Wenwen; Zhang, Zhuo; Shen, Aijun; Hu, Youhong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112868</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">According to the binding mode of ABBV-744 with bromodomains and the cape space of HDAC, the novel selective HDAC/BRD4 dual inhibitors were designed and synthesized by the pharmacophore fusion strategy.  Evaluating the biomol. activities through SARs exploration identified three kinds of selective dual inhibitors 41c (HDAC1/BRD4), 43a (pan-HDAC/BRD4) and 43d (HDAC6/BRD4(BD2)), whose target-related cellular activities in MV-4-11 cells were also confirmed.  Significantly, the selective dual inhibitor 41c (HDAC1/BRD4) exhibited synergistic effects against MV-4-11 cells, which strongly induced G0/G1 cell cycle arrest and apoptosis, and the first HDAC6/BRD4(BD2) dual inhibitor was found.  This study provides support for selective HDAC/BRD4 dual inhibitors as epigenetic probes based on pyrrolopyridone core for the future biol. evaluation in different cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbMygNv9rC2bVg90H21EOLACvtfcHk0lgT6aQfcZ07cw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFaht7nE&md5=b39c2be6ed98f0f5ffee7bf8ac1f7cf4</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112868%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DW.%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520selective%2520HDAC%252FBRD4%2520dual%2520inhibitors%2520as%2520epigenetic%2520probes%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D209%26spage%3D112868%26doi%3D10.1016%2Fj.ejmech.2020.112868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7593</span>â <span class="NLM_lpage">7613</span>, <span class="refDoi">Â DOI: 10.1021/jm300605m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300605m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFClurfP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7593-7613&author=G.+Dongauthor=S.+Wangauthor=Z.+Miaoauthor=J.+Yaoauthor=Y.+Zhangauthor=Z.+Guoauthor=W.+Zhangauthor=C.+Sheng&title=New+tricks+for+an+old+natural+product%3A+discovery+of+highly+potent+evodiamine+derivatives+as+novel+antitumor+agents+by+systemic+structure-activity+relationship+analysis+and+biological+evaluations&doi=10.1021%2Fjm300605m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">New Tricks for an Old Natural Product: Discovery of Highly Potent Evodiamine Derivatives as Novel Antitumor Agents by Systemic Structure-Activity Relationship Analysis and Biological Evaluations</span></div><div class="casAuthors">Dong, Guoqiang; Wang, Shengzheng; Miao, Zhenyuan; Yao, Jianzhong; Zhang, Yongqiang; Guo, Zizhao; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7593-7613</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Evodiamine is a quinazolinocarboline alkaloid isolated from the fruits of traditional Chinese herb Evodiae fructus.  Herein, a library of novel evodiamine derivs. bearing various substitutions or modified scaffold were synthesized.  Among them, a no. of evodiamine derivs. showed substantial increase of the antitumor activity, with GI50 values lower than 3 nM.  Moreover, these highly potent compds. can effectively induce the apoptosis of A549 cells.  Interestingly, further computational target prediction calcns. in combination with biol. assays confirmed that the evodiamine derivs. acted by dual inhibition of topoisomerases I and II.  Moreover, several hydroxyl derivs., such as 10-hydroxyevodiamine and 3-amino-10-hydroxyevodiamine, also showed good in vivo antitumor efficacy and low toxicity at the dose of 1 mg/kg or 2 mg/kg.  They represent promising candidates for the development of novel antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocJjv8REdBnrVg90H21EOLACvtfcHk0lgT6aQfcZ07cw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFClurfP&md5=6e7d03671ac1be56b8bd68dc0fc03062</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm300605m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300605m%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DNew%2520tricks%2520for%2520an%2520old%2520natural%2520product%253A%2520discovery%2520of%2520highly%2520potent%2520evodiamine%2520derivatives%2520as%2520novel%2520antitumor%2520agents%2520by%2520systemic%2520structure-activity%2520relationship%2520analysis%2520and%2520biological%2520evaluations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7593%26epage%3D7613%26doi%3D10.1021%2Fjm300605m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel multiacting topoisomerase i/ii and histone deacetylase inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">239</span>â <span class="NLM_lpage">243</span>, <span class="refDoi">Â DOI: 10.1021/ml500327q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500327q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVGitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=239-243&author=S.+Heauthor=G.+Dongauthor=Z.+Wangauthor=W.+Chenauthor=Y.+Huangauthor=Z.+Liauthor=Y.+Jiangauthor=N.+Liuauthor=J.+Yaoauthor=Z.+Miaoauthor=W.+Zhangauthor=C.+Sheng&title=Discovery+of+novel+multiacting+topoisomerase+i%2Fii+and+histone+deacetylase+inhibitors&doi=10.1021%2Fml500327q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors</span></div><div class="casAuthors">He, Shipeng; Dong, Guoqiang; Wang, Zhibin; Chen, Wei; Huang, Yahui; Li, Zhengang; Jiang, Yan; Liu, Na; Yao, Jianzhong; Miao, Zhenyuan; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-243</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget drugs remains a significant challenge in current antitumor drug discovery.  Because of the synergistic effect between topoisomerase and HDAC inhibitors, the present study reported the first-in-class triple inhibitors of topoisomerase I/II and HDAC.  On the basis of 3-amino-10-hydroxylevodiamine and SAHA, a series of hybrid mols. was successfully designed and synthesized.  In particular, compd. 8c was proven to be a potent inhibitor of topoisomerase I/II and HDAC with good antiproliferative and apoptotic activities.  This proof-of-concept study also validated the effectiveness of discovering triple topoisomerase I/II and HDAC inhibitors as novel antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNFr6sR4u6kbVg90H21EOLACvtfcHk0liW-kGuKaGx6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVGitw%253D%253D&md5=9630a82acaa4df7023a07aa7ed395e86</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Fml500327q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500327q%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520novel%2520multiacting%2520topoisomerase%2520i%252Fii%2520and%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D239%26epage%3D243%26doi%3D10.1021%2Fml500327q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.-B.</span></span> <span> </span><span class="NLM_article-title">Novel bioactive hybrid compound dual targeting estrogen receptor and histone deacetylase for the treatment of breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4550</span>â <span class="NLM_lpage">4572</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00099</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00099" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVShsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4550-4572&author=C.+Tangauthor=C.+Liauthor=S.+Zhangauthor=Z.+Huauthor=J.+Wuauthor=C.+Dongauthor=J.+Huangauthor=H.-B.+Zhou&title=Novel+bioactive+hybrid+compound+dual+targeting+estrogen+receptor+and+histone+deacetylase+for+the+treatment+of+breast+cancer&doi=10.1021%2Facs.jmedchem.5b00099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer</span></div><div class="casAuthors">Tang, Chu; Li, Changhao; Zhang, Silong; Hu, Zhiye; Wu, Jun; Dong, Chune; Huang, Jian; Zhou, Hai-Bing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4550-4572</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A strategy to develop chemotherapeutic agents by combining several active groups into a single mol. as a conjugate that can modulate multiple cellular pathways may produce compds. having higher efficacy compared to that of single-target drugs.  In this article, we describe the synthesis and evaluation of an array of dual-acting ER and histone deacetylase inhibitors.  These novel hybrid compds. combine an indirect antagonism structure motif of ER (OBHS, oxabicycloheptene sulfonate) with the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA).  These OBHS-HDACi conjugates I (R = OH, NHOH; Ar = Ph, 1-naphthyl, 2-naphthyl, 4-MeC6H5, 3-MeC6H5, 2-MeC6H5, 2-MeOC6H5, etc.) exhibited good ER binding affinity and excellent ERÎ± antagonistic activity, and they also exhibited potent inhibitory activities against HDACs.  Compared with the approved drug tamoxifen, these conjugates exhibited higher antitumor potency in ERÎ±-pos. breast cancer cells (MCF-7).  Moreover, these conjugates not only showed selective anticancer activity that was more potent against MCF-7 cells than DU 145 (prostate cancer), but they had no toxicity toward normal cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokzR9bn5jLU7Vg90H21EOLACvtfcHk0liW-kGuKaGx6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVShsbk%253D&md5=223b9c3c43e1f8f012efcd1771547ee1</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00099%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DH.-B.%26atitle%3DNovel%2520bioactive%2520hybrid%2520compound%2520dual%2520targeting%2520estrogen%2520receptor%2520and%2520histone%2520deacetylase%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4550%26epage%3D4572%26doi%3D10.1021%2Facs.jmedchem.5b00099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breitenlechner, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kairies, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honold, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiblich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koll, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engh, R. A.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of active SRC kinase domain complexes</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">222</span>â <span class="NLM_lpage">231</span>, <span class="refDoi">Â DOI: 10.1016/j.jmb.2005.08.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.jmb.2005.08.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=16168436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGrtrnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=222-231&author=C.+B.+Breitenlechnerauthor=N.+A.+Kairiesauthor=K.+Honoldauthor=S.+Scheiblichauthor=H.+Kollauthor=E.+Greiterauthor=S.+Kochauthor=W.+Schaferauthor=R.+Huberauthor=R.+A.+Engh&title=Crystal+structures+of+active+SRC+kinase+domain+complexes&doi=10.1016%2Fj.jmb.2005.08.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Active Src Kinase Domain Complexes</span></div><div class="casAuthors">Breitenlechner, Christine B.; Kairies, Norman A.; Honold, Konrad; Scheiblich, Stefan; Koll, Hans; Greiter, Eva; Koch, Stefan; Schaefer, Wolfgang; Huber, Robert; Engh, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">C-Src was the first proto-oncoprotein to be identified, and has become the focus of many drug discovery programs.  Src structures of a major inactive form have shown how the protein kinase is rigidified by several interdomain interactions; active configurations of Src are generated by release from this "assembled" or "bundled" form.  Despite the importance of Src as a drug target, there is relatively little structural information available regarding the presumably more flexible active forms.  Here we report three crystal structures of a dimeric active c-Src kinase domain, in an apo and two ligand complexed forms, with resolns. ranging from 2.9 Ã to 1.95 Ã.  The structures show how the kinase domain, in the absence of the rigidifying interdomain interactions of the inactivation state, adopts a more open and flexible conformation.  The ATP site inhibitor CGP77675 binds to the protein kinase with canonical hinge hydrogen bonds and also to the c-Src specific threonine 340.  In contrast to purvalanol B binding in CDK2, purvalanol A binds in c-Src with a conformational change in a more open ATP pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc3P258chhrbVg90H21EOLACvtfcHk0ljNCtE8t9U0Nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGrtrnF&md5=9bc8e1670457d34ac88e6b5b20efea21</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2005.08.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2005.08.023%26sid%3Dliteratum%253Aachs%26aulast%3DBreitenlechner%26aufirst%3DC.%2BB.%26aulast%3DKairies%26aufirst%3DN.%2BA.%26aulast%3DHonold%26aufirst%3DK.%26aulast%3DScheiblich%26aufirst%3DS.%26aulast%3DKoll%26aufirst%3DH.%26aulast%3DGreiter%26aufirst%3DE.%26aulast%3DKoch%26aufirst%3DS.%26aulast%3DSchafer%26aufirst%3DW.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DEngh%26aufirst%3DR.%2BA.%26atitle%3DCrystal%2520structures%2520of%2520active%2520SRC%2520kinase%2520domain%2520complexes%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2005%26volume%3D353%26spage%3D222%26epage%3D231%26doi%3D10.1016%2Fj.jmb.2005.08.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicheri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of hck in complex with a src family-selective tyrosine kinase inhibitor</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">639</span>â <span class="NLM_lpage">648</span>, <span class="refDoi">Â DOI: 10.1016/S1097-2765(00)80357-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS1097-2765%2800%2980357-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10360180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK1MXjslCqu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1999&pages=639-648&author=T.+Schindlerauthor=F.+Sicheriauthor=A.+Picoauthor=A.+Gazitauthor=J.+Kuriyan&title=Crystal+structure+of+hck+in+complex+with+a+src+family-selective+tyrosine+kinase+inhibitor&doi=10.1016%2FS1097-2765%2800%2980357-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of HcK in complex with a Src family-selective tyrosine kinase inhibitor</span></div><div class="casAuthors">Schindler, Thomas; Sicheri, Frank; Pico, Alexander; Gazit, Aviv; Levitzki, Alexander; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-648</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The crystal structure of the autoinhibited form of Hck has been detd. at 2.0 Ã resoln., in complex with a specific pyrazolo pyrimidine-type inhibitor, PP1.  The activation segment, a key regulatory component of the catalytic domain, is unphosphorylated and is visualized in its entirety.  Tyr-416, the site of activating autophosphorylation in the Src family kinases, is positioned such that access to the catalytic machinery is blocked.  PP1 is bound at the ATP-binding site of the kinase, and a methylphenyl group on PP1 is inserted into an adjacent hydrophobic pocket.  The enlargement of this pocket in autoinhibited Src kinases suggests a route toward the development of inhibitors that are specific for the inactive forms of these proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf3jZGeDrWtLVg90H21EOLACvtfcHk0ljNCtE8t9U0Nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjslCqu7s%253D&md5=33617bc9698224ed3f047749b9133874</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2800%2980357-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252800%252980357-3%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DPico%26aufirst%3DA.%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520hck%2520in%2520complex%2520with%2520a%2520src%2520family-selective%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cell%26date%3D1999%26volume%3D3%26spage%3D639%26epage%3D648%26doi%3D10.1016%2FS1097-2765%2800%2980357-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stamos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span> <span> </span><span class="NLM_article-title">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">46265</span>â <span class="NLM_lpage">46272</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M207135200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1074%2Fjbc.M207135200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=12196540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46265-46272&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+epidermal+growth+factor+receptor+kinase+domain+alone+and+in+complex+with+a+4-anilinoquinazoline+inhibitor&doi=10.1074%2Fjbc.M207135200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span></div><div class="casAuthors">Stamos, Jennifer; Sliwkowski, Mark X.; Eigenbrot, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">46265-46272</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been detd. to 2.6-Ã resoln., both with and without an EGFRK-specific inhibitor currently in Phase III clin. trials as an anti-cancer agent, erlotinib (OSI-774, CP-358,774, Tarceva).  The EGFR family members are distinguished from all other known receptor tyrosine kinases in possessing constitutive kinase activity without a phosphorylation event within their kinase domains.  Despite its lack of phosphorylation, we find that the EGFRK activation loop adopts a conformation similar to that of the phosphorylated active form of the kinase domain from the insulin receptor.  Surprisingly, key residues of a putative dimerization motif lying between the EGFRK domain and carboxyl-terminal substrate docking sites are found in close contact with the kinase domain.  Significant intermol. contacts involving the carboxyl-terminal tail are discussed with respect to receptor oligomerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsObp1WYFaC7Vg90H21EOLACvtfcHk0ljNCtE8t9U0Nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D&md5=c63c60b93756bd45fb2375c56ba38941</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M207135200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M207135200%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520domain%2520alone%2520and%2520in%2520complex%2520with%2520a%25204-anilinoquinazoline%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D46265%26epage%3D46272%26doi%3D10.1074%2Fjbc.M207135200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barchechath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saade, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauwagie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B.</span></span> <span> </span><span class="NLM_article-title">Rational design of multitargeted tyrosine kinase inhibitors: a novel approach</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">380</span>â <span class="NLM_lpage">387</span>, <span class="refDoi">Â DOI: 10.1111/j.1747-0285.2009.00786.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1111%2Fj.1747-0285.2009.00786.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=19291100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktVWhsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2009&pages=380-387&author=S.+Barchechathauthor=C.+Williamsauthor=K.+Saadeauthor=S.+Lauwagieauthor=B.+Jean-Claude&title=Rational+design+of+multitargeted+tyrosine+kinase+inhibitors%3A+a+novel+approach&doi=10.1111%2Fj.1747-0285.2009.00786.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of multitargeted tyrosine kinase inhibitors: a novel approach</span></div><div class="casAuthors">Barchechath, Sylvie; Williams, Christopher; Saade, Khalil; Lauwagie, Sylvia; Jean-Claude, Bertrand</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">380-387</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The non-receptor Src tyrosine kinase is known to cooperate with the epidermal growth factor receptor in a mechanism leading to invasion and metastasis of solid tumors.  With the purpose of developing agents targeted to both epidermal growth factor receptor and Src or related kinases, we embarked on the design of chimeric mols. termed combi-mols. capable of blocking both Src and epidermal growth factor receptor.  To this end, we have chosen to design mols. contg. a quinazoline moiety (directed at epidermal growth factor receptor) and a 7-phenyl-pyrazolopyrimidine (directed at Src).  Mol. modeling showed that the optimal position to attach the linker was the 6-position of the quinazoline and the 9-position of the pyrazolopyrimidine.  This has led to the synthesis of SB162, SB166 and SB163 (I).  I contg. the longest linker was the only mol. capable of inducing a dose-dependent inhibition of both Src and epidermal growth factor receptor.  I also induced a dose inhibition of Abl and PDGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqPD3kksVKFrVg90H21EOLACvtfcHk0ljNCtE8t9U0Nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktVWhsr4%253D&md5=e34498b737d90afbb9be065bb9ef0489</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2009.00786.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2009.00786.x%26sid%3Dliteratum%253Aachs%26aulast%3DBarchechath%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DSaade%26aufirst%3DK.%26aulast%3DLauwagie%26aufirst%3DS.%26aulast%3DJean-Claude%26aufirst%3DB.%26atitle%3DRational%2520design%2520of%2520multitargeted%2520tyrosine%2520kinase%2520inhibitors%253A%2520a%2520novel%2520approach%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2009%26volume%3D73%26spage%3D380%26epage%3D387%26doi%3D10.1111%2Fj.1747-0285.2009.00786.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpowich, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. N.</span></span> <span> </span><span class="NLM_article-title">Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">652</span>â <span class="NLM_lpage">657</span>, <span class="refDoi">Â DOI: 10.1038/nsmb.1602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fnsmb.1602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=19430461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1MXls1Cmtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=652-657&author=Z.+Zhouauthor=J.+Zhenauthor=N.+K.+Karpowichauthor=C.+J.+Lawauthor=M.+E.+Reithauthor=D.+N.+Wang&title=Antidepressant+specificity+of+serotonin+transporter+suggested+by+three+LeuT-SSRI+structures&doi=10.1038%2Fnsmb.1602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures</span></div><div class="casAuthors">Zhou, Zheng; Zhen, Juan; Karpowich, Nathan K.; Law, Christopher J.; Reith, Maarten E. A.; Wang, Da-Neng</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">652-657</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Sertraline and fluoxetine are selective serotonin re-uptake inhibitors (SSRIs) that are widely prescribed to treat depression.  They exert their effects by inhibiting the presynaptic plasma membrane serotonin transporter (SERT).  All SSRIs possess halogen atoms at specific positions, which are key determinants for the drugs' specificity for SERT.  For the SERT protein, however, the structural basis of its specificity for SSRIs is poorly understood.  Here we report the crystal structures of LeuT, a bacterial SERT homolog, in complex with sertraline, R-fluoxetine or S-fluoxetine.  The SSRI halogens all bind to exactly the same pocket within LeuT.  Mutation at this halogen-binding pocket (HBP) in SERT markedly reduces the transporter's affinity for SSRIs but not for tricyclic antidepressants.  Conversely, when the only nonconserved HBP residue in both norepinephrine and dopamine transporters is mutated into that found in SERT, their affinities for all the three SSRIs increase uniformly.  Thus, the specificity of SERT for SSRIs is dependent largely on interaction of the drug halogens with the protein's HBP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreUWPt0csx4bVg90H21EOLACvtfcHk0lhF6k4SheJLPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXls1Cmtrc%253D&md5=33444a0991503249c620e55159d7f09c</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.1602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.1602%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DZhen%26aufirst%3DJ.%26aulast%3DKarpowich%26aufirst%3DN.%2BK.%26aulast%3DLaw%26aufirst%3DC.%2BJ.%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DD.%2BN.%26atitle%3DAntidepressant%2520specificity%2520of%2520serotonin%2520transporter%2520suggested%2520by%2520three%2520LeuT-SSRI%2520structures%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D16%26spage%3D652%26epage%3D657%26doi%3D10.1038%2Fnsmb.1602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tago, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naruto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, R.</span></span> <span> </span><span class="NLM_article-title">A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimerâs disease</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4389</span>â <span class="NLM_lpage">4415</span>, <span class="refDoi">Â DOI: 10.1016/S0968-0896(03)00452-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS0968-0896%2803%2900452-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=13129577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1yisrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=4389-4415&author=N.+Todaauthor=K.+Tagoauthor=S.+Marumotoauthor=K.+Takamiauthor=M.+Oriauthor=N.+Yamadaauthor=K.+Koyamaauthor=S.+Narutoauthor=K.+Abeauthor=R.+Yamazaki&title=A+conformational+restriction+approach+to+the+development+of+dual+inhibitors+of+acetylcholinesterase+and+serotonin+transporter+as+potential+agents+for+Alzheimer%E2%80%99s+disease&doi=10.1016%2FS0968-0896%2803%2900452-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease</span></div><div class="casAuthors">Toda, Narihiro; Tago, Keiko; Marumoto, Shinji; Takami, Kazuko; Ori, Mayuko; Yamada, Naho; Koyama, Kazuo; Naruto, Shunji; Abe, Kazumi; Yamazaki, Reina; Hara, Takao; Aoyagi, Atsushi; Abe, Yasuyuki; Kaneko, Tsugio; Kogen, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4389-4415</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) has been treated with acetylcholinesterase (AChE) inhibitors such as donepezil.  However, the clin. usefulness of AChE inhibitors is limited mainly due to their adverse peripheral effects.  Depression seen in AD patients has been treated with serotonin transporter (SERT) inhibitors.  The authors considered that combining SERT and AChE inhibition could improve the clin. usefulness of AChE inhibitors.  In a previous paper, the authors found a potential dual inhibitor of AChE (IC50 = 101 nM) and SERT (IC50 = 42 nM), but its AChE inhibition activity was less than donepezil (IC50 = 10 nM).  Here, the authors report the conformationally restricted (R)-I considerably enhanced inhibitory activity against AChE (IC50 = 14 nM) and SERT (IC50 = 6 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhL6Fowj3gpbVg90H21EOLACvtfcHk0lhF6k4SheJLPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1yisrk%253D&md5=1b4b1fb9aeea5514e3246450c00f0add</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2803%2900452-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252803%252900452-8%26sid%3Dliteratum%253Aachs%26aulast%3DToda%26aufirst%3DN.%26aulast%3DTago%26aufirst%3DK.%26aulast%3DMarumoto%26aufirst%3DS.%26aulast%3DTakami%26aufirst%3DK.%26aulast%3DOri%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DN.%26aulast%3DKoyama%26aufirst%3DK.%26aulast%3DNaruto%26aufirst%3DS.%26aulast%3DAbe%26aufirst%3DK.%26aulast%3DYamazaki%26aufirst%3DR.%26atitle%3DA%2520conformational%2520restriction%2520approach%2520to%2520the%2520development%2520of%2520dual%2520inhibitors%2520of%2520acetylcholinesterase%2520and%2520serotonin%2520transporter%2520as%2520potential%2520agents%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D4389%26epage%3D4415%26doi%3D10.1016%2FS0968-0896%2803%2900452-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almenara, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrad, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varticovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2118</span>â <span class="NLM_lpage">2126</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=12727828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlGmsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=2118-2126&author=C.+Yuauthor=M.+Rahmaniauthor=J.+Almenaraauthor=M.+Sublerauthor=G.+Krystalauthor=D.+Conradauthor=L.+Varticovskiauthor=P.+Dentauthor=S.+Grant&title=Histone+deacetylase+inhibitors+promote+STI571-mediated+apoptosis+in+STI571-sensitive+and+-resistant+Bcr%2FAbl%2B+human+myeloid+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors Promote STI571-mediated Apoptosis in STI571-sensitive and -resistant Bcr/Abl+ Human Myeloid Leukemia Cells</span></div><div class="casAuthors">Yu, Chunrong; Rahmani, Mohamed; Almenara, Jorge; Subler, Mark; Krystal, Geoffrey; Conrad, Daniel; Varticovski, Lubya; Dent, Paul; Grant, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2118-2126</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Interactions between the Bcr/Abl kinase inhibitor STI571 (Gleevec, imatinib mesylate) and histone deacetylase inhibitors (HDIs) have been examd. in STI571-sensitive and -resistant Bcr/Abl+ human leukemia cells (K562 and LAMA 84).  Cotreatment of K562 cells with 250 nM imatinib mesylate and 2.0 Î¼M suberoylanilide hydroxamic acid (SAHA) for 24 h, exposures that were minimally toxic alone, resulted in a marked increase in mitochondrial damage (e.g., cytochrome c, Smac/DIABLO, and apoptosis-inducing factor release), caspase activation, and apoptosis.  Similar events were obsd. in other Bcr/Abl+ cells (i.e., LAMA 84), and in cells exposed to STI571 in combination with the HDI sodium butyrate.  Coexposure of cells to HDIs in conjunction with STI571 resulted in multiple perturbations in signaling and cell cycle-regulatory proteins, including down-regulation of Raf, phospho-mitogen-activated protein kinase kinase (MEK), phospho-extracellular signal-regulated kinase (ERK), phospho-Akt, phospho-signal transducers and activators of transcription 5, cyclin D1, and Mcl-1, accompanied by dephosphorylation and cleavage of retinoblastoma protein and a striking increase in phosphorylation of c-Jun NH2-terminal kinase.  Coexposure of Bcr/Abl+ cells to STI571 also blocked SAHA-mediated induction of p21CIP1 and resulted in down-regulation of Bcr/Abl protein expression.  STI571 and SAHA also interacted synergistically to induce apoptosis in STI571-resistant K562 and LAMA 84 cells that display increased Bcr/Abl protein expression.  Lastly, inducible expression of a constitutively active MEK1/2 construct significantly attenuated SAHA/STI571-mediated apoptosis in K562 cells, implicating disruption of the Raf/MEK/ERK axis in synergistic antileukemic effects of this drug combination.  Together, these findings indicate that combined exposure of Bcr/Abl+ cells to the kinase inhibitor STI571 and HDIs leads to diverse perturbations in signaling and cell cycle-regulatory proteins, assocd. with a marked increase in mitochondrial damage and cell death.  They also raise the possibility that this strategy may be effective in some Bcr/Abl+ cells that are resistant to STI571 through increased Bcr/Abl expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoYarKAuFpDLVg90H21EOLACvtfcHk0li7Mrb6Ci3QXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlGmsbc%253D&md5=f393cedee38afe31abe097d9c267db3e</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DC.%26aulast%3DRahmani%26aufirst%3DM.%26aulast%3DAlmenara%26aufirst%3DJ.%26aulast%3DSubler%26aufirst%3DM.%26aulast%3DKrystal%26aufirst%3DG.%26aulast%3DConrad%26aufirst%3DD.%26aulast%3DVarticovski%26aufirst%3DL.%26aulast%3DDent%26aufirst%3DP.%26aulast%3DGrant%26aufirst%3DS.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520promote%2520STI571-mediated%2520apoptosis%2520in%2520STI571-sensitive%2520and%2520-resistant%2520Bcr%252FAbl%252B%2520human%2520myeloid%2520leukemia%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D2118%26epage%3D2126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veach, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4236</span>â <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0li7Mrb6Ci3QXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dayam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span> <span> </span><span class="NLM_article-title">Î²-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">111</span>â <span class="NLM_lpage">120</span>, <span class="refDoi">Â DOI: 10.1021/jm0496077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0496077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKktbnK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=111-120&author=R.+Dayamauthor=T.+Sanchezauthor=O.+Clementauthor=R.+Shoemakerauthor=S.+Seiauthor=N.+Neamati&title=%CE%B2-diketo+acid+pharmacophore+hypothesis.+1.+Discovery+of+a+novel+class+of+HIV-1+integrase+inhibitors&doi=10.1021%2Fjm0496077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Î²-Diketo Acid Pharmacophore Hypothesis. 1. Discovery of a Novel Class of HIV-1 Integrase Inhibitors</span></div><div class="casAuthors">Dayam, Raveendra; Sanchez, Tino; Clement, Omoshile; Shoemaker, Robert; Sei, Shizuko; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-120</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HIV-1 Integrase (IN) is an essential enzyme for viral replication.  The discovery of Î²-diketo acids was crucial in the validation of IN as a legitimate target in drug discovery against HIV infection.  In this study, we discovered a novel class of IN inhibitors using a 3D pharmacophore guided database search.  We used S-1360 (1), the first IN inhibitor to undergo clin. trials, and three other analogs to develop a common feature pharmacophore hypothesis.  Testing this four-featured pharmacophore against a multiconformational database of 150 000 structurally diverse small mols. yielded 1700 compds. that satisfied the 3D query.  Subsequently, all 1700 compds. were docked into the active site of IN.  On the basis of docking scores, Lipinski's rule-of-five, and structural novelty, 110 compds. were selected for biol. screening.  We found that compds. that contain both salicylic acid and a 2-thioxo-4-thiazolidinone (rhodanine) group (e.g. 5-13) showed significant inhibitory potency against IN, while the presence of either salicylic acid or a rhodanine group alone did not.  Although some of the compds. contg. only a salicylic acid showed inhibitory potency against IN, none of the compds. contg. only rhodanine exhibited considerable potency.  Of the 52 compds. reported in this study, 11 compds. (5, 6, 8, 10-13, 32-33, 51, and 53) inhibited 3'-processing or strand transfer activities of IN with IC50 â¤ 25 Î¼M.  This is the first reported use of S-1360 and its analogs as leads in developing a pharmacophore hypothesis for IN inhibition and for identification of new compds. with potent inhibition of this enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrey20eMyZrv7Vg90H21EOLACvtfcHk0li7Mrb6Ci3QXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKktbnK&md5=ccfece093b49ab35c131ab85757ef50e</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fjm0496077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0496077%26sid%3Dliteratum%253Aachs%26aulast%3DDayam%26aufirst%3DR.%26aulast%3DSanchez%26aufirst%3DT.%26aulast%3DClement%26aufirst%3DO.%26aulast%3DShoemaker%26aufirst%3DR.%26aulast%3DSei%26aufirst%3DS.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3D%25CE%25B2-diketo%2520acid%2520pharmacophore%2520hypothesis.%25201.%2520Discovery%2520of%2520a%2520novel%2520class%2520of%2520HIV-1%2520integrase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D111%26epage%3D120%26doi%3D10.1021%2Fjm0496077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felock, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillmock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grobler, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espeseth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabryelski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleif, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. D.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">646</span>â <span class="NLM_lpage">650</span>, <span class="refDoi">Â DOI: 10.1126/science.287.5453.646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1126%2Fscience.287.5453.646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10649997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovVyjtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2000&pages=646-650&author=D.+J.+Hazudaauthor=P.+Felockauthor=M.+Witmerauthor=A.+Wolfeauthor=K.+Stillmockauthor=J.+A.+Groblerauthor=A.+Espesethauthor=L.+Gabryelskiauthor=W.+Schleifauthor=C.+Blauauthor=M.+D.+Miller&title=Inhibitors+of+strand+transfer+that+prevent+integration+and+inhibit+HIV-1+replication+in+cells&doi=10.1126%2Fscience.287.5453.646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells</span></div><div class="casAuthors">Hazuda, Daria J.; Felock, Peter; Witmer, Marc; Wolfe, Abigail; Stillmock, Kara; Grobler, Jay A.; Espeseth, Amy; Gabryelski, Lori; Schleif, William; Blau, Carol; Miller, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">5453</span>),
    <span class="NLM_cas:pages">646-650</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Integrase is essential for human immunodeficiency virus-type 1 (HIV-1) replication; however, potent inhibition of the isolated enzyme in biochem. assays has not readily translated into antiviral activity in a manner consistent with inhibition of integration.  In this report, we describe diketo acid inhibitors of HIV-1 integrase that manifest antiviral activity as a consequence of their effect on integration.  The antiviral activity of these compds. is due exclusively to inhibition of one of the two catalytic functions of integrase, strand transfer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLfQNYMkTCVrVg90H21EOLACvtfcHk0ljwMyiqHZ4n4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovVyjtQ%253D%253D&md5=d160c8fa31a9ca0a3530dceab66a892c</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1126%2Fscience.287.5453.646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.287.5453.646%26sid%3Dliteratum%253Aachs%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DFelock%26aufirst%3DP.%26aulast%3DWitmer%26aufirst%3DM.%26aulast%3DWolfe%26aufirst%3DA.%26aulast%3DStillmock%26aufirst%3DK.%26aulast%3DGrobler%26aufirst%3DJ.%2BA.%26aulast%3DEspeseth%26aufirst%3DA.%26aulast%3DGabryelski%26aufirst%3DL.%26aulast%3DSchleif%26aufirst%3DW.%26aulast%3DBlau%26aufirst%3DC.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26atitle%3DInhibitors%2520of%2520strand%2520transfer%2520that%2520prevent%2520integration%2520and%2520inhibit%2520HIV-1%2520replication%2520in%2520cells%26jtitle%3DScience%26date%3D2000%26volume%3D287%26spage%3D646%26epage%3D650%26doi%3D10.1126%2Fscience.287.5453.646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4202</span>â <span class="NLM_lpage">4211</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2010.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmc.2010.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=20576573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntV2rtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=4202-4211&author=Z.+Wangauthor=J.+Tangauthor=C.+E.+Salomonauthor=C.+D.+Dreisauthor=R.+Vince&title=Pharmacophore+and+structure-activity+relationships+of+integrase+inhibition+within+a+dual+inhibitor+scaffold+of+HIV+reverse+transcriptase+and+integrase&doi=10.1016%2Fj.bmc.2010.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase</span></div><div class="casAuthors">Wang, Zhengqiang; Tang, Jing; Salomon, Christine E.; Dreis, Christine D.; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4202-4211</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Rational design of dually active inhibitors against human immunodeficiency virus (HIV) reverse transcriptase (RT) and integrase (IN) has proved viable with 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) type of non-nucleoside RT inhibitors (NNRTIs).  To establish the pharmacophore and study the structure-activity relationships (SAR) of integrase inhibition within a previously disclosed RT/IN dual inhibitor scaffold, new analogs featuring substitution at different sites of the HEPT ring were designed and synthesized.  These studies have revealed an IN inhibition pharmacophore that is merged with the known RT pharmacophore through a shared C-6 benzyl group.  Further SAR also demonstrated that optimal IN inhibition within our dual inhibitor scaffold requires a regiospecific (N-1) diketoacid (DKA)-carrying pendant with a certain length.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhRvNGIpI8pbVg90H21EOLACvtfcHk0ljwMyiqHZ4n4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntV2rtb4%253D&md5=603652ca80d40b34489c6d6f1fa28dd6</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DSalomon%26aufirst%3DC.%2BE.%26aulast%3DDreis%26aufirst%3DC.%2BD.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DPharmacophore%2520and%2520structure-activity%2520relationships%2520of%2520integrase%2520inhibition%2520within%2520a%2520dual%2520inhibitor%2520scaffold%2520of%2520HIV%2520reverse%2520transcriptase%2520and%2520integrase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D4202%26epage%3D4211%26doi%3D10.1016%2Fj.bmc.2010.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esnouf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. I.</span></span> <span> </span><span class="NLM_article-title">Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis (heteroaryl) piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">3984</span>â <span class="NLM_lpage">3989</span>, <span class="refDoi">Â DOI: 10.1073/pnas.94.8.3984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1073%2Fpnas.94.8.3984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=9108091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK2sXis1ehuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=3984-3989&author=R.+M.+Esnoufauthor=J.+Renauthor=A.+L.+Hopkinsauthor=C.+K.+Rossauthor=E.+Y.+Jonesauthor=D.+K.+Stammersauthor=D.+I.+Stuart&title=Unique+features+in+the+structure+of+the+complex+between+HIV-1+reverse+transcriptase+and+the+bis+%28heteroaryl%29+piperazine+%28BHAP%29+U-90152+explain+resistance+mutations+for+this+nonnucleoside+inhibitor&doi=10.1073%2Fpnas.94.8.3984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor</span></div><div class="casAuthors">Esnouf, Robert M.; Ren, Jingshan; Hopkins, Andrew L.; Ross, Carl K.; Jones, E. Yvonne; Stammers, David K.; Stuart, David I.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3984-3989</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The viral reverse transcriptase (RT) provides an attractive target in the search for anti-HIV therapies.  The nonnucleoside inhibitors (NNIs) are a diverse set of compds. (usually HIV-1 specific) that function by distorting the polymerase active site upon binding in a nearby pocket.  Despite being potent and of generally low toxicity, their clin. use has been limited by rapid selection for resistant viral populations.  The 2.65-Ã resoln. structure of the complex between HIV-1 RT and the bis(heteroaryl)piperazine (BHAP) NNI, 1-(5-methanesulfonamido-1H-indol-2-yl-carbonyl)-4-[3-(1-methyl-ethylamino)pyridinyl] piperazine (U-90152), reveals the inhibitor conformation and bound water mols.  The bulky U-90152 mol. occupies the same pocket as other NNIs, but the complex is stabilized quite differently, in particular by hydrogen bonding to the main chain of Lys-103 and extensive hydrophobic contacts with Pro-236.  These interactions rationalize obsd. resistance mutations, notably Pro-236-Leu, which occurs characteristically for BHAPs.  When bound, part of U-90152 protrudes into the solvent creating a channel between Pro-236 and the polypeptide segments 225-226 and 105-106, giving the first clear evidence of the entry mode for NNIs.  The structure allows prediction of binding modes for related inhibitors [(altrylamino)piperidine-BHAPs] and suggests changes to U-90152, such as the addn. of a 6 amino group to the pyridine ring, which may make binding more resilient to mutations in the RT.  The observation of novel hydrogen bonding to the protein main chain may provide lessons for the improvement of quite different inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzQuIdPkm-oLVg90H21EOLACvtfcHk0ljwMyiqHZ4n4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1ehuro%253D&md5=d9027e0d3dc8ad612fb84d9e98b7f30e</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.8.3984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.8.3984%26sid%3Dliteratum%253Aachs%26aulast%3DEsnouf%26aufirst%3DR.%2BM.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DRoss%26aufirst%3DC.%2BK.%26aulast%3DJones%26aufirst%3DE.%2BY.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26aulast%3DStuart%26aufirst%3DD.%2BI.%26atitle%3DUnique%2520features%2520in%2520the%2520structure%2520of%2520the%2520complex%2520between%2520HIV-1%2520reverse%2520transcriptase%2520and%2520the%2520bis%2520%2528heteroaryl%2529%2520piperazine%2520%2528BHAP%2529%2520U-90152%2520explain%2520resistance%2520mutations%2520for%2520this%2520nonnucleoside%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26spage%3D3984%26epage%3D3989%26doi%3D10.1073%2Fpnas.94.8.3984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: introducing a diketoacid functionality into delavirdine</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3587</span>â <span class="NLM_lpage">3595</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2008.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmc.2008.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=18314335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1Gqsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=3587-3595&author=Z.+Wangauthor=R.+Vince&title=Design+and+synthesis+of+dual+inhibitors+of+HIV+reverse+transcriptase+and+integrase%3A+introducing+a+diketoacid+functionality+into+delavirdine&doi=10.1016%2Fj.bmc.2008.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: Introducing a diketoacid functionality into delavirdine</span></div><div class="casAuthors">Wang, Zhengqiang; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3587-3595</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cost and toxicity problems assocd. with highly active antiretroviral therapy (HAART) in HIV/AIDS treatment could be alleviated by using designed multiple ligands (DMLs).  Dual inhibitors of HIV reverse transcriptase (RT) and integrase (IN) were rationally designed by introducing a diketoacid (DKA) functionality into the tolerant C-5 site of RT inhibitor delavirdine.  The resulting compds. all demonstrate good activity against both RT and IN in enzymic assays and HIV in cell-based assay, whereas their C-7 regioisomers are all inactive in these assays.  Balanced activities were obsd. with C-3 halogenated inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8iOAhge6i37Vg90H21EOLACvtfcHk0ljwMyiqHZ4n4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1Gqsrg%253D&md5=3f90483b8bac1ee028a201690e34412c</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dual%2520inhibitors%2520of%2520HIV%2520reverse%2520transcriptase%2520and%2520integrase%253A%2520introducing%2520a%2520diketoacid%2520functionality%2520into%2520delavirdine%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D3587%26epage%3D3595%26doi%3D10.1016%2Fj.bmc.2008.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chander, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V.</span></span> <span> </span><span class="NLM_article-title">First dual aromatase-steroid sulfatase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3193</span>â <span class="NLM_lpage">3196</span>, <span class="refDoi">Â DOI: 10.1021/jm034033b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm034033b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksFWjsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3193-3196&author=L.+W.+Wooauthor=O.+B.+Sutcliffeauthor=C.+Bubertauthor=A.+Grassoauthor=S.+K.+Chanderauthor=A.+Purohitauthor=M.+J.+Reedauthor=B.+V.+Potter&title=First+dual+aromatase-steroid+sulfatase+inhibitors&doi=10.1021%2Fjm034033b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">First Dual Aromatase-Steroid Sulfatase Inhibitors</span></div><div class="casAuthors">Woo, L. W. Lawrence; Sutcliffe, Oliver B.; Bubert, Christian; Grasso, Anna; Chander, Surinder K.; Purohit, Atul; Reed, Michael J.; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3193-3196</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aromatase inhibitors in clin. use block the biosynthesis of estrogens.  Hydrolysis of estrone 3-sulfate by steroid sulfatase is an important addnl. source of tumor estrogen, and blockade of both enzymes should provide a more effective endocrine therapy.  Sulfamoylated derivs. of the aromatase inhibitor YM511 inhibited sulfatase and aromatase in JEG-3 cells with resp. IC50 values of 20-227 and 0.82-100 nM (cf. letrozole, 0.89 nM).  One dual inhibitor was potent against both enzymes in vivo, validating the concept.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOq7z9wm030LVg90H21EOLACvtfcHk0lifd4F3kvye9w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksFWjsrk%253D&md5=b487f4b92cab559a36f69b7aaebeb9d1</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Fjm034033b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034033b%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%26aulast%3DSutcliffe%26aufirst%3DO.%2BB.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DGrasso%26aufirst%3DA.%26aulast%3DChander%26aufirst%3DS.%2BK.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DB.%2BV.%26atitle%3DFirst%2520dual%2520aromatase-steroid%2520sulfatase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3193%26epage%3D3196%26doi%3D10.1021%2Fjm034033b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chander, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V.</span></span> <span> </span><span class="NLM_article-title">A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">123</span>â <span class="NLM_lpage">130</span>, <span class="refDoi">Â DOI: 10.1016/j.jsbmb.2004.12.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.jsbmb.2004.12.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15862957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVKksrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=123-130&author=P.+M.+Woodauthor=L.+W.+Wooauthor=A.+Humphreysauthor=S.+K.+Chanderauthor=A.+Purohitauthor=M.+J.+Reedauthor=B.+V.+Potter&title=A+letrozole-based+dual+aromatase-sulphatase+inhibitor+with+in+vivo+activity&doi=10.1016%2Fj.jsbmb.2004.12.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity</span></div><div class="casAuthors">Wood, Paul M.; Woo, L. W. Lawrence; Humphreys, Anna; Chander, Surinder K.; Purohit, Atul; Reed, Michael J.; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">123-130</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The role of aromatase inhibitors in the treatment of hormone-dependent breast cancer is well established.  However, it is now recognized that steroid sulfatase (STS) inhibitors represent a new form of endocrine therapy.  To explore the potential advantage of dual inhibition by a single agent, we recently developed a series of dual aromatase-sulfatase inhibitors (DASIs) based on the aromatase inhibitor YM511.  We report here a new structural class of DASI obtained by obtained introducing the pharmacophore for STS inhibition, i.e. a phenol sulfamate ester into another established aromatase inhibitor letrozole.  Hence, the bis-sulfamate (I) was synthesized which exhibited IC50 values of 3044 nM for aromatase and >10 Î¼M for STS in JEG-3 cells.  However, at a single oral dose of 10 mg/kg, I inhibited aromatase and rat liver STS by 60% and 88%, resp., 24 h after administration.  A proposed metabolite of I, carbinol (II), was synthesized.  Despite also showing weak STS inhibition in JEG-3 cells, II inhibited rat liver STS activity to the same extent as I at a single oral dose of 10 mg/kg.  Thus, the concept of a letrozole-based DASI has been validated and could be further developed and modified for therapeutic exploitation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo60rSRs5AQELVg90H21EOLACvtfcHk0lifd4F3kvye9w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVKksrc%253D&md5=90f007c68eeaef39b4ba5dc3fd2157fd</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.jsbmb.2004.12.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsbmb.2004.12.028%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DP.%2BM.%26aulast%3DWoo%26aufirst%3DL.%2BW.%26aulast%3DHumphreys%26aufirst%3DA.%26aulast%3DChander%26aufirst%3DS.%2BK.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DB.%2BV.%26atitle%3DA%2520letrozole-based%2520dual%2520aromatase-sulphatase%2520inhibitor%2520with%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2005%26volume%3D94%26spage%3D123%26epage%3D130%26doi%3D10.1016%2Fj.jsbmb.2004.12.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chander, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahon, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V.</span></span> <span> </span><span class="NLM_article-title">Dual aromatase-steroid sulfatase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">3540</span>â <span class="NLM_lpage">3560</span>, <span class="refDoi">Â DOI: 10.1021/jm061462b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061462b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1CjtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3540-3560&author=L.+W.+Wooauthor=C.+Bubertauthor=O.+B.+Sutcliffeauthor=A.+Smithauthor=S.+K.+Chanderauthor=M.+F.+Mahonauthor=A.+Purohitauthor=M.+J.+Reedauthor=B.+V.+Potter&title=Dual+aromatase-steroid+sulfatase+inhibitors&doi=10.1021%2Fjm061462b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Aromatase-Steroid Sulfatase Inhibitors</span></div><div class="casAuthors">Woo, L. W. Lawrence; Bubert, Christian; Sutcliffe, Oliver B.; Smith, Andrew; Chander, Surinder K.; Mahon, Mary F.; Purohit, Atul; Reed, Michael J.; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3540-3560</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By introducing the steroid sulfatase inhibitory pharmacophore into aromatase inhibitor 1 (YM511), two series of single agent dual aromatase-sulfatase inhibitors (DASIs) were generated.  Two best DASIs (I and II) in vitro (JEG-3 cells) had IC50(aromatase) = 0.82 nM; IC50(sulfatase) = 39 nM, and IC50(aromatase) = 0.77 nM; IC50(sulfatase) = 590 nM, resp.  X-ray crystallog. of I, and docking studies of selected compds. into an aromatase homol. model and the steroid sulfatase crystal structure are presented.  Both I and II inhibit aromatase and sulfatase in PMSG pretreated adult female Wistar rats potently 3 h after a single oral 10 mg/kg dose.  Almost complete dual inhibition is obsd. for I but the levels were reduced to 85% (aromatase) and 72% (sulfatase) after 24 h.  DASI I did not inhibit aldosterone synthesis.  The development of a potent and selective DASI should allow the therapeutic potential of dual aromatase-sulfatase inhibition in hormone-dependent breast cancer to be assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPvCTamzS0qbVg90H21EOLACvtfcHk0lifd4F3kvye9w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1CjtLs%253D&md5=69641aaecd430daad1c2f8074be4b436</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Fjm061462b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061462b%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DSutcliffe%26aufirst%3DO.%2BB.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DChander%26aufirst%3DS.%2BK.%26aulast%3DMahon%26aufirst%3DM.%2BF.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DB.%2BV.%26atitle%3DDual%2520aromatase-steroid%2520sulfatase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D3540%26epage%3D3560%26doi%3D10.1021%2Fjm061462b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sano, T.</span></span> <span> </span><span class="NLM_article-title">Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">341</span>â <span class="NLM_lpage">344</span>, <span class="refDoi">Â DOI: 10.1016/S0960-894X(01)00731-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS0960-894X%2801%2900731-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=11814792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XpslKlug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=341-344&author=M.+Fujitaauthor=T.+Sekiauthor=H.+Inadaauthor=K.+Shimizuauthor=A.+Takahamaauthor=T.+Sano&title=Approach+to+dual-acting+platelet+activating+factor+%28PAF%29+receptor+antagonist%2Fthromboxane+synthase+inhibitor+%28TxSI%29+based+on+the+link+of+PAF+antagonists+and+TxSIs&doi=10.1016%2FS0960-894X%2801%2900731-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs</span></div><div class="casAuthors">Fujita, Masakazu; Seki, Taketsugu; Inada, Haruaki; Shimizu, Kazuhiro; Takahama, Akane; Sano, Tetsuro</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-344</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of compds. which possess dual-acting PAF antagonist/TxSI have been generated by the approach of linking the known PAF antagonists and TxSIs, such as ridogrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5EjkkdRo9orVg90H21EOLACvtfcHk0lh8Rynj0dUOaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpslKlug%253D%253D&md5=7fb11467ba0f5afff9ff1c7ed37a0263</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900731-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900731-4%26sid%3Dliteratum%253Aachs%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DSeki%26aufirst%3DT.%26aulast%3DInada%26aufirst%3DH.%26aulast%3DShimizu%26aufirst%3DK.%26aulast%3DTakahama%26aufirst%3DA.%26aulast%3DSano%26aufirst%3DT.%26atitle%3DApproach%2520to%2520dual-acting%2520platelet%2520activating%2520factor%2520%2528PAF%2529%2520receptor%2520antagonist%252Fthromboxane%2520synthase%2520inhibitor%2520%2528TxSI%2529%2520based%2520on%2520the%2520link%2520of%2520PAF%2520antagonists%2520and%2520TxSIs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D341%26epage%3D344%26doi%3D10.1016%2FS0960-894X%2801%2900731-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DÃ­az, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuevas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ãlvarez-Bercedo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarmentero, M. Ã.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Font, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JimÃ©nez-Aquino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MorÃ³n, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dordal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portillo-Salido, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinoso, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Bicyclic diazepinones as dual ligands of the Î±2Î´-1 subunit of voltage-gated calcium channels and the norepinephrine transporter</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">2167</span>â <span class="NLM_lpage">2185</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c01867</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01867" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXktVyitLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=2167-2185&author=J.+L.+D%C3%ADazauthor=F.+Cuevasauthor=G.+Pazosauthor=P.+%C3%81lvarez-Bercedoauthor=A.+I.+Olivaauthor=M.+%C3%81.+Sarmenteroauthor=D.+Fontauthor=A.+Jim%C3%A9nez-Aquinoauthor=M.+Mor%C3%B3nauthor=A.+Portauthor=R.+Pascualauthor=A.+Dordalauthor=E.+Portillo-Salidoauthor=R.+F.+Reinosoauthor=J.+M.+Velaauthor=C.+Almansa&title=Bicyclic+diazepinones+as+dual+ligands+of+the+%CE%B12%CE%B4-1+subunit+of+voltage-gated+calcium+channels+and+the+norepinephrine+transporter&doi=10.1021%2Facs.jmedchem.0c01867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic Diazepinones as Dual Ligands of the Î±2Î´-1 Subunit of Voltage-Gated Calcium Channels and the Norepinephrine Transporter</span></div><div class="casAuthors">Diaz, Jose Luis; Cuevas, Felix; Pazos, Gonzalo; Alvarez-Bercedo, Paula; Oliva, Ana I.; Sarmentero, M. Angeles; Font, Daniel; Jimenez-Aquino, Agustin; Moron, Maria; Port, Adriana; Pascual, Rosalia; Dordal, Albert; Portillo-Salido, Enrique; Reinoso, Raquel F.; Vela, Jose Miguel; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2167-2185</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and pharmacol. activity of a new series of bicyclic diazepinones with dual activity toward the Î±2Î´-1 subunit of voltage-gated calcium channels (CavÎ±2Î´-1) and the norepinephrine transporter (NET) are reported.  Exploration of the positions amenable for substitution on a nonaminoacidic CavÎ±2Î´-1 scaffold allowed the identification of favorable positions for the attachment of NET pharmacophores.  Among the patterns explored, attachment of the 2-ethylamino-9-methyl-6-phenyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-e][1,4]diazepin-5-one framework to the meta-position of the Ph ring of the 3-methylamino-1-phenylpropoxy and 3-methylamino-1-thienylpropoxy moieties provided dual compds. with excellent NET functionality.  Alternative bicyclic frameworks were also explored, and some lead mols. were identified, which showed a balanced dual profile and exhibited good ADMET properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprt1hfjOiqhLVg90H21EOLACvtfcHk0lh8Rynj0dUOaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXktVyitLk%253D&md5=d83851f4eba811425d6366627d874ee5</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01867%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BL.%26aulast%3DCuevas%26aufirst%3DF.%26aulast%3DPazos%26aufirst%3DG.%26aulast%3D%25C3%2581lvarez-Bercedo%26aufirst%3DP.%26aulast%3DOliva%26aufirst%3DA.%2BI.%26aulast%3DSarmentero%26aufirst%3DM.%2B%25C3%2581.%26aulast%3DFont%26aufirst%3DD.%26aulast%3DJim%25C3%25A9nez-Aquino%26aufirst%3DA.%26aulast%3DMor%25C3%25B3n%26aufirst%3DM.%26aulast%3DPort%26aufirst%3DA.%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DDordal%26aufirst%3DA.%26aulast%3DPortillo-Salido%26aufirst%3DE.%26aulast%3DReinoso%26aufirst%3DR.%2BF.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3DBicyclic%2520diazepinones%2520as%2520dual%2520ligands%2520of%2520the%2520%25CE%25B12%25CE%25B4-1%2520subunit%2520of%2520voltage-gated%2520calcium%2520channels%2520and%2520the%2520norepinephrine%2520transporter%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D2167%26epage%3D2185%26doi%3D10.1021%2Facs.jmedchem.0c01867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battiti, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makarova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel dual-target Î¼-opioid receptor and dopamine D3 receptor ligands as potential nonaddictive pharmacotherapeutics for pain management</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">7778</span>â <span class="NLM_lpage">7808</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.1c00611</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.1c00611" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhtFSqtL%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=7778-7808&author=A.+Bonifaziauthor=F.+O.+Battitiauthor=J.+Sanchezauthor=S.+A.+Zaidiauthor=E.+Bowauthor=M.+Makarovaauthor=J.+Caoauthor=A.+B.+Shaikauthor=A.+Sulimaauthor=K.+C.+Riceauthor=V.+Katritchauthor=M.+Canalsauthor=J.+R.+Laneauthor=A.+H.+Newman&title=Novel+dual-target+%CE%BC-opioid+receptor+and+dopamine+D3+receptor+ligands+as+potential+nonaddictive+pharmacotherapeutics+for+pain+management&doi=10.1021%2Facs.jmedchem.1c00611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Dual-Target Î¼-Opioid Receptor and Dopamine D3 Receptor Ligands as Potential Nonaddictive Pharmacotherapeutics for Pain Management</span></div><div class="casAuthors">Bonifazi, Alessandro; Battiti, Francisco O.; Sanchez, Julie; Zaidi, Saheem A.; Bow, Eric; Makarova, Mariia; Cao, Jianjing; Shaik, Anver Basha; Sulima, Agnieszka; Rice, Kenner C.; Katritch, Vsevolod; Canals, Meritxell; Lane, J. Robert; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7778-7808</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The need for safer pain-management therapies with decreased abuse liability inspired a novel drug design that retains Î¼-opioid receptor (MOR)-mediated analgesia, while minimizing addictive liability.  We recently demonstrated that targeting the dopamine D3 receptor (D3R) with highly selective antagonists/partial agonists can reduce opioid self-administration and reinstatement to drug seeking in rodent models without diminishing antinociceptive effects.  The identification of the D3R as a target for the treatment of opioid use disorders prompted the idea of generating a class of ligands presenting bitopic or bivalent structures, allowing the dual-target binding of the MOR and D3R.  Structure-activity relationship studies using computationally aided drug design and in vitro binding assays led to the identification of potent dual-target leads (23, 28, and 40), based on different structural templates and scaffolds, with moderate (sub-micromolar) to high (low nanomolar/sub-nanomolar) binding affinities.  Bioluminescence resonance energy transfer-based functional studies revealed MOR agonist-D3R antagonist/partial agonist efficacies that suggest potential for maintaining analgesia with reduced opioid-abuse liability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6BTVlBxNrE7Vg90H21EOLACvtfcHk0li97B9bDYL-4Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhtFSqtL%252FO&md5=41a3caaeed5a9cc3000f724a1bf2cd8e</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.1c00611%26sid%3Dliteratum%253Aachs%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DBattiti%26aufirst%3DF.%2BO.%26aulast%3DSanchez%26aufirst%3DJ.%26aulast%3DZaidi%26aufirst%3DS.%2BA.%26aulast%3DBow%26aufirst%3DE.%26aulast%3DMakarova%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DSulima%26aufirst%3DA.%26aulast%3DRice%26aufirst%3DK.%2BC.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DCanals%26aufirst%3DM.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520dual-target%2520%25CE%25BC-opioid%2520receptor%2520and%2520dopamine%2520D3%2520receptor%2520ligands%2520as%2520potential%2520nonaddictive%2520pharmacotherapeutics%2520for%2520pain%2520management%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D7778%26epage%3D7808%26doi%3D10.1021%2Facs.jmedchem.1c00611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karakus, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godugu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajabi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S. A.</span></span> <span> </span><span class="NLM_article-title">Dual targeting of norepinephrine transporter (net) function and thyrointegrin Î±vÎ²3 receptors in the treatment of neuroblastoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">7653</span>â <span class="NLM_lpage">7662</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c00537</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00537" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1amu7fK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=7653-7662&author=O.+O.+Karakusauthor=K.+Goduguauthor=M.+Rajabiauthor=S.+A.+Mousa&title=Dual+targeting+of+norepinephrine+transporter+%28net%29+function+and+thyrointegrin+%CE%B1v%CE%B23+receptors+in+the+treatment+of+neuroblastoma&doi=10.1021%2Facs.jmedchem.0c00537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Targeting of Norepinephrine Transporter (NET) Function and Thyrointegrin Î±vÎ²3 Receptors in the Treatment of Neuroblastoma</span></div><div class="casAuthors">Karakus, Ozlem Ozen; Godugu, Kavitha; Rajabi, Mehdi; Mousa, Shaker A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7653-7662</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Therapeutic targeting of the norepinephrine transporter (NET) function with benzylguanidine (BG), conjugated with the high-affinity thyrointegrin Î±vÎ²3 antagonist triazole tetraiodothyroacetic acid, TAT, via noncleavable bonding to poly(ethylene glycol) (PEG400) (P) might allow for effective treatment options in neuroblastoma.  BG-P-TAT is a dual-targeting agent, targeting the NET function and the thyrointegrin Î±vÎ²3 receptors that are overexpressed in neuroblastoma and other neuroendocrine tumors.  Various cancer cells and actively dividing tumor-endothelial cells express the thyrointegrin Î±vÎ²3 receptors.  In this work, the novel compd. BG-P-TAT was synthesized and evaluated in the neuroblastoma SK-N-FI cell line for improved targeting and to offer a new strategy for patients with neuroblastoma.  BG-P-TAT demonstrated significant suppression of neuroblastoma tumor progression, growth, and viability in a dose-dependent manner.  In conclusion, BG-P-TAT represents a potential lead candidate for the treatment of neuroblastoma and other neuroendocrine tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSh2qLjmmFArVg90H21EOLACvtfcHk0li97B9bDYL-4Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1amu7fK&md5=3e6fb7e9dd08fe315abe6992f2a6314f</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00537%26sid%3Dliteratum%253Aachs%26aulast%3DKarakus%26aufirst%3DO.%2BO.%26aulast%3DGodugu%26aufirst%3DK.%26aulast%3DRajabi%26aufirst%3DM.%26aulast%3DMousa%26aufirst%3DS.%2BA.%26atitle%3DDual%2520targeting%2520of%2520norepinephrine%2520transporter%2520%2528net%2529%2520function%2520and%2520thyrointegrin%2520%25CE%25B1v%25CE%25B23%2520receptors%2520in%2520the%2520treatment%2520of%2520neuroblastoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D7653%26epage%3D7662%26doi%3D10.1021%2Facs.jmedchem.0c00537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiesinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flauaus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretschmer, S. B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angioni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert-Zsilavecz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidtko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogoryelov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeilschifter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwalm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structureactivity relationship studies of dual inhibitors of soluble epoxide hydrolase and 5-lipoxygenase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">11498</span>â <span class="NLM_lpage">11521</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c00561</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00561" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVant73O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=11498-11521&author=K.+Hiesingerauthor=J.+S.+Kramerauthor=S.+Beyerauthor=T.+Eckesauthor=S.+Brunstauthor=C.+Flauausauthor=S.+K.+Wittmannauthor=L.+Weizelauthor=A.+Kaiserauthor=S.+B.+M.+Kretschmerauthor=S.+Georgeauthor=C.+Angioniauthor=J.+Heeringauthor=G.+Geisslingerauthor=M.+Schubert-Zsilaveczauthor=A.+Schmidtkoauthor=D.+Pogoryelovauthor=J.+Pfeilschifterauthor=B.+Hofmannauthor=D.+Steinhilberauthor=S.+Schwalmauthor=E.+Proschak&title=Design%2C+synthesis%2C+and+structureactivity+relationship+studies+of+dual+inhibitors+of+soluble+epoxide+hydrolase+and+5-lipoxygenase&doi=10.1021%2Facs.jmedchem.0c00561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Structure-Activity Relationship Studies of Dual Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase</span></div><div class="casAuthors">Hiesinger, Kerstin; Kramer, Jan S.; Beyer, Sandra; Eckes, Timon; Brunst, Steffen; Flauaus, Cathrin; Wittmann, Sandra K.; Weizel, Lilia; Kaiser, Astrid; Kretschmer, Simon B. M.; George, Sven; Angioni, Carlo; Heering, Jan; Geisslinger, Gerd; Schubert-Zsilavecz, Manfred; Schmidtko, Achim; Pogoryelov, Denys; Pfeilschifter, Josef; Hofmann, Bettina; Steinhilber, Dieter; Schwalm, Stephanie; Proschak, Ewgenij</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">11498-11521</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of multiple enzymes of the arachidonic acid cascade leads to synergistic anti-inflammatory effects.  Merging of 5-lipoxygenase (5-LOX) and sol. epoxide hydrolase (sEH) pharmacophores led to the discovery of a dual 5-LOX/sEH inhibitor, which was subsequently optimized in terms of potency toward both targets and metabolic stability.  The optimized lead structure displayed cellular activity in human polymorphonuclear leukocytes, oral bioavailability, and target engagement in vivo and demonstrated profound anti-inflammatory and anti-fibrotic efficiency in a kidney injury model caused by unilateral ureteral obstruction in mice.  These results pave the way for investigating the therapeutic potential of dual 5-LOX/sEH inhibitors in other inflammation- and fibrosis-related disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXR2XHI9LgxbVg90H21EOLACvtfcHk0li97B9bDYL-4Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVant73O&md5=e9a04641492bd4a51ca9cfca9cf5c47d</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00561%26sid%3Dliteratum%253Aachs%26aulast%3DHiesinger%26aufirst%3DK.%26aulast%3DKramer%26aufirst%3DJ.%2BS.%26aulast%3DBeyer%26aufirst%3DS.%26aulast%3DEckes%26aufirst%3DT.%26aulast%3DBrunst%26aufirst%3DS.%26aulast%3DFlauaus%26aufirst%3DC.%26aulast%3DWittmann%26aufirst%3DS.%2BK.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DKretschmer%26aufirst%3DS.%2BB.%2BM.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DAngioni%26aufirst%3DC.%26aulast%3DHeering%26aufirst%3DJ.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DSchubert-Zsilavecz%26aufirst%3DM.%26aulast%3DSchmidtko%26aufirst%3DA.%26aulast%3DPogoryelov%26aufirst%3DD.%26aulast%3DPfeilschifter%26aufirst%3DJ.%26aulast%3DHofmann%26aufirst%3DB.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DSchwalm%26aufirst%3DS.%26aulast%3DProschak%26aufirst%3DE.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structureactivity%2520relationship%2520studies%2520of%2520dual%2520inhibitors%2520of%2520soluble%2520epoxide%2520hydrolase%2520and%25205-lipoxygenase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D11498%26epage%3D11521%26doi%3D10.1021%2Facs.jmedchem.0c00561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castaneda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chudasama, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chester, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caddick, S.</span></span> <span> </span><span class="NLM_article-title">Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">8187</span>â <span class="NLM_lpage">8189</span>, <span class="refDoi">Â DOI: 10.1039/c3cc45220d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1039%2Fc3cc45220d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23929130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlWjsrvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=8187-8189&author=L.+Castanedaauthor=A.+Maruaniauthor=F.+F.+Schumacherauthor=E.+Mirandaauthor=V.+Chudasamaauthor=K.+A.+Chesterauthor=J.+R.+Bakerauthor=M.+E.+Smithauthor=S.+Caddick&title=Acid-cleavable+thiomaleamic+acid+linker+for+homogeneous+antibody-drug+conjugation&doi=10.1039%2Fc3cc45220d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation</span></div><div class="casAuthors">Castaneda, Lourdes; Maruani, Antoine; Schumacher, Felix F.; Miranda, Enrique; Chudasama, Vijay; Chester, Kerry A.; Baker, James R.; Smith, Mark E. B.; Caddick, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">74</span>),
    <span class="NLM_cas:pages">8187-8189</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">In this communication we describe a novel acid-cleavable linker strategy for antibody-drug conjugation.  Functional disulfide bridging of the single interchain disulfide bond of a trastuzumab Fab fragment yields a homogeneous antibody-drug conjugate bearing a thiomaleamic acid linker.  This linker is stable at physiol. pH and temp., but quant. cleaves at lysosomal pH to release the drug payload.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo86GfXF_wrY7Vg90H21EOLACvtfcHk0lj8Aaqr35AsrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlWjsrvM&md5=63dbcd8a78a7bdbb599ff1e742cb35f5</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1039%2Fc3cc45220d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3cc45220d%26sid%3Dliteratum%253Aachs%26aulast%3DCastaneda%26aufirst%3DL.%26aulast%3DMaruani%26aufirst%3DA.%26aulast%3DSchumacher%26aufirst%3DF.%2BF.%26aulast%3DMiranda%26aufirst%3DE.%26aulast%3DChudasama%26aufirst%3DV.%26aulast%3DChester%26aufirst%3DK.%2BA.%26aulast%3DBaker%26aufirst%3DJ.%2BR.%26aulast%3DSmith%26aufirst%3DM.%2BE.%26aulast%3DCaddick%26aufirst%3DS.%26atitle%3DAcid-cleavable%2520thiomaleamic%2520acid%2520linker%2520for%2520homogeneous%2520antibody-drug%2520conjugation%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2013%26volume%3D49%26spage%3D8187%26epage%3D8189%26doi%3D10.1039%2Fc3cc45220d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstead, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosure, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knipe, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasch, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P. A.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">855</span>â <span class="NLM_lpage">869</span>, <span class="refDoi">Â DOI: 10.1021/bc025536j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc025536j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XksFentr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=855-869&author=G.+M.+Dubowchikauthor=R.+A.+Firestoneauthor=L.+Padillaauthor=D.+Willnerauthor=S.+J.+Hofsteadauthor=K.+Mosureauthor=J.+O.+Knipeauthor=S.+J.+Laschauthor=P.+A.+Trail&title=Cathepsin+B-labile+dipeptide+linkers+for+lysosomal+release+of+doxorubicin+from+internalizing+immunoconjugates%3A+model+studies+of+enzymatic+drug+release+and+antigen-specific+in+vitro+anticancer+activity&doi=10.1021%2Fbc025536j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity</span></div><div class="casAuthors">Dubowchik, Gene M.; Firestone, Raymond A.; Padilla, Linda; Willner, David; Hofstead, Sandra J.; Mosure, Kathleen; Knipe, Jay O.; Lasch, Shirley J.; Trail, Pamela A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">855-869</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The anticancer drug doxorubicin (DOX) was linked to chimeric BR96, an internalizing monoclonal antibody that binds to a Lewisy-related, tumor-assocd. antigen, through 2 lysosomally cleavable dipeptides, Phe-Lys and Val-Cit, giving immunoconjugates (I and II).  A self-immolative p-aminobenzyloxycarbonyl (PABC) spacer between the dipeptides and the DOX was required for rapid and quant. generation of free drug. DOX release from the model substrate Z-Phe-Lys-PABC-DOX was 30-fold faster than from Z-Val-Cit-PABC-DOX with the cysteine protease cathepsin B alone, but rates were identical in a rat liver lysosomal prepn. suggesting the participation of more than one enzyme.  Conjugates I and II showed rapid and near quant. drug release with cathepsin B and in a lysosomal prepn., while demonstrating excellent stability in human plasma.  Against tumor cell lines with varying levels of BR96 expression, both conjugates showed potent, antigen-specific cytotoxic activity, suggesting that they will be effective in delivering DOX selectively to antigen-expressing carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqolCImqg5WKbVg90H21EOLACvtfcHk0lj8Aaqr35AsrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksFentr8%253D&md5=09fb70d94d8997033b109fa3b5e79621</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fbc025536j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc025536j%26sid%3Dliteratum%253Aachs%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26aulast%3DFirestone%26aufirst%3DR.%2BA.%26aulast%3DPadilla%26aufirst%3DL.%26aulast%3DWillner%26aufirst%3DD.%26aulast%3DHofstead%26aufirst%3DS.%2BJ.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DLasch%26aufirst%3DS.%2BJ.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DCathepsin%2520B-labile%2520dipeptide%2520linkers%2520for%2520lysosomal%2520release%2520of%2520doxorubicin%2520from%2520internalizing%2520immunoconjugates%253A%2520model%2520studies%2520of%2520enzymatic%2520drug%2520release%2520and%2520antigen-specific%2520in%2520vitro%2520anticancer%2520activity%26jtitle%3DBioconjugate%2520Chem.%26date%3D2002%26volume%3D13%26spage%3D855%26epage%3D869%26doi%3D10.1021%2Fbc025536j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mhidia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beziere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanpain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommery, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, O.</span></span> <span> </span><span class="NLM_article-title">Assembly/disassembly of drug conjugates using imide ligation</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3982</span>â <span class="NLM_lpage">3985</span>, <span class="refDoi">Â DOI: 10.1021/ol101049g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol101049g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGjtbrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=3982-3985&author=R.+Mhidiaauthor=N.+Beziereauthor=A.+Blanpainauthor=N.+Pommeryauthor=O.+Melnyk&title=Assembly%2Fdisassembly+of+drug+conjugates+using+imide+ligation&doi=10.1021%2Fol101049g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Assembly/disassembly of drug conjugates using imide ligation</span></div><div class="casAuthors">Mhidia, Reda; Beziere, Nicolas; Blanpain, Annick; Pommery, Nicole; Melnyk, Oleg</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3982-3985</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A strategy is described that allows the easy assembly and controlled disassembly of drug conjugates.  Imide ligation, i.e., the reaction of a peptide thioacid with an azidoformate, is used for conjugate assembly.  The imide bond participates also with an endopeptidase-triggered cyclization-based disassembly mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYyi5Re83d27Vg90H21EOLACvtfcHk0lj8Aaqr35AsrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGjtbrJ&md5=e40965ea2a5a57947a867c637c3eccce</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Fol101049g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol101049g%26sid%3Dliteratum%253Aachs%26aulast%3DMhidia%26aufirst%3DR.%26aulast%3DBeziere%26aufirst%3DN.%26aulast%3DBlanpain%26aufirst%3DA.%26aulast%3DPommery%26aufirst%3DN.%26aulast%3DMelnyk%26aufirst%3DO.%26atitle%3DAssembly%252Fdisassembly%2520of%2520drug%2520conjugates%2520using%2520imide%2520ligation%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26spage%3D3982%26epage%3D3985%26doi%3D10.1021%2Fol101049g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreyka, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissler, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenox, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okeley, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">831</span>â <span class="NLM_lpage">840</span>, <span class="refDoi">Â DOI: 10.1021/bc0600214</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc0600214" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD28XktVert78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=831-840&author=S.+C.+Jeffreyauthor=J.+B.+Andreykaauthor=S.+X.+Bernhardtauthor=K.+M.+Kisslerauthor=T.+Klineauthor=J.+S.+Lenoxauthor=R.+F.+Moserauthor=M.+T.+Nguyenauthor=N.+M.+Okeleyauthor=I.+J.+Stoneauthor=X.+Zhangauthor=P.+D.+Senter&title=Development+and+properties+of+beta-glucuronide+linkers+for+monoclonal+antibody-drug+conjugates&doi=10.1021%2Fbc0600214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Properties of Î²-Glucuronide Linkers for Monoclonal Antibody-Drug Conjugates</span></div><div class="casAuthors">Jeffrey, Scott C.; Andreyka, Jamie B.; Bernhardt, Starr X.; Kissler, Kim M.; Kline, Toni; Lenox, Joel S.; Moser, Ruth F.; Nguyen, Minh T.; Okeley, Nicole M.; Stone, Ivan J.; Zhang, Xinqun; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">831-840</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A Î²-glucuronide-based linker for attaching cytotoxic agents to monoclonal antibodies (mAbs) was designed and evaluated.  We employed the cytotoxic Monomethyl auristatin E (MMAE) and Monomethyl auristatin F (MMAF)and doxorubicin propyloxazoline (DPO) to give the Î²-glucuronide MMAE, Î-glucuronide MMAF, and (I), resp.  Cysteine-quenched derivs. of Î-glucuronide MMAF and I were detd. to be substrates for E. Coli Î²-glucuronidase, resulting in facile drug release.  The Î²-glucuronide MMAF was highly stable in rat plasma with an extrapolated half-life of 81 days.  Each drug-linker when conjugated to mAbs c1F6 (anti-CD70) and cAC10 (anti-CD30) gave monomeric antibody-drug conjugates (ADCs) with as many as eight drugs per mAb and had high levels of immunol. specific cytotoxic activity on cancer cell lines.  CAC10-Î²-glucuronide MMAE displayed pronounced antitumor activity in a s.c. Karpas 299 lymphoma tumor model.  A single dose treatment led to cures in all animals at the 0.5 mg/kg dose level and above, and the conjugate was well tolerated at 100 mg/kg.  In mice with s.c. renal cell carcinoma xenografts, the MMAF conjugate c1F6-Î-glucuronide MMAF was tolerated at 25 mg/kg and efficacious at 0.75 mg/kg.  These results demonstrate that the Î²-glucuronide linker system is an effective strategy for targeting cytotoxic agents providing ADCs with high degrees of efficacy at well-tolerated doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoubdLz5MUdl7Vg90H21EOLACvtfcHk0lgk_i1P0AzRmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktVert78%253D&md5=eebae444d27717c44b521eeb8d6c7ed7</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Fbc0600214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0600214%26sid%3Dliteratum%253Aachs%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DAndreyka%26aufirst%3DJ.%2BB.%26aulast%3DBernhardt%26aufirst%3DS.%2BX.%26aulast%3DKissler%26aufirst%3DK.%2BM.%26aulast%3DKline%26aufirst%3DT.%26aulast%3DLenox%26aufirst%3DJ.%2BS.%26aulast%3DMoser%26aufirst%3DR.%2BF.%26aulast%3DNguyen%26aufirst%3DM.%2BT.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DStone%26aufirst%3DI.%2BJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DDevelopment%2520and%2520properties%2520of%2520beta-glucuronide%2520linkers%2520for%2520monoclonal%2520antibody-drug%2520conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2006%26volume%3D17%26spage%3D831%26epage%3D840%26doi%3D10.1021%2Fbc0600214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Catella-Lawson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cucchiara, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMarco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tournier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FitzGerald, G. A.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase inhibitors and the antiplatelet effects of aspirin</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">1809</span>â <span class="NLM_lpage">1817</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa003199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1056%2FNEJMoa003199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=11752357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38Xltl2juw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2001&pages=1809-1817&author=F.+Catella-Lawsonauthor=M.+P.+Reillyauthor=S.+C.+Kapoorauthor=A.+J.+Cucchiaraauthor=S.+DeMarcoauthor=B.+Tournierauthor=S.+N.+Vyasauthor=G.+A.+FitzGerald&title=Cyclooxygenase+inhibitors+and+the+antiplatelet+effects+of+aspirin&doi=10.1056%2FNEJMoa003199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase inhibitors and the antiplatelet effects of aspirin</span></div><div class="casAuthors">Catella-Lawson, Francesca; Reilly, Muredach P.; Kapoor, Shiv C.; Cucchiara, Andrew J.; DeMarco, Susan; Tournier, Barbara; Vyas, Sachin N.; FitzGerald, Garret A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">1809-1817</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Patients with arthritis and vascular disease may receive both low-dose aspirin and other nonsteroidal antiinflammatory drugs.  We therefore investigated potential interactions between aspirin and commonly prescribed arthritis therapies.  Methods: We administered the following combinations of drugs for six days: aspirin (81 mg every morning) two hours before ibuprofen (400 mg every morning) and the same medications in the reverse order; aspirin two hours before acetaminophen (1000 mg every morning) and the same medications in the reverse order; aspirin two hours before the cyclooxygenase-2 inhibitor rofecoxib (25 mg every morning) and the same medications in the reverse order; enteric-coated aspirin two hours before ibuprofen (400 mg three times a day); and enteric-coated aspirin two hours before delayed-release diclofenac (75 mg twice daily).  Results: Serum thromboxane B2 levels (an index of cyclooxygenase-1 activity in platelets) and platelet aggregation were maximally inhibited 24 h after the administration of aspirin on day 6 in the subjects who took aspirin before a single daily dose of any other drug, as well as in those who took rofecoxib or acetaminophen before taking aspirin.  In contrast, inhibition of serum thromboxane B2 formation and platelet aggregation by aspirin was blocked when a single daily dose of ibuprofen was given before aspirin, as well as when multiple daily doses of ibuprofen were given.  The concomitant administration of rofecoxib, acetaminophen, or diclofenac did not affect the pharmacodynamics of aspirin.  Conclusions: The concomitant administration of ibuprofen but not rofecoxib, acetaminophen, or diclofenac antagonizes the irreversible platelet inhibition induced by aspirin.  Treatment with ibuprofen in patients with increased cardiovascular risk may limit the cardioprotective effects of aspirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo41V4YILt3GbVg90H21EOLACvtfcHk0lgk_i1P0AzRmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xltl2juw%253D%253D&md5=786ae5c3d0b8af300113d944455e8fb6</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa003199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa003199%26sid%3Dliteratum%253Aachs%26aulast%3DCatella-Lawson%26aufirst%3DF.%26aulast%3DReilly%26aufirst%3DM.%2BP.%26aulast%3DKapoor%26aufirst%3DS.%2BC.%26aulast%3DCucchiara%26aufirst%3DA.%2BJ.%26aulast%3DDeMarco%26aufirst%3DS.%26aulast%3DTournier%26aufirst%3DB.%26aulast%3DVyas%26aufirst%3DS.%2BN.%26aulast%3DFitzGerald%26aufirst%3DG.%2BA.%26atitle%3DCyclooxygenase%2520inhibitors%2520and%2520the%2520antiplatelet%2520effects%2520of%2520aspirin%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D345%26spage%3D1809%26epage%3D1817%26doi%3D10.1056%2FNEJMoa003199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cryer, B.</span></span> <span> </span><span class="NLM_article-title">NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality</span>. <i>Am. J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">1694</span>â <span class="NLM_lpage">1695</span>, <span class="refDoi">Â DOI: 10.1111/j.1572-0241.2005.50565.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1111%2Fj.1572-0241.2005.50565.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=16144121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVent7%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2005&pages=1694-1695&author=B.+Cryer&title=NSAID-associated+deaths%3A+the+rise+and+fall+of+NSAID-associated+GI+mortality&doi=10.1111%2Fj.1572-0241.2005.50565.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality</span></div><div class="casAuthors">Cryer, Byron</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1694-1695</span>CODEN:
                <span class="NLM_cas:coden">AJGAAR</span>;
        ISSN:<span class="NLM_cas:issn">0002-9270</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  Although gastrointestinal (GI) morbidity and mortality from NSAIDs continues to be a significant problem, this study by Lanas et al. indicates that the magnitude of the concern is declining.  Explanations for this redn. are more likely related to the increased use of proton pump inhibitors (PPIs) than to the introduction of COX-2 inhibitors.  This study further reveals that one-third of NSAIDs' GI mortality comes from low-dose, daily aspirin.  Another important contribution derived from this report is a more reliable est. of NSAIDs' lower GI clin. consequences than previously available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHt9J5mvzChLVg90H21EOLACvtfcHk0livZZ26MIAT2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVent7%252FP&md5=07cdeba5a2093b4ca9fb383f93e0b88f</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1111%2Fj.1572-0241.2005.50565.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1572-0241.2005.50565.x%26sid%3Dliteratum%253Aachs%26aulast%3DCryer%26aufirst%3DB.%26atitle%3DNSAID-associated%2520deaths%253A%2520the%2520rise%2520and%2520fall%2520of%2520NSAID-associated%2520GI%2520mortality%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2005%26volume%3D100%26spage%3D1694%26epage%3D1695%26doi%3D10.1111%2Fj.1572-0241.2005.50565.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nemmani, K. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mali, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borhade, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karwa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamidiboina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senthilkumar, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangu, N. K.</span></span> <span> </span><span class="NLM_article-title">NO-NSAIDs: Gastric-sparing nitric oxide-releasable prodrugs of non-steroidal anti-inflammatory drugs</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5297</span>â <span class="NLM_lpage">5301</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.07.142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmcl.2009.07.142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=19683923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVeqsLzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5297-5301&author=K.+V.+S.+Nemmaniauthor=S.+V.+Maliauthor=N.+Borhadeauthor=A.+R.+Pathanauthor=M.+Karwaauthor=V.+Pamidiboinaauthor=S.+P.+Senthilkumarauthor=M.+Gundauthor=A.+K.+Jainauthor=N.+K.+Mangu&title=NO-NSAIDs%3A+Gastric-sparing+nitric+oxide-releasable+prodrugs+of+non-steroidal+anti-inflammatory+drugs&doi=10.1016%2Fj.bmcl.2009.07.142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">NO-NSAIDs: Gastric-sparing nitric oxide-releasable prodrugs of non-steroidal anti-inflammatory drugs</span></div><div class="casAuthors">Nemmani, Kumar V. S.; Mali, Sunil V.; Borhade, Namdev; Pathan, Asif R.; Karwa, Manoj; Pamidiboina, Venu; Senthilkumar, S. P.; Gund, Machhindra; Jain, Arun K.; Mangu, Naveen K.; Dubash, Nauzer P.; Desai, Dattatraya C.; Sharma, Somesh; Satyam, Apparao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5297-5301</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recently, a new class of nitric-oxide-releasing non-steroidal anti-inflammatory drugs (NO-NSAIDs) is being studied as Safe NSAIDs' because of their gastric-sparing properties.  As an extension of our novel disulfide linker technol., we have designed, synthesized and evaluated novel NO-releasing NSAID prodrugs such as NO-Aspirin (1b-d) and NO-Diclofenac (2b-c).  Although the amide-contg. deriv. 1d did not show any bioavailability, the remaining compds. have shown fair to excellent pharmacokinetic, anti-inflammatory and gastric-sparing properties.  Among them, however, the NO-Diclofenac (2b) has shown the most promising pharmacokinetic, anti-inflammatory and NO-releasing properties and protected rats from NSAID-induced gastric damage which could be attributable to the beneficial effects of NO released from these prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDr2S0liidLVg90H21EOLACvtfcHk0livZZ26MIAT2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVeqsLzP&md5=e2198fa5c52b30768a16ffd936cb699f</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.07.142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.07.142%26sid%3Dliteratum%253Aachs%26aulast%3DNemmani%26aufirst%3DK.%2BV.%2BS.%26aulast%3DMali%26aufirst%3DS.%2BV.%26aulast%3DBorhade%26aufirst%3DN.%26aulast%3DPathan%26aufirst%3DA.%2BR.%26aulast%3DKarwa%26aufirst%3DM.%26aulast%3DPamidiboina%26aufirst%3DV.%26aulast%3DSenthilkumar%26aufirst%3DS.%2BP.%26aulast%3DGund%26aufirst%3DM.%26aulast%3DJain%26aufirst%3DA.%2BK.%26aulast%3DMangu%26aufirst%3DN.%2BK.%26atitle%3DNO-NSAIDs%253A%2520Gastric-sparing%2520nitric%2520oxide-releasable%2520prodrugs%2520of%2520non-steroidal%2520anti-inflammatory%2520drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5297%26epage%3D5301%26doi%3D10.1016%2Fj.bmcl.2009.07.142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szoke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czompa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lekli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabados-Furjesi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herczeg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csavas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borbas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herczegh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosaki, A.</span></span> <span> </span><span class="NLM_article-title">A new, vasoactive hybrid aspirin containing nitrogen monoxide-releasing molsidomine moiety</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">159</span>â <span class="NLM_lpage">166</span>, <span class="refDoi">Â DOI: 10.1016/j.ejps.2019.02.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejps.2019.02.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=30779982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1Gms7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2019&pages=159-166&author=K.+Szokeauthor=A.+Czompaauthor=I.+Lekliauthor=P.+Szabados-Furjesiauthor=M.+Herczegauthor=M.+Csavasauthor=A.+Borbasauthor=P.+Herczeghauthor=A.+Tosaki&title=A+new%2C+vasoactive+hybrid+aspirin+containing+nitrogen+monoxide-releasing+molsidomine+moiety&doi=10.1016%2Fj.ejps.2019.02.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">A new, vasoactive hybrid aspirin containing nitrogen monoxide-releasing molsidomine moiety</span></div><div class="casAuthors">Szoke, Kitti; Czompa, Attila; Lekli, Istvan; Szabados-Furjesi, Peter; Herczeg, Mihaly; Csavas, Magdolna; Borbas, Aniko; Herczegh, Pal; Tosaki, Arpad</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159-166</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ischemic heart conditions are among the main causes of sudden cardiac death worldwide.  One of the strategies for avoiding myocardial infarction is the low-dose, prophylactic use of acetylsalicylic acid (ASA), an inhibitor of platelet aggregation.  To avoid the gastrointestinal damage, ASA prodrugs bearing nitric oxide (NO)-donating moiety covalently conjugated to ASA have been synthesized and evaluated extensively worldwide.  Herein the synthesis of a new hybrid ASA ester covalently attached to the NO donor linsidomine, an active metabolite of molsidomine (MOL) is reported.  Cell viability assay and hemolysis tests were performed in H9c2 cells and rat erythrocytes, resp.  Our new compd., the ERJ-500 not affected neg. the viability of living cells in the concn. range of 100 nM to 100 Î¼M.  Using the ex vivo Langendorff method on hearts originated from female rats, compd. ERJ-500 displayed a dose-dependent, outwashable vasodilative effect in coronary arteries.  Vasodilation was obsd. on isolated working heart model as well, with elevated stroke vol. in hearts treated with ERJ-500.  Furthermore, a decreased infarct size was also noticed in ERJ-500 treated hearts after ischemia/reperfusion.  Based on these observations it can be expected that our new hybrid ASA may contribute to new pharmacol. tool in the therapy of ischemic heart conditions and assocd. syndromes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_OImotZEyDrVg90H21EOLACvtfcHk0livZZ26MIAT2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1Gms7s%253D&md5=5e3bf72d23357ad06d39caa02f31fe9c</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2019.02.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2019.02.020%26sid%3Dliteratum%253Aachs%26aulast%3DSzoke%26aufirst%3DK.%26aulast%3DCzompa%26aufirst%3DA.%26aulast%3DLekli%26aufirst%3DI.%26aulast%3DSzabados-Furjesi%26aufirst%3DP.%26aulast%3DHerczeg%26aufirst%3DM.%26aulast%3DCsavas%26aufirst%3DM.%26aulast%3DBorbas%26aufirst%3DA.%26aulast%3DHerczegh%26aufirst%3DP.%26aulast%3DTosaki%26aufirst%3DA.%26atitle%3DA%2520new%252C%2520vasoactive%2520hybrid%2520aspirin%2520containing%2520nitrogen%2520monoxide-releasing%2520molsidomine%2520moiety%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D131%26spage%3D159%26epage%3D166%26doi%3D10.1016%2Fj.ejps.2019.02.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdellatif, K. R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VelÃ¡zquez, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knaus, E. E.</span></span> <span> </span><span class="NLM_article-title">Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: Synthesis, biological evaluation and nitric oxide release studies</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3014</span>â <span class="NLM_lpage">3018</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.04.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmcl.2009.04.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=19419861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVersr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3014-3018&author=K.+R.+A.+Abdellatifauthor=M.+A.+Chowdhuryauthor=Y.+Dongauthor=D.+Dasauthor=G.+Yuauthor=C.+A.+Vel%C3%A1zquezauthor=M.+R.+Sureshauthor=E.+E.+Knaus&title=Dinitroglyceryl+and+diazen-1-ium-1%2C2-diolated+nitric+oxide+donor+ester+prodrugs+of+aspirin%2C+indomethacin+and+ibuprofen%3A+Synthesis%2C+biological+evaluation+and+nitric+oxide+release+studies&doi=10.1016%2Fj.bmcl.2009.04.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: Synthesis, biological evaluation and nitric oxide release studies</span></div><div class="casAuthors">Abdellatif, Khaled R. A.; Chowdhury, Morshed Alam; Dong, Ying; Das, Dipankar; Yu, Gang; Velazquez, Carlos A.; Suresh, Mavanur R.; Knaus, Edward E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3014-3018</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new group of hybrid nitric oxide (NO) releasing anti-inflammatory (AI) ester prodrugs (NONO-NSAIDs) wherein a 1,3-dinitrooxy-2-Pr (12a-c), or O2-acetoxymethyl-1-[2-(methyl)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (14a-c), NO-donor moiety is directly attached to the carboxylic acid group of aspirin, indomethacin or ibuprofen were synthesized.  NO release from the dinitrooxypropyl, or diazen-1-ium-1,2-diolate, ester prodrugs was increased substantially upon incubation in the presence of L-cysteine (12a-c) or rat serum (14a-c).  The ester prodrugs (12a-c, 14a-c), which did not inhibit the COX-1 isoenzyme, exhibited modest inhibitory activity against the COX-2 isoenzyme.  The NONO-NSAIDs 12a-c and 14a-c exhibited in vivo AI activity that was similar to that exhibited by the parent drug aspirin, indomethacin or ibuprofen when the same oral dose (Î¼mol/kg) was administered.  These similarities in oral potency profiles suggest these NONO-NSAIDs act as classical prodrugs that require metabolic activation by esterase-mediated hydrolysis.  Hybrid NO-donor/anti-inflammatory prodrugs of this type (NONO-NSAIDs) offer a potential drug design concept targeted toward the development of anti-inflammatory drugs with reduced adverse gastrointestinal effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxVIWM0fQaMbVg90H21EOLACvtfcHk0lhCzj_Wb-CpTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVersr0%253D&md5=c91904610db38690e91823797ccb22f3</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.059%26sid%3Dliteratum%253Aachs%26aulast%3DAbdellatif%26aufirst%3DK.%2BR.%2BA.%26aulast%3DChowdhury%26aufirst%3DM.%2BA.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DDas%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DVel%25C3%25A1zquez%26aufirst%3DC.%2BA.%26aulast%3DSuresh%26aufirst%3DM.%2BR.%26aulast%3DKnaus%26aufirst%3DE.%2BE.%26atitle%3DDinitroglyceryl%2520and%2520diazen-1-ium-1%252C2-diolated%2520nitric%2520oxide%2520donor%2520ester%2520prodrugs%2520of%2520aspirin%252C%2520indomethacin%2520and%2520ibuprofen%253A%2520Synthesis%252C%2520biological%2520evaluation%2520and%2520nitric%2520oxide%2520release%2520studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3014%26epage%3D3018%26doi%3D10.1016%2Fj.bmcl.2009.04.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corazzi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maucci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corazzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresele, P.</span></span> <span> </span><span class="NLM_article-title">Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016)</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>315</i></span>,  <span class="NLM_fpage">1331</span>â <span class="NLM_lpage">1337</span>, <span class="refDoi">Â DOI: 10.1124/jpet.105.089896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1124%2Fjpet.105.089896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=16144976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlalurbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2005&pages=1331-1337&author=T.+Corazziauthor=M.+Leoneauthor=R.+Maucciauthor=L.+Corazziauthor=P.+Gresele&title=Direct+and+irreversible+inhibition+of+cyclooxygenase-1+by+nitroaspirin+%28NCX+4016%29&doi=10.1124%2Fjpet.105.089896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016)</span></div><div class="casAuthors">Corazzi, Teresa; Leone, Mario; Maucci, Raffaella; Corazzi, Lanfranco; Gresele, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1331-1337</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Benzoic acid, 2-(acetyl-oxy)-3-[(nitrooxy)methyl]phenyl ester (NCX 4016), a new drug made by an aspirin mol. linked, through a spacer, to a nitric oxide (NO)-donating moiety, is now under clin. testing for the treatment of atherothrombotic conditions.  Aspirin exerts its antithrombotic activity by irreversibly inactivating platelet cyclooxygenase (COX)-1.  NCX 4016 in vivo undergoes metab. into deacetylated and/or denitrated metabolites, and it is not known whether NCX 4016 needs to liberate aspirin to inhibit COX-1, or whether it can block it as a whole mol.  The aim of our study was to evaluate the effects of NCX 4016 and its analog or metabolites on platelet COX-1 and whole blood COX-2 and on purified ovine COX (oCOX)-1 and oCOX-2.  In particular, we have compared the mechanism by which NCX 4016 inhibits purified oCOX enzymes with that of aspirin using a spectrophotometric assay.  All the NCX 4016 derivs. contg. acetylsalicylic acid inhibited the activity of oCOX-1 and oCOX-2, whereas the deacetylated metabolites and the nitric oxide-donating moiety were inactive.  Dialysis expts. showed that oCOX-1 inhibition by NCX 4016, similar to aspirin, is irreversible.  Reversible COX inhibitors (indomethacin) or salicylic acid incubated with the enzyme before NCX 4016 prevent the irreversible inhibition of oCOX-1 by NCX 4016 as well as by aspirin.  In conclusion, our data show that NCX 4016 acts as a direct and irreversible inhibitor of COX-1 and that the presence of a spacer and NO-donating moiety in the mol. slows the kinetics of COX-1 inhibition by NCX 4016, compared with aspirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYu32WTBZEN7Vg90H21EOLACvtfcHk0lhCzj_Wb-CpTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlalurbI&md5=c2f8692899967afa23e52bbb4fe3aa8d</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.089896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.089896%26sid%3Dliteratum%253Aachs%26aulast%3DCorazzi%26aufirst%3DT.%26aulast%3DLeone%26aufirst%3DM.%26aulast%3DMaucci%26aufirst%3DR.%26aulast%3DCorazzi%26aufirst%3DL.%26aulast%3DGresele%26aufirst%3DP.%26atitle%3DDirect%2520and%2520irreversible%2520inhibition%2520of%2520cyclooxygenase-1%2520by%2520nitroaspirin%2520%2528NCX%25204016%2529%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D315%26spage%3D1331%26epage%3D1337%26doi%3D10.1124%2Fjpet.105.089896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiroli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ongini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Soldato, P.</span></span> <span> </span><span class="NLM_article-title">Nitric oxide-donating non-steroidal anti-inflammatory drugs: the case of nitroderivatives of aspirin</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">441</span>â <span class="NLM_lpage">446</span>, <span class="refDoi">Â DOI: 10.1016/S0223-5234(03)00055-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS0223-5234%2803%2900055-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=12750033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjs1CltLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=441-446&author=V.+Chiroliauthor=F.+Benediniauthor=E.+Onginiauthor=P.+Del+Soldato&title=Nitric+oxide-donating+non-steroidal+anti-inflammatory+drugs%3A+the+case+of+nitroderivatives+of+aspirin&doi=10.1016%2FS0223-5234%2803%2900055-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide-donating non-steroidal anti-inflammatory drugs: the case of nitro derivatives of aspirin</span></div><div class="casAuthors">Chiroli, Valerio; Benedini, Francesca; Ongini, Ennio; Del Soldato, Piero</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-446</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review.  Nitric oxide (NO) acts as a key signaling mechanism in a no. of cells and tissues in the mammalian organism.  Modulation of the biosynthesis of NO has emerged to be relevant to the treatment of a variety of human diseases.  In the attempt to reduce the serious side effects of non-steroidal anti-inflammatory drugs (NSAIDs), esp. in the gastrointestinal tract, a NO-releasing moiety has been linked to conventional NSAIDs.  A prototypical example is that of NO-releasing derivs. of aspirin.  Thanks to the cytoprotective action of NO such compds. do not produce gastric damage and are emerging as an interesting novel group of drugs for their unique pharmacol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqThAb9XNHkO7Vg90H21EOLACvtfcHk0lhCzj_Wb-CpTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjs1CltLY%253D&md5=2fb87b379c00b12d1b15bc7694104a56</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2803%2900055-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252803%252900055-2%26sid%3Dliteratum%253Aachs%26aulast%3DChiroli%26aufirst%3DV.%26aulast%3DBenedini%26aufirst%3DF.%26aulast%3DOngini%26aufirst%3DE.%26aulast%3DDel%2BSoldato%26aufirst%3DP.%26atitle%3DNitric%2520oxide-donating%2520non-steroidal%2520anti-inflammatory%2520drugs%253A%2520the%2520case%2520of%2520nitroderivatives%2520of%2520aspirin%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2003%26volume%3D38%26spage%3D441%26epage%3D446%26doi%3D10.1016%2FS0223-5234%2803%2900055-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praveen Rao, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knaus, E. E.</span></span> <span> </span><span class="NLM_article-title">Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4061</span>â <span class="NLM_lpage">4067</span>, <span class="refDoi">Â DOI: 10.1021/jm050211k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050211k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktlCrsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4061-4067&author=C.+Velazquezauthor=P.+N.+Praveen+Raoauthor=E.+E.+Knaus&title=Novel+nonsteroidal+antiinflammatory+drugs+possessing+a+nitric+oxide+donor+diazen-1-ium-1%2C2-diolate+moiety%3A+design%2C+synthesis%2C+biological+evaluation%2C+and+nitric+oxide+release+studies&doi=10.1021%2Fjm050211k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Nonsteroidal Antiinflammatory Drugs Possessing a Nitric Oxide Donor Diazen-1-ium-1,2-diolate Moiety: Design, Synthesis, Biological Evaluation, and Nitric Oxide Release Studies</span></div><div class="casAuthors">Velazquez, Carlos; Rao, P. N. Praveen; Knaus, Edward E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4061-4067</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel group of hybrid nitric oxide-releasing nonsteroidal antiinflammatory drugs (â¢NO-NSAIDs) possessing a 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate or 1-(N,N-dimethylamino)diazen-1-ium-1,2-diolate moiety attached via a one-carbon methylene spacer to the carboxylic acid group of the traditional NSAIDs aspirin, ibuprofen, and indomethacin were synthesized.  Although none of these ester prodrugs exhibited in vitro cyclooxygenase (COX) inhibitory activity against the COX-1 and COX-2 isoenzymes (IC50 > 100 Î¼M), all of the compds. significantly decreased carrageenan-induced rat paw edema.  In this regard, the ester prodrugs showed equipotent antiinflammatory activities in vivo to that of the parent drugs aspirin, ibuprofen, and indomethacin.  All of the compds. released nitric oxide upon incubation with either phosphate buffer soln. at pH 7.4 (14-16% range) or porcine liver esterase (16-19% range), but the percentage of â¢NO released was up to sixfold higher (93%) when these ester prodrugs were incubated with guinea pig serum.  These incubation studies suggest that both â¢NO and the parent NSAID would be released upon in vivo cleavage by nonspecific serum esterases.  The simultaneous release of aspirin and nitric oxide from the â¢NO-aspirin prodrugs constitutes a potentially beneficial property for the prophylactic prevention of thrombus formation and adverse cardiovascular events such as stroke and myocardial infarction.  The data acquired in an in vivo ulcer index (UI) assay showed that for this group of ester prodrugs, particularly the â¢NO-aspirins and â¢NO-ibuprofens, no lesions were obsd. (UI = 0) when compared to the parent drugs aspirin (UI = 57, 250 mg/kg po dose), ibuprofen (UI = 45, 250 mg/kg po dose), or indomethacin (UI = 34, 30 mg/kg po dose) at equiv. doses.  Accordingly, these hybrid â¢NO-NSAID prodrugs possessing a diazen-1-ium-1,2-diolate moiety, represent a new approach for the rational design of antiinflammatory drugs with reduced gastric ulcerogenicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGIFGzgY0hoLVg90H21EOLACvtfcHk0lhCzj_Wb-CpTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktlCrsLo%253D&md5=0727fa37e4d644eb55942793ffdcdf62</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fjm050211k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050211k%26sid%3Dliteratum%253Aachs%26aulast%3DVelazquez%26aufirst%3DC.%26aulast%3DPraveen%2BRao%26aufirst%3DP.%2BN.%26aulast%3DKnaus%26aufirst%3DE.%2BE.%26atitle%3DNovel%2520nonsteroidal%2520antiinflammatory%2520drugs%2520possessing%2520a%2520nitric%2520oxide%2520donor%2520diazen-1-ium-1%252C2-diolate%2520moiety%253A%2520design%252C%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520nitric%2520oxide%2520release%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4061%26epage%3D4067%26doi%3D10.1021%2Fjm050211k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praveen Rao, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citro, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keefer, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knaus, E. E.</span></span> <span> </span><span class="NLM_article-title">O2-acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): synthesis, nitric oxide release, and biological evaluation studies</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">4767</span>â <span class="NLM_lpage">4774</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2007.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmc.2007.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=17509888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtFOjs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=4767-4774&author=C.+A.+Velazquezauthor=P.+N.+Praveen+Raoauthor=M.+L.+Citroauthor=L.+K.+Keeferauthor=E.+E.+Knaus&title=O2-acetoxymethyl-protected+diazeniumdiolate-based+NSAIDs+%28NONO-NSAIDs%29%3A+synthesis%2C+nitric+oxide+release%2C+and+biological+evaluation+studies&doi=10.1016%2Fj.bmc.2007.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">O2-Acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): Synthesis, nitric oxide release, and biological evaluation studies</span></div><div class="casAuthors">Velazquez, Carlos A.; Rao, P. N. Praveen; Citro, Michael L.; Keefer, Larry K.; Knaus, Edward E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4767-4774</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A novel group of O2-acetoxymethyl-protected diazeniumdiolate-based nonsteroidal anti-inflammatory prodrugs (NONO-NSAIDs) were synthesized by esterifying the carboxylate group of aspirin, ibuprofen, or indomethacin with O2-acetoxymethyl 1-[N-(2-hydroxyethyl)-N-methylamino]diazeniumdiolate.  The resulting nitric oxide (â¢>NO)-releasing prodrugs (7-9) did not exhibit in vitro cyclooxygenase (COX) inhibitory activity against the COX-1 and COX-2 isoenzymes (IC50s > 100 Î¼M).  In contrast, prodrugs 7 and 8 significantly decreased carrageenan-induced rat paw edema showing enhanced in vivo anti-inflammatory activities (ID50's = 552 and 174 Î¼mol/kg, resp.) relative to those of the parent NSAIDs aspirin (ID50 = 714 Î¼mol/kg) and ibuprofen (ID50 = 326 Î¼mol/kg).  The rate of porcine liver esterase-mediated â¢NO release from prodrugs 7-9 (2 mol of â¢NO/mol of test compd. in 0.6-6.5 min) was substantially higher compared to that obsd. without enzymic catalysis (about 1 mol of â¢NO/mol of test compd. in 40-48 h).  These incubation studies suggest that both â¢NO and the parent NSAID would be released upon in vivo activation (hydrolysis) by esterases.  Data acquired in an in vivo ulcer index (UI) assay showed that NONO-aspirin (UI = 0.8), NONO-indomethacin (UI = 1.3), and particularly NONO-ibuprofen (UI = 0) were significantly less ulcerogenic compared to the parent drugs aspirin (UI = 57), ibuprofen (UI = 46) or indomethacin (UI = 34) at equimolar doses.  The release of aspirin and Â·NO from the NONO-aspirin (7) prodrug constitutes a potentially beneficial property for the prophylactic prevention of thrombus formation and adverse cardiovascular events such as stroke and myocardial infarction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopHdbh33BY9LVg90H21EOLACvtfcHk0li_5DNQjbK_tg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtFOjs7g%253D&md5=4b8171adcf7540bab147a80636691e96</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DVelazquez%26aufirst%3DC.%2BA.%26aulast%3DPraveen%2BRao%26aufirst%3DP.%2BN.%26aulast%3DCitro%26aufirst%3DM.%2BL.%26aulast%3DKeefer%26aufirst%3DL.%2BK.%26aulast%3DKnaus%26aufirst%3DE.%2BE.%26atitle%3DO2-acetoxymethyl-protected%2520diazeniumdiolate-based%2520NSAIDs%2520%2528NONO-NSAIDs%2529%253A%2520synthesis%252C%2520nitric%2520oxide%2520release%252C%2520and%2520biological%2520evaluation%2520studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D4767%26epage%3D4774%26doi%3D10.1016%2Fj.bmc.2007.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ait-Tihyaty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachid, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larroque-Lombard, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B. J.</span></span> <span> </span><span class="NLM_article-title">ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule,;requires carboxylesterase-mediated hydrolysis for optimal activity</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1409</span>â <span class="NLM_lpage">1423</span>, <span class="refDoi">Â DOI: 10.1007/s10637-013-0008-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1007%2Fs10637-013-0008-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23959266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCmtLfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1409-1423&author=M.+Ait-Tihyatyauthor=Z.+Rachidauthor=A.-L.+Larroque-Lombardauthor=B.+J.+Jean-Claude&title=ZRX1%2C+the+first+EGFR+inhibitor-capecitabine+based+combi-molecule%2C%3Brequires+carboxylesterase-mediated+hydrolysis+for+optimal+activity&doi=10.1007%2Fs10637-013-0008-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity</span></div><div class="casAuthors">Ait-Tihyaty, Maria; Rachid, Zakaria; Larroque-Lombard, Anne-Laure; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1409-1423</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Capecitabine, an orally available prodrug of 5-FU, requires activation by carboxylesterase (CES) enzymes present in the liver to generate 5'-deoxy-5-flurocytidine ribose (5'-DFCR).  The deamination of the latter by cytidine deaminase gives 5'-deoxy-5-fluorouridine ribose (5'-DFUR).  Finally, the conversion of 5'-DFUR to the cytotoxic drug 5-FU, occurs primarily in the tumor and is catalyzed by thymidine phosphorylase (TP).  Accordingly, it was surmised that events assocd. with an increase of TP levels should enhance the potency of capecitabine and its metabolites.  EGFR inhibition was found to be one such event.  The obsd. synergy between gefitinib and 5'-DFUR has inspired the design of single mols. capable of acting as prodrugs of both an EGFR inhibitor and 5-FU.  Here, we report on the synthesis and characterization of one such mol., ZRX1, that consists of an acetylated 5'-DFCR moiety linked to a quinazoline inhibitor of EGFR through an alkyl dicarbamate spacer that requires CES activation to generate the two active metabolites.  Our results showed that ZRX1 was ineffective as an intact mol.  However, when CES was present, ZRX1 induced an increase in EGFR inhibition, TP expression, DNA damage and apoptosis.  ZRX1 was, at least, 3-fold more potent than capecitabine and 5'-DFUR and recapitulated the effects of the combination treatments.  LC-MS anal. showed that in the presence of CES, ZRX1 is metabolized into a mixt. of bioactive quinazoline derivs. and 5'-DFCR derived metabolites.  Our results in toto, suggest that capecitabine-based EGFR targeting combi-mols. of the same type than ZRX1, have the potential to induce stronger growth inhibitory potency than capecitabine, 5'-DFUR or single EGFR inhibitors and equiv. potency when compared with combinations of EGFR inhibitors + 5'-DFUR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbcy_7Wffws7Vg90H21EOLACvtfcHk0li_5DNQjbK_tg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCmtLfN&md5=376a62ece2525242f53ec798afe80e71</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1007%2Fs10637-013-0008-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-013-0008-y%26sid%3Dliteratum%253Aachs%26aulast%3DAit-Tihyaty%26aufirst%3DM.%26aulast%3DRachid%26aufirst%3DZ.%26aulast%3DLarroque-Lombard%26aufirst%3DA.-L.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DZRX1%252C%2520the%2520first%2520EGFR%2520inhibitor-capecitabine%2520based%2520combi-molecule%252C%253Brequires%2520carboxylesterase-mediated%2520hydrolysis%2520for%2520optimal%2520activity%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D1409%26epage%3D1423%26doi%3D10.1007%2Fs10637-013-0008-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cassata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Procoplo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrario, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beretta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longarini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajetta, E.</span></span> <span> </span><span class="NLM_article-title">Capecitabine: indications and future perspectives in the treatment of metastatic colorectal and breast cancer</span>. <i>Tumori</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">364</span>â <span class="NLM_lpage">371</span>, <span class="refDoi">Â DOI: 10.1177/030089160108700602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1177%2F030089160108700602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=11989587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFGltr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2001&pages=364-371&author=A.+Cassataauthor=G.+Procoploauthor=M.+Aluauthor=L.+Ferrariauthor=E.+Ferrarioauthor=E.+Berettaauthor=R.+Longariniauthor=G.+Bustoauthor=C.+D.+Deauthor=E.+Bajetta&title=Capecitabine%3A+indications+and+future+perspectives+in+the+treatment+of+metastatic+colorectal+and+breast+cancer&doi=10.1177%2F030089160108700602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Capecitabine: Indications and future perspectives in the treatment of metastatic colorectal and breast cancer</span></div><div class="casAuthors">Cassata, Antonino; Procopio, Giuseppe; Alu, Massimiliano; Ferrari, Leonardo; Ferrario, Erminia; Beretta, Elena; Longarini, Raffaella; Busto, Giuseppina; De Candis, Daniela; Bajetta, Emilio</div><div class="citationInfo"><span class="NLM_cas:title">Tumori</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">364-371</span>CODEN:
                <span class="NLM_cas:coden">TUMOAB</span>;
        ISSN:<span class="NLM_cas:issn">0300-8916</span>.
    
            (<span class="NLM_cas:orgname">Il Pensiero Scientifico Editore</span>)
        </div><div class="casAbstract">A review.  Fluoropyrimidines remain the most important drugs in the treatment of breast and colorectal carcinoma, but response rates and survival time have been disappointing.  Optimal administration is by continuous i.v. infusion, which makes it cumbersome to use and compromises patient independence.  Recently, a no. of new agents, including fluorouracil prodrugs and selective dihydropyrimidine dehydrogenase inhibitors, have been studied, with promising results.  Capecitabine is the first in a new class of fluoropyrimidines.  It is an oral, tumor-activated anticancer drug whose activity mimics that of continuously infused 5-fluorouracil.  Capecitabine circumvents dihydropyrimidine dehydrogenase catabolism and appears to be at least as active against metastatic colorectal and breast cancer as conventionally administered i.v. 5-fluorouracil, with significantly less toxicity, an improved quality of life, and lesser cost.  Capecitabine may ultimately provide enhanced antitumor activity to fluorouracil-contg. regimes for advanced colorectal and breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplvofxN29QBrVg90H21EOLACvtfcHk0li_5DNQjbK_tg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFGltr4%253D&md5=12d0cd949abafa436e72da6531e47e51</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1177%2F030089160108700602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F030089160108700602%26sid%3Dliteratum%253Aachs%26aulast%3DCassata%26aufirst%3DA.%26aulast%3DProcoplo%26aufirst%3DG.%26aulast%3DAlu%26aufirst%3DM.%26aulast%3DFerrari%26aufirst%3DL.%26aulast%3DFerrario%26aufirst%3DE.%26aulast%3DBeretta%26aufirst%3DE.%26aulast%3DLongarini%26aufirst%3DR.%26aulast%3DBusto%26aufirst%3DG.%26aulast%3DDe%26aufirst%3DC.%2BD.%26aulast%3DBajetta%26aufirst%3DE.%26atitle%3DCapecitabine%253A%2520indications%2520and%2520future%2520perspectives%2520in%2520the%2520treatment%2520of%2520metastatic%2520colorectal%2520and%2520breast%2520cancer%26jtitle%3DTumori%26date%3D2001%26volume%3D87%26spage%3D364%26epage%3D371%26doi%3D10.1177%2F030089160108700602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brahimi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudouit, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcnamee, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tari, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JeanClaude, B. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of epidermal growth factor receptor-mediated signaling by âcombi-triazeneâ BJ2000, a new probe for combi-targeting postulates</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>303</i></span>,  <span class="NLM_fpage">238</span>â <span class="NLM_lpage">246</span>, <span class="refDoi">Â DOI: 10.1124/jpet.102.039099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1124%2Fjpet.102.039099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=12235257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsV2qsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2002&pages=238-246&author=F.+Brahimiauthor=S.+L.+Mathesonauthor=F.+Dudouitauthor=J.+P.+Mcnameeauthor=A.+M.+Tariauthor=B.+J.+JeanClaude&title=Inhibition+of+epidermal+growth+factor+receptor-mediated+signaling+by+%E2%80%9Ccombi-triazene%E2%80%9D+BJ2000%2C+a+new+probe+for+combi-targeting+postulates&doi=10.1124%2Fjpet.102.039099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-Triazene" BJ2000, a new probe for Combi-Targeting postulates</span></div><div class="casAuthors">Brahimi, Fouad; Matheson, Stephanie L.; Dudouit, Fabienne; McNamee, James P.; Tari, Ana M.; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">238-246</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The Combi-Targeting concept postulates that a mol. termed combi-mol. (C-mol.) with binary epidermal growth factor receptor (EGFR) targeting/DNA-damaging properties and with the ability to be hydrolyzed to another EGFR inhibitor should induce sustained antiproliferative activity in cells overexpressing EGFR.  Because we postulate that the EGFR affinity of the C-mol. and that of its hydrolytic metabolites are crit. parameters for sustained potency against EGFR-overexpressing cells, we synthesized BJ2000 (IC50 = 0.1 Î¼M, competitive binding at ATP site), a novel C-mol. that can decomp. into a 6-amino-4-anilinoquinazoline FD105 (IC50 = 0.2 Î¼M).  Studies using the EGFR-overexpressing A431 cells revealed that BJ2000 could damage DNA and block epidermal growth factor-stimulated EGFR autophosphorylation by a partially irreversible mechanism.  Blockade of EGFR autophosphorylation subsequently induced inhibition of mitogen-activated protein kinase activation and c-fos gene expression.  ELISA and growth factor-mediated stimulation of proliferation assays in the EGFR-expressing NIH3T3HER14 demonstrated the preferential EGFR-targeting properties of BJ2000, and more importantly suggest that blockade of EGFR phosphorylation by this drug translate into significant growth inhibitory effects.  These properties culminated into irreversible antiproliferative effects as confirmed by a sulforhodamine B assay.  Five days after a 2-h treatment, BJ2000 retained significant antiproliferative effect in A431 cells, whereas its reversible metabolite FD105 almost completely lost its activity.  This result in toto lend support to the Combi-Targeting concept according to which a mol. conjugate kept small enough to interact with EGFR and designed to degrade into another inhibitor of the same target plus a DNA-damaging species may induce sustained growth inhibitory effect in EGFR-overexpressing cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbJ9ASdjBjlLVg90H21EOLACvtfcHk0lhuXSkHtPBt0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsV2qsLY%253D&md5=c10a7f1cc231cbf64fbe468e89df26d7</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.039099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.039099%26sid%3Dliteratum%253Aachs%26aulast%3DBrahimi%26aufirst%3DF.%26aulast%3DMatheson%26aufirst%3DS.%2BL.%26aulast%3DDudouit%26aufirst%3DF.%26aulast%3DMcnamee%26aufirst%3DJ.%2BP.%26aulast%3DTari%26aufirst%3DA.%2BM.%26aulast%3DJeanClaude%26aufirst%3DB.%2BJ.%26atitle%3DInhibition%2520of%2520epidermal%2520growth%2520factor%2520receptor-mediated%2520signaling%2520by%2520%25E2%2580%259Ccombi-triazene%25E2%2580%259D%2520BJ2000%252C%2520a%2520new%2520probe%2520for%2520combi-targeting%2520postulates%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D303%26spage%3D238%26epage%3D246%26doi%3D10.1124%2Fjpet.102.039099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katsoulas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachid, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamee, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B. J.</span></span> <span> </span><span class="NLM_article-title">Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1033</span>â <span class="NLM_lpage">1043</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-07-0179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1158%2F1535-7163.MCT-07-0179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=18483293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvFanurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1033-1043&author=A.+Katsoulasauthor=Z.+Rachidauthor=J.+P.+McNameeauthor=C.+Williamsauthor=B.+J.+Jean-Claude&title=Combi-targeting+concept%3A+an+optimized+single-molecule+dual-targeting+model+for+the+treatment+of+chronic+myelogenous+leukemia&doi=10.1158%2F1535-7163.MCT-07-0179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia</span></div><div class="casAuthors">Katsoulas, Athanasia; Rachid, Zakaria; McNamee, James P.; Williams, Christopher; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1033-1043</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Blockade of Bcr-Abl by the inhibitor Imatinib has proven efficacious in the therapy of chronic myelogenous leukemia (CML).  However resistance to the drug emerges at the advanced phases of the disease.  Therefore, novel therapy models remained to be designed.  We have developed a novel dual targeted agent termed "combi-mol." designed to not only block Bcr-Abl but also damage DNA.  ZRF1, the first optimized prototype of the approach, was "programmed" to degrade into another inhibitor ZRF0 plus a Me diazonium species.  It was â¼2-fold stronger Abl tyrosine kinase inhibitor than Imatinib and a more potent DNA-damaging agent than Temodal.  In the p53 wild-type Mo7p210 cells, the potency of ZRF1 was â¼1,000-fold superior to that of the equieffective combinations of Imatinib plus Temodal.  More importantly, its superior potency over Imatinib was more pronounced in Bcr-Abl-pos. cells coexpressing wild-type p53.  Studies to rationalize these results showed that, through its Bcr-Abl inhibitory function, it down-regulated p53.  However, sufficient level of the latter protein was available for transactivating p21 and Bax, which are required for cell cycle arrest and apoptosis.  The results suggest that, in p53 wild-type cells, apoptosis is induced not only through Bcr-Abl inhibition but also through the p53-controlled DNA-damaging pathway, leading to an additive effect that translates into enhanced cell death.  The study conclusively showed that p53 is a major determinant for the cytotoxic advantages of the novel combi-mol. approach in CML, a disease in which 70% to 85% of all the cases express wild-type p53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3Jd6SPmBpWLVg90H21EOLACvtfcHk0lim_3ce9DXxlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvFanurk%253D&md5=111e62c06bf9a6930449308ff354294f</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0179%26sid%3Dliteratum%253Aachs%26aulast%3DKatsoulas%26aufirst%3DA.%26aulast%3DRachid%26aufirst%3DZ.%26aulast%3DMcNamee%26aufirst%3DJ.%2BP.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DCombi-targeting%2520concept%253A%2520an%2520optimized%2520single-molecule%2520dual-targeting%2520model%2520for%2520the%2520treatment%2520of%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1033%26epage%3D1043%26doi%3D10.1158%2F1535-7163.MCT-07-0179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. P.</span></span> <span> </span><span class="NLM_article-title">Multi-target drug design strategy and its research progress</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2012</span>â <span class="NLM_lpage">2025</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2018&pages=2012-2025&author=J.+T.+Zhouauthor=X.+Y.+Jiangauthor=F.+Fengauthor=H.+P.+Sun&title=Multi-target+drug+design+strategy+and+its+research+progress"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%2BT.%26aulast%3DJiang%26aufirst%3DX.%2BY.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DH.%2BP.%26atitle%3DMulti-target%2520drug%2520design%2520strategy%2520and%2520its%2520research%2520progress%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2018%26volume%3D53%26spage%3D2012%26epage%3D2025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benson, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pershadsingh, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chittiboyina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pravenec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, T. W.</span></span> <span> </span><span class="NLM_article-title">Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARÎ³-modulating activity</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">993</span>â <span class="NLM_lpage">1002</span>, <span class="refDoi">Â DOI: 10.1161/01.HYP.0000123072.34629.57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1161%2F01.HYP.0000123072.34629.57" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15007034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1GmtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=993-1002&author=S.+C.+Bensonauthor=H.+A.+Pershadsinghauthor=C.+I.+Hoauthor=A.+Chittiboyinaauthor=P.+Desaiauthor=M.+Pravenecauthor=N.+Qiauthor=J.+Wangauthor=M.+A.+Averyauthor=T.+W.+Kurtz&title=Identification+of+telmisartan+as+a+unique+angiotensin+II+receptor+antagonist+with+selective+PPAR%CE%B3-modulating+activity&doi=10.1161%2F01.HYP.0000123072.34629.57"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARÎ³-Modulating Activity</span></div><div class="casAuthors">Benson, Stephen C.; Pershadsingh, Harrihar A.; Ho, Christopher I.; Chittiboyina, Amar; Desai, Prashant; Pravenec, Michal; Qi, Nianning; Wang, Jiaming; Avery, Mitchell A.; Kurtz, Theodore W.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">993-1002</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The metabolic syndrome is a common precursor of cardiovascular disease and type 2 diabetes that is characterized by the clustering of insulin resistance, dyslipidemia, and increased blood pressure.  In humans, mutations in the peroxisome proliferator-activated receptor-Î³ (PPARÎ³) have been reported to cause the full-blown metabolic syndrome, and drugs that activate PPARÎ³ have proven to be effective agents for the prevention and treatment of insulin resistance and type 2 diabetes.  Here the authors report that telmisartan, a structurally unique angiotensin II receptor antagonist used for the treatment of hypertension, can function as a partial agonist of PPARÎ³; influence the expression of PPARÎ³ target genes involved in carbohydrate and lipid metab.; and reduce glucose, insulin, and triglyceride levels in rats fed a high-fat, high-carbohydrate diet.  None of the other com. available angiotensin II receptor antagonists appeared to activate PPARÎ³ when tested at concns. typically achieved in plasma with conventional oral dosing.  In contrast to ordinary antihypertensive and antidiabetic agents, mols. that can simultaneously block the angiotensin II receptor and activate PPARÎ³ have the potential to treat both hemodynamic and biochem. features of the metabolic syndrome and could provide unique opportunities for the prevention and treatment of diabetes and cardiovascular disease in high-risk populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVMnSBXhf_gLVg90H21EOLACvtfcHk0li6S2kaDt9mAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1GmtrY%253D&md5=9f3075e771df41d59ac75d2e78ac304b</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.0000123072.34629.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.0000123072.34629.57%26sid%3Dliteratum%253Aachs%26aulast%3DBenson%26aufirst%3DS.%2BC.%26aulast%3DPershadsingh%26aufirst%3DH.%2BA.%26aulast%3DHo%26aufirst%3DC.%2BI.%26aulast%3DChittiboyina%26aufirst%3DA.%26aulast%3DDesai%26aufirst%3DP.%26aulast%3DPravenec%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAvery%26aufirst%3DM.%2BA.%26aulast%3DKurtz%26aufirst%3DT.%2BW.%26atitle%3DIdentification%2520of%2520telmisartan%2520as%2520a%2520unique%2520angiotensin%2520II%2520receptor%2520antagonist%2520with%2520selective%2520PPAR%25CE%25B3-modulating%2520activity%26jtitle%3DHypertension%26date%3D2004%26volume%3D43%26spage%3D993%26epage%3D1002%26doi%3D10.1161%2F01.HYP.0000123072.34629.57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kroker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruning, J. B.</span></span> <span> </span><span class="NLM_article-title">Review of the structural and dynamic mechanisms of PPARÎ³ partial agonism</span>. <i>PPAR Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi">Â DOI: 10.1155/2015/816856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1155%2F2015%2F816856" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=1&author=A.+J.+Krokerauthor=J.+B.+Bruning&title=Review+of+the+structural+and+dynamic+mechanisms+of+PPAR%CE%B3+partial+agonism&doi=10.1155%2F2015%2F816856"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1155%2F2015%2F816856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F816856%26sid%3Dliteratum%253Aachs%26aulast%3DKroker%26aufirst%3DA.%2BJ.%26aulast%3DBruning%26aufirst%3DJ.%2BB.%26atitle%3DReview%2520of%2520the%2520structural%2520and%2520dynamic%2520mechanisms%2520of%2520PPAR%25CE%25B3%2520partial%2520agonism%26jtitle%3DPPAR%2520Res.%26date%3D2015%26volume%3D2015%26spage%3D1%26doi%3D10.1155%2F2015%2F816856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niimi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, M.</span></span> <span> </span><span class="NLM_article-title">Structural basis for telmisartan-mediated partial activation of PPARÎ³</span>. <i>Hypertens. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">715</span>â <span class="NLM_lpage">719</span>, <span class="refDoi">Â DOI: 10.1038/hr.2012.17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fhr.2012.17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=22357520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVShsL%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=715-719&author=Y.+Amanoauthor=T.+Yamaguchiauthor=K.+Ohnoauthor=T.+Niimiauthor=M.+Oritaauthor=H.+Sakashitaauthor=M.+Takeuchi&title=Structural+basis+for+telmisartan-mediated+partial+activation+of+PPAR%CE%B3&doi=10.1038%2Fhr.2012.17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for telmisartan-mediated partial activation of PPAR gamma</span></div><div class="casAuthors">Amano, Yasushi; Yamaguchi, Tomohiko; Ohno, Kazuki; Niimi, Tatsuya; Orita, Masaya; Sakashita, Hitoshi; Takeuchi, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">715-719</span>CODEN:
                <span class="NLM_cas:coden">HRESE4</span>;
        ISSN:<span class="NLM_cas:issn">0916-9636</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Telmisartan, a selective angiotensin II type 1 receptor blocker, has recently been shown to act as a partial agonist for peroxisome proliferator-activated receptor gamma (PPARÎ³).  To understand how telmisartan partially activates PPARÎ³, we detd. the ternary complex structure of PPARÎ³, telmisartan, and a coactivator peptide from steroid receptor coactivator-1 at a resoln. of 2.18 Ã.  Crystallog. anal. revealed that telmisartan exhibits an unexpected binding mode in which the central benzimidazole ring is engaged in a non-canonical-and suboptimal-hydrogen-bonding network around helix 12 (H12).  This network differs greatly from that obsd. when full-agonists bind with PPARÎ³ and prompt high-coactivator recruitment through H12 stabilized by multiple hydrogen bonds.  Binding with telmisartan results in a less stable H12 that in turn leads to attenuated coactivator binding, thus explaining the mechanism of partial activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD76Y2UnrUDLVg90H21EOLACvtfcHk0li6S2kaDt9mAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVShsL%252FF&md5=1d6ca7d77310cf145825253a5ff9ee5c</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1038%2Fhr.2012.17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fhr.2012.17%26sid%3Dliteratum%253Aachs%26aulast%3DAmano%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DOhno%26aufirst%3DK.%26aulast%3DNiimi%26aufirst%3DT.%26aulast%3DOrita%26aufirst%3DM.%26aulast%3DSakashita%26aufirst%3DH.%26aulast%3DTakeuchi%26aufirst%3DM.%26atitle%3DStructural%2520basis%2520for%2520telmisartan-mediated%2520partial%2520activation%2520of%2520PPAR%25CE%25B3%26jtitle%3DHypertens.%2520Res.%26date%3D2012%26volume%3D35%26spage%3D715%26epage%3D719%26doi%3D10.1038%2Fhr.2012.17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemenz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gust, R.</span></span> <span> </span><span class="NLM_article-title">Characterization of new PPARÎ³ agonists: analysis of telmisartanâs structural components</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">445</span>â <span class="NLM_lpage">456</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.200800285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1002%2Fcmdc.200800285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=19197922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktlSmsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=445-456&author=M.+Goebelauthor=M.+Clemenzauthor=B.+Staelsauthor=T.+Ungerauthor=U.+Kintscherauthor=R.+Gust&title=Characterization+of+new+PPAR%CE%B3+agonists%3A+analysis+of+telmisartan%E2%80%99s+structural+components&doi=10.1002%2Fcmdc.200800285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of new PPARÎ³ agonists: analysis of telmisartan's structural components</span></div><div class="casAuthors">Goebel, Matthias; Clemenz, Markus; Staels, Bart; Unger, Thomas; Kintscher, Ulrich; Gust, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">445-456</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In addn. to a proven efficacy in lowering blood pressure, the AT1 receptor blocker telmisartan has recently been shown to exert pleiotropic effects as a partial agonist of the nuclear peroxisome proliferator-activated receptor gamma (PPARÎ³).  Based on these findings and an excellent side-effect profile, telmisartan may serve as a lead structure for the development of new PPARÎ³ ligands.  Therefore, we analyzed the structural components of telmisartan to identify those necessary for PPARÎ³ activation.  Synthesized compds. were tested in a differentiation assay using 3T3-L1 preadipocytes and a luciferase assay with COS-7 cells transiently transfected with pGal4-hPPARÎ³DEF, pGal5-TK-pGL3 and pRL-CMV.  The data obtained in this structure-activity relation (SAR) study provide the basis for the development of new PPARÎ³ ligands, which could lead to active compds. with a distinct, beneficial pharmacol. profile compared with the existing full agonists.  The basic 1-(biphenyl-4-ylmethyl)-1H-benzimidazole scaffold of telmisartan was identified as an essential moiety with either a carboxylic acid or tetrazole group at the C-2 position of the biphenyl.  For max. potency and activity, the alkyl chain in position 2 requires a min. length of at least two C atoms (Et group), while the Me group at position 4 of the benzimidazole core seems to contribute to partial activity.  An addnl. benzimidazole at position 6 appears to be a further determinant of potency.  Similar conclusions can be drawn for the Me group in position 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxb6_WFCseB7Vg90H21EOLACvtfcHk0li6S2kaDt9mAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktlSmsr4%253D&md5=eaeb7ddf68e80e1c88dc5efa738fce7d</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200800285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200800285%26sid%3Dliteratum%253Aachs%26aulast%3DGoebel%26aufirst%3DM.%26aulast%3DClemenz%26aufirst%3DM.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DKintscher%26aufirst%3DU.%26aulast%3DGust%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520new%2520PPAR%25CE%25B3%2520agonists%253A%2520analysis%2520of%2520telmisartan%25E2%2580%2599s%2520structural%2520components%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D445%26epage%3D456%26doi%3D10.1002%2Fcmdc.200800285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Q.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, W.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.-L.</span></span> <span> </span><span class="NLM_article-title">Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARg</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">25612</span>â <span class="NLM_lpage">25627</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.15778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.18632%2Foncotarget.15778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=28445965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A280%3ADC%252BC1crhsVKhsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=25612-25627&author=J.+Zhangauthor=Q.-Q.+Haoauthor=X.+Liuauthor=Z.+Jingauthor=W.-Q.+Jiaauthor=S.-Q.+Wangauthor=W.-R.+Xuauthor=X.-C.+Chengauthor=R.-L.+Wang&title=Molecular+docking%2C+3D-QSAR+and+structural+optimization+on+imidazo-pyridine+derivatives+dually+targeting+AT1+and+PPARg&doi=10.18632%2Foncotarget.15778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARg</span></div><div class="casAuthors">Zhang Jun; Hao Qing-Qing; Liu Xin; Jing Zhi; Jia Wen-Qing; Wang Shu-Qing; Cheng Xian-Chao; Wang Run-Ling; Xu Wei-Ren</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">25612-25627</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Telmisartan, a bifunctional agent of blood pressure lowering and glycemia reduction, was previously reported to antagonize angiotensin II type 1 (AT1) receptor and partially activate peroxisome proliferator-activated receptor Î³ (PPARÎ³) simultaneously.  Through the modification to telmisartan, researchers designed and obtained imidazo-\pyridine derivatives with the IC50s of 0.49~94.1 nM against AT1 and EC50s of 20~3640 nM towards PPARÎ³ partial activation.  For minutely inquiring the interaction modes with the relevant receptor and analyzing the structure-activity relationships, molecular docking and 3D-QSAR (Quantitative structure-activity relationships) analysis of these imidazo-\pyridines on dual targets were conducted in this work.  Docking approaches of these derivatives with both receptors provided explicit interaction behaviors and excellent matching degree with the binding pockets.  The best CoMFA (Comparative Molecular Field Analysis) models exhibited predictive results of q2=0.553, r2=0.954, SEE=0.127, r2pred=0.779 for AT1 and q2=0.503, r2=1.00, SEE=0.019, r2pred=0.604 for PPARÎ³, respectively.  The contour maps from the optimal model showed detailed information of structural features (steric and electrostatic fields) towards the biological activity.  Combining the bioisosterism with the valuable information from above studies, we designed six molecules with better predicted activities towards AT1 and PPARÎ³ partial activation.  Overall, these results could be useful for designing potential dual AT1 antagonists and partial PPARÎ³ agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFNV941LRTlMScOqQTSkOffW6udTcc2eaoywD4FzLtTrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crhsVKhsw%253D%253D&md5=4d6ca0b4a7fa900370afb5e5e515376c</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.15778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.15778%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DQ.-Q.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DJing%26aufirst%3DZ.%26aulast%3DJia%26aufirst%3DW.-Q.%26aulast%3DWang%26aufirst%3DS.-Q.%26aulast%3DXu%26aufirst%3DW.-R.%26aulast%3DCheng%26aufirst%3DX.-C.%26aulast%3DWang%26aufirst%3DR.-L.%26atitle%3DMolecular%2520docking%252C%25203D-QSAR%2520and%2520structural%2520optimization%2520on%2520imidazo-pyridine%2520derivatives%2520dually%2520targeting%2520AT1%2520and%2520PPARg%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D25612%26epage%3D25627%26doi%3D10.18632%2Foncotarget.15778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gust, R.</span></span> <span> </span><span class="NLM_article-title">Characterization of new PPARÎ³ agonists: benzimidazole derivatives - the importance of position 2</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1136</span>â <span class="NLM_lpage">1142</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.200900067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1002%2Fcmdc.200900067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=19504532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFCntLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1136-1142&author=M.+Goebelauthor=B.+Staelsauthor=T.+Ungerauthor=U.+Kintscherauthor=R.+Gust&title=Characterization+of+new+PPAR%CE%B3+agonists%3A+benzimidazole+derivatives+-+the+importance+of+position+2&doi=10.1002%2Fcmdc.200900067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of New PPARÎ³ Agonists: Benzimidazole Derivatives - the Importance of Position 2</span></div><div class="casAuthors">Goebel, Matthias; Staels, Bart; Unger, Thomas; Kintscher, Ulrich; Gust, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1136-1142</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Probing SAR: The 1-(biphenyl-4-ylmethyl)-1H-benzo[d]imidazole moiety is known to be an essential structural component of telmisartan for PPARÎ³ activation.  This study focused on the substituents at position 2 of the benzimidazole in an attempt to optimize PPARÎ³ activation.  In particular, the elongation of the alkyl chain and the introduction of an arom. ring system were studied (shown).  The relevance of substituents at C-2 of the central benzimidazole of telmisartan for PPARÎ³ activation has recently been demonstrated, and the most active compd. identified in our previous work, 4'-[(2-propyl-1H-benzo[d]imidazol-1-yl)methyl]biphenyl-2-carboxylic acid (4 a), is used as lead structure in the present study.  Modifications at C-2 included Bu (4 b), iso-Bu (4 c), tert-Bu (4 d), Ph (4 e), benzyl (4 f), phenethyl (4 g), 4-chlorobenzyl (4 h), 4-methoxyphenyl (4 i), and 4-hydroxyphenyl (4 j) moieties.  The compds. were tested in a differentiation assay using 3T3-L1 preadipocytes and a luciferase assay with COS-7 cells, transiently transfected with pGal4-hPPARÎ³DEF, pGal5-TK-pGL3 and pRL-CMV, as established models for the assessment of cellular PPARÎ³ activation.  The activity in the luciferase assay increased in the alkyl series: Pr (4 a) <iso-Bu (4 c) â¤ tert-Bu (4 d) <butyl (4 b).  A Ph group at C-2 led to the most active compd. (4 e) in this study with an EC50 value of 0.27 Î¼M. 4-Hydroxylation of the C-2 Ph group (4 j) drastically decreased the activity (EC50=5.8 Î¼m) presumably due to hydrophilic repulsion.  This assumption was verified by O-methylation to give compd. 4 i, which maintained activity (EC50=0.29 Î¼M).  The weak effect of the benzyl deriv. 4 f (EC50=1.4 Î¼M) was abolished by an addnl. hydrophobic 4-chloro substituent (4 h; EC50=0.55 Î¼M) or an elongation of the alkyl chain between the Ph and the benzimidazole core (4 g; EC50=0.31 Î¼M).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkNWcnWGEbI7Vg90H21EOLACvtfcHk0lgr2tGpAeRqYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFCntLY%253D&md5=f4344257770e0fb3911ad43ac44de3ec</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900067%26sid%3Dliteratum%253Aachs%26aulast%3DGoebel%26aufirst%3DM.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DKintscher%26aufirst%3DU.%26aulast%3DGust%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520new%2520PPAR%25CE%25B3%2520agonists%253A%2520benzimidazole%2520derivatives%2520-%2520the%2520importance%2520of%2520position%25202%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D1136%26epage%3D1142%26doi%3D10.1002%2Fcmdc.200900067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandholtz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gust, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span> <span> </span><span class="NLM_article-title">Characterization of telmisartan-derived PPARÎ³ agonists: importance of moiety shift from position 6 to 5 on potency, efficacy and cofactor recruitment</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1935</span>â <span class="NLM_lpage">1942</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201200337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1002%2Fcmdc.201200337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=24155042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFyjs73P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1935-1942&author=L.+Herbstauthor=M.+Goebelauthor=S.+Bandholtzauthor=R.+Gustauthor=U.+Kintscher&title=Characterization+of+telmisartan-derived+PPAR%CE%B3+agonists%3A+importance+of+moiety+shift+from+position+6+to+5+on+potency%2C+efficacy+and+cofactor+recruitment&doi=10.1002%2Fcmdc.201200337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Telmisartan-Derived PPARÎ³ Agonists: Importance of Moiety Shift from Position 6 to 5 on Potency, Efficacy and Cofactor Recruitment</span></div><div class="casAuthors">Herbst, Lena; Goebel, Matthias; Bandholtz, Sebastian; Gust, Ronald; Kintscher, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1935-1942, S1935/1-S1935/2</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Selective modulation of the peroxisome proliferator-activated receptor gamma (PPARÎ³) by direct binding of small mols. demonstrates a promising tool for treatment of insulin resistance and type 2 diabetes mellitus.  Besides its blood pressure-lowering properties, the AT1-receptor blocker telmisartan has been shown to be a partial agonist of PPARÎ³ with beneficial metabolic effects in vitro and in mice.  In our previous work, comprehensive structure-activity relationship (SAR) studies discussed the different parts of the telmisartan structure and various moieties.  Based on these findings, we designed and synthesized new PPARÎ³ ligands with a benzimidazole (agonists 4-5 and 4-6), benzothiophene (agonists 5-5 and 5-6) or benzofuran (agonists 6-5 and 6-6) moiety either at position 5 or 6 of the benzimidazole core structure.  Lipophilicity and EC50 values were improved for all new compds. compared with telmisartan.  Regarding PPARÎ³ activation, the compds. were characterized by a differentiation assay using 3T3-L1 cells and a luciferase assay with COS-7 cells transiently transfected with pGal4-hPPARgDEF, pGal5-TK-pGL3 and pRL-CMV.  A decrease in both potency and efficacy was obsd. after the shift of either the benzothiophene or the benzofuran moiety from position 6 to position 5.  Selective recruitment of the coactivators TRAP220, SRC-1 and PGC-1Î±, and release of corepressor NCoR1 detd. by time-resolved fluorescence resonance energy transfer (TR-FRET) was detected depending on residues in position 5 or 6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq18_XrltNtqLVg90H21EOLACvtfcHk0lgr2tGpAeRqYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFyjs73P&md5=5ca7670906a95157cf8710726cfceeaf</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200337%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DL.%26aulast%3DGoebel%26aufirst%3DM.%26aulast%3DBandholtz%26aufirst%3DS.%26aulast%3DGust%26aufirst%3DR.%26aulast%3DKintscher%26aufirst%3DU.%26atitle%3DCharacterization%2520of%2520telmisartan-derived%2520PPAR%25CE%25B3%2520agonists%253A%2520importance%2520of%2520moiety%2520shift%2520from%2520position%25206%2520to%25205%2520on%2520potency%252C%2520efficacy%2520and%2520cofactor%2520recruitment%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D1935%26epage%3D1942%26doi%3D10.1002%2Fcmdc.201200337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolber, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gust, R.</span></span> <span> </span><span class="NLM_article-title">Characterization of new PPARÎ³ agonists: benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5885</span>â <span class="NLM_lpage">5895</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2010.06.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmc.2010.06.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=20656494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFOitbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=5885-5895&author=M.+Goebelauthor=G.+Wolberauthor=P.+Marktauthor=B.+Staelsauthor=T.+Ungerauthor=U.+Kintscherauthor=R.+Gust&title=Characterization+of+new+PPAR%CE%B3+agonists%3A+benzimidazole+derivatives-importance+of+positions+5+and+6%2C+and+computational+studies+on+the+binding+mode&doi=10.1016%2Fj.bmc.2010.06.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of new PPARÎ³ agonists: Benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode</span></div><div class="casAuthors">Goebel, Matthias; Wolber, Gerhard; Markt, Patrick; Staels, Bart; Unger, Thomas; Kintscher, Ulrich; Gust, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5885-5895</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this and previous studies we investigated the importance of partial structures of Telmisartan on PPARÎ³ activation.  The biphenyl-4-ylmethyl moiety at N1 and residues at C2 of the central benzimidazole were identified to be essential for receptor activation and potency of receptor binding.  Now we focused our attention on positions 5 and 6 of the central benzimidazole and introduced bromine (3b-5/6, 3c), phenylcarbonyl (3d-5/6), hydroxy(phenyl)methyl (3g-5/6), hydroxymethyl (3h-5/6) and formyl (3i) groups.  The selection of these moieties was inspired by the structure of Losartan and its metabolite EXP3179.  In order to increase the hydrophobicity of the central part of the mol., the benzimidazole was exchanged by a naphtho[2,3-d]imidazole (5).  The compds. 3a-3i and 5 were tested in a differentiation assay using 3T3-L1 preadipocytes and a luciferase assay using COS-7 cells, transiently transfected with pGal4-hPPARÎ³DEF, pGal5-TK-pGL3 and pRL-CMV, as established models for the assessment of cellular PPARÎ³ activation.  An enhanced effect on PPARÎ³ activation could be obsd. if lipophilic moieties are introduced in these positions. 4'-[(2-Propyl-1H-naphtho[2,3-d]imidazol-1-yl)methyl]biphenyl-2-carboxylic acid (5) was identified as the most potent compd. with an EC50 of 0.26 Î¼M and the profile of a full agonist.  Together with compds. of the former structure-activity relationship study (position 2-substituted benzimidazole derivs. 4a-4j), the binding mode of Telmisartan and its derivs. have been analyzed in 3D pharmacophore-driven docking expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYCcUBmRTotbVg90H21EOLACvtfcHk0lh9IfeZkfAT8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFOitbc%253D&md5=04e94f4096fda01c9aec8e5911e00771</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.06.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.06.102%26sid%3Dliteratum%253Aachs%26aulast%3DGoebel%26aufirst%3DM.%26aulast%3DWolber%26aufirst%3DG.%26aulast%3DMarkt%26aufirst%3DP.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DKintscher%26aufirst%3DU.%26aulast%3DGust%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520new%2520PPAR%25CE%25B3%2520agonists%253A%2520benzimidazole%2520derivatives-importance%2520of%2520positions%25205%2520and%25206%252C%2520and%2520computational%2520studies%2520on%2520the%2520binding%2520mode%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D5885%26epage%3D5895%26doi%3D10.1016%2Fj.bmc.2010.06.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamotte, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martres, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laroze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ancellin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saintillan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beneton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampe, R. T.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological activities of novel indole derivatives as potent and selective PPARÎ³ modulators</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1399</span>â <span class="NLM_lpage">1404</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.12.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmcl.2009.12.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=20079636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSmt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1399-1404&author=Y.+Lamotteauthor=P.+Martresauthor=N.+Faucherauthor=A.+Larozeauthor=D.+Grillotauthor=N.+Ancellinauthor=Y.+Saintillanauthor=V.+Benetonauthor=R.+T.+Gampe&title=Synthesis+and+biological+activities+of+novel+indole+derivatives+as+potent+and+selective+PPAR%CE%B3+modulators&doi=10.1016%2Fj.bmcl.2009.12.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological activities of novel indole derivatives as potent and selective PPARÎ³ modulators</span></div><div class="casAuthors">Lamotte, Yann; Martres, Paul; Faucher, Nicolas; Laroze, Alain; Grillot, Didier; Ancellin, Nicolas; Saintillan, Yannick; Beneton, Veronique; Gampe, Robert T., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1399-1404</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting from the structure of Telmisartan, a new series of potent and selective PPARÎ³ modulators was identified.  The synthesis, in vitro and in vivo evaluation of the most potent compds. were reported and the X-ray structure of compd. I bound to the PPARÎ³ ligand binding domain was described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWHoAwEeXKBLVg90H21EOLACvtfcHk0lh9IfeZkfAT8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSmt7k%253D&md5=46afddd230373777320d0d96668810ba</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.12.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.12.107%26sid%3Dliteratum%253Aachs%26aulast%3DLamotte%26aufirst%3DY.%26aulast%3DMartres%26aufirst%3DP.%26aulast%3DFaucher%26aufirst%3DN.%26aulast%3DLaroze%26aufirst%3DA.%26aulast%3DGrillot%26aufirst%3DD.%26aulast%3DAncellin%26aufirst%3DN.%26aulast%3DSaintillan%26aufirst%3DY.%26aulast%3DBeneton%26aufirst%3DV.%26aulast%3DGampe%26aufirst%3DR.%2BT.%26atitle%3DSynthesis%2520and%2520biological%2520activities%2520of%2520novel%2520indole%2520derivatives%2520as%2520potent%2520and%2520selective%2520PPAR%25CE%25B3%2520modulators%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1399%26epage%3D1404%26doi%3D10.1016%2Fj.bmcl.2009.12.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asteian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blayo, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruvilla, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corzo, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busby, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marciano, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ordonez, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamenecka, T. M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of indole biphenylcarboxylic acids as PPARÎ³ antagonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">998</span>â <span class="NLM_lpage">1003</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.5b00218</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00218" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1OqsbrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=998-1003&author=A.+Asteianauthor=A.+L.+Blayoauthor=Y.+Heauthor=M.+Koenigauthor=Y.+Shinauthor=D.+S.+Kuruvillaauthor=C.+A.+Corzoauthor=M.+D.+Cameronauthor=L.+Linauthor=C.+Ruizauthor=S.+Khanauthor=N.+Kumarauthor=S.+Busbyauthor=D.+P.+Marcianoauthor=R.+D.+Garcia-Ordonezauthor=P.+R.+Griffinauthor=T.+M.+Kamenecka&title=Design%2C+synthesis%2C+and+biological+evaluation+of+indole+biphenylcarboxylic+acids+as+PPAR%CE%B3+antagonists&doi=10.1021%2Facsmedchemlett.5b00218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Indole Biphenylcarboxylic Acids as PPARÎ³ Antagonists</span></div><div class="casAuthors">Asteian, Alice; Blayo, Anne-Laure; He, Yuanjun; Koenig, Marcel; Shin, Youseung; Kuruvilla, Dana S.; Corzo, Cesar A.; Cameron, Michael D.; Lin, Li; Ruiz, Claudia; Khan, Susan; Kumar, Naresh; Busby, Scott; Marciano, David P.; Garcia-Ordonez, Ruben D.; Griffin, Patrick R.; Kamenecka, Theodore M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">998-1003</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The thiazolidinediones (TZD) typified by rosiglitazone are the only approved therapeutics targeting PPARÎ³ for the treatment of type-2 diabetes (T2DM).  Unfortunately, despite robust insulin sensitizing properties, they are accompanied by a no. of severe side effects including congestive heart failure, edema, wt. gain, and osteoporosis.  We recently identified PPARÎ³ antagonists that bind reversibly with high affinity but do not induce transactivation of the receptor, yet they act as insulin sensitizers in mouse models of diabetes (SR1664).  This Letter details our synthetic exploration around this novel series of PPARÎ³ antagonists based on an N-biphenylmethylindole scaffold.  Structure-activity relationship studies led to the identification of compd. I as a high affinity PPARÎ³ antagonist that exhibits antidiabetic properties following oral administration in diet-induced obese mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4gdyYHx7BVLVg90H21EOLACvtfcHk0lhxdN3PXRc8mQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1OqsbrM&md5=14a7474d13ff91dd8f68adc9a20fdc5b</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00218%26sid%3Dliteratum%253Aachs%26aulast%3DAsteian%26aufirst%3DA.%26aulast%3DBlayo%26aufirst%3DA.%2BL.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DKoenig%26aufirst%3DM.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DKuruvilla%26aufirst%3DD.%2BS.%26aulast%3DCorzo%26aufirst%3DC.%2BA.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DRuiz%26aufirst%3DC.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DBusby%26aufirst%3DS.%26aulast%3DMarciano%26aufirst%3DD.%2BP.%26aulast%3DGarcia-Ordonez%26aufirst%3DR.%2BD.%26aulast%3DGriffin%26aufirst%3DP.%2BR.%26aulast%3DKamenecka%26aufirst%3DT.%2BM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520indole%2520biphenylcarboxylic%2520acids%2520as%2520PPAR%25CE%25B3%2520antagonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D998%26epage%3D1003%26doi%3D10.1021%2Facsmedchemlett.5b00218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filzen, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigge, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmunds, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmaeil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heemstra, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalaie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohren, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostroski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaum, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoner, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-Î³</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4219</span>â <span class="NLM_lpage">4233</span>, <span class="refDoi">Â DOI: 10.1021/jm200409s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200409s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGls78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4219-4233&author=A.+Casimiro-Garciaauthor=G.+F.+Filzenauthor=D.+Flynnauthor=C.+F.+Biggeauthor=J.+Chenauthor=J.+A.+Davisauthor=D.+A.+Dudleyauthor=J.+J.+Edmundsauthor=N.+Esmaeilauthor=A.+Geyerauthor=R.+J.+Heemstraauthor=M.+Jalaieauthor=J.+F.+Ohrenauthor=R.+Ostroskiauthor=T.+Ellisauthor=R.+P.+Schaumauthor=C.+Stoner&title=Discovery+of+a+series+of+imidazo%5B4%2C5-b%5Dpyridines+with+dual+activity+at+angiotensin+II+type+1+receptor+and+peroxisome+proliferator-activated+receptor-%CE%B3&doi=10.1021%2Fjm200409s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Series of Imidazo[4,5-b]pyridines with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-Î³</span></div><div class="casAuthors">Casimiro-Garcia, Agustin; Filzen, Gary F.; Flynn, Declan; Bigge, Christopher F.; Chen, Jing; Davis, Jo Ann; Dudley, Danette A.; Edmunds, Jeremy J.; Esmaeil, Nadia; Geyer, Andrew; Heemstra, Ronald J.; Jalaie, Mehran; Ohren, Jeffrey F.; Ostroski, Robert; Ellis, Teresa; Schaum, Robert P.; Stoner, Chad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4219-4233</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mining of an inhouse collection of angiotensin II type 1 receptor antagonists to identify compds. with activity at the peroxisome proliferator-activated receptor-Î³ (PPARÎ³) revealed a new series of imidazo[4,5-b]pyridines 2 possessing activity at these two receptors.  Early availability of the crystal structure of the lead compd. bound to the ligand binding domain of human PPARÎ³ confirmed the mode of interaction of this scaffold to the nuclear receptor and assisted in the optimization of PPARÎ³ activity.  Among the new compds., (S)-3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2-ethyl-5-isobutyl-7-methyl-3H-imidazo[4,5-b]pyridine (I) was identified as a potent angiotensin II type I receptor blocker (IC50 = 1.6 nM) with partial PPARÎ³ agonism (EC50 = 212 nM, 31% max) and oral bioavailability in rat.  The dual pharmacol. of I was demonstrated in animal models of hypertension (SHR) and insulin resistance (ZDF rat).  In the SHR, I was highly efficacious in lowering blood pressure, while robust lowering of glucose and triglycerides was obsd. in the male ZDF rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMdOow5t9CALVg90H21EOLACvtfcHk0ljtlhYy-xKiQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGls78%253D&md5=cd55be8d481fccc319ca10c7a2ca2d8b</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Fjm200409s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200409s%26sid%3Dliteratum%253Aachs%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26aulast%3DFilzen%26aufirst%3DG.%2BF.%26aulast%3DFlynn%26aufirst%3DD.%26aulast%3DBigge%26aufirst%3DC.%2BF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DJ.%2BA.%26aulast%3DDudley%26aufirst%3DD.%2BA.%26aulast%3DEdmunds%26aufirst%3DJ.%2BJ.%26aulast%3DEsmaeil%26aufirst%3DN.%26aulast%3DGeyer%26aufirst%3DA.%26aulast%3DHeemstra%26aufirst%3DR.%2BJ.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DOhren%26aufirst%3DJ.%2BF.%26aulast%3DOstroski%26aufirst%3DR.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DSchaum%26aufirst%3DR.%2BP.%26aulast%3DStoner%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520a%2520series%2520of%2520imidazo%255B4%252C5-b%255Dpyridines%2520with%2520dual%2520activity%2520at%2520angiotensin%2520II%2520type%25201%2520receptor%2520and%2520peroxisome%2520proliferator-activated%2520receptor-%25CE%25B3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4219%26epage%3D4233%26doi%3D10.1021%2Fjm200409s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heemstra, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigge, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciske, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmaeil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalaie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohren, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, N. A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-Î³</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">767</span>â <span class="NLM_lpage">772</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2012.11.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmcl.2012.11.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23265881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVyhsLfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=767-772&author=A.+Casimiro-Garciaauthor=R.+J.+Heemstraauthor=C.+F.+Biggeauthor=J.+Chenauthor=F.+A.+Ciskeauthor=J.+A.+Davisauthor=T.+Ellisauthor=N.+Esmaeilauthor=D.+Flynnauthor=S.+Hanauthor=M.+Jalaieauthor=J.+F.+Ohrenauthor=N.+A.+Powell&title=Design%2C+synthesis%2C+and+evaluation+of+imidazo%5B4%2C5-c%5Dpyridin-4-one+derivatives+with+dual+activity+at+angiotensin+II+type+1+receptor+and+peroxisome+proliferator-activated+receptor-%CE%B3&doi=10.1016%2Fj.bmcl.2012.11.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-Î³</span></div><div class="casAuthors">Casimiro-Garcia, Agustin; Heemstra, Ronald J.; Bigge, Christopher F.; Chen, Jing; Ciske, Fred A.; Davis, Jo Ann; Ellis, Teresa; Esmaeil, Nadia; Flynn, Declan; Han, Seungil; Jalaie, Mehran; Ohren, Jeffrey F.; Powell, Noel A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">767-772</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Identification of a series of imidazo[4,5-c]pyridin-4-one derivs., e.g., I and II, that act as dual angiotensin II type 1 (AT1) receptor antagonists and peroxisome proliferator-activated receptor-Î³ (PPARÎ³) partial agonists is described.  Starting from a known AT1 antagonist template, conformational restriction was introduced by incorporation of an indane ring that when combined with appropriate substitution at the imidazo[4,5-c]pyridin-4-one provided a novel series possessing the desired dual activity.  The mode of interaction of this series with PPARÎ³ was corroborated through the X-ray crystal structure of I bound to the human PPARÎ³ ligand binding domain.  Modulation of activity at both receptors through substitution at the pyridone nitrogen led to the identification of potent dual AT1 antagonists/PPARÎ³ partial agonists.  Among them, II was identified possessing potent dual pharmacol. (AT1 IC50 = 7 nM; PPARÎ³ EC50 = 295 nM, 27% max) and good ADME properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOIcJ8jeqs_LVg90H21EOLACvtfcHk0ljtlhYy-xKiQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVyhsLfL&md5=9b0e0040ee11355d29fdfa7b3dad3427</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.088%26sid%3Dliteratum%253Aachs%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26aulast%3DHeemstra%26aufirst%3DR.%2BJ.%26aulast%3DBigge%26aufirst%3DC.%2BF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCiske%26aufirst%3DF.%2BA.%26aulast%3DDavis%26aufirst%3DJ.%2BA.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DEsmaeil%26aufirst%3DN.%26aulast%3DFlynn%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DOhren%26aufirst%3DJ.%2BF.%26aulast%3DPowell%26aufirst%3DN.%2BA.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520imidazo%255B4%252C5-c%255Dpyridin-4-one%2520derivatives%2520with%2520dual%2520activity%2520at%2520angiotensin%2520II%2520type%25201%2520receptor%2520and%2520peroxisome%2520proliferator-activated%2520receptor-%25CE%25B3%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D767%26epage%3D772%26doi%3D10.1016%2Fj.bmcl.2012.11.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menear, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adcock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockcroft, X.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copsey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cranston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drzewiecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javaid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerrigan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knights, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, I. T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. M. B.</span></span> <span> </span><span class="NLM_article-title">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">6581</span>â <span class="NLM_lpage">6591</span>, <span class="refDoi">Â DOI: 10.1021/jm8001263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8001263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6581-6591&author=K.+A.+Menearauthor=C.+Adcockauthor=R.+Boulterauthor=X.-l.+Cockcroftauthor=L.+Copseyauthor=A.+Cranstonauthor=K.+J.+Dillonauthor=J.+Drzewieckiauthor=S.+Garmanauthor=S.+Gomezauthor=H.+Javaidauthor=F.+Kerriganauthor=C.+Knightsauthor=A.+Lauauthor=V.+M.+Lohauthor=I.+T.+W.+Matthewsauthor=S.+Mooreauthor=M.+J.+O%E2%80%99Connorauthor=G.+C.+M.+Smithauthor=N.+M.+B.+Martin&title=4-%5B3-%284-Cyclopropanecarbonylpiperazine-1-carbonyl%29-4-fluorobenzyl%5D-2H-phthalazin-1-one%3A+A+Novel+Bioavailable+Inhibitor+of+Poly%28ADP-ribose%29+Polymerase-1&doi=10.1021%2Fjm8001263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1</span></div><div class="casAuthors">Menear, Keith A.; Adcock, Claire; Boulter, Robert; Cockcroft, Xiao-ling; Copsey, Louise; Cranston, Aaron; Dillon, Krystyna J.; Drzewiecki, Jan; Garman, Sheila; Gomez, Sylvie; Javaid, Hashim; Kerrigan, Frank; Knights, Charlotte; Lau, Alan; Loh, Vincent M., Jr.; Matthews, Ian T. W.; Moore, Stephen; O'Connor, Mark J.; Smith, Graeme C. M.; Martin, Niall M. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6581-6591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase activation is an immediate cellular response to metabolic-, chem.-, or ionizing radiation-induced DNA damage and represents a new target for cancer therapy.  In this article, we disclose a novel series of substituted 4-benzyl-2H-phthalazin-1-ones that possess high inhibitory enzyme and cellular potency for both PARP-1 and PARP-2.  Optimized compds. from the series also demonstrate good pharmacokinetic profiles, oral bioavailability, and activity in vivo in an SW620 colorectal cancer xenograft model. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one (KU-0059436, AZD2281) 47 is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines.  Compd. 47 is currently undergoing clin. development for the treatment of BRCA1- and BRCA2-defective cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IKtdcfeWCbVg90H21EOLACvtfcHk0ljd7_qcPG2Hzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs7vE&md5=45aff9bb506360ec26c1c0039388240e</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1021%2Fjm8001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001263%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DAdcock%26aufirst%3DC.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCockcroft%26aufirst%3DX.-l.%26aulast%3DCopsey%26aufirst%3DL.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DMatthews%26aufirst%3DI.%2BT.%2BW.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26atitle%3D4-%255B3-%25284-Cyclopropanecarbonylpiperazine-1-carbonyl%2529-4-fluorobenzyl%255D-2H-phthalazin-1-one%253A%2520A%2520Novel%2520Bioavailable%2520Inhibitor%2520of%2520Poly%2528ADP-ribose%2529%2520Polymerase-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6581%26epage%3D6591%26doi%3D10.1021%2Fjm8001263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dawicki-McKenna, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langelier, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeNizio, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccio, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karch, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascal, J. M.</span></span> <span> </span><span class="NLM_article-title">PARP-1 activation requires local unfolding of an autoinhibitory domain</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">755</span>â <span class="NLM_lpage">768</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2015.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.molcel.2015.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=26626480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFagurvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2015&pages=755-768&author=J.+M.+Dawicki-McKennaauthor=M.-F.+Langelierauthor=J.+E.+DeNizioauthor=A.+A.+Riccioauthor=C.+D.+Caoauthor=K.+R.+Karchauthor=M.+McCauleyauthor=J.+D.+Steffenauthor=B.+E.+Blackauthor=J.+M.+Pascal&title=PARP-1+activation+requires+local+unfolding+of+an+autoinhibitory+domain&doi=10.1016%2Fj.molcel.2015.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain</span></div><div class="casAuthors">Dawicki-McKenna, Jennine M.; Langelier, Marie-France; DeNizio, Jamie E.; Riccio, Amanda A.; Cao, Connie D.; Karch, Kelly R.; McCauley, Michael; Steffen, Jamin D.; Black, Ben E.; Pascal, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">755-768</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase-1 (PARP-1) creates the posttranslational modification PAR from substrate NAD+ to regulate multiple cellular processes.  DNA breaks sharply elevate PARP-1 catalytic activity to mount a cell survival repair response, whereas persistent PARP-1 hyperactivation during severe genotoxic stress is assocd. with cell death.  The mechanism for tight control of the robust catalytic potential of PARP-1 remains unclear.  By monitoring PARP-1 dynamics using hydrogen/deuterium exchange-mass spectrometry (HXMS), we unexpectedly find that a specific portion of the helical subdomain (HD) of the catalytic domain rapidly unfolds when PARP-1 encounters a DNA break.  Together with biochem. and crystallog. anal. of HD deletion mutants, we show that the HD is an autoinhibitory domain that blocks productive NAD+ binding.  Our mol. model explains how PARP-1 DNA damage detection leads to local unfolding of the HD that relieves autoinhibition, and has important implications for the design of PARP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJje_1KBikFbVg90H21EOLACvtfcHk0lh6rAAasOefQw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFagurvK&md5=cf24c86d7d942be40929b8aee2d797c7</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2015.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2015.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DDawicki-McKenna%26aufirst%3DJ.%2BM.%26aulast%3DLangelier%26aufirst%3DM.-F.%26aulast%3DDeNizio%26aufirst%3DJ.%2BE.%26aulast%3DRiccio%26aufirst%3DA.%2BA.%26aulast%3DCao%26aufirst%3DC.%2BD.%26aulast%3DKarch%26aufirst%3DK.%2BR.%26aulast%3DMcCauley%26aufirst%3DM.%26aulast%3DSteffen%26aufirst%3DJ.%2BD.%26aulast%3DBlack%26aufirst%3DB.%2BE.%26aulast%3DPascal%26aufirst%3DJ.%2BM.%26atitle%3DPARP-1%2520activation%2520requires%2520local%2520unfolding%2520of%2520an%2520autoinhibitory%2520domain%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D60%26spage%3D755%26epage%3D768%26doi%3D10.1016%2Fj.molcel.2015.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel dual poly(adp-ribose)polymerase and phosphoinositide 3-kinase inhibitors as a promising strategy for cancer therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">122</span>â <span class="NLM_lpage">139</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00622</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00622" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVWqsL%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=122-139&author=J.+Wangauthor=H.+Liauthor=G.+Heauthor=Z.+Chuauthor=K.+Pengauthor=Y.+Geauthor=Q.+Zhuauthor=Y.+Xu&title=Discovery+of+novel+dual+poly%28adp-ribose%29polymerase+and+phosphoinositide+3-kinase+inhibitors+as+a+promising+strategy+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.9b00622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy</span></div><div class="casAuthors">Wang, Junwei; Li, Hui; He, Guangchao; Chu, Zhaoxing; Peng, Kewen; Ge, Yiran; Zhu, Qihua; Xu, Yungen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">122-139</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of PARP and PI3K pathways has been recognized as a promising strategy for cancer therapy, which may expand the clin. utility of PARP inhibitors.  Herein, we report the discovery of dual PARP/PI3K inhibitors that merge the pharmacophores of PARP and PI3K inhibitors.  Among them, compd. 15 stands out as the most promising candidate with potent inhibitory activities against both PARP-1/2 and PI3KÎ±/Î´ with pIC50 values greater than 8.  Compd. 15 displayed superior antiproliferative profiles against both BRCA-deficient and BRCA-proficient cancer cells in cellular assays.  The prominent synergistic effects produced by the concomitant inhibition of the two targets were elucidated by comprehensive biochem. and cellular mechanistic studies.  In vivo, 15 showed more efficacious antitumor activity than the corresponding drug combination (Olaparib + BKM120) in the MDA-MB-468 xenograft model with a tumor growth inhibitory rate of 73.4% without causing observable toxic effects.  All of the results indicate that 15, a first potent dual PARP/PI3K inhibitor, is a highly effective anticancer compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWkhMLZTxXSLVg90H21EOLACvtfcHk0liEYCekYEGtQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVWqsL%252FF&md5=e6e0472af7ddb346c311c5e01483b370</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00622%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DChu%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DK.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520dual%2520poly%2528adp-ribose%2529polymerase%2520and%2520phosphoinositide%25203-kinase%2520inhibitors%2520as%2520a%2520promising%2520strategy%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D122%26epage%3D139%26doi%3D10.1021%2Facs.jmedchem.9b00622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atallah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haznedar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaror, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">774</span>â <span class="NLM_lpage">779</span>, <span class="refDoi">Â DOI: 10.1021/ml200156t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200156t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=774-779&author=M.+T.+Burgerauthor=S.+Pecchiauthor=A.+Wagmanauthor=Z.-J.+Niauthor=M.+Knappauthor=T.+Hendricksonauthor=G.+Atallahauthor=K.+Pfisterauthor=Y.+Zhangauthor=S.+Bartulisauthor=K.+Frazierauthor=S.+Ngauthor=A.+Smithauthor=J.+Verhagenauthor=J.+Haznedarauthor=K.+Huhauthor=E.+Iwanowiczauthor=X.+Xinauthor=D.+Menezesauthor=H.+Merrittauthor=I.+Leeauthor=M.+Wiesmannauthor=S.+Kaufmanauthor=K.+Crawfordauthor=M.+Chinauthor=D.+Bussiereauthor=K.+Shoemakerauthor=I.+Zarorauthor=S.-M.+Mairaauthor=C.+F.+Voliva&title=Identification+of+NVP-BKM120+as+a+potent%2C+selective%2C+orally+bioavailable+class+I+PI3+kinase+inhibitor+for+treating+cancer&doi=10.1021%2Fml200156t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span></div><div class="casAuthors">Burger, Matthew T.; Pecchi, Sabina; Wagman, Allan; Ni, Zhi-Jie; Knapp, Mark; Hendrickson, Thomas; Atallah, Gordana; Pfister, Keith; Zhang, Yanchen; Bartulis, Sarah; Frazier, Kelly; Ng, Simon; Smith, Aaron; Verhagen, Joelle; Haznedar, Joshua; Huh, Kay; Iwanowicz, Ed; Xin, Xiaohua; Menezes, Daniel; Merritt, Hanne; Lee, Isabelle; Wiesmann, Marion; Kaufman, Susan; Crawford, Kenneth; Chin, Michael; Bussiere, Dirksen; Shoemaker, Kevin; Zaror, Isabel; Maira, Sauveur-Michel; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">774-779</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinases (PI3Ks) are important oncol. targets due to the deregulation of this signaling pathway in a wide variety of human cancers.  Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent.  The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma).  These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJ68B9pPbMbVg90H21EOLACvtfcHk0ljdhiMw65qcqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI&md5=5d00d73dda1fc0d8f0f07d12900282ed</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1021%2Fml200156t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200156t%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DWagman%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DZ.-J.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DHendrickson%26aufirst%3DT.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBartulis%26aufirst%3DS.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DHaznedar%26aufirst%3DJ.%26aulast%3DHuh%26aufirst%3DK.%26aulast%3DIwanowicz%26aufirst%3DE.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DZaror%26aufirst%3DI.%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520of%2520NVP-BKM120%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520class%2520I%2520PI3%2520kinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D774%26epage%3D779%26doi%3D10.1021%2Fml200156t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ChÃ¨ne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martiny-Baron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GarcÃ­a-EcheverrÃ­a, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of nvp-bkm120, an orally available pan-class i PI3-kinase inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">317</span>â <span class="NLM_lpage">328</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-11-0474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1158%2F1535-7163.MCT-11-0474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=22188813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWltb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=317-328&author=S.-M.+Mairaauthor=S.+Pecchiauthor=A.+Huangauthor=M.+Burgerauthor=M.+Knappauthor=D.+Sterkerauthor=C.+Schnellauthor=D.+Guthyauthor=T.+Nagelauthor=M.+Wiesmannauthor=S.+Brachmannauthor=C.+Fritschauthor=M.+Dorschauthor=P.+Ch%C3%A8neauthor=K.+Shoemakerauthor=A.+De+Poverauthor=D.+Menezesauthor=G.+Martiny-Baronauthor=D.+Fabbroauthor=C.+J.+Wilsonauthor=R.+Schlegelauthor=F.+Hofmannauthor=C.+Garc%C3%ADa-Echeverr%C3%ADaauthor=W.+R.+Sellersauthor=C.+F.+Voliva&title=Identification+and+characterization+of+nvp-bkm120%2C+an+orally+available+pan-class+i+PI3-kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-11-0474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor</span></div><div class="casAuthors">Maira, Sauveur-Michel; Pecchi, Sabina; Huang, Alan; Burger, Matthew; Knapp, Mark; Sterker, Dario; Schnell, Christian; Guthy, Daniel; Nagel, Tobi; Wiesmann, Marion; Brachmann, Saskia; Fritsch, Christine; Dorsch, Marion; Chene, Patrick; Shoemaker, Kevin; De Pover, Alain; Menezes, Daniel; Martiny-Baron, Georg; Fabbro, Doriano; Wilson, Christopher J.; Schlegel, Robert; Hofmann, Francesco; Garcia-Echeverria, Carlos; Sellers, William R.; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">317-328</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Following the discovery of NVP-BEZ235, our first dual pan-PI3K/mTOR clin. compd., we sought to identify addnl. phosphoinositide 3-kinase (PI3K) inhibitors from different chem. classes with a different selectivity profile.  The key to achieve these objectives was to couple a structure-based design approach with intensive pharmacol. evaluation of selected compds. during the medicinal chem. optimization process.  Here, we report on the biol. characterization of the 2-morpholino pyrimidine deriv. pan-PI3K inhibitor NVP-BKM120.  This compd. inhibits all four class I PI3K isoforms in biochem. assays with at least 50-fold selectivity against other protein kinases.  The compd. is also active against the most common somatic PI3KÎ± mutations but does not significantly inhibit the related class III (Vps34) and class IV (mTOR, DNA-PK) PI3K kinases.  Consistent with its mechanism of action, NVP-BKM120 decreases the cellular levels of p-Akt in mechanistic models and relevant tumor cell lines, as well as downstream effectors in a concn.-dependent and pathway-specific manner.  Tested in a panel of 353 cell lines, NVP-BKM120 exhibited preferential inhibition of tumor cells bearing PIK3CA mutations, in contrast to either KRAS or PTEN mutant models.  NVP-BKM120 shows dose-dependent in vivo pharmacodynamic activity as measured by significant inhibition of p-Akt and tumor growth inhibition in mechanistic xenograft models.  NVP-BKM120 behaves synergistically when combined with either targeted agents such as MEK or HER2 inhibitors or with cytotoxic agents such as docetaxel or temozolomide.  The pharmacol., biol., and preclin. safety profile of NVP-BKM120 supports its clin. development and the compd. is undergoing phase II clin. trials in patients with cancer.  Mol Cancer Ther; 11(2); 317-28.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps2mNHzJneaLVg90H21EOLACvtfcHk0ljdhiMw65qcqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWltb8%253D&md5=4c3b225d45591e9cd49800baa06e8152</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0474%26sid%3Dliteratum%253Aachs%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DBurger%26aufirst%3DM.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DGuthy%26aufirst%3DD.%26aulast%3DNagel%26aufirst%3DT.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DBrachmann%26aufirst%3DS.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DDorsch%26aufirst%3DM.%26aulast%3DCh%25C3%25A8ne%26aufirst%3DP.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMartiny-Baron%26aufirst%3DG.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DGarc%25C3%25ADa-Echeverr%25C3%25ADa%26aufirst%3DC.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520nvp-bkm120%252C%2520an%2520orally%2520available%2520pan-class%2520i%2520PI3-kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D317%26epage%3D328%26doi%3D10.1158%2F1535-7163.MCT-11-0474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuckowree, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouge, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7579</span>â <span class="NLM_lpage">7587</span>, <span class="refDoi">Â DOI: 10.1021/jm2009327</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2009327" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7579-7587&author=D.+P.+Sutherlinauthor=L.+Baoauthor=M.+Berryauthor=G.+Castanedoauthor=I.+Chuckowreeauthor=J.+Dotsonauthor=A.+Folksauthor=L.+Friedmanauthor=R.+Goldsmithauthor=J.+Gunznerauthor=T.+Heffronauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=Q.+Tianauthor=V.+Tsuiauthor=N.+C.+Wanauthor=S.+Wangauthor=B.+Weiauthor=C.+Wiesmannauthor=P.+Wuauthor=B.-Y.+Zhuauthor=A.+Olivero&title=Discovery+of+a+potent%2C+selective%2C+and+orally+available+class+I+phosphatidylinositol+3-kinase+%28PI3K%29%2Fmammalian+target+of+rapamycin+%28mTOR%29+kinase+inhibitor+%28GDC-0980%29+for+the+treatment+of+cancer&doi=10.1021%2Fjm2009327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer</span></div><div class="casAuthors">Sutherlin, Daniel P.; Bao, Linda; Berry, Megan; Castanedo, Georgette; Chuckowree, Irina; Dotson, Jenna; Folks, Adrian; Friedman, Lori; Goldsmith, Richard; Gunzner, Janet; Heffron, Timothy; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Murray, Jeremy; Nonomiya, Jim; Pang, Jodie; Pegg, Niel; Prior, Wei Wei; Rouge, Lionel; Salphati, Laurent; Sampath, Deepak; Tian, Qingping; Tsui, Vickie; Wan, Nan Chi; Wang, Shumei; Wei, Bin Qing; Wiesmann, Christian; Wu, Ping; Zhu, Bing-Yan; Olivero, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7579-7587</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of 2 (GDC-0980, I), a class I PI3K and mTOR kinase inhibitor for oncol. indications, is described. mTOR inhibition was added to the class I PI3K inhibitor 1 (GDC-0941) scaffold primarily through the substitution of the indazole in 1 for a 2-aminopyrimidine.  This substitution also increased the microsomal stability and the free fraction of compds. as evidenced through a pairwise comparison of mols. that were otherwise identical.  Highlighted in detail are analogs of an advanced compd. 4 that were designed to improve soly., resulting in 2.  This compd., is potent across PI3K class I isoforms with IC50s of 5, 27, 7, and 14 nM for PI3KÎ±, Î², Î´, and Î³, resp., inhibits mTOR with a Ki of 17 nM yet is highly selective vs. a large panel of kinases including others in the PIKK family.  On the basis of the cell potency, low clearance in mouse, and high free fraction, 2 demonstrated significant efficacy in mouse xenografts when dosed as low as 1 mg/kg orally and is currently in phase I clin. trials for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-3-5KDI509bVg90H21EOLACvtfcHk0li7dMu0DKSLgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ&md5=ba7ede710885b51fffa63977fc64d3f5</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Fjm2009327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009327%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolks%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DHeffron%26aufirst%3DT.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DQ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DB.-Y.%26aulast%3DOlivero%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520class%2520I%2520phosphatidylinositol%25203-kinase%2520%2528PI3K%2529%252Fmammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520kinase%2520inhibitor%2520%2528GDC-0980%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7579%26epage%3D7587%26doi%3D10.1021%2Fjm2009327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>213</i></span>,  <span class="NLM_fpage">113054</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2020.113054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2020.113054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=33309164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFyqsrvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2021&pages=113054&author=J.+Wangauthor=G.+Heauthor=H.+Liauthor=Y.+Geauthor=S.+Wangauthor=Y.+Xuauthor=Q.+Zhu&title=Discovery+of+novel+PARP%2FPI3K+dual+inhibitors+with+high+efficiency+against+BRCA-proficient+triple+negative+breast+cancer&doi=10.1016%2Fj.ejmech.2020.113054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer</span></div><div class="casAuthors">Wang, Junwei; He, Guangchao; Li, Hui; Ge, Yiran; Wang, Shuping; Xu, Yungen; Zhu, Qihua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113054</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Co-targeting PARP and PI3K by PARP/PI3K dual inhibitors has been recognized as a promising chemotherapeutic strategy for the treatment of triple neg. breast cancer (TNBC) in our previous work.  To further explore novel and more potent PARP/PI3K dual inhibitors, a series of compds. were designed, synthesized and evaluated for their pharmacol. properties, resulting in the candidate compd. 12, a potent and highly selective PARP/PI3K dual inhibitor.  Compared to Olaparib, compd. 12 exhibits a superior antiproliferative profile against BRCA-proficient MDA-MB-468 cells.  In MDA-MB-468 cell-derived xenograft model, compd. 12 displayed excellent antitumor efficacy at a dose of 50 mg/kg, which is considerably more efficacious than the single administration of Olaparib or BKM120.  Furthermore, compd. 12 displayed good metabolic stability and high safety.  Taken together, these results suggest that compd. 12 as a novel PARP/PI3K dual inhibitor is worthy for further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok5C_ptVUYF7Vg90H21EOLACvtfcHk0liBmauXo_4gHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFyqsrvF&md5=633744af8efcaaa0de77a98f6093cf69</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.113054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.113054%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520novel%2520PARP%252FPI3K%2520dual%2520inhibitors%2520with%2520high%2520efficiency%2520against%2520BRCA-proficient%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D213%26spage%3D113054%26doi%3D10.1016%2Fj.ejmech.2020.113054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lensun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassees, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span> <span> </span><span class="NLM_article-title">GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2426</span>â <span class="NLM_lpage">2436</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-11-0446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1158%2F1535-7163.MCT-11-0446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=21998291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2426-2436&author=J.+J.+Wallinauthor=K.+A.+Edgarauthor=J.+Guanauthor=M.+Berryauthor=W.+W.+Priorauthor=L.+Leeauthor=J.+D.+Lesnickauthor=C.+Lewisauthor=J.+Nonomiyaauthor=J.+Pangauthor=L.+Salphatiauthor=A.+G.+Oliveroauthor=D.+P.+Sutherlinauthor=C.+O%E2%80%99Brienauthor=J.+M.+Spoerkeauthor=S.+Patelauthor=L.+Lensunauthor=R.+Kasseesauthor=L.+Rossauthor=M.+R.+Lacknerauthor=D.+Sampathauthor=M.+Belvinauthor=L.+S.+Friedman&title=GDC-0980+is+a+novel+class+I+PI3K%2FmTOR+kinase+inhibitor+with+robust+activity+in+cancer+models+driven+by+the+PI3K+pathway&doi=10.1158%2F1535-7163.MCT-11-0446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway</span></div><div class="casAuthors">Wallin, Jeffrey J.; Edgar, Kyle A.; Guan, Jane; Berry, Megan; Prior, Wei Wei; Lee, Leslie; Lesnick, John D.; Lewis, Cristina; Nonomiya, Jim; Pang, Jodie; Salphati, Laurent; Olivero, Alan G.; Sutherlin, Daniel P.; O'Brien, Carol; Spoerke, Jill M.; Patel, Sonal; Lensun, Letitia; Kassees, Robert; Ross, Leanne; Lackner, Mark R.; Sampath, Deepak; Belvin, Marcia; Friedman, Lori S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2426-2436</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Alterations of the phosphoinositide-3 kinase (PI3K)/Akt signaling pathway occur broadly in cancer via multiple mechanisms including mutation of the PIK3CA gene, loss or mutation of phosphatase and tensin homolog (PTEN), and deregulation of mammalian target of rapamycin (mTOR) complexes.  The dysregulation of this pathway has been implicated in tumor initiation, cell growth and survival, invasion and angiogenesis, thus, PI3K and mTOR are promising therapeutic targets for cancer.  We discovered GDC-0980, a selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with excellent pharmacokinetic and pharmaceutical properties.  GDC-0980 potently inhibits signal transduction downstream of both PI3K and mTOR, as measured by pharmacodynamic (PD) biomarkers, thereby acting upon two key pathway nodes to produce the strongest attainable inhibition of signaling in the pathway.  Correspondingly, GDC-0980 was potent across a broad panel of cancer cell lines, with the greatest potency in breast, prostate, and lung cancers and less activity in melanoma and pancreatic cancers, consistent with KRAS and BRAF acting as resistance markers.  Treatment of cancer cell lines with GDC-0980 resulted in G1 cell-cycle arrest, and in contrast to mTOR inhibitors, GDC-0980 induced apoptosis in certain cancer cell lines, including those with direct pathway activation via PI3K and PTEN.  Low doses of GDC-0980 potently inhibited tumor growth in xenograft models including those with activated PI3K, loss of LKB1 or PTEN, and elicited an exposure-related decrease in PD biomarkers.  These preclin. data show that GDC-0980 is a potent and effective dual PI3K/mTOR inhibitor with promise for the clinic.  Mol Cancer Ther; 10(12); 2426-36.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4yjwxW7TM3bVg90H21EOLACvtfcHk0liBmauXo_4gHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurfJ&md5=756410aaf86377284a63d8ee70ad36ec</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0446%26sid%3Dliteratum%253Aachs%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DKassees%26aufirst%3DR.%26aulast%3DRoss%26aufirst%3DL.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26atitle%3DGDC-0980%2520is%2520a%2520novel%2520class%2520I%2520PI3K%252FmTOR%2520kinase%2520inhibitor%2520with%2520robust%2520activity%2520in%2520cancer%2520models%2520driven%2520by%2520the%2520PI3K%2520pathway%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2426%26epage%3D2436%26doi%3D10.1158%2F1535-7163.MCT-11-0446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>217</i></span>,  <span class="NLM_fpage">113357</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2021.113357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2021.113357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=33740547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXmvVOqs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=2021&pages=113357&author=Z.+Wuauthor=Y.+Baiauthor=J.+Jinauthor=T.+Jiangauthor=H.+Shenauthor=Q.+Juauthor=Q.+Zhuauthor=Y.+Xu&title=Discovery+of+novel+and+potent+PARP%2FPI3K+dual+inhibitors+for+the+treatment+of+cancer&doi=10.1016%2Fj.ejmech.2021.113357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer</span></div><div class="casAuthors">Wu, Zhengyang; Bai, Ying; Jin, Jiaming; Jiang, Teng; Shen, Hui; Ju, Qiurong; Zhu, Qihua; Xu, Yungen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113357</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">PARP inhibitors have achieved great success in cancers with BRCA mutations, but only a small portion of patients carry BRCA mutations, which results in their narrow indication spectrum.  Recently, emerging evidence has demonstrated that combinations of PARP and PI3K inhibitors could evoke unanticipated synergistic effects in various cancers, even including BRCA-proficient ones.  In this work, a series of PARP/PI3K dual inhibitors were designed, synthesized, and evaluated for their biol. activities.  It was found that compds. 9a and 23a exhibited excellent inhibitory activities against PARP-1 (9a: IC50 = 1.57 nM, 23a: IC50 = 0.91 nM) and PI3KÎ± (9a: IC50 = 2.0 nM, 23a: IC50 = 1.5 nM), and showed promising antiproliferative activities against both BRCA-deficient (HCT-116, HCC-1937) and BRCA-proficient (SW620, MDA-MB-231/468) tumor cells. 9a and 23a also exhibited considerable in vivo antitumor efficacy in an MDA-MB-468 xenograft mouse model, with TGI values of 56.39% and 48.77%, resp.  Addnl., 23a possessed promising profiles including high kinase selectivity and low cardiotoxicity.  Overall, this work indicates 9a and 23a might be potential PARP/PI3K dual inhibitors for cancer therapy and deserve further research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwMjgqJTJmtLVg90H21EOLACvtfcHk0lgfahh8gD9UaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXmvVOqs7g%253D&md5=1890ee4b8f7b6017a5004ef2c08464bf</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113357%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DJu%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520and%2520potent%2520PARP%252FPI3K%2520dual%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D217%26spage%3D113357%26doi%3D10.1016%2Fj.ejmech.2021.113357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0038.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Four types of the multipharmacophore model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design strategy of dual target inhibitors. The blue graphics represent the molecular scaffold, and the red graphics represent the pharmacophoric elements.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structures of (A) HDAC with SAHA (<b>1</b>), PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1C3S">1C3S</a>; (B) HMGR with lovastatin (<b>2</b>), PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1HW9">1HW9</a>. Compounds <b>1</b> and <b>2</b> are shown with green carbon in stick representation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Design of MTDL <b>3</b> targeting HDACs and HMGR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Design of MTDL <b>6</b> targeting HDACs and VDR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Design of MTDL <b>9</b> targeting RT and IN.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Design of MTDL <b>12</b> targeting sEH and FXR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Design of MTDL <b>15</b> targeting FXR and PPARÎ´.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Design of MTDLs <b>18</b> and <b>19</b> targeting AT<sub>1</sub> and ET<sub>A</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Design of MTDLs <b>22</b> and <b>23</b> targeting NAMPT and HDAC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Design of MTDL <b>27</b> with multiple anti-AD activities.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Design of MTDL <b>30</b> targeting MMP and cathepsin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. X-ray crystal structures of (A, B) AChE with <b>31</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ACJ">1ACJ</a>; (C, D) GSK-3Î² with <b>32</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PTC">4PTC</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Design of MTDL <b>33</b> targeting AChE and GSK-3Î².</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Design of MTDLs <b>34</b> and <b>35</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. X-ray crystal structures of HDAC with <b>1</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1C3S">1C3S</a>: (A) side view; (B) front view.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Design of MTDL <b>37</b> targeting HDAC and JAK2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Docking studies of compound <b>37</b> with (A) HDAC6 and (B) JAK1.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Design of MTDL <b>39</b> targeting HDACs, EGFR, and HER2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. (A,B) X-ray crystal structures of EGFR with <b>38</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Design of MTDLs with linked-pharmacophore mode.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. X-ray crystal structures of (A) Src with <b>44</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QCF">1QCF</a>; (B) EGFR with <b>45</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Design of MTDL <b>46</b> targeting Src and EGFR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Design of MTDLs <b>49</b> and <b>50</b> targeting AChE and SERT.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. X-ray crystal structures of (A) SERT with fluoxetine (<b>48</b>), PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3gwv">3gwv</a>. (B) Tyrosine kinase with Imatinib (<b>51</b>), PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP">1IEP</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Design of MTDLs <b>54</b> and <b>55</b> targeting HDAC and tyrosine kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. (A, B) X-ray crystal structures of RT with <b>7</b>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RT2">1RT2</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Design of MTDLs <b>56</b> and <b>57</b> targeting RT and IN.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Design of some MTDLs without binding mode.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0030.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Design of some MTDLs without binding mode.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0031.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Nonsteroidal anti-inflammatory drug (NO-NSAID).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0032.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Design of cleavable MTDL ZRX1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0033.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Crystal structure of Telmisartan (<b>72</b>) bound to the PPAR ligand binding domain, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VN2">3VN2</a>. (A) 2D diagram. (B) 3D stereogram.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0034.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Overview of important moieties of <b>72</b> for PPARÎ³ activation and the design of <b>73</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0035.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. X-ray crystal structures of (A) PARP-1 with Olaparib (<b>74</b>), PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DS3">5DS3</a>. (B) PI3Ka with BKM120 (<b>75</b>), PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JPS">4JPS</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig36" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0036.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 36. Design of MTDL <b>76</b> targeting PARP and PI3K.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig36"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig37" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/medium/jm1c00683_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0037.jpeg" id="rightTab-gr37" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 37. Further structural optimization of lead compound <b>76</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00683/20210727/images/large/jm1c00683_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00683&amp;id=fig37"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i42">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85033" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85033" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 180 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: challenges and opportunities in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7874</span>â <span class="NLM_lpage">7887</span>, <span class="refDoi">Â DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lgMTkuXojEjcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">641</span>â <span class="NLM_lpage">651</span>, <span class="refDoi">Â DOI: 10.1016/S1359-6446(04)03163-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands&doi=10.1016%2FS1359-6446%2804%2903163-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lgMTkuXojEjcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D641%26epage%3D651%26doi%3D10.1016%2FS1359-6446%2804%2903163-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minarini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Multi-target-directed ligands to combat neurodegenerative diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">347</span>â <span class="NLM_lpage">372</span>, <span class="refDoi">Â DOI: 10.1021/jm7009364</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7009364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=347-372&author=A.+Cavalliauthor=M.+L.+Bolognesiauthor=A.+Minariniauthor=M.+Rosiniauthor=V.+Tumiattiauthor=M.+Recanatiniauthor=C.+Melchiorre&title=Multi-target-directed+ligands+to+combat+neurodegenerative+diseases&doi=10.1021%2Fjm7009364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-Directed Ligands to Combat Neurodegenerative Diseases</span></div><div class="casAuthors">Cavalli, Andrea; Bolognesi, Maria Laura; Minarini, Anna; Rosini, Michela; Tumiatti, Vincenzo; Recanatini, Maurizio; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The authors review the investigations reported in the past decade that illustrate the ability of medicinal chemists to design multi-target-directed ligands (MTDLs) to confront neurodegenerative diseases.  The authors briefly illustrate the multifactorial nature of these diseases before discussing the possible development of MTDLs in light of the known mol. bases of the main neurodegenerative pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYY0I0UHEir7Vg90H21EOLACvtfcHk0ligCmmTitltmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D&md5=c682235151489316d043cf97f78e56f3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm7009364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7009364%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMulti-target-directed%2520ligands%2520to%2520combat%2520neurodegenerative%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D347%26epage%3D372%26doi%3D10.1021%2Fjm7009364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>â <span class="NLM_lpage">6543</span>, <span class="refDoi">Â DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0ligCmmTitltmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Besnard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruda, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidah, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constam, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickerton, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Automated design of ligands to polypharmacological profiles</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>492</i></span>,  <span class="NLM_fpage">215</span>â <span class="NLM_lpage">220</span>, <span class="refDoi">Â DOI: 10.1038/nature11691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fnature11691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23235874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=215-220&author=J.+Besnardauthor=G.+F.+Rudaauthor=V.+Setolaauthor=K.+Abecassisauthor=R.+M.+Rodriguizauthor=X.-P.+Huangauthor=S.+Norvalauthor=M.+F.+Sassanoauthor=A.+I.+Shinauthor=L.+A.+Websterauthor=F.+R.+C.+Simeonsauthor=L.+Stojanovskiauthor=A.+Pratauthor=N.+G.+Seidahauthor=D.+B.+Constamauthor=G.+R.+Bickertonauthor=K.+D.+Readauthor=W.+C.+Wetselauthor=I.+H.+Gilbertauthor=B.+L.+Rothauthor=A.+L.+Hopkins&title=Automated+design+of+ligands+to+polypharmacological+profiles&doi=10.1038%2Fnature11691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Automated design of ligands to polypharmacological profiles</span></div><div class="casAuthors">Besnard, Jeremy; Ruda, Gian Filippo; Setola, Vincent; Abecassis, Keren; Rodriguiz, Ramona M.; Huang, Xi-Ping; Norval, Suzanne; Sassano, Maria F.; Shin, Antony I.; Webster, Lauren A.; Simeons, Frederick R. C.; Stojanovski, Laste; Prat, Annik; Seidah, Nabil G.; Constam, Daniel B.; Bickerton, G. Richard; Read, Kevin D.; Wetsel, William C.; Gilbert, Ian H.; Roth, Bryan L.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7428</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy and safety of a drug is detd. by its activity profile across many proteins in the proteome.  However, designing drugs with a specific multi-target profile is both complex and difficult.  Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery.  Here is described a new approach for the automated design of ligands against profiles of multiple drug targets.  The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug donepezil (I) into brain-penetrable ligands with either specific polypharmacol. or exquisite selectivity profiles for G-protein-coupled receptors.  Overall, 800 ligand-target predictions of prospectively designed ligands were tested exptl., of which 75% were confirmed to be correct.  Target engagement in vivo is also demonstrated.  The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNu5bwrBD3tbVg90H21EOLACvtfcHk0ligCmmTitltmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN&md5=ace6cced250cf968d327b482a5bf1798</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature11691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11691%26sid%3Dliteratum%253Aachs%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAbecassis%26aufirst%3DK.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DShin%26aufirst%3DA.%2BI.%26aulast%3DWebster%26aufirst%3DL.%2BA.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DConstam%26aufirst%3DD.%2BB.%26aulast%3DBickerton%26aufirst%3DG.%2BR.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DAutomated%2520design%2520of%2520ligands%2520to%2520polypharmacological%2520profiles%26jtitle%3DNature%26date%3D2012%26volume%3D492%26spage%3D215%26epage%3D220%26doi%3D10.1038%2Fnature11691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of ligand efficient dual inhibitors of janus kinase (JAK) and histone deacetylase (HDAC) based on ruxolitinib and vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>â <span class="NLM_lpage">8357</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.+D.+Duong-Thiauthor=J.+X.+T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yen&title=Design+and+synthesis+of+ligand+efficient+dual+inhibitors+of+janus+kinase+%28JAK%29+and+histone+deacetylase+%28HDAC%29+based+on+ruxolitinib+and+vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0li3tbaTJCPOsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BX.%2BT.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520ligand%2520efficient%2520dual%2520inhibitors%2520of%2520janus%2520kinase%2520%2528JAK%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520based%2520on%2520ruxolitinib%2520and%2520vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, S.</span></span> <span> </span><span class="NLM_article-title">From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">422</span>â <span class="NLM_lpage">432</span>, <span class="refDoi">Â DOI: 10.2174/092986708783503212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.2174%2F092986708783503212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=18288997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVyisL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=422-432&author=A.+Petrelliauthor=S.+Giordano&title=From+single-+to+multi-target+drugs+in+cancer+therapy%3A+when+aspecificity+becomes+an+advantage&doi=10.2174%2F092986708783503212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">From single- to multi-target drugs in cancer therapy: when a specificity becomes an advantage</span></div><div class="casAuthors">Petrelli, A.; Giordano, S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">422-432</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeted therapies by means of compds. that inhibit a specific target mol. represent a new perspective in the treatment of cancer.  In contrast to conventional chemotherapy which acts on all dividing cells generating toxic effects and damage of normal tissues, targeted drugs allow to hit, in a more specific manner, subpopulations of cells directly involved in tumor progression.  Mols. controlling cell proliferation and death, such as Tyrosine Kinase Receptors (RTKs) for growth factors, are among the best targets for this type of therapeutic approach.  Two classes of compds. targeting RTKs are currently used in clin. practice: monoclonal antibodies and tyrosine kinase inhibitors.  The era of targeted therapy began with the approval of Trastuzumab, a monoclonal antibody against HER2, for treatment of metastatic breast cancer, and Imatinib, a small tyrosine kinase inhibitor targeting BCR-Abl, in Chronic Myeloid Leukemia.  Despite the initial enthusiasm for the efficacy of these treatments, clinicians had to face soon the problem of relapse, as almost invariably cancer patients developed drug resistance, often due to the activation of alternative RTKs pathways.  In this view, the rationale at the basis of targeting drugs is radically shifting.  In the past, the main effort was aimed at developing highly specific inhibitors acting on single RTKs.  Now, there is a general agreement that mols. interfering simultaneously with multiple RTKs might be more effective than single target agents.  With the recent approval by FDA of Sorafenib and Sunitinib - targeting VEGFR, PDGFR, FLT-3 and c-Kit - a different scenario has been emerging, where a new generation of anti-cancer drugs, able to inhibit more than one pathway, would probably play a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8AXb2ROTStLVg90H21EOLACvtfcHk0li3tbaTJCPOsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVyisL0%253D&md5=d90df6a670921b6fad58caa46db01fa5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F092986708783503212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708783503212%26sid%3Dliteratum%253Aachs%26aulast%3DPetrelli%26aufirst%3DA.%26aulast%3DGiordano%26aufirst%3DS.%26atitle%3DFrom%2520single-%2520to%2520multi-target%2520drugs%2520in%2520cancer%2520therapy%253A%2520when%2520aspecificity%2520becomes%2520an%2520advantage%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D422%26epage%3D432%26doi%3D10.2174%2F092986708783503212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Rahman, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouad, M.</span></span> <span> </span><span class="NLM_article-title">Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1275</span>â <span class="NLM_lpage">1290</span>, <span class="refDoi">Â DOI: 10.2217/fon.14.302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.2217%2Ffon.14.302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=25832882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslaqsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=1275-1290&author=O.+Abdel-Rahmanauthor=M.+Fouad&title=Temozolomide-based+combination+for+advanced+neuroendocrine+neoplasms%3A+a+systematic+review+of+the+literature&doi=10.2217%2Ffon.14.302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature</span></div><div class="casAuthors">Abdel-Rahman, Omar; Fouad, Mona</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1275-1290</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Background: In this systematic review, we explored the value of using temozolomide (TMZ)-based combinations for advanced neuroendocrine neoplasms (NENs).  Methods: Database search were conducted using the terms 'NENs' and 'TMZ' and 'systemic therapy.  ' Outcomes of interest included progression-free survival and overall survival, toxicities and tumor response.  Results: In total, 16 trials including 348 patients were included.  Median progression-free survival ranged from 6 to 31 mo.  The disease control rate ranged from 65 to 100%.  Frequently reported grade 3/4 toxicities were leukopenia, lymphopenia and elevated transaminases.  Conclusion: The published clin. data suggest that TMZ-based combination with some anticancer agents (esp. capecitabine) could be an effective treatment option for advanced low-intermediate grade NENs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUw4muUhdI07Vg90H21EOLACvtfcHk0li3tbaTJCPOsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslaqsbs%253D&md5=671f80ff6f8e109a62d8b6022d171ee9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2217%2Ffon.14.302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.14.302%26sid%3Dliteratum%253Aachs%26aulast%3DAbdel-Rahman%26aufirst%3DO.%26aulast%3DFouad%26aufirst%3DM.%26atitle%3DTemozolomide-based%2520combination%2520for%2520advanced%2520neuroendocrine%2520neoplasms%253A%2520a%2520systematic%2520review%2520of%2520the%2520literature%26jtitle%3DFuture%2520Oncol.%26date%3D2015%26volume%3D11%26spage%3D1275%26epage%3D1290%26doi%3D10.2217%2Ffon.14.302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, R.</span></span> <span> </span><span class="NLM_article-title">The potential of combi-molecules with DNA-damaging function as anticancer agents</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">403</span>â <span class="NLM_lpage">435</span>, <span class="refDoi">Â DOI: 10.4155/fmc-2016-0229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.4155%2Ffmc-2016-0229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=28263086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Smu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=403-435&author=G.+Sunauthor=T.+Fanauthor=L.+Zhaoauthor=Y.+Zhouauthor=R.+Zhong&title=The+potential+of+combi-molecules+with+DNA-damaging+function+as+anticancer+agents&doi=10.4155%2Ffmc-2016-0229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The potential of combi-molecules with DNA-damaging function as anticancer agents</span></div><div class="casAuthors">Sun, Guohui; Fan, Tengjiao; Zhao, Lijiao; Zhou, Yue; Zhong, Rugang</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">403-435</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">DNA-damaging agents, such as methylating agents, chloroethylating agents and platinum-based agents, have been extensively used as anticancer drugs.  However, the side effects, high toxicity, lack of selectivity and resistance severely limit their clin. applications.  In recent years, a strategy combining a DNA-damaging agent with a bioactive mol. (e.g., enzyme inhibitors) or carrier (e.g., steroid hormone and DNA intercalators) to produce a new 'combi-mol.' with improved efficacy or selectivity has been attempted to overcome these drawbacks.  The combi-mol. simultaneously acts on two targets and is expected to possess better potency than the parent compds.  Many studies have shown DNA-damaging combi-mols. exhibiting excellent anticancer activity in vitro and in vivo.  This review focuses on the development of combi-mols., which possess increased DNA-damaging potency, anticancer efficacy and tumor selectivity and reduced side reactions than the parent compds.  The future opportunities and challenges in the discovery of combi-mols. were also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9Yal02uIMu7Vg90H21EOLACvtfcHk0lgQ1heNyGBMMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Smu7g%253D&md5=a1017aca1482b8bd1052cfd376009650</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2016-0229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2016-0229%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DG.%26aulast%3DFan%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhong%26aufirst%3DR.%26atitle%3DThe%2520potential%2520of%2520combi-molecules%2520with%2520DNA-damaging%2520function%2520as%2520anticancer%2520agents%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2017%26volume%3D9%26spage%3D403%26epage%3D435%26doi%3D10.4155%2Ffmc-2016-0229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">GarcÃ­a, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virgili, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alegret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farran, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FernÃ¡ndez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BurgueÃ±o, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal-Torres, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FernÃ¡ndez de Henestrosa, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-SalamÃ¡n, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of EST73502, a dual Î¼-opioid receptor agonist and Ï 1 receptor antagonist clinical candidate for the treatment of pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">15508</span>â <span class="NLM_lpage">15526</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c01127</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01127" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVykurnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=15508-15526&author=M.+Garc%C3%ADaauthor=M.+Virgiliauthor=M.+Alonsoauthor=C.+Alegretauthor=J.+Farranauthor=B.+Fern%C3%A1ndezauthor=M.+Bordasauthor=R.+Pascualauthor=J.+Burgue%C3%B1oauthor=A.+Vidal-Torresauthor=A.+R.+Fern%C3%A1ndez+de+Henestrosaauthor=E.+Ayetauthor=M.+Merlosauthor=J.+M.+Velaauthor=C.+R.+Plata-Salam%C3%A1nauthor=C.+Almansa&title=Discovery+of+EST73502%2C+a+dual+%CE%BC-opioid+receptor+agonist+and+%CF%83+1+receptor+antagonist+clinical+candidate+for+the+treatment+of+pain&doi=10.1021%2Facs.jmedchem.0c01127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of EST73502, a Dual Î¼-Opioid Receptor Agonist and Ï1 Receptor Antagonist Clinical Candidate for the Treatment of Pain</span></div><div class="casAuthors">Garcia, Monica; Virgili, Marina; Alonso, Monica; Alegret, Carles; Farran, Joan; Fernandez, Begona; Bordas, Magda; Pascual, Rosalia; Burgueno, Javier; Vidal-Torres, Alba; Fernandez de Henestrosa, Antonio R.; Ayet, Eva; Merlos, Manuel; Vela, Jose Miguel; Plata-Salaman, Carlos R.; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">15508-15526</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and pharmacol. activity of a new series of 4-alkyl-1-oxa-4,9-diazaspiro[5.5]undecane derivs. as potent dual ligands for the Ï1 receptor (Ï1R) and the Î¼-opioid receptor (MOR) are reported.  A lead optimization program over the initial 4-aryl analogs provided 4-alkyl derivs. with the desired functionality and good selectivity and ADME profiles.  Compd. I (EST73502) showed MOR agonism and Ï1R antagonism and a potent analgesic activity, comparable to the MOR agonist oxycodone in animal models of acute and chronic pain after single and repeated administration.  Contrary to oxycodone, I produces analgesic activity with reduced opioid-induced relevant adverse events, like intestinal transit inhibition and naloxone-pptd. behavioral signs of opiate withdrawal.  These results provide evidence that dual MOR agonism and Ï1R antagonism may be a useful strategy for obtaining potent and safer analgesics and were the basis for the selection of I as a clin. candidate for the treatment of pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaRTQFyc0JxrVg90H21EOLACvtfcHk0lgQ1heNyGBMMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVykurnM&md5=099d21c6d818c53a8e195be0ff5d7b77</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01127%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa%26aufirst%3DM.%26aulast%3DVirgili%26aufirst%3DM.%26aulast%3DAlonso%26aufirst%3DM.%26aulast%3DAlegret%26aufirst%3DC.%26aulast%3DFarran%26aufirst%3DJ.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DB.%26aulast%3DBordas%26aufirst%3DM.%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DBurgue%25C3%25B1o%26aufirst%3DJ.%26aulast%3DVidal-Torres%26aufirst%3DA.%26aulast%3DFern%25C3%25A1ndez%2Bde%2BHenestrosa%26aufirst%3DA.%2BR.%26aulast%3DAyet%26aufirst%3DE.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DPlata-Salam%25C3%25A1n%26aufirst%3DC.%2BR.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520EST73502%252C%2520a%2520dual%2520%25CE%25BC-opioid%2520receptor%2520agonist%2520and%2520%25CF%2583%25201%2520receptor%2520antagonist%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D15508%26epage%3D15526%26doi%3D10.1021%2Facs.jmedchem.0c01127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D. F.</span></span> <span> </span><span class="NLM_article-title">Designing multi-targeted agents: An emerging anticancer drug discovery paradigm</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">195</span>â <span class="NLM_lpage">211</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2017.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2017.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=28494256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsV2rtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2017&pages=195-211&author=R.+G.+Fuauthor=Y.+Sunauthor=W.+B.+Shengauthor=D.+F.+Liao&title=Designing+multi-targeted+agents%3A+An+emerging+anticancer+drug+discovery+paradigm&doi=10.1016%2Fj.ejmech.2017.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multi-targeted agents: An emerging anticancer drug discovery paradigm</span></div><div class="casAuthors">Fu, Rong-geng; Sun, Yuan; Sheng, Wen-bing; Liao, Duan-fang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">195-211</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The dominant paradigm in drug discovery is to design ligands with max. selectivity to act on individual drug targets.  With the target-based approach, many new chem. entities have been discovered, developed, and further approved as drugs.  However, there are a large no. of complex diseases such as cancer that cannot be effectively treated or cured only with one medicine to modulate the biol. function of a single target.  As simultaneous intervention of two (or multiple) cancer progression relevant targets has shown improved therapeutic efficacy, the innovation of multi-targeted drugs has become a promising and prevailing research topic and numerous multi-targeted anticancer agents are currently at various developmental stages.  However, most multi-pharmacophore scaffolds are usually discovered by serendipity or screening, while rational design by combining existing pharmacophore scaffolds remains an enormous challenge.  In this review, four types of multi-pharmacophore modes are discussed, and the examples from literature will be used to introduce attractive lead compds. with the capability of simultaneously interfering with different enzyme or signaling pathway of cancer progression, which will reveal the trends and insights to help the design of the next generation multi-targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGjXR-zscrArVg90H21EOLACvtfcHk0lgQ1heNyGBMMQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsV2rtL8%253D&md5=511561bd2cd186d5dafa905b7257bf32</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DR.%2BG.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DW.%2BB.%26aulast%3DLiao%26aufirst%3DD.%2BF.%26atitle%3DDesigning%2520multi-targeted%2520agents%253A%2520An%2520emerging%2520anticancer%2520drug%2520discovery%2520paradigm%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D136%26spage%3D195%26epage%3D211%26doi%3D10.1016%2Fj.ejmech.2017.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mondello, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derenzini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asgari, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brea, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheinberg, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14017</span>â <span class="NLM_lpage">14028</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.14876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.18632%2Foncotarget.14876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=28147336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A280%3ADC%252BC1c3hslamtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14017-14028&author=P.+Mondelloauthor=E.+Derenziniauthor=Z.+Asgariauthor=J.+Philipauthor=E.+J.+Breaauthor=V.+Seshanauthor=R.+C.+Hendricksonauthor=E.+de+Stanchinaauthor=D.+A.+Scheinbergauthor=A.+Younes&title=Dual+inhibition+of+histone+deacetylases+and+phosphoinositide+3-kinase+enhances+therapeutic+activity+against+B+cell+lymphoma&doi=10.18632%2Foncotarget.14876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma</span></div><div class="casAuthors">Mondello Patrizia; Derenzini Enrico; Asgari Zahra; Younes Anas; Philip John; Hendrickson Ronald C; Brea Elliott J; Scheinberg David A; Seshan Venkatraman; de Stanchina Elisa</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">14017-14028</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K) and Myc are known to cooperate in promoting the survival and growth of a variety of B-cell lymphomas.  While currently there are no small molecule inhibitors of Myc protein, histone deacetylase (HDAC) inhibitors have been shown to reduce levels of Myc protein by suppressing its transcription.  We assessed the efficacy of CUDC-907, a new rationally designed dual inhibitor of PI3K and HDACs, in a panel of lymphoma cell lines.  CUDC-907 treatment resulted in a dose- and time-dependent growth inhibition and cell death of DLBCL cell lines, irrespective of the cell of origin.  CUDC-907 treatment down-regulated the phosphorylation of PI3K downstream targets, including AKT, PRAS40, S6, and 4EBP1, increased histone 3 acetylation, and decreased Myc protein levels.  SILAC-based quantitative mass spectrometry demonstrated that CUDC-907 treatment decreased the protein levels of several components of the B cell receptor (BCR) and Toll like receptor (TLR) pathways, including BTK, SYK, and MyD88 proteins.  These cellular changes were associated with an inhibition of NF-kB activation.  CUDC-907 demonstrated in vivo efficacy with no significant toxicity in a human DLBCL xenograft mouse model.  Collectively, these data provide a mechanistic rationale for evaluating CUDC-907 for the treatment of patients with Myc and PI3K-dependent lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHhpmYpq2kzUwlCcfExbvbfW6udTcc2eaAdyZVgvE3krntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3hslamtg%253D%253D&md5=57e637ca88cd4a23c0c069a8564404d1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14876%26sid%3Dliteratum%253Aachs%26aulast%3DMondello%26aufirst%3DP.%26aulast%3DDerenzini%26aufirst%3DE.%26aulast%3DAsgari%26aufirst%3DZ.%26aulast%3DPhilip%26aufirst%3DJ.%26aulast%3DBrea%26aufirst%3DE.%2BJ.%26aulast%3DSeshan%26aufirst%3DV.%26aulast%3DHendrickson%26aufirst%3DR.%2BC.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DScheinberg%26aufirst%3DD.%2BA.%26aulast%3DYounes%26aufirst%3DA.%26atitle%3DDual%2520inhibition%2520of%2520histone%2520deacetylases%2520and%2520phosphoinositide%25203-kinase%2520enhances%2520therapeutic%2520activity%2520against%2520B%2520cell%2520lymphoma%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D14017%26epage%3D14028%26doi%3D10.18632%2Foncotarget.14876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibli, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tews, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kircher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Olmos, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scriba, G. K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krait, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer-Posovszky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span> <span> </span><span class="NLM_article-title">Combined cardioprotective and adipocyte browning effects promoted by the eutomer of dual seh/pparÎ³ modulator</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">2815</span>â <span class="NLM_lpage">2828</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c02063</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c02063" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXks1Oqu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=2815-2828&author=M.+Hartmannauthor=S.+I.+Bibliauthor=D.+Tewsauthor=X.+Niauthor=T.+Kircherauthor=J.+S.+Kramerauthor=W.+Kiluauthor=J.+Heeringauthor=V.+Hernandez-Olmosauthor=L.+Weizelauthor=G.+K.+E.+Scribaauthor=S.+Kraitauthor=S.+Knappauthor=A.+Chaikuadauthor=D.+Merkauthor=I.+Flemingauthor=P.+Fischer-Posovszkyauthor=E.+Proschak&title=Combined+cardioprotective+and+adipocyte+browning+effects+promoted+by+the+eutomer+of+dual+seh%2Fppar%CE%B3+modulator&doi=10.1021%2Facs.jmedchem.0c02063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Cardioprotective and Adipocyte Browning Effects Promoted by the Eutomer of Dual sEH/PPARÎ³ Modulator</span></div><div class="casAuthors">Hartmann, Markus; Bibli, Sofia-Iris; Tews, Daniel; Ni, Xiaomin; Kircher, Theresa; Kramer, Jan S.; Kilu, Whitney; Heering, Jan; Hernandez-Olmos, Victor; Weizel, Lilia; Scriba, Gerhard K. E.; Krait, Sulaiman; Knapp, Stefan; Chaikuad, Apirat; Merk, Daniel; Fleming, Ingrid; Fischer-Posovszky, Pamela; Proschak, Ewgenij</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2815-2828</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The metabolic syndrome (MetS) is a constellation of cardiovascular and metabolic symptoms involving insulin resistance, steatohepatitis, obesity, hypertension, and heart disease, and patients suffering from MetS often require polypharmaceutical treatment.  PPARÎ³ agonists are highly effective oral antidiabetics with great potential in MetS, which promote adipocyte browning and insulin sensitization.  However, the application of PPARÎ³ agonists in clinics is restricted by potential cardiovascular adverse events.  We have previously demonstrated that the racemic dual sEH/PPARÎ³ modulator RB394 (3) simultaneously improves all risk factors of MetS in vivo.  In this study, we identify and characterize the eutomer of 3.  We provide structural rationale for mol. recognition of the eutomer.  Furthermore, we could show that the dual sEH/PPARÎ³ modulator is able to promote adipocyte browning and simultaneously exhibits cardioprotective activity which underlines its exciting potential in treatment of MetS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqETySvJySH6rVg90H21EOLACvtfcHk0lhgrnY6YhiKnw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXks1Oqu7w%253D&md5=bb534a62931621e09a9a610290059ec8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c02063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c02063%26sid%3Dliteratum%253Aachs%26aulast%3DHartmann%26aufirst%3DM.%26aulast%3DBibli%26aufirst%3DS.%2BI.%26aulast%3DTews%26aufirst%3DD.%26aulast%3DNi%26aufirst%3DX.%26aulast%3DKircher%26aufirst%3DT.%26aulast%3DKramer%26aufirst%3DJ.%2BS.%26aulast%3DKilu%26aufirst%3DW.%26aulast%3DHeering%26aufirst%3DJ.%26aulast%3DHernandez-Olmos%26aufirst%3DV.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DScriba%26aufirst%3DG.%2BK.%2BE.%26aulast%3DKrait%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DMerk%26aufirst%3DD.%26aulast%3DFleming%26aufirst%3DI.%26aulast%3DFischer-Posovszky%26aufirst%3DP.%26aulast%3DProschak%26aufirst%3DE.%26atitle%3DCombined%2520cardioprotective%2520and%2520adipocyte%2520browning%2520effects%2520promoted%2520by%2520the%2520eutomer%2520of%2520dual%2520seh%252Fppar%25CE%25B3%2520modulator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D2815%26epage%3D2828%26doi%3D10.1021%2Facs.jmedchem.0c02063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ko, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffey, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandvold, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soellner, M. B.</span></span> <span> </span><span class="NLM_article-title">Development of a chimeric c-Src kinase and HDAC inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">779</span>â <span class="NLM_lpage">783</span>, <span class="refDoi">Â DOI: 10.1021/ml400175d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400175d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKit7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=779-783&author=K.+S.+Koauthor=M.+E.+Steffeyauthor=K.+R.+Brandvoldauthor=M.+B.+Soellner&title=Development+of+a+chimeric+c-Src+kinase+and+HDAC+inhibitor&doi=10.1021%2Fml400175d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Chimeric c-Src Kinase and HDAC Inhibitor</span></div><div class="casAuthors">Ko, Kristin S.; Steffey, Michael E.; Brandvold, Kristoffer R.; Soellner, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">779-783</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of synergism obsd. between a selective c-Src kinase inhibitor with an HDAC inhibitor, the development of the first chimeric c-Src kinase and HDAC inhibitor is described.  The optimized chimeric inhibitor is shown to be a potent c-Src and HDAC inhibitor.  Chimeric inhibitor (I) is further shown to be highly efficacious in cancer cell lines and significantly more efficacious than a dual-targeting strategy using discrete c-Src and HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzi2suGn-7ErVg90H21EOLACvtfcHk0lhgrnY6YhiKnw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKit7rL&md5=5f34ce3b1f65a8ac1a4341f563a5e1d9</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fml400175d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400175d%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DK.%2BS.%26aulast%3DSteffey%26aufirst%3DM.%2BE.%26aulast%3DBrandvold%26aufirst%3DK.%2BR.%26aulast%3DSoellner%26aufirst%3DM.%2BB.%26atitle%3DDevelopment%2520of%2520a%2520chimeric%2520c-Src%2520kinase%2520and%2520HDAC%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D779%26epage%3D783%26doi%3D10.1021%2Fml400175d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choong-Kun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myung Eun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won Suk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong Min, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyu Hyun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tae Soo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joong
Bae, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyun Cheol, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. S.</span></span> <span> </span><span class="NLM_article-title">Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer</span>. <i>Am. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">72</span>â <span class="NLM_lpage">86</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=25628921" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=72-86&author=L.+Choong-Kunauthor=L.+Myung+Eunauthor=L.+Won+Sukauthor=K.+Jeong+Minauthor=P.+Kyu+Hyunauthor=K.+Tae+Sooauthor=L.+K.+Youngauthor=A.+Joong%0ABaeauthor=C.+Hyun+Cheolauthor=R.+S.+Young&title=Dovitinib+%28TKI258%29%2C+a+multi-target+angiokinase+inhibitor%2C+is+effective+regardless+of+KRAS+or+BRAF+mutation+status+in+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChoong-Kun%26aufirst%3DL.%26aulast%3DMyung%2BEun%26aufirst%3DL.%26aulast%3DWon%2BSuk%26aufirst%3DL.%26aulast%3DJeong%2BMin%26aufirst%3DK.%26aulast%3DKyu%2BHyun%26aufirst%3DP.%26aulast%3DTae%2BSoo%26aufirst%3DK.%26aulast%3DYoung%26aufirst%3DL.%2BK.%26aulast%3DJoong%2BBae%26aufirst%3DA.%26aulast%3DHyun%2BCheol%26aufirst%3DC.%26aulast%3DYoung%26aufirst%3DR.%2BS.%26atitle%3DDovitinib%2520%2528TKI258%2529%252C%2520a%2520multi-target%2520angiokinase%2520inhibitor%252C%2520is%2520effective%2520regardless%2520of%2520KRAS%2520or%2520BRAF%2520mutation%2520status%2520in%2520colorectal%2520cancer%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2015%26volume%3D5%26spage%3D72%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. T.</span></span> <span> </span><span class="NLM_article-title">Multi-target drugs: the trend of drug research and development</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e40262</span> <span class="refDoi">Â DOI: 10.1371/journal.pone.0040262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1371%2Fjournal.pone.0040262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=22768266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVaisr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=J.+J.+Luauthor=W.+Panauthor=Y.+J.+Huauthor=Y.+T.+Wang&title=Multi-target+drugs%3A+the+trend+of+drug+research+and+development&doi=10.1371%2Fjournal.pone.0040262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target drugs: the trend of drug research and development</span></div><div class="casAuthors">Lu, Jin-Jian; Pan, Wei; Hu, Yuan-Jia; Wang, Yi-Tao</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e40262</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Summarizing the status of drugs in the market and examg. the trend of drug research and development is important in drug discovery.  In this study, we compared the drug targets and the market sales of the new mol. entities approved by the U.S. Food and Drug Administration from Jan. 2000 to Dec. 2009.  Two networks, namely, the target-target and drug-drug networks, have been set up using the network anal. tools.  The multi-target drugs have much more potential, as shown by the network visualization and the market trends.  We discussed the possible reasons and proposed the rational strategies for drug research and development in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrapZATY1GnWbVg90H21EOLACvtfcHk0lht6jcuChwkyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVaisr8%253D&md5=79489aaf7a36ee9c30287621a7244a6a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0040262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0040262%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.%2BJ.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DY.%2BJ.%26aulast%3DWang%26aufirst%3DY.%2BT.%26atitle%3DMulti-target%2520drugs%253A%2520the%2520trend%2520of%2520drug%2520research%2520and%2520development%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0040262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorja, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laster, K. V.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel dual-target inhibitor against RSK1 and MSK2 to suppress growth of human colon cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">6733</span>â <span class="NLM_lpage">6746</span>, <span class="refDoi">Â DOI: 10.1038/s41388-020-01467-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fs41388-020-01467-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=32963350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFOqu7nF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2020&pages=6733-6746&author=G.+Jinauthor=M.+Yanauthor=K.+Liuauthor=K.+Yaoauthor=H.+Chenauthor=C.+Zhangauthor=Y.+Yiauthor=K.+Reddyauthor=D.+R.+Gorjaauthor=K.+V.+Laster&title=Discovery+of+a+novel+dual-target+inhibitor+against+RSK1+and+MSK2+to+suppress+growth+of+human+colon+cancer&doi=10.1038%2Fs41388-020-01467-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel dual-target inhibitor against RSK1 and MSK2 to suppress growth of human colon cancer</span></div><div class="casAuthors">Jin, Guoguo; Yan, Mingyang; Liu, Kangdong; Yao, Ke; Chen, Hanyong; Zhang, Chengjuan; Yi, Yang; Reddy, Kanamata; Gorja, Dhilli Rao; Laster, Kyle Vaughn; Guo, Zhiping; Dong, Zigang</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">6733-6746</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Colon cancer is the most aggressive tumor in both men and women globally.  As many the chemotherapeutic regimens have adverse side effects and contribute to the resistance and recurrence, therefore, finding novel therapeutic targets and developing effective agents are urgent.  Based on the TCGA and GTEx database anal., RSK1 and MSK2 were found abnormal expressed in colon cancer.  RSK1 and MSK2 were overexpressed in colon cancer tissues confirmed by western blot and IHC.  After knocking down RSK1 or MSK2, cell proliferation and anchorage-independent cell growth were markedly inhibited.  Using a computer docking model, we identified a novel dual-target inhibitor, APIO-EE-07, that could block both RSK1 and MSK2 kinase activity in a dose-dependent manner.  APIO-EE-07 inhibited cell growth and induced apoptosis and also increased expression of Bax as well as cleaved caspase-3 and -PARP in colon cancer cells by downregulating RSK1 and MSK2 downstream targets, including CREB and ATF1.  Furthermore, APIO-EE-07 decreased tumor vol. and wt. in human patient-derived xenografts tumors implanted in SCID mice.  In summary, our results demonstrate that RSK1 and MSK2 are the potential targets for the treatment of colon cancer.  APIO-EE-07, a novel dual-target inhibitor of RSK1 and MSK2, can suppress the growth of colon cancer by attenuating RSK1 and MSK2 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8s_EQXi7hv7Vg90H21EOLACvtfcHk0lht6jcuChwkyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFOqu7nF&md5=806739debaeb3e24aa15630344a265cf</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fs41388-020-01467-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-020-01467-w%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DG.%26aulast%3DYan%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DYi%26aufirst%3DY.%26aulast%3DReddy%26aufirst%3DK.%26aulast%3DGorja%26aufirst%3DD.%2BR.%26aulast%3DLaster%26aufirst%3DK.%2BV.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520dual-target%2520inhibitor%2520against%2520RSK1%2520and%2520MSK2%2520to%2520suppress%2520growth%2520of%2520human%2520colon%2520cancer%26jtitle%3DOncogene%26date%3D2020%26volume%3D39%26spage%3D6733%26epage%3D6746%26doi%3D10.1038%2Fs41388-020-01467-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span> <span> </span><span class="NLM_article-title">Recent advances of dual FGFR inhibitors as a novel therapy for cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>214</i></span>,  <span class="NLM_fpage">113205</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2021.113205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2021.113205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=33556787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXjvVemtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2021&pages=113205&author=Q.+Liangauthor=J.+Wangauthor=L.+Zhaoauthor=J.+Houauthor=Y.+Huauthor=J.+Shi&title=Recent+advances+of+dual+FGFR+inhibitors+as+a+novel+therapy+for+cancer&doi=10.1016%2Fj.ejmech.2021.113205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances of dual FGFR inhibitors as a novel therapy for cancer</span></div><div class="casAuthors">Liang, Qi; Wang, Juelan; Zhao, Liyun; Hou, Jun; Hu, Yonghe; Shi, Jianyou</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113205</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Fibroblast growth factor receptor (FGFR) includes four highly conserved transmembrane receptor tyrosine kinases (FGFR1-4).  FGF and FGFR regulate many biol. processes, such as angiogenesis, wound healing and tissue regeneration.  The abnormal expression of FGFR is related to the tumorigenesis, tumor progression and drug resistance of anti-tumor treatments in many types of tumors.  Nowadays there are many anti-cancer drugs targeting FGFR.  However, traditional single-target anti-tumor drugs are easy to acquire drug resistance.  The therapeutic effect can be enhanced by simultaneously inhibiting FGFR and another target (such as VEGFR, EGFR, PI3K, CSF-1R, etc.).  We know drug combination can bring problems such as drug interactions.  Therefore, the development of FGFR dual target inhibitors is an important direction.  In this paper, we reviewed the research on dual FGFR inhibitors in recent years and made brief comments on them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotL9RCNkt2O7Vg90H21EOLACvtfcHk0lht6jcuChwkyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXjvVemtbc%253D&md5=1666f197816386044b0a9def9933d2da</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113205%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DJ.%26atitle%3DRecent%2520advances%2520of%2520dual%2520FGFR%2520inhibitors%2520as%2520a%2520novel%2520therapy%2520for%2520cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D214%26spage%3D113205%26doi%3D10.1016%2Fj.ejmech.2021.113205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minarini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Tacrine derivatives and Alzheimerâs disease</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1825</span>â <span class="NLM_lpage">1838</span>, <span class="refDoi">Â DOI: 10.2174/092986710791111206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.2174%2F092986710791111206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=20345341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmvFCnu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=1825-1838&author=V.+Tumiattiauthor=A.+Minariniauthor=M.+L.+Bolognesiauthor=A.+Milelliauthor=M.+Rosiniauthor=C.+Melchiorre&title=Tacrine+derivatives+and+Alzheimer%E2%80%99s+disease&doi=10.2174%2F092986710791111206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Tacrine derivatives and Alzheimer's disease</span></div><div class="casAuthors">Tumiatti, V.; Minarini, A.; Bolognesi, M. L.; Milelli, A.; Rosini, M.; Melchiorre, C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1825-1838</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  To date, the pharmacotherapy of Alzheimer's disease (AD) has relied on acetylcholinesterase (AChE) inhibitors (AChEIs) and, more recently, an N-methyl-D-aspartate receptor (NMDAR) antagonist.  AD is a multifactorial syndrome with several target proteins contributing to its etiol.  "Multi-target-directed ligands" (MTDLs) have great potential for treating complex diseases such as AD because they can interact with multiple targets.  The design of compds. that can hit more than one specific AD target thus represents an innovative strategy for AD treatment.  Tacrine was the first AChEI introduced in therapy.  Recent studies have demonstrated its ability to interact with different AD targets.  Furthermore, numerous tacrine homo- and heterodimers were developed with the aim of improving and enlarging its biol. profile beyond its ability to act as an AChEI.  Several tacrine hybrid derivs. were designed and synthesized with the same goal.  This review will focus on and summarize the last 2 years of research into the development of tacrine derivs. able to hit AD targets beyond simple AChE inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoAUhZIxP33LVg90H21EOLACvtfcHk0lglD1-F-wUcmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmvFCnu78%253D&md5=0506197d9fdaa47d5a76bdf2099cf483</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F092986710791111206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986710791111206%26sid%3Dliteratum%253Aachs%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMilelli%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DTacrine%2520derivatives%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2010%26volume%3D17%26spage%3D1825%26epage%3D1838%26doi%3D10.2174%2F092986710791111206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, J. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albuquerque, H. M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, A. M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, V. L. M.</span></span> <span> </span><span class="NLM_article-title">Dual-target compounds for Alzheimerâs disease: natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>221</i></span>,  <span class="NLM_fpage">113492</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2021.113492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2021.113492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=33984802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhtVynur7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=221&publication_year=2021&pages=113492&author=J.+P.+S.+Ferreiraauthor=H.+M.+T.+Albuquerqueauthor=S.+M.+Cardosoauthor=A.+M.+S.+Silvaauthor=V.+L.+M.+Silva&title=Dual-target+compounds+for+Alzheimer%E2%80%99s+disease%3A+natural+and+synthetic+AChE+and+BACE-1+dual-inhibitors+and+their+structure-activity+relationship+%28SAR%29&doi=10.1016%2Fj.ejmech.2021.113492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR)</span></div><div class="casAuthors">Ferreira, Joao P. S.; Albuquerque, Helio M. T.; Cardoso, Susana M.; Silva, Artur M. S.; Silva, Vera L. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">221</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113492</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a chronic neurodegenerative disease and represents the major cause of dementia worldwide.  Currently, there are no available treatments capable to deliver disease-modifying effects, and the available drugs can only alleviate the symptoms.  The exact pathol. of AD is not yet fully understood and several hallmarks such as the presence of amyloid-Î² (AÎ²) senile plaques, neurofibrillary tangles (NFTs) as well as the loss of cholinergic function have been assocd. to AD.  Distinct pharmacol. targets have been validated to address AD, with acetylcholinesterase (AChE) and Î²-secretase-1 (BACE-1) being two of the most explored ones.  A great deal of research has been devoted to the development of new AChE and BACE-1 effective inhibitors, tackled sep. or in combination of both.  The multi-factorial nature of AD conducted to the development of multi-target directed ligands (MTDLs), defined as single mols. capable to modulate more than one biol. target, as an alternative approach to the old paradigm one-target one-drug.  In this context, this review describes a collection of natural and synthetic compds. with dual-inhibitory properties towards both AChE and BACE-1 in the MTDLs context.  Furthermore, this review also provides a crit. comprehensive anal. of structure-activity relationships (SAR) of the synthetic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb68thD_MLErVg90H21EOLACvtfcHk0lglD1-F-wUcmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhtVynur7O&md5=adf20088921c4b80c74f17917bcc66d3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113492%26sid%3Dliteratum%253Aachs%26aulast%3DFerreira%26aufirst%3DJ.%2BP.%2BS.%26aulast%3DAlbuquerque%26aufirst%3DH.%2BM.%2BT.%26aulast%3DCardoso%26aufirst%3DS.%2BM.%26aulast%3DSilva%26aufirst%3DA.%2BM.%2BS.%26aulast%3DSilva%26aufirst%3DV.%2BL.%2BM.%26atitle%3DDual-target%2520compounds%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520natural%2520and%2520synthetic%2520AChE%2520and%2520BACE-1%2520dual-inhibitors%2520and%2520their%2520structure-activity%2520relationship%2520%2528SAR%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D221%26spage%3D113492%26doi%3D10.1016%2Fj.ejmech.2021.113492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malafaia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albuquerque, H. M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, A. M. S.</span></span> <span> </span><span class="NLM_article-title">Amyloid-Î² and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>214</i></span>,  <span class="NLM_fpage">113209</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2021.113209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2021.113209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=33548635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXjsVCgsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2021&pages=113209&author=D.+Malafaiaauthor=H.+M.+T.+Albuquerqueauthor=A.+M.+S.+Silva&title=Amyloid-%CE%B2+and+tau+aggregation+dual-inhibitors%3A+A+synthetic+and+structure-activity+relationship+focused+review&doi=10.1016%2Fj.ejmech.2021.113209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid-Î² and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review</span></div><div class="casAuthors">Malafaia, Daniela; Albuquerque, Helio M. T.; Silva, Artur M. S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113209</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is one of the most common types of dementia, esp. in elderly, with an increasing no. of people suffering from this disease worldwide.  There are no available disease-modifying therapies and only four drugs are approved for the relief of symptoms.  Currently, the therapeutic approach used for AD treatment is based on single target drugs, which are not capable to stop its progression.  To address this issue, multi-target compds., combining two or more pharmacophores in a single mol. entity, have gained increasing interest to deal with the multiple factors related to AD.  The exact cause of AD is not yet completely disclosed, and several hallmarks have been assocd. to this neurodegenerative disease.  Even though, the accumulation of both amyloid-Î² plaques (AÎ²) and neurofibrillary tangles (NFTs) are fully accepted as the main AD hallmarks, being object of lots of research for early-stage diagnosis and pharmacol. therapy.  In this context, this review summarizes the state-of-the-art in the field of dual-target inhibitors of both AÎ² and tau aggregation simultaneously, including the design and synthetic strategy of the dual-target compds., as well as a brief structure-activity relationships (SAR) anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp59jHb3soMnLVg90H21EOLACvtfcHk0lglD1-F-wUcmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXjsVCgsLo%253D&md5=cb2925fe31b2a1597540ad49bdb062da</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113209%26sid%3Dliteratum%253Aachs%26aulast%3DMalafaia%26aufirst%3DD.%26aulast%3DAlbuquerque%26aufirst%3DH.%2BM.%2BT.%26aulast%3DSilva%26aufirst%3DA.%2BM.%2BS.%26atitle%3DAmyloid-%25CE%25B2%2520and%2520tau%2520aggregation%2520dual-inhibitors%253A%2520A%2520synthetic%2520and%2520structure-activity%2520relationship%2520focused%2520review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D214%26spage%3D113209%26doi%3D10.1016%2Fj.ejmech.2021.113209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qandil, A. M.</span></span> <span> </span><span class="NLM_article-title">Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: a critical review</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">17244</span>â <span class="NLM_lpage">17274</span>, <span class="refDoi">Â DOI: 10.3390/ijms131217244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.3390%2Fijms131217244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23247285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVagtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=17244-17274&author=A.+M.+Qandil&title=Prodrugs+of+nonsteroidal+anti-inflammatory+drugs+%28NSAIDs%29%2C+more+than+meets+the+eye%3A+a+critical+review&doi=10.3390%2Fijms131217244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: a critical review</span></div><div class="casAuthors">Qandil, Amjad M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17244-17274</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The design and the synthesis of prodrugs for nonsteroidal anti-inflammatory drugs (NSAIDs) have been given much attention by medicinal chemists, esp. in the last decade.  As a therapeutic group, NSAIDs are among the most widely used prescribed and over the counter (OTC) medications.  The rich literature about potential NSAID prodrugs clearly shows a shift from alkyl, aryalkyl or aryl esters with the sole role of masking the carboxylic acid group, to more elaborate conjugates that contain carefully chosen groups to serve specific purposes, such as enhancement of water soly. and dissoln., nitric oxide release, hydrogen sulfide release, antioxidant activity, anticholinergic and acetylcholinesterase inhibitory (AChEI) activity and site-specific targeting and delivery.  This review will focus on NSAID prodrugs that have been designed or were, later, found to possess intrinsic pharmacol. activity as an intact chem. entity.  Such intrinsic activity might augment the anti-inflammatory activity of the NSAID, reduce its side effects or transform the potential therapeutic use from classical anti-inflammatory action to something else.  Reports discussed in this review will be those of NO-NSAIDs, anticholinergic and AChEI-NSAIDs, Phospho-NSAIDs and some misc. agents.  In most cases, this review will cover literature dealing with these NSAID prodrugs from the year 2006 and later.  Older literature will be used when necessary, e.g., to explain the chem. and biol. mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocrOffS6FFb7Vg90H21EOLACvtfcHk0lhz1KFQgk8O4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVagtA%253D%253D&md5=33e4147b763e4f6ccf1700572d45b236</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3390%2Fijms131217244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms131217244%26sid%3Dliteratum%253Aachs%26aulast%3DQandil%26aufirst%3DA.%2BM.%26atitle%3DProdrugs%2520of%2520nonsteroidal%2520anti-inflammatory%2520drugs%2520%2528NSAIDs%2529%252C%2520more%2520than%2520meets%2520the%2520eye%253A%2520a%2520critical%2520review%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2012%26volume%3D13%26spage%3D17244%26epage%3D17274%26doi%3D10.3390%2Fijms131217244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LehÃ¡r, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, C. T.</span></span> <span> </span><span class="NLM_article-title">Multi-target therapeutics: when the whole is greater than the sum of the parts</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">34</span>â <span class="NLM_lpage">42</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2006.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.drudis.2006.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=17198971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=34-42&author=G.+R.+Zimmermannauthor=J.+Leh%C3%A1rauthor=C.+T.+Keith&title=Multi-target+therapeutics%3A+when+the+whole+is+greater+than+the+sum+of+the+parts&doi=10.1016%2Fj.drudis.2006.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics: when the whole is greater than the sum of the parts</span></div><div class="casAuthors">Zimmermann Grant R; Lehar Joseph; Keith Curtis T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Drugs designed to act against individual molecular targets cannot usually combat multigenic diseases such as cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders.  Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in many important therapeutic areas.  The combination drugs currently employed are primarily of rational design, but the increased efficacy they provide justifies in vitro discovery efforts for identifying novel multi-target mechanisms.  In this review, we discuss the biological rationale for combination therapeutics, review some existing combination drugs and present a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI14vYK2Q1LENHe_gFldTbfW6udTcc2eYeFAhWbPuXirntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D&md5=66715499ce21c2855dc6c477aa87f161</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DLeh%25C3%25A1r%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DMulti-target%2520therapeutics%253A%2520when%2520the%2520whole%2520is%2520greater%2520than%2520the%2520sum%2520of%2520the%2520parts%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D34%26epage%3D42%26doi%3D10.1016%2Fj.drudis.2006.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Rational design of multi-target-directed ligands: strategies and emerging paradigms</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8881</span>â <span class="NLM_lpage">8914</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlKrt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8881-8914&author=J.+Zhouauthor=X.+Jiangauthor=S.+Heauthor=H.+Jiangauthor=F.+Fengauthor=W.+Liuauthor=W.+Quauthor=H.+Sun&title=Rational+design+of+multi-target-directed+ligands%3A+strategies+and+emerging+paradigms&doi=10.1021%2Facs.jmedchem.9b00017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms</span></div><div class="casAuthors">Zhou, Junting; Jiang, Xueyang; He, Siyu; Jiang, Hongli; Feng, Feng; Liu, Wenyuan; Qu, Wei; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8881-8914</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Due to the complexity of multifactorial diseases, single-target drugs do not always exhibit satisfactory efficacy.  Recently, increasing evidence indicates that simultaneous modulation of multiple targets may improve both therapeutic safety and efficacy, compared with single-target drugs.  However, few multitarget drugs are on market or in clin. trials, despite the best efforts of medicinal chemists.  This article discusses the systematic establishment of target combination, lead generation, and optimization of multitarget-directed ligands (MTDLs).  Moreover, we analyze some MTDLs research cases for several complex diseases in recent years and the physicochem. properties of 117 clin. multitarget drugs, with the aim to reveal the trends and insights of the potential use of MTDLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraLqk7hMZnoLVg90H21EOLACvtfcHk0lhz1KFQgk8O4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlKrt7k%253D&md5=37adb9bc31802e62fd7f8d0d6e7697e3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00017%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DQu%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DRational%2520design%2520of%2520multi-target-directed%2520ligands%253A%2520strategies%2520and%2520emerging%2520paradigms%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8881%26epage%3D8914%26doi%3D10.1021%2Facs.jmedchem.9b00017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by Design: A Medicinal Chemistâs Perspective on Multitargeting Compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">420</span>â <span class="NLM_lpage">444</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+Design%3A+A+Medicinal+Chemist%E2%80%99s+Perspective+on+Multitargeting+Compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0li7sz9nuXKqKg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520Design%253A%2520A%2520Medicinal%2520Chemist%25E2%2580%2599s%2520Perspective%2520on%2520Multitargeting%2520Compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">Can we rationally design promiscuous drugs?</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">127</span>â <span class="NLM_lpage">136</span>, <span class="refDoi">Â DOI: 10.1016/j.sbi.2006.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.sbi.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=16442279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=127-136&author=A.+L.+Hopkinsauthor=J.+S.+Masonauthor=J.+P.+Overington&title=Can+we+rationally+design+promiscuous+drugs%3F&doi=10.1016%2Fj.sbi.2006.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Can we rationally design promiscuous drugs?</span></div><div class="casAuthors">Hopkins, Andrew L.; Mason, Jonathan S.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Structure-based drug design is now used widely in modern medicinal chem.  The application of structural biol. to medicinal chem. has heralded the 'rational drug design' vision of discovering exquisitely selective ligands.  However, recent advances in post-genomic biol. are indicating that polypharmacol. may be a necessary trait for the efficacy of many drugs, therefore questioning the 'one drug, one target' assumption of current rational drug design.  By combining advances in chemoinformatics and structural biol., it might be possible to rationally design the next generation of promiscuous drugs with polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWdh60x9AHrVg90H21EOLACvtfcHk0li7sz9nuXKqKg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D&md5=8f9e95a41976b8e3ac790f2fff2c406f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DCan%2520we%2520rationally%2520design%2520promiscuous%2520drugs%253F%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2006%26volume%3D16%26spage%3D127%26epage%3D136%26doi%3D10.1016%2Fj.sbi.2006.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, T.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J.-M.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3645</span>â <span class="NLM_lpage">3655</span>, <span class="refDoi">Â DOI: 10.1021/jm400179b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400179b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsV2gt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3645-3655&author=J.-B.+Chenauthor=T.-R.+Chernauthor=T.-T.+Weiauthor=C.-C.+Chenauthor=J.-H.+Linauthor=J.-M.+Fang&title=Design+and+synthesis+of+dual-action+inhibitors+targeting+histone+deacetylases+and+3-hydroxy-3-methylglutaryl+coenzyme+A+reductase+for+cancer+treatment&doi=10.1021%2Fjm400179b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Dual-Action Inhibitors Targeting Histone Deacetylases and 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase for Cancer Treatment</span></div><div class="casAuthors">Chen, Jhih-Bin; Chern, Ting-Rong; Wei, Tzu-Tang; Chen, Ching-Chow; Lin, Jung-Hsin; Fang, Jim-Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3645-3655</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual inhibitors of histone deacetylase (HDAC) and 3-hydroxy-3-methylglutaryl CoA reductase (HMGR) such as I (X = bond, CH2; Y = bond, 1,4-benzenediyl; Z = bond, 1,2,3-triazole-4,1-diyl) and II were prepd. by incorporating the hydroxamate moieties of HDAC inhibitors into statins such as lovastatin known as HMGR inhibitors.  Hydroxamic acids such as II derived from ring-opening of the lactone moieties of statins were the most effective of the compds. tested at inhibiting HDAC and HMGR in vitro and in human leukemia cells, with IC50 values of 12-44 nM against HMGR, 63-125 nM against HDAC1, 414-600 nM against HDAC2, and 51-133 nM against HDAC6.  Statin-derived hydroxamic acids such as II inhibited the growth of human cancer cells with IC50 values of 18-20 Î¼M and greater than five-fold selectivity for human cancer cells over normal human cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYxyB-8TwI0LVg90H21EOLACvtfcHk0li7sz9nuXKqKg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsV2gt7c%253D&md5=e212e0f2e9d565b215f69e66dfd8adac</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm400179b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400179b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.-B.%26aulast%3DChern%26aufirst%3DT.-R.%26aulast%3DWei%26aufirst%3DT.-T.%26aulast%3DChen%26aufirst%3DC.-C.%26aulast%3DLin%26aufirst%3DJ.-H.%26aulast%3DFang%26aufirst%3DJ.-M.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dual-action%2520inhibitors%2520targeting%2520histone%2520deacetylases%2520and%25203-hydroxy-3-methylglutaryl%2520coenzyme%2520A%2520reductase%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3645%26epage%3D3655%26doi%3D10.1021%2Fjm400179b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tavera-Mendoza, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quach, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dabbas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palijan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleason, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. H.</span></span> <span> </span><span class="NLM_article-title">Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">8250</span>â <span class="NLM_lpage">8255</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0709279105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1073%2Fpnas.0709279105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=18550844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVyku7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=8250-8255&author=L.+E.+Tavera-Mendozaauthor=T.+D.+Quachauthor=B.+Dabbasauthor=J.+Hudonauthor=X.+Liaoauthor=A.+Palijanauthor=J.+L.+Gleasonauthor=J.+H.+White&title=Incorporation+of+histone+deacetylase+inhibition+into+the+structure+of+a+nuclear+receptor+agonist&doi=10.1073%2Fpnas.0709279105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist</span></div><div class="casAuthors">Tavera-Mendoza, Luz E.; Quach, Tan D.; Dabbas, Basel; Hudon, Jonathan; Liao, Xiaohong; Palijan, Ana; Gleason, James L.; White, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8250-8255</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">1,25-Dihydroxyvitamin D3 (1,25D) regulates gene expression by signaling through the nuclear vitamin D receptor (VDR) transcription factor and exhibits calcium homeostatic, anticancer, and immunomodulatory properties.  Histone deacetylase inhibitors (HDACis) alter nuclear and cytoplasmic protein acetylation, modify gene expression, and have potential for treatment of cancer and other indications.  The function of nuclear receptor ligands, including 1,25D, can be enhanced in combination with HDACi.  The authors designed triciferol, a hybrid mol. in which the 1,25D side chain was replaced with the dienyl hydroxamic acid of HDACi trichostatin A.  Triciferol binds directly to the VDR, and functions as an agonist with 1,25D-like potency on several 1,25D target genes.  Moreover, unlike 1,25D, triciferol induces marked tubulin hyperacetylation, and augments histone acetylation at concns. that largely overlap those where VDR agonism is obsd.  Triciferol also exhibits more efficacious antiproliferative and cytotoxic activities than 1,25D in four cancer cell models in vitro.  The bifunctionality of triciferol is notable because (i) the HDACi activity is generated by modifying the 1,25D side chain without resorting to linker technol. and (ii) 1,25D and HDACi have sympathetic, but very distinct biochem. targets; the hydrophobic VDR ligand binding domain and the active sites of HDACs, which are zinc metalloenzymes.  These studies demonstrate the feasibility of combining HDAC inhibition with nuclear receptor agonism to enhance their therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqnUsEiyCAYbVg90H21EOLACvtfcHk0li7sz9nuXKqKg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVyku7o%253D&md5=ae7adac8555096f10e4bf0f90976155d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709279105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709279105%26sid%3Dliteratum%253Aachs%26aulast%3DTavera-Mendoza%26aufirst%3DL.%2BE.%26aulast%3DQuach%26aufirst%3DT.%2BD.%26aulast%3DDabbas%26aufirst%3DB.%26aulast%3DHudon%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DX.%26aulast%3DPalijan%26aufirst%3DA.%26aulast%3DGleason%26aufirst%3DJ.%2BL.%26aulast%3DWhite%26aufirst%3DJ.%2BH.%26atitle%3DIncorporation%2520of%2520histone%2520deacetylase%2520inhibition%2520into%2520the%2520structure%2520of%2520a%2520nuclear%2520receptor%2520agonist%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D8250%26epage%3D8255%26doi%3D10.1073%2Fpnas.0709279105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sham, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">N-3 hydroxylation of pyrimidine-2,4-diones yields dual inhibitors of HIV reverse transcriptase and integrase</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">63</span>â <span class="NLM_lpage">67</span>, <span class="refDoi">Â DOI: 10.1021/ml1002162</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1002162" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlalurzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=63-67&author=J.+Tangauthor=K.+Maddaliauthor=C.+D.+Dreisauthor=Y.+Y.+Shamauthor=R.+Vinceauthor=Y.+Pommierauthor=Z.+Wang&title=N-3+hydroxylation+of+pyrimidine-2%2C4-diones+yields+dual+inhibitors+of+HIV+reverse+transcriptase+and+integrase&doi=10.1021%2Fml1002162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase</span></div><div class="casAuthors">Tang, Jing; Maddali, Kasthuraiah; Dreis, Christine D.; Sham, Yuk Y.; Vince, Robert; Pommier, Yves; Wang, Zhengqiang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-67</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new mol. scaffold featuring an N-hydroxyimide functionality and capable of inhibiting both reverse transcriptase (RT) and integrase (IN) of human immunodeficiency virus (HIV) was rationally designed based on 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) non-nucleoside RT inhibitors (NNRTIs).  The design involves a minimal 3-N hydroxylation of the pyrimidine ring of HEPT compd. to yield a chelating triad which, along with the existing benzyl group, appeared to satisfy major structural requirements for IN binding.  In the mean time, this chem. modification did not severely compromise the compd.'s ability to inhibit RT.  A preliminary structure-activity relationship (SAR) study reveals that this N-3 OH is essential for IN inhibition and that the benzyl group on N-1 side chain is more important for IN binding than the one on C-6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqONtaoARK-6bVg90H21EOLACvtfcHk0lgYubQkO0Y4yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlalurzP&md5=8b20b2ac50ef44513cdcfe51664790ca</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fml1002162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1002162%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DMaddali%26aufirst%3DK.%26aulast%3DDreis%26aufirst%3DC.%2BD.%26aulast%3DSham%26aufirst%3DY.%2BY.%26aulast%3DVince%26aufirst%3DR.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DN-3%2520hydroxylation%2520of%2520pyrimidine-2%252C4-diones%2520yields%2520dual%2520inhibitors%2520of%2520HIV%2520reverse%2520transcriptase%2520and%2520integrase%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D63%26epage%3D67%26doi%3D10.1021%2Fml1002162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angioni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurglics, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahnt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span> <span> </span><span class="NLM_article-title">A dual modulator of farnesoid x receptor and soluble epoxide hydrolase to counter nonalcoholic steatohepatitis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7703</span>â <span class="NLM_lpage">7724</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00398</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00398" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2ls73J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7703-7724&author=J.+Schmidtauthor=M.+Rotterauthor=T.+Weiserauthor=S.+Wittmannauthor=L.+Weizelauthor=A.+Kaiserauthor=J.+Heeringauthor=T.+Goebelauthor=C.+Angioniauthor=M.+Wurglicsauthor=A.+Paulkeauthor=G.+Geisslingerauthor=A.+Kahntauthor=D.+Steinhilberauthor=E.+Proschak&title=A+dual+modulator+of+farnesoid+x+receptor+and+soluble+epoxide+hydrolase+to+counter+nonalcoholic+steatohepatitis&doi=10.1021%2Facs.jmedchem.7b00398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis</span></div><div class="casAuthors">Schmidt, Jurema; Rotter, Marco; Weiser, Tim; Wittmann, Sandra; Weizel, Lilia; Kaiser, Astrid; Heering, Jan; Goebel, Tamara; Angioni, Carlo; Wurglics, Mario; Paulke, Alexander; Geisslinger, Gerd; Kahnt, Astrid; Steinhilber, Dieter; Proschak, Ewgenij; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7703-7724</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonalcoholic steatohepatitis arising from Western diet and lifestyle is characterized by accumulation of fat in liver causing inflammation and fibrosis.  It evolves as serious health burden with alarming incidence, but there is no satisfying pharmacol. therapy to date.  Considering the disease's multifactorial nature, modulation of multiple targets might provide superior therapeutic efficacy.  In particular, farnesoid X receptor (FXR) activation that revealed antisteatotic and antifibrotic effects in clin. trials combined with inhibition of sol. epoxide hydrolase (sEH) as anti-inflammatory strategy promises synergies.  To exploit this dual concept, we developed agents exerting partial FXR agonism and sEH inhibitory activity.  Merging known pharmacophores and systematic exploration of the structure-activity relationship on both targets produced dual modulators with low nanomolar potency.  Extensive in vitro characterization confirmed high dual efficacy in cellular context combined with low toxicity, and pilot in vivo data revealed favorable pharmacokinetics as well as engagement on both targets in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUx3OFEKCgyrVg90H21EOLACvtfcHk0lgYubQkO0Y4yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2ls73J&md5=a35ceea141c78ed9885d7f9a99f4852b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00398%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DRotter%26aufirst%3DM.%26aulast%3DWeiser%26aufirst%3DT.%26aulast%3DWittmann%26aufirst%3DS.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DHeering%26aufirst%3DJ.%26aulast%3DGoebel%26aufirst%3DT.%26aulast%3DAngioni%26aufirst%3DC.%26aulast%3DWurglics%26aufirst%3DM.%26aulast%3DPaulke%26aufirst%3DA.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DKahnt%26aufirst%3DA.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DProschak%26aufirst%3DE.%26atitle%3DA%2520dual%2520modulator%2520of%2520farnesoid%2520x%2520receptor%2520and%2520soluble%2520epoxide%2520hydrolase%2520to%2520counter%2520nonalcoholic%2520steatohepatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7703%26epage%3D7724%26doi%3D10.1021%2Facs.jmedchem.7b00398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Dual-target-directed 1,3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimerâs disease</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5610</span>â <span class="NLM_lpage">5615</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2010.06.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmc.2010.06.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=20620068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlGhur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=5610-5615&author=W.+Huangauthor=D.+Lvauthor=H.+Yuauthor=R.+Shengauthor=C.+K.+Sunauthor=P.+Wuauthor=K.+Luoauthor=J.+Liauthor=Y.+Hu&title=Dual-target-directed+1%2C3-diphenylurea+derivatives%3A+BACE+1+inhibitor+and+metal+chelator+against+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.bmc.2010.06.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-target-directed 1,3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer's disease</span></div><div class="casAuthors">Huang, Wenhai; Lv, Dan; Yu, Haiping; Sheng, Rong; Kim, Sun Chol; Wu, Peng; Luo, Kedi; Li, Jia; Hu, Yongzhou</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5610-5615</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dual-target-directed 1,3-diphenylurea derivs. were designed by hybridizing BACE 1 inhibitor 1 with metal chelator LR-90.  A database consisted of 1,3-diphenylurea derivs. was built and screened by the pharmacophore model (Hypo 1) of BACE 1 inhibitor.  Based on the predicted results, 11 compds. (6a-d, 9a-g) with favorable Fitvalues were selected, synthesized and evaluated for their BACE 1 inhibitory activities, which showed that the predicted results were in good agreement with the exptl. values.  Besides, the synthesized compds. also displayed the ability to chelate metal ions.  The most effective BACE 1 inhibitor 9f (27.85 Â± 2.46Î¼mol/L) was selected for further receptor-binding studies, the result of which indicated that an essential hydrogen bonds was formed between the urea group of 9f and the catalytic aspartate Asp228.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgKAHualJvhbVg90H21EOLACvtfcHk0lgYubQkO0Y4yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlGhur8%253D&md5=eba5ad753bbf43134f7f3acc1561bc5a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.06.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.06.042%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DLv%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DSheng%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DC.%2BK.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DLuo%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DDual-target-directed%25201%252C3-diphenylurea%2520derivatives%253A%2520BACE%25201%2520inhibitor%2520and%2520metal%2520chelator%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D5610%26epage%3D5615%26doi%3D10.1016%2Fj.bmc.2010.06.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kogen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tago, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naruto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyagi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter targeting potential agents for Alzheimerâs disease</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">3359</span>â <span class="NLM_lpage">3362</span>, <span class="refDoi">Â DOI: 10.1021/ol026418e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol026418e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1Omtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=3359-3362&author=H.+Kogenauthor=N.+Todaauthor=K.+Tagoauthor=S.+Marumotoauthor=K.+Takamiauthor=M.+Oriauthor=N.+Yamadaauthor=K.+Koyamaauthor=S.+Narutoauthor=K.+Abeauthor=R.+Yamazakiauthor=T.+Haraauthor=A.+Aoyagiauthor=Y.+Abeauthor=T.+Kaneko&title=Design+and+synthesis+of+dual+inhibitors+of+acetylcholinesterase+and+serotonin+transporter+targeting+potential+agents+for+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fol026418e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Dual Inhibitors of Acetylcholinesterase and Serotonin Transporter Targeting Potential Agents for Alzheimer's Disease</span></div><div class="casAuthors">Kogen, Hiroshi; Toda, Narihiro; Tago, Keiko; Marumoto, Shinji; Takami, Kazuko; Ori, Mayuko; Yamada, Naho; Koyama, Kazuo; Naruto, Shunji; Abe, Kazumi; Yamazaki, Reina; Hara, Takao; Aoyagi, Atsushi; Abe, Yasuyuki; Kaneko, Tsugio</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3359-3362</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Highly efficient acetylcholinesterase (AChE) and serotonin transporter (SERT) dual inhibitors, I and II, were designed on the basis of the hypothetical model of AChE active site and synthesized.  Both compds. showed potent inhibitory activities against AChE and SERT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ_JFWyj5kyLVg90H21EOLACvtfcHk0liAkOZboSSIVg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1Omtbg%253D&md5=1bb01165b917e2e896f0b489e04f3d5a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fol026418e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol026418e%26sid%3Dliteratum%253Aachs%26aulast%3DKogen%26aufirst%3DH.%26aulast%3DToda%26aufirst%3DN.%26aulast%3DTago%26aufirst%3DK.%26aulast%3DMarumoto%26aufirst%3DS.%26aulast%3DTakami%26aufirst%3DK.%26aulast%3DOri%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DN.%26aulast%3DKoyama%26aufirst%3DK.%26aulast%3DNaruto%26aufirst%3DS.%26aulast%3DAbe%26aufirst%3DK.%26aulast%3DYamazaki%26aufirst%3DR.%26aulast%3DHara%26aufirst%3DT.%26aulast%3DAoyagi%26aufirst%3DA.%26aulast%3DAbe%26aufirst%3DY.%26aulast%3DKaneko%26aufirst%3DT.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dual%2520inhibitors%2520of%2520acetylcholinesterase%2520and%2520serotonin%2520transporter%2520targeting%2520potential%2520agents%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DOrg.%2520Lett.%26date%3D2002%26volume%3D4%26spage%3D3359%26epage%3D3362%26doi%3D10.1021%2Fol026418e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dove, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongratz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciossek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckers, T.</span></span> <span> </span><span class="NLM_article-title">Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2265</span>â <span class="NLM_lpage">2279</span>, <span class="refDoi">Â DOI: 10.1021/jm800988r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800988r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFemurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2265-2279&author=S.+Mahboobiauthor=S.+Doveauthor=A.+Sellmerauthor=M.+Winklerauthor=E.+Eichhornauthor=H.+Pongratzauthor=T.+Ciossekauthor=T.+Baerauthor=T.+Maierauthor=T.+Beckers&title=Design+of+chimeric+histone+deacetylase-+and+tyrosine+kinase-inhibitors%3A+a+series+of+imatinib+hybrides+as+potent+inhibitors+of+wild-type+and+mutant+BCR-ABL%2C+PDGF-Rbeta%2C+and+histone+deacetylases&doi=10.1021%2Fjm800988r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-RÎ², and Histone Deacetylases</span></div><div class="casAuthors">Mahboobi, Siavosh; Dove, Stefan; Sellmer, Andreas; Winkler, Matthias; Eichhorn, Emerich; Pongratz, Herwig; Ciossek, Thomas; Baer, Thomas; Maier, Thomas; Beckers, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2265-2279</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of histone deacetylases are a new class of cancer therapeutics with possibly broad applicability.  Combinations of HDAC inhibitors with the kinase inhibitor 1 (Imatinib) in recent studies showed additive and synergistic effects.  Here we present a new concept by combining inhibition of protein kinases and HDACs, two independent pharmacol. activities, in one synthetic small mol.  In general, the HDAC inhibition profile, the potencies, and the probable binding modes to HDAC1 and HDAC6 were similar as for 6 (SAHA).  Inhibition of Abl kinase in biochem. assays was maintained for most compds., but in general the kinase selectivity profile differed from that of 1 with nearly equipotent inhibition of the wild-type and the Imatinib resistant Abl T315I mutant.  A potent cellular inhibition of PDGFR and cytotoxicity toward EOL-1 cells, a model for idiopathic hypereosinophilic syndrome (HES), are restored or enhanced for selected analogs (12b, 14b, and 18b).  Cytotoxicity was evaluated by using a broad panel of tumor cell lines, with selected analogs displaying mean IC50 values between 3.6 and 7.1 Î¼M.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCa_uPm33uzLVg90H21EOLACvtfcHk0liAkOZboSSIVg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFemurc%253D&md5=2e65e8c0cf3daed2cc7415173209d630</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm800988r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800988r%26sid%3Dliteratum%253Aachs%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DDove%26aufirst%3DS.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DWinkler%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DCiossek%26aufirst%3DT.%26aulast%3DBaer%26aufirst%3DT.%26aulast%3DMaier%26aufirst%3DT.%26aulast%3DBeckers%26aufirst%3DT.%26atitle%3DDesign%2520of%2520chimeric%2520histone%2520deacetylase-%2520and%2520tyrosine%2520kinase-inhibitors%253A%2520a%2520series%2520of%2520imatinib%2520hybrides%2520as%2520potent%2520inhibitors%2520of%2520wild-type%2520and%2520mutant%2520BCR-ABL%252C%2520PDGF-Rbeta%252C%2520and%2520histone%2520deacetylases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2265%26epage%3D2279%26doi%3D10.1021%2Fjm800988r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Rationally designed dual inhibitors of HIV reverse transcriptase and integrase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">3416</span>â <span class="NLM_lpage">3419</span>, <span class="refDoi">Â DOI: 10.1021/jm070512p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070512p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVehtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3416-3419&author=Z.+Wangauthor=E.+M.+Bennettauthor=D.+J.+Wilsonauthor=C.+Salomonauthor=R.+Vince&title=Rationally+designed+dual+inhibitors+of+HIV+reverse+transcriptase+and+integrase&doi=10.1021%2Fjm070512p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally Designed Dual Inhibitors of HIV Reverse Transcriptase and Integrase</span></div><div class="casAuthors">Wang, Zhengqiang; Bennett, Eric M.; Wilson, Daniel J.; Salomon, Christine; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3416-3419</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bifunctional inhibitors were designed and synthesized based on 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) non-nucleoside reverse transcriptase (RT) inhibitors and diketoacid (DKA) integrase (IN) inhibitors.  Biochem. studies revealed activity against RT and IN at low nanomolar and low micromolar concns., resp.  Exceptionally low IC50 values from a cell-based assay were achieved along with remarkably high therapeutic indexes.  Compd. I was identified as the best compd. of the series (IC50: 24 nM against RT, 4.4 Î¼M against IN, and 10 nM against HIV-1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvKQ5ZDoIQqLVg90H21EOLACvtfcHk0lgzCD6IN8EERw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVehtbo%253D&md5=021d763f7f62919cc1fe9d010ab56e60</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm070512p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070512p%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBennett%26aufirst%3DE.%2BM.%26aulast%3DWilson%26aufirst%3DD.%2BJ.%26aulast%3DSalomon%26aufirst%3DC.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DRationally%2520designed%2520dual%2520inhibitors%2520of%2520HIV%2520reverse%2520transcriptase%2520and%2520integrase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D3416%26epage%3D3419%26doi%3D10.1021%2Fjm070512p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. P.</span></span> <span> </span><span class="NLM_article-title">Dual GSK-3Î²/AChE inhibitors as a new strategy for multitargeting anti-alzheimerâs disease drug discovery</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">171</span>â <span class="NLM_lpage">176</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.7b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2gtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=171-176&author=X.+Y.+Jiangauthor=T.+K.+Chenauthor=J.+T.+Zhouauthor=S.+Y.+Heauthor=H.+Y.+Yangauthor=Y.+Chenauthor=W.+Quauthor=F.+Fengauthor=H.+P.+Sun&title=Dual+GSK-3%CE%B2%2FAChE+inhibitors+as+a+new+strategy+for+multitargeting+anti-alzheimer%E2%80%99s+disease+drug+discovery&doi=10.1021%2Facsmedchemlett.7b00463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Dual GSK-3Î²/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer's Disease Drug Discovery</span></div><div class="casAuthors">Jiang, Xue-Yang; Chen, Ting-Kai; Zhou, Jun-Ting; He, Si-Yu; Yang, Hong-Yu; Chen, Yao; Qu, Wei; Feng, Feng; Sun, Hao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-176</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget-directed ligands (MTDLs) is considered to be a promising approach to address complex and multifactorial maladies such as Alzheimer's disease (AD).  The concurrent inhibition of the two crucial AD targets, glycogen synthase kinase-3Î² (GSK-3Î²) and human acetylcholinesterase (hAChE), might represent a breakthrough in the quest for clin. efficacy.  Thus, a novel family of GSK-3Î²/AChE dual-target inhibitors was designed and synthesized.  Among these hybrids, I showed the most promising profile as a nanomolar inhibitor on both hAChE (IC50 = 6.5 nM) and hGSK-3Î² kinase activity (IC50 = 66 nM).  It also showed good inhibitory effect on Î²-amyloid self-aggregation (inhibitory rate = 46%) at 20 Î¼M.  Western blot anal. revealed that compd. I inhibited hyperphosphorylation of tau protein in mouse neuroblastoma N2a-Tau cells.  In vivo studies confirmed that I significantly ameliorated the cognitive disorders in scopolamine-treated ICR mice and less hepatotoxicity than tacrine.  This study provides new leads for assessment of GSK-3Î² and AChE pathway dual inhibition as a promising strategy for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq103h9q_6uaLVg90H21EOLACvtfcHk0lgzCD6IN8EERw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2gtrY%253D&md5=8858bb4cbc503c79896ccbc00fb23153</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00463%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DX.%2BY.%26aulast%3DChen%26aufirst%3DT.%2BK.%26aulast%3DZhou%26aufirst%3DJ.%2BT.%26aulast%3DHe%26aufirst%3DS.%2BY.%26aulast%3DYang%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DH.%2BP.%26atitle%3DDual%2520GSK-3%25CE%25B2%252FAChE%2520inhibitors%2520as%2520a%2520new%2520strategy%2520for%2520multitargeting%2520anti-alzheimer%25E2%2580%2599s%2520disease%2520drug%2520discovery%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D171%26epage%3D176%26doi%3D10.1021%2Facsmedchemlett.7b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>205</i></span>,  <span class="NLM_fpage">112645</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2020.112645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2020.112645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=32791399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsF2ju7nN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2020&pages=112645&author=B.+Sunauthor=Y.+Dongauthor=Y.+Anauthor=M.+Liuauthor=X.+Y.+Liu&title=Design%2C+synthesis+and+bioactivity+evaluation+of+novel+arylalkene-amide+derivatives+as+dual-target+antifungal+inhibitors&doi=10.1016%2Fj.ejmech.2020.112645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors</span></div><div class="casAuthors">Sun, Bin; Dong, Yue; An, Yunfei; Liu, Min; Han, Jun; Zhao, Liyu; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112645</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Ergosterol as the core component of fungal cell membrane plays a key role in maintaining cell morphol. and permeability.  The squalenee epoxidase (SE) and 14-demethylase (CYP51) are the important rate-limiting enzymes for ergosterol synthesis.  In the study, these active fragments, which is derived from the structural groups of the common antifungal agents, were docked into the active sites of dual targets (SE, CYP51), resp.  Some of active fragments with the matching MCSS_Score values were selected and connected to construct three different series of novel arylalkene-amide derivs. as dual-target (SE, CYP51) antifungal inhibitors.  Subsequently, these compds. were further synthesized, and their bioactivity was evaluated.  Most of compds. showed a certain degree of antifungal activity in vitro.  It was worth noting that the target compds. 17a and 25a with excellent antifungal activity (0.125-4 Î¼g/mL) can inhibit the fluconazole-resistant Candida Strain 17#, CaR, 632, and 901 in the range of MIC values (4-8 Î¼g/mL).  Furthermore, their mol. mechanism, structural stability and low toxicity were further confirmed.  The mol. docking and ADMET properties were predicted to guide the subsequent optimization of target compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhh-pS7MDiqLVg90H21EOLACvtfcHk0lgzCD6IN8EERw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsF2ju7nN&md5=b3a1142e95bea42964d78009f670924a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112645%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DB.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26atitle%3DDesign%252C%2520synthesis%2520and%2520bioactivity%2520evaluation%2520of%2520novel%2520arylalkene-amide%2520derivatives%2520as%2520dual-target%2520antifungal%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D205%26spage%3D112645%26doi%3D10.1016%2Fj.ejmech.2020.112645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span> <span> </span><span class="NLM_article-title">Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">112991</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2020.112991</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2020.112991" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=33183866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlemsbjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2021&pages=112991&author=Y.+Anauthor=Y.+Dongauthor=M.+Liuauthor=J.+Hanauthor=L.+Zhaoauthor=B.+Sun&title=Novel+naphthylamide+derivatives+as+dual-target+antifungal+inhibitors%3A+Design%2C+synthesis+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2020.112991"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation</span></div><div class="casAuthors">An, Yunfei; Dong, Yue; Liu, Min; Han, Jun; Zhao, Liyu; Sun, Bin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112991</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In the study, a series of active fragments were screened through the method of De Novo Link, and these active fragments with the higher Ludi_Scores were selected, which can show the obvious binding ability with the dual targets (SE, CYP51).  Subsequently, three series of target compds. with naphthyl amide scaffolds were constructed by connecting these core fragments, and their structures were synthesized.  Most of compds. showed the antifungal activity in the treatment of pathogenic fungi.  It was worth noting that compds.I [R = pyridin-4-ylmethyl] and II [R = methyl] with the excellent broad-spectrum antifungal properties also exhibited the obvious antifungal effects against drug-resistant fungi.  Preliminary mechanism study has proved these target compds. can block the biosynthesis of ergosterol by inhibiting the activity of dual targets (SE, CYP51).  Furthermore, target compds. I [R = pyridin-4-ylmethyl] and II [R = methyl] with low toxicity side effects also demonstrated the excellent pharmacol. effects in vivo.  The mol. docking and ADMET prediction were performed, which can guide the optimization of subsequent lead compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTY6whYEevkbVg90H21EOLACvtfcHk0lgZqSeANtAGEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlemsbjM&md5=d10af85cc7298f8961dbba6abc1408eb</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112991%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DB.%26atitle%3DNovel%2520naphthylamide%2520derivatives%2520as%2520dual-target%2520antifungal%2520inhibitors%253A%2520Design%252C%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D210%26spage%3D112991%26doi%3D10.1016%2Fj.ejmech.2020.112991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falkenberg, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">673</span>, <span class="refDoi">Â DOI: 10.1038/nrd4360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fnrd4360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=25131830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=673&author=K.+J.+Falkenbergauthor=R.+W.+Johnstone&title=Histone+deacetylases+and+their+inhibitors+in+cancer%2C+neurological+diseases+and+immune+disorders&doi=10.1038%2Fnrd4360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span></div><div class="casAuthors">Falkenberg, Katrina J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-691</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters.  Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small mols.  This Review discusses the role of altered expression and/or function of one class of epigenetic regulators - histone deacetylases (HDACs) - and their role in cancer, neurol. diseases and immune disorders.  We highlight the development of small-mol. HDAC inhibitors and their use in the lab., in preclin. models and in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXiWEG49LhebVg90H21EOLACvtfcHk0lgZqSeANtAGEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI&md5=ccfb68fa3fd4685e2305cdf8a6a9c81a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnrd4360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4360%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenberg%26aufirst%3DK.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DHistone%2520deacetylases%2520and%2520their%2520inhibitors%2520in%2520cancer%252C%2520neurological%2520diseases%2520and%2520immune%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D673%26doi%3D10.1038%2Fnrd4360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span> <span> </span><span class="NLM_article-title">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">84</span>â <span class="NLM_lpage">90</span>, <span class="refDoi">Â DOI: 10.1038/nbt1272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fnbt1272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=17211407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=84-90&author=P.+A.+Marksauthor=R.+Breslow&title=Dimethyl+sulfoxide+to+vorinostat%3A+development+of+this+histone+deacetylase+inhibitor+as+an+anticancer+drug&doi=10.1038%2Fnbt1272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span></div><div class="casAuthors">Marks, Paul A.; Breslow, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-90</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In our quest to understand why DMSO (DMSO) can cause growth arrest and terminal differentiation of transformed cells, we followed a path that led us to discover suberoylanilide hydroxamic acid (SAHA; vorinostat (Zolinza)), which is a histone deacetylase inhibitor.  SAHA reacts with and blocks the catalytic site of these enzymes.  Extensive structure-activity studies were done along the path from DMSO to SAHA.  SAHA can cause growth arrest and death of a broad variety of transformed cells both in vitro and in tumor-bearing animals at concns. not toxic to normal cells.  SAHA has many protein targets whose structure and function are altered by acetylation, including chromatin-assocd. histones, nonhistone gene transcription factors and proteins involved in regulation of cell proliferation, migration and death.  In clin. trials, SAHA has shown significant anticancer activity against both hematol. and solid tumors at doses well tolerated by patients.  A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma.  More potent analogs of SAHA have shown unacceptable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK3endE54rQ7Vg90H21EOLACvtfcHk0lgZqSeANtAGEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D&md5=cc2a39d80d5d5bea0a1377bdf48a957d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnbt1272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1272%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26atitle%3DDimethyl%2520sulfoxide%2520to%2520vorinostat%253A%2520development%2520of%2520this%2520histone%2520deacetylase%2520inhibitor%2520as%2520an%2520anticancer%2520drug%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D84%26epage%3D90%26doi%3D10.1038%2Fnbt1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawk, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span> <span> </span><span class="NLM_article-title">Statins and cancer--beyond the âone drug, one diseaseâ model</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">2238</span>â <span class="NLM_lpage">2239</span>, <span class="refDoi">Â DOI: 10.1056/NEJMe058074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1056%2FNEJMe058074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15917390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFOltrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=2238-2239&author=E.+Hawkauthor=J.+L.+Viner&title=Statins+and+cancer%2D%2Dbeyond+the+%E2%80%9Cone+drug%2C+one+disease%E2%80%9D+model&doi=10.1056%2FNEJMe058074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Statins and cancer - beyond the "one drug, one disease" model</span></div><div class="casAuthors">Hawk, Ernest; Viner, Jaye L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2238-2239</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp06htVsp0AYLVg90H21EOLACvtfcHk0lgZqSeANtAGEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFOltrw%253D&md5=464f54c85ef32f740839de5baa9c6f68</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1056%2FNEJMe058074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe058074%26sid%3Dliteratum%253Aachs%26aulast%3DHawk%26aufirst%3DE.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26atitle%3DStatins%2520and%2520cancer--beyond%2520the%2520%25E2%2580%259Cone%2520drug%252C%2520one%2520disease%25E2%2580%259D%2520model%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D2238%26epage%3D2239%26doi%3D10.1056%2FNEJMe058074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Istvan, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deisenhofer, J.</span></span> <span> </span><span class="NLM_article-title">Structural mechanism for statin inhibition of HMG-CoA reductase</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">1160</span>â <span class="NLM_lpage">1164</span>, <span class="refDoi">Â DOI: 10.1126/science.1059344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1126%2Fscience.1059344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=11349148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjs1Cgtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2001&pages=1160-1164&author=E.+S.+Istvanauthor=J.+Deisenhofer&title=Structural+mechanism+for+statin+inhibition+of+HMG-CoA+reductase&doi=10.1126%2Fscience.1059344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for statin inhibition of HMG-CoA reductase</span></div><div class="casAuthors">Istvan, Eva S.; Deisenhofer, Johann</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">5519</span>),
    <span class="NLM_cas:pages">1160-1164</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase (HMGR) catalyzes the committed step in cholesterol biosynthesis.  Statins are HMGR inhibitors with inhibition const. values in the nanomolar range that effectively lower serum cholesterol levels and are widely prescribed in the treatment of hypercholesterolemia.  We have detd. structures of the catalytic portion of human HMGR complexed with six different statins.  The statins occupy a portion of the binding site of HMG-CoA, thus blocking access of this substrate to the active site.  Near the carboxyl terminus of HMGR, several catalytically relevant residues are disordered in the enzyme-statin complexes.  If these residues were not flexible, they would sterically hinder statin binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDsSOnK9675bVg90H21EOLACvtfcHk0lhStM-IrUuFGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjs1Cgtbo%253D&md5=235644ee8cca3d2e061093e93bd1d702</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1126%2Fscience.1059344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1059344%26sid%3Dliteratum%253Aachs%26aulast%3DIstvan%26aufirst%3DE.%2BS.%26aulast%3DDeisenhofer%26aufirst%3DJ.%26atitle%3DStructural%2520mechanism%2520for%2520statin%2520inhibition%2520of%2520HMG-CoA%2520reductase%26jtitle%3DScience%26date%3D2001%26volume%3D292%26spage%3D1160%26epage%3D1164%26doi%3D10.1126%2Fscience.1059344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span> <span> </span><span class="NLM_article-title">Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2375</span>â <span class="NLM_lpage">2383</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-07-5807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1158%2F0008-5472.CAN-07-5807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=18381445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktV2jsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=2375-2383&author=Y.+Linauthor=J.+Linauthor=C.+Chouauthor=Y.+Changauthor=S.+Yehauthor=C.+Chen&title=Statins+increase+p21+through+inhibition+of+histone+deacetylase+activity+and+release+of+promoter-associated+HDAC1%2F2&doi=10.1158%2F0008-5472.CAN-07-5807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Statins Increase p21 through Inhibition of Histone Deacetylase Activity and Release of Promoter-Associated HDAC1/2</span></div><div class="casAuthors">Lin, Yi-Chu; Lin, Jung-Hsin; Chou, Chia-Wei; Chang, Yu-Fan; Yeh, Shu-Hao; Chen, Ching-Chow</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2375-2383</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Statins are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors broadly used for the control of hypercholesterolemia.  Recently, they are reported to have beneficial effects on certain cancers.  In this study, we show that statins inhibited the histone deacetylase (HDAC) activity and increased the accumulation of acetylated histone-H3 and the expression of p21WAF/CIP in human cancer cells.  Computational modeling showed the direct interaction of the carboxylic acid moiety of statins with the catalytic site of HDAC2.  In the subsequent enzymic assay, it was shown that lovastatin inhibited HDAC2 activity competitively with a Ki value of 31.6 Î¼mol/L.  Sp1 but not p53 sites were the statins-responsive element shown by p21 luciferase-promoter assays.  DNA affinity protein binding assay and chromatin immunopptn. assay showed the dissocn. of HDAC1/2 and assocn. of CBP, leading to the histone-H3 acetylation on the Sp1 sites of p21 promoter.  In vitro cell proliferation and in vivo tumor growth were both inhibited by statins.  These results suggest a novel mechanism for statins through abrogation of the HDAC activity and promoter histone-H3 acetylation to regulate p21 expression.  Therefore, statins might serve as novel HDAC inhibitors for cancer therapy and chemoprevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWO3elyAbZFLVg90H21EOLACvtfcHk0lhStM-IrUuFGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktV2jsrk%253D&md5=2a8cfc0aa492b742d2c00cd695710030</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-5807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-5807%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DStatins%2520increase%2520p21%2520through%2520inhibition%2520of%2520histone%2520deacetylase%2520activity%2520and%2520release%2520of%2520promoter-associated%2520HDAC1%252F2%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D2375%26epage%3D2383%26doi%3D10.1158%2F0008-5472.CAN-07-5807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villar-Garea, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteller, M.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: understanding a new wave of anticancer agents</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">171</span>â <span class="NLM_lpage">178</span>, <span class="refDoi">Â DOI: 10.1002/ijc.20372</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1002%2Fijc.20372" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15352027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvVejs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2004&pages=171-178&author=A.+Villar-Gareaauthor=M.+Esteller&title=Histone+deacetylase+inhibitors%3A+understanding+a+new+wave+of+anticancer+agents&doi=10.1002%2Fijc.20372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: Understanding a new wave of anticancer agents</span></div><div class="casAuthors">Villar-Garea, Ana; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-178</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Cancer is as much an epigenetic disease as it is a genetic and cytogenetic disease.  The discovery that drastic changes in DNA methylation and histone modifications are commonly found in human tumors has inspired various labs. and pharmaceutical companies to develop and study epigenetic drugs.  One of the most promising groups of agents is the inhibitors of histone deacetylases (HDACs), which have different biochem. and biol. properties but have a single common activity: induction of acetylation in histones, the key proteins in nucleosome and chromatin structure.  One of the main mechanisms of action of HDAC inhibitors is the transcriptional reactivation of dormant tumor-suppressor genes, such as p21WAF1.  However, their pleiotropic nature leaves open the possibility that their well-known differentiation, cell-cycle arrest and apoptotic properties are also involved in other functions assocd. with HDAC inhibition.  Many phase I clin. trials indicate that HDAC inhibitors appear to be well-tolerated drugs.  Thus, the field is ready for rigorous biol. and clin. scrutiny to validate the therapeutic potential of these drugs.  Our current data indicate that the use of HDAC inhibitors, probably in assocn. with classical chemotherapy drugs or in combination with DNA-demethylating agents, could be promising for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrobWV6s_G7N7Vg90H21EOLACvtfcHk0lj9ZR-RPnVE4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvVejs70%253D&md5=e30161130cd0bee731ca196a2a635da1</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fijc.20372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.20372%26sid%3Dliteratum%253Aachs%26aulast%3DVillar-Garea%26aufirst%3DA.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520understanding%2520a%2520new%2520wave%2520of%2520anticancer%2520agents%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2004%26volume%3D112%26spage%3D171%26epage%3D178%26doi%3D10.1002%2Fijc.20372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanim, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gommersall, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalvo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peehl, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M. J.</span></span> <span> </span><span class="NLM_article-title">Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6712</span>â <span class="NLM_lpage">6725</span>, <span class="refDoi">Â DOI: 10.1038/sj.onc.1207772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fsj.onc.1207772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15300237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFGnu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=6712-6725&author=F.+L.+Khanimauthor=L.+M.+Gommersallauthor=V.+H.+Woodauthor=K.+L.+Smithauthor=L.+Montalvoauthor=L.+P.+O%E2%80%99Neillauthor=Y.+Xuauthor=D.+M.+Peehlauthor=P.+M.+Stewartauthor=B.+M.+Turnerauthor=M.+J.+Campbell&title=Altered+SMRT+levels+disrupt+vitamin+D3+receptor+signalling+in+prostate+cancer+cells&doi=10.1038%2Fsj.onc.1207772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells</span></div><div class="casAuthors">Khanim, Farhat L.; Gommersall, Lyndon M.; Wood, Victoria H. J.; Smith, Kirsty L.; Montalvo, Leire; O'Neill, Laura P.; Xu, Yue; Peehl, Donna M.; Stewart, Paul M.; Turner, Bryan M.; Campbell, Moray J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">6712-6725</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We hypothesized that key antiproliferative target genes for the vitamin D receptor (VDR) were repressed by an epigenetic mechanism in prostate cancer cells resulting in apparent hormonal insensitivity.  To explore this possibility, we examd. nuclear receptor corepressor expression in a panel of nonmalignant and malignant cell lines and primary cultures, and found frequently elevated SMRT corepressor mRNA expression often assocd. with reduced sensitivity to 1Î±,25-dihydroxyvitamin D3 (1Î±,25(OH)2D3).  For example, PC-3 and DU-145 prostate cancer cell lines had 1.8-fold and twofold increases in SMRT mRNA relative to normal PrEC cells (P<0.05).  Similarly, 10/15 primary tumor cultures (including three matched to normal cells from the same donors) had elevated SMRT mRNA levels; generally NCoR1 and Alien were not as commonly elevated.  Corepressor proteins often have assocd. histone deacetylases (HDAC) and reflectively the antiproliferative action of 1Î±,25(OH)2D3 can be 'restored' by cotreatment with low doses of HDAC inhibitors such as trichostatin A (TSA, 15 nM) to induce apoptosis in prostate cancer cell lines.  To decipher the transcriptional events that lead to these cellular responses, we undertook gene expression studies in PC-3 cells after cotreatment of 1Î±,25(OH)2D3 plus TSA after 6 h.  Examn. of known VDR target genes and cDNA microarray analyses revealed cotreatment of 1Î±,25(OH)2D3 plus TSA cooperatively upregulated eight (out of 1176) genes, including MAPK-APK2 and GADD45Î±.  MRNA and protein time courses and inhibitor studies confirmed these patterns of regulation.  Subsequently, we knocked down SMRT levels in PC-3 cells using a small interfering RNA (siRNA) approach and found that GADD45Î± induction by 1Î±,25(OH)2D3 alone became very significantly enhanced.  The same distortion of gene responsiveness, with repressed induction of GADD45Î± was found in primary tumor cultures compared and to matched peripheral zone (normal) cultures from the same donor.  These data demonstrate that elevated SMRT levels are common in prostate cancer cells, resulting in suppression of target genes assocd. with antiproliferative action and apparent 1Î±,25(OH)2D3-insensitivity.  This can be targeted therapeutically by combination treatments with HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9l8XsE78U77Vg90H21EOLACvtfcHk0lj9ZR-RPnVE4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFGnu74%253D&md5=2dcf1e06322b812483950d388c1a4dec</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207772%26sid%3Dliteratum%253Aachs%26aulast%3DKhanim%26aufirst%3DF.%2BL.%26aulast%3DGommersall%26aufirst%3DL.%2BM.%26aulast%3DWood%26aufirst%3DV.%2BH.%26aulast%3DSmith%26aufirst%3DK.%2BL.%26aulast%3DMontalvo%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%2BP.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DPeehl%26aufirst%3DD.%2BM.%26aulast%3DStewart%26aufirst%3DP.%2BM.%26aulast%3DTurner%26aufirst%3DB.%2BM.%26aulast%3DCampbell%26aufirst%3DM.%2BJ.%26atitle%3DAltered%2520SMRT%2520levels%2520disrupt%2520vitamin%2520D3%2520receptor%2520signalling%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D6712%26epage%3D6725%26doi%3D10.1038%2Fsj.onc.1207772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span> <span> </span><span class="NLM_article-title">Promise of vitamin D analogues in the treatment of hyperproliferative conditions</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">797</span>â <span class="NLM_lpage">808</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-05-0539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1158%2F1535-7163.MCT-05-0539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=16648549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFCksb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=797-808&author=S.+Masudaauthor=G.+Jones&title=Promise+of+vitamin+D+analogues+in+the+treatment+of+hyperproliferative+conditions&doi=10.1158%2F1535-7163.MCT-05-0539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Promise of vitamin D analogs in the treatment of hyperproliferative conditions</span></div><div class="casAuthors">Masuda, Sonoko; Jones, Glenville</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">797-808</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  1Î±,25-Dihydroxyvitamin D3 [1Î±,25-(OH)2D3; calcitriol] is best known as a hormone involved in calcium homeostasis but is also a potent antiproliferative agent in many cell types, particularly epithelial cells.  1Î±,25(OH)2D3 mediates its actions through a classic steroid hormone-like transcriptional mechanism by influencing the expression of hundreds of genes.  Effects of 1Î±,25(OH)2D3 have been obsd. on the expression of cell cycle regulators, growth factors and their receptors, apoptotic machinery, metastatic potential, and angiogenesis; all of which have some effect on hyperproliferative conditions.  This minireview focuses on the anticancer potential of 1Î±,25(OH)2D3 and its analogs by summarizing the promising data from animal and human trials of 1Î±,25(OH)2D3 and some of the more interesting synthetic vitamin D analogs in the treatment of a variety of different animal cancer models and in human patients with advanced cancer.  Optimal administration of vitamin D analogs is only just being achieved with high-dose intermittent administration overcoming bioavailability and hypercalcemia problems and combination therapy with cytotoxic agents (taxols and cisplatins), antiresorptive agents (bisphosphonates), or cytochrome P 450 inhibitors being attempted.  Although the potential of vitamin D as an antiproliferative drug has been realized in the treatment of psoriasis and in parathyroid cell hyperplasia assocd. with secondary hyperparathyroidism, the search for an anticancer treatment incorporating a vitamin D analog remains elusive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovCSrw9h-W57Vg90H21EOLACvtfcHk0lhTq9Yxjyepng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFCksb8%253D&md5=80a25e1feb2d3f2e6d591f12ebb656b8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0539%26sid%3Dliteratum%253Aachs%26aulast%3DMasuda%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DG.%26atitle%3DPromise%2520of%2520vitamin%2520D%2520analogues%2520in%2520the%2520treatment%2520of%2520hyperproliferative%2520conditions%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D797%26epage%3D808%26doi%3D10.1158%2F1535-7163.MCT-05-0539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanim, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gommersall, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, V. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalvo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peehl, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M. J.</span></span> <span> </span><span class="NLM_article-title">Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6712</span>â <span class="NLM_lpage">6725</span>, <span class="refDoi">Â DOI: 10.1038/sj.onc.1207772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fsj.onc.1207772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15300237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFGnu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=6712-6725&author=F.+L.+Khanimauthor=L.+M.+Gommersallauthor=V.+H.+J.+Woodauthor=K.+L.+Smithauthor=L.+Montalvoauthor=L.+P.+O%E2%80%99Neillauthor=Y.+Xuauthor=D.+M.+Peehlauthor=P.+M.+Stewartauthor=B.+M.+Turnerauthor=M.+J.+Campbell&title=Altered+SMRT+levels+disrupt+vitamin+D3+receptor+signalling+in+prostate+cancer+cells&doi=10.1038%2Fsj.onc.1207772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells</span></div><div class="casAuthors">Khanim, Farhat L.; Gommersall, Lyndon M.; Wood, Victoria H. J.; Smith, Kirsty L.; Montalvo, Leire; O'Neill, Laura P.; Xu, Yue; Peehl, Donna M.; Stewart, Paul M.; Turner, Bryan M.; Campbell, Moray J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">6712-6725</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We hypothesized that key antiproliferative target genes for the vitamin D receptor (VDR) were repressed by an epigenetic mechanism in prostate cancer cells resulting in apparent hormonal insensitivity.  To explore this possibility, we examd. nuclear receptor corepressor expression in a panel of nonmalignant and malignant cell lines and primary cultures, and found frequently elevated SMRT corepressor mRNA expression often assocd. with reduced sensitivity to 1Î±,25-dihydroxyvitamin D3 (1Î±,25(OH)2D3).  For example, PC-3 and DU-145 prostate cancer cell lines had 1.8-fold and twofold increases in SMRT mRNA relative to normal PrEC cells (P<0.05).  Similarly, 10/15 primary tumor cultures (including three matched to normal cells from the same donors) had elevated SMRT mRNA levels; generally NCoR1 and Alien were not as commonly elevated.  Corepressor proteins often have assocd. histone deacetylases (HDAC) and reflectively the antiproliferative action of 1Î±,25(OH)2D3 can be 'restored' by cotreatment with low doses of HDAC inhibitors such as trichostatin A (TSA, 15 nM) to induce apoptosis in prostate cancer cell lines.  To decipher the transcriptional events that lead to these cellular responses, we undertook gene expression studies in PC-3 cells after cotreatment of 1Î±,25(OH)2D3 plus TSA after 6 h.  Examn. of known VDR target genes and cDNA microarray analyses revealed cotreatment of 1Î±,25(OH)2D3 plus TSA cooperatively upregulated eight (out of 1176) genes, including MAPK-APK2 and GADD45Î±.  MRNA and protein time courses and inhibitor studies confirmed these patterns of regulation.  Subsequently, we knocked down SMRT levels in PC-3 cells using a small interfering RNA (siRNA) approach and found that GADD45Î± induction by 1Î±,25(OH)2D3 alone became very significantly enhanced.  The same distortion of gene responsiveness, with repressed induction of GADD45Î± was found in primary tumor cultures compared and to matched peripheral zone (normal) cultures from the same donor.  These data demonstrate that elevated SMRT levels are common in prostate cancer cells, resulting in suppression of target genes assocd. with antiproliferative action and apparent 1Î±,25(OH)2D3-insensitivity.  This can be targeted therapeutically by combination treatments with HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9l8XsE78U77Vg90H21EOLACvtfcHk0lhTq9Yxjyepng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFGnu74%253D&md5=2dcf1e06322b812483950d388c1a4dec</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207772%26sid%3Dliteratum%253Aachs%26aulast%3DKhanim%26aufirst%3DF.%2BL.%26aulast%3DGommersall%26aufirst%3DL.%2BM.%26aulast%3DWood%26aufirst%3DV.%2BH.%2BJ.%26aulast%3DSmith%26aufirst%3DK.%2BL.%26aulast%3DMontalvo%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%2BP.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DPeehl%26aufirst%3DD.%2BM.%26aulast%3DStewart%26aufirst%3DP.%2BM.%26aulast%3DTurner%26aufirst%3DB.%2BM.%26aulast%3DCampbell%26aufirst%3DM.%2BJ.%26atitle%3DAltered%2520SMRT%2520levels%2520disrupt%2520vitamin%2520D3%2520receptor%2520signalling%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D6712%26epage%3D6725%26doi%3D10.1038%2Fsj.onc.1207772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tocchini-Valentini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurtz, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moras, D.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1956</span>â <span class="NLM_lpage">1961</span>, <span class="refDoi">Â DOI: 10.1021/jm0310582</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0310582" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitValsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1956-1961&author=G.+Tocchini-Valentiniauthor=N.+Rochelauthor=J.+M.+Wurtzauthor=D.+Moras&title=Crystal+structures+of+the+vitamin+D+nuclear+receptor+liganded+with+the+vitamin+D+side+chain+analogues+calcipotriol+and+seocalcitol%2C+receptor+agonists+of+clinical+importance.+Insights+into+a+structural+basis+for+the+switching+of+calcipotriol+to+a+receptor+antagonist+by+further+side+chain+modification&doi=10.1021%2Fjm0310582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of the Vitamin D Nuclear Receptor Liganded with the Vitamin D Side Chain Analogues Calcipotriol and Seocalcitol, Receptor Agonists of Clinical Importance. Insights into a Structural Basis for the Switching of Calcipotriol to a Receptor Antagonist by Further Side Chain Modification</span></div><div class="casAuthors">Tocchini-Valentini, Giuseppe; Rochel, Natacha; Wurtz, Jean-Marie; Moras, Dino</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1956-1961</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The plethora of actions of 1Î±,25(OH)2D3 in various systems suggested wide clin. applications of vitamin D nuclear receptor (VDR) ligands in treatments of inflammation, dermatol. indication, osteoporosis, cancers, and autoimmune diseases.  More than 3000 vitamin D analogs have been synthesized in order to reduce the calcemic side effects while maintaining the transactivation potency of these ligands.  Here, we report the crystal structures of VDR ligand binding domain bound to two vitamin D agonists of therapeutical interest, calcipotriol and seocalcitol, which are characterized by their side chain modifications.  These structures show the conservation of the VDR structure and the adaptation of the side chain anchored by hydroxyl moieties.  The structure of VDR-calcipotriol helps us to understand the structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification.  The VDR-seocalcitol structure, in comparison with the structure of VDR-KH1060, a superagonist ligand closely related to seocalcitol, shows adaptation of the D ring and position of C-21 in order to adapt its more rigid side chain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPCp9Utnz2tbVg90H21EOLACvtfcHk0lhqj2DRStlKTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitValsLk%253D&md5=8a30a7bfca5475f48e2a1583915ec494</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm0310582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0310582%26sid%3Dliteratum%253Aachs%26aulast%3DTocchini-Valentini%26aufirst%3DG.%26aulast%3DRochel%26aufirst%3DN.%26aulast%3DWurtz%26aufirst%3DJ.%2BM.%26aulast%3DMoras%26aufirst%3DD.%26atitle%3DCrystal%2520structures%2520of%2520the%2520vitamin%2520D%2520nuclear%2520receptor%2520liganded%2520with%2520the%2520vitamin%2520D%2520side%2520chain%2520analogues%2520calcipotriol%2520and%2520seocalcitol%252C%2520receptor%2520agonists%2520of%2520clinical%2520importance.%2520Insights%2520into%2520a%2520structural%2520basis%2520for%2520the%2520switching%2520of%2520calcipotriol%2520to%2520a%2520receptor%2520antagonist%2520by%2520further%2520side%2520chain%2520modification%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1956%26epage%3D1961%26doi%3D10.1021%2Fjm0310582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sham, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">6-Benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV reverse transcriptase and integrase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2400</span>â <span class="NLM_lpage">2402</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2011.02.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmcl.2011.02.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=21392991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt12ku7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2400-2402&author=J.+Tangauthor=K.+Maddaliauthor=C.+D.+Dreisauthor=Y.+Y.+Shamauthor=R.+Vinceauthor=Y.+Pommierauthor=Z.+Wang&title=6-Benzoyl-3-hydroxypyrimidine-2%2C4-diones+as+dual+inhibitors+of+HIV+reverse+transcriptase+and+integrase&doi=10.1016%2Fj.bmcl.2011.02.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">6-Benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV reverse transcriptase and integrase</span></div><div class="casAuthors">Tang, Jing; Maddali, Kasthuraiah; Dreis, Christine D.; Sham, Yuk Y.; Vince, Robert; Pommier, Yves; Wang, Zhengqiang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2400-2402</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">N-3-Hydroxylation of pyrimidine-2,4-diones was recently found to yield inhibitors of both HIV-1 reverse transcriptase (RT) and integrase (IN).  An extended series of analogs featuring a benzoyl group at the C-6 position of the pyrimidine ring was synthesized.  Through biochem. studies it was found that these new analogs are dually active against both RT and IN in low micromolar range.  Antiviral assays confirmed that these new inhibitors are active against HIV-1 in cell culture at nanomolar to low micromolar range, further validating 3-hydroxypyrimidine-2,4-diones as a viable scaffold for antiviral development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsIm-OLOGzF7Vg90H21EOLACvtfcHk0lhqj2DRStlKTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt12ku7w%253D&md5=bcbbf988ce7835a8c6fcdf43241dc24e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.02.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.02.069%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DMaddali%26aufirst%3DK.%26aulast%3DDreis%26aufirst%3DC.%2BD.%26aulast%3DSham%26aufirst%3DY.%2BY.%26aulast%3DVince%26aufirst%3DR.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3D6-Benzoyl-3-hydroxypyrimidine-2%252C4-diones%2520as%2520dual%2520inhibitors%2520of%2520HIV%2520reverse%2520transcriptase%2520and%2520integrase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2400%26epage%3D2402%26doi%3D10.1016%2Fj.bmcl.2011.02.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esnouf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willcox, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span> <span> </span><span class="NLM_article-title">Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1589</span>â <span class="NLM_lpage">1600</span>, <span class="refDoi">Â DOI: 10.1021/jm960056x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960056x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK28XhslGqsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=1589-1600&author=A.+L.+Hopkinsauthor=J.+Renauthor=R.+M.+Esnoufauthor=B.+E.+Willcoxauthor=E.+Y.+Jonesauthor=C.+Rossauthor=T.+Miyasakaauthor=R.+T.+Walkerauthor=H.+Tanakaauthor=D.+K.+Stammers&title=Complexes+of+HIV-1+reverse+transcriptase+with+inhibitors+of+the+HEPT+series+reveal+conformational+changes+relevant+to+the+design+of+potent+non-nucleoside+inhibitors&doi=10.1021%2Fjm960056x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside Inhibitors</span></div><div class="casAuthors">Hopkins, Andrew L.; Ren, Jingshan; Esnouf, Robert M.; Willcox, Benjamin E.; Jones, E. Yvonne; Ross, Carl; Miyasaka, Tadashi; Walker, Richard T.; Tanaka, Hiromichi; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1589-600</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Crystal structures of HIV-1 reverse transcriptase (RT) complexed with a range of chem. diverse non-nucleoside inhibitors (NNIs) have shown a single pocket in which the inhibitors bind and details of the inhibitor-protein interactions.  To delineate the structural requirements for an effective inhibitor, the authors have detd. the structures of three closely related NNIs which vary widely in their potencies.  Crystal structures of HIV-1 RT complexed with two very potent inhibitors, MKC-442 and TNK-651, at 2.55 Ã resoln. complement the authors previous anal. of the complex with the less effective inhibitor, HEPT.  These structures reveal conformational changes which correlate with changes in potency.  The authors suggest that a major determinant of increased potency in the analogs of HEPT is an improved interaction between residue Tyr181 in the protein and the 6-benzyl ring of the inhibitors which stabilizes the structure of the complex.  This arises through a conformational switching of the protein structure triggered by the steric bulk of the 5-substituent of the inhibitor pyrimidine ring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1BU3pXNwf67Vg90H21EOLACvtfcHk0liYNA1FkjuUXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhslGqsrc%253D&md5=a279a5fe9e82e231f0e898c3dff5bb66</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm960056x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960056x%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DEsnouf%26aufirst%3DR.%2BM.%26aulast%3DWillcox%26aufirst%3DB.%2BE.%26aulast%3DJones%26aufirst%3DE.%2BY.%26aulast%3DRoss%26aufirst%3DC.%26aulast%3DMiyasaka%26aufirst%3DT.%26aulast%3DWalker%26aufirst%3DR.%2BT.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26atitle%3DComplexes%2520of%2520HIV-1%2520reverse%2520transcriptase%2520with%2520inhibitors%2520of%2520the%2520HEPT%2520series%2520reveal%2520conformational%2520changes%2520relevant%2520to%2520the%2520design%2520of%2520potent%2520non-nucleoside%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D1589%26epage%3D1600%26doi%3D10.1021%2Fjm960056x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grobler, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillmock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felock, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espeseth, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egbertson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourgeois, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melamed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span> <span> </span><span class="NLM_article-title">Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">6661</span>â <span class="NLM_lpage">6666</span>, <span class="refDoi">Â DOI: 10.1073/pnas.092056199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1073%2Fpnas.092056199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=11997448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFCrs78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=6661-6666&author=J.+A.+Groblerauthor=K.+Stillmockauthor=B.+Huauthor=M.+Witmerauthor=P.+Felockauthor=A.+S.+Espesethauthor=A.+Wolfeauthor=M.+Egbertsonauthor=M.+Bourgeoisauthor=J.+Melamedauthor=J.+S.+Waiauthor=S.+Youngauthor=J.+Vaccaauthor=D.+J.+Hazuda&title=Diketo+acid+inhibitor+mechanism+and+HIV-1+integrase%3A+implications+for+metal+binding+in+the+active+site+of+phosphotransferase+enzymes&doi=10.1073%2Fpnas.092056199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes</span></div><div class="casAuthors">Grobler, Jay A.; Stillmock, Kara; Hu, Binghua; Witmer, Marc; Felock, Peter; Espeseth, Amy S.; Wolfe, Abigail; Egbertson, Melissa; Bourgeois, Michele; Melamed, Jeffrey; Wai, John S.; Young, Steve; Vacca, Joseph; Hazuda, Daria J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6661-6666</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The process of integrating the reverse-transcribed HIV-1 DNA into the host chromosomal DNA is catalyzed by the virally encoded enzyme integrase (IN).  Integration requires two metal-dependent reactions, 3' end processing and strand transfer.  Compds. that contain a diketo acid moiety have been shown to selectively inhibit the strand transfer reaction of IN in vitro and in infected cells and are effective as inhibitors of HIV-1 replication.  To characterize the mol. basis of inhibition, we used functional assays and binding assays to evaluate a series of structurally related analogs.  These studies focused on investigating the role of the conserved carboxylate and metal binding.  We demonstrate that an acidic moiety such as a carboxylate or isosteric heterocycle is not required for binding to the enzyme complex but is essential for inhibition and confers distinct metal-dependent properties on the inhibitor.  Binding requires divalent metal and resistance is metal dependent with active site mutants displaying resistance only when the enzymes are evaluated in the context of Mg2+.  The mechanism of action of these inhibitors is therefore likely a consequence of the interaction between the acid moiety and metal ion(s) in the IN active site, resulting in a functional sequestration of the crit. metal cofactor(s).  These studies thus have implications for modeling active site inhibitors of IN, designing and evaluating analogs with improved efficacy, and identifying inhibitors of other metal-dependent phosphotransferases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkSyCLCLHKbrVg90H21EOLACvtfcHk0liYNA1FkjuUXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFCrs78%253D&md5=a5d2ccbecd621eaeb1901416e5154fc1</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1073%2Fpnas.092056199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.092056199%26sid%3Dliteratum%253Aachs%26aulast%3DGrobler%26aufirst%3DJ.%2BA.%26aulast%3DStillmock%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DWitmer%26aufirst%3DM.%26aulast%3DFelock%26aufirst%3DP.%26aulast%3DEspeseth%26aufirst%3DA.%2BS.%26aulast%3DWolfe%26aufirst%3DA.%26aulast%3DEgbertson%26aufirst%3DM.%26aulast%3DBourgeois%26aufirst%3DM.%26aulast%3DMelamed%26aufirst%3DJ.%26aulast%3DWai%26aufirst%3DJ.%2BS.%26aulast%3DYoung%26aufirst%3DS.%26aulast%3DVacca%26aufirst%3DJ.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26atitle%3DDiketo%2520acid%2520inhibitor%2520mechanism%2520and%2520HIV-1%2520integrase%253A%2520implications%2520for%2520metal%2520binding%2520in%2520the%2520active%2520site%2520of%2520phosphotransferase%2520enzymes%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D6661%26epage%3D6666%26doi%3D10.1073%2Fpnas.092056199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratanasuwan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prada, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Ramirez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crumpacker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilde, L.</span></span> <span> </span><span class="NLM_article-title">Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">125</span>â <span class="NLM_lpage">133</span>, <span class="refDoi">Â DOI: 10.1097/QAI.0b013e318157131c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1097%2FQAI.0b013e318157131c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=17721395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVOktbfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=125-133&author=M.+Markowitzauthor=B.+E.+Nguyenauthor=F.+Mendoauthor=W.+Ratanasuwanauthor=C.+Kovacsauthor=G.+Pradaauthor=J.+Morales-Ramirezauthor=C.+Crumpackerauthor=R.+Isaacsauthor=L.+Gilde&title=Rapid+and+durable+antiretroviral+effect+of+the+HIV-1+Integrase+inhibitor+raltegravir+as+part+of+combination+therapy+in+treatment-naive+patients+with+HIV-1+infection%3A+results+of+a+48-week+controlled+study&doi=10.1097%2FQAI.0b013e318157131c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study</span></div><div class="casAuthors">Markowitz, Martin; Nguyen, Bach-Yen; Gotuzzo, Eduardo; Mendo, Fernando; Ratanasuwan, Winai; Kovacs, Colin; Prada, Guillermo; Morales-Ramirez, Javier O.; Crumpacker, Clyde S.; Isaacs, Robin D.; Gilde, Lucinda R.; Wan, Hong; Miller, Michael D.; Wenning, Larissa A.; Teppler, Hedy</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-133</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>;
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Raltegravir is an HIV-1 integrase strand-transfer inhibitor with potent in vitro activity.  This study explored the antiretroviral activity and safety of raltegravir in treatment-naive patients with plasma HIV-1 RNA levels â¥5000 copies/mL and CD4 T-cell counts â¥100 cells/mm.  Methods: Multicenter, double-blind, randomized, controlled study of raltegravir at doses of 100, 200, 400, and 600 mg twice daily vs. efavirenz at a dose of 600 mg/d, all in combination with tenofovir at a dose of 300 mg/d and lamivudine at a dose of 300 mg/d (clinicaltrials.gov identifier: NCT00100048).  Results: In the 198 patients treated (160 on raltegravir and 38 on efavirenz), the mean HIV-1 RNA level ranged from 4.6 to 4.8 log10 copies/mL at baseline.  At weeks 2, 4, and 8, the proportion of patients achieving an HIV-1 RNA level <50 copies/mL was greater in each of the raltegravir treatment groups than in the efavirenz group.  By week 24, all treatment groups appeared similar, with plasma HIV-1 RNA levels <400 copies/mL in 85% to 98% of patients and <50 copies/mL in 85% to 95% of patients.  These redns. were maintained through week 48 in 85% to 98% of patients and in 83% to 88% of patients, resp.  Five (3%) patients on raltegravir and 1 (3%) on efavirenz experienced virol. failure before week 48.  Drug-related clin. adverse events were less common with raltegravir than with efavirenz.  After 24 and 48 wk of treatment, raltegravir did not result in increased serum levels of total cholesterol, low-d. lipoprotein cholesterol, or triglycerides.  Conclusions: Raltegravir at all doses studied was generally well tolerated in combination with tenofovir and lamivudine.  Raltegravir exhibited potent and durable antiretroviral activity similar to that of efavirenz at 24 and 48 wk but achieved HIV-1 RNA levels below detection at a more rapid rate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp70m84QdKjhLVg90H21EOLACvtfcHk0ljiGlcYZFSEqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVOktbfL&md5=cf4286357ea0f2daa2c7d7b919d56a21</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1097%2FQAI.0b013e318157131c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAI.0b013e318157131c%26sid%3Dliteratum%253Aachs%26aulast%3DMarkowitz%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DB.%2BE.%26aulast%3DMendo%26aufirst%3DF.%26aulast%3DRatanasuwan%26aufirst%3DW.%26aulast%3DKovacs%26aufirst%3DC.%26aulast%3DPrada%26aufirst%3DG.%26aulast%3DMorales-Ramirez%26aufirst%3DJ.%26aulast%3DCrumpacker%26aufirst%3DC.%26aulast%3DIsaacs%26aufirst%3DR.%26aulast%3DGilde%26aufirst%3DL.%26atitle%3DRapid%2520and%2520durable%2520antiretroviral%2520effect%2520of%2520the%2520HIV-1%2520Integrase%2520inhibitor%2520raltegravir%2520as%2520part%2520of%2520combination%2520therapy%2520in%2520treatment-naive%2520patients%2520with%2520HIV-1%2520infection%253A%2520results%2520of%2520a%252048-week%2520controlled%2520study%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2007%26volume%3D46%26spage%3D125%26epage%3D133%26doi%3D10.1097%2FQAI.0b013e318157131c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolly, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linghang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guare, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egbertson, M. S.</span></span> <span> </span><span class="NLM_article-title">A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">11233</span>â <span class="NLM_lpage">11238</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0402357101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1073%2Fpnas.0402357101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15277684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVKgtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=11233-11238&author=D.+J.+Hazudaauthor=N.+J.+Anthonyauthor=R.+P.+Gomezauthor=S.+M.+Jollyauthor=J.+S.+Waiauthor=Z.+Linghangauthor=T.+E.+Fisherauthor=E.+Markauthor=J.+P.+Guareauthor=M.+S.+Egbertson&title=A+naphthyridine+carboxamide+provides+evidence+for+discordant+resistance+between+mechanistically+identical+inhibitors+of+HIV-1+integrase&doi=10.1073%2Fpnas.0402357101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase</span></div><div class="casAuthors">Hazuda, Daria J.; Anthony, Neville J.; Gomez, Robert P.; Jolly, Samson M.; Wai, John S.; Zhuang, Linghang; Fisher, Thorsten E.; Embrey, Mark; Guare, James P., Jr.; Egbertson, Melissa S.; Vacca, Joseph P.; Huff, Joel R.; Felock, Peter J.; Witmer, Marc V.; Stillmock, Kara A.; Danovich, Robert; Grobler, Jay; Miller, Michael D.; Espeseth, Amy S.; Jin, Lixia; Chen, I-Wu; Lin, Jiunn H.; Kassahun, Kelem; Ellis, Joan D.; Wong, Bradley K.; Xu, Wei; Pearson, Paul G.; Schleif, William A.; Cortese, Riccardo; Emini, Emilio; Summa, Vincenzo; Holloway, M. Katharine; Young, Steven D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">11233-11238</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The increasing incidence of resistance to current HIV-1 therapy underscores the need to develop antiretroviral agents with new mechanisms of action.  Integrase, one of three viral enzymes essential for HIV-1 replication, presents an important yet unexploited opportunity for drug development.  The authors describe here the identification and characterization of L-870,810, a small-mol. inhibitor of HIV-1 integrase with potent antiviral activity in cell culture and good pharmacokinetic properties.  L-870,810 is an inhibitor with an 8-hydroxy-(1,6)-naphthyridine-7-carboxamide pharmacophore.  The compd. inhibits HIV-1 integrase-mediated strand transfer, and its antiviral activity in vitro is a direct consequence of this ascribed effect on integration.  L-870,810 is mechanistically identical to previously described inhibitors from the diketo acid series; however, viruses selected for resistance to L-870,810 contain mutations (integrase residues 72, 121, and 125) that uniquely confer resistance to the naphthyridine.  Conversely, mutations assocd. with resistance to the diketo acid do not engender naphthyridine resistance.  Importantly, the mutations assocd. with resistance to each of these inhibitors map to distinct regions within the integrase active site.  Therefore, the authors propose a model of the two inhibitors that is consistent with this observation and suggests specific interactions with discrete binding sites for each ligand.  These studies provide a structural basis and rationale for developing integrase inhibitors with the potential for unique and nonoverlapping resistance profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRpHqKKxVFjLVg90H21EOLACvtfcHk0lj0_n4b20ErpA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVKgtrY%253D&md5=a94bedb2c16c751c5a9298708504fa4d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0402357101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0402357101%26sid%3Dliteratum%253Aachs%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DAnthony%26aufirst%3DN.%2BJ.%26aulast%3DGomez%26aufirst%3DR.%2BP.%26aulast%3DJolly%26aufirst%3DS.%2BM.%26aulast%3DWai%26aufirst%3DJ.%2BS.%26aulast%3DLinghang%26aufirst%3DZ.%26aulast%3DFisher%26aufirst%3DT.%2BE.%26aulast%3DMark%26aufirst%3DE.%26aulast%3DGuare%26aufirst%3DJ.%2BP.%26aulast%3DEgbertson%26aufirst%3DM.%2BS.%26atitle%3DA%2520naphthyridine%2520carboxamide%2520provides%2520evidence%2520for%2520discordant%2520resistance%2520between%2520mechanistically%2520identical%2520inhibitors%2520of%2520HIV-1%2520integrase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D11233%26epage%3D11238%26doi%3D10.1073%2Fpnas.0402357101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metifiot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sham, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2282</span>â <span class="NLM_lpage">2292</span>, <span class="refDoi">Â DOI: 10.1021/jm1014378</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1014378" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisl2qu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2282-2292&author=J.+Tangauthor=K.+Maddaliauthor=M.+Metifiotauthor=Y.+Y.+Shamauthor=R.+Vinceauthor=Y.+Pommierauthor=Z.+Wang&title=3-Hydroxypyrimidine-2%2C4-diones+as+an+inhibitor+scaffold+of+HIV+integrase&doi=10.1021%2Fjm1014378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">3-Hydroxypyrimidine-2,4-diones as an Inhibitor Scaffold of HIV Integrase</span></div><div class="casAuthors">Tang, Jing; Maddali, Kasthuraiah; Sham, Yuk Y.; Vince, Robert; Pommier, Yves; Wang, Zhengqiang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2282-2292</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Integrase (IN) represents a clin. validated target for the development of antivirals against human immunodeficiency virus (HIV).  Inhibitors with a novel structure core are essential for combating resistance assocd. with known IN inhibitors (INIs).  We have previously disclosed a novel dual inhibitor scaffold of HIV IN and reverse transcriptase (RT).  Here we report the complete structure-activity relationship (SAR), mol. modeling, and resistance profile of this inhibitor type on IN inhibition.  These studies support an antiviral mechanism of dual inhibition against both IN and RT and validate 3-hydroxypyrimidine-2,4-diones as an IN inhibitor scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBxF_3fkEp67Vg90H21EOLACvtfcHk0lj0_n4b20ErpA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisl2qu7Y%253D&md5=8b53b8997bd2623f3f17851dce6c2ed0</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm1014378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1014378%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DMaddali%26aufirst%3DK.%26aulast%3DMetifiot%26aufirst%3DM.%26aulast%3DSham%26aufirst%3DY.%2BY.%26aulast%3DVince%26aufirst%3DR.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3D3-Hydroxypyrimidine-2%252C4-diones%2520as%2520an%2520inhibitor%2520scaffold%2520of%2520HIV%2520integrase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2282%26epage%3D2292%26doi%3D10.1021%2Fjm1014378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4716</span>â <span class="NLM_lpage">4723</span>, <span class="refDoi">Â DOI: 10.1021/bi036189j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi036189j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Ols7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=4716-4723&author=G.+A.+Gomezauthor=C.+Morisseauauthor=B.+D.+Hammockauthor=D.+W.+Christianson&title=Structure+of+human+epoxide+hydrolase+reveals+mechanistic+inferences+on+bifunctional+catalysis+in+epoxide+and+phosphate+ester+hydrolysis&doi=10.1021%2Fbi036189j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis</span></div><div class="casAuthors">Gomez, German A.; Morisseau, Christophe; Hammock, Bruce D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4716-4723</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The x-ray crystal structure of human sol. epoxide hydrolase (sEH) was detd. at 2.6 Ã resoln., revealing a domain-swapped quaternary structure identical to that obsd. for the murine enzyme.  As with the murine enzyme, the epoxide hydrolytic mechanism of the human enzyme proceeded through an alkyl-enzyme intermediate with Asp-333 in the C-terminal domain.  The structure of human sEH complexed with the inhibitor, N-cyclohexyl-N'-(iodophenyl)urea (CIU), at 2.35 Ã resoln. was also detd.  Tyr-381 and Tyr-465 donated H-bonds to the alkylurea carbonyl group of CIU, consistent with the proposed roles of these residues as proton donors in the 1st step of catalysis.  The N-terminal domain of mammalian sEH contained a 15 Ã deep cleft, but its biol. function was unclear.  Recent expts. demonstrated that the N-terminal domain of human sEH catalyzes the metal-dependent hydrolysis of phosphate esters.  The binding of Mg2+-HPO42- to the N-terminal domain of human sEH in its CIU complex revealed structural features relevant to those of the enzyme-substrate complex in the phosphatase reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRgQ3Rx-U2trVg90H21EOLACvtfcHk0lj0_n4b20ErpA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Ols7g%253D&md5=c6cc1850d50daf2d1690c4024cb8d7bb</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fbi036189j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi036189j%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DG.%2BA.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructure%2520of%2520human%2520epoxide%2520hydrolase%2520reveals%2520mechanistic%2520inferences%2520on%2520bifunctional%2520catalysis%2520in%2520epoxide%2520and%2520phosphate%2520ester%2520hydrolysis%26jtitle%3DBiochemistry%26date%3D2004%26volume%3D43%26spage%3D4716%26epage%3D4723%26doi%3D10.1021%2Fbi036189j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eldrup, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soleymanzadeh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muegge, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrow, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKellop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukulka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lombaert, S.</span></span> <span> </span><span class="NLM_article-title">Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">5880</span>â <span class="NLM_lpage">5895</span>, <span class="refDoi">Â DOI: 10.1021/jm9005302</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9005302" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWqurvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5880-5895&author=A.+B.+Eldrupauthor=F.+Soleymanzadehauthor=S.+J.+Taylorauthor=I.+Mueggeauthor=N.+A.+Farrowauthor=D.+Josephauthor=K.+McKellopauthor=C.+C.+Manauthor=A.+Kukulkaauthor=S.+De+Lombaert&title=Structure-based+optimization+of+arylamides+as+inhibitors+of+soluble+epoxide+hydrolase&doi=10.1021%2Fjm9005302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Optimization of Arylamides as Inhibitors of Soluble Epoxide Hydrolase</span></div><div class="casAuthors">Eldrup, Anne B.; Soleymanzadeh, Fariba; Taylor, Steven J.; Muegge, Ingo; Farrow, Neil A.; Joseph, David; McKellop, Keith; Man, Chuk C.; Kukulka, Alison; De Lombaert, Stephane</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5880-5895</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Arylamides, particularly N-diarylethyl arylamides such as I, are prepd. as sol. epoxide hydrolase (sEH) inhibitors for potential use as antiinflammatory agents; their inhibition of human and rat sol. epoxide hydrolases and their half-lives on exposure to microsomes are detd., and the in vivo concns. in rats for selected compds. are detd.  While N-(3,3-diphenyl-propyl)nicotinamide (II) is found to be a potent inhibitor of sEH, it has short metabolic half-lives in microsomes and is cleared rapidly from the bodies of rats; the in vitro metabolic profile of II in rat liver microsomes shows extensive oxidative metab. and a propensity for metabolite switching.  The conformation of N-(3,3-diphenyl-propyl)-3-pyridinesulfonamide bound to sEH is detd. to understand its lack of activity and for further structure optimization; the conformation of N-(3,3-diphenyl-propyl)-2-pyridinecarboxamide bound to human sEH is also detd.  Based on the calcd. structures of compds. bound to sEH, N-diarylethyl arylamides such as I are prepd.  The racemate of I shows an attractive in vitro metabolic profile and high and sustained plasma exposure in the rat after oral administration; the structure of racemic I bound to sEH is also detd. by X-ray crystallog.  I and its enantiomer differ significantly in sEH-inhibiting activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm33erk-C157Vg90H21EOLACvtfcHk0lgfE8uvvLPwmQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWqurvL&md5=ceedf0d50217a4bb8b6fc87c34a65b27</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm9005302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9005302%26sid%3Dliteratum%253Aachs%26aulast%3DEldrup%26aufirst%3DA.%2BB.%26aulast%3DSoleymanzadeh%26aufirst%3DF.%26aulast%3DTaylor%26aufirst%3DS.%2BJ.%26aulast%3DMuegge%26aufirst%3DI.%26aulast%3DFarrow%26aufirst%3DN.%2BA.%26aulast%3DJoseph%26aufirst%3DD.%26aulast%3DMcKellop%26aufirst%3DK.%26aulast%3DMan%26aufirst%3DC.%2BC.%26aulast%3DKukulka%26aufirst%3DA.%26aulast%3DDe%2BLombaert%26aufirst%3DS.%26atitle%3DStructure-based%2520optimization%2520of%2520arylamides%2520as%2520inhibitors%2520of%2520soluble%2520epoxide%2520hydrolase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5880%26epage%3D5895%26doi%3D10.1021%2Fjm9005302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco Gomez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert-Zsilavecz, M.</span></span> <span> </span><span class="NLM_article-title">Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8035</span>â <span class="NLM_lpage">8055</span>, <span class="refDoi">Â DOI: 10.1021/jm500937v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500937v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCjt7bE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8035-8055&author=D.+Merkauthor=C.+Lamersauthor=K.+Ahmadauthor=R.+Carrasco+Gomezauthor=G.+Schneiderauthor=D.+Steinhilberauthor=M.+Schubert-Zsilavecz&title=Extending+the+structure-activity+relationship+of+anthranilic+acid+derivatives+as+farnesoid+X+receptor+modulators%3A+development+of+a+highly+potent+partial+farnesoid+X+receptor+agonist&doi=10.1021%2Fjm500937v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Extending the Structure-Activity Relationship of Anthranilic Acid Derivatives As Farnesoid X Receptor Modulators: Development of a Highly Potent Partial Farnesoid X Receptor Agonist</span></div><div class="casAuthors">Merk, Daniel; Lamers, Christina; Ahmad, Khalil; Carrasco Gomez, Roberto; Schneider, Gisbert; Steinhilber, Dieter; Schubert-Zsilavecz, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8035-8055</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ligand activated transcription factor nuclear farnesoid X receptor (FXR) is involved as a regulator in many metabolic pathways including bile acid and glucose homeostasis.  Therefore, pharmacol. activation of FXR seems a valuable therapeutic approach for several conditions including metabolic diseases linked to insulin resistance, liver disorders such as primary biliary cirrhosis or nonalcoholic steatohepatitis, and certain forms of cancer.  The available FXR agonists, however, activate the receptor to the full extent which might be disadvantageous over a longer time period.  Hence, partial FXR activators are required for long-term treatment of metabolic disorders.  Reported here are the SAR of anthranilic acid derivs. as FXR modulators and development, synthesis, and characterization of compd. (I), which is a highly potent partial FXR agonist in a reporter gene assay with an EC50 value of 8Â±3 nM and on mRNA level in liver cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxZMafrXUE1LVg90H21EOLACvtfcHk0liBvf4NHjzNkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCjt7bE&md5=1b0b248cf689ad910d91a078823a0001</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm500937v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500937v%26sid%3Dliteratum%253Aachs%26aulast%3DMerk%26aufirst%3DD.%26aulast%3DLamers%26aufirst%3DC.%26aulast%3DAhmad%26aufirst%3DK.%26aulast%3DCarrasco%2BGomez%26aufirst%3DR.%26aulast%3DSchneider%26aufirst%3DG.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DSchubert-Zsilavecz%26aufirst%3DM.%26atitle%3DExtending%2520the%2520structure-activity%2520relationship%2520of%2520anthranilic%2520acid%2520derivatives%2520as%2520farnesoid%2520X%2520receptor%2520modulators%253A%2520development%2520of%2520a%2520highly%2520potent%2520partial%2520farnesoid%2520X%2520receptor%2520agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8035%26epage%3D8055%26doi%3D10.1021%2Fjm500937v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kompa, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisennagel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thalji, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, J. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krum, H.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction</span>. <i>Int. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">210</span>â <span class="NLM_lpage">219</span>, <span class="refDoi">Â DOI: 10.1016/j.ijcard.2011.12.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ijcard.2011.12.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=22236509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A280%3ADC%252BC38vgt1Shug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2013&pages=210-219&author=A.+R.+Kompaauthor=B.+H.+Wangauthor=G.+Xuauthor=Y.+Zhangauthor=P.+Y.+Hoauthor=S.+Eisennagelauthor=R.+K.+Thaljiauthor=J.+P.+Marinoauthor=D.+J.+Kellyauthor=D.+J.+Behmauthor=H.+Krum&title=Soluble+epoxide+hydrolase+inhibition+exerts+beneficial+anti-remodeling+actions+post-myocardial+infarction&doi=10.1016%2Fj.ijcard.2011.12.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction</span></div><div class="casAuthors">Kompa Andrew R; Wang Bing H; Xu Guoying; Zhang Yuan; Ho Pei-Yu; Eisennagel Stephen; Thalji Reema K; Marino Joseph P Jr; Kelly Darren J; Behm David J; Krum Henry</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cardiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  A contributory role for soluble epoxide hydrolase (sEH) in cardiac remodeling post-myocardial infarction (MI) has been suggested; however effects of sEH inhibition following MI have not been evaluated.  In this study, we examined in vivo post-MI anti-remodeling effects of a novel sEH inhibitor (GSK2188931B) in the rat, and evaluated its direct in vitro effects on hypertrophy, fibrosis and inflammation.  METHODS AND RESULTS:  Post-MI administered GSK2188931B (80 mg/kg/d in chow) for 5 weeks improved left ventricular (LV) ejection fraction compared to vehicle-treated (Veh) rats (P<0.01; Sham 65 Â± 2%, MI+Veh 30 Â± 2%, MI+GSK 43 Â± 2%) without affecting systolic blood pressure.  Percentage area of LV tissue sections stained positive for picrosirius red (PS) and collagen I (CI) were elevated in LV non-infarct zone (P<0.05; NIZ; PS: Sham 1.46 Â± 0.13%, MI+Veh 2.14 Â± 0.22%, MI+GSK 1.28 Â± 0.14%; CI: Sham 2.57 Â± 0.17%, MI+Veh 5.06 Â± 0.58%, MI+GSK 2.97 Â± 0.34%) and peri-infarct zone (P<0.001; PIZ; PS: Sham 1.46 Â± 0.13%, MI+Veh 9.06 Â± 0.48%, MI+GSK 6.31 Â± 0.63%; CI: Sham 2.57Â±0.17%, MI+Veh 10.51 Â± 0.64%, MI+GSK 7.77 Â± 0.57%); GSK2188931B attenuated this increase (P<0.05).  GSK2188931B reduced macrophage infiltration into the PIZ (P<0.05).  GSK2188931B reduced AngII- and TNFÎ±-stimulated myocyte hypertrophy, AngII- and TGFÎ²-stimulated cardiac fibroblast collagen synthesis, including markers of gene expression ANP, Î²-MHC, CTGF and CI (P<0.05).  GSK2188931B reduced TNFÎ± gene expression in lipopolysaccharide (LPS)-stimulated monocytes (P<0.05).  CONCLUSION:  sEH inhibition exerts beneficial effects on cardiac function and ventricular remodeling post-MI, and direct effects on fibrosis and hypertrophy in cardiac cells.  These findings suggest that sEH is an important contributor to the pathological remodeling following MI, and may be a useful target for therapeutic blockade in this setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTn2zWSRyKzFjToTC3aBaesfW6udTcc2eZ0XbB25VjCbbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vgt1Shug%253D%253D&md5=576dd1ea415dc3a2a144f89110b296af</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.ijcard.2011.12.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijcard.2011.12.062%26sid%3Dliteratum%253Aachs%26aulast%3DKompa%26aufirst%3DA.%2BR.%26aulast%3DWang%26aufirst%3DB.%2BH.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHo%26aufirst%3DP.%2BY.%26aulast%3DEisennagel%26aufirst%3DS.%26aulast%3DThalji%26aufirst%3DR.%2BK.%26aulast%3DMarino%26aufirst%3DJ.%2BP.%26aulast%3DKelly%26aufirst%3DD.%2BJ.%26aulast%3DBehm%26aufirst%3DD.%2BJ.%26aulast%3DKrum%26aufirst%3DH.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520inhibition%2520exerts%2520beneficial%2520anti-remodeling%2520actions%2520post-myocardial%2520infarction%26jtitle%3DInt.%2520J.%2520Cardiol.%26date%3D2013%26volume%3D167%26spage%3D210%26epage%3D219%26doi%3D10.1016%2Fj.ijcard.2011.12.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schierle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Design and structural optimization of dual fxr/pparÎ´ activators</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8369</span>â <span class="NLM_lpage">8379</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c00618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVSiu7vI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8369-8379&author=S.+Schierleauthor=S.+Neumannauthor=P.+Heitelauthor=S.+Willemsauthor=A.+Kaiserauthor=J.+Pollingerauthor=D.+Merk&title=Design+and+structural+optimization+of+dual+fxr%2Fppar%CE%B4+activators&doi=10.1021%2Facs.jmedchem.0c00618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Structural Optimization of Dual FXR/PPARÎ´ Activators</span></div><div class="casAuthors">Schierle, Simone; Neumann, Sebastian; Heitel, Pascal; Willems, Sabine; Kaiser, Astrid; Pollinger, Julius; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8369-8379</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonalcoholic steatohepatitis (NASH) is considered as severe hepatic manifestation of the metabolic syndrome and has alarming global prevalence.  The ligand-activated transcription factors farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) Î´ have been validated as mol. targets to counter NASH.  To achieve robust therapeutic efficacy in this multifactorial pathol., combined peripheral PPARÎ´-mediated activity and hepatic effects of FXR activation appear as a promising multitarget approach.  We have designed a minimal dual FXR/PPARÎ´ activator scaffold by rational fusion of pharmacophores derived from selective agonists.  Our dual agonist lead compd. exhibited weak agonism on FXR and PPARÎ´ and was structurally refined to a potent and balanced FXR/PPARÎ´ activator in a computer-aided fashion.  The resulting dual FXR/PPARÎ´ modulator(I) comprises high selectivity over related nuclear receptors and activates the two target transcription factors in native cellular settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ1fSCkdgD7rVg90H21EOLACvtfcHk0lg16fYv-v5OZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVSiu7vI&md5=ac821255509f52504ede8d644c446db8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00618%26sid%3Dliteratum%253Aachs%26aulast%3DSchierle%26aufirst%3DS.%26aulast%3DNeumann%26aufirst%3DS.%26aulast%3DHeitel%26aufirst%3DP.%26aulast%3DWillems%26aufirst%3DS.%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DPollinger%26aufirst%3DJ.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DDesign%2520and%2520structural%2520optimization%2520of%2520dual%2520fxr%252Fppar%25CE%25B4%2520activators%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8369%26epage%3D8379%26doi%3D10.1021%2Facs.jmedchem.0c00618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akwabi-Ameyaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravella, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creech, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deaton, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaldor, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madauss, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadyen, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iii, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parks, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spearing, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisely, G. B.</span></span> <span> </span><span class="NLM_article-title">Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4339</span>â <span class="NLM_lpage">4343</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2008.06.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmcl.2008.06.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=18621523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVeqtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4339-4343&author=A.+Akwabi-Ameyawauthor=J.+Y.+Bassauthor=R.+D.+Caldwellauthor=J.+A.+Caravellaauthor=L.+Chenauthor=K.+L.+Creechauthor=D.+N.+Deatonauthor=S.+A.+Jonesauthor=I.+Kaldorauthor=Y.+Liuauthor=K.+P.+Madaussauthor=H.+B.+Marrauthor=R.+B.+McFadyenauthor=A.+B.+Millerauthor=F.+N.+Iiiauthor=D.+J.+Parksauthor=P.+K.+Spearingauthor=D.+Toddauthor=S.+P.+Williamsauthor=G.+B.+Wisely&title=Conformationally+constrained+farnesoid+X+receptor+%28FXR%29+agonists%3A+Naphthoic+acid-based+analogs+of+GW+4064&doi=10.1016%2Fj.bmcl.2008.06.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064</span></div><div class="casAuthors">Akwabi-Ameyaw, Adwoa; Bass, Jonathan Y.; Caldwell, Richard D.; Caravella, Justin A.; Chen, Lihong; Creech, Katrina L.; Deaton, David N.; Jones, Stacey A.; Kaldor, Istvan; Liu, Yaping; Madauss, Kevin P.; Marr, Harry B.; McFadyen, Robert B.; Miller, Aaron B.; Navas, Frank, III; Parks, Derek J.; Spearing, Paul K.; Todd, Dan; Williams, Shawn P.; Wisely, G. Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4339-4343</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Starting from the known FXR agonist GW 4064 I, a series of stilbene replacements were prepd.  The 6-substituted 1-naphthoic acid II was an equipotent FXR agonist with improved developability parameters relative to I.  Analog II also reduced the severity of cholestasis in the ANIT acute cholestatic rat model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0IzFOXAysDrVg90H21EOLACvtfcHk0lg16fYv-v5OZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVeqtbk%253D&md5=1007683ff89fa4257f063c63cd16481b</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.06.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.06.073%26sid%3Dliteratum%253Aachs%26aulast%3DAkwabi-Ameyaw%26aufirst%3DA.%26aulast%3DBass%26aufirst%3DJ.%2BY.%26aulast%3DCaldwell%26aufirst%3DR.%2BD.%26aulast%3DCaravella%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCreech%26aufirst%3DK.%2BL.%26aulast%3DDeaton%26aufirst%3DD.%2BN.%26aulast%3DJones%26aufirst%3DS.%2BA.%26aulast%3DKaldor%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DMarr%26aufirst%3DH.%2BB.%26aulast%3DMcFadyen%26aufirst%3DR.%2BB.%26aulast%3DMiller%26aufirst%3DA.%2BB.%26aulast%3DIii%26aufirst%3DF.%2BN.%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DSpearing%26aufirst%3DP.%2BK.%26aulast%3DTodd%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DS.%2BP.%26aulast%3DWisely%26aufirst%3DG.%2BB.%26atitle%3DConformationally%2520constrained%2520farnesoid%2520X%2520receptor%2520%2528FXR%2529%2520agonists%253A%2520Naphthoic%2520acid-based%2520analogs%2520of%2520GW%25204064%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4339%26epage%3D4343%26doi%3D10.1016%2Fj.bmcl.2008.06.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacintho, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccei, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhead, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorrain, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messmer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective PPARÎ±/Î´ dual antagonists and initial biological studies</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">503</span>â <span class="NLM_lpage">508</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2018.12.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmcl.2018.12.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=30594433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1WhsLjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=503-508&author=J.+D.+Jacinthoauthor=C.+S.+Bacceiauthor=Y.+Bravoauthor=A.+Broadheadauthor=A.+Chenauthor=L.+Correaauthor=K.+Fischerauthor=B.+Laffitteauthor=C.+Leeauthor=D.+S.+Lorrainauthor=D.+Messmerauthor=P.+Prasitauthor=K.+J.+Stebbinsauthor=N.+S.+Stock&title=Discovery+of+potent+and+selective+PPAR%CE%B1%2F%CE%B4+dual+antagonists+and+initial+biological+studies&doi=10.1016%2Fj.bmcl.2018.12.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent and selective PPARÎ±/Î´ dual antagonists and initial biological studies</span></div><div class="casAuthors">Jacintho, Jason D.; Baccei, Christopher S.; Bravo, Yalda; Broadhead, Alex; Chen, Austin; Correa, Lucia; Fischer, Kim; Laffitte, Bryan; Lee, Catherine; Lorrain, Daniel S.; Messmer, Davorka; Prasit, Peppi; Stebbins, Karin J.; Stock, Nicholas S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">503-508</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We previously published on the design and synthesis of novel, potent and selective PPARÎ± antagonists suitable for either i.p. or oral in vivo administration for the potential treatment of cancer.  Described herein is SAR for a subsequent program, where we set out to identify selective and potent PPARÎ±/Î´ dual antagonist mols.  Emerging literature indicates that both PPARÎ± and PPARÎ´ antagonism may be helpful in curbing the proliferation of certain types of cancer.  This dual antagonism could also be used to study PPARs in other settings.  After testing for selective and dual potency, off-target counter screening, metabolic stability, oral bioavailability and assocd. toxicity, compd. 11, the first reported PPARÎ±/Î´ dual antagonist was chosen for more advanced preclin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIewbYoy3dErVg90H21EOLACvtfcHk0ljpFoxTRzAPzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1WhsLjE&md5=b03ca081eb0222dfe7632060154c5d36</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.12.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.12.045%26sid%3Dliteratum%253Aachs%26aulast%3DJacintho%26aufirst%3DJ.%2BD.%26aulast%3DBaccei%26aufirst%3DC.%2BS.%26aulast%3DBravo%26aufirst%3DY.%26aulast%3DBroadhead%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DCorrea%26aufirst%3DL.%26aulast%3DFischer%26aufirst%3DK.%26aulast%3DLaffitte%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26aulast%3DMessmer%26aufirst%3DD.%26aulast%3DPrasit%26aufirst%3DP.%26aulast%3DStebbins%26aufirst%3DK.%2BJ.%26aulast%3DStock%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520PPAR%25CE%25B1%252F%25CE%25B4%2520dual%2520antagonists%2520and%2520initial%2520biological%2520studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D503%26epage%3D508%26doi%3D10.1016%2Fj.bmcl.2018.12.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunst, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadnis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baska, R. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monshizadegan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowala, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of n-isoxazolyl biphenylsulfonamides as potent dual angiotensin ii and endothelin a receptor antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3829</span>â <span class="NLM_lpage">3835</span>, <span class="refDoi">Â DOI: 10.1021/jm020138n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020138n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvVOrt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3829-3835&author=N.+Murugesanauthor=J.+E.+Tellewauthor=Z.+Guauthor=B.+L.+Kunstauthor=L.+Fadnisauthor=L.+A.+Corneliusauthor=R.+A.+F.+Baskaauthor=Y.+Yangauthor=S.+M.+Beyerauthor=H.+Monshizadeganauthor=K.+E.+Dickinsonauthor=B.+Panchalauthor=M.+T.+Valentineauthor=S.+Chongauthor=R.+A.+Morrisonauthor=K.+E.+Carlsonauthor=J.+R.+Powellauthor=S.+Morelandauthor=J.+C.+Barrishauthor=M.+C.+Kowalaauthor=J.+E.+Macor&title=Discovery+of+n-isoxazolyl+biphenylsulfonamides+as+potent+dual+angiotensin+ii+and+endothelin+a+receptor+antagonists&doi=10.1021%2Fjm020138n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists</span></div><div class="casAuthors">Murugesan, Natesan; Tellew, John E.; Gu, Zhengxiang; Kunst, Bridgette L.; Fadnis, Leena; Cornelius, Lyndon A.; Baska, Rose Ann F.; Yang, Yifan; Beyer, Sophie M.; Monshizadegan, Hossain; Dickinson, Kenneth E.; Panchal, Balkrushna; Valentine, Maria T.; Chong, Saeho; Morrison, Richard A.; Carlson, Kenneth E.; Powell, James R.; Moreland, Suzanne; Barrish, Joel C.; Kowala, Mark C.; Macor, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3829-3835</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ETA receptor antagonist N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-[1,1'-biphenyl]-2-sulfonamide (BMS-193884) shares the same biphenyl core as a large no. of AT1 receptor antagonists, including irbesartan.  Thus, it was hypothesized that merging the structural elements of BMS-193884 with those of the biphenyl AT1 antagonists (e.g., irbesartan) would yield a compd. with dual activity for both receptors.  This strategy led to the design, synthesis, and discovery of 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-[1,1'-biphenyl]-2-sulfonamide (BMS-248360) as a potent and orally active dual antagonist of both AT1 and ETA receptors.  Compd. BMS-248360 represents a new approach to treating hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocfowlxhsw47Vg90H21EOLACvtfcHk0ljpFoxTRzAPzg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvVOrt7Y%253D&md5=cd53a7af3c175c5877d45f0a25ea1159</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm020138n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020138n%26sid%3Dliteratum%253Aachs%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DTellew%26aufirst%3DJ.%2BE.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DKunst%26aufirst%3DB.%2BL.%26aulast%3DFadnis%26aufirst%3DL.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%26aulast%3DBaska%26aufirst%3DR.%2BA.%2BF.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DBeyer%26aufirst%3DS.%2BM.%26aulast%3DMonshizadegan%26aufirst%3DH.%26aulast%3DDickinson%26aufirst%3DK.%2BE.%26aulast%3DPanchal%26aufirst%3DB.%26aulast%3DValentine%26aufirst%3DM.%2BT.%26aulast%3DChong%26aufirst%3DS.%26aulast%3DMorrison%26aufirst%3DR.%2BA.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DPowell%26aufirst%3DJ.%2BR.%26aulast%3DMoreland%26aufirst%3DS.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DKowala%26aufirst%3DM.%2BC.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26atitle%3DDiscovery%2520of%2520n-isoxazolyl%2520biphenylsulfonamides%2520as%2520potent%2520dual%2520angiotensin%2520ii%2520and%2520endothelin%2520a%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3829%26epage%3D3835%26doi%3D10.1021%2Fjm020138n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadnis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baska, R. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monshizadegan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowala, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span> <span> </span><span class="NLM_article-title">Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2â²-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">171</span>â <span class="NLM_lpage">179</span>, <span class="refDoi">Â DOI: 10.1021/jm049548x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049548x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVyltrzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=171-179&author=N.+Murugesanauthor=Z.+Guauthor=L.+Fadnisauthor=J.+E.+Tellewauthor=R.+A.+F.+Baskaauthor=Y.+Yangauthor=S.+M.+Beyerauthor=H.+Monshizadeganauthor=K.+E.+Dickinsonauthor=M.+T.+Valentineauthor=W.+G.+Humphreysauthor=S.-J.+Lanauthor=W.+R.+Ewingauthor=K.+E.+Carlsonauthor=M.+C.+Kowalaauthor=R.+Zahlerauthor=J.+E.+Macor&title=Dual+angiotensin+II+and+endothelin+A+receptor+antagonists%3A+synthesis+of+2%E2%80%B2-substituted+N-3-isoxazolyl+biphenylsulfonamides+with+improved+potency+and+pharmacokinetics&doi=10.1021%2Fjm049548x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Angiotensin II and Endothelin A Receptor Antagonists: Synthesis of 2'-Substituted N-3-Isoxazolyl Biphenylsulfonamides with Improved Potency and Pharmacokinetics</span></div><div class="casAuthors">Murugesan, Natesan; Gu, Zhengxiang; Fadnis, Leena; Tellew, John E.; Baska, Rose Ann F.; Yang, Yifan; Beyer, Sophie M.; Monshizadegan, Hossain; Dickinson, Kenneth E.; Valentine, Maria T.; Humphreys, W. Griffith; Lan, Shih-Jung; Ewing, William R.; Carlson, Kenneth E.; Kowala, Mark C.; Zahler, Robert; Macor, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-179</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a previous report its was demonstrated that merging together key structural elements present in an AT1 receptor antagonist (irbesartan) with key structural elements in a biphenylsulfonamide ETA receptor antagonist followed by addnl. optimization provided a product which is a dual-action receptor antagonist (DARA), which potently blocked both AT1 and ETA receptors.  Described herein are our efforts directed toward improving both the pharmacokinetic profile as well as the AT1 and ETA receptor potency of 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-2-sulfonamide (I).  Efforts centered on modifying the 2'-side chain of I and examg. the (isoxazolyl)sulfonamide moiety in I.  This effort resulted in the discovery of 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)[1,1'-biphenyl]-2-sulfonamide (II) as a highly potent second-generation DARA.  This compd. also showed substantially improved pharmacokinetic properties compared to I.  In rats, DARA II reduced blood pressure elevations caused by i.v. infusion of Ang II or big ET-1 to a greater extent and with longer duration than DARA I or AT1 or ETA receptor antagonists alone.  II clearly demonstrated superiority over irbesartan (an AT1 receptor antagonist) in the normal SHR model of hypertension in a dose-dependent manner, demonstrating the synergy of AT1 and ETA receptor blockade in a single mol.  The crystal and mol. structures of II were reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2G8_AfjEVOrVg90H21EOLACvtfcHk0lg75G21JO8ZBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVyltrzO&md5=d4e66dc82cd65970cde8ca8f3094c8c6</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm049548x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049548x%26sid%3Dliteratum%253Aachs%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DFadnis%26aufirst%3DL.%26aulast%3DTellew%26aufirst%3DJ.%2BE.%26aulast%3DBaska%26aufirst%3DR.%2BA.%2BF.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DBeyer%26aufirst%3DS.%2BM.%26aulast%3DMonshizadegan%26aufirst%3DH.%26aulast%3DDickinson%26aufirst%3DK.%2BE.%26aulast%3DValentine%26aufirst%3DM.%2BT.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DLan%26aufirst%3DS.-J.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DKowala%26aufirst%3DM.%2BC.%26aulast%3DZahler%26aufirst%3DR.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26atitle%3DDual%2520angiotensin%2520II%2520and%2520endothelin%2520A%2520receptor%2520antagonists%253A%2520synthesis%2520of%25202%25E2%2580%25B2-substituted%2520N-3-isoxazolyl%2520biphenylsulfonamides%2520with%2520improved%2520potency%2520and%2520pharmacokinetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D171%26epage%3D179%26doi%3D10.1021%2Fjm049548x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisaha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misra, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafino, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abboa-Offei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giancarli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span> <span> </span><span class="NLM_article-title">Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2â²-amino-N-(3,4-dimethyl-5-isoxazolyl)-4â²-(2-ethylpropyl)[1,1â²-biphenyl]-2-sulfonamide (BMS-187308)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">5198</span>â <span class="NLM_lpage">5218</span>, <span class="refDoi">Â DOI: 10.1021/jm970872k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970872k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK1cXnsV2ksbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=5198-5218&author=N.+Murugesanauthor=Z.+Guauthor=P.+D.+Steinauthor=S.+Bisahaauthor=S.+Spergelauthor=R.+Girotraauthor=V.+G.+Leeauthor=J.+Lloydauthor=R.+N.+Misraauthor=J.+Schmidtauthor=A.+Mathurauthor=L.+Strattonauthor=Y.+F.+Kellyauthor=E.+Birdauthor=T.+Waldronauthor=E.+C.+K.+Liuauthor=R.+Zhangauthor=H.+Leeauthor=R.+Serafinoauthor=B.+Abboa-Offeiauthor=P.+Mathersauthor=M.+Giancarliauthor=A.+A.+Seymourauthor=M.+L.+Webbauthor=S.+Morelandauthor=J.+C.+Barrishauthor=J.+T.+Hunt&title=Biphenylsulfonamide+endothelin+antagonists%3A+structure-activity+relationships+of+a+series+of+mono-+and+disubstituted+analogues+and+pharmacology+of+the+orally+active+endothelin+antagonist+2%E2%80%B2-amino-N-%283%2C4-dimethyl-5-isoxazolyl%29-4%E2%80%B2-%282-ethylpropyl%29%5B1%2C1%E2%80%B2-biphenyl%5D-2-sulfonamide+%28BMS-187308%29&doi=10.1021%2Fjm970872k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Biphenylsulfonamide Endothelin Antagonists: Structure-Activity Relationships of a Series of Mono- and Disubstituted Analogs and Pharmacology of the Orally Active Endothelin Antagonist 2'-Amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1,1'-biphenyl]-2-sulfonamide (BMS-187308)</span></div><div class="casAuthors">Murugesan, Natesan; Gu, Zhengxiang; Stein, Philip D.; Bisaha, Sharon; Spergel, Steve; Girotra, Ravi; Lee, Ving G.; Lloyd, John; Misra, Raj N.; Schmidt, Joan; Mathur, Arvind; Stratton, Leslie; Kelly, Yolanda F.; Bird, Eileen; Waldron, Tom; Liu, Eddie C.-K.; Zhang, Rongan; Lee, Helen; Serafino, Randy; Abboa-Offei, Benoni; Mathers, Parker; Giancarli, Mary; Seymour, Andrea Ann; Webb, Maria L.; Moreland, Suzanne; Barrish, Joel C.; Hunt, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">5198-5218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Substitution at the ortho position of N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamide led to the identification of the biphenylsulfonamides as a novel series of endothelin-A (ETA) selective antagonists.  Appropriate substitution on the pendant Ph ring led to improved binding as well as functional activity.  A hydrophobic group such as iso-Bu or isopropoxy was found to be optimal at the 4'-position.  Introduction of an amino group at the 2'-position also led to improved analogs.  Combination of the optimal 4'-iso-Bu substituent with the 2'-amino function afforded an analog (BMS-187308) with improved ETA binding affinity and functional activity.  BMS-187308 also has good oral activity in inhibiting the pressor effect caused by an ET-1 infusion in rats.  Doses of 10 and 30 Î¼mol/kg i.v. BMS-187308 attenuated the pressor responses due to the administration of exogenous ET-1 to conscious monkeys, indicating that the compd. inhibits the in vivo activity of endothelin-1 in nonhuman primates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5OtFgVY5JrrVg90H21EOLACvtfcHk0lg75G21JO8ZBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnsV2ksbs%253D&md5=cf1a51cbfe916ab0f373d38e62db4eda</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm970872k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970872k%26sid%3Dliteratum%253Aachs%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DStein%26aufirst%3DP.%2BD.%26aulast%3DBisaha%26aufirst%3DS.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DGirotra%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DV.%2BG.%26aulast%3DLloyd%26aufirst%3DJ.%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DStratton%26aufirst%3DL.%26aulast%3DKelly%26aufirst%3DY.%2BF.%26aulast%3DBird%26aufirst%3DE.%26aulast%3DWaldron%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DE.%2BC.%2BK.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DSerafino%26aufirst%3DR.%26aulast%3DAbboa-Offei%26aufirst%3DB.%26aulast%3DMathers%26aufirst%3DP.%26aulast%3DGiancarli%26aufirst%3DM.%26aulast%3DSeymour%26aufirst%3DA.%2BA.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26aulast%3DMoreland%26aufirst%3DS.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26atitle%3DBiphenylsulfonamide%2520endothelin%2520antagonists%253A%2520structure-activity%2520relationships%2520of%2520a%2520series%2520of%2520mono-%2520and%2520disubstituted%2520analogues%2520and%2520pharmacology%2520of%2520the%2520orally%2520active%2520endothelin%2520antagonist%25202%25E2%2580%25B2-amino-N-%25283%252C4-dimethyl-5-isoxazolyl%2529-4%25E2%2580%25B2-%25282-ethylpropyl%2529%255B1%252C1%25E2%2580%25B2-biphenyl%255D-2-sulfonamide%2520%2528BMS-187308%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D5198%26epage%3D5218%26doi%3D10.1021%2Fjm970872k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugesan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leith, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span> <span> </span><span class="NLM_article-title">Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4â²-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">3111</span>â <span class="NLM_lpage">3117</span>, <span class="refDoi">Â DOI: 10.1021/jm000105c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000105c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvV2mu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3111-3117&author=N.+Murugesanauthor=Z.+Guauthor=P.+D.+Steinauthor=S.+Spergelauthor=A.+Mathurauthor=L.+Leithauthor=E.+C.+Liuauthor=R.+Zhangauthor=E.+Birdauthor=T.+Waldronauthor=A.+Marinoauthor=R.+A.+Morrisonauthor=M.+L.+Webbauthor=S.+Morelandauthor=J.+C.+Barrish&title=Biphenylsulfonamide+endothelin+receptor+antagonists.+2.+Discovery+of+4%E2%80%B2-oxazolyl+biphenylsulfonamides+as+a+new+class+of+potent%2C+highly+selective+ET%28A%29+antagonists&doi=10.1021%2Fjm000105c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Biphenylsulfonamide endothelin receptor antagonists: discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ETA antagonists</span></div><div class="casAuthors">Murugesan, Natesan; Gu, Zhengxiang; Stein, Philip D.; Spergel, Steven; Mathur, Arvind; Leith, Leslie; Liu, Eddie C.-K.; Zhang, Rongan; Bird, Eileen; Waldron, Tom; Marino, Anthony; Morrison, Richard A.; Webb, Maria L.; Moreland, Suzanne; Barrish, Joel C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3111-3117</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and structure-activity relationship (SAR) studies of a series of 4'-oxazolyl-N-(3,4-dimethyl-5-isoxazolyl)[1,1'-biphenyl]-2-sulfonamide derivs. as endothelin-A (ETA) receptor antagonists are described.  The data reveal a remarkable improvement in potency and metabolic stability when the 4'-position of the biphenylsulfonamide is substituted with an oxazole ring.  Addnl. 2'-substitution of an acylaminomethyl group further increased the binding activity and provided one of the first subnanomolar ETA-selective antagonists in the biphenylsulfonamide series (ETA Ki = 0.2 nM).  Among the compds. described, (N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfonamide; BMS-193884) had the optimum pharmacol. profile and was therefore selected as a clin. candidate for studies in congestive heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofLpYwTBrboLVg90H21EOLACvtfcHk0ljCPzQra1cTGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvV2mu78%253D&md5=de37003e51c462ddfb538829ab8f2718</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm000105c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000105c%26sid%3Dliteratum%253Aachs%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DStein%26aufirst%3DP.%2BD.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DLeith%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DE.%2BC.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DBird%26aufirst%3DE.%26aulast%3DWaldron%26aufirst%3DT.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DMorrison%26aufirst%3DR.%2BA.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26aulast%3DMoreland%26aufirst%3DS.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26atitle%3DBiphenylsulfonamide%2520endothelin%2520receptor%2520antagonists.%25202.%2520Discovery%2520of%25204%25E2%2580%25B2-oxazolyl%2520biphenylsulfonamides%2520as%2520a%2520new%2520class%2520of%2520potent%252C%2520highly%2520selective%2520ET%2528A%2529%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3111%26epage%3D3117%26doi%3D10.1021%2Fjm000105c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burnier, M.</span></span> <span> </span><span class="NLM_article-title">Angiotensin II type 1 receptor blockers</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">904</span>â <span class="NLM_lpage">912</span>, <span class="refDoi">Â DOI: 10.1161/01.CIR.103.6.904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1161%2F01.CIR.103.6.904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=11171802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhs1Whtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2001&pages=904-912&author=M.+Burnier&title=Angiotensin+II+type+1+receptor+blockers&doi=10.1161%2F01.CIR.103.6.904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin II type 1 receptor blockers</span></div><div class="casAuthors">Burnier, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">904-912</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 121 refs. regarding the use of angiotensin II type 1 receptor blockers for treatment of patients with hypertension.  There is now convincing evidence that the new class of specific, angiotensin II receptor antagonists is as effective as ACE inhibitors, Î²-blockers, calcium antagonists, and diuretics in treating patients with mild to moderate hypertension.  However, these antagonists are characterized by a better tolerability profile.  In contrast to most other recent classes of antihypertensive drugs, a large no. of outcome trials have been initiated to evaluate angiotensin II antagonists.  Their results will demonstrate whether angiotensin II receptor antagonists can prevent target organ damage and reduce cardiovascular morbidity and mortality.  They will also enable the more appropriate definition of the role of these antagonists in the management of patients with hypertension, heart failure, or renal diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDKCT3YAzeubVg90H21EOLACvtfcHk0ljCPzQra1cTGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhs1Whtbk%253D&md5=f09230c7fa494dfcb03fea7da94fd057</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.103.6.904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.103.6.904%26sid%3Dliteratum%253Aachs%26aulast%3DBurnier%26aufirst%3DM.%26atitle%3DAngiotensin%2520II%2520type%25201%2520receptor%2520blockers%26jtitle%3DCirculation%26date%3D2001%26volume%3D103%26spage%3D904%26epage%3D912%26doi%3D10.1161%2F01.CIR.103.6.904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmermans, P. B.</span></span> <span> </span><span class="NLM_article-title">Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">625</span>â <span class="NLM_lpage">656</span>, <span class="refDoi">Â DOI: 10.1021/jm9504722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9504722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK28Xjt1Oltw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=625-656&author=R.+R.+Wexlerauthor=W.+J.+Greenleeauthor=J.+D.+Irvinauthor=M.+R.+Goldbergauthor=K.+Prendergastauthor=R.+D.+Smithauthor=P.+B.+Timmermans&title=Nonpeptide+angiotensin+II+receptor+antagonists%3A+the+next+generation+in+antihypertensive+therapy&doi=10.1021%2Fjm9504722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Nonpeptide Angiotensin II Receptor Antagonists: The Next Generation in Antihypertensive Therapy</span></div><div class="casAuthors">Wexler, Ruth R.; Greenlee, William J.; Irvin, John D.; Goldberg, Michael R.; Prendergast, Kristine; Smith, Ronald D.; Timmermans, Pieter B. M. W. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">625-56</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review, with 326 refs. which includes AT1-selective antagonists, AT2-selective antagonists, mol. modeling, and clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox8R0LMBNKD7Vg90H21EOLACvtfcHk0ljCPzQra1cTGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjt1Oltw%253D%253D&md5=218425943d7b9f3bcf37c205eca08c6f</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjm9504722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9504722%26sid%3Dliteratum%253Aachs%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DIrvin%26aufirst%3DJ.%2BD.%26aulast%3DGoldberg%26aufirst%3DM.%2BR.%26aulast%3DPrendergast%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DR.%2BD.%26aulast%3DTimmermans%26aufirst%3DP.%2BB.%26atitle%3DNonpeptide%2520angiotensin%2520II%2520receptor%2520antagonists%253A%2520the%2520next%2520generation%2520in%2520antihypertensive%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D625%26epage%3D656%26doi%3D10.1021%2Fjm9504722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5766</span>â <span class="NLM_lpage">5779</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00324</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00324" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFSmu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5766-5779&author=J.+Baiauthor=C.+Liaoauthor=Y.+Liuauthor=X.+Qinauthor=J.+Chenauthor=Y.+Qiuauthor=D.+Qinauthor=Z.+Liauthor=Z.-C.+Tuauthor=S.+Jiang&title=Structure-Based+Design+of+Potent+Nicotinamide+Phosphoribosyltransferase+Inhibitors+with+Promising+in+Vitro+and+in+Vivo+Antitumor+Activities&doi=10.1021%2Facs.jmedchem.6b00324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities</span></div><div class="casAuthors">Bai, Jinhong; Liao, Chenzhong; Liu, Yanghan; Qin, Xiaochu; Chen, Jiaxuan; Qiu, Yatao; Qin, Dongguang; Li, Zheng; Tu, Zheng-Chao; Jiang, Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5766-5779</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) has the potential to directly limit NAD prodn. in cancer cells and is an effective strategy for cancer treatment.  Using a structure-based strategy, we have designed a new class of potent small-mol. inhibitors of NAMPT.  Several designed compds. showed promising antiproliferative activities in vitro. (E)-N-(5-((4-(((2-(1H-Indol-3-yl)ethyl)(isopropyl)amino)methyl)phenyl)amino)pentyl)-3-(pyridin-3-yl)acrylamide (I), bearing an indole moiety, has an IC50 of 25.3 nM for binding to the NAMPT protein and demonstrated promising inhibitory activities in the nanomolar range against several cancer cell lines (MCF-7 GI50 = 0.13 nM; MDA-MB-231 GI50 = 0.15 nM).  Triple-neg. breast cancer is the most malignant subtype of breast cancer with no effective targeted treatments currently available.  Significant antitumor efficacy of compd. 30 was achieved (TGI was 73.8%) in an orthotopic MDA-MB-231 triple-neg. breast cancer xenograft tumor model.  This paper reports promising lead mols. for the inhibition of NAMPT which could serve as a basis for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr87ZYT0b1BybVg90H21EOLACvtfcHk0lhgrxqKirn54Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFSmu7c%253D&md5=bbebaf9e5036168d0f30a141effce0aa</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00324%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DTu%26aufirst%3DZ.-C.%26aulast%3DJiang%26aufirst%3DS.%26atitle%3DStructure-Based%2520Design%2520of%2520Potent%2520Nicotinamide%2520Phosphoribosyltransferase%2520Inhibitors%2520with%2520Promising%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Antitumor%2520Activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5766%26epage%3D5779%26doi%3D10.1021%2Facs.jmedchem.6b00324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cea, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soncini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruscione, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffaghello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garuti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emionite, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoppoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reverberi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagnetta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamaschi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casciaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierri, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansaldi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pistoia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballestrero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patrone, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nencioni, A.</span></span> <span> </span><span class="NLM_article-title">Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">22739</span>â <span class="NLM_lpage">22739</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0022739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1371%2Fjournal.pone.0022739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOrsbnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=22739-22739&author=M.+Ceaauthor=D.+Sonciniauthor=F.+Fruscioneauthor=L.+Raffaghelloauthor=A.+Garutiauthor=L.+Emioniteauthor=E.+Moranauthor=M.+Magnoneauthor=G.+Zoppoliauthor=D.+Reverberiauthor=I.+Caffaauthor=A.+Salisauthor=A.+Cagnettaauthor=M.+Bergamaschiauthor=S.+Casciaroauthor=I.+Pierriauthor=G.+Damonteauthor=F.+Ansaldiauthor=M.+Gobbiauthor=V.+Pistoiaauthor=A.+Ballestreroauthor=F.+Patroneauthor=S.+Bruzzoneauthor=A.+Nencioni&title=Synergistic+interactions+between+HDAC+and+sirtuin+inhibitors+in+human+leukemia+cells&doi=10.1371%2Fjournal.pone.0022739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells</span></div><div class="casAuthors">Cea, Michele; Soncini, Debora; Fruscione, Floriana; Raffaghello, Lizzia; Garuti, Anna; Emionite, Laura; Moran, Eva; Magnone, Mirko; Zoppoli, Gabriele; Reverberi, Daniele; Caffa, Irene; Salis, Annalisa; Cagnetta, Antonia; Bergamaschi, Micaela; Casciaro, Salvatore; Pierri, Ivana; Damonte, Gianluca; Ansaldi, Filippo; Gobbi, Marco; Pistoia, Vito; Ballestrero, Alberto; Patrone, Franco; Bruzzone, Santina; Nencioni, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e22739</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Aberrant histone deacetylase (HDAC) activity is frequent in human leukemias.  However, while classical, NAD+-independent HDACs are an established therapeutic target, the relevance of NAD+-dependent HDACs (sirtuins) in leukemia treatment remains unclear.  Here, we assessed the antileukemic activity of sirtuin inhibitors and of the NAD+-lowering drug FK866, alone and in combination with traditional HDAC inhibitors.  Primary leukemia cells, leukemia cell lines, healthy leukocytes and hematopoietic progenitors were treated with sirtuin inhibitors (sirtinol, cambinol, EX527) and with FK866, with or without addn. of the HDAC inhibitors valproic acid, sodium butyrate, and vorinostat.  Cell death was quantified by propidium iodide cell staining and subsequent flow-cytometry.  Apoptosis induction was monitored by cell staining with FITC-Annexin-V/propidium iodide or with TMRE followed by flow-cytometric anal., and by measuring caspase3/7 activity.  Intracellular Bax was detected by flow-cytometry and western blotting.  Cellular NAD+ levels were measured by enzymic cycling assays.  Bax was overexpressed by retroviral transduction.  Bax and SIRT1 were silenced by RNA-interference.  Sirtuin inhibitors and FK866 synergistically enhanced HDAC inhibitor activity in leukemia cells, but not in healthy leukocytes and hematopoietic progenitors.  In leukemia cells, HDAC inhibitors were found to induce upregulation of Bax, a pro-apoptotic Bcl2 family-member whose translocation to mitochondria is normally prevented by SIRT1.  As a result, leukemia cells become sensitized to sirtuin inhibitor-induced apoptosis.  In conclusion, NAD+-independent HDACs and sirtuins cooperate in leukemia cells to avoid apoptosis.  Combining sirtuin with HDAC inhibitors results in synergistic antileukemic activity that could be therapeutically exploited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCsDV0zHyQfbVg90H21EOLACvtfcHk0lhgrxqKirn54Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOrsbnE&md5=382cf45927d9cb0b3555154246f28444</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0022739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0022739%26sid%3Dliteratum%253Aachs%26aulast%3DCea%26aufirst%3DM.%26aulast%3DSoncini%26aufirst%3DD.%26aulast%3DFruscione%26aufirst%3DF.%26aulast%3DRaffaghello%26aufirst%3DL.%26aulast%3DGaruti%26aufirst%3DA.%26aulast%3DEmionite%26aufirst%3DL.%26aulast%3DMoran%26aufirst%3DE.%26aulast%3DMagnone%26aufirst%3DM.%26aulast%3DZoppoli%26aufirst%3DG.%26aulast%3DReverberi%26aufirst%3DD.%26aulast%3DCaffa%26aufirst%3DI.%26aulast%3DSalis%26aufirst%3DA.%26aulast%3DCagnetta%26aufirst%3DA.%26aulast%3DBergamaschi%26aufirst%3DM.%26aulast%3DCasciaro%26aufirst%3DS.%26aulast%3DPierri%26aufirst%3DI.%26aulast%3DDamonte%26aufirst%3DG.%26aulast%3DAnsaldi%26aufirst%3DF.%26aulast%3DGobbi%26aufirst%3DM.%26aulast%3DPistoia%26aufirst%3DV.%26aulast%3DBallestrero%26aufirst%3DA.%26aulast%3DPatrone%26aufirst%3DF.%26aulast%3DBruzzone%26aufirst%3DS.%26aulast%3DNencioni%26aufirst%3DA.%26atitle%3DSynergistic%2520interactions%2520between%2520HDAC%2520and%2520sirtuin%2520inhibitors%2520in%2520human%2520leukemia%2520cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3D22739%26epage%3D22739%26doi%3D10.1371%2Fjournal.pone.0022739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors simultaneously targeting cancer metabolism and epigenetics: discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC) dual inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7965</span>â <span class="NLM_lpage">7983</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00467</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00467" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKhurrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7965-7983&author=G.+Dongauthor=W.+Chenauthor=X.+Wangauthor=X.+Yangauthor=T.+Xuauthor=P.+Wangauthor=W.+Zhangauthor=Y.+Raoauthor=C.+Y.+Miaoauthor=C.+Sheng&title=Small+molecule+inhibitors+simultaneously+targeting+cancer+metabolism+and+epigenetics%3A+discovery+of+novel+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+and+histone+deacetylase+%28HDAC%29+dual+inhibitors&doi=10.1021%2Facs.jmedchem.7b00467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors</span></div><div class="casAuthors">Dong, Guoqiang; Chen, Wei; Wang, Xia; Yang, Xinglin; Xu, Tianying; Wang, Pei; Zhang, Wannian; Rao, Yu; Miao, Chaoyu; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7965-7983</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer metab. and epigenetics are among the most intensely pursued research areas in anticancer drug discovery.  Here we report the first small mols. that simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT)and histone deacetylase (HDAC), two important targets of cancer metab. and epigenetics, resp.  Through iterative structure-based drug design, chem. synthesis, and biol. assays, a highly potent dual NAMPT and HDAC inhibitor was successfully identified.  Compd. 35 possessed excellent and balanced activities against both NAMPT (IC50 = 31 nM) and HDAC1 (IC50 = 55 nM).  It could effectively induce cell apoptosis and autophagy and ultimately led to cell death.  Importantly, compd. 35 showed excellent in vivo antitumor efficacy in the HCT116 xenograft model.  This proof-of-concept study demonstrates the feasibility of discovering an inhibitor targeting cancer metab. and epigenetics and provides an efficient strategy for multitarget antitumor drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9UvfGattu1rVg90H21EOLACvtfcHk0lgFvi5jhMAmPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKhurrO&md5=65df0b485cbbc169886d34ae4421f814</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00467%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DC.%2BY.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DSmall%2520molecule%2520inhibitors%2520simultaneously%2520targeting%2520cancer%2520metabolism%2520and%2520epigenetics%253A%2520discovery%2520of%2520novel%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7965%26epage%3D7983%26doi%3D10.1021%2Facs.jmedchem.7b00467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moradei, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallais, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frechette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessier, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leit, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonfils, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trachy-Bourget, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahil, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaisburg, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besterman, J. M.</span></span> <span> </span><span class="NLM_article-title">Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5543</span>â <span class="NLM_lpage">5546</span>, <span class="refDoi">Â DOI: 10.1021/jm701079h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701079h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKksLrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5543-5546&author=O.+M.+Moradeiauthor=T.+C.+Mallaisauthor=S.+Frechetteauthor=I.+Paquinauthor=P.+E.+Tessierauthor=S.+M.+Leitauthor=M.+Fournelauthor=C.+Bonfilsauthor=M.+C.+Trachy-Bourgetauthor=J.+Liuauthor=T.+P.+Yanauthor=A.+H.+Luauthor=J.+Rahilauthor=J.+Wangauthor=S.+Lefebvreauthor=Z.+Liauthor=A.+F.+Vaisburgauthor=J.+M.+Besterman&title=Novel+aminophenyl+benzamide-type+histone+deacetylase+inhibitors+with+enhanced+potency+and+selectivity&doi=10.1021%2Fjm701079h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Aminophenyl Benzamide-Type Histone Deacetylase Inhibitors with Enhanced Potency and Selectivity</span></div><div class="casAuthors">Moradei, Oscar M.; Mallais, Tammy C.; Frechette, Sylvie; Paquin, Isabelle; Tessier, Pierre E.; Leit, Silvana M.; Fournel, Marielle; Bonfils, Claire; Trachy-Bourget, Marie-Claude; Liu, Jianhong; Yan, Theresa P.; Lu, Ai-Hua; Rahil, Jubrail; Wang, James; Lefebvre, Sylvain; Li, Zuomei; Vaisburg, Arkadii F.; Besterman, Jeffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5543-5546</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant effort is being made to understand the role of HDAC isotypes in human cancer and to develop antitumor agents with better therapeutic windows.  A part of this endeavor was the exploration of the 14 Ã internal cavity adjacent to the enzyme catalytic site, which led to the design and synthesis of compd. 4 (I) with the unusual bis(aryl)-type pharmacophore.  SAR studies around this lead resulted in optimization to potent, selective, nonhydroxamic acid HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlM848KF3mo7Vg90H21EOLACvtfcHk0lgFvi5jhMAmPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKksLrL&md5=17012416f4be84479762acac0cff5e6f</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Fjm701079h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701079h%26sid%3Dliteratum%253Aachs%26aulast%3DMoradei%26aufirst%3DO.%2BM.%26aulast%3DMallais%26aufirst%3DT.%2BC.%26aulast%3DFrechette%26aufirst%3DS.%26aulast%3DPaquin%26aufirst%3DI.%26aulast%3DTessier%26aufirst%3DP.%2BE.%26aulast%3DLeit%26aufirst%3DS.%2BM.%26aulast%3DFournel%26aufirst%3DM.%26aulast%3DBonfils%26aufirst%3DC.%26aulast%3DTrachy-Bourget%26aufirst%3DM.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DT.%2BP.%26aulast%3DLu%26aufirst%3DA.%2BH.%26aulast%3DRahil%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DVaisburg%26aufirst%3DA.%2BF.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26atitle%3DNovel%2520aminophenyl%2520benzamide-type%2520histone%2520deacetylase%2520inhibitors%2520with%2520enhanced%2520potency%2520and%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5543%26epage%3D5546%26doi%3D10.1021%2Fjm701079h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as multifunctional agents for the therapy of alzheimerâs disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">69</span>â <span class="NLM_lpage">81</span>, <span class="refDoi">Â DOI: 10.1021/acschemneuro.5b00224</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00224" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1OhurnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=69-81&author=R.+Shengauthor=L.+Tangauthor=L.+Jiangauthor=L.+Hongauthor=Y.+Shiauthor=N.+Zhouauthor=Y.+Hu&title=Novel+1-phenyl-3-hydroxy-4-pyridinone+derivatives+as+multifunctional+agents+for+the+therapy+of+alzheimer%E2%80%99s+disease&doi=10.1021%2Facschemneuro.5b00224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 1-Phenyl-3-hydroxy-4-pyridinone Derivatives as Multifunctional Agents for the Therapy of Alzheimer's Disease</span></div><div class="casAuthors">Sheng, Rong; Tang, Li; Jiang, Liu; Hong, Lingjuan; Shi, Ying; Zhou, Naiming; Hu, Yongzhou</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-81</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 1-phenyl-3-hydroxy-4-pyridinone derivs. were designed and synthesized as multifunctional agents for Alzheimer's disease (AD) therapy through incorporation of 3-hydroxy-4-pyridinone moiety from deferiprone into the scaffold of H3 receptor antagonists.  Most of these new compds. displayed designed quadruple functions, H3 receptor antagonism, AÎ² aggregation inhibition, metal ion chelation, and radical scavenging.  Esp., the most promising compd. I displayed nanomolar IC50 values in H3 receptor antagonism with high selectivity, efficient capability to interrupt the formation of AÎ²1-42 fibrils, good copper and iron chelating properties, and more potent 2,2'-azino-bis(3-ethyl-benzothiazoline-6-sulfonic acid) radical cation (ABTSâ¢+) scavenging activity than Trolox.  Further biol. evaluation revealed that it did not show obvious cytotoxicity and hERG potassium channel inhibition at micromolar concn.  In addn., compd. I demonstrated suitable pharmacokinetic properties and acceptable blood-brain barrier permeability in vivo.  All these results indicate that compd. I is a potential multifunctional candidate for AD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOIWDXJyxn1bVg90H21EOLACvtfcHk0lgFvi5jhMAmPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1OhurnJ&md5=66c8440d6a02d18c7cbbd948f5b97540</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00224%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DHong%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DNovel%25201-phenyl-3-hydroxy-4-pyridinone%2520derivatives%2520as%2520multifunctional%2520agents%2520for%2520the%2520therapy%2520of%2520alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D69%26epage%3D81%26doi%3D10.1021%2Facschemneuro.5b00224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bajda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzior, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ignasik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malawska, B.</span></span> <span> </span><span class="NLM_article-title">Multi-target-directed ligands in Alzheimerâs disease treatment</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4949</span>â <span class="NLM_lpage">4975</span>, <span class="refDoi">Â DOI: 10.2174/092986711797535245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.2174%2F092986711797535245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=22050745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOrtL3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=4949-4975&author=M.+Bajdaauthor=N.+Guziorauthor=M.+Ignasikauthor=B.+Malawska&title=Multi-target-directed+ligands+in+Alzheimer%E2%80%99s+disease+treatment&doi=10.2174%2F092986711797535245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-directed ligands in Alzheimer's disease treatment</span></div><div class="casAuthors">Bajda, M.; Guzior, N.; Ignasik, M.; Malawska, B.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">4949-4975</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Among the various drug discovery methods, a very promising modern approach consists in designing multi-target-directed ligands (MTDLs).  This methodol. has been specifically developed for treatment of disorders with complex pathol. mechanisms.  One such disorder is Alzheimer's disease (AD), currently the most common multifactorial neurodegenerative disease.  AD is related to increased levels of the amyloid Î² peptide (AÎ²) and the hyperphosphorylated tau protein, along with loss of neurons and synapses.  Moreover, there is some evidence pointing to the role of oxidative stress, metal ion deregulation, inflammation and cell cycle regulatory failure in its pathogenesis.  There are many attractive targets for the development of anti-AD drugs, and the multi-factor nature of this disease calls for multi-target-directed compds. which can be beneficial for AD treatment.  This review presents the discovery of dual- and multi-acting anti-AD drug candidates, focusing on the novel design strategy and the compds. it yields - particularly hybrids obtained by linking structurally active moieties interacting with different targets.  The first group of compds. includes cholinesterase inhibitors acting as dual binding site inhibitors and/or inhibitors with addnl. properties.  These compds. are characterized by increased potency against acetylcholinesterase (AChE) and AÎ² plaque formation with addnl. properties such as antioxidant activity, neuroprotective, and metal-complexing property, voltage-dependent calcium channel antagonistic activity, inhibitory activity against glutamate-induced excitotoxicity, histamine H3 receptor antagonism, cannabinoid CB1 receptor antagonism and Î²-secretase (BACE1) inhibition.  A novel class of compds. represents the combination of dual BACE1 inhibitors with metal chelators, and dual modulators of Î³-secretase with peroxisome proliferator-activated receptor Î³ (PPARÎ³).  We have reviewed the latest reports (2008-2011) presenting new multi-target-directed compds. in Alzheimer's disease treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZHSluHvxy4bVg90H21EOLACvtfcHk0lgzJj1hox6yAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOrtL3F&md5=c8f35f849c399d43c90570f71ca10e13</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.2174%2F092986711797535245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711797535245%26sid%3Dliteratum%253Aachs%26aulast%3DBajda%26aufirst%3DM.%26aulast%3DGuzior%26aufirst%3DN.%26aulast%3DIgnasik%26aufirst%3DM.%26aulast%3DMalawska%26aufirst%3DB.%26atitle%3DMulti-target-directed%2520ligands%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520treatment%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D4949%26epage%3D4975%26doi%3D10.2174%2F092986711797535245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitobe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimoto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takenaga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, N.</span></span> <span> </span><span class="NLM_article-title">Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4780</span>â <span class="NLM_lpage">4789</span>, <span class="refDoi">Â DOI: 10.1021/jm8003834</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8003834" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotFyisrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4780-4789&author=T.+Nagaseauthor=T.+Mizutaniauthor=S.+Ishikawaauthor=E.+Sekinoauthor=T.+Sasakiauthor=T.+Fujimuraauthor=S.+Itoauthor=Y.+Mitobeauthor=Y.+Miyamotoauthor=R.+Yoshimotoauthor=T.+Tanakaauthor=A.+Ishiharaauthor=N.+Takenagaauthor=S.+Tokitaauthor=T.+Fukamiauthor=N.+Sato&title=Synthesis%2C+structure-activity+relationships%2C+and+biological+profiles+of+a+quinazolinone+class+of+histamine+H3+receptor+inverse+agonists&doi=10.1021%2Fjm8003834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and Biological Profiles of a Quinazolinone Class of Histamine H3 Receptor Inverse Agonists</span></div><div class="casAuthors">Nagase, Tsuyoshi; Mizutani, Takashi; Ishikawa, Shiho; Sekino, Etsuko; Sasaki, Takahide; Fujimura, Takashi; Ito, Sayaka; Mitobe, Yuko; Miyamoto, Yasuhisa; Yoshimoto, Ryo; Tanaka, Takeshi; Ishihara, Akane; Takenaga, Norihiro; Tokita, Shigeru; Fukami, Takehiro; Sato, Nagaaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4780-4789</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new series of quinazolinone derivs. was synthesized and evaluated as nonimidazole H3 receptor inverse agonists.  2-Methyl-3-(4-{[3-(1-pyrrolidinyl)propyl]oxy}phenyl)-5-(trifluoromethyl)-4(3H)-quinazolinone (I) was identified as a promising deriv. for further evaluation following optimization of key parameters.  Compd. I has potent H3 inverse agonist activity and excellent selectivity over other histamine receptor subtypes and a panel of 115 unrelated diverse binding sites.  Compd. I also shows satisfactory pharmacokinetic profiles and brain penetrability in lab. animals.  Two hours after oral administration of 30 mg/kg of I to SD rats, significant elevation of brain histamine levels was obsd. where the brain H3 receptor was highly occupied (>90%).  On the basis of species differences in P-glycoprotein (P-gp) susceptibility of I between human and rodent P-gps, the obsd. rodent brain permeability of I is significantly limited by P-gp mediated efflux in rodents, whereas the extent of P-gp mediated efflux in humans should be very small or negligible.  The potential of I to be an efficacious drug was demonstrated by its excellent brain penetrability and receptor occupancy in P-gp-deficient CF-1 mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYR_RpqlBn7LVg90H21EOLACvtfcHk0lgzJj1hox6yAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotFyisrg%253D&md5=c65380137974083d49df8012687832c2</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fjm8003834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8003834%26sid%3Dliteratum%253Aachs%26aulast%3DNagase%26aufirst%3DT.%26aulast%3DMizutani%26aufirst%3DT.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DSekino%26aufirst%3DE.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DFujimura%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DS.%26aulast%3DMitobe%26aufirst%3DY.%26aulast%3DMiyamoto%26aufirst%3DY.%26aulast%3DYoshimoto%26aufirst%3DR.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DIshihara%26aufirst%3DA.%26aulast%3DTakenaga%26aufirst%3DN.%26aulast%3DTokita%26aufirst%3DS.%26aulast%3DFukami%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DN.%26atitle%3DSynthesis%252C%2520structure-activity%2520relationships%252C%2520and%2520biological%2520profiles%2520of%2520a%2520quinazolinone%2520class%2520of%2520histamine%2520H3%2520receptor%2520inverse%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4780%26epage%3D4789%26doi%3D10.1021%2Fjm8003834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazewska, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiec-Kononowicz, K.</span></span> <span> </span><span class="NLM_article-title">New developments around histamine H(3) receptor antagonists/inverse agonists: a patent review (2010 - present)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">111</span>, <span class="refDoi">Â DOI: 10.1517/13543776.2014.848197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1517%2F13543776.2014.848197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=24131059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFSlurvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=89-111&author=D.+Lazewskaauthor=K.+Kiec-Kononowicz&title=New+developments+around+histamine+H%283%29+receptor+antagonists%2Finverse+agonists%3A+a+patent+review+%282010+-+present%29&doi=10.1517%2F13543776.2014.848197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">New developments around histamine H3 receptor antagonists/inverse agonists: a patent review (2010 - present)</span></div><div class="casAuthors">Lazewska, Dorota; Kiec-Kononowicz, Katarzyna</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-111</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Histamine H3 receptor (H3R) is involved in the central and peripheral regulation of levels of histamine and other neurotransmitters (e.g., acetylcholine, noradrenaline, dopamine or serotonin).  H3R antagonists/inverse agonists constitute attractive targets in the search for new drugs.  Preclin. data indicate their potential utility in the treatment of various central nervous system (CNS), metabolic, pain and allergic disorders.  So far, many structurally diverse H3R ligands have been synthesized and pharmacol. evaluated.  Certain compds. have reached clin. trials.  The first results from these studies have appeared.  Areas covered: The literature covering patent applications (2010 through June 2013) found in the Espacenet database will be reported.  Expert opinion: In comparison with previous years, recently the no. of patent applications concerning H3R antagonists/inverse agonists has decreased.  The utility of compds. is still being verified in pharmacol. studies.  The first published results from clin. trials have shown not only pos. effects but also emerging drawbacks.  So far, BF2.649 is the most advanced in human trials (tiprolisant; Phase III trials).  New ligands are being intensively tested in preclin. tests.  Thus, it is expected that they will soon undergo clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrODgwIR7-v9bVg90H21EOLACvtfcHk0lgzJj1hox6yAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFSlurvF&md5=c621d18e4bb0a3e8d3c5fb99fc3ebbee</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.848197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.848197%26sid%3Dliteratum%253Aachs%26aulast%3DLazewska%26aufirst%3DD.%26aulast%3DKiec-Kononowicz%26aufirst%3DK.%26atitle%3DNew%2520developments%2520around%2520histamine%2520H%25283%2529%2520receptor%2520antagonists%252Finverse%2520agonists%253A%2520a%2520patent%2520review%2520%25282010%2520-%2520present%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D89%26epage%3D111%26doi%3D10.1517%2F13543776.2014.848197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Does, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantjes, A.</span></span> <span> </span><span class="NLM_article-title">Iron (III)-chelating resins. 3. Synthesis, iron (III)-chelating properties, and in vitro antibacterial activity of compounds containing 3-hydroxy-2-methyl-4(1H)-pyridinone ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2822</span>â <span class="NLM_lpage">2827</span>, <span class="refDoi">Â DOI: 10.1021/jm00071a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00071a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK3sXlsFKjsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=2822-2827&author=M.+H.+Fengauthor=L.+van+der+Doesauthor=A.+Bantjes&title=Iron+%28III%29-chelating+resins.+3.+Synthesis%2C+iron+%28III%29-chelating+properties%2C+and+in+vitro+antibacterial+activity+of+compounds+containing+3-hydroxy-2-methyl-4%281H%29-pyridinone+ligands&doi=10.1021%2Fjm00071a013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Iron(III)-chelating resins. 3. Synthesis, iron(III)-chelating properties, and in vitro antibacterial activity of compounds containing 3-hydroxy-2-methyl-4(1H)-pyridinone ligands</span></div><div class="casAuthors">Feng, Min Hua; van der Does, Leen; Bantjes, Adriaan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2822-7</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The synthesis, iron(III)-chelating properties, and antibacterial activity of several compds. contg. the 3-hydroxy-2-methyl-4(1H)-pyridinone (HMP) moiety are described.  Using the HMP derivs., iron(III) could be mobilized from iron(III)-binding proteins at physiol. pH with a rate order of transferrin > lactoferrin > ferritin.  Addn. of HMP-contg. compds. to a growth medium at a concn. of 20 mM/L resulted in a complete inhibition of the growth of Escherichia coli and about 90% inhibition for Listeria inocua after 7 h of incubation at 37 Â°C.  After inhibition of bacteria growth by the HMP derivs., growth started again when ferric ions were added to the medium, which implies that the antibacterial activity is due to a limitation of iron available to the organisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjP8tmq10cPbVg90H21EOLACvtfcHk0lhsrqnhO_Mrug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsFKjsLg%253D&md5=bb48168ab601c31942907e798617b027</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm00071a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00071a013%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DM.%2BH.%26aulast%3Dvan%2Bder%2BDoes%26aufirst%3DL.%26aulast%3DBantjes%26aufirst%3DA.%26atitle%3DIron%2520%2528III%2529-chelating%2520resins.%25203.%2520Synthesis%252C%2520iron%2520%2528III%2529-chelating%2520properties%252C%2520and%2520in%2520vitro%2520antibacterial%2520activity%2520of%2520compounds%2520containing%25203-hydroxy-2-methyl-4%25281H%2529-pyridinone%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D2822%26epage%3D2827%26doi%3D10.1021%2Fjm00071a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howlett, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godfrey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swatton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzfaden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadsworth, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markwell, R. E.</span></span> <span> </span><span class="NLM_article-title">Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>340</i></span>,  <span class="NLM_fpage">283</span>â <span class="NLM_lpage">289</span>, <span class="refDoi">Â DOI: 10.1042/bj3400283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1042%2Fbj3400283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10229684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK1MXjs12ks7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=1999&pages=283-289&author=D.+R.+Howlettauthor=A.+E.+Perryauthor=F.+Godfreyauthor=J.+E.+Swattonauthor=K.+H.+Jenningsauthor=C.+Spitzfadenauthor=H.+Wadsworthauthor=S.+J.+Woodauthor=R.+E.+Markwell&title=Inhibition+of+fibril+formation+in+beta-amyloid+peptide+by+a+novel+series+of+benzofurans&doi=10.1042%2Fbj3400283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of fibril formation in Î²-amyloid peptide by a novel series of benzofurans</span></div><div class="casAuthors">Howlett, David R.; Perry, Amanda E.; Godfrey, Fiona; Swatton, Jane E.; Jennings, Kevin H.; Spitzfaden, Claus; Wadsworth, Harry; Wood, Stephen J.; Markwell, Roger E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">283-289</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A series of benzofuran derivs. have been identified as inhibitors of fibril formation in the Î²-amyloid peptide.  The activity of these compds. has been assessed by a novel fibril-formation-specific immunoassay and for their effects on the prodn. of a biol. active fibril product.  The inhibition afforded by the compds. seems to be assocd. with their binding to Î²-amyloid, as identified by scintillation proximity binding assay.  Binding assays and NMR studies also indicate that the inhibition is assocd. with self-aggregation of the compds.  There is a close correlation between the activity of the benzofurans as inhibitors of fibril formation and their ability to bind to Î²-amyloid.  Non-benzofuran inhibitors of the fibril formation process do not seem to bind to the same site on the Î²-amyloid mol. as the benzofurans.  Thus a specific recognition site might exist for benzofurans on Î²-amyloid, binding to which seems to interfere with the ability of the peptide to form fibrils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxXU-nZHkgI7Vg90H21EOLACvtfcHk0lhsrqnhO_Mrug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjs12ks7c%253D&md5=bac96c369fe13814e21fcea7adfc4efc</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1042%2Fbj3400283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3400283%26sid%3Dliteratum%253Aachs%26aulast%3DHowlett%26aufirst%3DD.%2BR.%26aulast%3DPerry%26aufirst%3DA.%2BE.%26aulast%3DGodfrey%26aufirst%3DF.%26aulast%3DSwatton%26aufirst%3DJ.%2BE.%26aulast%3DJennings%26aufirst%3DK.%2BH.%26aulast%3DSpitzfaden%26aufirst%3DC.%26aulast%3DWadsworth%26aufirst%3DH.%26aulast%3DWood%26aufirst%3DS.%2BJ.%26aulast%3DMarkwell%26aufirst%3DR.%2BE.%26atitle%3DInhibition%2520of%2520fibril%2520formation%2520in%2520beta-amyloid%2520peptide%2520by%2520a%2520novel%2520series%2520of%2520benzofurans%26jtitle%3DBiochem.%2520J.%26date%3D1999%26volume%3D340%26spage%3D283%26epage%3D289%26doi%3D10.1042%2Fbj3400283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, S.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of dual inhibitors for matrix metalloproteinase and cathepsin</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">375</span>â <span class="NLM_lpage">378</span>, <span class="refDoi">Â DOI: 10.1016/S0960-894X(01)00755-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS0960-894X%2801%2900755-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=11814800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XpslKktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=375-378&author=M.+Yamamotoauthor=S.+Ikedaauthor=H.+Kondoauthor=S.+Inoue&title=Design+and+synthesis+of+dual+inhibitors+for+matrix+metalloproteinase+and+cathepsin&doi=10.1016%2FS0960-894X%2801%2900755-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of dual inhibitors for matrix metalloproteinase and cathepsin</span></div><div class="casAuthors">Yamamoto, Minoru; Ikeda, Shoji; Kondo, Hirosato; Inoue, Shintaro</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-378</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The first example of dual inhibitors for matrix metalloproteinase (MMP) and cathepsin is described.  An appropriate alignment of peptide parts and two different specific functional groups in one mol. led to the discovery of a potent dual inhibitor in pseudopeptide aldehyde I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWufpXfVOslrVg90H21EOLACvtfcHk0lhsrqnhO_Mrug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpslKktA%253D%253D&md5=f12ee37183639244b07ab55c4d5690fc</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900755-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900755-7%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DIkeda%26aufirst%3DS.%26aulast%3DKondo%26aufirst%3DH.%26aulast%3DInoue%26aufirst%3DS.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dual%2520inhibitors%2520for%2520matrix%2520metalloproteinase%2520and%2520cathepsin%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D375%26epage%3D378%26doi%3D10.1016%2FS0960-894X%2801%2900755-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grams, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crimmin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinnes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huxley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieper, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschesche, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, W.</span></span> <span> </span><span class="NLM_article-title">Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">14012</span>â <span class="NLM_lpage">14020</span>, <span class="refDoi">Â DOI: 10.1021/bi00043a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00043a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK2MXos1WmsLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1995&pages=14012-14020&author=F.+Gramsauthor=M.+Crimminauthor=L.+Hinnesauthor=P.+Huxleyauthor=M.+Pieperauthor=H.+Tschescheauthor=W.+Bode&title=Structure+determination+and+analysis+of+human+neutrophil+collagenase+complexed+with+a+hydroxamate+inhibitor&doi=10.1021%2Fbi00043a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor</span></div><div class="casAuthors">Grams, Frank; Crimmin, Mike; Hinnes, Laurie; Huxley, Philip; Pieper, Michael; Tschesche, Harald; Bode, Wolfram</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">14012-20</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human neutrophil collagenase (I) represents 1 of the 3 interstitial collagenases that cleave triple-helical collagens types I, II, and III.  Its 163-residue catalytic domain (Met-80 to Gly-242) was expressed in Escherichia coli and crystd. as a noncovalent complex with the hydroxamate inhibitor, batimastat (II).  The crystal structure, refined to 2.1 Ã, demonstrated that II bound to the S1-S2' sites and coordinated to the catalytic Zn in a bidentate manner via the OH group and carbonyl O atoms of the hydroxamate group.  The I-II complex is described in detail, and the activities of II analogs are discussed in the light of the protein-inhibitor interactions revealed by the crystallog. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3Rs2OmOhJ1LVg90H21EOLACvtfcHk0lgW2MfiMeCBtg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXos1WmsLs%253D&md5=7b1fb4b420e580c72583b298265d7112</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fbi00043a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00043a007%26sid%3Dliteratum%253Aachs%26aulast%3DGrams%26aufirst%3DF.%26aulast%3DCrimmin%26aufirst%3DM.%26aulast%3DHinnes%26aufirst%3DL.%26aulast%3DHuxley%26aufirst%3DP.%26aulast%3DPieper%26aufirst%3DM.%26aulast%3DTschesche%26aufirst%3DH.%26aulast%3DBode%26aufirst%3DW.%26atitle%3DStructure%2520determination%2520and%2520analysis%2520of%2520human%2520neutrophil%2520collagenase%2520complexed%2520with%2520a%2520hydroxamate%2520inhibitor%26jtitle%3DBiochemistry%26date%3D1995%26volume%3D34%26spage%3D14012%26epage%3D14020%26doi%3D10.1021%2Fbi00043a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigeizumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K.</span></span> <span> </span><span class="NLM_article-title">Peptidyl aldehyde derivatives as potent and selective inhibitors of cathepsin L</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1501</span>â <span class="NLM_lpage">1504</span>, <span class="refDoi">Â DOI: 10.1016/0960-894X(95)00236-M</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2F0960-894X%2895%2900236-M" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK2MXntFKisrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1995&pages=1501-1504&author=J.+T.+Wooauthor=S.+Sigeizumiauthor=K.+Yamaguchiauthor=K.+Sugimotoauthor=T.+Koboriauthor=T.+Tsujiauthor=K.+Kondo&title=Peptidyl+aldehyde+derivatives+as+potent+and+selective+inhibitors+of+cathepsin+L&doi=10.1016%2F0960-894X%2895%2900236-M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Peptidyl aldehyde derivatives as potent and selective inhibitors of cathepsin L</span></div><div class="casAuthors">Woo, Je-Tae; Sigeizumi, Sanae; Yamaguchi, Kohji; Sugimoto, Kikuo; Kobori, Takeo; Tsuji, Tomoko; Kondo, Kiyosi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1501-4</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A series of peptidyl aldehyde derivs. were synthesized and tested for their inhibitory effects on several cysteine proteases and a serine protease.  These compds. showed no inhibition. for Î±-chymotrypsin at the concn. less than 1000 ng/mL, while they exhibited prominent inhibition for calpain II and cathepsins, esp. cathepsin L.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTkB6eOZAZ9rVg90H21EOLACvtfcHk0lgW2MfiMeCBtg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXntFKisrk%253D&md5=d070ff4b3c5775837b8d10cf58894daf</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2895%2900236-M&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252895%252900236-M%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DJ.%2BT.%26aulast%3DSigeizumi%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DSugimoto%26aufirst%3DK.%26aulast%3DKobori%26aufirst%3DT.%26aulast%3DTsuji%26aufirst%3DT.%26aulast%3DKondo%26aufirst%3DK.%26atitle%3DPeptidyl%2520aldehyde%2520derivatives%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520cathepsin%2520L%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1995%26volume%3D5%26spage%3D1501%26epage%3D1504%26doi%3D10.1016%2F0960-894X%2895%2900236-M" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3</span>â <span class="NLM_lpage">25</span>, <span class="refDoi">Â DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0lgW2MfiMeCBtg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberry, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallender, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, J. L.</span></span> <span> </span><span class="NLM_article-title">Three-dimensional structures of Drosophila melanogaster acetylcholinesterase and of its complexes with two potent inhibitors</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1063</span>â <span class="NLM_lpage">1072</span>, <span class="refDoi">Â DOI: 10.1110/ps.9.6.1063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1110%2Fps.9.6.1063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10892800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1Kqs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2000&pages=1063-1072&author=M.+Harelauthor=G.+Krygerauthor=T.+L.+Rosenberryauthor=W.+D.+Mallenderauthor=T.+Lewisauthor=R.+J.+Fletcherauthor=J.+M.+Gussauthor=I.+Silmanauthor=J.+L.+Sussman&title=Three-dimensional+structures+of+Drosophila+melanogaster+acetylcholinesterase+and+of+its+complexes+with+two+potent+inhibitors&doi=10.1110%2Fps.9.6.1063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Three-dimensional structures of Drosophila melanogaster acetylcholinesterase and of its complexes with two potent inhibitors</span></div><div class="casAuthors">Harel, Michal; Kryger, Gitay; Rosenberry, Terrone L.; Mallender, William D.; Lewis, Terence; Fletcher, Rodney J.; Guss, J. Mitchell; Silman, Israel; Sussman, Joel L.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1063-1072</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">We have crystd. Drosophila melanogaster acetylcholinesterase and solved the structure of the native enzyme and of its complexes with two potent reversible inhibitors, I and II, all three at 2.7 Ã resoln.  The refined structure of D. melanogaster acetylcholinesterase is similar to that of vertebrate acetylcholinesterases, for example, human, mouse, and fish, in its overall fold, charge distribution, and deep active-site gorge, but some of the surface loops deviate by up to 8 Ã from their position in the vertebrate structures, and the C-terminal helix is shifted substantially.  The active-site gorge of the insect enzyme is significantly narrower than that of Torpedo californica AChE, and its trajectory is shifted several angstroms.  The vol. of the lower part of the gorge of the insect enzyme is â¼50% of that of the vertebrate enzyme.  Upon binding of either of the two inhibitors, nine arom. side chains within the active-site gorge change their conformation so as to interact with the inhibitors.  Some differences in activity and specificity between the insect and vertebrate enzymes can be explained by comparison of their three-dimensional structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfFvuVy44a8LVg90H21EOLACvtfcHk0ljV63MyRCg64A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1Kqs70%253D&md5=b664cffd676e44e0311fc30920bcd280</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1110%2Fps.9.6.1063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1110%252Fps.9.6.1063%26sid%3Dliteratum%253Aachs%26aulast%3DHarel%26aufirst%3DM.%26aulast%3DKryger%26aufirst%3DG.%26aulast%3DRosenberry%26aufirst%3DT.%2BL.%26aulast%3DMallender%26aufirst%3DW.%2BD.%26aulast%3DLewis%26aufirst%3DT.%26aulast%3DFletcher%26aufirst%3DR.%2BJ.%26aulast%3DGuss%26aufirst%3DJ.%2BM.%26aulast%3DSilman%26aufirst%3DI.%26aulast%3DSussman%26aufirst%3DJ.%2BL.%26atitle%3DThree-dimensional%2520structures%2520of%2520Drosophila%2520melanogaster%2520acetylcholinesterase%2520and%2520of%2520its%2520complexes%2520with%2520two%2520potent%2520inhibitors%26jtitle%3DProtein%2520Sci.%26date%3D2000%26volume%3D9%26spage%3D1063%26epage%3D1072%26doi%3D10.1110%2Fps.9.6.1063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schalk, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehret-Sabatier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goeldner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axelsen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, J. L.</span></span> <span> </span><span class="NLM_article-title">Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">9031</span>â <span class="NLM_lpage">9035</span>, <span class="refDoi">Â DOI: 10.1073/pnas.90.19.9031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1073%2Fpnas.90.19.9031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=8415649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK3sXmsVCgtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=9031-9035&author=M.+Harelauthor=I.+Schalkauthor=L.+Ehret-Sabatierauthor=F.+Bouetauthor=M.+Goeldnerauthor=C.+Hirthauthor=P.+H.+Axelsenauthor=I.+Silmanauthor=J.+L.+Sussman&title=Quaternary+ligand+binding+to+aromatic+residues+in+the+active-site+gorge+of+acetylcholinesterase&doi=10.1073%2Fpnas.90.19.9031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase</span></div><div class="casAuthors">Harel, M.; Schalk, I.; Ehret-Sabatier, L.; Bouet, F.; Goeldner, M.; Hirth, C.; Axelsen, P. H.; Silman, I.; Sussman, J. L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9031-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The binding sites of Torpedo acetylcholinesterase (AChE; EC 3.1.1.7) for quaternary ligands were investigated by x-ray crystallog. and photoaffinity labeling.  The crystal structures of complexes with ligands were detd. at 2.8-Ã resoln.  In a complex with edrophonium, the quaternary N atom of the ligand interacted with the indole of Trp-84, and its m-OH group displayed bifurcated H-bonding to 2 members of the catalytic triad, Ser-200 and His-440.  In a complex with tacrine, the acridine was stacked against the indole of Trp-84.  The bisquaternary ligand, decamethonium, was oriented along the narrow gorge leading to the active site; one quaternary group was apposed to the indole of Trp-84 and the other to that of Trp-279, near the top of the gorge.  The only major conformational difference between the 3 complexes was in the orientation of the Ph ring of Phe-330.  In the decamethonium complex, it lay parallel to the surface of the gorge; in the other 2 complexes it was positioned to make contact with the bound ligand.  This close interaction was confirmed by photoaffinity labeling by the photosensitive probe, 3H-labeled p-(N,N-dimethylamino)benzenediazonium fluoroborate, which labeled, predominantly, Phe-330 within the active site.  The labeling of Trp-279 was also obsd.  One mole of label was incorporated per mol of AChE inactivated, indicating that the labeling of Trp-279 and that of Phe-330 were mutually exclusive.  The structural and chem. data, together, showed the important role of arom. groups as binding sites for quaternary ligands, and they provided complementary evidence assigning Trp-84 and Phe-330 to the anionic subsite of the active site and Trp-279 to the peripheral anionic site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVCccIwJSrW7Vg90H21EOLACvtfcHk0ljV63MyRCg64A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmsVCgtrc%253D&md5=6ee8dbaf1919d254a1cb62895f1a4444</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.19.9031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.19.9031%26sid%3Dliteratum%253Aachs%26aulast%3DHarel%26aufirst%3DM.%26aulast%3DSchalk%26aufirst%3DI.%26aulast%3DEhret-Sabatier%26aufirst%3DL.%26aulast%3DBouet%26aufirst%3DF.%26aulast%3DGoeldner%26aufirst%3DM.%26aulast%3DHirth%26aufirst%3DC.%26aulast%3DAxelsen%26aufirst%3DP.%2BH.%26aulast%3DSilman%26aufirst%3DI.%26aulast%3DSussman%26aufirst%3DJ.%2BL.%26atitle%3DQuaternary%2520ligand%2520binding%2520to%2520aromatic%2520residues%2520in%2520the%2520active-site%2520gorge%2520of%2520acetylcholinesterase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1993%26volume%3D90%26spage%3D9031%26epage%3D9035%26doi%3D10.1073%2Fpnas.90.19.9031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Arias, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez-GonzÃ¡lez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, E. H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espelosin, M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of first-in-class dual acting HDAC and PDE5 inhibitors for the treatment of Alzheimerâs disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8967</span>â <span class="NLM_lpage">9004</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00908</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00908" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyqtL7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8967-9004&author=O.+Rabalauthor=J.+A.+Sanchez-Ariasauthor=M.+D.+M.+Cuadrado-Tejedorauthor=I.+D.+Miguelauthor=M.+P%C3%A9rez-Gonz%C3%A1lezauthor=C.+Garcia-Barrosoauthor=A.+Ugarteauthor=E.+H.+D.+Mendozaauthor=E.+Saezauthor=M.+Espelosin&title=Design%2C+synthesis%2C+and+biological+evaluation+of+first-in-class+dual+acting+HDAC+and+PDE5+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Facs.jmedchem.6b00908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Rabal, Obdulia; Sanchez-Arias, Juan A.; Cuadrado-Tejedor, Mar; de Miguel, Irene; Perez-Gonzalez, Marta; Garcia-Barroso, Carolina; Ugarte, Ana; Estella-Hermoso de Mendoza, Ander; Saez, Elena; Espelosin, Maria; Ursua, Susana; Haizhong, Tan; Wei, Wu; Musheng, Xu; Garcia-Osta, Ana; Oyarzabal, Julen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8967-9004</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylases (HDAC) has recently been validated as a potentially novel therapeutic approach for Alzheimer's Disease (AD).  To further extend this concept, the authors designed and synthesized the first chem. series of dual acting PDE5 and HDAC inhibitors, and the authors validated this systems therapeutics approach.  Following the implementation of structure- and knowledge-based approaches, initial hits were designed and were shown to validate the hypothesis of dual in vitro inhibition.  Then, an optimization strategy was pursued to obtain a proper tool compd. for in vivo testing in AD models.  Initial hits were translated into mols. with adequate cellular functional responses (histone acetylation and cAMP/cGMP response element-binding (CREB) phosphorylation in the nanomolar range), an acceptable therapeutic window (>1 log unit) and the ability to cross the blood-brain barrier, leading to the identification of 7 as a candidate for in vivo proof-of-concept testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbHBoJlefNEbVg90H21EOLACvtfcHk0ljV63MyRCg64A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyqtL7O&md5=756a252809f05f5d7fc59e828736cfba</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00908%26sid%3Dliteratum%253Aachs%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DSanchez-Arias%26aufirst%3DJ.%2BA.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%2BD.%2BM.%26aulast%3DMiguel%26aufirst%3DI.%2BD.%26aulast%3DP%25C3%25A9rez-Gonz%25C3%25A1lez%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DMendoza%26aufirst%3DE.%2BH.%2BD.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DEspelosin%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520first-in-class%2520dual%2520acting%2520HDAC%2520and%2520PDE5%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8967%26epage%3D9004%26doi%3D10.1021%2Facs.jmedchem.6b00908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sivaprakasam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civiello, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacutin-Porte, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szapiel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newitt, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nophsker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1856</span>â <span class="NLM_lpage">1863</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.03.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmcl.2015.03.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=25845281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVKrsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1856-1863&author=P.+Sivaprakasamauthor=X.+Hanauthor=R.+L.+Civielloauthor=S.+Jacutin-Porteauthor=K.+Kishauthor=M.+Pokrossauthor=H.+A.+Lewisauthor=N.+Ahmedauthor=N.+Szapielauthor=J.+A.+Newittauthor=E.+T.+Baldwinauthor=H.+Xiaoauthor=C.+M.+Krauseauthor=H.+Parkauthor=M.+Nophskerauthor=J.+S.+Lippyauthor=C.+R.+Burtonauthor=D.+R.+Langleyauthor=J.+E.+Macorauthor=G.+M.+Dubowchik&title=Discovery+of+new+acylaminopyridines+as+GSK-3+inhibitors+by+a+structure+guided+in-depth+exploration+of+chemical+space+around+a+pyrrolopyridinone+core&doi=10.1016%2Fj.bmcl.2015.03.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core</span></div><div class="casAuthors">Sivaprakasam, Prasanna; Han, Xiaojun; Civiello, Rita L.; Jacutin-Porte, Swanee; Kish, Kevin; Pokross, Matt; Lewis, Hal A.; Ahmed, Nazia; Szapiel, Nicolas; Newitt, John A.; Baldwin, Eric T.; Xiao, Hong; Krause, Carol M.; Park, Hyunsoo; Nophsker, Michelle; Lippy, Jonathan S.; Burton, Catherine R.; Langley, David R.; Macor, John E.; Dubowchik, Gene M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1856-1863</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Glycogen synthase kinase-3 (GSK-3) has been proposed to play a crucial role in the pathogenesis of many diseases including cancer, stroke, bipolar disorders, diabetes and neurodegenerative diseases.  GSK-3 inhibition has been a major area of pharmaceutical interest over the last two decades.  A plethora of reports appeared recently on selective inhibitors and their co-crystal structures in GSK-3Î².  We identified several series of promising new GSK-3Î² inhibitors from a coherent design around a pyrrolopyridinone core structure.  A systematic exploration of the chem. space around the central spacer led to potent single digit and sub-nanomolar GSK-3Î² inhibitors.  When dosed orally in a transgenic mouse model of Alzheimer's disease (AD), an exemplary compd. showed significant lowering of Tau phosphorylation at one of the GSK-3 phosphorylating sites, Ser396.  X-ray crystallog. greatly aided in validating the binding hypotheses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTULEgiCtJ_bVg90H21EOLACvtfcHk0liNtoLp-QAv_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVKrsro%253D&md5=207523726b69167ee5318f90b2822af0</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.03.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.03.046%26sid%3Dliteratum%253Aachs%26aulast%3DSivaprakasam%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DJacutin-Porte%26aufirst%3DS.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DH.%2BA.%26aulast%3DAhmed%26aufirst%3DN.%26aulast%3DSzapiel%26aufirst%3DN.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DBaldwin%26aufirst%3DE.%2BT.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DKrause%26aufirst%3DC.%2BM.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DNophsker%26aufirst%3DM.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DBurton%26aufirst%3DC.%2BR.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26atitle%3DDiscovery%2520of%2520new%2520acylaminopyridines%2520as%2520GSK-3%2520inhibitors%2520by%2520a%2520structure%2520guided%2520in-depth%2520exploration%2520of%2520chemical%2520space%2520around%2520a%2520pyrrolopyridinone%2520core%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1856%26epage%3D1863%26doi%3D10.1016%2Fj.bmcl.2015.03.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimerâs disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">745</span>â <span class="NLM_lpage">753</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2013.01.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2013.01.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23454517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslWgu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=745-753&author=C.+Luauthor=Q.+Zhouauthor=J.+Yanauthor=Z.+Duauthor=L.+Huangauthor=X.+Li&title=A+novel+series+of+tacrine-selegiline+hybrids+with+cholinesterase+and+monoamine+oxidase+inhibition+activities+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2013.01.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Lu, Chuanjun; Zhou, Qi; Yan, Jun; Du, Zhiyun; Huang, Ling; Li, Xingshu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">745-753</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of tacrine-selegiline hybrids was synthesized and evaluated for application as inhibitors of cholinesterase (AChE/BuChE) and monoamine oxidase (MAO-A/B).  The results demonstrate that most of the synthesized compds. exhibit high inhibitory activity.  Among these compds., compd. I provided a good balance of activity towards all targets (with IC50 values of 22.6 nM, 9.37 nM, 0.3724 Î¼M, and 0.1810 Î¼M for AChE, BuChE, MAO-A and MAO-B, resp.).  These results indicated that I has the potential to be a multi-functional candidate for Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB-OnHqpBtBrVg90H21EOLACvtfcHk0liNtoLp-QAv_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslWgu7g%253D&md5=9e0cfdecbe4e8a2890482f8b32cbf4a4</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.01.039%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DA%2520novel%2520series%2520of%2520tacrine-selegiline%2520hybrids%2520with%2520cholinesterase%2520and%2520monoamine%2520oxidase%2520inhibition%2520activities%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D62%26spage%3D745%26epage%3D753%26doi%3D10.1016%2Fj.ejmech.2013.01.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Am, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amit, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinreb, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandel, S.</span></span> <span> </span><span class="NLM_article-title">Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">361</span>â <span class="NLM_lpage">371</span>, <span class="refDoi">Â DOI: 10.3233/JAD-2010-100150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.3233%2FJAD-2010-100150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=20555137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVKiurbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=361-371&author=O.+Bar-Amauthor=T.+Amitauthor=O.+Weinrebauthor=M.+B.+Youdimauthor=S.+Mandel&title=Propargylamine+containing+compounds+as+modulators+of+proteolytic+cleavage+of+amyloid-beta+protein+precursor%3A+involvement+of+MAPK+and+PKC+activation&doi=10.3233%2FJAD-2010-100150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Propargylamine Containing Compounds as Modulators of Proteolytic Cleavage of Amyloid Protein Precursor: Involvement of MAPK and PKC Activation</span></div><div class="casAuthors">Bar-Am, Orit; Amit, Tamar; Weinreb, Orly; Youdim, Moussa B. H.; Mandel, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-371</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  The anti-Parkinsonian, irreversible, selective monoamine oxidase (MAO)-B inhibitors, selegiline (deprenyl, (R)-N-methyl-N-(1-phenylpropan-2-yl) prop-2-yn-1-amine) and rasagiline (Azilect, N-propargyl-1(R)-aminoindan), have been proven to possess neuroprotective/neurorestorative activities in cell cultures and animal models of neurodegenerative diseases.  Structure-activity studies provide evidence that neuroprotection is assocd. with some intrinsic pharmacol. action of the propargylamine moiety in these drugs.  This indication and recent therapeutic approaches, entailing new drug candidates possessing diverse pharmacol. properties and acting on multiple targets, have stimulated the development of two multifunctional chimeric propargylamine-derivs.: 1) ladostigil (TV3326, [(N-propargyl-(3R) 1-(R)-aminoindan-5yl)-Et Me carbamate)], which combines the pharmacophore of rasagiline, with the carbamate moiety of the cholinesterase inhibitor rivastigmine, as a potential treatment for Alzheimer's disease and Lewy body disease; and 2) M30 5-[(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline], where the propargylamine moiety of rasagiline was embedded onto the backbone of the neuroprotective and brain permeable iron chelator 8-hydroxyquinoline-deriv., VK28 as a potential treatment for various neurodegenerative disorders.  Both multifunctional propargylamine-derivs. were found to possess neuroprotective and anti-apoptotic properties.  An addnl. and new neuroprotective effect, shared by the propargylamine-deriv. compds., is related to their ability to regulate the processing of amyloid-Î² protein precursor (AÎ²PP) by the non-amyloidogenic Î±-secretase pathway.  This effect was shown to involve activation of p42/44 mitogen-activated protein kinase (MAPK) and protein kinase C (PKC) signaling pathway.  This review will summarize and discuss current research, focused on the effect of propargylamine-related derivs. on the proteolytic processing of AÎ²PP and signal transduction mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotFS9dzcnX37Vg90H21EOLACvtfcHk0liNtoLp-QAv_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVKiurbE&md5=8250c3767772a7872029118692aba8fc</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.3233%2FJAD-2010-100150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2010-100150%26sid%3Dliteratum%253Aachs%26aulast%3DBar-Am%26aufirst%3DO.%26aulast%3DAmit%26aufirst%3DT.%26aulast%3DWeinreb%26aufirst%3DO.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DMandel%26aufirst%3DS.%26atitle%3DPropargylamine%2520containing%2520compounds%2520as%2520modulators%2520of%2520proteolytic%2520cleavage%2520of%2520amyloid-beta%2520protein%2520precursor%253A%2520involvement%2520of%2520MAPK%2520and%2520PKC%2520activation%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2010%26volume%3D21%26spage%3D361%26epage%3D371%26doi%3D10.3233%2FJAD-2010-100150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Bachiller, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monjas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rademann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Franco, M. I.</span></span> <span> </span><span class="NLM_article-title">New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimerâs disease, with cholinergic, antioxidant, and Î²-amyloid-reducing properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1303</span>â <span class="NLM_lpage">1317</span>, <span class="refDoi">Â DOI: 10.1021/jm201460y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201460y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFKisw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1303-1317&author=M.+I.+Fernandez-Bachillerauthor=C.+Perezauthor=L.+Monjasauthor=J.+Rademannauthor=M.+I.+Rodriguez-Franco&title=New+tacrine-4-oxo-4H-chromene+hybrids+as+multifunctional+agents+for+the+treatment+of+Alzheimer%E2%80%99s+disease%2C+with+cholinergic%2C+antioxidant%2C+and+%CE%B2-amyloid-reducing+properties&doi=10.1021%2Fjm201460y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">New Tacrine-4-Oxo-4H-chromene Hybrids as Multifunctional Agents for the Treatment of Alzheimer's Disease, with Cholinergic, Antioxidant, and Î²-Amyloid-Reducing Properties</span></div><div class="casAuthors">Fernandez-Bachiller, Maria Isabel; Perez, Concepcion; Monjas, Leticia; Rademann, Jorg; Rodriguez-Franco, Maria Isabel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1303-1317</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By using fragments endowed with interesting and complementary properties for the treatment of Alzheimer's disease (AD), a new family of tacrine-4-oxo-4H-chromene hybrids has been designed, synthesized, and evaluated biol.  The tacrine fragment was selected for its inhibition of cholinesterases, and the flavonoid scaffold derived from 4-oxo-4H -chromene was chosen for its radical capture and Î²-secretase 1 (BACE-1) inhibitory activities.  At nano- and picomolar concns., the new tacrine-4-oxo-4H-chromene hybrids inhibit human acetyl- and butyrylcholinesterase (h-AChE and h-BuChE), being more potent than the parent inhibitor, tacrine.  They are also potent inhibitors of human BACE-1, better than the parent flavonoid, apigenin.  They show interesting antioxidant properties and could be able to penetrate into the CNS according to the in vitro PAMPA-BBB assay.  Among the hybrids investigated, 6-hydroxy-4-oxo- N-{10-[(1,2,3,4-tetrahydroacridin-9-yl)amino]decyl}-4 H-chromene-2-carboxamide (I) shows potent combined inhibition of human BACE-1 and ChEs, as well as good antioxidant and CNS-permeable properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiMx-NagCpeLVg90H21EOLACvtfcHk0lih-8iNrOmX-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFKisw%253D%253D&md5=9391af9439e43f5eda518919839bd473</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjm201460y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201460y%26sid%3Dliteratum%253Aachs%26aulast%3DFernandez-Bachiller%26aufirst%3DM.%2BI.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DMonjas%26aufirst%3DL.%26aulast%3DRademann%26aufirst%3DJ.%26aulast%3DRodriguez-Franco%26aufirst%3DM.%2BI.%26atitle%3DNew%2520tacrine-4-oxo-4H-chromene%2520hybrids%2520as%2520multifunctional%2520agents%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%252C%2520with%2520cholinergic%252C%2520antioxidant%252C%2520and%2520%25CE%25B2-amyloid-reducing%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1303%26epage%3D1317%26doi%3D10.1021%2Fjm201460y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osseni, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debbasch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christen, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnet, J. M.</span></span> <span> </span><span class="NLM_article-title">Tacrine-induced reactive oxygen species in a human liver cell line: the role of anethole dithiolethione as a scavenger</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">683</span>â <span class="NLM_lpage">688</span>, <span class="refDoi">Â DOI: 10.1016/S0887-2333(99)00050-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS0887-2333%2899%2900050-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=20654534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK1MXlslWit7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1999&pages=683-688&author=R.+A.+Osseniauthor=C.+Debbaschauthor=M.+O.+Christenauthor=P.+Ratauthor=J.+M.+Warnet&title=Tacrine-induced+reactive+oxygen+species+in+a+human+liver+cell+line%3A+the+role+of+anethole+dithiolethione+as+a+scavenger&doi=10.1016%2FS0887-2333%2899%2900050-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Tacrine-induced reactive oxygen species in a human liver cell line: the role of anethole dithiolethione as a scavenger</span></div><div class="casAuthors">Osseni, R. A.; Debbasch, C.; Christen, M.-O.; Rat, P.; Warnet, J.-M.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology in Vitro</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4/5</span>),
    <span class="NLM_cas:pages">683-688</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The mechanisms leading to tacrine (THA) hepatotoxic effects are not yet fully understood.  Reactive oxygen species (ROS) overprodn. and intracellular reduced glutathione (GSH) depletion are common mechanisms involved in drug toxicity.  The aim of this study was to investigate, on the human liver cell line HepG2, whether THA at human blood concns. induces ROS prodn. stimulation and(or) GSH depletion.  A possible effect of a free radical scavenger, anethole dithiolethione (ADT), was also assessed.  ROS prodn. was measured with a fluorogen probe 2',7'-dichlorofluorescin diacetate (DCFH-DA).  Reduced GSH and cell viability were measured with, resp., monochlorobimane (mBCl) and neutral red probes.  Assays were performed directly on living adherent cells in 96-well microplates, and sensitive fluorescent detection used microplate cytofluorometry with cold light fluorometry technol.  The results showed that THA induced a concn.-dependent increase in ROS prodn. and a decrease in GSH.  Furthermore, for THA concns. between 10 and 100 Î¼M, ADT protected cells from ROS prodn. stimulation and GSH depletion induced by THA.  Thus, this in vitro study demonstrates that oxidative stress, evidenced by enhanced ROS prodn. and GSH depletion, is a mechanism involved in THA cytotoxicity.  Moreover, ADT is effective in preventing THA-induced injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsG1G2puSbFLVg90H21EOLACvtfcHk0lih-8iNrOmX-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlslWit7o%253D&md5=b3aedfa565619d92bb7cb27019a60be8</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2FS0887-2333%2899%2900050-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0887-2333%252899%252900050-8%26sid%3Dliteratum%253Aachs%26aulast%3DOsseni%26aufirst%3DR.%2BA.%26aulast%3DDebbasch%26aufirst%3DC.%26aulast%3DChristen%26aufirst%3DM.%2BO.%26aulast%3DRat%26aufirst%3DP.%26aulast%3DWarnet%26aufirst%3DJ.%2BM.%26atitle%3DTacrine-induced%2520reactive%2520oxygen%2520species%2520in%2520a%2520human%2520liver%2520cell%2520line%253A%2520the%2520role%2520of%2520anethole%2520dithiolethione%2520as%2520a%2520scavenger%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D1999%26volume%3D13%26spage%3D683%26epage%3D688%26doi%3D10.1016%2FS0887-2333%2899%2900050-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimmyo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akaike, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niidome, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, H.</span></span> <span> </span><span class="NLM_article-title">Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1780</i></span>,  <span class="NLM_fpage">819</span>â <span class="NLM_lpage">825</span>, <span class="refDoi">Â DOI: 10.1016/j.bbagen.2008.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bbagen.2008.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=18295609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvFWqurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1780&publication_year=2008&pages=819-825&author=Y.+Shimmyoauthor=T.+Kiharaauthor=A.+Akaikeauthor=T.+Niidomeauthor=H.+Sugimoto&title=Flavonols+and+flavones+as+BACE-1+inhibitors%3A+structure-activity+relationship+in+cell-free%2C+cell-based+and+in+silico+studies+reveal+novel+pharmacophore+features&doi=10.1016%2Fj.bbagen.2008.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Flavonols and flavones as BACE-1 inhibitors: Structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features</span></div><div class="casAuthors">Shimmyo, Yoshiari; Kihara, Takeshi; Akaike, Akinori; Niidome, Tetsuhiro; Sugimoto, Hachiro</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1780</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">819-825</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Generation and accumulation of the amyloid Î² peptide (AÎ²) following proteolytic processing of the amyloid precursor protein (APP) by BACE-1 (Beta-site APP Cleaving Enzyme-1, Î²-secretase) and Î³-secretase is a main causal factor of Alzheimer's disease (AD).  Consequently, inhibition of BACE-1, a rate-limiting enzyme in the prodn. of AÎ², is an attractive therapeutic approach for the treatment of AD.  In this study, we discovered that natural flavonoids act as non-peptidic BACE-1 inhibitors and potently inhibit BACE-1 activity and reduce the level of secreted AÎ² in primary cortical neurons.  In addn., we demonstrated the calcd. docking poses of flavonoids to BACE-1 and revealed the interactions of flavonoids with the BACE-1 catalytic center.  We firstly revealed novel pharmacophore features of flavonoids by using cell-free, cell-based and in silico docking studies.  These results contribute to the development of new BACE-1 inhibitors for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr69BA7p_u0orVg90H21EOLACvtfcHk0lih-8iNrOmX-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFWqurw%253D&md5=9e4ecbe2a53f79bdcc25581725e39ac7</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2008.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2008.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DShimmyo%26aufirst%3DY.%26aulast%3DKihara%26aufirst%3DT.%26aulast%3DAkaike%26aufirst%3DA.%26aulast%3DNiidome%26aufirst%3DT.%26aulast%3DSugimoto%26aufirst%3DH.%26atitle%3DFlavonols%2520and%2520flavones%2520as%2520BACE-1%2520inhibitors%253A%2520structure-activity%2520relationship%2520in%2520cell-free%252C%2520cell-based%2520and%2520in%2520silico%2520studies%2520reveal%2520novel%2520pharmacophore%2520features%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2008%26volume%3D1780%26spage%3D819%26epage%3D825%26doi%3D10.1016%2Fj.bbagen.2008.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolden, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Anticancer activities of histone deacetylase inhibitors</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">769</span>â <span class="NLM_lpage">784</span>, <span class="refDoi">Â DOI: 10.1038/nrd2133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fnrd2133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=16955068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=769-784&author=J.+E.+Boldenauthor=M.+J.+Peartauthor=R.+W.+Johnstone&title=Anticancer+activities+of+histone+deacetylase+inhibitors&doi=10.1038%2Fnrd2133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer activities of histone deacetylase inhibitors</span></div><div class="casAuthors">Bolden, Jessica E.; Peart, Melissa J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">769-784</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic regulation of gene expression.  In addn., the activity of non-histone proteins can be regulated through HDAC-mediated hypo-acetylation.  In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes assocd. with cancer, and several classes of HDAC inhibitors have been found to have potent and specific anticancer activities in preclin. studies.  However, such studies have also indicated that the effects of HDAC inhibitors could be considerably broader and more complicated than originally understood.  Here we summarize recent advances in the understanding of the mol. events that underlie the anticancer effects of HDAC inhibitors, and discuss how such information could be used in optimizing the development and application of these agents in the clinic, either as monotherapies or in combination with other anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhfqS1awkOHbVg90H21EOLACvtfcHk0ligIDyUBzjtpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltrY%253D&md5=91e55ee942fda3e4e2055ddf299fc866</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fnrd2133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2133%26sid%3Dliteratum%253Aachs%26aulast%3DBolden%26aufirst%3DJ.%2BE.%26aulast%3DPeart%26aufirst%3DM.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DAnticancer%2520activities%2520of%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D769%26epage%3D784%26doi%3D10.1038%2Fnrd2133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">27</span>â <span class="NLM_lpage">37</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2016.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmc.2016.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=27769671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslShu7%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=27-37&author=C.+Dingauthor=S.+Chenauthor=C.+Zhangauthor=G.+Huauthor=W.+Zhangauthor=L.+Liauthor=Y.+Z.+Chenauthor=C.+Tanauthor=Y.+Jiang&title=Synthesis+and+investigation+of+novel+6-%281%2C2%2C3-triazol-4-yl%29-4-aminoquinazolin+derivatives+possessing+hydroxamic+acid+moiety+for+cancer+therapy&doi=10.1016%2Fj.bmc.2016.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy</span></div><div class="casAuthors">Ding, Chao; Chen, Shaopeng; Zhang, Cunlong; Hu, Guangnan; Zhang, Wei; Li, Lulu; Chen, Yu Zong; Tan, Chunyan; Jiang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-37</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">By merging the crit. pharmacophore of EGFR/HER2 and HDAC inhibitors into one compd., a novel series of EGFR, HER-2, and HDAC multitarget inhibitors were synthesized.  Compds. 9a-l contained 4-anilinoquinazolines with C-6 triazole-linked long alkyl chains of hydroxamic acid and displayed excellent inhibition against these enzymes (compd. 9d exhibited the best inhibitory potency on wild-type EGFR, HDAC1, and HDAC6 with IC50 values 0.12 nM, 0.72 nM and 3.2 nM individually).  Furthermore, compds. 9b and 9d potently inhibited proliferation of five human cancer cell lines (with IC50 values between 0.49 and 8.76 Î¼M).  Further mechanistic study revealed that compd. 9d also regulated the phosphorylation of EGFR and HER2 and histone H3 hyperacetylation on the cellular level and induced remarkable apoptosis in BT-474 cells.  Therefore, our study suggested that a system network-based multi-target drug design strategy might provided an alternate drug design method, by taking into account the synergy effect of EGFR, HER-2 and HDAC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9Ow9m5nCSsbVg90H21EOLACvtfcHk0ligIDyUBzjtpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslShu7%252FO&md5=8be7d3dbffe5f5b9b305280864e5b633</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520investigation%2520of%2520novel%25206-%25281%252C2%252C3-triazol-4-yl%2529-4-aminoquinazolin%2520derivatives%2520possessing%2520hydroxamic%2520acid%2520moiety%2520for%2520cancer%2520therapy%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D27%26epage%3D37%26doi%3D10.1016%2Fj.bmc.2016.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ali, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gisslinger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waltzman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalbovskaya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuitty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoops, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barosi, G.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">787</span>â <span class="NLM_lpage">798</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1110556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1056%2FNEJMoa1110556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=22375970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2qurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=787-798&author=C.+Harrisonauthor=J.+J.+Kiladjianauthor=H.+K.+Al-Aliauthor=H.+Gisslingerauthor=R.+Waltzmanauthor=V.+Stalbovskayaauthor=M.+McQuittyauthor=D.+S.+Hunterauthor=R.+Levyauthor=L.+Knoopsauthor=F.+Cervantesauthor=A.+M.+Vannucchiauthor=T.+Barbuiauthor=G.+Barosi&title=JAK+inhibition+with+ruxolitinib+versus+best+available+therapy+for+myelofibrosis&doi=10.1056%2FNEJMoa1110556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis</span></div><div class="casAuthors">Harrison, Claire; Kiladjian, Jean-Jacques; Al-Ali, Haifa Kathrin; Gisslinger, Heinz; Waltzman, Roger; Stalbovskaya, Viktoriya; McQuitty, Mari; Hunter, Deborah S.; Levy, Richard; Knoops, Laurent; Cervantes, Francisco; Vannucchi, Alessandro M.; Barbui, Tiziano; Barosi, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">787-798</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Treatment options for myelofibrosis are limited.  We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis.  METHODS: We assigned 219 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis to receive oral ruxolitinib or the best available therapy.  The primary end point and key secondary end point of the study were the percentage of patients with at least a 35% redn. in spleen vol. at week 48 and at week 24, resp., as assessed with the use of magnetic resonance imaging or computed tomog.  RESULTS: A total of 28% of the patients in the ruxolitinib group had at least a 35% redn. in spleen vol. at week 48, as compared with 0% in the group receiving the best available therapy (P<0.001); the corresponding percentages at week 24 were 32% and 0% (P<0.001).  At 48 wk, the mean palpable spleen length had decreased by 56% with ruxolitinib but had increased by 4% with the best available therapy.  The median duration of response with ruxolitinib was not reached, with 80% of patients still having a response at a median follow-up of 12 mo.  Patients in the ruxolitinib group had an improvement in overall quality-of-life measures and a redn. in symptoms assocd. with myelofibrosis.  The most common hematol. abnormalities of grade 3 or higher in either group were thrombocytopenia and anemia, which were managed with a dose redn., interruption of treatment, or transfusion.  One patient in each group discontinued treatment owing to thrombocytopenia, and none discontinued owing to anemia.  Nonhematol. adverse events were rare and mostly grade 1 or 2.  Two cases of acute myeloid leukemia were reported with the best available therapy.  CONCLUSIONS: Continuous ruxolitinib therapy, as compared with the best available therapy, was assocd. with marked and durable redns. in splenomegaly and disease-related symptoms, improvements in role functioning and quality of life, and modest toxic effects.  An influence on overall survival has not yet been shown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP7WEm5MUTc7Vg90H21EOLACvtfcHk0ligIDyUBzjtpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2qurs%253D&md5=80494b8923fa49536383523066b22b19</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1110556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1110556%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DKiladjian%26aufirst%3DJ.%2BJ.%26aulast%3DAl-Ali%26aufirst%3DH.%2BK.%26aulast%3DGisslinger%26aufirst%3DH.%26aulast%3DWaltzman%26aufirst%3DR.%26aulast%3DStalbovskaya%26aufirst%3DV.%26aulast%3DMcQuitty%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DD.%2BS.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DKnoops%26aufirst%3DL.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DBarbui%26aufirst%3DT.%26aulast%3DBarosi%26aufirst%3DG.%26atitle%3DJAK%2520inhibition%2520with%2520ruxolitinib%2520versus%2520best%2520available%2520therapy%2520for%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D787%26epage%3D798%26doi%3D10.1056%2FNEJMoa1110556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8233</span>â <span class="NLM_lpage">8262</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Yenauthor=B.+W.+Dymock&title=Design+and+synthesis+of+janus+kinase+2+%28JAK2%29+and+histone+deacetlyase+%28HDAC%29+bispecific+inhibitors+based+on+pacritinib+and+evidence+of+dual+pathway+inhibition+in+hematological+cell+lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0lgRyrgu0YVMAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520histone%2520deacetlyase%2520%2528HDAC%2529%2520bispecific%2520inhibitors%2520based%2520on%2520pacritinib%2520and%2520evidence%2520of%2520dual%2520pathway%2520inhibition%2520in%2520hematological%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ning, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, N. F.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic compounds as anti-cancer agents: Design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">104</span>â <span class="NLM_lpage">115</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.03.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2015.03.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=25800646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVWitbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=104-115&author=C.+Q.+Ningauthor=C.+Luauthor=L.+Huauthor=Y.+J.+Biauthor=L.+Yaoauthor=Y.+J.+Heauthor=L.+F.+Liuauthor=X.+Y.+Liuauthor=N.+F.+Yu&title=Macrocyclic+compounds+as+anti-cancer+agents%3A+Design+and+synthesis+of+multi-acting+inhibitors+against+HDAC%2C+FLT3+and+JAK2&doi=10.1016%2Fj.ejmech.2015.03.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic compounds as anti-cancer agents: Design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2</span></div><div class="casAuthors">Ning, Cheng-Qing; Lu, Cheng; Hu, Liang; Bi, Yan-Jing; Yao, Lei; He, Yu-Jun; Liu, Li-Fei; Liu, Xiao-Yu; Yu, Nie-Fang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104-115</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of macrocyclic compds. I [X = O, CH2O; Y = CH2, CO; n = 1, 2; m = 1-5] were designed and synthesized as multi-target inhibitors targeting HDAC, FLT3 and JAK2.  Some of these compds. exhibited potent HDAC inhibition as well as FLT3 and JAK2 inhibition under both cell-free and cellular conditions.  In vitro antiproliferative assay indicated that these compds. were interestingly more cytotoxic to MV4-11 cells bearing FLT3-ITD mutation and HEL cells bearing JAK2V617F mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvwiDjzqtazLVg90H21EOLACvtfcHk0lgRyrgu0YVMAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVWitbY%253D&md5=fc2b93fcbce2998ecd2d6de46a01811d</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.034%26sid%3Dliteratum%253Aachs%26aulast%3DNing%26aufirst%3DC.%2BQ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DBi%26aufirst%3DY.%2BJ.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DY.%2BJ.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26aulast%3DYu%26aufirst%3DN.%2BF.%26atitle%3DMacrocyclic%2520compounds%2520as%2520anti-cancer%2520agents%253A%2520Design%2520and%2520synthesis%2520of%2520multi-acting%2520inhibitors%2520against%2520HDAC%252C%2520FLT3%2520and%2520JAK2%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D95%26spage%3D104%26epage%3D115%26doi%3D10.1016%2Fj.ejmech.2015.03.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6). 1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4638</span>â <span class="NLM_lpage">4658</span>, <span class="refDoi">Â DOI: 10.1021/jm200326p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.+1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2Ffms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma&doi=10.1021%2Fjm200326p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Tan, Evelyn; Chen, Dizhong; Williams, Meredith; Sun, Eric T.; Goh, Kee Chuan; Ong, Wai Chung; Goh, Siok Kun; Hart, Stefan; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4638-4658</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF).  Herein, we describe the design and synthesis of a series of small mol. 4-aryl-2-aminopyrimidine macrocycles and their biol. evaluation against the JAK family of kinase enzymes and FLT3.  The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of I, a potent JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, resp.) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, resp.).  Further profiling of I in preclin. species and mouse xenograft and allograft models is described.  Compd. I (SB1518) was selected as a development candidate and progressed into clin. trials where it is currently in phase 2 for MF and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXtMiC4eaIMLVg90H21EOLACvtfcHk0lgRyrgu0YVMAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D&md5=1fa1a5250cae6ec8c59db67e593fb1f6</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.%25201%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252Ffms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658%26doi%3D10.1021%2Fjm200326p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duenas-Perez, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mead, A. J.</span></span> <span> </span><span class="NLM_article-title">Clinical potential of pacritinib in the treatment of myelofibrosis</span>. <i>Ther. Adv. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">186</span>, <span class="refDoi">Â DOI: 10.1177/2040620715586527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1177%2F2040620715586527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=26288713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1Wgurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=186&author=A.+B.+Duenas-Perezauthor=A.+J.+Mead&title=Clinical+potential+of+pacritinib+in+the+treatment+of+myelofibrosis&doi=10.1177%2F2040620715586527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical potential of pacritinib in the treatment of myelofibrosis</span></div><div class="casAuthors">Duenas-Perez, Ana B.; Mead, Adam J.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Hematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">186-201</span>CODEN:
                <span class="NLM_cas:coden">TAHHAT</span>;
        ISSN:<span class="NLM_cas:issn">2040-6207</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Myelofibrosis (MF) is a myeloid disorder caused by a clonal hematopoietic stem-cell proliferation assocd. with activation of the Janus kinase (JAK) signal transducer and activator of transcription (STAT) signaling pathways.  Patients with MF often develop severe splenomegaly, marked symptom burden and significant cytopenias, with a consequent marked neg. impact on quality of life and survival.  The management of MF patients has dramatically improved with the development of a group of drugs that inhibit JAK signaling.  The first of these agents to be approved was ruxolitinib, a JAK1/JAK2 inhibitor, which has been shown to improve both spleen size and symptoms in patients with MF.  However, myelotoxicity, particularly of the platelet lineage, significantly limits the patient population who can benefit from this agent.  Thus, there is an unmet need for novel agents with limited myelotoxicity to treat MF.  Pacritinib, a JAK2 and FMS-like tyrosine kinase 3 (FLT3) inhibitor, has shown promising results in early phase trials with limited myelotoxicity and clin. responses that are comparable with those seen with ruxolitinib, even in patients with severe thrombocytopenia.  Currently there are two large phase III clin. trials of pacritinib in MF, including patients with thrombocytopenia, and those previously treated with ruxolitinib.  If the encouraging results obsd. in early phase clin. trials are confirmed, pacritinib will represent a new and exciting treatment option for patients with MF and particularly patients with significant cytopenias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql0G1-XMNABbVg90H21EOLACvtfcHk0ljMbCaMjAz1ig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1Wgurw%253D&md5=853e744c924e2ba7886dbd6cada43c4c</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1177%2F2040620715586527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040620715586527%26sid%3Dliteratum%253Aachs%26aulast%3DDuenas-Perez%26aufirst%3DA.%2BB.%26aulast%3DMead%26aufirst%3DA.%2BJ.%26atitle%3DClinical%2520potential%2520of%2520pacritinib%2520in%2520the%2520treatment%2520of%2520myelofibrosis%26jtitle%3DTher.%2520Adv.%2520Hematol.%26date%3D2015%26volume%3D6%26spage%3D186%26doi%3D10.1177%2F2040620715586527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Press, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, H. J.</span></span> <span> </span><span class="NLM_article-title">EGFR, HER2 and VEGF pathways: validated targets for cancer treatment</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">2045</span>â <span class="NLM_lpage">2075</span>, <span class="refDoi">Â DOI: 10.2165/00003495-200767140-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.2165%2F00003495-200767140-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=17883287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtleqsrrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=2045-2075&author=M.+F.+Pressauthor=H.+J.+Lenz&title=EGFR%2C+HER2+and+VEGF+pathways%3A+validated+targets+for+cancer+treatment&doi=10.2165%2F00003495-200767140-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR, HER2 and VEGF pathways: validated targets for cancer treatment</span></div><div class="casAuthors">Press, Michael F.; Lenz, Heinz-Josef</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2045-2075</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Targeted therapies are rationally designed to interfere with specific mol. events that are important in tumor growth, progression or survival.  Several targeted therapies with anti-tumor activity in human cancer cell lines and xenograft models have now been shown to produce objective responses, delay disease progression and, in some cases, improve survival of patients with advanced malignancies.  These targeted therapies include cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody; gefitinib and erlotinib, EGFR-specific tyrosine kinase inhibitors; trastuzumab, an anti-human EGFR type 2 (HER2)-related monoclonal antibody; lapatinib, a dual inhibitor of both EGFR- and HER2-assocd. tyrosine kinases; and bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody.  On the basis of preclin. and clin. evidence, EGFR, HER2 and VEGF represent validated targets for cancer therapy and remain the subject of intensive investigation.  Both EGFR and HER2 are targets found on cancer cells, whereas VEGF is a target that acts in the tumor microenvironment.  Clin. studies are focusing on how to best incorporate targeted therapy into current treatment regimens and other studies are exploring whether different strategies for inhibiting these targets will offer greater benefit.  It is clear that optimal use of targeted therapy will depend on understanding how these drugs work mechanistically, and recognising that their activities may differ across patient populations, tumor types and disease stages, as well as when and how they are used in cancer treatment.  The results achieved with targeted therapies to date are promising, although they illustrate the need for addnl. preclin. and clin. study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruB8rVI305xrVg90H21EOLACvtfcHk0ljMbCaMjAz1ig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtleqsrrF&md5=d4e6b3997f2b0a252753cdc6a5137a15</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.2165%2F00003495-200767140-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200767140-00006%26sid%3Dliteratum%253Aachs%26aulast%3DPress%26aufirst%3DM.%2BF.%26aulast%3DLenz%26aufirst%3DH.%2BJ.%26atitle%3DEGFR%252C%2520HER2%2520and%2520VEGF%2520pathways%253A%2520validated%2520targets%2520for%2520cancer%2520treatment%26jtitle%3DDrugs%26date%3D2007%26volume%3D67%26spage%3D2045%26epage%3D2075%26doi%3D10.2165%2F00003495-200767140-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongratz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciossek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckers, T.</span></span> <span> </span><span class="NLM_article-title">Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8546</span>â <span class="NLM_lpage">8555</span>, <span class="refDoi">Â DOI: 10.1021/jm100665z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100665z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8546-8555&author=S.+Mahboobiauthor=A.+Sellmerauthor=M.+Winklerauthor=E.+Eichhornauthor=H.+Pongratzauthor=T.+Ciossekauthor=T.+Baerauthor=T.+Maierauthor=T.+Beckers&title=Novel+chimeric+histone+deacetylase+inhibitors%3A+a+series+of+lapatinib+hybrides+as+potent+inhibitors+of+epidermal+growth+factor+receptor+%28EGFR%29%2C+human+epidermal+growth+factor+receptor+2+%28HER2%29%2C+and+histone+deacetylase+activity&doi=10.1021%2Fjm100665z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrids as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity</span></div><div class="casAuthors">Mahboobi, Siavosh; Sellmer, Andreas; Winkler, Matthias; Eichhorn, Emerich; Pongratz, Herwig; Ciossek, Thomas; Baer, Thomas; Maier, Thomas; Beckers, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8546-8555</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reversible lysine-specific acetylation has been described as an important posttranslational modification, regulating chromatin structure and transcriptional activity in the case of core histone proteins.  Histone deacetylases (HDAC) are considered as a promising target for anticancer drug development, with I as pan-HDAC inhibitor approved for cutaneous T-cell lymphoma therapy and several other HDAC inhibitors currently in preclin. and clin. development.  Protein kinases are a well-established target for cancer therapy with the EGFR/HER2 inhibitor II approved for treatment of advanced, HER2 pos. breast cancer as a prominent example.  The present report presents a novel strategy for cancer drug development by combination of EGFR/HER2 kinase and HDAC inhibitory activity in one mol.  By combining the structural features of II with an (E)-3-(aryl)-N-hydroxyacrylamide motif known from HDAC inhibitors like III or IV, selective inhibitors were obtained for both targets with potent cellular activity (target inhibition and cytotoxicity) of selected compds. V (X = m-phenylene, 2,5-furandiyl).  By combining two distinct pharmacol. properties in one mol., a broader activity spectrum is postulated and less likelihood of drug resistance in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEElZRNfAQZ7Vg90H21EOLACvtfcHk0ljMbCaMjAz1ig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL3I&md5=81bba7c00bb26b42c54075acce5ba525</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm100665z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100665z%26sid%3Dliteratum%253Aachs%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DWinkler%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DCiossek%26aufirst%3DT.%26aulast%3DBaer%26aufirst%3DT.%26aulast%3DMaier%26aufirst%3DT.%26aulast%3DBeckers%26aufirst%3DT.%26atitle%3DNovel%2520chimeric%2520histone%2520deacetylase%2520inhibitors%253A%2520a%2520series%2520of%2520lapatinib%2520hybrides%2520as%2520potent%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%252C%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520%2528HER2%2529%252C%2520and%2520histone%2520deacetylase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8546%26epage%3D8555%26doi%3D10.1021%2Fjm100665z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truesdale, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennisi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alligood, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shewchuk, L.</span></span> <span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">6652</span>â <span class="NLM_lpage">6659</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-04-1168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28Lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells&doi=10.1158%2F0008-5472.CAN-04-1168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0lhoF_5DsYBSKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659%26doi%3D10.1158%2F0008-5472.CAN-04-1168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finnin, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donigian, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rifkind, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span> <span> </span><span class="NLM_article-title">Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>401</i></span>,  <span class="NLM_fpage">188</span>â <span class="NLM_lpage">193</span>, <span class="refDoi">Â DOI: 10.1038/43710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2F43710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10490031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFKgtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=1999&pages=188-193&author=M.+S.+Finninauthor=J.+R.+Donigianauthor=A.+Cohenauthor=V.+M.+Richonauthor=R.+A.+Rifkindauthor=P.+A.+Marksauthor=R.+Breslowauthor=N.+P.+Pavletich&title=Structures+of+a+histone+deacetylase+homologue+bound+to+the+TSA+and+SAHA+inhibitors&doi=10.1038%2F43710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors</span></div><div class="casAuthors">Finnin, Michael S.; Donigian, Jill R.; Cohen, Alona; Richon, Victoria M.; Rifkind, Richard A.; Marks, Paul A.; Breslow, Ronald; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">401</span>
        (<span class="NLM_cas:issue">6749</span>),
    <span class="NLM_cas:pages">188-193</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression.  HDACs are involved in cell-cycle progression and differentiation, and their deregulation is assocd. with several cancers.  HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumor effects, as they can inhibit cell growth, induce terminal differentiation and prevent the formation of tumors in mice models, and they are effective in the treatment of promyelocytic leukemia.  Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homolog from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% identity with human HDAC1 over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA.  The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition.  The residues that make up the active site and contact the inhibitors are conserved across the HDAC family.  These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrG0lsZMMo37Vg90H21EOLACvtfcHk0lhoF_5DsYBSKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFKgtrc%253D&md5=29bbc6d3ba9a9d2a8c330349ae8199a8</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2F43710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F43710%26sid%3Dliteratum%253Aachs%26aulast%3DFinnin%26aufirst%3DM.%2BS.%26aulast%3DDonigian%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DStructures%2520of%2520a%2520histone%2520deacetylase%2520homologue%2520bound%2520to%2520the%2520TSA%2520and%2520SAHA%2520inhibitors%26jtitle%3DNature%26date%3D1999%26volume%3D401%26spage%3D188%26epage%3D193%26doi%3D10.1038%2F43710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2000</span>â <span class="NLM_lpage">2009</span>, <span class="refDoi">Â DOI: 10.1021/jm901453q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901453q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2000-2009&author=X.+Caiauthor=H.+X.+Zhaiauthor=J.+Wangauthor=J.+Forresterauthor=H.+Quauthor=L.+Yinauthor=C.+J.+Laiauthor=R.+Baoauthor=C.+Qian&title=Discovery+of+7-%284-%283-ethynylphenylamino%29-7-methoxyquinazolin-6-yloxy%29-N-hydroxyheptanamide+%28CUDc-101%29+as+a+potent+multi-acting+HDAC%2C+EGFR%2C+and+HER2+inhibitor+for+the+treatment+of+cancer&doi=10.1021%2Fjm901453q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Cai, Xiong; Zhai, Hai-Xiao; Wang, Jing; Forrester, Jeffrey; Qu, Hui; Yin, Ling; Lai, Cheng-Jung; Bao, Rudi; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compds. with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clin. development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, resp.  In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib.  In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers.  These results suggest that a single compd. that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBQl1iMXW3rVg90H21EOLACvtfcHk0lhoF_5DsYBSKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D&md5=d4dc339f2fd750d52e511abf3dbf18bd</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjm901453q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901453q%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25207-%25284-%25283-ethynylphenylamino%2529-7-methoxyquinazolin-6-yloxy%2529-N-hydroxyheptanamide%2520%2528CUDc-101%2529%2520as%2520a%2520potent%2520multi-acting%2520HDAC%252C%2520EGFR%252C%2520and%2520HER2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2000%26epage%3D2009%26doi%3D10.1021%2Fjm901453q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mann, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1247</span>â <span class="NLM_lpage">1252</span>, <span class="refDoi">Â DOI: 10.1634/theoncologist.12-10-1247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1634%2Ftheoncologist.12-10-1247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=17962618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1247-1252&author=B.+S.+Mannauthor=J.+R.+Johnsonauthor=M.+H.+Cohenauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+approval+summary%3A+vorinostat+for+treatment+of+advanced+primary+cutaneous+T-cell+lymphoma&doi=10.1634%2Ftheoncologist.12-10-1247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</span></div><div class="casAuthors">Mann, Bhupinder S.; Johnson, John R.; Cohen, Martin H.; Justice, Robert; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1247-1252</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">On Oct. 6, 2006, the U.S. Food and Drug Administration granted regular approval to vorinostat (Zolinza; Merck & Co., Inc., Whitehouse Station, NJ), a histone deacetylase inhibitor, for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease on or following two systemic therapies.  The pivotal study supporting approval was a single-arm open-label phase II trial that enrolled 74 patients with stage IB and higher CTCL who had failed two systemic therapies (one of which must have contained bexarotene).  Patients received vorinostat at a dose of 400 mg orally once daily, which could be reduced for toxicity to 300 mg daily or 300 mg 5 days a week.  The median age of patients was 61 years.  Sixty-one patients (82%) had stage IIB or higher CTCL and 30 patients (41%) had Sezary syndrome.  The median duration of protocol treatment was 118 days.  The primary efficacy endpoint was objective response assessed by the Severity-Weighted Assessment Tool.  The objective response rate was 30% (95% confidence interval [CI], 19.7%-41.5%), the estd. median response duration was 168 days, and the median time to tumor progression was 202 days.  An addnl. single-center study enrolled 33 patients with similar baseline and demog. features as the pivotal trial.  Thirteen of the 33 received vorinostat (400 mg/day).  The response rate in these 13 patients was 31% (95% CI, 9.1%-61.4%).  The most common clin. adverse events (AEs) of any grade were diarrhea (52%), fatigue (52%), nausea (41%), and anorexia (24%).  Grade 3 or 4 clin. AEs included fatigue (4%) and pulmonary embolism (5%).  Hematol. lab. abnormalities included thrombocytopenia (26%) and anemia (14%).  Chem. lab. abnormalities included increased creatinine (16%), increased serum glucose (69%), and proteinuria (51%).  Most abnormalities were National Cancer Institute Common Terminol. Criteria for Adverse Events grade 1 or 2.  Grade 3 or greater chem. abnormalities included hyperglycemia, hypertriglyceridemia, and hyperuricemia, hypoglycemia, hypokalemia, hyponatremia, hyperkalemia, hypercholesterolemia, hypophosphatemia, and increased creatinine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPuO0Kd_rs9LVg90H21EOLACvtfcHk0ljUvCF7yrQf-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrL&md5=c93fc0a46ebbed81873f1347db45421d</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-10-1247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-10-1247%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DB.%2BS.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520vorinostat%2520for%2520treatment%2520of%2520advanced%2520primary%2520cutaneous%2520T-cell%2520lymphoma%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D1247%26epage%3D1252%26doi%3D10.1634%2Ftheoncologist.12-10-1247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramaniam, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wax, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaron, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lara, P. N.,  Jr.</span></span> <span> </span><span class="NLM_article-title">A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">923</span>â <span class="NLM_lpage">932</span>, <span class="refDoi">Â DOI: 10.1007/s00280-017-3283-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1007%2Fs00280-017-3283-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=28352985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlt1SrsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2017&pages=923-932&author=H.+A.+Wakeleeauthor=S.+Gettingerauthor=J.+Engelmanauthor=P.+A.+Janneauthor=H.+Westauthor=D.+S.+Subramaniamauthor=J.+Leachauthor=M.+Waxauthor=Y.+Yaronauthor=D.+R.+Milesauthor=P.+N.+Lara&title=A+phase+Ib%2FII+study+of+cabozantinib+%28XL184%29+with+or+without+erlotinib+in+patients+with+non-small+cell+lung+cancer&doi=10.1007%2Fs00280-017-3283-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer</span></div><div class="casAuthors">Wakelee, Heather A.; Gettinger, Scott; Engelman, Jeffrey; Janne, Pasi A.; West, Howard; Subramaniam, Deepa S.; Leach, Joseph; Wax, Michael; Yaron, Yifah; Miles, Dale R.; Lara, Primo N., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">923-932</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Cabozantinib is a multi-kinase inhibitor that targets MET, AXL, and VEGFR2, and may synergize with EGFR inhibition in NSCLC.  Cabozantinib was assessed alone or in combination with erlotinib in patients with progressive NSCLC and EGFR mutations who had previously received erlotinib.  Methods: This was a phase Ib/II study (NCT00596648).  The primary objectives of phase I were to assess the safety, pharmacokinetics, and pharmacodynamics and to det. max. tolerated dose (MTD) of cabozantinib plus erlotinib in patients who failed prior erlotinib treatment.  In phase II, patients with prior response or stable disease with erlotinib who progressed were randomized to single-agent cabozantinib 100 mg qd vs cabozantinib 100 mg qd and erlotinib 50 mg qd (phase I MTD), with a primary objective of estg. objective response rate (ORR).  Results: Sixty-four patients were treated in phase I.  Doses of 100 mg cabozantinib plus 50 mg erlotinib, or 40 mg cabozantinib plus 150 mg erlotinib were detd. to be MTDs.  Diarrhea was the most frequent dose-limiting toxicity and the most frequent AE (87.5% of patients).  The ORR for phase I was 8.2% (90% CI 3.3-16.5).  In phase II, one patient in the cabozantinib arm (N = 15) experienced a partial response, for an ORR of 6.7% (90% CI 0.3-27.9), with no responses for cabozantinib plus erlotinib (N = 13).  There was no evidence that co-administration of cabozantinib markedly altered erlotinib pharmacokinetics or vice versa.  Conclusions: Despite responses with cabozantinib/erlotinib in phase I, there were no responses in the combination arm of phase II in patients with acquired resistance to erlotinib.  Cabozantinib did not appear to re-sensitize these patients to erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgi1kyff75wrVg90H21EOLACvtfcHk0ljUvCF7yrQf-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlt1SrsL8%253D&md5=95e3a80264e1413085360de2d5e03e07</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1007%2Fs00280-017-3283-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-017-3283-z%26sid%3Dliteratum%253Aachs%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DGettinger%26aufirst%3DS.%26aulast%3DEngelman%26aufirst%3DJ.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DWest%26aufirst%3DH.%26aulast%3DSubramaniam%26aufirst%3DD.%2BS.%26aulast%3DLeach%26aufirst%3DJ.%26aulast%3DWax%26aufirst%3DM.%26aulast%3DYaron%26aufirst%3DY.%26aulast%3DMiles%26aufirst%3DD.%2BR.%26aulast%3DLara%26aufirst%3DP.%2BN.%26atitle%3DA%2520phase%2520Ib%252FII%2520study%2520of%2520cabozantinib%2520%2528XL184%2529%2520with%2520or%2520without%2520erlotinib%2520in%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2017%26volume%3D79%26spage%3D923%26epage%3D932%26doi%3D10.1007%2Fs00280-017-3283-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radhakrishnan, R.</span></span> <span> </span><span class="NLM_article-title">Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">417</span>â <span class="NLM_lpage">423</span>, <span class="refDoi">Â DOI: 10.1042/BJ20121513</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1042%2FBJ20121513" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23101586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslelt7zK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2012&pages=417-423&author=J.+H.+Parkauthor=Y.+Liuauthor=M.+A.+Lemmonauthor=R.+Radhakrishnan&title=Erlotinib+binds+both+inactive+and+active+conformations+of+the+EGFR+tyrosine+kinase+domain&doi=10.1042%2FBJ20121513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain</span></div><div class="casAuthors">Park, Jin H.; Liu, Yingting; Lemmon, Mark A.; Radhakrishnan, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">417-423</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Erlotinib and gefitinib, tyrosine kinase inhibitors used to block EGFR (epidermal growth factor receptor) signalling in cancer, are thought to bind only the active conformation of the EGFR-TKD (tyrosine kinase domain).  Through parallel computational and crystallog. studies, we show in the present study that erlotinib also binds the inactive EGFR-TKD conformation, which may have significant implications for its use in EGFR-mutated cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprbzRYtaWcm7Vg90H21EOLACvtfcHk0ljUvCF7yrQf-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslelt7zK&md5=170e0fe51a413edfbc15d4357ba6877b</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1042%2FBJ20121513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20121513%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DRadhakrishnan%26aufirst%3DR.%26atitle%3DErlotinib%2520binds%2520both%2520inactive%2520and%2520active%2520conformations%2520of%2520the%2520EGFR%2520tyrosine%2520kinase%2520domain%26jtitle%3DBiochem.%2520J.%26date%3D2012%26volume%3D448%26spage%3D417%26epage%3D423%26doi%3D10.1042%2FBJ20121513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimmesgern, E.</span></span> <span> </span><span class="NLM_article-title">The structure of inosine 5â²-monophosphate dehydrogenase and the design of novel inhibitors</span>. <i>Immunopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">163</span>â <span class="NLM_lpage">184</span>, <span class="refDoi">Â DOI: 10.1016/S0162-3109(00)00193-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS0162-3109%2800%2900193-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10878288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlKkt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2000&pages=163-184&author=M.+D.+Sintchakauthor=E.+Nimmesgern&title=The+structure+of+inosine+5%E2%80%B2-monophosphate+dehydrogenase+and+the+design+of+novel+inhibitors&doi=10.1016%2FS0162-3109%2800%2900193-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors</span></div><div class="casAuthors">Sintchak, M. D.; Nimmesgern, E.</div><div class="citationInfo"><span class="NLM_cas:title">Immunopharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">163-184</span>CODEN:
                <span class="NLM_cas:coden">IMMUDP</span>;
        ISSN:<span class="NLM_cas:issn">0162-3109</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with â¼120 refs.  The enzyme IMPDH is a homotetramer of â¼55 kDa subunits and consists of a (Î²/Î±)8 barrel core domain and a smaller subdomain.  The active site has binding pockets for the two substrates IMP and NAD.  The enzymic reaction of oxidn. of IMP to XMP proceeds through a covalent mechanism involving an active site cysteine residue.  This enzyme is a target for immunosuppressive agents because it catalyzes a key step in purine nucleotide biosynthesis which is important for the proliferation of lymphocytes.  Several x-ray structures of inhibitors bound to IMPDH have been published.  The uncompetitive IMPDH inhibitor MPA is the active metabolite of the immunosuppressive agent mycophenolate mofetil (CellCept) which is approved for the prevention of acute rejection after kidney and heart transplantation.  The bicyclic ring system of MPA packs underneath the hypoxanthine ring of XMP*, thereby trapping this covalent intermediate of the enzymic reaction.  Ribavirin monophosphate, the active metabolite of the antiviral agent ribavirin, is a substrate mimic of IMP.  The structure of the two inhibitors 6-Cl-IMP and SAD binding in the IMP and NAD pockets of IMPDH, resp., gives information for the binding mode of the di-nucleotide cofactor to the enzyme.  At Vertex Pharmaceuticals a structure-based drug design program for the design of IMPDH inhibitors was initiated.  Several new lead compd. classes unrelated to other IMPDH inhibitors were found.  Integrating structural information into an iterative drug-design process led to the design of VX-497.  VX-497 is a potent uncompetitive enzyme inhibitor of IMPDH.  The phenyl-oxazole moiety of the mol. packs underneath XMP*, analogous to MPA.  VX-497 also makes several new interactions that are not obsd. in the binding of MPA.  VX-497 is a potent immunosuppressive agent in vitro and in vivo.  A Phase I clin. trial has been successfully concluded and the compd. is currently in Phase II trials in psoriasis and hepatitis C.  The rapid progress from initiation of the drug design program to a compd. entering clin. trials illustrates the power of structure-based drug design to accelerate the drug discovery process.  The structural information on IMPDH has also significantly increased our knowledge about the mechanistic details of this fascinating enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfJBlQKGh0E7Vg90H21EOLACvtfcHk0lgWIKwtl2xAzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlKkt7k%253D&md5=4141aa3b8d3343008473914bc0fc7edb</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2FS0162-3109%2800%2900193-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0162-3109%252800%252900193-4%26sid%3Dliteratum%253Aachs%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DNimmesgern%26aufirst%3DE.%26atitle%3DThe%2520structure%2520of%2520inosine%25205%25E2%2580%25B2-monophosphate%2520dehydrogenase%2520and%2520the%2520design%2520of%2520novel%2520inhibitors%26jtitle%3DImmunopharmacology%26date%3D2000%26volume%3D47%26spage%3D163%26epage%3D184%26doi%3D10.1016%2FS0162-3109%2800%2900193-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaram, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pankiewicz, K. W.</span></span> <span> </span><span class="NLM_article-title">Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">6685</span>â <span class="NLM_lpage">6691</span>, <span class="refDoi">Â DOI: 10.1021/jm070864w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070864w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOnurvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6685-6691&author=L.+Chenauthor=D.+Wilsonauthor=H.+N.+Jayaramauthor=K.+W.+Pankiewicz&title=Dual+inhibitors+of+inosine+monophosphate+dehydrogenase+and+histone+deacetylases+for+cancer+treatment&doi=10.1021%2Fjm070864w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibitors of Inosine Monophosphate Dehydrogenase and Histone Deacetylases for Cancer Treatment</span></div><div class="casAuthors">Chen, Liqiang; Wilson, Daniel; Jayaram, Hiremagalur N.; Pankiewicz, Krzysztof W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">6685-6691</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mycophenolic acid (MPA), an inhibitor of IMP-dehydrogenase (IMPDH), is used worldwide in transplantation.  Recently, numerous studies showed its importance in cancer treatment.  Consequently, MPA entered clin. trials in advanced multiple myeloma patients.  Suberoylanilide hydroxamic acid (SAHA), a potent differentiation agent acting through inhibition of histone deacetylases (HDACs), was recently approved for treatment of cutaneous T cell lymphoma.  The authors report herein the synthesis of dual inhibitors of IMPDH and HDACs.  The authors found that mycophenolic hydroxamic acid (MAHA) inhibits both IMPDH (Ki = 30 nM) and HDAC (IC50 = 5.0 Î¼M).  A modification of SAHA with groups known to interact with IMPDH afforded a SAHA analog (I), which inhibits IMPDH (Ki = 1.7 Î¼M) and HDAC (IC50 = 0.06 Î¼M).  Both MAHA (IC50 = 4.8 Î¼M) and SAHA analog I (IC50 = 7.7 Î¼M) were more potent than parent compds. as antiproliferation agents.  They were also significantly more potent as differentiation inducers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN5m_NrQtZGrVg90H21EOLACvtfcHk0lgWIKwtl2xAzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOnurvO&md5=d23d2cfe279a638ec27431b89909626b</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm070864w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070864w%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DWilson%26aufirst%3DD.%26aulast%3DJayaram%26aufirst%3DH.%2BN.%26aulast%3DPankiewicz%26aufirst%3DK.%2BW.%26atitle%3DDual%2520inhibitors%2520of%2520inosine%2520monophosphate%2520dehydrogenase%2520and%2520histone%2520deacetylases%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D6685%26epage%3D6691%26doi%3D10.1021%2Fjm070864w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Card, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neiman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">279</span>â <span class="NLM_lpage">286</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2004.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.molcel.2004.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15260978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXms1ektLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=279-286&author=K.+Y.+Zhangauthor=G.+L.+Cardauthor=Y.+Suzukiauthor=D.+R.+Artisauthor=D.+Fongauthor=S.+Gilletteauthor=D.+Hsiehauthor=J.+Neimanauthor=B.+L.+Westauthor=C.+Zhangauthor=M.+V.+Milburnauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=G.+Bollag&title=A+glutamine+switch+mechanism+for+nucleotide+selectivity+by+phosphodiesterases&doi=10.1016%2Fj.molcel.2004.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases</span></div><div class="casAuthors">Zhang, Kam Y. J.; Card, Graeme L.; Suzuki, Yoshihisa; Artis, D. Richard; Fong, Daniel; Gillette, Sam; Hsieh, Davin; Neiman, Joshua; West, Brian L.; Zhang, Chao; Milburn, Michael V.; Kim, Sung-Hou; Schlessinger, Joseph; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-286</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) comprise a family of enzymes that modulate the immune response, inflammation, and memory, among many other functions.  There are three types of PDEs: cAMP-specific, cGMP-specific, and dual-specific.  Here we describe the mechanism of nucleotide selectivity on the basis of high-resoln. co-crystal structures of the cAMP-specific PDE4B and PDE4D with AMP, the cGMP-specific PDE5A with GMP, and the apo-structure of the dual-specific PDE1B.  These structures show that an invariant glutamine functions as the key specificity determinant by a "glutamine switch" mechanism for recognizing the purine moiety in cAMP or cGMP.  The surrounding residues anchor the glutamine residue in different orientations for cAMP and for cGMP.  The PDE1B structure shows that in dual-specific PDEs a key histidine residue may enable the invariant glutamine to toggle between cAMP and cGMP.  The structural understanding of nucleotide binding enables the design of new PDE inhibitors that may treat diseases in which cyclic nucleotides play a crit. role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorRXGTDdAa1bVg90H21EOLACvtfcHk0lgWIKwtl2xAzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXms1ektLs%253D&md5=32fab6a75031a67290ec5eda2c3e080b</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DHsieh%26aufirst%3DD.%26aulast%3DNeiman%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DA%2520glutamine%2520switch%2520mechanism%2520for%2520nucleotide%2520selectivity%2520by%2520phosphodiesterases%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D15%26spage%3D279%26epage%3D286%26doi%3D10.1016%2Fj.molcel.2004.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lauffer, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mintzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zilberleyb, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flicke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritscher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorowicz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallero, R.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">26926</span>â <span class="NLM_lpage">26943</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M113.490706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1074%2Fjbc.M113.490706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23897821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=26926-26943&author=B.+E.+Laufferauthor=R.+Mintzerauthor=R.+Fongauthor=S.+Mukundauthor=C.+Tamauthor=I.+Zilberleybauthor=B.+Flickeauthor=A.+Ritscherauthor=G.+Fedorowiczauthor=R.+Vallero&title=Histone+deacetylase+%28HDAC%29+inhibitor+kinetic+rate+constants+correlate+with+cellular+histone+acetylation+but+not+transcription+and+cell+viability&doi=10.1074%2Fjbc.M113.490706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability</span></div><div class="casAuthors">Lauffer, Benjamin E. L.; Mintzer, Robert; Fong, Rina; Mukund, Susmith; Tam, Christine; Zilberleyb, Inna; Flicke, Birgit; Ritscher, Allegra; Fedorowicz, Grazyna; Vallero, Roxanne; Ortwine, Daniel F.; Gunzner, Janet; Modrusan, Zora; Neumann, Lars; Koth, Christopher M.; Lupardus, Patrick J.; Kaminker, Joshua S.; Heise, Christopher E.; Steiner, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">26926-26943</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are crit. in the control of gene expression, and dysregulation of their activity has been implicated in a broad range of diseases, including cancer, cardiovascular, and neurol. diseases.  HDAC inhibitors (HDACi) employing different zinc chelating functionalities such as hydroxamic acids and benzamides have shown promising results in cancer therapy.  Although it has also been suggested that HDACi with increased isoenzyme selectivity and potency may broaden their clin. utility and minimize side effects, the translation of this idea to the clinic remains to be investigated.  Moreover, a detailed understanding of how HDACi with different pharmacol. properties affect biol. functions in vitro and in vivo is still missing.  Here, we show that a panel of benzamide-contg. HDACi are slow tight-binding inhibitors with long residence times unlike the hydroxamate-contg. HDACi vorinostat and trichostatin-A.  Characterization of changes in H2BK5 and H4K14 acetylation following HDACi treatment in the neuroblastoma cell line SH-SY5Y revealed that the timing and magnitude of histone acetylation mirrored both the assocn. and dissocn. kinetic rates of the inhibitors.  In contrast, cell viability and microarray gene expression anal. indicated that cell death induction and changes in transcriptional regulation do not correlate with the dissocn. kinetic rates of the HDACi.  Therefore, our study suggests that detg. how the selective and kinetic inhibition properties of HDACi affect cell function will help to evaluate their therapeutic utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2goaOx8CDGbVg90H21EOLACvtfcHk0ljh7iHBXhzzzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM&md5=af1074c79e8abd932313f4ae13333a98</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.490706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.490706%26sid%3Dliteratum%253Aachs%26aulast%3DLauffer%26aufirst%3DB.%2BE.%26aulast%3DMintzer%26aufirst%3DR.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DMukund%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DFlicke%26aufirst%3DB.%26aulast%3DRitscher%26aufirst%3DA.%26aulast%3DFedorowicz%26aufirst%3DG.%26aulast%3DVallero%26aufirst%3DR.%26atitle%3DHistone%2520deacetylase%2520%2528HDAC%2529%2520inhibitor%2520kinetic%2520rate%2520constants%2520correlate%2520with%2520cellular%2520histone%2520acetylation%2520but%2520not%2520transcription%2520and%2520cell%2520viability%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D26926%26epage%3D26943%26doi%3D10.1074%2Fjbc.M113.490706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amalini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">151</span>â <span class="NLM_lpage">161</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-12-0466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1158%2F1535-7163.MCT-12-0466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23270925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlWisr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=151-161&author=S.+Hartauthor=V.+Novotny-Diermayrauthor=K.+C.+Gohauthor=M.+Williamsauthor=Y.+C.+Tanauthor=L.+C.+Ongauthor=A.+Cheongauthor=B.+K.+Ngauthor=C.+Amaliniauthor=B.+Madanauthor=H.+Nagarajauthor=R.+Jayaramanauthor=K.+M.+Pashaauthor=K.+Ethirajuluauthor=W.+J.+Chngauthor=N.+Mustafaauthor=B.+C.+Gohauthor=C.+Benesauthor=U.+McDermottauthor=M.+Garnettauthor=B.+Dymockauthor=J.+M.+Wood&title=VS-5584%2C+a+novel+and+highly+selective+PI3K%2FmTOR+kinase+inhibitor+for+the+treatment+of+cancer&doi=10.1158%2F1535-7163.MCT-12-0466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Hart, Stefan; Novotny-Diermayr, Veronica; Goh, Kee Chuan; Williams, Meredith; Tan, Yong Cheng; Ong, Lai Chun; Cheong, Albert; Ng, Bee Kheng; Amalini, Chithra; Madan, Babita; Nagaraj, Harish; Jayaraman, Ramesh; Pasha, Khalid M.; Ethirajulu, Kantharaj; Chng, Wee Joo; Mustafa, Nurulhuda; Goh, Boon Cher; Benes, Cyril; McDermott, Ultan; Garnett, Mathew; Dymock, Brian; Wood, Jeanette M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-161</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Dysregulation of the PI3K/mTOR pathway, either through amplifications, deletions, or as a direct result of mutations, has been closely linked to the development and progression of a wide range of cancers.  Moreover, this pathway activation is a poor prognostic marker for many tumor types and confers resistance to various cancer therapies.  Here, we describe VS-5584, a novel, low-mol. wt. compd. with equiv. potent activity against mTOR (IC50 = 37 nmol/L) and all class I phosphoinositide 3-kinase (PI3K) isoforms IC50: PI3KÎ± = 16 nmol/L; PI3KÎ² = 68 nmol/L; PI3KÎ³ = 25 nmol/L; PI3KÎ´ = 42 nmol/L, without relevant activity on 400 lipid and protein kinases.  VS-5584 shows robust modulation of cellular PI3K/mTOR pathways, inhibiting phosphorylation of substrates downstream of PI3K and mTORC1/2.  A large human cancer cell line panel screen (436 lines) revealed broad antiproliferative sensitivity and that cells harboring mutations in PI3KCA are generally more sensitive toward VS-5584 treatment.  VS-5584 exhibits favorable pharmacokinetic properties after oral dosing in mice and is well tolerated.  VS-5584 induces long-lasting and dose-dependent inhibition of PI3K/mTOR signaling in tumor tissue, leading to tumor growth inhibition in various rapalog-sensitive and -resistant human xenograft models.  Furthermore, VS-5584 is synergistic with an EGF receptor inhibitor in a gastric tumor model.  The unique selectivity profile and favorable pharmacol. and pharmaceutical properties of VS-5584 and its efficacy in a wide range of human tumor models supports further investigations of VS-5584 in clin. trials.  Mol Cancer Ther; 12(2); 151-61. Â©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreO7JDy5Ta17Vg90H21EOLACvtfcHk0ljh7iHBXhzzzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlWisr0%253D&md5=5fac255eea66aed674cc863fc578d975</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0466%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DNg%26aufirst%3DB.%2BK.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DK.%2BM.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DGoh%26aufirst%3DB.%2BC.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DGarnett%26aufirst%3DM.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DVS-5584%252C%2520a%2520novel%2520and%2520highly%2520selective%2520PI3K%252FmTOR%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D151%26epage%3D161%26doi%3D10.1158%2F1535-7163.MCT-12-0466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and preclinical evaluation of fused pyrimidine-based hydroxamates for the treatment of hepatocellular carcinoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1552</span>â <span class="NLM_lpage">1575</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01465</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01465" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGhsLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1552-1575&author=D.+Chenauthor=K.+S.+Changauthor=H.+G.+Weiauthor=H.+Wang&title=Design%2C+synthesis%2C+and+preclinical+evaluation+of+fused+pyrimidine-based+hydroxamates+for+the+treatment+of+hepatocellular+carcinoma&doi=10.1021%2Facs.jmedchem.7b01465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma</span></div><div class="casAuthors">Chen, Dizhong; Soh, Chang Kai; Goh, Wei Huang; Wang, Haishan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1552-1575</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Class I histone deacetylases (HDACs) are highly expressed and/or upregulated in hepatocellular carcinoma (HCC) and are assocd. with aggressiveness, spread, and increased mortality of HCC.  Activation of phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway was involved in the development of HCC and acquired resistance to sorafenib.  A series of purine or 5H-pyrrolo[3,2-d]pyrimidine based hydroxamates were designed and developed as multitarget drugs to modulate both HDACs and the PI3K/Akt/mTOR pathway.  Among 39 cell lines screened, the mols. (e.g., I, II, and III) were the most selective against leukemia, lymphoma, and HCC cells; they also demonstrated target modulation in cancer cell lines and in mice bearing MV4-11 and HepG2 tumors.  Compd. II in particular showed significant single agent oral efficacy in hypervascular liver cancer models (e.g., HepG2, HuH-7, and Hep3B) and was well-tolerated.  These encouraging results, along with its favorable target profile and tissue distribution, warrant further development of II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOkc89pglhFLVg90H21EOLACvtfcHk0ljh7iHBXhzzzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGhsLk%253D&md5=7261ba423c033773f4b1b5cea80af725</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01465%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DK.%2BS.%26aulast%3DWei%26aufirst%3DH.%2BG.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520preclinical%2520evaluation%2520of%2520fused%2520pyrimidine-based%2520hydroxamates%2520for%2520the%2520treatment%2520of%2520hepatocellular%2520carcinoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1552%26epage%3D1575%26doi%3D10.1021%2Facs.jmedchem.7b01465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M.</span></span> <span> </span><span class="NLM_article-title">Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4104</span>â <span class="NLM_lpage">4113</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-12-0055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1158%2F1078-0432.CCR-12-0055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=22693356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4104-4113&author=C.+Qianauthor=C.+J.+Laiauthor=R.+Baoauthor=D.+G.+Wangauthor=J.+Wangauthor=G.+X.+Xuauthor=R.+Atoyanauthor=H.+Quauthor=L.+Yinauthor=M.+Samson&title=Cancer+network+disruption+by+a+single+molecule+inhibitor+targeting+both+histone+deacetylase+activity+and+phosphatidylinositol+3-kinase+signaling&doi=10.1158%2F1078-0432.CCR-12-0055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling</span></div><div class="casAuthors">Qian, Changgeng; Lai, Cheng-Jung; Bao, Rudi; Wang, Da-Gong; Wang, Jing; Xu, Guang-Xin; Atoyan, Ruzanna; Qu, Hui; Yin, Ling; Samson, Maria; Zifcak, Brian; Ma, Anna Wai See; Della Rocca, Steven; Borek, Mylissa; Zhai, Hai-Xiao; Cai, Xiong; Voi, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4104-4113</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Given that histone deacetylase (HDAC) inhibitors are known to induce multiple epigenetic modifications affecting signaling networks and act synergistically with phosphatidylinositol 3-kinase (PI3K) inhibitors, we developed a strategy to simultaneously inhibit HDACs and PI3K in cancer cells.  Exptl. Design: We constructed dual-acting inhibitors by incorporating HDAC inhibitory functionality into a PI3K inhibitor pharmacophore.  CUDC-907, a development candidate selected from these dual inhibitors, was evaluated in vitro and in vivo to det. its pharmacol. properties, anticancer activity, and mechanism of action.  Results: CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes.  Through its integrated HDAC inhibitory activity, CUDC-907 durably inhibits the PI3K-AKT-mTOR pathway and compensatory signaling mols. such as RAF, MEK, MAPK, and STAT-3, as well as upstream receptor tyrosine kinases.  CUDC-907 shows greater growth inhibition and proapoptotic activity than single-target PI3K or HDAC inhibitors in both cultured and implanted cancer cells.  Conclusions: CUDC-907 may offer improved therapeutic benefits through simultaneous, sustained disruption of multiple oncogenic signaling networks.  Clin Cancer Res; 18(15); 4104-13. Â©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnvXaG5-2QzbVg90H21EOLACvtfcHk0ljvFzsU1777DQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL&md5=be0d379f13fded2bed326cece99af8d7</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0055%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DC.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26atitle%3DCancer%2520network%2520disruption%2520by%2520a%2520single%2520molecule%2520inhibitor%2520targeting%2520both%2520histone%2520deacetylase%2520activity%2520and%2520phosphatidylinositol%25203-kinase%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4104%26epage%3D4113%26doi%3D10.1158%2F1078-0432.CCR-12-0055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel dual histone deacetylases (HDACs) and mammalian target of rapamycin (mTOR) target inhibitor as a promising strategy for cancer therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1577</span>â <span class="NLM_lpage">1592</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01825</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01825" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFeguw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1577-1592&author=Y.+Chenauthor=X.+Yuanauthor=W.+Zhangauthor=M.+Tangauthor=L.+Zhengauthor=F.+Wangauthor=W.+Yanauthor=S.+Yang&title=Discovery+of+a+novel+dual+histone+deacetylases+%28HDACs%29+and+mammalian+target+of+rapamycin+%28mTOR%29+target+inhibitor+as+a+promising+strategy+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.8b01825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy</span></div><div class="casAuthors">Chen, Yong; Yuan, Xue; Zhang, Wanhua; Tang, Minghai; Zheng, Li; Wang, Fang; Yan, Wei; Yang, Shengyong; Wei, Yuquan; He, Jun; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1577-1592</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present study, a series of novel dual-target histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors were designed and synthesized using pyrimidine-pyrazolyl pharmacophore to append HDAC recognition cap and hydroxamic acid as a zinc-binding motif.  Among them, I was the optimal lead compd. with potent inhibition activities against mTOR and HDAC1 with half-maximal inhibitory concn. of 1.2 and 0.19 nM, resp.  Western blot confirmed that I could upregulate acetylation of H3 and Î±-tubulin and downregulate mTOR-related downstream mediators.  I could also stimulate cell cycle arrest in G0/G1 phase and induce tumor cell apoptosis.  I showed comparable antitumor activity with the combination medication in MM1S xenograft model with a tumor growth inhibitory rate of 72.5%, without causing significant loss of body wt. and toxicity.  All of the results indicated that I could be a promising dual target inhibitor for treating hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ3AdehNv1ObVg90H21EOLACvtfcHk0ljvMAA115CQAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFeguw%253D%253D&md5=7a2ff5020aedb0e3c302e65d993301e6</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01825%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520dual%2520histone%2520deacetylases%2520%2528HDACs%2529%2520and%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520target%2520inhibitor%2520as%2520a%2520promising%2520strategy%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1577%26epage%3D1592%26doi%3D10.1021%2Facs.jmedchem.8b01825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. G.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">12</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2015.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=26741358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVOj" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2016&pages=1-12&author=F.+W.+Pengauthor=J.+Xuanauthor=T.+T.+Wuauthor=J.+Y.+Xueauthor=Z.+W.+Renauthor=D.+K.+Liuauthor=X.+Q.+Wangauthor=X.+H.+Chenauthor=J.+W.+Zhangauthor=Y.+G.+Xu&title=Design%2C+synthesis+and+biological+evaluation+of+N-phenylquinazolin-4-amine+hybrids+as+dual+inhibitors+of+VEGFR-2+and+HDAC&doi=10.1016%2Fj.ejmech.2015.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC</span></div><div class="casAuthors">Peng, Fan-Wei; Xuan, Ji; Wu, Ting-Ting; Xue, Jia-Yu; Ren, Zi-Wei; Liu, Da-Ke; Wang, Xiu-Qi; Chen, Xin-Hang; Zhang, Jia-Wei; Xu, Yun-Gen; Shi, Lei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this work, a series of hybrids bearing N-phenylquinazolin-4-amine and hydroxamic acid moieties I (R1, R2 = H, F, Cl, Br, n = 2, 3, 4, 5) were designed and identified as dual VEGFR-2/HDAC inhibitors.  Compd. I (R1 = H, R2 = Br, n = 5) exhibited the most potent inhibitory activity against HDAC with IC50 of 2.2 nM and strong inhibitory effect against VEGFR-2 with IC50 of 74 nM.  It also showed the most potent inhibitory activity against a human breast cancer cell line MCF-7 with IC50 of 0.85 Î¼M.  Docking simulation supported the initial pharmacophoric hypothesis and suggested a common mode of interaction at the active binding sites of VEGFR-2 and HDLP (Histone Deacetylase-Like Protein), which demonstrates that compd. I (R1 = H, R2 = Br, n = 5) is a potential agent for cancer therapy deserving further researching.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT_jbaom_UR7Vg90H21EOLACvtfcHk0ljvMAA115CQAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVOj&md5=1a0c299ec484daa522da5969e8a35cec</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DF.%2BW.%26aulast%3DXuan%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DT.%2BT.%26aulast%3DXue%26aufirst%3DJ.%2BY.%26aulast%3DRen%26aufirst%3DZ.%2BW.%26aulast%3DLiu%26aufirst%3DD.%2BK.%26aulast%3DWang%26aufirst%3DX.%2BQ.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%2BW.%26aulast%3DXu%26aufirst%3DY.%2BG.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520N-phenylquinazolin-4-amine%2520hybrids%2520as%2520dual%2520inhibitors%2520of%2520VEGFR-2%2520and%2520HDAC%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D109%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.ejmech.2015.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of STAT3 and histone deacetylase (HDAC) dual-Pathway inhibitors for the treatment of solid cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">7468</span>â <span class="NLM_lpage">7482</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.1c00136</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.1c00136" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhtFKhur3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=7468-7482&author=Y.+Renauthor=S.+Liauthor=R.+Zhuauthor=C.+Wanauthor=D.+Songauthor=J.+Zhuauthor=G.+Caiauthor=S.+Longauthor=L.+Kongauthor=W.+Yu&title=Discovery+of+STAT3+and+histone+deacetylase+%28HDAC%29+dual-Pathway+inhibitors+for+the+treatment+of+solid+cancer&doi=10.1021%2Facs.jmedchem.1c00136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer</span></div><div class="casAuthors">Ren, Yuhao; Li, Shanshan; Zhu, Ren; Wan, Chengying; Song, Dongmei; Zhu, Jiawen; Cai, Guiping; Long, Sihui; Kong, Lingyi; Yu, Wenying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7468-7482</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nowadays, simultaneous inhibition of multiple targets through drug combination is an important anticancer strategy owing to the complex mechanism behind tumorigenesis.  Recent studies have demonstrated that the inhibition of histone deacetylases (HDACs) will lead to compensated activation of a notorious cancer-related drug target, signal transducer and activator of transcription 3 (STAT3), in breast cancer through a cascade, which probably limits the anti-proliferation effect of HDAC inhibitors in solid tumors.  By incorporating the pharmacophore of the HDAC inhibitor SAHA (vorinostat) into the STAT3 inhibitor pterostilbene, a series of potent pterostilbene hydroxamic acid derivs. with dual-target inhibition activity were synthesized.  An excellent hydroxamate derivate, compd. 14, inhibited STAT3 (KD = 33 nM) and HDAC (IC50 = 23.15 nM) with robust potency in vitro.  Compd. 14 also showed potent anti-proliferation ability in vivo and in vitro.  Our study provides the first STAT3 and HDAC dual-target inhibitor for further exploration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPTnVkCD3wdbVg90H21EOLACvtfcHk0ljvMAA115CQAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhtFKhur3K&md5=7e54efab8eae1fa04e867d6522551b4e</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.1c00136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.1c00136%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DG.%26aulast%3DLong%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520STAT3%2520and%2520histone%2520deacetylase%2520%2528HDAC%2529%2520dual-Pathway%2520inhibitors%2520for%2520the%2520treatment%2520of%2520solid%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D7468%26epage%3D7482%26doi%3D10.1021%2Facs.jmedchem.1c00136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Lanosterol 14Î±-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>221</i></span>,  <span class="NLM_fpage">113524</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2021.113524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2021.113524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=33992927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhtFSgurfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=221&publication_year=2021&pages=113524&author=T.+Zhuauthor=X.+Chenauthor=C.+Liauthor=J.+Tuauthor=N.+Liuauthor=D.+Xuauthor=C.+Sheng&title=Lanosterol+14%CE%B1-demethylase+%28CYP51%29%2Fhistone+deacetylase+%28HDAC%29+dual+inhibitors+for+treatment+of+Candida+tropicalis+and+Cryptococcus+neoformans+infections&doi=10.1016%2Fj.ejmech.2021.113524"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Lanosterol 14Î±-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections</span></div><div class="casAuthors">Zhu, Tianbao; Chen, Xi; Li, Chenglan; Tu, Jie; Liu, Na; Xu, Defeng; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">221</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113524</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Invasive fungal infections remain a challenge due to lack of effective antifungal agents and serious drug resistance.  Discovery of antifungal agents with novel antifungal mechanism is important and urgent.  Previously, we designed the first CYP51/HDAC dual inhibitors with potent activity against resistant Candida albicans infections.  To better understand the antifungal spectrum and synergistic mechanism, herein new CYP51/HDAC dual inhibitors were designed which showed potent in vitro and in vivo antifungal activity against C. neoformans and C. tropicalis infections.  Antifungal mechanism studies revealed that the CYP51/HDAC dual inhibitors acted by inhibiting various virulence factors of C. tropicalis and C. neoformans and down-regulating resistance-assocd. genes.  This study highlights the potential of CYP51/HDAC dual inhibitors as a promising strategy for the discovery of novel broad-spectrum antifungal agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_kDz4IKxl3LVg90H21EOLACvtfcHk0ljihtTkRnk-Dg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhtFSgurfN&md5=caccd81358057ff760f9e3fad53bf087</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113524%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DLanosterol%252014%25CE%25B1-demethylase%2520%2528CYP51%2529%252Fhistone%2520deacetylase%2520%2528HDAC%2529%2520dual%2520inhibitors%2520for%2520treatment%2520of%2520Candida%2520tropicalis%2520and%2520Cryptococcus%2520neoformans%2520infections%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D221%26spage%3D113524%26doi%3D10.1016%2Fj.ejmech.2021.113524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abd El-Hafeez, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelhamid, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katkar, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mostafa, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayallah, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abuo-Rahma, G. E.-D. A.</span></span> <span> </span><span class="NLM_article-title">A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>222</i></span>,  <span class="NLM_fpage">113569</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2021.113569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2021.113569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=34111829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXht1yrsbnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=222&publication_year=2021&pages=113569&author=M.+Mustafaauthor=A.+A.+Abd+El-Hafeezauthor=D.+Abdelhamidauthor=G.+D.+Katkarauthor=Y.+A.+Mostafaauthor=P.+Ghoshauthor=A.+M.+Hayallahauthor=G.+E.-D.+A.+Abuo-Rahma&title=A+first-in-class+anticancer+dual+HDAC2%2FFAK+inhibitors+bearing+hydroxamates%2Fbenzamides+capped+by+pyridinyl-1%2C2%2C4-triazoles&doi=10.1016%2Fj.ejmech.2021.113569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles</span></div><div class="casAuthors">Mustafa, Muhamad; Abd El-Hafeez, Amer Ali; Abdelhamid, Dalia; Katkar, Gajanan D.; Mostafa, Yaser A.; Ghosh, Pradipta; Hayallah, Alaa M.; Abuo-Rahma, Gamal El-Din A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">222</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113569</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Novel 5-pyridinyl-1,2,4-triazoles were designed as dual inhibitors of histone deacetylase 2 (HDAC2) and focal adhesion kinase (FAK).  Compds. 5d, 6a, 7c, and 11c were detd. as potential inhibitors of both HDAC2 (IC50 = 0.09-1.40 Î¼M) and FAK (IC50 = 12.59-36.11 nM); 6a revealed the highest activity with IC50 values of 0.09 Î¼M and 12.59 nM for HDAC2 and FAK, resp.  Compd. 6a was superior to ref. drugs vorinostat and valproic acid in its ability to inhibit growth/proliferation of A-498 and Caki-1 renal cancer cells.  Further investigation proved that 6a strongly arrests the cell cycle at the G2/M phase and triggers apoptosis in both A-498 and Caki-1 cells.  Moreover, the enhanced Akt activity that is obsd. upon chronic application of HDAC inhibitors was effectively suppressed by the dual HDAC2/FAK inhibitor.  Finally, the high potency and selectivity of 6a towards HDAC2 and FAK proteins were rationalized by mol. docking.  Taken together, these findings highlight the potential of 6a as a promising dual-acting HDAC2/FAK inhibitor that could benefit from further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozexEs2PUj_bVg90H21EOLACvtfcHk0ljihtTkRnk-Dg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXht1yrsbnM&md5=608d373857e2c87916557b09702b445a</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113569%26sid%3Dliteratum%253Aachs%26aulast%3DMustafa%26aufirst%3DM.%26aulast%3DAbd%2BEl-Hafeez%26aufirst%3DA.%2BA.%26aulast%3DAbdelhamid%26aufirst%3DD.%26aulast%3DKatkar%26aufirst%3DG.%2BD.%26aulast%3DMostafa%26aufirst%3DY.%2BA.%26aulast%3DGhosh%26aufirst%3DP.%26aulast%3DHayallah%26aufirst%3DA.%2BM.%26aulast%3DAbuo-Rahma%26aufirst%3DG.%2BE.-D.%2BA.%26atitle%3DA%2520first-in-class%2520anticancer%2520dual%2520HDAC2%252FFAK%2520inhibitors%2520bearing%2520hydroxamates%252Fbenzamides%2520capped%2520by%2520pyridinyl-1%252C2%252C4-triazoles%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D222%26spage%3D113569%26doi%3D10.1016%2Fj.ejmech.2021.113569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">112868</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2020.112868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2020.112868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=33077265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFaht7nE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2021&pages=112868&author=J.+Chenauthor=Y.+Liauthor=J.+Zhangauthor=M.+Zhangauthor=A.+Weiauthor=H.+Liuauthor=Z.+Xieauthor=W.+Renauthor=W.+Duanauthor=Z.+Zhangauthor=A.+Shenauthor=Y.+Hu&title=Discovery+of+selective+HDAC%2FBRD4+dual+inhibitors+as+epigenetic+probes&doi=10.1016%2Fj.ejmech.2020.112868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes</span></div><div class="casAuthors">Chen, Jingjing; Li, Yalei; Zhang, Jie; Zhang, Minmin; Wei, Aihuan; Liu, Hongchun; Xie, Zhicheng; Ren, Wenming; Duan, Wenwen; Zhang, Zhuo; Shen, Aijun; Hu, Youhong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112868</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">According to the binding mode of ABBV-744 with bromodomains and the cape space of HDAC, the novel selective HDAC/BRD4 dual inhibitors were designed and synthesized by the pharmacophore fusion strategy.  Evaluating the biomol. activities through SARs exploration identified three kinds of selective dual inhibitors 41c (HDAC1/BRD4), 43a (pan-HDAC/BRD4) and 43d (HDAC6/BRD4(BD2)), whose target-related cellular activities in MV-4-11 cells were also confirmed.  Significantly, the selective dual inhibitor 41c (HDAC1/BRD4) exhibited synergistic effects against MV-4-11 cells, which strongly induced G0/G1 cell cycle arrest and apoptosis, and the first HDAC6/BRD4(BD2) dual inhibitor was found.  This study provides support for selective HDAC/BRD4 dual inhibitors as epigenetic probes based on pyrrolopyridone core for the future biol. evaluation in different cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbMygNv9rC2bVg90H21EOLACvtfcHk0ljihtTkRnk-Dg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFaht7nE&md5=b39c2be6ed98f0f5ffee7bf8ac1f7cf4</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112868%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DW.%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520selective%2520HDAC%252FBRD4%2520dual%2520inhibitors%2520as%2520epigenetic%2520probes%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D209%26spage%3D112868%26doi%3D10.1016%2Fj.ejmech.2020.112868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7593</span>â <span class="NLM_lpage">7613</span>, <span class="refDoi">Â DOI: 10.1021/jm300605m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300605m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFClurfP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7593-7613&author=G.+Dongauthor=S.+Wangauthor=Z.+Miaoauthor=J.+Yaoauthor=Y.+Zhangauthor=Z.+Guoauthor=W.+Zhangauthor=C.+Sheng&title=New+tricks+for+an+old+natural+product%3A+discovery+of+highly+potent+evodiamine+derivatives+as+novel+antitumor+agents+by+systemic+structure-activity+relationship+analysis+and+biological+evaluations&doi=10.1021%2Fjm300605m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">New Tricks for an Old Natural Product: Discovery of Highly Potent Evodiamine Derivatives as Novel Antitumor Agents by Systemic Structure-Activity Relationship Analysis and Biological Evaluations</span></div><div class="casAuthors">Dong, Guoqiang; Wang, Shengzheng; Miao, Zhenyuan; Yao, Jianzhong; Zhang, Yongqiang; Guo, Zizhao; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7593-7613</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Evodiamine is a quinazolinocarboline alkaloid isolated from the fruits of traditional Chinese herb Evodiae fructus.  Herein, a library of novel evodiamine derivs. bearing various substitutions or modified scaffold were synthesized.  Among them, a no. of evodiamine derivs. showed substantial increase of the antitumor activity, with GI50 values lower than 3 nM.  Moreover, these highly potent compds. can effectively induce the apoptosis of A549 cells.  Interestingly, further computational target prediction calcns. in combination with biol. assays confirmed that the evodiamine derivs. acted by dual inhibition of topoisomerases I and II.  Moreover, several hydroxyl derivs., such as 10-hydroxyevodiamine and 3-amino-10-hydroxyevodiamine, also showed good in vivo antitumor efficacy and low toxicity at the dose of 1 mg/kg or 2 mg/kg.  They represent promising candidates for the development of novel antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocJjv8REdBnrVg90H21EOLACvtfcHk0lhBgkLydpZ_lQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFClurfP&md5=6e7d03671ac1be56b8bd68dc0fc03062</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm300605m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300605m%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DNew%2520tricks%2520for%2520an%2520old%2520natural%2520product%253A%2520discovery%2520of%2520highly%2520potent%2520evodiamine%2520derivatives%2520as%2520novel%2520antitumor%2520agents%2520by%2520systemic%2520structure-activity%2520relationship%2520analysis%2520and%2520biological%2520evaluations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7593%26epage%3D7613%26doi%3D10.1021%2Fjm300605m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel multiacting topoisomerase i/ii and histone deacetylase inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">239</span>â <span class="NLM_lpage">243</span>, <span class="refDoi">Â DOI: 10.1021/ml500327q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500327q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVGitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=239-243&author=S.+Heauthor=G.+Dongauthor=Z.+Wangauthor=W.+Chenauthor=Y.+Huangauthor=Z.+Liauthor=Y.+Jiangauthor=N.+Liuauthor=J.+Yaoauthor=Z.+Miaoauthor=W.+Zhangauthor=C.+Sheng&title=Discovery+of+novel+multiacting+topoisomerase+i%2Fii+and+histone+deacetylase+inhibitors&doi=10.1021%2Fml500327q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors</span></div><div class="casAuthors">He, Shipeng; Dong, Guoqiang; Wang, Zhibin; Chen, Wei; Huang, Yahui; Li, Zhengang; Jiang, Yan; Liu, Na; Yao, Jianzhong; Miao, Zhenyuan; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-243</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget drugs remains a significant challenge in current antitumor drug discovery.  Because of the synergistic effect between topoisomerase and HDAC inhibitors, the present study reported the first-in-class triple inhibitors of topoisomerase I/II and HDAC.  On the basis of 3-amino-10-hydroxylevodiamine and SAHA, a series of hybrid mols. was successfully designed and synthesized.  In particular, compd. 8c was proven to be a potent inhibitor of topoisomerase I/II and HDAC with good antiproliferative and apoptotic activities.  This proof-of-concept study also validated the effectiveness of discovering triple topoisomerase I/II and HDAC inhibitors as novel antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNFr6sR4u6kbVg90H21EOLACvtfcHk0lhBgkLydpZ_lQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVGitw%253D%253D&md5=9630a82acaa4df7023a07aa7ed395e86</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Fml500327q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500327q%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520novel%2520multiacting%2520topoisomerase%2520i%252Fii%2520and%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D239%26epage%3D243%26doi%3D10.1021%2Fml500327q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.-B.</span></span> <span> </span><span class="NLM_article-title">Novel bioactive hybrid compound dual targeting estrogen receptor and histone deacetylase for the treatment of breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4550</span>â <span class="NLM_lpage">4572</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00099</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00099" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVShsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4550-4572&author=C.+Tangauthor=C.+Liauthor=S.+Zhangauthor=Z.+Huauthor=J.+Wuauthor=C.+Dongauthor=J.+Huangauthor=H.-B.+Zhou&title=Novel+bioactive+hybrid+compound+dual+targeting+estrogen+receptor+and+histone+deacetylase+for+the+treatment+of+breast+cancer&doi=10.1021%2Facs.jmedchem.5b00099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer</span></div><div class="casAuthors">Tang, Chu; Li, Changhao; Zhang, Silong; Hu, Zhiye; Wu, Jun; Dong, Chune; Huang, Jian; Zhou, Hai-Bing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4550-4572</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A strategy to develop chemotherapeutic agents by combining several active groups into a single mol. as a conjugate that can modulate multiple cellular pathways may produce compds. having higher efficacy compared to that of single-target drugs.  In this article, we describe the synthesis and evaluation of an array of dual-acting ER and histone deacetylase inhibitors.  These novel hybrid compds. combine an indirect antagonism structure motif of ER (OBHS, oxabicycloheptene sulfonate) with the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA).  These OBHS-HDACi conjugates I (R = OH, NHOH; Ar = Ph, 1-naphthyl, 2-naphthyl, 4-MeC6H5, 3-MeC6H5, 2-MeC6H5, 2-MeOC6H5, etc.) exhibited good ER binding affinity and excellent ERÎ± antagonistic activity, and they also exhibited potent inhibitory activities against HDACs.  Compared with the approved drug tamoxifen, these conjugates exhibited higher antitumor potency in ERÎ±-pos. breast cancer cells (MCF-7).  Moreover, these conjugates not only showed selective anticancer activity that was more potent against MCF-7 cells than DU 145 (prostate cancer), but they had no toxicity toward normal cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokzR9bn5jLU7Vg90H21EOLACvtfcHk0lhBgkLydpZ_lQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVShsbk%253D&md5=223b9c3c43e1f8f012efcd1771547ee1</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00099%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DH.-B.%26atitle%3DNovel%2520bioactive%2520hybrid%2520compound%2520dual%2520targeting%2520estrogen%2520receptor%2520and%2520histone%2520deacetylase%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4550%26epage%3D4572%26doi%3D10.1021%2Facs.jmedchem.5b00099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breitenlechner, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kairies, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honold, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiblich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koll, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engh, R. A.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of active SRC kinase domain complexes</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">222</span>â <span class="NLM_lpage">231</span>, <span class="refDoi">Â DOI: 10.1016/j.jmb.2005.08.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.jmb.2005.08.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=16168436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGrtrnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=222-231&author=C.+B.+Breitenlechnerauthor=N.+A.+Kairiesauthor=K.+Honoldauthor=S.+Scheiblichauthor=H.+Kollauthor=E.+Greiterauthor=S.+Kochauthor=W.+Schaferauthor=R.+Huberauthor=R.+A.+Engh&title=Crystal+structures+of+active+SRC+kinase+domain+complexes&doi=10.1016%2Fj.jmb.2005.08.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Active Src Kinase Domain Complexes</span></div><div class="casAuthors">Breitenlechner, Christine B.; Kairies, Norman A.; Honold, Konrad; Scheiblich, Stefan; Koll, Hans; Greiter, Eva; Koch, Stefan; Schaefer, Wolfgang; Huber, Robert; Engh, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">C-Src was the first proto-oncoprotein to be identified, and has become the focus of many drug discovery programs.  Src structures of a major inactive form have shown how the protein kinase is rigidified by several interdomain interactions; active configurations of Src are generated by release from this "assembled" or "bundled" form.  Despite the importance of Src as a drug target, there is relatively little structural information available regarding the presumably more flexible active forms.  Here we report three crystal structures of a dimeric active c-Src kinase domain, in an apo and two ligand complexed forms, with resolns. ranging from 2.9 Ã to 1.95 Ã.  The structures show how the kinase domain, in the absence of the rigidifying interdomain interactions of the inactivation state, adopts a more open and flexible conformation.  The ATP site inhibitor CGP77675 binds to the protein kinase with canonical hinge hydrogen bonds and also to the c-Src specific threonine 340.  In contrast to purvalanol B binding in CDK2, purvalanol A binds in c-Src with a conformational change in a more open ATP pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc3P258chhrbVg90H21EOLACvtfcHk0liDBwi9ZYvtYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGrtrnF&md5=9bc8e1670457d34ac88e6b5b20efea21</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2005.08.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2005.08.023%26sid%3Dliteratum%253Aachs%26aulast%3DBreitenlechner%26aufirst%3DC.%2BB.%26aulast%3DKairies%26aufirst%3DN.%2BA.%26aulast%3DHonold%26aufirst%3DK.%26aulast%3DScheiblich%26aufirst%3DS.%26aulast%3DKoll%26aufirst%3DH.%26aulast%3DGreiter%26aufirst%3DE.%26aulast%3DKoch%26aufirst%3DS.%26aulast%3DSchafer%26aufirst%3DW.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DEngh%26aufirst%3DR.%2BA.%26atitle%3DCrystal%2520structures%2520of%2520active%2520SRC%2520kinase%2520domain%2520complexes%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2005%26volume%3D353%26spage%3D222%26epage%3D231%26doi%3D10.1016%2Fj.jmb.2005.08.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicheri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of hck in complex with a src family-selective tyrosine kinase inhibitor</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">639</span>â <span class="NLM_lpage">648</span>, <span class="refDoi">Â DOI: 10.1016/S1097-2765(00)80357-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS1097-2765%2800%2980357-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10360180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK1MXjslCqu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1999&pages=639-648&author=T.+Schindlerauthor=F.+Sicheriauthor=A.+Picoauthor=A.+Gazitauthor=J.+Kuriyan&title=Crystal+structure+of+hck+in+complex+with+a+src+family-selective+tyrosine+kinase+inhibitor&doi=10.1016%2FS1097-2765%2800%2980357-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of HcK in complex with a Src family-selective tyrosine kinase inhibitor</span></div><div class="casAuthors">Schindler, Thomas; Sicheri, Frank; Pico, Alexander; Gazit, Aviv; Levitzki, Alexander; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-648</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The crystal structure of the autoinhibited form of Hck has been detd. at 2.0 Ã resoln., in complex with a specific pyrazolo pyrimidine-type inhibitor, PP1.  The activation segment, a key regulatory component of the catalytic domain, is unphosphorylated and is visualized in its entirety.  Tyr-416, the site of activating autophosphorylation in the Src family kinases, is positioned such that access to the catalytic machinery is blocked.  PP1 is bound at the ATP-binding site of the kinase, and a methylphenyl group on PP1 is inserted into an adjacent hydrophobic pocket.  The enlargement of this pocket in autoinhibited Src kinases suggests a route toward the development of inhibitors that are specific for the inactive forms of these proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf3jZGeDrWtLVg90H21EOLACvtfcHk0liDBwi9ZYvtYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjslCqu7s%253D&md5=33617bc9698224ed3f047749b9133874</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2800%2980357-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252800%252980357-3%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DPico%26aufirst%3DA.%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520hck%2520in%2520complex%2520with%2520a%2520src%2520family-selective%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cell%26date%3D1999%26volume%3D3%26spage%3D639%26epage%3D648%26doi%3D10.1016%2FS1097-2765%2800%2980357-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stamos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span> <span> </span><span class="NLM_article-title">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">46265</span>â <span class="NLM_lpage">46272</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M207135200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1074%2Fjbc.M207135200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=12196540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46265-46272&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+epidermal+growth+factor+receptor+kinase+domain+alone+and+in+complex+with+a+4-anilinoquinazoline+inhibitor&doi=10.1074%2Fjbc.M207135200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span></div><div class="casAuthors">Stamos, Jennifer; Sliwkowski, Mark X.; Eigenbrot, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">46265-46272</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been detd. to 2.6-Ã resoln., both with and without an EGFRK-specific inhibitor currently in Phase III clin. trials as an anti-cancer agent, erlotinib (OSI-774, CP-358,774, Tarceva).  The EGFR family members are distinguished from all other known receptor tyrosine kinases in possessing constitutive kinase activity without a phosphorylation event within their kinase domains.  Despite its lack of phosphorylation, we find that the EGFRK activation loop adopts a conformation similar to that of the phosphorylated active form of the kinase domain from the insulin receptor.  Surprisingly, key residues of a putative dimerization motif lying between the EGFRK domain and carboxyl-terminal substrate docking sites are found in close contact with the kinase domain.  Significant intermol. contacts involving the carboxyl-terminal tail are discussed with respect to receptor oligomerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsObp1WYFaC7Vg90H21EOLACvtfcHk0liDBwi9ZYvtYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D&md5=c63c60b93756bd45fb2375c56ba38941</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M207135200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M207135200%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520domain%2520alone%2520and%2520in%2520complex%2520with%2520a%25204-anilinoquinazoline%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D46265%26epage%3D46272%26doi%3D10.1074%2Fjbc.M207135200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barchechath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saade, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauwagie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B.</span></span> <span> </span><span class="NLM_article-title">Rational design of multitargeted tyrosine kinase inhibitors: a novel approach</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">380</span>â <span class="NLM_lpage">387</span>, <span class="refDoi">Â DOI: 10.1111/j.1747-0285.2009.00786.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1111%2Fj.1747-0285.2009.00786.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=19291100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktVWhsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2009&pages=380-387&author=S.+Barchechathauthor=C.+Williamsauthor=K.+Saadeauthor=S.+Lauwagieauthor=B.+Jean-Claude&title=Rational+design+of+multitargeted+tyrosine+kinase+inhibitors%3A+a+novel+approach&doi=10.1111%2Fj.1747-0285.2009.00786.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of multitargeted tyrosine kinase inhibitors: a novel approach</span></div><div class="casAuthors">Barchechath, Sylvie; Williams, Christopher; Saade, Khalil; Lauwagie, Sylvia; Jean-Claude, Bertrand</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">380-387</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The non-receptor Src tyrosine kinase is known to cooperate with the epidermal growth factor receptor in a mechanism leading to invasion and metastasis of solid tumors.  With the purpose of developing agents targeted to both epidermal growth factor receptor and Src or related kinases, we embarked on the design of chimeric mols. termed combi-mols. capable of blocking both Src and epidermal growth factor receptor.  To this end, we have chosen to design mols. contg. a quinazoline moiety (directed at epidermal growth factor receptor) and a 7-phenyl-pyrazolopyrimidine (directed at Src).  Mol. modeling showed that the optimal position to attach the linker was the 6-position of the quinazoline and the 9-position of the pyrazolopyrimidine.  This has led to the synthesis of SB162, SB166 and SB163 (I).  I contg. the longest linker was the only mol. capable of inducing a dose-dependent inhibition of both Src and epidermal growth factor receptor.  I also induced a dose inhibition of Abl and PDGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqPD3kksVKFrVg90H21EOLACvtfcHk0ljsfb5r3oXqgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktVWhsr4%253D&md5=e34498b737d90afbb9be065bb9ef0489</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2009.00786.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2009.00786.x%26sid%3Dliteratum%253Aachs%26aulast%3DBarchechath%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DSaade%26aufirst%3DK.%26aulast%3DLauwagie%26aufirst%3DS.%26aulast%3DJean-Claude%26aufirst%3DB.%26atitle%3DRational%2520design%2520of%2520multitargeted%2520tyrosine%2520kinase%2520inhibitors%253A%2520a%2520novel%2520approach%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2009%26volume%3D73%26spage%3D380%26epage%3D387%26doi%3D10.1111%2Fj.1747-0285.2009.00786.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpowich, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. N.</span></span> <span> </span><span class="NLM_article-title">Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">652</span>â <span class="NLM_lpage">657</span>, <span class="refDoi">Â DOI: 10.1038/nsmb.1602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fnsmb.1602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=19430461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1MXls1Cmtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=652-657&author=Z.+Zhouauthor=J.+Zhenauthor=N.+K.+Karpowichauthor=C.+J.+Lawauthor=M.+E.+Reithauthor=D.+N.+Wang&title=Antidepressant+specificity+of+serotonin+transporter+suggested+by+three+LeuT-SSRI+structures&doi=10.1038%2Fnsmb.1602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures</span></div><div class="casAuthors">Zhou, Zheng; Zhen, Juan; Karpowich, Nathan K.; Law, Christopher J.; Reith, Maarten E. A.; Wang, Da-Neng</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">652-657</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Sertraline and fluoxetine are selective serotonin re-uptake inhibitors (SSRIs) that are widely prescribed to treat depression.  They exert their effects by inhibiting the presynaptic plasma membrane serotonin transporter (SERT).  All SSRIs possess halogen atoms at specific positions, which are key determinants for the drugs' specificity for SERT.  For the SERT protein, however, the structural basis of its specificity for SSRIs is poorly understood.  Here we report the crystal structures of LeuT, a bacterial SERT homolog, in complex with sertraline, R-fluoxetine or S-fluoxetine.  The SSRI halogens all bind to exactly the same pocket within LeuT.  Mutation at this halogen-binding pocket (HBP) in SERT markedly reduces the transporter's affinity for SSRIs but not for tricyclic antidepressants.  Conversely, when the only nonconserved HBP residue in both norepinephrine and dopamine transporters is mutated into that found in SERT, their affinities for all the three SSRIs increase uniformly.  Thus, the specificity of SERT for SSRIs is dependent largely on interaction of the drug halogens with the protein's HBP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreUWPt0csx4bVg90H21EOLACvtfcHk0ljsfb5r3oXqgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXls1Cmtrc%253D&md5=33444a0991503249c620e55159d7f09c</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.1602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.1602%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DZhen%26aufirst%3DJ.%26aulast%3DKarpowich%26aufirst%3DN.%2BK.%26aulast%3DLaw%26aufirst%3DC.%2BJ.%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DD.%2BN.%26atitle%3DAntidepressant%2520specificity%2520of%2520serotonin%2520transporter%2520suggested%2520by%2520three%2520LeuT-SSRI%2520structures%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D16%26spage%3D652%26epage%3D657%26doi%3D10.1038%2Fnsmb.1602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tago, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naruto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, R.</span></span> <span> </span><span class="NLM_article-title">A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimerâs disease</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4389</span>â <span class="NLM_lpage">4415</span>, <span class="refDoi">Â DOI: 10.1016/S0968-0896(03)00452-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS0968-0896%2803%2900452-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=13129577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1yisrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=4389-4415&author=N.+Todaauthor=K.+Tagoauthor=S.+Marumotoauthor=K.+Takamiauthor=M.+Oriauthor=N.+Yamadaauthor=K.+Koyamaauthor=S.+Narutoauthor=K.+Abeauthor=R.+Yamazaki&title=A+conformational+restriction+approach+to+the+development+of+dual+inhibitors+of+acetylcholinesterase+and+serotonin+transporter+as+potential+agents+for+Alzheimer%E2%80%99s+disease&doi=10.1016%2FS0968-0896%2803%2900452-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease</span></div><div class="casAuthors">Toda, Narihiro; Tago, Keiko; Marumoto, Shinji; Takami, Kazuko; Ori, Mayuko; Yamada, Naho; Koyama, Kazuo; Naruto, Shunji; Abe, Kazumi; Yamazaki, Reina; Hara, Takao; Aoyagi, Atsushi; Abe, Yasuyuki; Kaneko, Tsugio; Kogen, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4389-4415</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) has been treated with acetylcholinesterase (AChE) inhibitors such as donepezil.  However, the clin. usefulness of AChE inhibitors is limited mainly due to their adverse peripheral effects.  Depression seen in AD patients has been treated with serotonin transporter (SERT) inhibitors.  The authors considered that combining SERT and AChE inhibition could improve the clin. usefulness of AChE inhibitors.  In a previous paper, the authors found a potential dual inhibitor of AChE (IC50 = 101 nM) and SERT (IC50 = 42 nM), but its AChE inhibition activity was less than donepezil (IC50 = 10 nM).  Here, the authors report the conformationally restricted (R)-I considerably enhanced inhibitory activity against AChE (IC50 = 14 nM) and SERT (IC50 = 6 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhL6Fowj3gpbVg90H21EOLACvtfcHk0ljsfb5r3oXqgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1yisrk%253D&md5=1b4b1fb9aeea5514e3246450c00f0add</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2803%2900452-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252803%252900452-8%26sid%3Dliteratum%253Aachs%26aulast%3DToda%26aufirst%3DN.%26aulast%3DTago%26aufirst%3DK.%26aulast%3DMarumoto%26aufirst%3DS.%26aulast%3DTakami%26aufirst%3DK.%26aulast%3DOri%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DN.%26aulast%3DKoyama%26aufirst%3DK.%26aulast%3DNaruto%26aufirst%3DS.%26aulast%3DAbe%26aufirst%3DK.%26aulast%3DYamazaki%26aufirst%3DR.%26atitle%3DA%2520conformational%2520restriction%2520approach%2520to%2520the%2520development%2520of%2520dual%2520inhibitors%2520of%2520acetylcholinesterase%2520and%2520serotonin%2520transporter%2520as%2520potential%2520agents%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D4389%26epage%3D4415%26doi%3D10.1016%2FS0968-0896%2803%2900452-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahmani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almenara, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrad, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varticovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2118</span>â <span class="NLM_lpage">2126</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=12727828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlGmsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=2118-2126&author=C.+Yuauthor=M.+Rahmaniauthor=J.+Almenaraauthor=M.+Sublerauthor=G.+Krystalauthor=D.+Conradauthor=L.+Varticovskiauthor=P.+Dentauthor=S.+Grant&title=Histone+deacetylase+inhibitors+promote+STI571-mediated+apoptosis+in+STI571-sensitive+and+-resistant+Bcr%2FAbl%2B+human+myeloid+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors Promote STI571-mediated Apoptosis in STI571-sensitive and -resistant Bcr/Abl+ Human Myeloid Leukemia Cells</span></div><div class="casAuthors">Yu, Chunrong; Rahmani, Mohamed; Almenara, Jorge; Subler, Mark; Krystal, Geoffrey; Conrad, Daniel; Varticovski, Lubya; Dent, Paul; Grant, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2118-2126</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Interactions between the Bcr/Abl kinase inhibitor STI571 (Gleevec, imatinib mesylate) and histone deacetylase inhibitors (HDIs) have been examd. in STI571-sensitive and -resistant Bcr/Abl+ human leukemia cells (K562 and LAMA 84).  Cotreatment of K562 cells with 250 nM imatinib mesylate and 2.0 Î¼M suberoylanilide hydroxamic acid (SAHA) for 24 h, exposures that were minimally toxic alone, resulted in a marked increase in mitochondrial damage (e.g., cytochrome c, Smac/DIABLO, and apoptosis-inducing factor release), caspase activation, and apoptosis.  Similar events were obsd. in other Bcr/Abl+ cells (i.e., LAMA 84), and in cells exposed to STI571 in combination with the HDI sodium butyrate.  Coexposure of cells to HDIs in conjunction with STI571 resulted in multiple perturbations in signaling and cell cycle-regulatory proteins, including down-regulation of Raf, phospho-mitogen-activated protein kinase kinase (MEK), phospho-extracellular signal-regulated kinase (ERK), phospho-Akt, phospho-signal transducers and activators of transcription 5, cyclin D1, and Mcl-1, accompanied by dephosphorylation and cleavage of retinoblastoma protein and a striking increase in phosphorylation of c-Jun NH2-terminal kinase.  Coexposure of Bcr/Abl+ cells to STI571 also blocked SAHA-mediated induction of p21CIP1 and resulted in down-regulation of Bcr/Abl protein expression.  STI571 and SAHA also interacted synergistically to induce apoptosis in STI571-resistant K562 and LAMA 84 cells that display increased Bcr/Abl protein expression.  Lastly, inducible expression of a constitutively active MEK1/2 construct significantly attenuated SAHA/STI571-mediated apoptosis in K562 cells, implicating disruption of the Raf/MEK/ERK axis in synergistic antileukemic effects of this drug combination.  Together, these findings indicate that combined exposure of Bcr/Abl+ cells to the kinase inhibitor STI571 and HDIs leads to diverse perturbations in signaling and cell cycle-regulatory proteins, assocd. with a marked increase in mitochondrial damage and cell death.  They also raise the possibility that this strategy may be effective in some Bcr/Abl+ cells that are resistant to STI571 through increased Bcr/Abl expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoYarKAuFpDLVg90H21EOLACvtfcHk0lgvAKf2xFcKvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlGmsbc%253D&md5=f393cedee38afe31abe097d9c267db3e</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DC.%26aulast%3DRahmani%26aufirst%3DM.%26aulast%3DAlmenara%26aufirst%3DJ.%26aulast%3DSubler%26aufirst%3DM.%26aulast%3DKrystal%26aufirst%3DG.%26aulast%3DConrad%26aufirst%3DD.%26aulast%3DVarticovski%26aufirst%3DL.%26aulast%3DDent%26aufirst%3DP.%26aulast%3DGrant%26aufirst%3DS.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520promote%2520STI571-mediated%2520apoptosis%2520in%2520STI571-sensitive%2520and%2520-resistant%2520Bcr%252FAbl%252B%2520human%2520myeloid%2520leukemia%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D2118%26epage%3D2126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veach, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4236</span>â <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0lgvAKf2xFcKvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dayam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span> <span> </span><span class="NLM_article-title">Î²-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">111</span>â <span class="NLM_lpage">120</span>, <span class="refDoi">Â DOI: 10.1021/jm0496077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0496077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKktbnK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=111-120&author=R.+Dayamauthor=T.+Sanchezauthor=O.+Clementauthor=R.+Shoemakerauthor=S.+Seiauthor=N.+Neamati&title=%CE%B2-diketo+acid+pharmacophore+hypothesis.+1.+Discovery+of+a+novel+class+of+HIV-1+integrase+inhibitors&doi=10.1021%2Fjm0496077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Î²-Diketo Acid Pharmacophore Hypothesis. 1. Discovery of a Novel Class of HIV-1 Integrase Inhibitors</span></div><div class="casAuthors">Dayam, Raveendra; Sanchez, Tino; Clement, Omoshile; Shoemaker, Robert; Sei, Shizuko; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-120</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HIV-1 Integrase (IN) is an essential enzyme for viral replication.  The discovery of Î²-diketo acids was crucial in the validation of IN as a legitimate target in drug discovery against HIV infection.  In this study, we discovered a novel class of IN inhibitors using a 3D pharmacophore guided database search.  We used S-1360 (1), the first IN inhibitor to undergo clin. trials, and three other analogs to develop a common feature pharmacophore hypothesis.  Testing this four-featured pharmacophore against a multiconformational database of 150 000 structurally diverse small mols. yielded 1700 compds. that satisfied the 3D query.  Subsequently, all 1700 compds. were docked into the active site of IN.  On the basis of docking scores, Lipinski's rule-of-five, and structural novelty, 110 compds. were selected for biol. screening.  We found that compds. that contain both salicylic acid and a 2-thioxo-4-thiazolidinone (rhodanine) group (e.g. 5-13) showed significant inhibitory potency against IN, while the presence of either salicylic acid or a rhodanine group alone did not.  Although some of the compds. contg. only a salicylic acid showed inhibitory potency against IN, none of the compds. contg. only rhodanine exhibited considerable potency.  Of the 52 compds. reported in this study, 11 compds. (5, 6, 8, 10-13, 32-33, 51, and 53) inhibited 3'-processing or strand transfer activities of IN with IC50 â¤ 25 Î¼M.  This is the first reported use of S-1360 and its analogs as leads in developing a pharmacophore hypothesis for IN inhibition and for identification of new compds. with potent inhibition of this enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrey20eMyZrv7Vg90H21EOLACvtfcHk0lgvAKf2xFcKvA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKktbnK&md5=ccfece093b49ab35c131ab85757ef50e</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fjm0496077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0496077%26sid%3Dliteratum%253Aachs%26aulast%3DDayam%26aufirst%3DR.%26aulast%3DSanchez%26aufirst%3DT.%26aulast%3DClement%26aufirst%3DO.%26aulast%3DShoemaker%26aufirst%3DR.%26aulast%3DSei%26aufirst%3DS.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3D%25CE%25B2-diketo%2520acid%2520pharmacophore%2520hypothesis.%25201.%2520Discovery%2520of%2520a%2520novel%2520class%2520of%2520HIV-1%2520integrase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D111%26epage%3D120%26doi%3D10.1021%2Fjm0496077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felock, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillmock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grobler, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espeseth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabryelski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleif, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. D.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">646</span>â <span class="NLM_lpage">650</span>, <span class="refDoi">Â DOI: 10.1126/science.287.5453.646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1126%2Fscience.287.5453.646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10649997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovVyjtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2000&pages=646-650&author=D.+J.+Hazudaauthor=P.+Felockauthor=M.+Witmerauthor=A.+Wolfeauthor=K.+Stillmockauthor=J.+A.+Groblerauthor=A.+Espesethauthor=L.+Gabryelskiauthor=W.+Schleifauthor=C.+Blauauthor=M.+D.+Miller&title=Inhibitors+of+strand+transfer+that+prevent+integration+and+inhibit+HIV-1+replication+in+cells&doi=10.1126%2Fscience.287.5453.646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells</span></div><div class="casAuthors">Hazuda, Daria J.; Felock, Peter; Witmer, Marc; Wolfe, Abigail; Stillmock, Kara; Grobler, Jay A.; Espeseth, Amy; Gabryelski, Lori; Schleif, William; Blau, Carol; Miller, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">5453</span>),
    <span class="NLM_cas:pages">646-650</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Integrase is essential for human immunodeficiency virus-type 1 (HIV-1) replication; however, potent inhibition of the isolated enzyme in biochem. assays has not readily translated into antiviral activity in a manner consistent with inhibition of integration.  In this report, we describe diketo acid inhibitors of HIV-1 integrase that manifest antiviral activity as a consequence of their effect on integration.  The antiviral activity of these compds. is due exclusively to inhibition of one of the two catalytic functions of integrase, strand transfer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLfQNYMkTCVrVg90H21EOLACvtfcHk0ljmn4Bvf6v0NQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovVyjtQ%253D%253D&md5=d160c8fa31a9ca0a3530dceab66a892c</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1126%2Fscience.287.5453.646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.287.5453.646%26sid%3Dliteratum%253Aachs%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DFelock%26aufirst%3DP.%26aulast%3DWitmer%26aufirst%3DM.%26aulast%3DWolfe%26aufirst%3DA.%26aulast%3DStillmock%26aufirst%3DK.%26aulast%3DGrobler%26aufirst%3DJ.%2BA.%26aulast%3DEspeseth%26aufirst%3DA.%26aulast%3DGabryelski%26aufirst%3DL.%26aulast%3DSchleif%26aufirst%3DW.%26aulast%3DBlau%26aufirst%3DC.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26atitle%3DInhibitors%2520of%2520strand%2520transfer%2520that%2520prevent%2520integration%2520and%2520inhibit%2520HIV-1%2520replication%2520in%2520cells%26jtitle%3DScience%26date%3D2000%26volume%3D287%26spage%3D646%26epage%3D650%26doi%3D10.1126%2Fscience.287.5453.646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4202</span>â <span class="NLM_lpage">4211</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2010.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmc.2010.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=20576573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntV2rtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=4202-4211&author=Z.+Wangauthor=J.+Tangauthor=C.+E.+Salomonauthor=C.+D.+Dreisauthor=R.+Vince&title=Pharmacophore+and+structure-activity+relationships+of+integrase+inhibition+within+a+dual+inhibitor+scaffold+of+HIV+reverse+transcriptase+and+integrase&doi=10.1016%2Fj.bmc.2010.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase</span></div><div class="casAuthors">Wang, Zhengqiang; Tang, Jing; Salomon, Christine E.; Dreis, Christine D.; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4202-4211</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Rational design of dually active inhibitors against human immunodeficiency virus (HIV) reverse transcriptase (RT) and integrase (IN) has proved viable with 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) type of non-nucleoside RT inhibitors (NNRTIs).  To establish the pharmacophore and study the structure-activity relationships (SAR) of integrase inhibition within a previously disclosed RT/IN dual inhibitor scaffold, new analogs featuring substitution at different sites of the HEPT ring were designed and synthesized.  These studies have revealed an IN inhibition pharmacophore that is merged with the known RT pharmacophore through a shared C-6 benzyl group.  Further SAR also demonstrated that optimal IN inhibition within our dual inhibitor scaffold requires a regiospecific (N-1) diketoacid (DKA)-carrying pendant with a certain length.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhRvNGIpI8pbVg90H21EOLACvtfcHk0ljmn4Bvf6v0NQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntV2rtb4%253D&md5=603652ca80d40b34489c6d6f1fa28dd6</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DSalomon%26aufirst%3DC.%2BE.%26aulast%3DDreis%26aufirst%3DC.%2BD.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DPharmacophore%2520and%2520structure-activity%2520relationships%2520of%2520integrase%2520inhibition%2520within%2520a%2520dual%2520inhibitor%2520scaffold%2520of%2520HIV%2520reverse%2520transcriptase%2520and%2520integrase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D4202%26epage%3D4211%26doi%3D10.1016%2Fj.bmc.2010.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esnouf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. I.</span></span> <span> </span><span class="NLM_article-title">Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis (heteroaryl) piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">3984</span>â <span class="NLM_lpage">3989</span>, <span class="refDoi">Â DOI: 10.1073/pnas.94.8.3984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1073%2Fpnas.94.8.3984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=9108091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADyaK2sXis1ehuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=3984-3989&author=R.+M.+Esnoufauthor=J.+Renauthor=A.+L.+Hopkinsauthor=C.+K.+Rossauthor=E.+Y.+Jonesauthor=D.+K.+Stammersauthor=D.+I.+Stuart&title=Unique+features+in+the+structure+of+the+complex+between+HIV-1+reverse+transcriptase+and+the+bis+%28heteroaryl%29+piperazine+%28BHAP%29+U-90152+explain+resistance+mutations+for+this+nonnucleoside+inhibitor&doi=10.1073%2Fpnas.94.8.3984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor</span></div><div class="casAuthors">Esnouf, Robert M.; Ren, Jingshan; Hopkins, Andrew L.; Ross, Carl K.; Jones, E. Yvonne; Stammers, David K.; Stuart, David I.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3984-3989</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The viral reverse transcriptase (RT) provides an attractive target in the search for anti-HIV therapies.  The nonnucleoside inhibitors (NNIs) are a diverse set of compds. (usually HIV-1 specific) that function by distorting the polymerase active site upon binding in a nearby pocket.  Despite being potent and of generally low toxicity, their clin. use has been limited by rapid selection for resistant viral populations.  The 2.65-Ã resoln. structure of the complex between HIV-1 RT and the bis(heteroaryl)piperazine (BHAP) NNI, 1-(5-methanesulfonamido-1H-indol-2-yl-carbonyl)-4-[3-(1-methyl-ethylamino)pyridinyl] piperazine (U-90152), reveals the inhibitor conformation and bound water mols.  The bulky U-90152 mol. occupies the same pocket as other NNIs, but the complex is stabilized quite differently, in particular by hydrogen bonding to the main chain of Lys-103 and extensive hydrophobic contacts with Pro-236.  These interactions rationalize obsd. resistance mutations, notably Pro-236-Leu, which occurs characteristically for BHAPs.  When bound, part of U-90152 protrudes into the solvent creating a channel between Pro-236 and the polypeptide segments 225-226 and 105-106, giving the first clear evidence of the entry mode for NNIs.  The structure allows prediction of binding modes for related inhibitors [(altrylamino)piperidine-BHAPs] and suggests changes to U-90152, such as the addn. of a 6 amino group to the pyridine ring, which may make binding more resilient to mutations in the RT.  The observation of novel hydrogen bonding to the protein main chain may provide lessons for the improvement of quite different inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzQuIdPkm-oLVg90H21EOLACvtfcHk0ljmn4Bvf6v0NQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1ehuro%253D&md5=d9027e0d3dc8ad612fb84d9e98b7f30e</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.8.3984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.8.3984%26sid%3Dliteratum%253Aachs%26aulast%3DEsnouf%26aufirst%3DR.%2BM.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DRoss%26aufirst%3DC.%2BK.%26aulast%3DJones%26aufirst%3DE.%2BY.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26aulast%3DStuart%26aufirst%3DD.%2BI.%26atitle%3DUnique%2520features%2520in%2520the%2520structure%2520of%2520the%2520complex%2520between%2520HIV-1%2520reverse%2520transcriptase%2520and%2520the%2520bis%2520%2528heteroaryl%2529%2520piperazine%2520%2528BHAP%2529%2520U-90152%2520explain%2520resistance%2520mutations%2520for%2520this%2520nonnucleoside%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26spage%3D3984%26epage%3D3989%26doi%3D10.1073%2Fpnas.94.8.3984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vince, R.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: introducing a diketoacid functionality into delavirdine</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3587</span>â <span class="NLM_lpage">3595</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2008.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmc.2008.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=18314335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1Gqsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=3587-3595&author=Z.+Wangauthor=R.+Vince&title=Design+and+synthesis+of+dual+inhibitors+of+HIV+reverse+transcriptase+and+integrase%3A+introducing+a+diketoacid+functionality+into+delavirdine&doi=10.1016%2Fj.bmc.2008.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: Introducing a diketoacid functionality into delavirdine</span></div><div class="casAuthors">Wang, Zhengqiang; Vince, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3587-3595</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cost and toxicity problems assocd. with highly active antiretroviral therapy (HAART) in HIV/AIDS treatment could be alleviated by using designed multiple ligands (DMLs).  Dual inhibitors of HIV reverse transcriptase (RT) and integrase (IN) were rationally designed by introducing a diketoacid (DKA) functionality into the tolerant C-5 site of RT inhibitor delavirdine.  The resulting compds. all demonstrate good activity against both RT and IN in enzymic assays and HIV in cell-based assay, whereas their C-7 regioisomers are all inactive in these assays.  Balanced activities were obsd. with C-3 halogenated inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8iOAhge6i37Vg90H21EOLACvtfcHk0lg4FrwcfJyKNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1Gqsrg%253D&md5=3f90483b8bac1ee028a201690e34412c</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DVince%26aufirst%3DR.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dual%2520inhibitors%2520of%2520HIV%2520reverse%2520transcriptase%2520and%2520integrase%253A%2520introducing%2520a%2520diketoacid%2520functionality%2520into%2520delavirdine%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D3587%26epage%3D3595%26doi%3D10.1016%2Fj.bmc.2008.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chander, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V.</span></span> <span> </span><span class="NLM_article-title">First dual aromatase-steroid sulfatase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3193</span>â <span class="NLM_lpage">3196</span>, <span class="refDoi">Â DOI: 10.1021/jm034033b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm034033b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksFWjsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3193-3196&author=L.+W.+Wooauthor=O.+B.+Sutcliffeauthor=C.+Bubertauthor=A.+Grassoauthor=S.+K.+Chanderauthor=A.+Purohitauthor=M.+J.+Reedauthor=B.+V.+Potter&title=First+dual+aromatase-steroid+sulfatase+inhibitors&doi=10.1021%2Fjm034033b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">First Dual Aromatase-Steroid Sulfatase Inhibitors</span></div><div class="casAuthors">Woo, L. W. Lawrence; Sutcliffe, Oliver B.; Bubert, Christian; Grasso, Anna; Chander, Surinder K.; Purohit, Atul; Reed, Michael J.; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3193-3196</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aromatase inhibitors in clin. use block the biosynthesis of estrogens.  Hydrolysis of estrone 3-sulfate by steroid sulfatase is an important addnl. source of tumor estrogen, and blockade of both enzymes should provide a more effective endocrine therapy.  Sulfamoylated derivs. of the aromatase inhibitor YM511 inhibited sulfatase and aromatase in JEG-3 cells with resp. IC50 values of 20-227 and 0.82-100 nM (cf. letrozole, 0.89 nM).  One dual inhibitor was potent against both enzymes in vivo, validating the concept.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOq7z9wm030LVg90H21EOLACvtfcHk0lg4FrwcfJyKNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksFWjsrk%253D&md5=b487f4b92cab559a36f69b7aaebeb9d1</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Fjm034033b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034033b%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%26aulast%3DSutcliffe%26aufirst%3DO.%2BB.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DGrasso%26aufirst%3DA.%26aulast%3DChander%26aufirst%3DS.%2BK.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DB.%2BV.%26atitle%3DFirst%2520dual%2520aromatase-steroid%2520sulfatase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3193%26epage%3D3196%26doi%3D10.1021%2Fjm034033b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chander, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V.</span></span> <span> </span><span class="NLM_article-title">A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">123</span>â <span class="NLM_lpage">130</span>, <span class="refDoi">Â DOI: 10.1016/j.jsbmb.2004.12.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.jsbmb.2004.12.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15862957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVKksrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=123-130&author=P.+M.+Woodauthor=L.+W.+Wooauthor=A.+Humphreysauthor=S.+K.+Chanderauthor=A.+Purohitauthor=M.+J.+Reedauthor=B.+V.+Potter&title=A+letrozole-based+dual+aromatase-sulphatase+inhibitor+with+in+vivo+activity&doi=10.1016%2Fj.jsbmb.2004.12.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity</span></div><div class="casAuthors">Wood, Paul M.; Woo, L. W. Lawrence; Humphreys, Anna; Chander, Surinder K.; Purohit, Atul; Reed, Michael J.; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">123-130</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The role of aromatase inhibitors in the treatment of hormone-dependent breast cancer is well established.  However, it is now recognized that steroid sulfatase (STS) inhibitors represent a new form of endocrine therapy.  To explore the potential advantage of dual inhibition by a single agent, we recently developed a series of dual aromatase-sulfatase inhibitors (DASIs) based on the aromatase inhibitor YM511.  We report here a new structural class of DASI obtained by obtained introducing the pharmacophore for STS inhibition, i.e. a phenol sulfamate ester into another established aromatase inhibitor letrozole.  Hence, the bis-sulfamate (I) was synthesized which exhibited IC50 values of 3044 nM for aromatase and >10 Î¼M for STS in JEG-3 cells.  However, at a single oral dose of 10 mg/kg, I inhibited aromatase and rat liver STS by 60% and 88%, resp., 24 h after administration.  A proposed metabolite of I, carbinol (II), was synthesized.  Despite also showing weak STS inhibition in JEG-3 cells, II inhibited rat liver STS activity to the same extent as I at a single oral dose of 10 mg/kg.  Thus, the concept of a letrozole-based DASI has been validated and could be further developed and modified for therapeutic exploitation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo60rSRs5AQELVg90H21EOLACvtfcHk0lg4FrwcfJyKNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVKksrc%253D&md5=90f007c68eeaef39b4ba5dc3fd2157fd</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.jsbmb.2004.12.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsbmb.2004.12.028%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DP.%2BM.%26aulast%3DWoo%26aufirst%3DL.%2BW.%26aulast%3DHumphreys%26aufirst%3DA.%26aulast%3DChander%26aufirst%3DS.%2BK.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DB.%2BV.%26atitle%3DA%2520letrozole-based%2520dual%2520aromatase-sulphatase%2520inhibitor%2520with%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2005%26volume%3D94%26spage%3D123%26epage%3D130%26doi%3D10.1016%2Fj.jsbmb.2004.12.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chander, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahon, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V.</span></span> <span> </span><span class="NLM_article-title">Dual aromatase-steroid sulfatase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">3540</span>â <span class="NLM_lpage">3560</span>, <span class="refDoi">Â DOI: 10.1021/jm061462b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061462b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1CjtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3540-3560&author=L.+W.+Wooauthor=C.+Bubertauthor=O.+B.+Sutcliffeauthor=A.+Smithauthor=S.+K.+Chanderauthor=M.+F.+Mahonauthor=A.+Purohitauthor=M.+J.+Reedauthor=B.+V.+Potter&title=Dual+aromatase-steroid+sulfatase+inhibitors&doi=10.1021%2Fjm061462b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Aromatase-Steroid Sulfatase Inhibitors</span></div><div class="casAuthors">Woo, L. W. Lawrence; Bubert, Christian; Sutcliffe, Oliver B.; Smith, Andrew; Chander, Surinder K.; Mahon, Mary F.; Purohit, Atul; Reed, Michael J.; Potter, Barry V. L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3540-3560</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By introducing the steroid sulfatase inhibitory pharmacophore into aromatase inhibitor 1 (YM511), two series of single agent dual aromatase-sulfatase inhibitors (DASIs) were generated.  Two best DASIs (I and II) in vitro (JEG-3 cells) had IC50(aromatase) = 0.82 nM; IC50(sulfatase) = 39 nM, and IC50(aromatase) = 0.77 nM; IC50(sulfatase) = 590 nM, resp.  X-ray crystallog. of I, and docking studies of selected compds. into an aromatase homol. model and the steroid sulfatase crystal structure are presented.  Both I and II inhibit aromatase and sulfatase in PMSG pretreated adult female Wistar rats potently 3 h after a single oral 10 mg/kg dose.  Almost complete dual inhibition is obsd. for I but the levels were reduced to 85% (aromatase) and 72% (sulfatase) after 24 h.  DASI I did not inhibit aldosterone synthesis.  The development of a potent and selective DASI should allow the therapeutic potential of dual aromatase-sulfatase inhibition in hormone-dependent breast cancer to be assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPvCTamzS0qbVg90H21EOLACvtfcHk0lg4FrwcfJyKNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1CjtLs%253D&md5=69641aaecd430daad1c2f8074be4b436</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Fjm061462b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061462b%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DL.%2BW.%26aulast%3DBubert%26aufirst%3DC.%26aulast%3DSutcliffe%26aufirst%3DO.%2BB.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DChander%26aufirst%3DS.%2BK.%26aulast%3DMahon%26aufirst%3DM.%2BF.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DB.%2BV.%26atitle%3DDual%2520aromatase-steroid%2520sulfatase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D3540%26epage%3D3560%26doi%3D10.1021%2Fjm061462b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sano, T.</span></span> <span> </span><span class="NLM_article-title">Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">341</span>â <span class="NLM_lpage">344</span>, <span class="refDoi">Â DOI: 10.1016/S0960-894X(01)00731-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS0960-894X%2801%2900731-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=11814792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XpslKlug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=341-344&author=M.+Fujitaauthor=T.+Sekiauthor=H.+Inadaauthor=K.+Shimizuauthor=A.+Takahamaauthor=T.+Sano&title=Approach+to+dual-acting+platelet+activating+factor+%28PAF%29+receptor+antagonist%2Fthromboxane+synthase+inhibitor+%28TxSI%29+based+on+the+link+of+PAF+antagonists+and+TxSIs&doi=10.1016%2FS0960-894X%2801%2900731-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs</span></div><div class="casAuthors">Fujita, Masakazu; Seki, Taketsugu; Inada, Haruaki; Shimizu, Kazuhiro; Takahama, Akane; Sano, Tetsuro</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-344</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of compds. which possess dual-acting PAF antagonist/TxSI have been generated by the approach of linking the known PAF antagonists and TxSIs, such as ridogrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5EjkkdRo9orVg90H21EOLACvtfcHk0lh7bGGZqJeZEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpslKlug%253D%253D&md5=7fb11467ba0f5afff9ff1c7ed37a0263</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900731-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900731-4%26sid%3Dliteratum%253Aachs%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DSeki%26aufirst%3DT.%26aulast%3DInada%26aufirst%3DH.%26aulast%3DShimizu%26aufirst%3DK.%26aulast%3DTakahama%26aufirst%3DA.%26aulast%3DSano%26aufirst%3DT.%26atitle%3DApproach%2520to%2520dual-acting%2520platelet%2520activating%2520factor%2520%2528PAF%2529%2520receptor%2520antagonist%252Fthromboxane%2520synthase%2520inhibitor%2520%2528TxSI%2529%2520based%2520on%2520the%2520link%2520of%2520PAF%2520antagonists%2520and%2520TxSIs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D341%26epage%3D344%26doi%3D10.1016%2FS0960-894X%2801%2900731-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DÃ­az, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuevas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ãlvarez-Bercedo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarmentero, M. Ã.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Font, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JimÃ©nez-Aquino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MorÃ³n, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dordal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portillo-Salido, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinoso, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span> <span> </span><span class="NLM_article-title">Bicyclic diazepinones as dual ligands of the Î±2Î´-1 subunit of voltage-gated calcium channels and the norepinephrine transporter</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">2167</span>â <span class="NLM_lpage">2185</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c01867</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01867" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXktVyitLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=2167-2185&author=J.+L.+D%C3%ADazauthor=F.+Cuevasauthor=G.+Pazosauthor=P.+%C3%81lvarez-Bercedoauthor=A.+I.+Olivaauthor=M.+%C3%81.+Sarmenteroauthor=D.+Fontauthor=A.+Jim%C3%A9nez-Aquinoauthor=M.+Mor%C3%B3nauthor=A.+Portauthor=R.+Pascualauthor=A.+Dordalauthor=E.+Portillo-Salidoauthor=R.+F.+Reinosoauthor=J.+M.+Velaauthor=C.+Almansa&title=Bicyclic+diazepinones+as+dual+ligands+of+the+%CE%B12%CE%B4-1+subunit+of+voltage-gated+calcium+channels+and+the+norepinephrine+transporter&doi=10.1021%2Facs.jmedchem.0c01867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic Diazepinones as Dual Ligands of the Î±2Î´-1 Subunit of Voltage-Gated Calcium Channels and the Norepinephrine Transporter</span></div><div class="casAuthors">Diaz, Jose Luis; Cuevas, Felix; Pazos, Gonzalo; Alvarez-Bercedo, Paula; Oliva, Ana I.; Sarmentero, M. Angeles; Font, Daniel; Jimenez-Aquino, Agustin; Moron, Maria; Port, Adriana; Pascual, Rosalia; Dordal, Albert; Portillo-Salido, Enrique; Reinoso, Raquel F.; Vela, Jose Miguel; Almansa, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2167-2185</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and pharmacol. activity of a new series of bicyclic diazepinones with dual activity toward the Î±2Î´-1 subunit of voltage-gated calcium channels (CavÎ±2Î´-1) and the norepinephrine transporter (NET) are reported.  Exploration of the positions amenable for substitution on a nonaminoacidic CavÎ±2Î´-1 scaffold allowed the identification of favorable positions for the attachment of NET pharmacophores.  Among the patterns explored, attachment of the 2-ethylamino-9-methyl-6-phenyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-e][1,4]diazepin-5-one framework to the meta-position of the Ph ring of the 3-methylamino-1-phenylpropoxy and 3-methylamino-1-thienylpropoxy moieties provided dual compds. with excellent NET functionality.  Alternative bicyclic frameworks were also explored, and some lead mols. were identified, which showed a balanced dual profile and exhibited good ADMET properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprt1hfjOiqhLVg90H21EOLACvtfcHk0lh7bGGZqJeZEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXktVyitLk%253D&md5=d83851f4eba811425d6366627d874ee5</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01867%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BL.%26aulast%3DCuevas%26aufirst%3DF.%26aulast%3DPazos%26aufirst%3DG.%26aulast%3D%25C3%2581lvarez-Bercedo%26aufirst%3DP.%26aulast%3DOliva%26aufirst%3DA.%2BI.%26aulast%3DSarmentero%26aufirst%3DM.%2B%25C3%2581.%26aulast%3DFont%26aufirst%3DD.%26aulast%3DJim%25C3%25A9nez-Aquino%26aufirst%3DA.%26aulast%3DMor%25C3%25B3n%26aufirst%3DM.%26aulast%3DPort%26aufirst%3DA.%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DDordal%26aufirst%3DA.%26aulast%3DPortillo-Salido%26aufirst%3DE.%26aulast%3DReinoso%26aufirst%3DR.%2BF.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DAlmansa%26aufirst%3DC.%26atitle%3DBicyclic%2520diazepinones%2520as%2520dual%2520ligands%2520of%2520the%2520%25CE%25B12%25CE%25B4-1%2520subunit%2520of%2520voltage-gated%2520calcium%2520channels%2520and%2520the%2520norepinephrine%2520transporter%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D2167%26epage%3D2185%26doi%3D10.1021%2Facs.jmedchem.0c01867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battiti, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makarova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel dual-target Î¼-opioid receptor and dopamine D3 receptor ligands as potential nonaddictive pharmacotherapeutics for pain management</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">7778</span>â <span class="NLM_lpage">7808</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.1c00611</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.1c00611" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhtFSqtL%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=7778-7808&author=A.+Bonifaziauthor=F.+O.+Battitiauthor=J.+Sanchezauthor=S.+A.+Zaidiauthor=E.+Bowauthor=M.+Makarovaauthor=J.+Caoauthor=A.+B.+Shaikauthor=A.+Sulimaauthor=K.+C.+Riceauthor=V.+Katritchauthor=M.+Canalsauthor=J.+R.+Laneauthor=A.+H.+Newman&title=Novel+dual-target+%CE%BC-opioid+receptor+and+dopamine+D3+receptor+ligands+as+potential+nonaddictive+pharmacotherapeutics+for+pain+management&doi=10.1021%2Facs.jmedchem.1c00611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Dual-Target Î¼-Opioid Receptor and Dopamine D3 Receptor Ligands as Potential Nonaddictive Pharmacotherapeutics for Pain Management</span></div><div class="casAuthors">Bonifazi, Alessandro; Battiti, Francisco O.; Sanchez, Julie; Zaidi, Saheem A.; Bow, Eric; Makarova, Mariia; Cao, Jianjing; Shaik, Anver Basha; Sulima, Agnieszka; Rice, Kenner C.; Katritch, Vsevolod; Canals, Meritxell; Lane, J. Robert; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7778-7808</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The need for safer pain-management therapies with decreased abuse liability inspired a novel drug design that retains Î¼-opioid receptor (MOR)-mediated analgesia, while minimizing addictive liability.  We recently demonstrated that targeting the dopamine D3 receptor (D3R) with highly selective antagonists/partial agonists can reduce opioid self-administration and reinstatement to drug seeking in rodent models without diminishing antinociceptive effects.  The identification of the D3R as a target for the treatment of opioid use disorders prompted the idea of generating a class of ligands presenting bitopic or bivalent structures, allowing the dual-target binding of the MOR and D3R.  Structure-activity relationship studies using computationally aided drug design and in vitro binding assays led to the identification of potent dual-target leads (23, 28, and 40), based on different structural templates and scaffolds, with moderate (sub-micromolar) to high (low nanomolar/sub-nanomolar) binding affinities.  Bioluminescence resonance energy transfer-based functional studies revealed MOR agonist-D3R antagonist/partial agonist efficacies that suggest potential for maintaining analgesia with reduced opioid-abuse liability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6BTVlBxNrE7Vg90H21EOLACvtfcHk0li3-ZC3oD8V6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhtFSqtL%252FO&md5=41a3caaeed5a9cc3000f724a1bf2cd8e</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.1c00611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.1c00611%26sid%3Dliteratum%253Aachs%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DBattiti%26aufirst%3DF.%2BO.%26aulast%3DSanchez%26aufirst%3DJ.%26aulast%3DZaidi%26aufirst%3DS.%2BA.%26aulast%3DBow%26aufirst%3DE.%26aulast%3DMakarova%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DSulima%26aufirst%3DA.%26aulast%3DRice%26aufirst%3DK.%2BC.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DCanals%26aufirst%3DM.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520dual-target%2520%25CE%25BC-opioid%2520receptor%2520and%2520dopamine%2520D3%2520receptor%2520ligands%2520as%2520potential%2520nonaddictive%2520pharmacotherapeutics%2520for%2520pain%2520management%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D7778%26epage%3D7808%26doi%3D10.1021%2Facs.jmedchem.1c00611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karakus, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godugu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajabi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S. A.</span></span> <span> </span><span class="NLM_article-title">Dual targeting of norepinephrine transporter (net) function and thyrointegrin Î±vÎ²3 receptors in the treatment of neuroblastoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">7653</span>â <span class="NLM_lpage">7662</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c00537</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00537" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1amu7fK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=7653-7662&author=O.+O.+Karakusauthor=K.+Goduguauthor=M.+Rajabiauthor=S.+A.+Mousa&title=Dual+targeting+of+norepinephrine+transporter+%28net%29+function+and+thyrointegrin+%CE%B1v%CE%B23+receptors+in+the+treatment+of+neuroblastoma&doi=10.1021%2Facs.jmedchem.0c00537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Targeting of Norepinephrine Transporter (NET) Function and Thyrointegrin Î±vÎ²3 Receptors in the Treatment of Neuroblastoma</span></div><div class="casAuthors">Karakus, Ozlem Ozen; Godugu, Kavitha; Rajabi, Mehdi; Mousa, Shaker A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7653-7662</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Therapeutic targeting of the norepinephrine transporter (NET) function with benzylguanidine (BG), conjugated with the high-affinity thyrointegrin Î±vÎ²3 antagonist triazole tetraiodothyroacetic acid, TAT, via noncleavable bonding to poly(ethylene glycol) (PEG400) (P) might allow for effective treatment options in neuroblastoma.  BG-P-TAT is a dual-targeting agent, targeting the NET function and the thyrointegrin Î±vÎ²3 receptors that are overexpressed in neuroblastoma and other neuroendocrine tumors.  Various cancer cells and actively dividing tumor-endothelial cells express the thyrointegrin Î±vÎ²3 receptors.  In this work, the novel compd. BG-P-TAT was synthesized and evaluated in the neuroblastoma SK-N-FI cell line for improved targeting and to offer a new strategy for patients with neuroblastoma.  BG-P-TAT demonstrated significant suppression of neuroblastoma tumor progression, growth, and viability in a dose-dependent manner.  In conclusion, BG-P-TAT represents a potential lead candidate for the treatment of neuroblastoma and other neuroendocrine tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSh2qLjmmFArVg90H21EOLACvtfcHk0li3-ZC3oD8V6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1amu7fK&md5=3e6fb7e9dd08fe315abe6992f2a6314f</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00537%26sid%3Dliteratum%253Aachs%26aulast%3DKarakus%26aufirst%3DO.%2BO.%26aulast%3DGodugu%26aufirst%3DK.%26aulast%3DRajabi%26aufirst%3DM.%26aulast%3DMousa%26aufirst%3DS.%2BA.%26atitle%3DDual%2520targeting%2520of%2520norepinephrine%2520transporter%2520%2528net%2529%2520function%2520and%2520thyrointegrin%2520%25CE%25B1v%25CE%25B23%2520receptors%2520in%2520the%2520treatment%2520of%2520neuroblastoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D7653%26epage%3D7662%26doi%3D10.1021%2Facs.jmedchem.0c00537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiesinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flauaus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretschmer, S. B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angioni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert-Zsilavecz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidtko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogoryelov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeilschifter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwalm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structureactivity relationship studies of dual inhibitors of soluble epoxide hydrolase and 5-lipoxygenase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">11498</span>â <span class="NLM_lpage">11521</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c00561</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00561" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVant73O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=11498-11521&author=K.+Hiesingerauthor=J.+S.+Kramerauthor=S.+Beyerauthor=T.+Eckesauthor=S.+Brunstauthor=C.+Flauausauthor=S.+K.+Wittmannauthor=L.+Weizelauthor=A.+Kaiserauthor=S.+B.+M.+Kretschmerauthor=S.+Georgeauthor=C.+Angioniauthor=J.+Heeringauthor=G.+Geisslingerauthor=M.+Schubert-Zsilaveczauthor=A.+Schmidtkoauthor=D.+Pogoryelovauthor=J.+Pfeilschifterauthor=B.+Hofmannauthor=D.+Steinhilberauthor=S.+Schwalmauthor=E.+Proschak&title=Design%2C+synthesis%2C+and+structureactivity+relationship+studies+of+dual+inhibitors+of+soluble+epoxide+hydrolase+and+5-lipoxygenase&doi=10.1021%2Facs.jmedchem.0c00561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Structure-Activity Relationship Studies of Dual Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase</span></div><div class="casAuthors">Hiesinger, Kerstin; Kramer, Jan S.; Beyer, Sandra; Eckes, Timon; Brunst, Steffen; Flauaus, Cathrin; Wittmann, Sandra K.; Weizel, Lilia; Kaiser, Astrid; Kretschmer, Simon B. M.; George, Sven; Angioni, Carlo; Heering, Jan; Geisslinger, Gerd; Schubert-Zsilavecz, Manfred; Schmidtko, Achim; Pogoryelov, Denys; Pfeilschifter, Josef; Hofmann, Bettina; Steinhilber, Dieter; Schwalm, Stephanie; Proschak, Ewgenij</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">11498-11521</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of multiple enzymes of the arachidonic acid cascade leads to synergistic anti-inflammatory effects.  Merging of 5-lipoxygenase (5-LOX) and sol. epoxide hydrolase (sEH) pharmacophores led to the discovery of a dual 5-LOX/sEH inhibitor, which was subsequently optimized in terms of potency toward both targets and metabolic stability.  The optimized lead structure displayed cellular activity in human polymorphonuclear leukocytes, oral bioavailability, and target engagement in vivo and demonstrated profound anti-inflammatory and anti-fibrotic efficiency in a kidney injury model caused by unilateral ureteral obstruction in mice.  These results pave the way for investigating the therapeutic potential of dual 5-LOX/sEH inhibitors in other inflammation- and fibrosis-related disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXR2XHI9LgxbVg90H21EOLACvtfcHk0li3-ZC3oD8V6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVant73O&md5=e9a04641492bd4a51ca9cfca9cf5c47d</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00561%26sid%3Dliteratum%253Aachs%26aulast%3DHiesinger%26aufirst%3DK.%26aulast%3DKramer%26aufirst%3DJ.%2BS.%26aulast%3DBeyer%26aufirst%3DS.%26aulast%3DEckes%26aufirst%3DT.%26aulast%3DBrunst%26aufirst%3DS.%26aulast%3DFlauaus%26aufirst%3DC.%26aulast%3DWittmann%26aufirst%3DS.%2BK.%26aulast%3DWeizel%26aufirst%3DL.%26aulast%3DKaiser%26aufirst%3DA.%26aulast%3DKretschmer%26aufirst%3DS.%2BB.%2BM.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DAngioni%26aufirst%3DC.%26aulast%3DHeering%26aufirst%3DJ.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DSchubert-Zsilavecz%26aufirst%3DM.%26aulast%3DSchmidtko%26aufirst%3DA.%26aulast%3DPogoryelov%26aufirst%3DD.%26aulast%3DPfeilschifter%26aufirst%3DJ.%26aulast%3DHofmann%26aufirst%3DB.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DSchwalm%26aufirst%3DS.%26aulast%3DProschak%26aufirst%3DE.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structureactivity%2520relationship%2520studies%2520of%2520dual%2520inhibitors%2520of%2520soluble%2520epoxide%2520hydrolase%2520and%25205-lipoxygenase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D11498%26epage%3D11521%26doi%3D10.1021%2Facs.jmedchem.0c00561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castaneda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chudasama, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chester, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caddick, S.</span></span> <span> </span><span class="NLM_article-title">Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">8187</span>â <span class="NLM_lpage">8189</span>, <span class="refDoi">Â DOI: 10.1039/c3cc45220d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1039%2Fc3cc45220d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23929130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlWjsrvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=8187-8189&author=L.+Castanedaauthor=A.+Maruaniauthor=F.+F.+Schumacherauthor=E.+Mirandaauthor=V.+Chudasamaauthor=K.+A.+Chesterauthor=J.+R.+Bakerauthor=M.+E.+Smithauthor=S.+Caddick&title=Acid-cleavable+thiomaleamic+acid+linker+for+homogeneous+antibody-drug+conjugation&doi=10.1039%2Fc3cc45220d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation</span></div><div class="casAuthors">Castaneda, Lourdes; Maruani, Antoine; Schumacher, Felix F.; Miranda, Enrique; Chudasama, Vijay; Chester, Kerry A.; Baker, James R.; Smith, Mark E. B.; Caddick, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">74</span>),
    <span class="NLM_cas:pages">8187-8189</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">In this communication we describe a novel acid-cleavable linker strategy for antibody-drug conjugation.  Functional disulfide bridging of the single interchain disulfide bond of a trastuzumab Fab fragment yields a homogeneous antibody-drug conjugate bearing a thiomaleamic acid linker.  This linker is stable at physiol. pH and temp., but quant. cleaves at lysosomal pH to release the drug payload.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo86GfXF_wrY7Vg90H21EOLACvtfcHk0lisklfyvE69mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlWjsrvM&md5=63dbcd8a78a7bdbb599ff1e742cb35f5</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1039%2Fc3cc45220d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3cc45220d%26sid%3Dliteratum%253Aachs%26aulast%3DCastaneda%26aufirst%3DL.%26aulast%3DMaruani%26aufirst%3DA.%26aulast%3DSchumacher%26aufirst%3DF.%2BF.%26aulast%3DMiranda%26aufirst%3DE.%26aulast%3DChudasama%26aufirst%3DV.%26aulast%3DChester%26aufirst%3DK.%2BA.%26aulast%3DBaker%26aufirst%3DJ.%2BR.%26aulast%3DSmith%26aufirst%3DM.%2BE.%26aulast%3DCaddick%26aufirst%3DS.%26atitle%3DAcid-cleavable%2520thiomaleamic%2520acid%2520linker%2520for%2520homogeneous%2520antibody-drug%2520conjugation%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2013%26volume%3D49%26spage%3D8187%26epage%3D8189%26doi%3D10.1039%2Fc3cc45220d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstead, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosure, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knipe, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasch, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P. A.</span></span> <span> </span><span class="NLM_article-title">Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">855</span>â <span class="NLM_lpage">869</span>, <span class="refDoi">Â DOI: 10.1021/bc025536j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc025536j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XksFentr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=855-869&author=G.+M.+Dubowchikauthor=R.+A.+Firestoneauthor=L.+Padillaauthor=D.+Willnerauthor=S.+J.+Hofsteadauthor=K.+Mosureauthor=J.+O.+Knipeauthor=S.+J.+Laschauthor=P.+A.+Trail&title=Cathepsin+B-labile+dipeptide+linkers+for+lysosomal+release+of+doxorubicin+from+internalizing+immunoconjugates%3A+model+studies+of+enzymatic+drug+release+and+antigen-specific+in+vitro+anticancer+activity&doi=10.1021%2Fbc025536j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity</span></div><div class="casAuthors">Dubowchik, Gene M.; Firestone, Raymond A.; Padilla, Linda; Willner, David; Hofstead, Sandra J.; Mosure, Kathleen; Knipe, Jay O.; Lasch, Shirley J.; Trail, Pamela A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">855-869</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The anticancer drug doxorubicin (DOX) was linked to chimeric BR96, an internalizing monoclonal antibody that binds to a Lewisy-related, tumor-assocd. antigen, through 2 lysosomally cleavable dipeptides, Phe-Lys and Val-Cit, giving immunoconjugates (I and II).  A self-immolative p-aminobenzyloxycarbonyl (PABC) spacer between the dipeptides and the DOX was required for rapid and quant. generation of free drug. DOX release from the model substrate Z-Phe-Lys-PABC-DOX was 30-fold faster than from Z-Val-Cit-PABC-DOX with the cysteine protease cathepsin B alone, but rates were identical in a rat liver lysosomal prepn. suggesting the participation of more than one enzyme.  Conjugates I and II showed rapid and near quant. drug release with cathepsin B and in a lysosomal prepn., while demonstrating excellent stability in human plasma.  Against tumor cell lines with varying levels of BR96 expression, both conjugates showed potent, antigen-specific cytotoxic activity, suggesting that they will be effective in delivering DOX selectively to antigen-expressing carcinomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqolCImqg5WKbVg90H21EOLACvtfcHk0lisklfyvE69mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksFentr8%253D&md5=09fb70d94d8997033b109fa3b5e79621</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fbc025536j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc025536j%26sid%3Dliteratum%253Aachs%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26aulast%3DFirestone%26aufirst%3DR.%2BA.%26aulast%3DPadilla%26aufirst%3DL.%26aulast%3DWillner%26aufirst%3DD.%26aulast%3DHofstead%26aufirst%3DS.%2BJ.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DLasch%26aufirst%3DS.%2BJ.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DCathepsin%2520B-labile%2520dipeptide%2520linkers%2520for%2520lysosomal%2520release%2520of%2520doxorubicin%2520from%2520internalizing%2520immunoconjugates%253A%2520model%2520studies%2520of%2520enzymatic%2520drug%2520release%2520and%2520antigen-specific%2520in%2520vitro%2520anticancer%2520activity%26jtitle%3DBioconjugate%2520Chem.%26date%3D2002%26volume%3D13%26spage%3D855%26epage%3D869%26doi%3D10.1021%2Fbc025536j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mhidia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beziere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanpain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommery, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, O.</span></span> <span> </span><span class="NLM_article-title">Assembly/disassembly of drug conjugates using imide ligation</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3982</span>â <span class="NLM_lpage">3985</span>, <span class="refDoi">Â DOI: 10.1021/ol101049g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol101049g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGjtbrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=3982-3985&author=R.+Mhidiaauthor=N.+Beziereauthor=A.+Blanpainauthor=N.+Pommeryauthor=O.+Melnyk&title=Assembly%2Fdisassembly+of+drug+conjugates+using+imide+ligation&doi=10.1021%2Fol101049g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Assembly/disassembly of drug conjugates using imide ligation</span></div><div class="casAuthors">Mhidia, Reda; Beziere, Nicolas; Blanpain, Annick; Pommery, Nicole; Melnyk, Oleg</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3982-3985</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A strategy is described that allows the easy assembly and controlled disassembly of drug conjugates.  Imide ligation, i.e., the reaction of a peptide thioacid with an azidoformate, is used for conjugate assembly.  The imide bond participates also with an endopeptidase-triggered cyclization-based disassembly mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYyi5Re83d27Vg90H21EOLACvtfcHk0lisklfyvE69mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGjtbrJ&md5=e40965ea2a5a57947a867c637c3eccce</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Fol101049g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol101049g%26sid%3Dliteratum%253Aachs%26aulast%3DMhidia%26aufirst%3DR.%26aulast%3DBeziere%26aufirst%3DN.%26aulast%3DBlanpain%26aufirst%3DA.%26aulast%3DPommery%26aufirst%3DN.%26aulast%3DMelnyk%26aufirst%3DO.%26atitle%3DAssembly%252Fdisassembly%2520of%2520drug%2520conjugates%2520using%2520imide%2520ligation%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26spage%3D3982%26epage%3D3985%26doi%3D10.1021%2Fol101049g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreyka, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissler, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenox, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okeley, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">831</span>â <span class="NLM_lpage">840</span>, <span class="refDoi">Â DOI: 10.1021/bc0600214</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc0600214" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD28XktVert78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=831-840&author=S.+C.+Jeffreyauthor=J.+B.+Andreykaauthor=S.+X.+Bernhardtauthor=K.+M.+Kisslerauthor=T.+Klineauthor=J.+S.+Lenoxauthor=R.+F.+Moserauthor=M.+T.+Nguyenauthor=N.+M.+Okeleyauthor=I.+J.+Stoneauthor=X.+Zhangauthor=P.+D.+Senter&title=Development+and+properties+of+beta-glucuronide+linkers+for+monoclonal+antibody-drug+conjugates&doi=10.1021%2Fbc0600214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Properties of Î²-Glucuronide Linkers for Monoclonal Antibody-Drug Conjugates</span></div><div class="casAuthors">Jeffrey, Scott C.; Andreyka, Jamie B.; Bernhardt, Starr X.; Kissler, Kim M.; Kline, Toni; Lenox, Joel S.; Moser, Ruth F.; Nguyen, Minh T.; Okeley, Nicole M.; Stone, Ivan J.; Zhang, Xinqun; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">831-840</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A Î²-glucuronide-based linker for attaching cytotoxic agents to monoclonal antibodies (mAbs) was designed and evaluated.  We employed the cytotoxic Monomethyl auristatin E (MMAE) and Monomethyl auristatin F (MMAF)and doxorubicin propyloxazoline (DPO) to give the Î²-glucuronide MMAE, Î-glucuronide MMAF, and (I), resp.  Cysteine-quenched derivs. of Î-glucuronide MMAF and I were detd. to be substrates for E. Coli Î²-glucuronidase, resulting in facile drug release.  The Î²-glucuronide MMAF was highly stable in rat plasma with an extrapolated half-life of 81 days.  Each drug-linker when conjugated to mAbs c1F6 (anti-CD70) and cAC10 (anti-CD30) gave monomeric antibody-drug conjugates (ADCs) with as many as eight drugs per mAb and had high levels of immunol. specific cytotoxic activity on cancer cell lines.  CAC10-Î²-glucuronide MMAE displayed pronounced antitumor activity in a s.c. Karpas 299 lymphoma tumor model.  A single dose treatment led to cures in all animals at the 0.5 mg/kg dose level and above, and the conjugate was well tolerated at 100 mg/kg.  In mice with s.c. renal cell carcinoma xenografts, the MMAF conjugate c1F6-Î-glucuronide MMAF was tolerated at 25 mg/kg and efficacious at 0.75 mg/kg.  These results demonstrate that the Î²-glucuronide linker system is an effective strategy for targeting cytotoxic agents providing ADCs with high degrees of efficacy at well-tolerated doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoubdLz5MUdl7Vg90H21EOLACvtfcHk0ljjLvZ41NRUcQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktVert78%253D&md5=eebae444d27717c44b521eeb8d6c7ed7</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Fbc0600214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0600214%26sid%3Dliteratum%253Aachs%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DAndreyka%26aufirst%3DJ.%2BB.%26aulast%3DBernhardt%26aufirst%3DS.%2BX.%26aulast%3DKissler%26aufirst%3DK.%2BM.%26aulast%3DKline%26aufirst%3DT.%26aulast%3DLenox%26aufirst%3DJ.%2BS.%26aulast%3DMoser%26aufirst%3DR.%2BF.%26aulast%3DNguyen%26aufirst%3DM.%2BT.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DStone%26aufirst%3DI.%2BJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DDevelopment%2520and%2520properties%2520of%2520beta-glucuronide%2520linkers%2520for%2520monoclonal%2520antibody-drug%2520conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2006%26volume%3D17%26spage%3D831%26epage%3D840%26doi%3D10.1021%2Fbc0600214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Catella-Lawson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cucchiara, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMarco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tournier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FitzGerald, G. A.</span></span> <span> </span><span class="NLM_article-title">Cyclooxygenase inhibitors and the antiplatelet effects of aspirin</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>345</i></span>,  <span class="NLM_fpage">1809</span>â <span class="NLM_lpage">1817</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa003199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1056%2FNEJMoa003199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=11752357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38Xltl2juw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2001&pages=1809-1817&author=F.+Catella-Lawsonauthor=M.+P.+Reillyauthor=S.+C.+Kapoorauthor=A.+J.+Cucchiaraauthor=S.+DeMarcoauthor=B.+Tournierauthor=S.+N.+Vyasauthor=G.+A.+FitzGerald&title=Cyclooxygenase+inhibitors+and+the+antiplatelet+effects+of+aspirin&doi=10.1056%2FNEJMoa003199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase inhibitors and the antiplatelet effects of aspirin</span></div><div class="casAuthors">Catella-Lawson, Francesca; Reilly, Muredach P.; Kapoor, Shiv C.; Cucchiara, Andrew J.; DeMarco, Susan; Tournier, Barbara; Vyas, Sachin N.; FitzGerald, Garret A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">1809-1817</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Patients with arthritis and vascular disease may receive both low-dose aspirin and other nonsteroidal antiinflammatory drugs.  We therefore investigated potential interactions between aspirin and commonly prescribed arthritis therapies.  Methods: We administered the following combinations of drugs for six days: aspirin (81 mg every morning) two hours before ibuprofen (400 mg every morning) and the same medications in the reverse order; aspirin two hours before acetaminophen (1000 mg every morning) and the same medications in the reverse order; aspirin two hours before the cyclooxygenase-2 inhibitor rofecoxib (25 mg every morning) and the same medications in the reverse order; enteric-coated aspirin two hours before ibuprofen (400 mg three times a day); and enteric-coated aspirin two hours before delayed-release diclofenac (75 mg twice daily).  Results: Serum thromboxane B2 levels (an index of cyclooxygenase-1 activity in platelets) and platelet aggregation were maximally inhibited 24 h after the administration of aspirin on day 6 in the subjects who took aspirin before a single daily dose of any other drug, as well as in those who took rofecoxib or acetaminophen before taking aspirin.  In contrast, inhibition of serum thromboxane B2 formation and platelet aggregation by aspirin was blocked when a single daily dose of ibuprofen was given before aspirin, as well as when multiple daily doses of ibuprofen were given.  The concomitant administration of rofecoxib, acetaminophen, or diclofenac did not affect the pharmacodynamics of aspirin.  Conclusions: The concomitant administration of ibuprofen but not rofecoxib, acetaminophen, or diclofenac antagonizes the irreversible platelet inhibition induced by aspirin.  Treatment with ibuprofen in patients with increased cardiovascular risk may limit the cardioprotective effects of aspirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo41V4YILt3GbVg90H21EOLACvtfcHk0ljjLvZ41NRUcQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xltl2juw%253D%253D&md5=786ae5c3d0b8af300113d944455e8fb6</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa003199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa003199%26sid%3Dliteratum%253Aachs%26aulast%3DCatella-Lawson%26aufirst%3DF.%26aulast%3DReilly%26aufirst%3DM.%2BP.%26aulast%3DKapoor%26aufirst%3DS.%2BC.%26aulast%3DCucchiara%26aufirst%3DA.%2BJ.%26aulast%3DDeMarco%26aufirst%3DS.%26aulast%3DTournier%26aufirst%3DB.%26aulast%3DVyas%26aufirst%3DS.%2BN.%26aulast%3DFitzGerald%26aufirst%3DG.%2BA.%26atitle%3DCyclooxygenase%2520inhibitors%2520and%2520the%2520antiplatelet%2520effects%2520of%2520aspirin%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D345%26spage%3D1809%26epage%3D1817%26doi%3D10.1056%2FNEJMoa003199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cryer, B.</span></span> <span> </span><span class="NLM_article-title">NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality</span>. <i>Am. J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">1694</span>â <span class="NLM_lpage">1695</span>, <span class="refDoi">Â DOI: 10.1111/j.1572-0241.2005.50565.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1111%2Fj.1572-0241.2005.50565.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=16144121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVent7%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2005&pages=1694-1695&author=B.+Cryer&title=NSAID-associated+deaths%3A+the+rise+and+fall+of+NSAID-associated+GI+mortality&doi=10.1111%2Fj.1572-0241.2005.50565.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality</span></div><div class="casAuthors">Cryer, Byron</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1694-1695</span>CODEN:
                <span class="NLM_cas:coden">AJGAAR</span>;
        ISSN:<span class="NLM_cas:issn">0002-9270</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  Although gastrointestinal (GI) morbidity and mortality from NSAIDs continues to be a significant problem, this study by Lanas et al. indicates that the magnitude of the concern is declining.  Explanations for this redn. are more likely related to the increased use of proton pump inhibitors (PPIs) than to the introduction of COX-2 inhibitors.  This study further reveals that one-third of NSAIDs' GI mortality comes from low-dose, daily aspirin.  Another important contribution derived from this report is a more reliable est. of NSAIDs' lower GI clin. consequences than previously available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHt9J5mvzChLVg90H21EOLACvtfcHk0ljjLvZ41NRUcQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVent7%252FP&md5=07cdeba5a2093b4ca9fb383f93e0b88f</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1111%2Fj.1572-0241.2005.50565.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1572-0241.2005.50565.x%26sid%3Dliteratum%253Aachs%26aulast%3DCryer%26aufirst%3DB.%26atitle%3DNSAID-associated%2520deaths%253A%2520the%2520rise%2520and%2520fall%2520of%2520NSAID-associated%2520GI%2520mortality%26jtitle%3DAm.%2520J.%2520Gastroenterol.%26date%3D2005%26volume%3D100%26spage%3D1694%26epage%3D1695%26doi%3D10.1111%2Fj.1572-0241.2005.50565.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nemmani, K. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mali, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borhade, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karwa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamidiboina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senthilkumar, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangu, N. K.</span></span> <span> </span><span class="NLM_article-title">NO-NSAIDs: Gastric-sparing nitric oxide-releasable prodrugs of non-steroidal anti-inflammatory drugs</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5297</span>â <span class="NLM_lpage">5301</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.07.142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmcl.2009.07.142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=19683923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVeqsLzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5297-5301&author=K.+V.+S.+Nemmaniauthor=S.+V.+Maliauthor=N.+Borhadeauthor=A.+R.+Pathanauthor=M.+Karwaauthor=V.+Pamidiboinaauthor=S.+P.+Senthilkumarauthor=M.+Gundauthor=A.+K.+Jainauthor=N.+K.+Mangu&title=NO-NSAIDs%3A+Gastric-sparing+nitric+oxide-releasable+prodrugs+of+non-steroidal+anti-inflammatory+drugs&doi=10.1016%2Fj.bmcl.2009.07.142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">NO-NSAIDs: Gastric-sparing nitric oxide-releasable prodrugs of non-steroidal anti-inflammatory drugs</span></div><div class="casAuthors">Nemmani, Kumar V. S.; Mali, Sunil V.; Borhade, Namdev; Pathan, Asif R.; Karwa, Manoj; Pamidiboina, Venu; Senthilkumar, S. P.; Gund, Machhindra; Jain, Arun K.; Mangu, Naveen K.; Dubash, Nauzer P.; Desai, Dattatraya C.; Sharma, Somesh; Satyam, Apparao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5297-5301</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Recently, a new class of nitric-oxide-releasing non-steroidal anti-inflammatory drugs (NO-NSAIDs) is being studied as Safe NSAIDs' because of their gastric-sparing properties.  As an extension of our novel disulfide linker technol., we have designed, synthesized and evaluated novel NO-releasing NSAID prodrugs such as NO-Aspirin (1b-d) and NO-Diclofenac (2b-c).  Although the amide-contg. deriv. 1d did not show any bioavailability, the remaining compds. have shown fair to excellent pharmacokinetic, anti-inflammatory and gastric-sparing properties.  Among them, however, the NO-Diclofenac (2b) has shown the most promising pharmacokinetic, anti-inflammatory and NO-releasing properties and protected rats from NSAID-induced gastric damage which could be attributable to the beneficial effects of NO released from these prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDr2S0liidLVg90H21EOLACvtfcHk0lgLO7EhRn0oAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVeqsLzP&md5=e2198fa5c52b30768a16ffd936cb699f</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.07.142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.07.142%26sid%3Dliteratum%253Aachs%26aulast%3DNemmani%26aufirst%3DK.%2BV.%2BS.%26aulast%3DMali%26aufirst%3DS.%2BV.%26aulast%3DBorhade%26aufirst%3DN.%26aulast%3DPathan%26aufirst%3DA.%2BR.%26aulast%3DKarwa%26aufirst%3DM.%26aulast%3DPamidiboina%26aufirst%3DV.%26aulast%3DSenthilkumar%26aufirst%3DS.%2BP.%26aulast%3DGund%26aufirst%3DM.%26aulast%3DJain%26aufirst%3DA.%2BK.%26aulast%3DMangu%26aufirst%3DN.%2BK.%26atitle%3DNO-NSAIDs%253A%2520Gastric-sparing%2520nitric%2520oxide-releasable%2520prodrugs%2520of%2520non-steroidal%2520anti-inflammatory%2520drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5297%26epage%3D5301%26doi%3D10.1016%2Fj.bmcl.2009.07.142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szoke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czompa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lekli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabados-Furjesi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herczeg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csavas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borbas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herczegh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosaki, A.</span></span> <span> </span><span class="NLM_article-title">A new, vasoactive hybrid aspirin containing nitrogen monoxide-releasing molsidomine moiety</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">159</span>â <span class="NLM_lpage">166</span>, <span class="refDoi">Â DOI: 10.1016/j.ejps.2019.02.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejps.2019.02.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=30779982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1Gms7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2019&pages=159-166&author=K.+Szokeauthor=A.+Czompaauthor=I.+Lekliauthor=P.+Szabados-Furjesiauthor=M.+Herczegauthor=M.+Csavasauthor=A.+Borbasauthor=P.+Herczeghauthor=A.+Tosaki&title=A+new%2C+vasoactive+hybrid+aspirin+containing+nitrogen+monoxide-releasing+molsidomine+moiety&doi=10.1016%2Fj.ejps.2019.02.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">A new, vasoactive hybrid aspirin containing nitrogen monoxide-releasing molsidomine moiety</span></div><div class="casAuthors">Szoke, Kitti; Czompa, Attila; Lekli, Istvan; Szabados-Furjesi, Peter; Herczeg, Mihaly; Csavas, Magdolna; Borbas, Aniko; Herczegh, Pal; Tosaki, Arpad</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159-166</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ischemic heart conditions are among the main causes of sudden cardiac death worldwide.  One of the strategies for avoiding myocardial infarction is the low-dose, prophylactic use of acetylsalicylic acid (ASA), an inhibitor of platelet aggregation.  To avoid the gastrointestinal damage, ASA prodrugs bearing nitric oxide (NO)-donating moiety covalently conjugated to ASA have been synthesized and evaluated extensively worldwide.  Herein the synthesis of a new hybrid ASA ester covalently attached to the NO donor linsidomine, an active metabolite of molsidomine (MOL) is reported.  Cell viability assay and hemolysis tests were performed in H9c2 cells and rat erythrocytes, resp.  Our new compd., the ERJ-500 not affected neg. the viability of living cells in the concn. range of 100 nM to 100 Î¼M.  Using the ex vivo Langendorff method on hearts originated from female rats, compd. ERJ-500 displayed a dose-dependent, outwashable vasodilative effect in coronary arteries.  Vasodilation was obsd. on isolated working heart model as well, with elevated stroke vol. in hearts treated with ERJ-500.  Furthermore, a decreased infarct size was also noticed in ERJ-500 treated hearts after ischemia/reperfusion.  Based on these observations it can be expected that our new hybrid ASA may contribute to new pharmacol. tool in the therapy of ischemic heart conditions and assocd. syndromes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_OImotZEyDrVg90H21EOLACvtfcHk0lgLO7EhRn0oAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1Gms7s%253D&md5=5e3bf72d23357ad06d39caa02f31fe9c</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2019.02.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2019.02.020%26sid%3Dliteratum%253Aachs%26aulast%3DSzoke%26aufirst%3DK.%26aulast%3DCzompa%26aufirst%3DA.%26aulast%3DLekli%26aufirst%3DI.%26aulast%3DSzabados-Furjesi%26aufirst%3DP.%26aulast%3DHerczeg%26aufirst%3DM.%26aulast%3DCsavas%26aufirst%3DM.%26aulast%3DBorbas%26aufirst%3DA.%26aulast%3DHerczegh%26aufirst%3DP.%26aulast%3DTosaki%26aufirst%3DA.%26atitle%3DA%2520new%252C%2520vasoactive%2520hybrid%2520aspirin%2520containing%2520nitrogen%2520monoxide-releasing%2520molsidomine%2520moiety%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D131%26spage%3D159%26epage%3D166%26doi%3D10.1016%2Fj.ejps.2019.02.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdellatif, K. R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VelÃ¡zquez, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suresh, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knaus, E. E.</span></span> <span> </span><span class="NLM_article-title">Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: Synthesis, biological evaluation and nitric oxide release studies</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3014</span>â <span class="NLM_lpage">3018</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.04.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmcl.2009.04.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=19419861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVersr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3014-3018&author=K.+R.+A.+Abdellatifauthor=M.+A.+Chowdhuryauthor=Y.+Dongauthor=D.+Dasauthor=G.+Yuauthor=C.+A.+Vel%C3%A1zquezauthor=M.+R.+Sureshauthor=E.+E.+Knaus&title=Dinitroglyceryl+and+diazen-1-ium-1%2C2-diolated+nitric+oxide+donor+ester+prodrugs+of+aspirin%2C+indomethacin+and+ibuprofen%3A+Synthesis%2C+biological+evaluation+and+nitric+oxide+release+studies&doi=10.1016%2Fj.bmcl.2009.04.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: Synthesis, biological evaluation and nitric oxide release studies</span></div><div class="casAuthors">Abdellatif, Khaled R. A.; Chowdhury, Morshed Alam; Dong, Ying; Das, Dipankar; Yu, Gang; Velazquez, Carlos A.; Suresh, Mavanur R.; Knaus, Edward E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3014-3018</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new group of hybrid nitric oxide (NO) releasing anti-inflammatory (AI) ester prodrugs (NONO-NSAIDs) wherein a 1,3-dinitrooxy-2-Pr (12a-c), or O2-acetoxymethyl-1-[2-(methyl)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (14a-c), NO-donor moiety is directly attached to the carboxylic acid group of aspirin, indomethacin or ibuprofen were synthesized.  NO release from the dinitrooxypropyl, or diazen-1-ium-1,2-diolate, ester prodrugs was increased substantially upon incubation in the presence of L-cysteine (12a-c) or rat serum (14a-c).  The ester prodrugs (12a-c, 14a-c), which did not inhibit the COX-1 isoenzyme, exhibited modest inhibitory activity against the COX-2 isoenzyme.  The NONO-NSAIDs 12a-c and 14a-c exhibited in vivo AI activity that was similar to that exhibited by the parent drug aspirin, indomethacin or ibuprofen when the same oral dose (Î¼mol/kg) was administered.  These similarities in oral potency profiles suggest these NONO-NSAIDs act as classical prodrugs that require metabolic activation by esterase-mediated hydrolysis.  Hybrid NO-donor/anti-inflammatory prodrugs of this type (NONO-NSAIDs) offer a potential drug design concept targeted toward the development of anti-inflammatory drugs with reduced adverse gastrointestinal effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxVIWM0fQaMbVg90H21EOLACvtfcHk0lgLO7EhRn0oAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVersr0%253D&md5=c91904610db38690e91823797ccb22f3</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.059%26sid%3Dliteratum%253Aachs%26aulast%3DAbdellatif%26aufirst%3DK.%2BR.%2BA.%26aulast%3DChowdhury%26aufirst%3DM.%2BA.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DDas%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DVel%25C3%25A1zquez%26aufirst%3DC.%2BA.%26aulast%3DSuresh%26aufirst%3DM.%2BR.%26aulast%3DKnaus%26aufirst%3DE.%2BE.%26atitle%3DDinitroglyceryl%2520and%2520diazen-1-ium-1%252C2-diolated%2520nitric%2520oxide%2520donor%2520ester%2520prodrugs%2520of%2520aspirin%252C%2520indomethacin%2520and%2520ibuprofen%253A%2520Synthesis%252C%2520biological%2520evaluation%2520and%2520nitric%2520oxide%2520release%2520studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3014%26epage%3D3018%26doi%3D10.1016%2Fj.bmcl.2009.04.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corazzi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maucci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corazzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresele, P.</span></span> <span> </span><span class="NLM_article-title">Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016)</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>315</i></span>,  <span class="NLM_fpage">1331</span>â <span class="NLM_lpage">1337</span>, <span class="refDoi">Â DOI: 10.1124/jpet.105.089896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1124%2Fjpet.105.089896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=16144976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlalurbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2005&pages=1331-1337&author=T.+Corazziauthor=M.+Leoneauthor=R.+Maucciauthor=L.+Corazziauthor=P.+Gresele&title=Direct+and+irreversible+inhibition+of+cyclooxygenase-1+by+nitroaspirin+%28NCX+4016%29&doi=10.1124%2Fjpet.105.089896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016)</span></div><div class="casAuthors">Corazzi, Teresa; Leone, Mario; Maucci, Raffaella; Corazzi, Lanfranco; Gresele, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1331-1337</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Benzoic acid, 2-(acetyl-oxy)-3-[(nitrooxy)methyl]phenyl ester (NCX 4016), a new drug made by an aspirin mol. linked, through a spacer, to a nitric oxide (NO)-donating moiety, is now under clin. testing for the treatment of atherothrombotic conditions.  Aspirin exerts its antithrombotic activity by irreversibly inactivating platelet cyclooxygenase (COX)-1.  NCX 4016 in vivo undergoes metab. into deacetylated and/or denitrated metabolites, and it is not known whether NCX 4016 needs to liberate aspirin to inhibit COX-1, or whether it can block it as a whole mol.  The aim of our study was to evaluate the effects of NCX 4016 and its analog or metabolites on platelet COX-1 and whole blood COX-2 and on purified ovine COX (oCOX)-1 and oCOX-2.  In particular, we have compared the mechanism by which NCX 4016 inhibits purified oCOX enzymes with that of aspirin using a spectrophotometric assay.  All the NCX 4016 derivs. contg. acetylsalicylic acid inhibited the activity of oCOX-1 and oCOX-2, whereas the deacetylated metabolites and the nitric oxide-donating moiety were inactive.  Dialysis expts. showed that oCOX-1 inhibition by NCX 4016, similar to aspirin, is irreversible.  Reversible COX inhibitors (indomethacin) or salicylic acid incubated with the enzyme before NCX 4016 prevent the irreversible inhibition of oCOX-1 by NCX 4016 as well as by aspirin.  In conclusion, our data show that NCX 4016 acts as a direct and irreversible inhibitor of COX-1 and that the presence of a spacer and NO-donating moiety in the mol. slows the kinetics of COX-1 inhibition by NCX 4016, compared with aspirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYu32WTBZEN7Vg90H21EOLACvtfcHk0liA6uq0nB4sZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlalurbI&md5=c2f8692899967afa23e52bbb4fe3aa8d</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.089896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.089896%26sid%3Dliteratum%253Aachs%26aulast%3DCorazzi%26aufirst%3DT.%26aulast%3DLeone%26aufirst%3DM.%26aulast%3DMaucci%26aufirst%3DR.%26aulast%3DCorazzi%26aufirst%3DL.%26aulast%3DGresele%26aufirst%3DP.%26atitle%3DDirect%2520and%2520irreversible%2520inhibition%2520of%2520cyclooxygenase-1%2520by%2520nitroaspirin%2520%2528NCX%25204016%2529%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D315%26spage%3D1331%26epage%3D1337%26doi%3D10.1124%2Fjpet.105.089896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiroli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ongini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Soldato, P.</span></span> <span> </span><span class="NLM_article-title">Nitric oxide-donating non-steroidal anti-inflammatory drugs: the case of nitroderivatives of aspirin</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">441</span>â <span class="NLM_lpage">446</span>, <span class="refDoi">Â DOI: 10.1016/S0223-5234(03)00055-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2FS0223-5234%2803%2900055-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=12750033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjs1CltLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=441-446&author=V.+Chiroliauthor=F.+Benediniauthor=E.+Onginiauthor=P.+Del+Soldato&title=Nitric+oxide-donating+non-steroidal+anti-inflammatory+drugs%3A+the+case+of+nitroderivatives+of+aspirin&doi=10.1016%2FS0223-5234%2803%2900055-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide-donating non-steroidal anti-inflammatory drugs: the case of nitro derivatives of aspirin</span></div><div class="casAuthors">Chiroli, Valerio; Benedini, Francesca; Ongini, Ennio; Del Soldato, Piero</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-446</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review.  Nitric oxide (NO) acts as a key signaling mechanism in a no. of cells and tissues in the mammalian organism.  Modulation of the biosynthesis of NO has emerged to be relevant to the treatment of a variety of human diseases.  In the attempt to reduce the serious side effects of non-steroidal anti-inflammatory drugs (NSAIDs), esp. in the gastrointestinal tract, a NO-releasing moiety has been linked to conventional NSAIDs.  A prototypical example is that of NO-releasing derivs. of aspirin.  Thanks to the cytoprotective action of NO such compds. do not produce gastric damage and are emerging as an interesting novel group of drugs for their unique pharmacol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqThAb9XNHkO7Vg90H21EOLACvtfcHk0liA6uq0nB4sZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjs1CltLY%253D&md5=2fb87b379c00b12d1b15bc7694104a56</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2803%2900055-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252803%252900055-2%26sid%3Dliteratum%253Aachs%26aulast%3DChiroli%26aufirst%3DV.%26aulast%3DBenedini%26aufirst%3DF.%26aulast%3DOngini%26aufirst%3DE.%26aulast%3DDel%2BSoldato%26aufirst%3DP.%26atitle%3DNitric%2520oxide-donating%2520non-steroidal%2520anti-inflammatory%2520drugs%253A%2520the%2520case%2520of%2520nitroderivatives%2520of%2520aspirin%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2003%26volume%3D38%26spage%3D441%26epage%3D446%26doi%3D10.1016%2FS0223-5234%2803%2900055-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praveen Rao, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knaus, E. E.</span></span> <span> </span><span class="NLM_article-title">Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4061</span>â <span class="NLM_lpage">4067</span>, <span class="refDoi">Â DOI: 10.1021/jm050211k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050211k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktlCrsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4061-4067&author=C.+Velazquezauthor=P.+N.+Praveen+Raoauthor=E.+E.+Knaus&title=Novel+nonsteroidal+antiinflammatory+drugs+possessing+a+nitric+oxide+donor+diazen-1-ium-1%2C2-diolate+moiety%3A+design%2C+synthesis%2C+biological+evaluation%2C+and+nitric+oxide+release+studies&doi=10.1021%2Fjm050211k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Nonsteroidal Antiinflammatory Drugs Possessing a Nitric Oxide Donor Diazen-1-ium-1,2-diolate Moiety: Design, Synthesis, Biological Evaluation, and Nitric Oxide Release Studies</span></div><div class="casAuthors">Velazquez, Carlos; Rao, P. N. Praveen; Knaus, Edward E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4061-4067</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel group of hybrid nitric oxide-releasing nonsteroidal antiinflammatory drugs (â¢NO-NSAIDs) possessing a 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate or 1-(N,N-dimethylamino)diazen-1-ium-1,2-diolate moiety attached via a one-carbon methylene spacer to the carboxylic acid group of the traditional NSAIDs aspirin, ibuprofen, and indomethacin were synthesized.  Although none of these ester prodrugs exhibited in vitro cyclooxygenase (COX) inhibitory activity against the COX-1 and COX-2 isoenzymes (IC50 > 100 Î¼M), all of the compds. significantly decreased carrageenan-induced rat paw edema.  In this regard, the ester prodrugs showed equipotent antiinflammatory activities in vivo to that of the parent drugs aspirin, ibuprofen, and indomethacin.  All of the compds. released nitric oxide upon incubation with either phosphate buffer soln. at pH 7.4 (14-16% range) or porcine liver esterase (16-19% range), but the percentage of â¢NO released was up to sixfold higher (93%) when these ester prodrugs were incubated with guinea pig serum.  These incubation studies suggest that both â¢NO and the parent NSAID would be released upon in vivo cleavage by nonspecific serum esterases.  The simultaneous release of aspirin and nitric oxide from the â¢NO-aspirin prodrugs constitutes a potentially beneficial property for the prophylactic prevention of thrombus formation and adverse cardiovascular events such as stroke and myocardial infarction.  The data acquired in an in vivo ulcer index (UI) assay showed that for this group of ester prodrugs, particularly the â¢NO-aspirins and â¢NO-ibuprofens, no lesions were obsd. (UI = 0) when compared to the parent drugs aspirin (UI = 57, 250 mg/kg po dose), ibuprofen (UI = 45, 250 mg/kg po dose), or indomethacin (UI = 34, 30 mg/kg po dose) at equiv. doses.  Accordingly, these hybrid â¢NO-NSAID prodrugs possessing a diazen-1-ium-1,2-diolate moiety, represent a new approach for the rational design of antiinflammatory drugs with reduced gastric ulcerogenicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGIFGzgY0hoLVg90H21EOLACvtfcHk0lgDIHtUHF3haw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktlCrsLo%253D&md5=0727fa37e4d644eb55942793ffdcdf62</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fjm050211k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050211k%26sid%3Dliteratum%253Aachs%26aulast%3DVelazquez%26aufirst%3DC.%26aulast%3DPraveen%2BRao%26aufirst%3DP.%2BN.%26aulast%3DKnaus%26aufirst%3DE.%2BE.%26atitle%3DNovel%2520nonsteroidal%2520antiinflammatory%2520drugs%2520possessing%2520a%2520nitric%2520oxide%2520donor%2520diazen-1-ium-1%252C2-diolate%2520moiety%253A%2520design%252C%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520nitric%2520oxide%2520release%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4061%26epage%3D4067%26doi%3D10.1021%2Fjm050211k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praveen Rao, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citro, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keefer, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knaus, E. E.</span></span> <span> </span><span class="NLM_article-title">O2-acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): synthesis, nitric oxide release, and biological evaluation studies</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">4767</span>â <span class="NLM_lpage">4774</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2007.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmc.2007.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=17509888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtFOjs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=4767-4774&author=C.+A.+Velazquezauthor=P.+N.+Praveen+Raoauthor=M.+L.+Citroauthor=L.+K.+Keeferauthor=E.+E.+Knaus&title=O2-acetoxymethyl-protected+diazeniumdiolate-based+NSAIDs+%28NONO-NSAIDs%29%3A+synthesis%2C+nitric+oxide+release%2C+and+biological+evaluation+studies&doi=10.1016%2Fj.bmc.2007.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">O2-Acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): Synthesis, nitric oxide release, and biological evaluation studies</span></div><div class="casAuthors">Velazquez, Carlos A.; Rao, P. N. Praveen; Citro, Michael L.; Keefer, Larry K.; Knaus, Edward E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4767-4774</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A novel group of O2-acetoxymethyl-protected diazeniumdiolate-based nonsteroidal anti-inflammatory prodrugs (NONO-NSAIDs) were synthesized by esterifying the carboxylate group of aspirin, ibuprofen, or indomethacin with O2-acetoxymethyl 1-[N-(2-hydroxyethyl)-N-methylamino]diazeniumdiolate.  The resulting nitric oxide (â¢>NO)-releasing prodrugs (7-9) did not exhibit in vitro cyclooxygenase (COX) inhibitory activity against the COX-1 and COX-2 isoenzymes (IC50s > 100 Î¼M).  In contrast, prodrugs 7 and 8 significantly decreased carrageenan-induced rat paw edema showing enhanced in vivo anti-inflammatory activities (ID50's = 552 and 174 Î¼mol/kg, resp.) relative to those of the parent NSAIDs aspirin (ID50 = 714 Î¼mol/kg) and ibuprofen (ID50 = 326 Î¼mol/kg).  The rate of porcine liver esterase-mediated â¢NO release from prodrugs 7-9 (2 mol of â¢NO/mol of test compd. in 0.6-6.5 min) was substantially higher compared to that obsd. without enzymic catalysis (about 1 mol of â¢NO/mol of test compd. in 40-48 h).  These incubation studies suggest that both â¢NO and the parent NSAID would be released upon in vivo activation (hydrolysis) by esterases.  Data acquired in an in vivo ulcer index (UI) assay showed that NONO-aspirin (UI = 0.8), NONO-indomethacin (UI = 1.3), and particularly NONO-ibuprofen (UI = 0) were significantly less ulcerogenic compared to the parent drugs aspirin (UI = 57), ibuprofen (UI = 46) or indomethacin (UI = 34) at equimolar doses.  The release of aspirin and Â·NO from the NONO-aspirin (7) prodrug constitutes a potentially beneficial property for the prophylactic prevention of thrombus formation and adverse cardiovascular events such as stroke and myocardial infarction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopHdbh33BY9LVg90H21EOLACvtfcHk0lgDIHtUHF3haw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtFOjs7g%253D&md5=4b8171adcf7540bab147a80636691e96</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DVelazquez%26aufirst%3DC.%2BA.%26aulast%3DPraveen%2BRao%26aufirst%3DP.%2BN.%26aulast%3DCitro%26aufirst%3DM.%2BL.%26aulast%3DKeefer%26aufirst%3DL.%2BK.%26aulast%3DKnaus%26aufirst%3DE.%2BE.%26atitle%3DO2-acetoxymethyl-protected%2520diazeniumdiolate-based%2520NSAIDs%2520%2528NONO-NSAIDs%2529%253A%2520synthesis%252C%2520nitric%2520oxide%2520release%252C%2520and%2520biological%2520evaluation%2520studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D4767%26epage%3D4774%26doi%3D10.1016%2Fj.bmc.2007.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ait-Tihyaty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachid, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larroque-Lombard, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B. J.</span></span> <span> </span><span class="NLM_article-title">ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule,;requires carboxylesterase-mediated hydrolysis for optimal activity</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1409</span>â <span class="NLM_lpage">1423</span>, <span class="refDoi">Â DOI: 10.1007/s10637-013-0008-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1007%2Fs10637-013-0008-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23959266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCmtLfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1409-1423&author=M.+Ait-Tihyatyauthor=Z.+Rachidauthor=A.-L.+Larroque-Lombardauthor=B.+J.+Jean-Claude&title=ZRX1%2C+the+first+EGFR+inhibitor-capecitabine+based+combi-molecule%2C%3Brequires+carboxylesterase-mediated+hydrolysis+for+optimal+activity&doi=10.1007%2Fs10637-013-0008-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity</span></div><div class="casAuthors">Ait-Tihyaty, Maria; Rachid, Zakaria; Larroque-Lombard, Anne-Laure; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1409-1423</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Capecitabine, an orally available prodrug of 5-FU, requires activation by carboxylesterase (CES) enzymes present in the liver to generate 5'-deoxy-5-flurocytidine ribose (5'-DFCR).  The deamination of the latter by cytidine deaminase gives 5'-deoxy-5-fluorouridine ribose (5'-DFUR).  Finally, the conversion of 5'-DFUR to the cytotoxic drug 5-FU, occurs primarily in the tumor and is catalyzed by thymidine phosphorylase (TP).  Accordingly, it was surmised that events assocd. with an increase of TP levels should enhance the potency of capecitabine and its metabolites.  EGFR inhibition was found to be one such event.  The obsd. synergy between gefitinib and 5'-DFUR has inspired the design of single mols. capable of acting as prodrugs of both an EGFR inhibitor and 5-FU.  Here, we report on the synthesis and characterization of one such mol., ZRX1, that consists of an acetylated 5'-DFCR moiety linked to a quinazoline inhibitor of EGFR through an alkyl dicarbamate spacer that requires CES activation to generate the two active metabolites.  Our results showed that ZRX1 was ineffective as an intact mol.  However, when CES was present, ZRX1 induced an increase in EGFR inhibition, TP expression, DNA damage and apoptosis.  ZRX1 was, at least, 3-fold more potent than capecitabine and 5'-DFUR and recapitulated the effects of the combination treatments.  LC-MS anal. showed that in the presence of CES, ZRX1 is metabolized into a mixt. of bioactive quinazoline derivs. and 5'-DFCR derived metabolites.  Our results in toto, suggest that capecitabine-based EGFR targeting combi-mols. of the same type than ZRX1, have the potential to induce stronger growth inhibitory potency than capecitabine, 5'-DFUR or single EGFR inhibitors and equiv. potency when compared with combinations of EGFR inhibitors + 5'-DFUR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbcy_7Wffws7Vg90H21EOLACvtfcHk0lgDIHtUHF3haw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCmtLfN&md5=376a62ece2525242f53ec798afe80e71</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1007%2Fs10637-013-0008-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-013-0008-y%26sid%3Dliteratum%253Aachs%26aulast%3DAit-Tihyaty%26aufirst%3DM.%26aulast%3DRachid%26aufirst%3DZ.%26aulast%3DLarroque-Lombard%26aufirst%3DA.-L.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DZRX1%252C%2520the%2520first%2520EGFR%2520inhibitor-capecitabine%2520based%2520combi-molecule%252C%253Brequires%2520carboxylesterase-mediated%2520hydrolysis%2520for%2520optimal%2520activity%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D1409%26epage%3D1423%26doi%3D10.1007%2Fs10637-013-0008-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cassata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Procoplo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrario, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beretta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longarini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajetta, E.</span></span> <span> </span><span class="NLM_article-title">Capecitabine: indications and future perspectives in the treatment of metastatic colorectal and breast cancer</span>. <i>Tumori</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">364</span>â <span class="NLM_lpage">371</span>, <span class="refDoi">Â DOI: 10.1177/030089160108700602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1177%2F030089160108700602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=11989587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFGltr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2001&pages=364-371&author=A.+Cassataauthor=G.+Procoploauthor=M.+Aluauthor=L.+Ferrariauthor=E.+Ferrarioauthor=E.+Berettaauthor=R.+Longariniauthor=G.+Bustoauthor=C.+D.+Deauthor=E.+Bajetta&title=Capecitabine%3A+indications+and+future+perspectives+in+the+treatment+of+metastatic+colorectal+and+breast+cancer&doi=10.1177%2F030089160108700602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Capecitabine: Indications and future perspectives in the treatment of metastatic colorectal and breast cancer</span></div><div class="casAuthors">Cassata, Antonino; Procopio, Giuseppe; Alu, Massimiliano; Ferrari, Leonardo; Ferrario, Erminia; Beretta, Elena; Longarini, Raffaella; Busto, Giuseppina; De Candis, Daniela; Bajetta, Emilio</div><div class="citationInfo"><span class="NLM_cas:title">Tumori</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">364-371</span>CODEN:
                <span class="NLM_cas:coden">TUMOAB</span>;
        ISSN:<span class="NLM_cas:issn">0300-8916</span>.
    
            (<span class="NLM_cas:orgname">Il Pensiero Scientifico Editore</span>)
        </div><div class="casAbstract">A review.  Fluoropyrimidines remain the most important drugs in the treatment of breast and colorectal carcinoma, but response rates and survival time have been disappointing.  Optimal administration is by continuous i.v. infusion, which makes it cumbersome to use and compromises patient independence.  Recently, a no. of new agents, including fluorouracil prodrugs and selective dihydropyrimidine dehydrogenase inhibitors, have been studied, with promising results.  Capecitabine is the first in a new class of fluoropyrimidines.  It is an oral, tumor-activated anticancer drug whose activity mimics that of continuously infused 5-fluorouracil.  Capecitabine circumvents dihydropyrimidine dehydrogenase catabolism and appears to be at least as active against metastatic colorectal and breast cancer as conventionally administered i.v. 5-fluorouracil, with significantly less toxicity, an improved quality of life, and lesser cost.  Capecitabine may ultimately provide enhanced antitumor activity to fluorouracil-contg. regimes for advanced colorectal and breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplvofxN29QBrVg90H21EOLACvtfcHk0lgDIHtUHF3haw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFGltr4%253D&md5=12d0cd949abafa436e72da6531e47e51</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1177%2F030089160108700602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F030089160108700602%26sid%3Dliteratum%253Aachs%26aulast%3DCassata%26aufirst%3DA.%26aulast%3DProcoplo%26aufirst%3DG.%26aulast%3DAlu%26aufirst%3DM.%26aulast%3DFerrari%26aufirst%3DL.%26aulast%3DFerrario%26aufirst%3DE.%26aulast%3DBeretta%26aufirst%3DE.%26aulast%3DLongarini%26aufirst%3DR.%26aulast%3DBusto%26aufirst%3DG.%26aulast%3DDe%26aufirst%3DC.%2BD.%26aulast%3DBajetta%26aufirst%3DE.%26atitle%3DCapecitabine%253A%2520indications%2520and%2520future%2520perspectives%2520in%2520the%2520treatment%2520of%2520metastatic%2520colorectal%2520and%2520breast%2520cancer%26jtitle%3DTumori%26date%3D2001%26volume%3D87%26spage%3D364%26epage%3D371%26doi%3D10.1177%2F030089160108700602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brahimi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudouit, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcnamee, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tari, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JeanClaude, B. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of epidermal growth factor receptor-mediated signaling by âcombi-triazeneâ BJ2000, a new probe for combi-targeting postulates</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>303</i></span>,  <span class="NLM_fpage">238</span>â <span class="NLM_lpage">246</span>, <span class="refDoi">Â DOI: 10.1124/jpet.102.039099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1124%2Fjpet.102.039099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=12235257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsV2qsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2002&pages=238-246&author=F.+Brahimiauthor=S.+L.+Mathesonauthor=F.+Dudouitauthor=J.+P.+Mcnameeauthor=A.+M.+Tariauthor=B.+J.+JeanClaude&title=Inhibition+of+epidermal+growth+factor+receptor-mediated+signaling+by+%E2%80%9Ccombi-triazene%E2%80%9D+BJ2000%2C+a+new+probe+for+combi-targeting+postulates&doi=10.1124%2Fjpet.102.039099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-Triazene" BJ2000, a new probe for Combi-Targeting postulates</span></div><div class="casAuthors">Brahimi, Fouad; Matheson, Stephanie L.; Dudouit, Fabienne; McNamee, James P.; Tari, Ana M.; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">238-246</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The Combi-Targeting concept postulates that a mol. termed combi-mol. (C-mol.) with binary epidermal growth factor receptor (EGFR) targeting/DNA-damaging properties and with the ability to be hydrolyzed to another EGFR inhibitor should induce sustained antiproliferative activity in cells overexpressing EGFR.  Because we postulate that the EGFR affinity of the C-mol. and that of its hydrolytic metabolites are crit. parameters for sustained potency against EGFR-overexpressing cells, we synthesized BJ2000 (IC50 = 0.1 Î¼M, competitive binding at ATP site), a novel C-mol. that can decomp. into a 6-amino-4-anilinoquinazoline FD105 (IC50 = 0.2 Î¼M).  Studies using the EGFR-overexpressing A431 cells revealed that BJ2000 could damage DNA and block epidermal growth factor-stimulated EGFR autophosphorylation by a partially irreversible mechanism.  Blockade of EGFR autophosphorylation subsequently induced inhibition of mitogen-activated protein kinase activation and c-fos gene expression.  ELISA and growth factor-mediated stimulation of proliferation assays in the EGFR-expressing NIH3T3HER14 demonstrated the preferential EGFR-targeting properties of BJ2000, and more importantly suggest that blockade of EGFR phosphorylation by this drug translate into significant growth inhibitory effects.  These properties culminated into irreversible antiproliferative effects as confirmed by a sulforhodamine B assay.  Five days after a 2-h treatment, BJ2000 retained significant antiproliferative effect in A431 cells, whereas its reversible metabolite FD105 almost completely lost its activity.  This result in toto lend support to the Combi-Targeting concept according to which a mol. conjugate kept small enough to interact with EGFR and designed to degrade into another inhibitor of the same target plus a DNA-damaging species may induce sustained growth inhibitory effect in EGFR-overexpressing cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbJ9ASdjBjlLVg90H21EOLACvtfcHk0ljG93HmbZMhpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsV2qsLY%253D&md5=c10a7f1cc231cbf64fbe468e89df26d7</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.039099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.039099%26sid%3Dliteratum%253Aachs%26aulast%3DBrahimi%26aufirst%3DF.%26aulast%3DMatheson%26aufirst%3DS.%2BL.%26aulast%3DDudouit%26aufirst%3DF.%26aulast%3DMcnamee%26aufirst%3DJ.%2BP.%26aulast%3DTari%26aufirst%3DA.%2BM.%26aulast%3DJeanClaude%26aufirst%3DB.%2BJ.%26atitle%3DInhibition%2520of%2520epidermal%2520growth%2520factor%2520receptor-mediated%2520signaling%2520by%2520%25E2%2580%259Ccombi-triazene%25E2%2580%259D%2520BJ2000%252C%2520a%2520new%2520probe%2520for%2520combi-targeting%2520postulates%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D303%26spage%3D238%26epage%3D246%26doi%3D10.1124%2Fjpet.102.039099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katsoulas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachid, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamee, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Claude, B. J.</span></span> <span> </span><span class="NLM_article-title">Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1033</span>â <span class="NLM_lpage">1043</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-07-0179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1158%2F1535-7163.MCT-07-0179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=18483293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvFanurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1033-1043&author=A.+Katsoulasauthor=Z.+Rachidauthor=J.+P.+McNameeauthor=C.+Williamsauthor=B.+J.+Jean-Claude&title=Combi-targeting+concept%3A+an+optimized+single-molecule+dual-targeting+model+for+the+treatment+of+chronic+myelogenous+leukemia&doi=10.1158%2F1535-7163.MCT-07-0179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia</span></div><div class="casAuthors">Katsoulas, Athanasia; Rachid, Zakaria; McNamee, James P.; Williams, Christopher; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1033-1043</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Blockade of Bcr-Abl by the inhibitor Imatinib has proven efficacious in the therapy of chronic myelogenous leukemia (CML).  However resistance to the drug emerges at the advanced phases of the disease.  Therefore, novel therapy models remained to be designed.  We have developed a novel dual targeted agent termed "combi-mol." designed to not only block Bcr-Abl but also damage DNA.  ZRF1, the first optimized prototype of the approach, was "programmed" to degrade into another inhibitor ZRF0 plus a Me diazonium species.  It was â¼2-fold stronger Abl tyrosine kinase inhibitor than Imatinib and a more potent DNA-damaging agent than Temodal.  In the p53 wild-type Mo7p210 cells, the potency of ZRF1 was â¼1,000-fold superior to that of the equieffective combinations of Imatinib plus Temodal.  More importantly, its superior potency over Imatinib was more pronounced in Bcr-Abl-pos. cells coexpressing wild-type p53.  Studies to rationalize these results showed that, through its Bcr-Abl inhibitory function, it down-regulated p53.  However, sufficient level of the latter protein was available for transactivating p21 and Bax, which are required for cell cycle arrest and apoptosis.  The results suggest that, in p53 wild-type cells, apoptosis is induced not only through Bcr-Abl inhibition but also through the p53-controlled DNA-damaging pathway, leading to an additive effect that translates into enhanced cell death.  The study conclusively showed that p53 is a major determinant for the cytotoxic advantages of the novel combi-mol. approach in CML, a disease in which 70% to 85% of all the cases express wild-type p53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3Jd6SPmBpWLVg90H21EOLACvtfcHk0ljG93HmbZMhpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvFanurk%253D&md5=111e62c06bf9a6930449308ff354294f</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0179%26sid%3Dliteratum%253Aachs%26aulast%3DKatsoulas%26aufirst%3DA.%26aulast%3DRachid%26aufirst%3DZ.%26aulast%3DMcNamee%26aufirst%3DJ.%2BP.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DCombi-targeting%2520concept%253A%2520an%2520optimized%2520single-molecule%2520dual-targeting%2520model%2520for%2520the%2520treatment%2520of%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1033%26epage%3D1043%26doi%3D10.1158%2F1535-7163.MCT-07-0179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. P.</span></span> <span> </span><span class="NLM_article-title">Multi-target drug design strategy and its research progress</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2012</span>â <span class="NLM_lpage">2025</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2018&pages=2012-2025&author=J.+T.+Zhouauthor=X.+Y.+Jiangauthor=F.+Fengauthor=H.+P.+Sun&title=Multi-target+drug+design+strategy+and+its+research+progress"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%2BT.%26aulast%3DJiang%26aufirst%3DX.%2BY.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DH.%2BP.%26atitle%3DMulti-target%2520drug%2520design%2520strategy%2520and%2520its%2520research%2520progress%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2018%26volume%3D53%26spage%3D2012%26epage%3D2025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benson, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pershadsingh, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chittiboyina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pravenec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, T. W.</span></span> <span> </span><span class="NLM_article-title">Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARÎ³-modulating activity</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">993</span>â <span class="NLM_lpage">1002</span>, <span class="refDoi">Â DOI: 10.1161/01.HYP.0000123072.34629.57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1161%2F01.HYP.0000123072.34629.57" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=15007034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1GmtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=993-1002&author=S.+C.+Bensonauthor=H.+A.+Pershadsinghauthor=C.+I.+Hoauthor=A.+Chittiboyinaauthor=P.+Desaiauthor=M.+Pravenecauthor=N.+Qiauthor=J.+Wangauthor=M.+A.+Averyauthor=T.+W.+Kurtz&title=Identification+of+telmisartan+as+a+unique+angiotensin+II+receptor+antagonist+with+selective+PPAR%CE%B3-modulating+activity&doi=10.1161%2F01.HYP.0000123072.34629.57"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARÎ³-Modulating Activity</span></div><div class="casAuthors">Benson, Stephen C.; Pershadsingh, Harrihar A.; Ho, Christopher I.; Chittiboyina, Amar; Desai, Prashant; Pravenec, Michal; Qi, Nianning; Wang, Jiaming; Avery, Mitchell A.; Kurtz, Theodore W.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">993-1002</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The metabolic syndrome is a common precursor of cardiovascular disease and type 2 diabetes that is characterized by the clustering of insulin resistance, dyslipidemia, and increased blood pressure.  In humans, mutations in the peroxisome proliferator-activated receptor-Î³ (PPARÎ³) have been reported to cause the full-blown metabolic syndrome, and drugs that activate PPARÎ³ have proven to be effective agents for the prevention and treatment of insulin resistance and type 2 diabetes.  Here the authors report that telmisartan, a structurally unique angiotensin II receptor antagonist used for the treatment of hypertension, can function as a partial agonist of PPARÎ³; influence the expression of PPARÎ³ target genes involved in carbohydrate and lipid metab.; and reduce glucose, insulin, and triglyceride levels in rats fed a high-fat, high-carbohydrate diet.  None of the other com. available angiotensin II receptor antagonists appeared to activate PPARÎ³ when tested at concns. typically achieved in plasma with conventional oral dosing.  In contrast to ordinary antihypertensive and antidiabetic agents, mols. that can simultaneously block the angiotensin II receptor and activate PPARÎ³ have the potential to treat both hemodynamic and biochem. features of the metabolic syndrome and could provide unique opportunities for the prevention and treatment of diabetes and cardiovascular disease in high-risk populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVMnSBXhf_gLVg90H21EOLACvtfcHk0lgSg-4uExGlhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1GmtrY%253D&md5=9f3075e771df41d59ac75d2e78ac304b</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.0000123072.34629.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.0000123072.34629.57%26sid%3Dliteratum%253Aachs%26aulast%3DBenson%26aufirst%3DS.%2BC.%26aulast%3DPershadsingh%26aufirst%3DH.%2BA.%26aulast%3DHo%26aufirst%3DC.%2BI.%26aulast%3DChittiboyina%26aufirst%3DA.%26aulast%3DDesai%26aufirst%3DP.%26aulast%3DPravenec%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAvery%26aufirst%3DM.%2BA.%26aulast%3DKurtz%26aufirst%3DT.%2BW.%26atitle%3DIdentification%2520of%2520telmisartan%2520as%2520a%2520unique%2520angiotensin%2520II%2520receptor%2520antagonist%2520with%2520selective%2520PPAR%25CE%25B3-modulating%2520activity%26jtitle%3DHypertension%26date%3D2004%26volume%3D43%26spage%3D993%26epage%3D1002%26doi%3D10.1161%2F01.HYP.0000123072.34629.57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kroker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruning, J. B.</span></span> <span> </span><span class="NLM_article-title">Review of the structural and dynamic mechanisms of PPARÎ³ partial agonism</span>. <i>PPAR Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi">Â DOI: 10.1155/2015/816856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1155%2F2015%2F816856" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=1&author=A.+J.+Krokerauthor=J.+B.+Bruning&title=Review+of+the+structural+and+dynamic+mechanisms+of+PPAR%CE%B3+partial+agonism&doi=10.1155%2F2015%2F816856"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1155%2F2015%2F816856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F816856%26sid%3Dliteratum%253Aachs%26aulast%3DKroker%26aufirst%3DA.%2BJ.%26aulast%3DBruning%26aufirst%3DJ.%2BB.%26atitle%3DReview%2520of%2520the%2520structural%2520and%2520dynamic%2520mechanisms%2520of%2520PPAR%25CE%25B3%2520partial%2520agonism%26jtitle%3DPPAR%2520Res.%26date%3D2015%26volume%3D2015%26spage%3D1%26doi%3D10.1155%2F2015%2F816856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niimi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, M.</span></span> <span> </span><span class="NLM_article-title">Structural basis for telmisartan-mediated partial activation of PPARÎ³</span>. <i>Hypertens. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">715</span>â <span class="NLM_lpage">719</span>, <span class="refDoi">Â DOI: 10.1038/hr.2012.17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1038%2Fhr.2012.17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=22357520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVShsL%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=715-719&author=Y.+Amanoauthor=T.+Yamaguchiauthor=K.+Ohnoauthor=T.+Niimiauthor=M.+Oritaauthor=H.+Sakashitaauthor=M.+Takeuchi&title=Structural+basis+for+telmisartan-mediated+partial+activation+of+PPAR%CE%B3&doi=10.1038%2Fhr.2012.17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for telmisartan-mediated partial activation of PPAR gamma</span></div><div class="casAuthors">Amano, Yasushi; Yamaguchi, Tomohiko; Ohno, Kazuki; Niimi, Tatsuya; Orita, Masaya; Sakashita, Hitoshi; Takeuchi, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">715-719</span>CODEN:
                <span class="NLM_cas:coden">HRESE4</span>;
        ISSN:<span class="NLM_cas:issn">0916-9636</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Telmisartan, a selective angiotensin II type 1 receptor blocker, has recently been shown to act as a partial agonist for peroxisome proliferator-activated receptor gamma (PPARÎ³).  To understand how telmisartan partially activates PPARÎ³, we detd. the ternary complex structure of PPARÎ³, telmisartan, and a coactivator peptide from steroid receptor coactivator-1 at a resoln. of 2.18 Ã.  Crystallog. anal. revealed that telmisartan exhibits an unexpected binding mode in which the central benzimidazole ring is engaged in a non-canonical-and suboptimal-hydrogen-bonding network around helix 12 (H12).  This network differs greatly from that obsd. when full-agonists bind with PPARÎ³ and prompt high-coactivator recruitment through H12 stabilized by multiple hydrogen bonds.  Binding with telmisartan results in a less stable H12 that in turn leads to attenuated coactivator binding, thus explaining the mechanism of partial activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD76Y2UnrUDLVg90H21EOLACvtfcHk0lgSg-4uExGlhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVShsL%252FF&md5=1d6ca7d77310cf145825253a5ff9ee5c</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1038%2Fhr.2012.17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fhr.2012.17%26sid%3Dliteratum%253Aachs%26aulast%3DAmano%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DOhno%26aufirst%3DK.%26aulast%3DNiimi%26aufirst%3DT.%26aulast%3DOrita%26aufirst%3DM.%26aulast%3DSakashita%26aufirst%3DH.%26aulast%3DTakeuchi%26aufirst%3DM.%26atitle%3DStructural%2520basis%2520for%2520telmisartan-mediated%2520partial%2520activation%2520of%2520PPAR%25CE%25B3%26jtitle%3DHypertens.%2520Res.%26date%3D2012%26volume%3D35%26spage%3D715%26epage%3D719%26doi%3D10.1038%2Fhr.2012.17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemenz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gust, R.</span></span> <span> </span><span class="NLM_article-title">Characterization of new PPARÎ³ agonists: analysis of telmisartanâs structural components</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">445</span>â <span class="NLM_lpage">456</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.200800285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1002%2Fcmdc.200800285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=19197922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktlSmsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=445-456&author=M.+Goebelauthor=M.+Clemenzauthor=B.+Staelsauthor=T.+Ungerauthor=U.+Kintscherauthor=R.+Gust&title=Characterization+of+new+PPAR%CE%B3+agonists%3A+analysis+of+telmisartan%E2%80%99s+structural+components&doi=10.1002%2Fcmdc.200800285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of new PPARÎ³ agonists: analysis of telmisartan's structural components</span></div><div class="casAuthors">Goebel, Matthias; Clemenz, Markus; Staels, Bart; Unger, Thomas; Kintscher, Ulrich; Gust, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">445-456</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In addn. to a proven efficacy in lowering blood pressure, the AT1 receptor blocker telmisartan has recently been shown to exert pleiotropic effects as a partial agonist of the nuclear peroxisome proliferator-activated receptor gamma (PPARÎ³).  Based on these findings and an excellent side-effect profile, telmisartan may serve as a lead structure for the development of new PPARÎ³ ligands.  Therefore, we analyzed the structural components of telmisartan to identify those necessary for PPARÎ³ activation.  Synthesized compds. were tested in a differentiation assay using 3T3-L1 preadipocytes and a luciferase assay with COS-7 cells transiently transfected with pGal4-hPPARÎ³DEF, pGal5-TK-pGL3 and pRL-CMV.  The data obtained in this structure-activity relation (SAR) study provide the basis for the development of new PPARÎ³ ligands, which could lead to active compds. with a distinct, beneficial pharmacol. profile compared with the existing full agonists.  The basic 1-(biphenyl-4-ylmethyl)-1H-benzimidazole scaffold of telmisartan was identified as an essential moiety with either a carboxylic acid or tetrazole group at the C-2 position of the biphenyl.  For max. potency and activity, the alkyl chain in position 2 requires a min. length of at least two C atoms (Et group), while the Me group at position 4 of the benzimidazole core seems to contribute to partial activity.  An addnl. benzimidazole at position 6 appears to be a further determinant of potency.  Similar conclusions can be drawn for the Me group in position 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxb6_WFCseB7Vg90H21EOLACvtfcHk0lgSg-4uExGlhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktlSmsr4%253D&md5=eaeb7ddf68e80e1c88dc5efa738fce7d</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200800285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200800285%26sid%3Dliteratum%253Aachs%26aulast%3DGoebel%26aufirst%3DM.%26aulast%3DClemenz%26aufirst%3DM.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DKintscher%26aufirst%3DU.%26aulast%3DGust%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520new%2520PPAR%25CE%25B3%2520agonists%253A%2520analysis%2520of%2520telmisartan%25E2%2580%2599s%2520structural%2520components%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D445%26epage%3D456%26doi%3D10.1002%2Fcmdc.200800285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Q.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, W.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.-L.</span></span> <span> </span><span class="NLM_article-title">Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARg</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">25612</span>â <span class="NLM_lpage">25627</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.15778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.18632%2Foncotarget.15778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=28445965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A280%3ADC%252BC1crhsVKhsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=25612-25627&author=J.+Zhangauthor=Q.-Q.+Haoauthor=X.+Liuauthor=Z.+Jingauthor=W.-Q.+Jiaauthor=S.-Q.+Wangauthor=W.-R.+Xuauthor=X.-C.+Chengauthor=R.-L.+Wang&title=Molecular+docking%2C+3D-QSAR+and+structural+optimization+on+imidazo-pyridine+derivatives+dually+targeting+AT1+and+PPARg&doi=10.18632%2Foncotarget.15778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARg</span></div><div class="casAuthors">Zhang Jun; Hao Qing-Qing; Liu Xin; Jing Zhi; Jia Wen-Qing; Wang Shu-Qing; Cheng Xian-Chao; Wang Run-Ling; Xu Wei-Ren</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">25612-25627</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Telmisartan, a bifunctional agent of blood pressure lowering and glycemia reduction, was previously reported to antagonize angiotensin II type 1 (AT1) receptor and partially activate peroxisome proliferator-activated receptor Î³ (PPARÎ³) simultaneously.  Through the modification to telmisartan, researchers designed and obtained imidazo-\pyridine derivatives with the IC50s of 0.49~94.1 nM against AT1 and EC50s of 20~3640 nM towards PPARÎ³ partial activation.  For minutely inquiring the interaction modes with the relevant receptor and analyzing the structure-activity relationships, molecular docking and 3D-QSAR (Quantitative structure-activity relationships) analysis of these imidazo-\pyridines on dual targets were conducted in this work.  Docking approaches of these derivatives with both receptors provided explicit interaction behaviors and excellent matching degree with the binding pockets.  The best CoMFA (Comparative Molecular Field Analysis) models exhibited predictive results of q2=0.553, r2=0.954, SEE=0.127, r2pred=0.779 for AT1 and q2=0.503, r2=1.00, SEE=0.019, r2pred=0.604 for PPARÎ³, respectively.  The contour maps from the optimal model showed detailed information of structural features (steric and electrostatic fields) towards the biological activity.  Combining the bioisosterism with the valuable information from above studies, we designed six molecules with better predicted activities towards AT1 and PPARÎ³ partial activation.  Overall, these results could be useful for designing potential dual AT1 antagonists and partial PPARÎ³ agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFNV941LRTlMScOqQTSkOffW6udTcc2ebQKAWnyahf5Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crhsVKhsw%253D%253D&md5=4d6ca0b4a7fa900370afb5e5e515376c</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.15778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.15778%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DQ.-Q.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DJing%26aufirst%3DZ.%26aulast%3DJia%26aufirst%3DW.-Q.%26aulast%3DWang%26aufirst%3DS.-Q.%26aulast%3DXu%26aufirst%3DW.-R.%26aulast%3DCheng%26aufirst%3DX.-C.%26aulast%3DWang%26aufirst%3DR.-L.%26atitle%3DMolecular%2520docking%252C%25203D-QSAR%2520and%2520structural%2520optimization%2520on%2520imidazo-pyridine%2520derivatives%2520dually%2520targeting%2520AT1%2520and%2520PPARg%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D25612%26epage%3D25627%26doi%3D10.18632%2Foncotarget.15778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gust, R.</span></span> <span> </span><span class="NLM_article-title">Characterization of new PPARÎ³ agonists: benzimidazole derivatives - the importance of position 2</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1136</span>â <span class="NLM_lpage">1142</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.200900067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1002%2Fcmdc.200900067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=19504532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFCntLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=1136-1142&author=M.+Goebelauthor=B.+Staelsauthor=T.+Ungerauthor=U.+Kintscherauthor=R.+Gust&title=Characterization+of+new+PPAR%CE%B3+agonists%3A+benzimidazole+derivatives+-+the+importance+of+position+2&doi=10.1002%2Fcmdc.200900067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of New PPARÎ³ Agonists: Benzimidazole Derivatives - the Importance of Position 2</span></div><div class="casAuthors">Goebel, Matthias; Staels, Bart; Unger, Thomas; Kintscher, Ulrich; Gust, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1136-1142</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Probing SAR: The 1-(biphenyl-4-ylmethyl)-1H-benzo[d]imidazole moiety is known to be an essential structural component of telmisartan for PPARÎ³ activation.  This study focused on the substituents at position 2 of the benzimidazole in an attempt to optimize PPARÎ³ activation.  In particular, the elongation of the alkyl chain and the introduction of an arom. ring system were studied (shown).  The relevance of substituents at C-2 of the central benzimidazole of telmisartan for PPARÎ³ activation has recently been demonstrated, and the most active compd. identified in our previous work, 4'-[(2-propyl-1H-benzo[d]imidazol-1-yl)methyl]biphenyl-2-carboxylic acid (4 a), is used as lead structure in the present study.  Modifications at C-2 included Bu (4 b), iso-Bu (4 c), tert-Bu (4 d), Ph (4 e), benzyl (4 f), phenethyl (4 g), 4-chlorobenzyl (4 h), 4-methoxyphenyl (4 i), and 4-hydroxyphenyl (4 j) moieties.  The compds. were tested in a differentiation assay using 3T3-L1 preadipocytes and a luciferase assay with COS-7 cells, transiently transfected with pGal4-hPPARÎ³DEF, pGal5-TK-pGL3 and pRL-CMV, as established models for the assessment of cellular PPARÎ³ activation.  The activity in the luciferase assay increased in the alkyl series: Pr (4 a) <iso-Bu (4 c) â¤ tert-Bu (4 d) <butyl (4 b).  A Ph group at C-2 led to the most active compd. (4 e) in this study with an EC50 value of 0.27 Î¼M. 4-Hydroxylation of the C-2 Ph group (4 j) drastically decreased the activity (EC50=5.8 Î¼m) presumably due to hydrophilic repulsion.  This assumption was verified by O-methylation to give compd. 4 i, which maintained activity (EC50=0.29 Î¼M).  The weak effect of the benzyl deriv. 4 f (EC50=1.4 Î¼M) was abolished by an addnl. hydrophobic 4-chloro substituent (4 h; EC50=0.55 Î¼M) or an elongation of the alkyl chain between the Ph and the benzimidazole core (4 g; EC50=0.31 Î¼M).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkNWcnWGEbI7Vg90H21EOLACvtfcHk0lgSABsuORmN3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFCntLY%253D&md5=f4344257770e0fb3911ad43ac44de3ec</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900067%26sid%3Dliteratum%253Aachs%26aulast%3DGoebel%26aufirst%3DM.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DKintscher%26aufirst%3DU.%26aulast%3DGust%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520new%2520PPAR%25CE%25B3%2520agonists%253A%2520benzimidazole%2520derivatives%2520-%2520the%2520importance%2520of%2520position%25202%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D1136%26epage%3D1142%26doi%3D10.1002%2Fcmdc.200900067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandholtz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gust, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span> <span> </span><span class="NLM_article-title">Characterization of telmisartan-derived PPARÎ³ agonists: importance of moiety shift from position 6 to 5 on potency, efficacy and cofactor recruitment</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1935</span>â <span class="NLM_lpage">1942</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201200337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1002%2Fcmdc.201200337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=24155042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFyjs73P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1935-1942&author=L.+Herbstauthor=M.+Goebelauthor=S.+Bandholtzauthor=R.+Gustauthor=U.+Kintscher&title=Characterization+of+telmisartan-derived+PPAR%CE%B3+agonists%3A+importance+of+moiety+shift+from+position+6+to+5+on+potency%2C+efficacy+and+cofactor+recruitment&doi=10.1002%2Fcmdc.201200337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Telmisartan-Derived PPARÎ³ Agonists: Importance of Moiety Shift from Position 6 to 5 on Potency, Efficacy and Cofactor Recruitment</span></div><div class="casAuthors">Herbst, Lena; Goebel, Matthias; Bandholtz, Sebastian; Gust, Ronald; Kintscher, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1935-1942, S1935/1-S1935/2</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Selective modulation of the peroxisome proliferator-activated receptor gamma (PPARÎ³) by direct binding of small mols. demonstrates a promising tool for treatment of insulin resistance and type 2 diabetes mellitus.  Besides its blood pressure-lowering properties, the AT1-receptor blocker telmisartan has been shown to be a partial agonist of PPARÎ³ with beneficial metabolic effects in vitro and in mice.  In our previous work, comprehensive structure-activity relationship (SAR) studies discussed the different parts of the telmisartan structure and various moieties.  Based on these findings, we designed and synthesized new PPARÎ³ ligands with a benzimidazole (agonists 4-5 and 4-6), benzothiophene (agonists 5-5 and 5-6) or benzofuran (agonists 6-5 and 6-6) moiety either at position 5 or 6 of the benzimidazole core structure.  Lipophilicity and EC50 values were improved for all new compds. compared with telmisartan.  Regarding PPARÎ³ activation, the compds. were characterized by a differentiation assay using 3T3-L1 cells and a luciferase assay with COS-7 cells transiently transfected with pGal4-hPPARgDEF, pGal5-TK-pGL3 and pRL-CMV.  A decrease in both potency and efficacy was obsd. after the shift of either the benzothiophene or the benzofuran moiety from position 6 to position 5.  Selective recruitment of the coactivators TRAP220, SRC-1 and PGC-1Î±, and release of corepressor NCoR1 detd. by time-resolved fluorescence resonance energy transfer (TR-FRET) was detected depending on residues in position 5 or 6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq18_XrltNtqLVg90H21EOLACvtfcHk0lgSABsuORmN3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFyjs73P&md5=5ca7670906a95157cf8710726cfceeaf</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200337%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DL.%26aulast%3DGoebel%26aufirst%3DM.%26aulast%3DBandholtz%26aufirst%3DS.%26aulast%3DGust%26aufirst%3DR.%26aulast%3DKintscher%26aufirst%3DU.%26atitle%3DCharacterization%2520of%2520telmisartan-derived%2520PPAR%25CE%25B3%2520agonists%253A%2520importance%2520of%2520moiety%2520shift%2520from%2520position%25206%2520to%25205%2520on%2520potency%252C%2520efficacy%2520and%2520cofactor%2520recruitment%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D1935%26epage%3D1942%26doi%3D10.1002%2Fcmdc.201200337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolber, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintscher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gust, R.</span></span> <span> </span><span class="NLM_article-title">Characterization of new PPARÎ³ agonists: benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">5885</span>â <span class="NLM_lpage">5895</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2010.06.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmc.2010.06.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=20656494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFOitbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=5885-5895&author=M.+Goebelauthor=G.+Wolberauthor=P.+Marktauthor=B.+Staelsauthor=T.+Ungerauthor=U.+Kintscherauthor=R.+Gust&title=Characterization+of+new+PPAR%CE%B3+agonists%3A+benzimidazole+derivatives-importance+of+positions+5+and+6%2C+and+computational+studies+on+the+binding+mode&doi=10.1016%2Fj.bmc.2010.06.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of new PPARÎ³ agonists: Benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode</span></div><div class="casAuthors">Goebel, Matthias; Wolber, Gerhard; Markt, Patrick; Staels, Bart; Unger, Thomas; Kintscher, Ulrich; Gust, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5885-5895</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this and previous studies we investigated the importance of partial structures of Telmisartan on PPARÎ³ activation.  The biphenyl-4-ylmethyl moiety at N1 and residues at C2 of the central benzimidazole were identified to be essential for receptor activation and potency of receptor binding.  Now we focused our attention on positions 5 and 6 of the central benzimidazole and introduced bromine (3b-5/6, 3c), phenylcarbonyl (3d-5/6), hydroxy(phenyl)methyl (3g-5/6), hydroxymethyl (3h-5/6) and formyl (3i) groups.  The selection of these moieties was inspired by the structure of Losartan and its metabolite EXP3179.  In order to increase the hydrophobicity of the central part of the mol., the benzimidazole was exchanged by a naphtho[2,3-d]imidazole (5).  The compds. 3a-3i and 5 were tested in a differentiation assay using 3T3-L1 preadipocytes and a luciferase assay using COS-7 cells, transiently transfected with pGal4-hPPARÎ³DEF, pGal5-TK-pGL3 and pRL-CMV, as established models for the assessment of cellular PPARÎ³ activation.  An enhanced effect on PPARÎ³ activation could be obsd. if lipophilic moieties are introduced in these positions. 4'-[(2-Propyl-1H-naphtho[2,3-d]imidazol-1-yl)methyl]biphenyl-2-carboxylic acid (5) was identified as the most potent compd. with an EC50 of 0.26 Î¼M and the profile of a full agonist.  Together with compds. of the former structure-activity relationship study (position 2-substituted benzimidazole derivs. 4a-4j), the binding mode of Telmisartan and its derivs. have been analyzed in 3D pharmacophore-driven docking expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYCcUBmRTotbVg90H21EOLACvtfcHk0lhSR7YlUjTSmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFOitbc%253D&md5=04e94f4096fda01c9aec8e5911e00771</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.06.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.06.102%26sid%3Dliteratum%253Aachs%26aulast%3DGoebel%26aufirst%3DM.%26aulast%3DWolber%26aufirst%3DG.%26aulast%3DMarkt%26aufirst%3DP.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DKintscher%26aufirst%3DU.%26aulast%3DGust%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520new%2520PPAR%25CE%25B3%2520agonists%253A%2520benzimidazole%2520derivatives-importance%2520of%2520positions%25205%2520and%25206%252C%2520and%2520computational%2520studies%2520on%2520the%2520binding%2520mode%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D5885%26epage%3D5895%26doi%3D10.1016%2Fj.bmc.2010.06.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamotte, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martres, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laroze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ancellin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saintillan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beneton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampe, R. T.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological activities of novel indole derivatives as potent and selective PPARÎ³ modulators</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1399</span>â <span class="NLM_lpage">1404</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.12.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmcl.2009.12.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=20079636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSmt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1399-1404&author=Y.+Lamotteauthor=P.+Martresauthor=N.+Faucherauthor=A.+Larozeauthor=D.+Grillotauthor=N.+Ancellinauthor=Y.+Saintillanauthor=V.+Benetonauthor=R.+T.+Gampe&title=Synthesis+and+biological+activities+of+novel+indole+derivatives+as+potent+and+selective+PPAR%CE%B3+modulators&doi=10.1016%2Fj.bmcl.2009.12.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological activities of novel indole derivatives as potent and selective PPARÎ³ modulators</span></div><div class="casAuthors">Lamotte, Yann; Martres, Paul; Faucher, Nicolas; Laroze, Alain; Grillot, Didier; Ancellin, Nicolas; Saintillan, Yannick; Beneton, Veronique; Gampe, Robert T., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1399-1404</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Starting from the structure of Telmisartan, a new series of potent and selective PPARÎ³ modulators was identified.  The synthesis, in vitro and in vivo evaluation of the most potent compds. were reported and the X-ray structure of compd. I bound to the PPARÎ³ ligand binding domain was described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWHoAwEeXKBLVg90H21EOLACvtfcHk0lhSR7YlUjTSmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSmt7k%253D&md5=46afddd230373777320d0d96668810ba</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.12.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.12.107%26sid%3Dliteratum%253Aachs%26aulast%3DLamotte%26aufirst%3DY.%26aulast%3DMartres%26aufirst%3DP.%26aulast%3DFaucher%26aufirst%3DN.%26aulast%3DLaroze%26aufirst%3DA.%26aulast%3DGrillot%26aufirst%3DD.%26aulast%3DAncellin%26aufirst%3DN.%26aulast%3DSaintillan%26aufirst%3DY.%26aulast%3DBeneton%26aufirst%3DV.%26aulast%3DGampe%26aufirst%3DR.%2BT.%26atitle%3DSynthesis%2520and%2520biological%2520activities%2520of%2520novel%2520indole%2520derivatives%2520as%2520potent%2520and%2520selective%2520PPAR%25CE%25B3%2520modulators%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1399%26epage%3D1404%26doi%3D10.1016%2Fj.bmcl.2009.12.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asteian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blayo, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruvilla, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corzo, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busby, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marciano, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ordonez, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamenecka, T. M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of indole biphenylcarboxylic acids as PPARÎ³ antagonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">998</span>â <span class="NLM_lpage">1003</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.5b00218</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00218" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1OqsbrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=998-1003&author=A.+Asteianauthor=A.+L.+Blayoauthor=Y.+Heauthor=M.+Koenigauthor=Y.+Shinauthor=D.+S.+Kuruvillaauthor=C.+A.+Corzoauthor=M.+D.+Cameronauthor=L.+Linauthor=C.+Ruizauthor=S.+Khanauthor=N.+Kumarauthor=S.+Busbyauthor=D.+P.+Marcianoauthor=R.+D.+Garcia-Ordonezauthor=P.+R.+Griffinauthor=T.+M.+Kamenecka&title=Design%2C+synthesis%2C+and+biological+evaluation+of+indole+biphenylcarboxylic+acids+as+PPAR%CE%B3+antagonists&doi=10.1021%2Facsmedchemlett.5b00218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Indole Biphenylcarboxylic Acids as PPARÎ³ Antagonists</span></div><div class="casAuthors">Asteian, Alice; Blayo, Anne-Laure; He, Yuanjun; Koenig, Marcel; Shin, Youseung; Kuruvilla, Dana S.; Corzo, Cesar A.; Cameron, Michael D.; Lin, Li; Ruiz, Claudia; Khan, Susan; Kumar, Naresh; Busby, Scott; Marciano, David P.; Garcia-Ordonez, Ruben D.; Griffin, Patrick R.; Kamenecka, Theodore M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">998-1003</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The thiazolidinediones (TZD) typified by rosiglitazone are the only approved therapeutics targeting PPARÎ³ for the treatment of type-2 diabetes (T2DM).  Unfortunately, despite robust insulin sensitizing properties, they are accompanied by a no. of severe side effects including congestive heart failure, edema, wt. gain, and osteoporosis.  We recently identified PPARÎ³ antagonists that bind reversibly with high affinity but do not induce transactivation of the receptor, yet they act as insulin sensitizers in mouse models of diabetes (SR1664).  This Letter details our synthetic exploration around this novel series of PPARÎ³ antagonists based on an N-biphenylmethylindole scaffold.  Structure-activity relationship studies led to the identification of compd. I as a high affinity PPARÎ³ antagonist that exhibits antidiabetic properties following oral administration in diet-induced obese mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4gdyYHx7BVLVg90H21EOLACvtfcHk0lhSR7YlUjTSmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1OqsbrM&md5=14a7474d13ff91dd8f68adc9a20fdc5b</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00218%26sid%3Dliteratum%253Aachs%26aulast%3DAsteian%26aufirst%3DA.%26aulast%3DBlayo%26aufirst%3DA.%2BL.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DKoenig%26aufirst%3DM.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DKuruvilla%26aufirst%3DD.%2BS.%26aulast%3DCorzo%26aufirst%3DC.%2BA.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DRuiz%26aufirst%3DC.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DBusby%26aufirst%3DS.%26aulast%3DMarciano%26aufirst%3DD.%2BP.%26aulast%3DGarcia-Ordonez%26aufirst%3DR.%2BD.%26aulast%3DGriffin%26aufirst%3DP.%2BR.%26aulast%3DKamenecka%26aufirst%3DT.%2BM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520indole%2520biphenylcarboxylic%2520acids%2520as%2520PPAR%25CE%25B3%2520antagonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D998%26epage%3D1003%26doi%3D10.1021%2Facsmedchemlett.5b00218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filzen, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigge, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmunds, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmaeil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heemstra, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalaie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohren, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostroski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaum, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoner, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-Î³</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4219</span>â <span class="NLM_lpage">4233</span>, <span class="refDoi">Â DOI: 10.1021/jm200409s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200409s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGls78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4219-4233&author=A.+Casimiro-Garciaauthor=G.+F.+Filzenauthor=D.+Flynnauthor=C.+F.+Biggeauthor=J.+Chenauthor=J.+A.+Davisauthor=D.+A.+Dudleyauthor=J.+J.+Edmundsauthor=N.+Esmaeilauthor=A.+Geyerauthor=R.+J.+Heemstraauthor=M.+Jalaieauthor=J.+F.+Ohrenauthor=R.+Ostroskiauthor=T.+Ellisauthor=R.+P.+Schaumauthor=C.+Stoner&title=Discovery+of+a+series+of+imidazo%5B4%2C5-b%5Dpyridines+with+dual+activity+at+angiotensin+II+type+1+receptor+and+peroxisome+proliferator-activated+receptor-%CE%B3&doi=10.1021%2Fjm200409s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Series of Imidazo[4,5-b]pyridines with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-Î³</span></div><div class="casAuthors">Casimiro-Garcia, Agustin; Filzen, Gary F.; Flynn, Declan; Bigge, Christopher F.; Chen, Jing; Davis, Jo Ann; Dudley, Danette A.; Edmunds, Jeremy J.; Esmaeil, Nadia; Geyer, Andrew; Heemstra, Ronald J.; Jalaie, Mehran; Ohren, Jeffrey F.; Ostroski, Robert; Ellis, Teresa; Schaum, Robert P.; Stoner, Chad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4219-4233</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mining of an inhouse collection of angiotensin II type 1 receptor antagonists to identify compds. with activity at the peroxisome proliferator-activated receptor-Î³ (PPARÎ³) revealed a new series of imidazo[4,5-b]pyridines 2 possessing activity at these two receptors.  Early availability of the crystal structure of the lead compd. bound to the ligand binding domain of human PPARÎ³ confirmed the mode of interaction of this scaffold to the nuclear receptor and assisted in the optimization of PPARÎ³ activity.  Among the new compds., (S)-3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2-ethyl-5-isobutyl-7-methyl-3H-imidazo[4,5-b]pyridine (I) was identified as a potent angiotensin II type I receptor blocker (IC50 = 1.6 nM) with partial PPARÎ³ agonism (EC50 = 212 nM, 31% max) and oral bioavailability in rat.  The dual pharmacol. of I was demonstrated in animal models of hypertension (SHR) and insulin resistance (ZDF rat).  In the SHR, I was highly efficacious in lowering blood pressure, while robust lowering of glucose and triglycerides was obsd. in the male ZDF rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMdOow5t9CALVg90H21EOLACvtfcHk0lgKkgQFtqF0ig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGls78%253D&md5=cd55be8d481fccc319ca10c7a2ca2d8b</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Fjm200409s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200409s%26sid%3Dliteratum%253Aachs%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26aulast%3DFilzen%26aufirst%3DG.%2BF.%26aulast%3DFlynn%26aufirst%3DD.%26aulast%3DBigge%26aufirst%3DC.%2BF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DJ.%2BA.%26aulast%3DDudley%26aufirst%3DD.%2BA.%26aulast%3DEdmunds%26aufirst%3DJ.%2BJ.%26aulast%3DEsmaeil%26aufirst%3DN.%26aulast%3DGeyer%26aufirst%3DA.%26aulast%3DHeemstra%26aufirst%3DR.%2BJ.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DOhren%26aufirst%3DJ.%2BF.%26aulast%3DOstroski%26aufirst%3DR.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DSchaum%26aufirst%3DR.%2BP.%26aulast%3DStoner%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520a%2520series%2520of%2520imidazo%255B4%252C5-b%255Dpyridines%2520with%2520dual%2520activity%2520at%2520angiotensin%2520II%2520type%25201%2520receptor%2520and%2520peroxisome%2520proliferator-activated%2520receptor-%25CE%25B3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4219%26epage%3D4233%26doi%3D10.1021%2Fjm200409s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heemstra, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigge, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciske, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmaeil, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalaie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohren, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, N. A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-Î³</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">767</span>â <span class="NLM_lpage">772</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2012.11.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.bmcl.2012.11.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=23265881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVyhsLfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=767-772&author=A.+Casimiro-Garciaauthor=R.+J.+Heemstraauthor=C.+F.+Biggeauthor=J.+Chenauthor=F.+A.+Ciskeauthor=J.+A.+Davisauthor=T.+Ellisauthor=N.+Esmaeilauthor=D.+Flynnauthor=S.+Hanauthor=M.+Jalaieauthor=J.+F.+Ohrenauthor=N.+A.+Powell&title=Design%2C+synthesis%2C+and+evaluation+of+imidazo%5B4%2C5-c%5Dpyridin-4-one+derivatives+with+dual+activity+at+angiotensin+II+type+1+receptor+and+peroxisome+proliferator-activated+receptor-%CE%B3&doi=10.1016%2Fj.bmcl.2012.11.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-Î³</span></div><div class="casAuthors">Casimiro-Garcia, Agustin; Heemstra, Ronald J.; Bigge, Christopher F.; Chen, Jing; Ciske, Fred A.; Davis, Jo Ann; Ellis, Teresa; Esmaeil, Nadia; Flynn, Declan; Han, Seungil; Jalaie, Mehran; Ohren, Jeffrey F.; Powell, Noel A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">767-772</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Identification of a series of imidazo[4,5-c]pyridin-4-one derivs., e.g., I and II, that act as dual angiotensin II type 1 (AT1) receptor antagonists and peroxisome proliferator-activated receptor-Î³ (PPARÎ³) partial agonists is described.  Starting from a known AT1 antagonist template, conformational restriction was introduced by incorporation of an indane ring that when combined with appropriate substitution at the imidazo[4,5-c]pyridin-4-one provided a novel series possessing the desired dual activity.  The mode of interaction of this series with PPARÎ³ was corroborated through the X-ray crystal structure of I bound to the human PPARÎ³ ligand binding domain.  Modulation of activity at both receptors through substitution at the pyridone nitrogen led to the identification of potent dual AT1 antagonists/PPARÎ³ partial agonists.  Among them, II was identified possessing potent dual pharmacol. (AT1 IC50 = 7 nM; PPARÎ³ EC50 = 295 nM, 27% max) and good ADME properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOIcJ8jeqs_LVg90H21EOLACvtfcHk0lgKkgQFtqF0ig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVyhsLfL&md5=9b0e0040ee11355d29fdfa7b3dad3427</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.088%26sid%3Dliteratum%253Aachs%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26aulast%3DHeemstra%26aufirst%3DR.%2BJ.%26aulast%3DBigge%26aufirst%3DC.%2BF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCiske%26aufirst%3DF.%2BA.%26aulast%3DDavis%26aufirst%3DJ.%2BA.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DEsmaeil%26aufirst%3DN.%26aulast%3DFlynn%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DOhren%26aufirst%3DJ.%2BF.%26aulast%3DPowell%26aufirst%3DN.%2BA.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520imidazo%255B4%252C5-c%255Dpyridin-4-one%2520derivatives%2520with%2520dual%2520activity%2520at%2520angiotensin%2520II%2520type%25201%2520receptor%2520and%2520peroxisome%2520proliferator-activated%2520receptor-%25CE%25B3%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D767%26epage%3D772%26doi%3D10.1016%2Fj.bmcl.2012.11.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menear, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adcock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockcroft, X.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copsey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cranston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drzewiecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javaid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerrigan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knights, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, I. T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. M. B.</span></span> <span> </span><span class="NLM_article-title">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">6581</span>â <span class="NLM_lpage">6591</span>, <span class="refDoi">Â DOI: 10.1021/jm8001263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8001263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6581-6591&author=K.+A.+Menearauthor=C.+Adcockauthor=R.+Boulterauthor=X.-l.+Cockcroftauthor=L.+Copseyauthor=A.+Cranstonauthor=K.+J.+Dillonauthor=J.+Drzewieckiauthor=S.+Garmanauthor=S.+Gomezauthor=H.+Javaidauthor=F.+Kerriganauthor=C.+Knightsauthor=A.+Lauauthor=V.+M.+Lohauthor=I.+T.+W.+Matthewsauthor=S.+Mooreauthor=M.+J.+O%E2%80%99Connorauthor=G.+C.+M.+Smithauthor=N.+M.+B.+Martin&title=4-%5B3-%284-Cyclopropanecarbonylpiperazine-1-carbonyl%29-4-fluorobenzyl%5D-2H-phthalazin-1-one%3A+A+Novel+Bioavailable+Inhibitor+of+Poly%28ADP-ribose%29+Polymerase-1&doi=10.1021%2Fjm8001263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1</span></div><div class="casAuthors">Menear, Keith A.; Adcock, Claire; Boulter, Robert; Cockcroft, Xiao-ling; Copsey, Louise; Cranston, Aaron; Dillon, Krystyna J.; Drzewiecki, Jan; Garman, Sheila; Gomez, Sylvie; Javaid, Hashim; Kerrigan, Frank; Knights, Charlotte; Lau, Alan; Loh, Vincent M., Jr.; Matthews, Ian T. W.; Moore, Stephen; O'Connor, Mark J.; Smith, Graeme C. M.; Martin, Niall M. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6581-6591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase activation is an immediate cellular response to metabolic-, chem.-, or ionizing radiation-induced DNA damage and represents a new target for cancer therapy.  In this article, we disclose a novel series of substituted 4-benzyl-2H-phthalazin-1-ones that possess high inhibitory enzyme and cellular potency for both PARP-1 and PARP-2.  Optimized compds. from the series also demonstrate good pharmacokinetic profiles, oral bioavailability, and activity in vivo in an SW620 colorectal cancer xenograft model. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one (KU-0059436, AZD2281) 47 is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines.  Compd. 47 is currently undergoing clin. development for the treatment of BRCA1- and BRCA2-defective cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IKtdcfeWCbVg90H21EOLACvtfcHk0ljLoHWZI3TFMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs7vE&md5=45aff9bb506360ec26c1c0039388240e</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1021%2Fjm8001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001263%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DAdcock%26aufirst%3DC.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCockcroft%26aufirst%3DX.-l.%26aulast%3DCopsey%26aufirst%3DL.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DMatthews%26aufirst%3DI.%2BT.%2BW.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26atitle%3D4-%255B3-%25284-Cyclopropanecarbonylpiperazine-1-carbonyl%2529-4-fluorobenzyl%255D-2H-phthalazin-1-one%253A%2520A%2520Novel%2520Bioavailable%2520Inhibitor%2520of%2520Poly%2528ADP-ribose%2529%2520Polymerase-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6581%26epage%3D6591%26doi%3D10.1021%2Fjm8001263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dawicki-McKenna, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langelier, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeNizio, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccio, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karch, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascal, J. M.</span></span> <span> </span><span class="NLM_article-title">PARP-1 activation requires local unfolding of an autoinhibitory domain</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">755</span>â <span class="NLM_lpage">768</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2015.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.molcel.2015.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=26626480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFagurvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2015&pages=755-768&author=J.+M.+Dawicki-McKennaauthor=M.-F.+Langelierauthor=J.+E.+DeNizioauthor=A.+A.+Riccioauthor=C.+D.+Caoauthor=K.+R.+Karchauthor=M.+McCauleyauthor=J.+D.+Steffenauthor=B.+E.+Blackauthor=J.+M.+Pascal&title=PARP-1+activation+requires+local+unfolding+of+an+autoinhibitory+domain&doi=10.1016%2Fj.molcel.2015.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain</span></div><div class="casAuthors">Dawicki-McKenna, Jennine M.; Langelier, Marie-France; DeNizio, Jamie E.; Riccio, Amanda A.; Cao, Connie D.; Karch, Kelly R.; McCauley, Michael; Steffen, Jamin D.; Black, Ben E.; Pascal, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">755-768</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase-1 (PARP-1) creates the posttranslational modification PAR from substrate NAD+ to regulate multiple cellular processes.  DNA breaks sharply elevate PARP-1 catalytic activity to mount a cell survival repair response, whereas persistent PARP-1 hyperactivation during severe genotoxic stress is assocd. with cell death.  The mechanism for tight control of the robust catalytic potential of PARP-1 remains unclear.  By monitoring PARP-1 dynamics using hydrogen/deuterium exchange-mass spectrometry (HXMS), we unexpectedly find that a specific portion of the helical subdomain (HD) of the catalytic domain rapidly unfolds when PARP-1 encounters a DNA break.  Together with biochem. and crystallog. anal. of HD deletion mutants, we show that the HD is an autoinhibitory domain that blocks productive NAD+ binding.  Our mol. model explains how PARP-1 DNA damage detection leads to local unfolding of the HD that relieves autoinhibition, and has important implications for the design of PARP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJje_1KBikFbVg90H21EOLACvtfcHk0ljLoHWZI3TFMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFagurvK&md5=cf24c86d7d942be40929b8aee2d797c7</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2015.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2015.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DDawicki-McKenna%26aufirst%3DJ.%2BM.%26aulast%3DLangelier%26aufirst%3DM.-F.%26aulast%3DDeNizio%26aufirst%3DJ.%2BE.%26aulast%3DRiccio%26aufirst%3DA.%2BA.%26aulast%3DCao%26aufirst%3DC.%2BD.%26aulast%3DKarch%26aufirst%3DK.%2BR.%26aulast%3DMcCauley%26aufirst%3DM.%26aulast%3DSteffen%26aufirst%3DJ.%2BD.%26aulast%3DBlack%26aufirst%3DB.%2BE.%26aulast%3DPascal%26aufirst%3DJ.%2BM.%26atitle%3DPARP-1%2520activation%2520requires%2520local%2520unfolding%2520of%2520an%2520autoinhibitory%2520domain%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D60%26spage%3D755%26epage%3D768%26doi%3D10.1016%2Fj.molcel.2015.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel dual poly(adp-ribose)polymerase and phosphoinositide 3-kinase inhibitors as a promising strategy for cancer therapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">122</span>â <span class="NLM_lpage">139</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b00622</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00622" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVWqsL%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=122-139&author=J.+Wangauthor=H.+Liauthor=G.+Heauthor=Z.+Chuauthor=K.+Pengauthor=Y.+Geauthor=Q.+Zhuauthor=Y.+Xu&title=Discovery+of+novel+dual+poly%28adp-ribose%29polymerase+and+phosphoinositide+3-kinase+inhibitors+as+a+promising+strategy+for+cancer+therapy&doi=10.1021%2Facs.jmedchem.9b00622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy</span></div><div class="casAuthors">Wang, Junwei; Li, Hui; He, Guangchao; Chu, Zhaoxing; Peng, Kewen; Ge, Yiran; Zhu, Qihua; Xu, Yungen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">122-139</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of PARP and PI3K pathways has been recognized as a promising strategy for cancer therapy, which may expand the clin. utility of PARP inhibitors.  Herein, we report the discovery of dual PARP/PI3K inhibitors that merge the pharmacophores of PARP and PI3K inhibitors.  Among them, compd. 15 stands out as the most promising candidate with potent inhibitory activities against both PARP-1/2 and PI3KÎ±/Î´ with pIC50 values greater than 8.  Compd. 15 displayed superior antiproliferative profiles against both BRCA-deficient and BRCA-proficient cancer cells in cellular assays.  The prominent synergistic effects produced by the concomitant inhibition of the two targets were elucidated by comprehensive biochem. and cellular mechanistic studies.  In vivo, 15 showed more efficacious antitumor activity than the corresponding drug combination (Olaparib + BKM120) in the MDA-MB-468 xenograft model with a tumor growth inhibitory rate of 73.4% without causing observable toxic effects.  All of the results indicate that 15, a first potent dual PARP/PI3K inhibitor, is a highly effective anticancer compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWkhMLZTxXSLVg90H21EOLACvtfcHk0ljLoHWZI3TFMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVWqsL%252FF&md5=e6e0472af7ddb346c311c5e01483b370</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00622%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DChu%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DK.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520dual%2520poly%2528adp-ribose%2529polymerase%2520and%2520phosphoinositide%25203-kinase%2520inhibitors%2520as%2520a%2520promising%2520strategy%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D122%26epage%3D139%26doi%3D10.1021%2Facs.jmedchem.9b00622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atallah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haznedar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaror, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">774</span>â <span class="NLM_lpage">779</span>, <span class="refDoi">Â DOI: 10.1021/ml200156t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200156t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=774-779&author=M.+T.+Burgerauthor=S.+Pecchiauthor=A.+Wagmanauthor=Z.-J.+Niauthor=M.+Knappauthor=T.+Hendricksonauthor=G.+Atallahauthor=K.+Pfisterauthor=Y.+Zhangauthor=S.+Bartulisauthor=K.+Frazierauthor=S.+Ngauthor=A.+Smithauthor=J.+Verhagenauthor=J.+Haznedarauthor=K.+Huhauthor=E.+Iwanowiczauthor=X.+Xinauthor=D.+Menezesauthor=H.+Merrittauthor=I.+Leeauthor=M.+Wiesmannauthor=S.+Kaufmanauthor=K.+Crawfordauthor=M.+Chinauthor=D.+Bussiereauthor=K.+Shoemakerauthor=I.+Zarorauthor=S.-M.+Mairaauthor=C.+F.+Voliva&title=Identification+of+NVP-BKM120+as+a+potent%2C+selective%2C+orally+bioavailable+class+I+PI3+kinase+inhibitor+for+treating+cancer&doi=10.1021%2Fml200156t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span></div><div class="casAuthors">Burger, Matthew T.; Pecchi, Sabina; Wagman, Allan; Ni, Zhi-Jie; Knapp, Mark; Hendrickson, Thomas; Atallah, Gordana; Pfister, Keith; Zhang, Yanchen; Bartulis, Sarah; Frazier, Kelly; Ng, Simon; Smith, Aaron; Verhagen, Joelle; Haznedar, Joshua; Huh, Kay; Iwanowicz, Ed; Xin, Xiaohua; Menezes, Daniel; Merritt, Hanne; Lee, Isabelle; Wiesmann, Marion; Kaufman, Susan; Crawford, Kenneth; Chin, Michael; Bussiere, Dirksen; Shoemaker, Kevin; Zaror, Isabel; Maira, Sauveur-Michel; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">774-779</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinases (PI3Ks) are important oncol. targets due to the deregulation of this signaling pathway in a wide variety of human cancers.  Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent.  The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma).  These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJ68B9pPbMbVg90H21EOLACvtfcHk0lj8vV8uUlC0jQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI&md5=5d00d73dda1fc0d8f0f07d12900282ed</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1021%2Fml200156t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200156t%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DWagman%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DZ.-J.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DHendrickson%26aufirst%3DT.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBartulis%26aufirst%3DS.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DHaznedar%26aufirst%3DJ.%26aulast%3DHuh%26aufirst%3DK.%26aulast%3DIwanowicz%26aufirst%3DE.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DZaror%26aufirst%3DI.%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520of%2520NVP-BKM120%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520class%2520I%2520PI3%2520kinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D774%26epage%3D779%26doi%3D10.1021%2Fml200156t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ChÃ¨ne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martiny-Baron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GarcÃ­a-EcheverrÃ­a, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of nvp-bkm120, an orally available pan-class i PI3-kinase inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">317</span>â <span class="NLM_lpage">328</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-11-0474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1158%2F1535-7163.MCT-11-0474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=22188813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWltb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=317-328&author=S.-M.+Mairaauthor=S.+Pecchiauthor=A.+Huangauthor=M.+Burgerauthor=M.+Knappauthor=D.+Sterkerauthor=C.+Schnellauthor=D.+Guthyauthor=T.+Nagelauthor=M.+Wiesmannauthor=S.+Brachmannauthor=C.+Fritschauthor=M.+Dorschauthor=P.+Ch%C3%A8neauthor=K.+Shoemakerauthor=A.+De+Poverauthor=D.+Menezesauthor=G.+Martiny-Baronauthor=D.+Fabbroauthor=C.+J.+Wilsonauthor=R.+Schlegelauthor=F.+Hofmannauthor=C.+Garc%C3%ADa-Echeverr%C3%ADaauthor=W.+R.+Sellersauthor=C.+F.+Voliva&title=Identification+and+characterization+of+nvp-bkm120%2C+an+orally+available+pan-class+i+PI3-kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-11-0474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor</span></div><div class="casAuthors">Maira, Sauveur-Michel; Pecchi, Sabina; Huang, Alan; Burger, Matthew; Knapp, Mark; Sterker, Dario; Schnell, Christian; Guthy, Daniel; Nagel, Tobi; Wiesmann, Marion; Brachmann, Saskia; Fritsch, Christine; Dorsch, Marion; Chene, Patrick; Shoemaker, Kevin; De Pover, Alain; Menezes, Daniel; Martiny-Baron, Georg; Fabbro, Doriano; Wilson, Christopher J.; Schlegel, Robert; Hofmann, Francesco; Garcia-Echeverria, Carlos; Sellers, William R.; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">317-328</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Following the discovery of NVP-BEZ235, our first dual pan-PI3K/mTOR clin. compd., we sought to identify addnl. phosphoinositide 3-kinase (PI3K) inhibitors from different chem. classes with a different selectivity profile.  The key to achieve these objectives was to couple a structure-based design approach with intensive pharmacol. evaluation of selected compds. during the medicinal chem. optimization process.  Here, we report on the biol. characterization of the 2-morpholino pyrimidine deriv. pan-PI3K inhibitor NVP-BKM120.  This compd. inhibits all four class I PI3K isoforms in biochem. assays with at least 50-fold selectivity against other protein kinases.  The compd. is also active against the most common somatic PI3KÎ± mutations but does not significantly inhibit the related class III (Vps34) and class IV (mTOR, DNA-PK) PI3K kinases.  Consistent with its mechanism of action, NVP-BKM120 decreases the cellular levels of p-Akt in mechanistic models and relevant tumor cell lines, as well as downstream effectors in a concn.-dependent and pathway-specific manner.  Tested in a panel of 353 cell lines, NVP-BKM120 exhibited preferential inhibition of tumor cells bearing PIK3CA mutations, in contrast to either KRAS or PTEN mutant models.  NVP-BKM120 shows dose-dependent in vivo pharmacodynamic activity as measured by significant inhibition of p-Akt and tumor growth inhibition in mechanistic xenograft models.  NVP-BKM120 behaves synergistically when combined with either targeted agents such as MEK or HER2 inhibitors or with cytotoxic agents such as docetaxel or temozolomide.  The pharmacol., biol., and preclin. safety profile of NVP-BKM120 supports its clin. development and the compd. is undergoing phase II clin. trials in patients with cancer.  Mol Cancer Ther; 11(2); 317-28.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps2mNHzJneaLVg90H21EOLACvtfcHk0lj8vV8uUlC0jQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWltb8%253D&md5=4c3b225d45591e9cd49800baa06e8152</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0474%26sid%3Dliteratum%253Aachs%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DBurger%26aufirst%3DM.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DGuthy%26aufirst%3DD.%26aulast%3DNagel%26aufirst%3DT.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DBrachmann%26aufirst%3DS.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DDorsch%26aufirst%3DM.%26aulast%3DCh%25C3%25A8ne%26aufirst%3DP.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMartiny-Baron%26aufirst%3DG.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DGarc%25C3%25ADa-Echeverr%25C3%25ADa%26aufirst%3DC.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520nvp-bkm120%252C%2520an%2520orally%2520available%2520pan-class%2520i%2520PI3-kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D317%26epage%3D328%26doi%3D10.1158%2F1535-7163.MCT-11-0474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuckowree, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouge, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7579</span>â <span class="NLM_lpage">7587</span>, <span class="refDoi">Â DOI: 10.1021/jm2009327</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2009327" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7579-7587&author=D.+P.+Sutherlinauthor=L.+Baoauthor=M.+Berryauthor=G.+Castanedoauthor=I.+Chuckowreeauthor=J.+Dotsonauthor=A.+Folksauthor=L.+Friedmanauthor=R.+Goldsmithauthor=J.+Gunznerauthor=T.+Heffronauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=W.+W.+Priorauthor=L.+Rougeauthor=L.+Salphatiauthor=D.+Sampathauthor=Q.+Tianauthor=V.+Tsuiauthor=N.+C.+Wanauthor=S.+Wangauthor=B.+Weiauthor=C.+Wiesmannauthor=P.+Wuauthor=B.-Y.+Zhuauthor=A.+Olivero&title=Discovery+of+a+potent%2C+selective%2C+and+orally+available+class+I+phosphatidylinositol+3-kinase+%28PI3K%29%2Fmammalian+target+of+rapamycin+%28mTOR%29+kinase+inhibitor+%28GDC-0980%29+for+the+treatment+of+cancer&doi=10.1021%2Fjm2009327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer</span></div><div class="casAuthors">Sutherlin, Daniel P.; Bao, Linda; Berry, Megan; Castanedo, Georgette; Chuckowree, Irina; Dotson, Jenna; Folks, Adrian; Friedman, Lori; Goldsmith, Richard; Gunzner, Janet; Heffron, Timothy; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Murray, Jeremy; Nonomiya, Jim; Pang, Jodie; Pegg, Niel; Prior, Wei Wei; Rouge, Lionel; Salphati, Laurent; Sampath, Deepak; Tian, Qingping; Tsui, Vickie; Wan, Nan Chi; Wang, Shumei; Wei, Bin Qing; Wiesmann, Christian; Wu, Ping; Zhu, Bing-Yan; Olivero, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7579-7587</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of 2 (GDC-0980, I), a class I PI3K and mTOR kinase inhibitor for oncol. indications, is described. mTOR inhibition was added to the class I PI3K inhibitor 1 (GDC-0941) scaffold primarily through the substitution of the indazole in 1 for a 2-aminopyrimidine.  This substitution also increased the microsomal stability and the free fraction of compds. as evidenced through a pairwise comparison of mols. that were otherwise identical.  Highlighted in detail are analogs of an advanced compd. 4 that were designed to improve soly., resulting in 2.  This compd., is potent across PI3K class I isoforms with IC50s of 5, 27, 7, and 14 nM for PI3KÎ±, Î², Î´, and Î³, resp., inhibits mTOR with a Ki of 17 nM yet is highly selective vs. a large panel of kinases including others in the PIKK family.  On the basis of the cell potency, low clearance in mouse, and high free fraction, 2 demonstrated significant efficacy in mouse xenografts when dosed as low as 1 mg/kg orally and is currently in phase I clin. trials for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-3-5KDI509bVg90H21EOLACvtfcHk0lh8nDQw2fHxXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ort7%252FJ&md5=ba7ede710885b51fffa63977fc64d3f5</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Fjm2009327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2009327%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolks%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DL.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DHeffron%26aufirst%3DT.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DRouge%26aufirst%3DL.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DQ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DB.-Y.%26aulast%3DOlivero%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520class%2520I%2520phosphatidylinositol%25203-kinase%2520%2528PI3K%2529%252Fmammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520kinase%2520inhibitor%2520%2528GDC-0980%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7579%26epage%3D7587%26doi%3D10.1021%2Fjm2009327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>213</i></span>,  <span class="NLM_fpage">113054</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2020.113054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2020.113054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=33309164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFyqsrvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2021&pages=113054&author=J.+Wangauthor=G.+Heauthor=H.+Liauthor=Y.+Geauthor=S.+Wangauthor=Y.+Xuauthor=Q.+Zhu&title=Discovery+of+novel+PARP%2FPI3K+dual+inhibitors+with+high+efficiency+against+BRCA-proficient+triple+negative+breast+cancer&doi=10.1016%2Fj.ejmech.2020.113054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer</span></div><div class="casAuthors">Wang, Junwei; He, Guangchao; Li, Hui; Ge, Yiran; Wang, Shuping; Xu, Yungen; Zhu, Qihua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113054</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Co-targeting PARP and PI3K by PARP/PI3K dual inhibitors has been recognized as a promising chemotherapeutic strategy for the treatment of triple neg. breast cancer (TNBC) in our previous work.  To further explore novel and more potent PARP/PI3K dual inhibitors, a series of compds. were designed, synthesized and evaluated for their pharmacol. properties, resulting in the candidate compd. 12, a potent and highly selective PARP/PI3K dual inhibitor.  Compared to Olaparib, compd. 12 exhibits a superior antiproliferative profile against BRCA-proficient MDA-MB-468 cells.  In MDA-MB-468 cell-derived xenograft model, compd. 12 displayed excellent antitumor efficacy at a dose of 50 mg/kg, which is considerably more efficacious than the single administration of Olaparib or BKM120.  Furthermore, compd. 12 displayed good metabolic stability and high safety.  Taken together, these results suggest that compd. 12 as a novel PARP/PI3K dual inhibitor is worthy for further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok5C_ptVUYF7Vg90H21EOLACvtfcHk0lh8nDQw2fHxXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFyqsrvF&md5=633744af8efcaaa0de77a98f6093cf69</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.113054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.113054%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520novel%2520PARP%252FPI3K%2520dual%2520inhibitors%2520with%2520high%2520efficiency%2520against%2520BRCA-proficient%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D213%26spage%3D113054%26doi%3D10.1016%2Fj.ejmech.2020.113054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edgar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesnick, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivero, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lensun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassees, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span> <span> </span><span class="NLM_article-title">GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2426</span>â <span class="NLM_lpage">2436</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-11-0446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1158%2F1535-7163.MCT-11-0446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=21998291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2426-2436&author=J.+J.+Wallinauthor=K.+A.+Edgarauthor=J.+Guanauthor=M.+Berryauthor=W.+W.+Priorauthor=L.+Leeauthor=J.+D.+Lesnickauthor=C.+Lewisauthor=J.+Nonomiyaauthor=J.+Pangauthor=L.+Salphatiauthor=A.+G.+Oliveroauthor=D.+P.+Sutherlinauthor=C.+O%E2%80%99Brienauthor=J.+M.+Spoerkeauthor=S.+Patelauthor=L.+Lensunauthor=R.+Kasseesauthor=L.+Rossauthor=M.+R.+Lacknerauthor=D.+Sampathauthor=M.+Belvinauthor=L.+S.+Friedman&title=GDC-0980+is+a+novel+class+I+PI3K%2FmTOR+kinase+inhibitor+with+robust+activity+in+cancer+models+driven+by+the+PI3K+pathway&doi=10.1158%2F1535-7163.MCT-11-0446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway</span></div><div class="casAuthors">Wallin, Jeffrey J.; Edgar, Kyle A.; Guan, Jane; Berry, Megan; Prior, Wei Wei; Lee, Leslie; Lesnick, John D.; Lewis, Cristina; Nonomiya, Jim; Pang, Jodie; Salphati, Laurent; Olivero, Alan G.; Sutherlin, Daniel P.; O'Brien, Carol; Spoerke, Jill M.; Patel, Sonal; Lensun, Letitia; Kassees, Robert; Ross, Leanne; Lackner, Mark R.; Sampath, Deepak; Belvin, Marcia; Friedman, Lori S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2426-2436</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Alterations of the phosphoinositide-3 kinase (PI3K)/Akt signaling pathway occur broadly in cancer via multiple mechanisms including mutation of the PIK3CA gene, loss or mutation of phosphatase and tensin homolog (PTEN), and deregulation of mammalian target of rapamycin (mTOR) complexes.  The dysregulation of this pathway has been implicated in tumor initiation, cell growth and survival, invasion and angiogenesis, thus, PI3K and mTOR are promising therapeutic targets for cancer.  We discovered GDC-0980, a selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with excellent pharmacokinetic and pharmaceutical properties.  GDC-0980 potently inhibits signal transduction downstream of both PI3K and mTOR, as measured by pharmacodynamic (PD) biomarkers, thereby acting upon two key pathway nodes to produce the strongest attainable inhibition of signaling in the pathway.  Correspondingly, GDC-0980 was potent across a broad panel of cancer cell lines, with the greatest potency in breast, prostate, and lung cancers and less activity in melanoma and pancreatic cancers, consistent with KRAS and BRAF acting as resistance markers.  Treatment of cancer cell lines with GDC-0980 resulted in G1 cell-cycle arrest, and in contrast to mTOR inhibitors, GDC-0980 induced apoptosis in certain cancer cell lines, including those with direct pathway activation via PI3K and PTEN.  Low doses of GDC-0980 potently inhibited tumor growth in xenograft models including those with activated PI3K, loss of LKB1 or PTEN, and elicited an exposure-related decrease in PD biomarkers.  These preclin. data show that GDC-0980 is a potent and effective dual PI3K/mTOR inhibitor with promise for the clinic.  Mol Cancer Ther; 10(12); 2426-36.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4yjwxW7TM3bVg90H21EOLACvtfcHk0lgrTneNqJgPWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurfJ&md5=756410aaf86377284a63d8ee70ad36ec</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0446%26sid%3Dliteratum%253Aachs%26aulast%3DWallin%26aufirst%3DJ.%2BJ.%26aulast%3DEdgar%26aufirst%3DK.%2BA.%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesnick%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DKassees%26aufirst%3DR.%26aulast%3DRoss%26aufirst%3DL.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26atitle%3DGDC-0980%2520is%2520a%2520novel%2520class%2520I%2520PI3K%252FmTOR%2520kinase%2520inhibitor%2520with%2520robust%2520activity%2520in%2520cancer%2520models%2520driven%2520by%2520the%2520PI3K%2520pathway%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2426%26epage%3D2436%26doi%3D10.1158%2F1535-7163.MCT-11-0446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>217</i></span>,  <span class="NLM_fpage">113357</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2021.113357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=10.1016%2Fj.ejmech.2021.113357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=33740547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;key=1%3ACAS%3A528%3ADC%252BB3MXmvVOqs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=217&publication_year=2021&pages=113357&author=Z.+Wuauthor=Y.+Baiauthor=J.+Jinauthor=T.+Jiangauthor=H.+Shenauthor=Q.+Juauthor=Q.+Zhuauthor=Y.+Xu&title=Discovery+of+novel+and+potent+PARP%2FPI3K+dual+inhibitors+for+the+treatment+of+cancer&doi=10.1016%2Fj.ejmech.2021.113357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer</span></div><div class="casAuthors">Wu, Zhengyang; Bai, Ying; Jin, Jiaming; Jiang, Teng; Shen, Hui; Ju, Qiurong; Zhu, Qihua; Xu, Yungen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">217</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113357</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">PARP inhibitors have achieved great success in cancers with BRCA mutations, but only a small portion of patients carry BRCA mutations, which results in their narrow indication spectrum.  Recently, emerging evidence has demonstrated that combinations of PARP and PI3K inhibitors could evoke unanticipated synergistic effects in various cancers, even including BRCA-proficient ones.  In this work, a series of PARP/PI3K dual inhibitors were designed, synthesized, and evaluated for their biol. activities.  It was found that compds. 9a and 23a exhibited excellent inhibitory activities against PARP-1 (9a: IC50 = 1.57 nM, 23a: IC50 = 0.91 nM) and PI3KÎ± (9a: IC50 = 2.0 nM, 23a: IC50 = 1.5 nM), and showed promising antiproliferative activities against both BRCA-deficient (HCT-116, HCC-1937) and BRCA-proficient (SW620, MDA-MB-231/468) tumor cells. 9a and 23a also exhibited considerable in vivo antitumor efficacy in an MDA-MB-468 xenograft mouse model, with TGI values of 56.39% and 48.77%, resp.  Addnl., 23a possessed promising profiles including high kinase selectivity and low cardiotoxicity.  Overall, this work indicates 9a and 23a might be potential PARP/PI3K dual inhibitors for cancer therapy and deserve further research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwMjgqJTJmtLVg90H21EOLACvtfcHk0lgrTneNqJgPWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXmvVOqs7g%253D&md5=1890ee4b8f7b6017a5004ef2c08464bf</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113357%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DJu%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520and%2520potent%2520PARP%252FPI3K%2520dual%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D217%26spage%3D113357%26doi%3D10.1016%2Fj.ejmech.2021.113357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1C3S" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1C3S','PDB','1C3S'); return false;">PDB: 1C3S</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1HW9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1HW9','PDB','1HW9'); return false;">PDB: 1HW9</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ACJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ACJ','PDB','1ACJ'); return false;">PDB: 1ACJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PTC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PTC','PDB','4PTC'); return false;">PDB: 4PTC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK','PDB','1XKK'); return false;">PDB: 1XKK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QCF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QCF','PDB','1QCF'); return false;">PDB: 1QCF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17','PDB','1M17'); return false;">PDB: 1M17</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3gwv" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3gwv','PDB','3gwv'); return false;">PDB: 3gwv</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP','PDB','1IEP'); return false;">PDB: 1IEP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RT2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RT2','PDB','1RT2'); return false;">PDB: 1RT2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KLM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KLM','PDB','1KLM'); return false;">PDB: 1KLM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VN2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VN2','PDB','3VN2'); return false;">PDB: 3VN2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DS3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5DS3','PDB','5DS3'); return false;">PDB: 5DS3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JPS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JPS','PDB','4JPS'); return false;">PDB: 4JPS</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i33"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00683">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_24110"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00683?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00683</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">X-ray crystal structures; Designs of multitargeted agents (Figures S1âS7) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00683/suppl_file/jm1c00683_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00683/suppl_file/jm1c00683_si_001.pdf">jm1c00683_si_001.pdf (263.01 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00683&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00683%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00683" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                11MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799d5c0a90c231a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
